| Entries |
| Document | Title | Date |
|---|
| 20080199437 | Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers - The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof. | 08-21-2008 |
| 20080199438 | Methods For Suppressing Tumor Proliferation - The present invention provides methods for suppressing tumor proliferation comprising the step of inhibiting the expression of PDGF-A or the binding between PDGF-A homodimers and PDGFRα. Activation of the PDGFRα-p70S6K signal transduction pathway by PDGF-AA is an important factor in tumor angiogenesis and relates to the prognosis of patients suffering from tumors. By inhibiting PDGF-A expression in tumors or in their surrounding tissues, or by inhibiting the binding between PDGF-A homodimers and PDGFRα, the formation and retention of tumor vasculature can be inhibited, thereby suppressing tumor proliferation. | 08-21-2008 |
| 20080199439 | IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods - The present invention features peptides, peptidomimetics and methods of their use for binding to Inhibitor of Apoptosis Proteins (IAPs) in cells and prevents the IAP's from exerting their apoptosis-suppressing function with caspases in the cell. An IAP binding cargo molecule having a binding portion mimicking the structural and biological features of the Smac amino-terminal tetrapeptide that is capable of relieving XIAP-mediated suppression of apoptosis in mammalian cells, and a cargo portion with a functional group having a detectable property or therapeutic function is disclosed. | 08-21-2008 |
| 20080199440 | Tissue Repair Using Allogenic Dermal Fibroblasts - The present invention provides a method for the repair of subcutaneous or dermal tissue in a subject, comprising in one aspect the injection of a suspension of allogeneic dermal fibroblasts into the subject. By injecting a suspension of allogeneic cells, the invention provides, for example, long-term augmentation of the subadjacent tissue without the disadvantages that accompany the preparation and/or use of presently available materials such as autologous fibroblasts cells or collagen. According to a first aspect of the invention there is provided a method for the augmentation of subcutaneous or dermal tissue in a subject, which method comprises the steps of: (i) providing a suspension of allogeneic dermal fibroblasts; and (ii) injecting an effective volume of the suspension into tissue subadjacent to the subcutaneous or dermal tissue so that the tissue is augmented. The method is preferably cosmetic. | 08-21-2008 |
| 20080199441 | Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases - Methods for cell therapy of peripheral vascular disease by local administration of ex-vivo cultured hematopoietic cells are provided. | 08-21-2008 |
| 20080206203 | Method for Inhibiting Tumor Metastasis - A leukotriene C4 and D4 antagonist is used to inhibit tumor metastasis by acting to inhibit tumor cell adhesion to endothelial cells, thereby preventing tumor cell extravasation. | 08-28-2008 |
| 20080206204 | Human parthenogenetic stem cells - The invention provides a method for establishing pluripotent cell lines from human parthenotes, the uses of said cell lines for producing differentiated cells or tissues and for therapeutic applications especially in regenerative medicine. | 08-28-2008 |
| 20080206205 | Cd34(+) Cells And Their Methods Of Use | 08-28-2008 |
| 20080206206 | BONE MARROW-DERIVED NEURONAL CELLS - Bone marrow stromal cells (BMSC) differentiate into neuron-like phenotypes in vitro and in vivo, engrafted into normal or denervated rat striatum. The BMSC administered into the ventricle did not remain localized to the site of the graft, but migrated throughout the brain and integrated into specific brain regions in various architectonic patterns. The most orderly integration of BMSC was in the laminar distribution of cerebellar Purkinje cells, where the BMSC-derived cells took on the Purkinje phenotype. The BMSC exhibited site-dependent differentiation and expressed several neuronal markers including neuron-specific nuclear protein, tyrosine hydroxylase and calbindin. Treated BMSC implanted intrastriatally stayed in the cortex and the striatum, produced tyrosine hydroxylase which produces the dopamine needed in Parkinson's disease. | 08-28-2008 |
| 20080206207 | Intracoronary Device And Method Of Use Thereof - Engraftment of therapeutic cells and agents to a target site in an organism is enhanced by mechanical, chemical and biological methods and systems. | 08-28-2008 |
| 20080206208 | EXTRAMEDULLARY ADIPOSE TISSUE CELLS AND USE THEREOF FOR REGENERATING HEMATOPOIETIC AND MUSCULAR TISSUES - The invention concerns cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue, methods for preparing them and their use in regeneration of hematopoietic lines and cardiac and skeletal muscular tissues, in particular for treating genetic or acquired hemopathies, myopathies and cardiomypathies. | 08-28-2008 |
| 20080206209 | MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS - One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. Oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells. | 08-28-2008 |
| 20080213227 | Mesenchymal stem cells and uses therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 09-04-2008 |
| 20080213228 | Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations - Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells. | 09-04-2008 |
| 20080213229 | Fibrin Contained Semi-Solid Osteoblast Composition for Curing Bone Fracture and Method for Producing the Same - A method for producing the fibrin contained semi-solid osteoblast composition has developed for treating the bone fracture. The method is comprised of: isolating osteoblasts from a bone tissue and culturing/proliferating the isolated osteoblasts in Dulbecco's Modified Eagle's Medium (DMEM) or Minimum Essential Medium, Alpha Modification (α-MEM) to prepare an osteoblast suspension. Then, mixing the resulting osteoblast suspension with a coagulation factor to prepare an osteoblast therapeutic agent. Accordingly, the fibrin contained semi-solid osteoblast composition of the present invention has capability to achieve the bone grafting for performing bone union without the clinical graft rejection. It is possible to uniformly distribute the fibrin mixed semi-solid osteoblast composition into the affected area of the bone fracture via injection. Therefore, the fibrin contained semi-solid osteoblast composition is effectively and rapidly cure the bone fracture via constant injection of into the affected area. | 09-04-2008 |
| 20080213230 | Enriched stem cell and progenitor cell populations, and methods of producing and using such populations - The present invention provides a novel method to isolate and expand pure progenitor/stem cells from a primary tissue explant, which produces a population enriched in multipotent functional progenitor/stem cells free of contaminating fibroblasts and other cell types. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal and clonogenic character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. The present invention also includes substantially pure populations of multipotent progenitor/stem cells, e.g., cardiac progenitor/stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction. | 09-04-2008 |
| 20080213231 | Pluripotent Stem Cell Cloned From Single Cell Derived From Skeletal Muscle Tissue - Techniques are provided which can isolate pluripotent stem cells at high purity capable of differentiation into at least a myocardial cell to regenerate the cardiac muscle. The pluripotent stem cells at high purity capable of differentiation into at least a myocardial cell to regenerate the cardiac muscle can be isolated through the following steps: (i) collecting a skeletal muscle tissue from a mammal and enzymatically treating the obtained skeletal muscle tissue to prepare a skeletal muscle tissue-derived cell; (ii) culturing the obtained skeletal muscle tissue-derived cell in a culture medium containing an epidermal growth factor and a fibroblast growth factor; (iii) selecting and separating a colony that is floating in the culture medium. | 09-04-2008 |
| 20080219955 | Method of Producing Purified Neural Stem Cells and Related Methods of Treating a Patient - The present invention provides a method of producing purified neural stem cells, comprising harvesting fluid containing neural stem cells from cerebrospinal fluid surrounding the spinal cord of an individual, isolating the neural stem cells from the fluid, culturing the neural stem cells in a culture medium effective to induce proliferation of the neural stem cells and purifying the cultured neural stem cells. Also provided is a method of treating a patient afflicted with a neurological condition, in which the purified neural stem cells are administered autologously into the same individual or heterologously to a patient other than the individual. Administration of the purified neural stem cells results in the purified neural stem cells propagating in the site of the brain region afflicted with the neurological condition. | 09-11-2008 |
| 20080219956 | HLA HOMOZYGOUS CELLS AND METHODS OF USE THEREOF - The present invention provides methods of generating a mammalian cell that is homozygous at a locus of interest, as well as cells made by the method. The present invention further provides methods of using the cells. | 09-11-2008 |
| 20080219957 | Method of Deriving Mesenchymal Stem Cells - We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line. | 09-11-2008 |
| 20080219958 | METHOD FOR INDUCING AN ANTI-TUMOR AND ANTI-CACHEXIA IMMUNE RESPONSE IN MAMMALS - The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can also be used to treat cachexia in cancer or AIDS patients. | 09-11-2008 |
| 20080226605 | Methods and Compositions Facilitating Entry of Compounds Into Cells - Disclosed are methods and compositions for facilitating entry of compounds to cells. In some forms, the compositions comprise one or more aminoglycosides and one or more lipids. The disclosed compositions can also comprise one or more compounds or compositions. It was discovered that the disclosed compositions increase the efficiency of delivery of compounds into cells. The disclosed compositions and methods increase both delivery into cells and the activity of compounds once delivered into cells. For example, the disclosed methods and compositions can be used to deliver nucleic acids to cells and to thereby increase the activity of such nucleic acids delivered to cells. The disclosed compositions can be used to deliver compounds and compositions to cells in vitro, ex vivo and in vivo. Delivery can be, for example, non-specific, non-directed, non-targeted, specific, directed or targeted. | 09-18-2008 |
| 20080226606 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer. | 09-18-2008 |
| 20080226607 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer. | 09-18-2008 |
| 20080226608 | Methods of Isolating and Using Enriched Subpopulations of Bone Marrow Progenitors for the Treatment of Diabetes - Enriched subpopulations of bone marrow progenitors are obtained according to methods that involve the staining of bone marrow cells and the identification of bone marrow progenitors within the stained cell population having specific intracellular fluorescence or orthogonal light scatter properties. Enriched subpopulations of the described progenitors may be used to lower blood glucose levels and treat hyperglycemia, and in particular hyperglycemia caused by Type 1 or Type 2 diabetes. | 09-18-2008 |
| 20080226609 | Transplantation of Glial Restricted Precursor-Derived Astrocytes for Promotion of Axon Growth - Provided herein are compositions and methods for the treatment of central nervous system (CNS) lesions comprising administration of glial restricted precursor (GRP) derived astrocytes (GDAs). | 09-18-2008 |
| 20080233087 | Methods for identifying, isolating, and utilizing endocrine progenitor cells from adult human pancreata - The presence of the cell surface marker CD133 or the presence of a glycosylated form of the prominin-1 gene product on adult pancreatic cells is used to identify pancreatic endocrine progenitor cells, and useful in methods of isolation and enrichment. Isolated pancreatic endocrine progenitor cells can be used for cell based therapy for insulin-dependent diabetes and pancreatectomy patients. | 09-25-2008 |
| 20080233088 | PREPARATIVE REGIMEN FOR ENGRAFTMENT, GROWTH AND DIFFERENTIATION OF NON-HEMATOPOEITIC CELLS IN VIVO AFTER TRANSPLANTATION - The invention relates to methods of obtaining an expanded population of mammalian ex vivo cells and/or for treating a mammalian subject by (a) administering to a subject an effective amount of an agent that confers a growth disadvantage to at least a subset of endogenous cells at the site of engraftment; (b) administering to the subject an effective amount of a mitogenic stimulus for the ex vivo cells; and (c) administering the ex vivo cells to the subject, wherein the ex vivo cells engraft at the site and proliferate to a greater extent than the subset of endogenous cells, to repopulate at least a portion of the engraftment site with the ex vivo cells. The repopulated cells can be harvested for further use or be left at the engraftment site of a subject to be treated. The invention also provides methods of treating brain injury in a subject by engrafting ex vivo cells at the site of injury. | 09-25-2008 |
| 20080241106 | Method for Preventing and Treating Diabetes Using Neurturin - The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product. | 10-02-2008 |
| 20080241107 | Methods and Compositions For Preparing Pancreatic Insulin Secreting Cells - The present invention concerns the use of transdifferentiated cells to treat pancreatic diseases. More particularly, it provides methods for the culture and transdifferentiation of human cord blood, cells into insulin-secreting cells. It also concerns the endocrine hormones, such as insulin, produced by such cultures, and the use of the transdifferentiated cells in the treatment of diabetes. | 10-02-2008 |
| 20080241108 | Bone Morphogenic Protein Binding Peptide - A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the over-all osteogenic activity of rgBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis. | 10-02-2008 |
| 20080241109 | Method for Ex-Vivo Purging in Autologous Transplantation - The present invention concerns a new method for ex-vivo purging of cells in autologous transplantation, wherein the sample of taken cells is treated with a sufficient amount of a multimeric form of the soluble portion of FasL to kill malignant cells without substantially affecting viability of cells to be transplanted. Autologous stem cell transplantation (ASCT) following high-dose chemotherapy with or without radiotherapy has become the standard therapy for the majority of patients with large-cell lymphomas, multiple myeloma, and refractory/recidivating Hodgkin's disease. Such therapy is nowadays also contemplated for selected patients with low-grade lymphomas (chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma) and for patients with acute myeloid leukemia (AML). Current treatments for cell purging include chemotherapy and antibody cocktails. These treatments are often toxic on stem cells and not efficient in eliminating cancer cells. Thus, there is an unmet medical need for cell purging in ASCT which this project will address. | 10-02-2008 |
| 20080241110 | Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS) - The present invention discloses nucleic acids, proteins, and antibodies for SALL4 (including isoforms SALL4A, SALL4B, and SALL4C), a zinc finger transcriptional factor. Further, methods are disclosed which demonstrate that constitutive expression of SALL4 increases leukemogenic potential in cells of model animal systems. Moreover, constitutive expression of select isoforms (e.g., SALL4B) in transgenic mice demonstrate that these animals develop myelodysplastic syndrome (MDS)-like signs and symptoms, including subsequent acute myeloid leukemia (AML), which is transplantable. The disclosure also provides methods for identifying and purifying embryonic stem cells, adult stem cells, cancer stem cells, including leukemia stem cells, methods for identifying substances which bind to and/or modulate SALL4, methods for diagnosing MDS in a subject, and methods of treating a subject presenting MDS, AML and other forms of leukemia. | 10-02-2008 |
| 20080241111 | Pluripotent Stem Cell Derived from Cardiac Tissue - An object of the present invention is to provide a stem cell applicable to regenerative therapeutic method, and to provide a technique to carry out regenerative therapy using the cell. A collected cardiac tissue fragment is enzymatically treated to prepare a cell suspension. Then using the cell suspension, following steps are carried out: (1) separation of cells by the density gradient method, (2) suspension-culture in a culture medium containing fibroblast growth factor and epidermal growth factor and (3) selection and separation of cells forming a floating sphere to obtain pluripotent stem cells. Thus-obtained pluripotent stem cells are used to carry out regenerative therapy. | 10-02-2008 |
| 20080241112 | Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media - Methods and a composition for the treatment of organ dysfunction, acute renal failure, multi-organ failure, early dysfunction of kidney transplant, graft rejection, chronic renal failure, wounds, and inflammatory disorders including media conditioned by mesenchymal stem cells are provided. Methods for modulation of growth factor and cytokine expression including administering a therapeutic amount of mesenchymal stem cells, endothelial cells derived from mesenchymal stem cells, or media conditioned by mesenchymal stem cells are also provided. | 10-02-2008 |
| 20080241113 | Procurement, isolation and cryopreservation of endometrial/menstrual cells - Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefor are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II. | 10-02-2008 |
| 20080247998 | Creation of a Biological Atrioventricular Bypass to Compensate for Atrioventricular Block - A method of creating an atrioventricular bypass tract for a heart comprises growing mesenchymal stem cells into a strip with two ends, attaching one end of the strip onto the atrium of the heart, and attaching the other end of the strip to the ventricle of the heart, to create a tract connecting the atrium to the ventricle to provide a path for electrical signals generated by the sinus node to propagate across the tract and excite the ventricle. | 10-09-2008 |
| 20080247999 | Treating Cancer - The present invention provides a peptide comprising an amino acid sequence that is part of the amino acid sequence of CDK4 protein, or homologous to part of the amino acid sequence of CDK4 protein, which peptide is cytotoxic to, and/or inhibiting to the growth of, a cancer cell and/or stimulating to the growth of a non-cancerous cell and/or a control cell. Methods of identifying such peptides and medical uses of such peptides are also disclosed. | 10-09-2008 |
| 20080248000 | Stem Cells, Method For Their Purification, Identification, and Use - Herein is described a new population of circulating CD14+cells, with a low density surface expression of CD34 and endowed with stem capacity, a method for their purification and identification, and their therapeutic use. | 10-09-2008 |
| 20080248001 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS - Methods for the treatment of a cell proliferation disorder in a subject, involving:
| 10-09-2008 |
| 20080248002 | ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER THERAPY - The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors. | 10-09-2008 |
| 20080248003 | Methods and Compositions for Growing Adipose Stem Cells - The present invention relates to adipose tissue-derived stem cells and to methods and compositions for enhancing growth and differentiation of such cells. The invention further relates to growing such cells in serum-free or low serum growth medium, and formulations thereof. | 10-09-2008 |
| 20080248004 | Cell fractions containing cells capable of differentiating into neural cells - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 10-09-2008 |
| 20080248005 | Isolation and Cultivation of Stem/Progenitor Cells From the Amniotic Membrane of Umbilical Cord and Uses of Cells Differentiated Therefrom - The present invention relates to a skin equivalent and a method for producing the same, wherein the skin equivalent comprises a scaffold and stem/progenitor cells isolated from the amniotic membrane of umbilical cord. These stem/progenitor cells may be mesenchymal (UCMC) and/or epithelial (UCEC) stem cells, which may then be further differentiated to fibroblast and keratinocytes. Further described is a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The invention also refers to therapeutic uses of these skin equivalents. Another aspect of the invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells. In yet another aspect, the invention relates to a method for generating an insulin-producing cell using stem/progenitor cells isolated from the amniotic membrane of umbilical cord and therapeutic uses thereof. The invention further refers to a method of treating a bone or cartilage disorder using UCMC. Furthermore, the invention refers to a method of generating a dopamin and tyrosin hydroxylase as well as a HLA-G and hepatocytes using UCMC and/or UCEC. The present invention also refers to a method of inducing proliferation of aged keratinocytes using UCMC. | 10-09-2008 |
| 20080248006 | Process For Ex Vivo Formation of Mammalian Bone And Uses Thereof - The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation. | 10-09-2008 |
| 20080254001 | Novel bone mineralization protein expression systems, and methods of studying their intracellular signaling pathways - The present invention is directed to methods of switching a differentiation of a cell from a non-osteogenic lineage into an osteogenic lineage. The present invention is also directed to methods of generating a model system for assessing the intracellular signaling pathways of bone growth factors. | 10-16-2008 |
| 20080254002 | Bone Marrow Derived Oct3/4+ Stem Cells - The invention provides bone-marrow derived stem cells, e.g., cardiomyocyte precursor cells, differentiated cardiomyocytes generated from the precursor cells, and a method for treating cardiac dysfunction in a subject by administering such cells. | 10-16-2008 |
| 20080254003 | Differentiation of Human Embryonic Stem Cells and Cardiomyocytes and Cardiomyocyte Progenitors Derived Therefrom - The present invention provides a method to improve current culturing methods for the differentiation of cardiomyocytes from hES cells. The method includes culturing the hES cells in the presence of ascorbic acid or a derivative thereof. Preferably the culturing is conducted in serum free conditions. The invention also includes isolated cardiomyocytes and cardiac progenitors differentiated by the methods as well as the use of these cells in methods of treating and preventing cardiac diseases and conditions. Culture media and extracellular media are also provided which include ascorbic acid for the differentiation of hES cells to cardiomyocytes. | 10-16-2008 |
| 20080254004 | Homogeneous Neural Precursor Cells - This invention provides pure populations of neural precursor cells, capable of differentiation into neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural precursor population. The precursors can be further differentiated in culture into a variety of different neural phenotypes. The neural precursors can be generated in pure form (at least 99%) and in large quantities for use in drug screening and the treatment of neurological disorders. | 10-16-2008 |
| 20080254005 | Stem Cell Therapy for the Treatment of Autism and Other Disorders - Disclosed are methods, compositions of matter, and cells, useful for the treatment of autism, social integrative disorders, and various cognitive abnormalities. The invention discloses, inter alia, means of inducing angiogenesis and immune modulation either in sequence or parallel in order to substantially ameliorate or reverse the progression of autism. The use of stem cells, and cells naturally possessing or endowed with angiogenic and anti-inflammatory activity are disclosed for autism either alone or in combination with various therapeutic interventions. | 10-16-2008 |
| 20080254006 | TREATMENT OF ALOPECIA BY MICROPORE DELIVERY OF STEM CELLS - A method of restoring hair to skin that has suffered hair loss includes optically ablating an array of spaced-apart microchannels or voids into the skin and transplanting into the voids stem cells, a scaffold and a differentiation factor for causing the stem cells to differentiate into hair follicles. | 10-16-2008 |
| 20080254007 | Human Mesenchymal Progenitor Cell - The present invention provides isolated pluri-differentiated human mesenchymal progenitor cells (MPCs), which simultaneously express a plurality of genes that are markers for multiple cell lineages, wherein the multiple cell lineages comprise at least four different mesenchymal cell lineages (e.g., adipocyte, osteoblast, fibroblast, and muscle cell) and wherein each of the markers is specific for a single cell lineage. The present invention also method for isolating and purifying human mesenchymal progenitor cells from Dexter-type cultures for characterization of and uses, particularly therapeutic uses for such cells. Specifically, isolated MPCs can be used for diagnostic purposes, to enhance the engraftment of hematopoietic progenitor cells, enhance bone marrow transplantation, or aid in the treatment or prevention of graft versus host disease. | 10-16-2008 |
| 20080260699 | Adminstration of intact mammalian cells to the brain by the intranasal route - The present invention provides an intranasal method for delivery of intact mammalian cells to the brain for treatment of neurological deficits. This approach applies an intranasal instillation to directly administer cells to the brain, and is useful as therapy for patients with neurological deficit or those who may benefit from cellular therapy as a result of stroke, Alzheimer's, Parkinson's, diabetes, traumatic injury, surgery, cancer, or other diseases of the brain. This non-invasive method of delivering neuronal cells is desirable and safe. | 10-23-2008 |
| 20080260700 | GENERATION OF PANCREATIC ENDOCRINE CELLS FROM PRIMARY DUCT CELL CULTURES AND METHODS OF USE FOR TREATMENT OF DIABETES - The invention is directed to spontaneously immortalized pancreatic duct cells and methods for generating pancreatic endocrine cells from spontaneously immortalized pancreatic duct cells that express the transcription factors Pdx1 and FoxO1. The invention also provides for methods for treating beta cell failure, the method comprising administering to a subject an effective amount of spontaneously immortalized pancreatic duct cells expressing a mutated version FoxO1. | 10-23-2008 |
| 20080260701 | ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER THERAPY - The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors. | 10-23-2008 |
| 20080260702 | Treatment of Retinopathies Using Gfra3 Agonists - The present invention relates to the use of GFRα3 agonists for the treatment of disorders of the retina. A preferred GFRα3 agonist is Neublastin. Neublastin may be administered to the eye using protein formulations, in vivo or ex vivo gene therapy, or implantation of encapsulated cells delivering Neublastin locally to the retina. | 10-23-2008 |
| 20080260703 | Treatment of Insulin Resistance and Diabetes - Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin. | 10-23-2008 |
| 20080260704 | Combination Treatment of Cardiovascular Disease - Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy. | 10-23-2008 |
| 20080267921 | Cardiac Stem Cells - Human cardiac stem cells can be isolated from endomyocardial biopsies. Such cells mediate cardiac regeneration and improve heart function in a mouse infarct model. The cells can be used for autologous, allogeneic, syngeneic, or xenogeneic therapeutic applications in patients. The stem cells can be genetically modified to enhance their therapeutic activity. | 10-30-2008 |
| 20080267922 | SLITRKS AS MARKERS FOR STEM AND PROGENITOR CELLS AND METHODS OF USE THEREOF - The present invention relates to slitrk proteins as markers of stem and progenitor cells, including embryonic stem cells and hematopoietic stem and progenitor cells, and also as a marker of leukemia and lymphoma cells, and of endothelial cells. The invention provides, inter alia, methods for purifying slitrk-positive cells, methods for detecting slitrk-positive cells, purified preparations of slitrk-positive cells, therapeutic compositions containing purified slitrk-positive cells, methods for targeting therapeutic agents to slitrk-positive cells, and methods of treatment, including but not limited to, methods of administering slitrk-positive cells to subjects in need thereof. | 10-30-2008 |
| 20080267924 | AUTOLOGOUS LYMPH NODE TRANSFER IN COMBINATION WITH VEGF-C OR VEGF-D GROWTH FACTOR THERAPY TO TREAT SECONDARY LYMPHEDEMA AND TO IMPROVE RECONSTRUCTIVE SURGERY - The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery. | 10-30-2008 |
| 20080267925 | Cell Therapy: A Method And A Composition For Treating Diabetes - A method of obtaining beta-islet cells from pancreases of rabbits and a composition for transplantation (xenografts or xenotransplants) of beta-islet cells isolated and cultured from rabbit pancreases to promote natural insulin production among people with diabetes. | 10-30-2008 |
| 20080267926 | METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy. | 10-30-2008 |
| 20080267927 | Methods for improving cell therapy and tissue regeneration in patients with cardiovascular diseases by means of shockwaves - Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain. | 10-30-2008 |
| 20080274086 | Use of Cxcr4 Protein Expression on the Surface of Stem Cells as a Marker for Tumor Tropic Potential - The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1. | 11-06-2008 |
| 20080274087 | BRAIN TISSUE DAMAGE THERAPIES - A cultured pluripotent animal cell that is CD13+, CD90+, and CD117−. Also disclosed are methods for making the cell and methods of treating a brain tissue damage and increasing the expression level of a neuraltrophic factor in a subject. | 11-06-2008 |
| 20080274088 | Mapc Generation of Lung Tissue - The present invention relates to methods of improving function in lung tissue by administering a population of multipotent adult progenitor cells (“MAPCs”) or differentiated progeny thereof. | 11-06-2008 |
| 20080274089 | Inflammation - This invention provides adult neural stem cell (aNSC) materials and methods for treating central nervous system disorders. | 11-06-2008 |
| 20080274090 | REVERSAL OF INSULIN-DEPENDENT DIABETES BY ISLET-PRODUCING STEM CELLS, ISLET PROGENITOR CELLS AND ISLET-LIKE STRUCTURES - The subject invention concerns new methods which make it possible, for the first time, to grow functional islet-producing stem cells (IPSCs), islet progenitor cells (IPCs) and IPC-derived islets (IdIs) in in vitro cultures. The subject invention also concerns the use of the in vitro grown IPSCs, IPCs and/or IdIs for implantation into a mammal for in vivo therapy of diabetes. The subject invention further concerns a process of using the implanted cells for growing a pancreas-like structure in vivo that has the same functional, morphological and histological characteristics as those observed in normal pancreatic endocrine tissue. The ability to grow these cells in vitro and pancreas-like structures in vivo opens up important new avenues for research and therapy relating to diabetes. | 11-06-2008 |
| 20080279825 | CARTILAGE MATERIAL - Cartilage materials such as cartilage fluff and a cartilage composition comprising a particulate material are disclosed. These are suitable for stimulating chondrogenesis and/or producing cartilage regeneration. Also disclosed are processes for their preparation. Methods for regenerating articular cartilage are also disclosed, which involve, for example, placing the cartilage fluff or cartilage composition into a cartilage defect. | 11-13-2008 |
| 20080279826 | Method for Expanding Cd4+ Cd25+ T Regulator Cells - A method for generating/expanding in vitro a CD4 | 11-13-2008 |
| 20080279827 | PREPARATION AND XENOTRANSPLANTATION OF PORCINE ISLETS - The invention relates to developments in the treatment of diabetes in mammals. Particularly it relates to a method of preparing a xenotransplantable porcine islet preparation capable upon xenotransplantation of producing porcine insulin in an appropriate recipient mammal, the method including or comprising the steps of:
| 11-13-2008 |
| 20080279828 | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby - Ex vivo and in vivo methods of expanding a population of stem and/or progenitor cells, while at the same time reversibly inhibiting differentiation of the stem and/or progenitor cells by providing the stem and/or progenitor cells with an effective amount of at least one copper chelate, so as to maintain a free copper concentration available to said cells substantially unchanged, to thereby expand the population of said stem and/or progenitor cells, while at the same time reversibly inhibit differentiation of said stem and/or progenitor cells. | 11-13-2008 |
| 20080279829 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance - The use of a phenyl-(4-phenyl-pyrimidin-2-yl)-amine for the preparation of a medicament for enhancing immunotolerance in a mammal; and uses, methods, processes and pharmaceutical combinations and compositions comprising such phenyl-(4-phenyl-pyrimidin-2-yl)-amine. | 11-13-2008 |
| 20080279830 | SPONGY EPITHELIAL CELL SCAFFOLD FOR VASCULARIZING WOUNDS - The present invention provides isolated apoptotic epithelial scaffolds. The scaffolds find use in promoting re-vascularization of wounded tissues. The present invention also provides isolated or ex vivo tri-layered cell sorted tissues comprised of a bottom layer comprised of an apoptotic epithelial scaffold, a middle layer comprised of mesenchymal cells, and a top layer comprised of non-differentiated epithelial cells. The invention further provides in vitro methods for generating isolated or ex vivo tri-layered cell sorted tissues by exposing cultured mixtures of epithelial and mesenchymal cells to an inflammatory cytokine. Further provided are methods of promoting wound healing and re-vascularization of wounds by contacting wounded tissue with the apoptotic epithelial scaffolds of the invention. | 11-13-2008 |
| 20080286241 | Transplantation of Differentiated Immature Adipocytes and Biodegradable Scaffold for Tissue Augmentation - Provided is a technology involving differentiating preadipocytes, derived from human adipose tissues, into adipocytes and transplanting the differentiated adipocytes in conjunction with a biodegradable scaffold into the body. According to the present invention, when immature adipocytes having a cell diameter of 20 to 40 μm, obtained by differentiation of adipose tissue-derived preadipocytes into adipose tissues, are used in conjunction with a scaffold in autologous or allogeneic transplantation, maturation of adipocytes at the target transplantation site leads to a gradual increase in the volume of adipocytes. Therefore, the adipocyte-scaffold composition according to the present invention can be utilized as an effective body volume replacement and can treat various disorders due to defects of soft tissues or aesthetic defects in appearance. | 11-20-2008 |
| 20080286243 | Method For Isolation of a Hair Follicle Stem Cell and a Composition For Hair Reproduction - The present invention relates to a method for isolating hair follicle stem cells and a composition for inducing hair growth. More specifically, relates to a method for isolating hair follicle stem cells showing a positive immunological response to CD34, by chemically degrading hair follicle-containing scalp tissue and then culturing the degraded tissue in a serum-containing medium and a serum-free medium, as well as a composition for inducing hair growth, which contains, as an active ingredient, CD34-positive hair follicle stem cells isolated by the method. The hair follicle-derived stem cells, which are obtained according to the disclosed method, are classified as autologous adult stem cells, have self-renewal capability, the ability to differentiate into adult hair follicle cells and the ability to induce hair growth, and can be used as a novel cell therapeutic agent against hair loss. In addition, the present invention relates to a method for culturing hair follicle cells, which has high yield compared to that of the prior art, as well as a method for identifying hair follicle stem cells. | 11-20-2008 |
| 20080286244 | Bio-Artificial Materials with Tuneable Properties - This invention relates to methods for preparing biomaterials by applying multiple cycles of tensile loading to compacted collagen gels in order to fuse the collagen fibrils together within the compacted gels. This produces a biomaterial with improved material properties. Biomaterials produced by such methods may be useful, for example, as tissue equivalent implants, in the repair and/or replacement of damaged tissue in an individual. | 11-20-2008 |
| 20080286245 | PREPARATION OF REGULATORY T CELLS USING ICAM-1 CO-STIMULATION - A method for generating a purified regulatory T cell composition having a CD4 | 11-20-2008 |
| 20080286246 | Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient - Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases. | 11-20-2008 |
| 20080292597 | Umbilical Cord Stem Cell Composition & Method of Treating Neurological Diseases - A neurological disease is treated by administering to a patient a therapeutically effective amount of a composition including human umbilical cord stem cells. The composition may include growth factors mixed with the stem cells immediately prior to being administered. A specific pre and post transplantation protocol provides optimal methods for obtaining favorable clinical results. | 11-27-2008 |
| 20080292598 | CHIMERIC TRANSPLANT - Compositions comprising amniotic fluid stem cells which are derived from non-identical donor sources. Donors may be non-identical siblings, non-identical twins, and/or donors which are unrelated by a familial relationship. Also disclosed are methods for making such amniotic stem cell compositions, and methods for their use, such as therapeutic stem cell transplantation. | 11-27-2008 |
| 20080292599 | Chondrogenic Compositions and Methods of Use - The invention provides a method of treatment joint and disk disease comprising administering to the subject in need thereof a novel composition comprising a substantially purified plurality of cells enhanced with at least one bioactive factor capable of causing at least a portion of the plurality of cells to express an increased amount of at least one chondrogenic marker. | 11-27-2008 |
| 20080292600 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE - This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient. | 11-27-2008 |
| 20080292601 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH IL-10 EXPRESSING CELLS - This present application describes a therapeutic agent for treating acute or chronic graft-versus-host disease using clonal marrow stem cells (cMSCs) as active ingredient. | 11-27-2008 |
| 20080299086 | Cultured muscle cells with high metabolic activity and method for production of the cultured muscle cells - The object of the present invention is to provide a method of preparing excellent cultured muscle cells having high metabolic capacity and insulin responsiveness, and further provide a method for the measurement of sensitive metabolic capacity using the cells. Moreover, its purpose is to provide a culture system/culture apparatus that can smoothly translocate such highly advanced cultured muscle cells intact to activity evaluation systems of a number of drugs. Moreover, the object of the present invention is to provide cultured muscle cells that are very suitable for measurement of the membrane-translocation activity of GLUT4 in an extraneous stimulus-dependent manner such as insulin, etc., and to provide a method for the measurement of the membrane-translocation activity of GLUT4 using the cells. The present invention is a method of preparing myotube cells, comprising a step (1) of culturing myoblast cells, a step (2) of differentiation-inducing the myotube cells into the myoblast cells in a culture medium with a high content of amino acids, and a step (3) of applying an electric pulse to the differentiation-induced myotube cells, and a method for the measurement of insulin-dependent sugar uptake using the myotube cells prepared by said method, and relates to the method for the measurement, comprising applying insulin stimulation by culturing the cells in a culture medium containing insulin, culturing the cells in the culture medium further supplemented with sugar, and measuring the sugar uptake. Furthermore, the present invention relates to a differentiation-type culture myotube cell constitutively expressing a recombinant GLUT4 having a labeled substance at its extra-cellular site, which is prepared by co-culturing wild-type myoblast cells and recombinant myoblast cells constitutively expressing said recombinant GLUT4, and a method for the measurement of membrane-translocation activity of the recombinant GLUT4 using the cells, and particularly a method for the measurement of insulin-dependent sugar uptake activity. | 12-04-2008 |
| 20080299087 | Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition - Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases. | 12-04-2008 |
| 20080299088 | Uses of Notch Receptors, Notch Ligands, and Notch Modulators in Methods Related to Metabolic Diseases - Disclosed are methods for identifying and isolating a precursor cell. Also, disclosed are methods of increasing insulin synthesis from a pancreatic β-cell. Further, disclosed are methods of improving pancreatic β-cell function. Still further, disclosed are methods of preventing or delaying the onset of a metabolic disease, methods of treating or preventing a metabolic disease in a subject, and to compositions for treating or preventing a metabolic disease in a subject in need of such treatment or prevention. | 12-04-2008 |
| 20080299089 | ENDOGENEOUS REPAIR FACTOR PRODUCTION PROMOTERS - It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) 12 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) 12 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases. | 12-04-2008 |
| 20080299090 | Use Of Umbilical Cord Matrix Cells - The invention relates to the isolation and use of stem cells from amniote species (potentially any animal with an umbilical cord, including humans). More particularly the invention relates to obtaining stem cells that are at least multipotent and may be totipotent or nearly totipotent and are envisaged to have a variety of end uses. The cells of the present invention are immunosuppressive and may be used to inhibit the immune response in a subject. | 12-04-2008 |
| 20080299091 | Patient-specific stem cell lines derived from human parthenogenetic blastocysts - Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application. | 12-04-2008 |
| 20080299092 | Cosmetic preparation and method for preparing the same - The present invention relates to the use of dedifferentiated plant cells in cosmetic preparations for protecting of stem cells against intrinsic and extrinsic stress factors, in particular for promoting proliferation of stem cells and for protecting them against apoptosis. In particular, the invention relates to the use of dedifferentiated plant cells from fruits of | 12-04-2008 |
| 20080299093 | Premixed biological hydraulic cement paste composition and using the same - A premixed cement paste for use in medical or dental applications. The premixed cement paste remains fluid when stored in a hermetically sealed condition, but hydrates and hardens to set when placed in a physiological environment. The cement paste includes at least one calcium silicate compound and at least one substantially water-free liquid carrier mixed with the at least one calcium silicate compound; the substantially water-free liquid carrier avoids hydration of the mixture during storage, but undergoes exchange with aqueous physiological solutions so that the cement past hydrates and hardens to set when placed in a physiological environment. The paste may be placed in the physiological environment by injection, for example. The at least one calcium silicate compound may be, for example, calcium silicate, dicalcium silicate, tricalcium silicate, or mixtures thereof. The substantially water-free liquid may be, for example, ethylene glycol, polyethylene glycol, liquid glycerol, glycerin, ethyl alcohol, vegetable oil, animal oil, silicon oil, hydroxypropyl methylcellulose, or mixtures thereof. The substantially water-free liquid carrier preferably includes water in an amount less than about 20% by weight percent of the paste. The paste may include a secondary phase for enhanced properties, such as, for example, a fibrous or particulate material for enhanced mechanical properties, biodegradable or soluble materials that provide room for bone in-growth, bioactive materials such as antibiotics that elute into the physiological environment from the set cement, and radio-opaque materials that enhance X-ray imaging of the cement. | 12-04-2008 |
| 20080305085 | Compositions And Methods For Stem Cell Expansion - The present invention features methods and compositions that are useful for promoting stem cell survival and expansion. In addition, the invention also provides compositions and methods for the treatment of neoplasia. | 12-11-2008 |
| 20080305086 | HUMAN LATE STAGE MOTOR NEURON PROGENITOR CELLS AND METHODS OF MAKING AND USING SAME - Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of making and using the same, including deriving late stage MNP cells from pluripotent embryonic stem cells, producing high-purity populations of late stage MNP cells, producing populations of viable MNP cells, transporting viable MNP cells, and transplanting MNP cells. | 12-11-2008 |
| 20080305087 | Device and Method Using Integrated Neuronal Cells and an Electronic Device - The present invention provides a device of integrated neuronal cells interfaced with an electronic device and a method of producing the same. | 12-11-2008 |
| 20080311083 | Methods of Modulating Beta Cell Function - Methods of modulating pancreatic function by modulating MCH signaling in a β cell. | 12-18-2008 |
| 20080311084 | Mapc Engraftment in the Hematopoietic System - The present invention relates to MAPCs and progeny derived therefrom to provide lymphohematopoietic cells in a tissue of the lymphohematopoietic system of a subject. | 12-18-2008 |
| 20080311085 | Method for treating an animal having damaged tissue structure - A method for treating an animal having damaged tissue structure includes harvesting a tissue sample from a subject harvesting a tissue sample from the animal, growing tendon-like cells from the tissue sample, and transplanting the tendon-like cells into the damaged tissue structure. Growing the tendon-like cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that tendon-like cells contained therein divide and grow. | 12-18-2008 |
| 20080311086 | Use of Keratinocyte Composition for the Treatment of Restenosis - Methods for treating and/or preventing restenosis in a subject by local administration to the subject of a composition that includes keratinocytes is disclosed. Administration is preferably by way of a catheter having an inflatable balloon, such as a double or dumbbell-shaped balloon. | 12-18-2008 |
| 20080311087 | Human Umbilical Tissue-Derived Cell Compositions for the Treatment of Incontinence - Compositions for the treatment of incontinence are disclosed. More particularly, compositions of human umbilical tissue-derived cells and a carrier are disclosed. The compositions are useful in the treatment urinary and fecal incontinence. | 12-18-2008 |
| 20080311088 | Method of Treating Lung Diseases Using Cells Separated Or Proliferated From Umbilical Cord Blood - There is provided a method of treating lung diseases including administering cells separated or proliferated from umbilical cord blood to a patient suffering from such diseases. | 12-18-2008 |
| 20080311089 | Augmentation and Repair of Vocal Cord Tissue Defects - The present invention provides a method for corrective surgery in a human subject of a vocal cord defect being amenable to rectification by the augmentation of tissue subjacent to the vocal cord defect comprising the steps of:
| 12-18-2008 |
| 20080317718 | Cell Differentiation Of Adipose-Derived Precursors Cells - The present invention provides a simple method for controlled differentiation of adipose-derived precursor cells. A method is provided for preparing a differentiated cell. The method comprises A) obtaining a mixture by mixing a) an adipose-derived precursor cell and b) a differentiated cell corresponding to a desired site; and B) culturing the mixture under sufficient conditions which allow the adipose-derived precursor cell to differentiate. The present invention also provides a composition for cell implantation comprising a) an adipose-derived precursor cell and b) a differentiated cell corresponding to a desired site. | 12-25-2008 |
| 20080317719 | Regulating stem cells - A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least 5 million cells that have a density of less than 1.072 g/ml, and at least 1% of which are CD34+CD45−/dim, to differentiate into a progenitor/precursor cell population (PCP). A method is provided, including in vitro stimulating an initiating cell population (ICP) of at least ten thousand cells that have a density of less than 1.072 g/ml to differentiate into a progenitor/precursor cell population (PCP). A method is provided, including separating lower density cells from higher density cells, the lower density cells defining an initiating cell population (ICP), and in vitro stimulating the ICP to differentiate into a progenitor/precursor cell population (PCP). Other embodiments are also described. | 12-25-2008 |
| 20080317720 | Fat-Derived Progenitor Cell and Use Thereof - An objective of the present invention is to provide methods for producing progenitor cells which show a high proliferation ability ex vivo and promote neovascularization or myocardium regeneration, by culturing pluripotent cells in a medium containing adrenomedullin (AM) and/or vascular endothelial growth factor (VEGF). Moreover, another objective of the present invention is to provide the progenitor cells and uses thereof. In order to solve the above problems, the inventors of the present application have successfully developed a novel culture technique for producing progenitor cells from adipose tissues more efficiently compared to the conventional techniques, by using adrenomedullin (AM) and/or vascular endothelial growth factor (VEGF). The progenitor cells produced by the present inventors are specialized cells having a potent proliferation ability, a revascularization ability, and a myocardium regeneration ability, and have the property of not differentiating into adipocytes even if subjected to differentiation induction into adipocytes. Therefore, the progenitor cells of the present invention can be effective pharmaceutical agents for intractable diseases in the brain, lung, liver, kidney and the like. | 12-25-2008 |
| 20090004150 | Method for Expanding Postembryonic Stem and Progenitor Cells from Umbilical Cord Blood and Immunotherapeutic Agent - Method for obtaining and expanding postembryonic hematopoietic stem cells from umbilical cord blood while avoiding unwanted differentiation. Initial cells from umbilical cord blood are proliferated and multiplied ex vivo in a stroma-free medium and in the presence of a regio-modified glycan or glycosaminoglycan. The regio-modified glycan or glycosaminoglycan, e.g. a heparin derivative, is N-desulfated, and N-reacetylated or N-reacylated, in essence, on C2 atoms. The heparin derivative advantageously comprises less than 5 percent of C3-O-sulfate, at least 60 percent C2-O-sulfate, and it is preferably added in a quantity of 15 to 50 mg/L to the medium in order to stop an unwanted differentiation. The stem cells generated in this manner can differentiate, after expansion, into myeloma cells and lymphatic cells, and they can be used as an immunotherapeutic agent against many diseases. | 01-01-2009 |
| 20090004151 | Method of Three-Dimesionally Culturing Chondrocytes - It is intended to provide a method of three-dimensionally culturing normal joint chondrocytes; the production and supply of chondrocytes; and a transplantation material to be used in an injured site in a joint tissue. | 01-01-2009 |
| 20090004152 | METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy. | 01-01-2009 |
| 20090004154 | Method for treating a mammal having damaged pancreatic tissue - A method for treating a mammal having damaged pancreatic tissue includes harvesting a tissue sample from the mammal, growing pancreatic cells from the tissue sample, and transplanting the pancreatic cells into the damaged tissue. Growing the pancreatic cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that pancreatic cells contained therein divide and grow. | 01-01-2009 |
| 20090004155 | Method for treating a mammal having damaged myocardium tissue - A method for treating a mammal having damaged myocardium tissue includes harvesting a tissue sample from the mammal, growing myocardium cells from the tissue sample, and transplanting the myocardium cells into the damaged tissue. Growing the myocardium cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that myocardium cells contained therein divide and grow. | 01-01-2009 |
| 20090004156 | POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha17 GENE - The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFNα-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFNα-17 protein comprising at least one mutation caused by at least one SNP of the invention, as well as their therapeutic uses. | 01-01-2009 |
| 20090004157 | MATURE TYPE-1 POLARIZED DENDRITIC CELLS WITH ENHANCED IL-12 PRODUCTION AND METHODS OF SERUM-FREE PRODUCTION AND USE - The present invention discloses novel dendritic cell maturation-inducing cytokine cocktails, and methods for inducting type-1 polarized dendritic cells in serum-free conditions which enhance the desirable properties of DC1s generated in serum-supplemented cultures. The invention further discloses methods and systems using IFNγ and other ligands of the IFNγ receptor, in combination with IFNα (or other type I interferons), poly I:C, and other IFNα (and IFNβ) inducers to enhance the IL-12-producing properties of dendritic cells. More specifically, the present invention discloses type-1 polarized dendritic cells that have a unique combination of a fully-mature status and an elevated, instead of “exhausted”, ability to produce IL-12p70. allows for the generation of fully-mature DC1s in serum-free AIM-V medium. The invention discloses systems that use the foregoing products and methods to facilitate the clinical application of DC1-based vaccines and the identification of novel factors involved in the induction of Th1 and CTL responses by DC1. | 01-01-2009 |
| 20090004158 | Methods of controlling proliferation and differentiation of stem and progenitor cells - A method of ex-vivo expanding a population of stem cells, while at the same time inhibiting differentiation of the stem cells. The method comprises ex-vivo providing the stem cells with conditions for cell proliferation and with at least one copper chelator in an amount and for a time period for permitting the stem cells to proliferate and, at the same time, for reducing a capacity of the stem cells to differentiate | 01-01-2009 |
| 20090004159 | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells - Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes. | 01-01-2009 |
| 20090004160 | Mass Producing Method of Growth Factor Using Adipose Derived Adult Stem Cells - The present invention relates to a method for producing large amounts of human growth factors from human adipose-derived stem cells. More specifically, the invention provides a method capable of synthesizing human growth factors in significantly large amounts by culturing adipose-derived stem cells extracted from human adipose cells in suitable media and conditions. Also, stem cell culture media produced according to the method of the invention, and human growth factors isolated from the culture media, can be advantageously used as raw materials for drugs and cosmetics. | 01-01-2009 |
| 20090004161 | Methods for treating pustular conditions of the skin - The invention is directed to methods for treating pustular conditions of the skin, for example, acne. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 01-01-2009 |
| 20090010895 | Isolated cells and populations comprising same for the treatment of CNS diseases - An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype. | 01-08-2009 |
| 20090010896 | METHODS AND COMPOSITIONS FOR OPTIMIZED EXPANSION AND IMPLANTATION OF MESENCHYMAL STEM CELLS - Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. Autologous mesenchymal stem cells (MSCs) to a patient in need of MSCs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the patient's platelets. | 01-08-2009 |
| 20090010897 | Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction. | 01-08-2009 |
| 20090010898 | Method for treating a mammal having damaged articular cartilage tissue - A method for treating a mammal having damaged articular cartilage tissue includes harvesting a tissue sample from the mammal, growing articular cartilage cells from the tissue sample, and transplanting the articular cartilage cells into the damaged tissue. Growing the articular cartilage cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that articular cartilage cells contained therein divide and grow. | 01-08-2009 |
| 20090010899 | Methods related to surgery - The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 01-08-2009 |
| 20090016994 | Preparation of fibroblast-populated connective tissue substitute - Disclosed is a method for in vitro growing of connective tissue substitute, said connective tissue substitute being populated with fibroblasts, a connective tissue substitute obtainable by such a method, as well as a method for closing of a wound, wherein such connective tissue substitute is applied onto a wound. | 01-15-2009 |
| 20090016995 | Method of Treating Cognitive Decline and Synaptic Loss Related to Alzheimer's Disease - A method treating a subject with Alzheimer's disease wherein Aβ-reactive immune cells, splenocytes and lymphocytes, are generated in vitro or in vivo, re-stimulated in vitro, and then adoptively transferred into the cognitively-impaired subject. The population of immune cells can be derived from a donor with a natural or adaptive immune response to Aβ, stimulated by exposure to Aβ in vivo. The donor cells are then collected and re-stimulated by subsequent exposure to Aβ in vitro prior to administration to the subject. Alternatively, the population of immune cells can be derived from the subject and then stimulated by exposure to Aβ in vitro. | 01-15-2009 |
| 20090016997 | Autologous/allogeneic human DNA grafting, anti-and reverse aging stem cell, and bone marrow compositions/methods - Anti-aging compositions and methods for delivering (engrafting) younger compatible human DNA to tissues, through the systematic periodic introduction of younger primordial whole (nucleated) stem cells and bone marrow into a recipient, resulting in re-establishment of an earlier relative biological clock set-point, with respect to the number of cell generations-divisions are disclosed. | 01-15-2009 |
| 20090016998 | NOVEL METHOD OF PRENATAL ADMINISTRATION OF MAMMALIAN UMBILICAL CORD STEM CELLS FOR THE INTRAUTERINE TREATMENT OF MAMMALIAN LYSOSOMAL STORAGE DISEASES - A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord blood cells to a mother carrying a fetus of embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher's disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease. | 01-15-2009 |
| 20090016999 | Embryonic cell compositions for wound treatment - Compositions including formulations comprising stem cells, such as umbilical cord blood stem cells, or embryonic germ cell derivatives, or embryonic stem cells, are provided for enhancement of wound healing. Methods for using the compositions and formulations for enhancing would healing are also provided. Wounds to both soft and bony tissues are encompassed, and include wounds created by surgical procedures. | 01-15-2009 |
| 20090022692 | THERAPEUTIC AGENT FOR HEART DISEASE USING MAP KINASE TNNI3K - An object to be achieved by the present invention is to provide a therapeutic means for heart disease such as myocardial ischemia or myocardial infarction. The present invention provides a therapeutic agent for heart disease which comprises a myocardial progenitor cell expressing MAP kinase TNNI3K at a high level as an active ingredient. | 01-22-2009 |
| 20090022693 | METHOD FORISOLATING STEM CELLS FROM CRYOPRESERVED DENTAL TISSUE - The invention relates to a method for isolation of multipotent stem cells from dental tissue in which the stem cells are extracted from a tissue structure and then cultured. The invention also relates to stem cells isolated by means of the method according to the invention as well as bone cells and nerve cells produced by means of the method according to the invention. The invention also relates to a method for producing a bank of stem cells in which the cells are stored by means of the method according to the invention. According to the present invention, the cells of a pad-like soft tissue that can be localized beneath the papilla directly on the apical side of an extracted immature tooth are cryopreserved in the tissue structure such that the tissue structure is disintegrated to extract the stem cells only after thawing. These results show that stem cells/progenitor cells can be isolated even after cryopreservation of the source tissue and these stem cells/progenitor cells respond to osteogenic stimulation. In addition, the response of cells after cryopreservation turns out to be stronger than that without cryopreservation. | 01-22-2009 |
| 20090022694 | SIRT1 INHIBITION - A method of culturing cells in the presence of a SIRT1 inhibitor is described. | 01-22-2009 |
| 20090022695 | METHOD FOR EXPANSION OF TUMOUR-REACTIVE T-LYMPHOCYTES FOR IMMUNOTHERAPY OF PATIENTS WITH SPECIFIC CANCER TYPES - Methods for treating a patient suffering from a neoplastic disease are disclosed and described. A number of diseases can be treated under the present methods, including without limitation gall bladder cancer, hepato cellular cancer, ovarian cancer, small intestine cancer, lung cancer, mesothelioma, breast cancer, kidney cancer, pancreas cancer, prostate cancer, carcinoid cancer, leiomyosarcoma, or metastasis thereof. A general method for providing such treatment may include: 1) identifying in a patient one or more sentinel and/or metinel lymph nodes draining the neoplasm; 2) resecting the one or more nodes and, optionally all or part of the tumour or metastasis; 3) isolating tumour-reactive T-lymphocytes from said lymph nodes; 4) in vitro expanding said tumour-reactive T-lymphocytes; and 5) administering the thus obtained tumour-reactive T-lymphocytes to the patient. | 01-22-2009 |
| 20090022696 | METHODS FOR IMMORTALIZING CELLS - The present invention provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, said methods comprising culturing the precursor cells in the presence of a Notch agonist and one or more growth factors that support the proliferation but not differentiation of the non-terminally differentiated cells. The present invention further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a Notch agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type. The immortalized and/or differentiated cells of the invention can be used to repopulate cell populations that have been diminished, for example as a result of infection or exposure to certain drugs. The invention further provides a cell culture comprising a population of non-terminally differentiated cells immortalized by the methods of the present invention and kits comprising reagents that promote the immortalization of precursor cells. The invention further provides methods for screening for Notch modulators and for identifying genes involved in processes of cellular differentiation. | 01-22-2009 |
| 20090022697 | System for the Implantation of Cardiac Staminal Cells with the "Ciuro? Method" - The system is composed of two inseparable parts that both make up one Device: I) A container for collecting staminal cells and for their growth factors which is the same as the portcat system with sylicon button to enable the entrance of the Huber needle through a hole. | 01-22-2009 |
| 20090022698 | Composition For Treatment Of Articular Cartilage Damage - Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood. | 01-22-2009 |
| 20090028829 | Fusion proteins for the treatment of CNS - This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules. | 01-29-2009 |
| 20090028830 | Preparation of multipotent stem cells and the use thereof - The invention relates to a method for the enriched induction of multipotent stem cells, named P-stem cells, from CD14 | 01-29-2009 |
| 20090028831 | STEM CELL REGULATOR, COMPOSITIONS AND METHODS OF USE - The disclosure provides methods and compositions comprising Slit2 agonists and antagonists useful for modulating hematopoietic stem cell (HSC) proliferation and growth. In some aspects, the disclosure provides methods and compositions for stimulating HSC proliferation in vivo, ex vivo, or in vitro. In other aspects, the disclosure provides methods and compositions for inhibiting HSC proliferation. | 01-29-2009 |
| 20090028832 | Compositions and methods for targeted tumor therapy - The present invention relates to a method of treating a human patient having one or more tumor cells. In one embodiment, the method comprises the step of implanting at or around the site of one or more tumor cells in the patient a cell population comprising one or more prostate cancer cells characterized in that the one or more prostate cancer cells have the propensity of metastasizing to skeleton and soft tissues which represent one or more lethal phenotypes of human prostate cancer. | 01-29-2009 |
| 20090028833 | Proliferative Primary Human Sertoli Cell Cultures And Their Applications - Technology for the isolation and propagation of primary human Sertoli cells from normal testes tissue, including cultures of proliferative primary human Sertoli cells for research and clinical applications, and a pharmaceutical composition for cell therapy, ex vivo gene therapy, and for the reduction of autoimmune, allograft, and xenograft immune reactions. | 01-29-2009 |
| 20090028834 | Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance P or an analog thereof - Compositions and methods are provided for stimulating cell proliferation and differentiation with substance P or a substance P analog. In one embodiment, the methods provide for stimulating or promoting stem cell differentiation by contacting a stem cell with substance P or a substance P analog. In another embodiment, the methods provide for administering to subject an effective amount of substance P or a substance P analog to treat an illness, disease or disorder. | 01-29-2009 |
| 20090035281 | COMBINATION OF INTERLEUKIN-6 ANTAGONISTS AND ANTIPROLIFERATIVE DRUGS - The combination of an interleukin-6 (IL-6) antagonist and an antiproliferative drug is described. In its preferred embodiment, the present invention describes the combination of an IL-6 superantagonist, particularly a superantagonist totally incapable of binding gp130 and an antiproliferative drug belonging to the glucocorticoid class (SANT-7 and dexamethasone). The combination according to the present invention has shown surprising synergism in an animal model of multiple myeloma and the ability to overcome the resistance to the antiproliferative drug developed by myeloid cells. The combination according to the present invention is useful for the preparation of a medicament for the treatment of tumours, particularly IL-6-dependent tumours. | 02-05-2009 |
| 20090035282 | Pluripotent embryonic-like stem cells derived from teeth and uses thereof - A stem cell which is obtainable from the non-embryonic tissue isolated from the dental follicle of tooth or wisdom tooth which are able to differentiate into a periodontal ligament like membrane structure. | 02-05-2009 |
| 20090035283 | Composition and Method for Inhibition of Melanin Synthesis - The present invention provides a whitening cosmetic composition comprising a stem cell, a culture medium thereof or a protein isolated from the culture medium and a method of whitening a skin which comprises administering to the skin an therapeutically effective amount of a stem cell, a culture medium thereof or a protein isolated from the culture medium. | 02-05-2009 |
| 20090035284 | DERIVATION OF NEURAL STEM CELLS FROM EMBRYONIC STEM CELLS AND METHODS OF USE THEREOF - Provided is a method for the derivation of neural stem cells (NSCs) from embryonic stem cells (ESCs) and the use of the NSCs for treatment of various neural disorders. The NSCs that are derived from the ESCs are tissue-specific multipotent NSCs with a stable growth rate, unlimited self-renewal capacity, and a predictable differentiation profile. Being both non-tumorigenic and engraftable, the NSCs of the present invention have utility in repopulation stroke-damaged tissue. The NSCs of the present invention may be differentiated to produce tyrosine-hydroxylase expressing neurons, which may be used as a source of dopaminergic neurons for subjects suffering from a condition characterized by dopaminergic dysfunction, such as Parkinson's disease. | 02-05-2009 |
| 20090035285 | Compositions and Methods for Enrichment of Neural Stem Cells Using Ceramide Analogs - The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the β-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent human cells. The methods alternatively comprise modulating apoptosis by modifying the levels of PAR-4, with or without the presence of amphiphilic lipid compounds and optionally employing MEDII conditioned medium. The methods alternatively encompass modulating apoptosis by modulating the intracellular concentration of endogenous lipid second messengers, such as ceramide. | 02-05-2009 |
| 20090035286 | Intracoronary, intracardiac, or intravenous infusion of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium - The present invention is a method for improving cardiac function and myocardial regeneration in living subjects after the occurrence of myocardial infarction. The method is a combination stem cell therapy involving a mixture of bone marrow-derived mesenchymal stem cells and bone marrow derived mononuclear cells surgically implanted by using either a direct or catheter-mediated injection into damaged myocardium. Studies have shown that the implant improves heart function and myocardial regeneration and echocardiographic measurements. | 02-05-2009 |
| 20090041729 | Process for Decellularizing Soft-Tissue Engineered Medical Implants, and Decellularized Soft-Tissue Medical Implants Produced - The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and non-immunogenic. The inventive method allows for the production of multiple decellularized soft tissue implants, where processing time is significantly less than prior art processes and the number of implants produced per day is increased over prior art processes. In clinical use, the decellularized grafts produced exhibit significantly improved in long-term durability and function. | 02-12-2009 |
| 20090041730 | Joint Repair Using Mesenchymal Stem Cells - A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue. | 02-12-2009 |
| 20090041731 | Treatment for Diabetes - Methods and compositions for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin/CCK receptor ligand, e.g., a gastrin, and/or an epidermal growth factor (EGF) receptor ligand, e.g., TGF-α, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF-α gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin/CCK receptor ligand and an EGF receptor ligand. | 02-12-2009 |
| 20090041732 | Survivin Peptides As Cancer Vaccines - Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual. | 02-12-2009 |
| 20090041733 | METHODS FOR CELL MOBILIZATION USING IN VIVO TREATMENT WITH HYALURONAN (HA) - The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF. | 02-12-2009 |
| 20090047256 | Biodegradable Elastomers - The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers. | 02-19-2009 |
| 20090047257 | Novel cell populations and uses thereof - The invention provides, among other things, novel cell populations of CD133 | 02-19-2009 |
| 20090047258 | COMPOSITIONS AND METHODS FOR REVERSING AGE-RELATED CHANGES IN EXTRACELLULAR MATRIX PROTEINS - The invention is directed to compositions and methods for reversing age-related changes in extracellular matrix proteins, particularly the collagen framework of basement membranes of various organs. The invention has particular application to age-related changes that impair Retinal Pigment Epithelium (RPE) cell repopulation of human Bruch's membrane. | 02-19-2009 |
| 20090047259 | Methods of Using the Calcineurin A Variant CnA-beta 1 - The present invention relates to an inhibitor or activator of the calcineurin subunit Aβ1 isoform (CnAβ1) and the production of a medicament for the treatment of skeletal muscle injury or degeneration or cancer in a subject. CnAβ1 is constitutively active, cyclosporin-insensitive, highly expressed in proliferating myoblasts and human tumors, where it inhibits FoxO transcription factors independently of its phosphatase activity. The CnAβ1 isoform is a candidate for interventional strategies in muscle wasting, and a target for cancer treatment. | 02-19-2009 |
| 20090047260 | KERATIN BIOMATERIALS FOR CELL CULTURE AND METHODS OF USE - Provided herein are cell culture substrates and microcarriers that include a keratin, e.g., in porous particulate form. The substrate may be provided in or further includes a liquid carrier and/or viable cells. The keratin may be alpha kerateines, gamma kerateines, and combinations thereof, and may be in the form of a meta keratin. In some embodiments, the keratin is acidic or basic. Methods of administering cultured cells are also provided, including administering the cell culture substrates or microcarriers to a subject in need thereof. Kits are further provided, and may include a suitable container; a plurality of cell culture substrates or microcarriers as described herein packaged into said container; and optionally, instructions for use. | 02-19-2009 |
| 20090047261 | Composition For Treatment Of Articular Cartilage Damage - Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood. | 02-19-2009 |
| 20090053180 | Tandem cardiac pacemaker system - This invention provides pacemaker systems comprising (1) an electronic pacemaker, and (2) a biological pacemaker, wherein the biological pacemaker comprises a cell that functionally expresses a chimeric hyperpolarization-activated, cyclic nucleotide-gated (HCN) ion channel at a level effective to induce pacemaker current in the cell. The invention also provides related biological pacemakers, atrioventricular bridges, methods of making same, and methods of treating a subject afflicted with a cardiac rhythm disorder. | 02-26-2009 |
| 20090053181 | Modulation of Cells - The present invention is directed to methods which can be used to test agents for their ability | 02-26-2009 |
| 20090053182 | ENDOMETRIAL STEM CELLS AND METHODS OF MAKING AND USING SAME - The invention provides pluripotent stem cells and methods for making and using pluripotent stem cells. Pluripotent stem cells, among other things, can differentiate into various cell lineages in vitro, ex vivo and in vivo. Pluripotent stem cells, among other things, can also be used to produce conditioned medium. | 02-26-2009 |
| 20090053183 | Treatment of Diseases and Disorders Using Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 02-26-2009 |
| 20090060882 | Method Of Treating Mouse Carrying Human Hepatocytes - Human adult hepatocytes are transplanted into an immunodeficient hepatopathy mouse and then human growth hormone is administered to the mouse to thereby elevate twice or more the replacement ratio by the human adult hepatocytes having been transplanted. Further, human growth hormone is administered to an immunodeficient hepatopathy mouse carrying human young hepatocytes transplanted thereinto so as to improve fatty liver of the mouse in which about 70% or more of the hepatocytes have been replaced by the human hepatocytes. | 03-05-2009 |
| 20090060883 | COMPOSITION FOR PROMOTION OF BONE GROWTH AND MAINTENANCE OF BONE HEALTH - The present invention relates to a composition for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders. It also relates to the use of the composition in the manufacture of a nutritional product, a supplement, a treat or a medicament; and a method of promoting bone growth or for the maintenance of bone health, which comprises administering an effective amount of the composition. | 03-05-2009 |
| 20090060884 | CONCENTRATION OF STEM CELLS OBTAINED DURING ORTHOPAEDIC SURGERIES - Methods for isolating and concentrating bone marrow stromal cells drawn from various surgical sites (for example, the proximal humeral head during rotator cuff repair, or the distal femur during ACL surgery) during arthroscopic or open orthopaedic surgery. The pluripotent cells obtained from the bone marrow aspirate can then be reimplanted during the same surgery to improve healing. | 03-05-2009 |
| 20090060885 | Composition For Treatment of Articular Cartilage Damage - Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood. | 03-05-2009 |
| 20090060886 | TRANSLUMINAL APPLICATION OF ADULT STEM CELLS FOR BODY ORGAN TISSUE REPAIR - A method for repairing tissue of a selected organ from among heart, brain, liver, pancreas, kidney, glands, and muscles in a patient's body. Adult stem cells that have the capability to repair tissue of the selected organ are recovered by harvesting from the patient's body. The harvested stem cells are then intraluminally applied through a designated natural body vessel. During the time the stem cells are being applied to the targeted tissue downstream, the designated vessel or duct is selectively occluded to increase concentration and pressure of the applied adult stem cells by the vessel. | 03-05-2009 |
| 20090060887 | Method for treating the pancreas of a human patient - The invention involves a method for treating a pancreas of a human patient by rejuvenating and restoring function of such pancreas by the steps of locally inserting a growth factor, such as stem cells and germinal cells, into the body of the patient into or around the pancreas and thereby growing Islets of Langerhans in the pancreas and restoring insulin production. | 03-05-2009 |
| 20090068152 | GENE TRANSFER FOR REGULATING SMOOTH MUSCLE TONE - The invention provides methods of regulating smooth muscle tone in a subject, comprising the introduction, into smooth muscle cells of the subject, of a DNA sequence encoding a potassium channel protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth muscle cells of the subject to regulate smooth muscle tone in the subject. The invention provides methods of gene transfer for treating erectile dysfunction, bladder dysfunction, and other smooth muscle disorders. | 03-12-2009 |
| 20090068153 | CELL COMPOSITION FOR TISSUE REGENERATION - A method of extracting human progenitor cells from perivascular tissue of human umbilical cord. The extracted cells are then co-cultured with hematopoetic stem cells and are useful to grow and repair human tissues including bone. Also included are related methods and compositions related thereto. | 03-12-2009 |
| 20090068154 | Cell Composition for Transplant - The present invention provides a cell composition for transplant comprising fibroblasts originating in buccal fat pad. | 03-12-2009 |
| 20090068155 | METHODS, PHARMACEUTICAL COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ADMINISTERING THERAPEUTIC CELLS TO THE ANIMAL CENTRAL NERVOUS SYSTEM - Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury. | 03-12-2009 |
| 20090068156 | TREATMENT OF MUSCULAR DYSTROPHY WITH CORD BLOOD CELLS - The invention features methods for treating a patient suffering from muscular dystrophy by administration of umbilical cord blood cells, e.g., by IV infusion. | 03-12-2009 |
| 20090074727 | METHOD OF TREATING SOLID TUMOR - The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method. | 03-19-2009 |
| 20090074728 | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase - The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells. | 03-19-2009 |
| 20090074730 | NOVEL STEM CELLS, NUCLEOTIDE SEQUENCES AND PROTEINS THEREFROM - The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5− stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein. | 03-19-2009 |
| 20090074731 | METHOD OF ISOLATION AND USE OF CELLS DERIVED FROM FIRST TRIMESTER UMBILICAL CORD TISSUE - A method of isolating a pluripotent cell from human umbilical cord is described herein. The method involves collecting a sample of umbilical cord from fetal tissue obtained at less than 20 weeks of gestation, for example a first trimester umbilical cord. The sample is treated to obtain isolated umbilical cord cells, after which the isolated umbilical cord cells are incubated. Stem cells obtained in this way can be differentiated for use in therapeutic applications. | 03-19-2009 |
| 20090074732 | Scaffold for Cell Growth and Differentiation - The present invention provides a devitalized mammalian parenchymatous tissue composition which includes an interstitial structure which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue. | 03-19-2009 |
| 20090081168 | METHOD OF FORMING A PEPTIDE-RECEPTOR COMPLEX WITH ZSIG33 - The present invention relates to a method of forming a peptide-receptor complex with zsig33 polypeptides and their receptors as well as antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included. | 03-26-2009 |
| 20090081169 | METHOD FOR OSTEOGENIC DIFFERENTIATION OF BONE MARROW STEM CELLS (BMSC) AND USES THEREOF - Methods for obtaining osteoprogenitors, osteoblasts or osteoblast phenotype cells, as well as cell populations including such cells, from human bone marrow stem cells in vitro or ex vivo are disclosed. Bone marrow stem cells are contacted with human serum or plasma and a growth factor or a biologically active variant or derivative thereof. In addition, osteoprogenitor, osteoblast or osteoblast phenotype cell types and cell populations are provided. The cell populations may include additional cell types, such as endothelial cells or progenitors. The osteoprogenitors, osteoblasts or osteoblast phenotype cells may be used in therapy, particularly bone therapy. | 03-26-2009 |
| 20090081170 | Cardiac progenitor cells - The present invention relates to the field of progenitor cells, and in particular to the field of cardiac progenitor cells. More particularly, the present invention pertains to the identification of a population of progenitor cells in the adult mammalian heart that is capable of giving rise to significant levels of de novo cardiomyocytes with the potential to replenish injured muscle post-infarction and/or promote neovascularisation to bring about complete cardiac regeneration. Accordingly, the present invention relates to methods for generating a population of mammalian post-natal epicardium derived cells (EPDCs), populations of EPDCs so generated, and methods of using same. | 03-26-2009 |
| 20090087414 | Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs - Disclosed herein are materials and methods for modulating an immunologically adverse response to an exogenous or endogenous immunogen, including a cell, tissue, or organ associated immunogen. An implantable material comprising cells, such as but not limited to endothelial cells, anchored or embedded in a biocompatible matrix can modulate an adverse immune or inflammatory reaction to exogenous or endogenous immunogens, including response to non-syngeneic or syngeneic cells, tissues or organs, exogenous immunogens or stimuli, as well as ameliorate an autoimmune condition. The implantable material can be provided prior to, coincident with, or subsequent to occurrence of the immune response or inflammatory reaction. The implantable material can induce immunological acceptance in a transplant patient, reduce graft rejection and reduce donor antigen immunogenicity. | 04-02-2009 |
| 20090087415 | Treatment of cardiovascular disorders using the cell differentiation signaling protein Nell1 - It has been identified in accordance with the present invention that Nell1 is essential for normal cardiovascular development by promoting proper formation of the heart and blood vessels. The present invention therefore provides therapeutic methods for treating cardiovascular disorders by employing a Nell1 protein or nucleic acid molecule. | 04-02-2009 |
| 20090092586 | DIFFERENTIATION OF NON-EMBRYONIC STEM CELLS TO CELLS HAVING A PANCREATIC PHENOTYPE - The invention provides methods for differentiating non-embryonic multipotent stem cells along the pancreatic lineage. The present invention further provides non-embryonic multipotent stem cells and progeny derived therefrom to provide pancreatic cells to a subject. | 04-09-2009 |
| 20090092587 | LAMININS, DERIVATIVES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE - In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The method, in yet another embodiment, is used to prevent or reduce muscle damage or injury. In specific implementations of these methods, the laminin or composition that includes laminin is administered in a therapeutically effective amount. In some implementations, the laminin is a complete laminin protein. In other implementations, the laminin is a laminin fragment, a laminin derivative, or a laminin analogue. | 04-09-2009 |
| 20090098090 | VITRO IMMUNIZATION - The present invention relates generally to a method of generating lymphocytes specific for particular antigens. More particularly, the present invention provides a method for generating antigen-reactive T- cells and even more particularly cytotoxic (CD8+) T-cells in 10 vitro specific for antigens such as peptide antigens. The method of the present invention enables in vitro T-cell priming for particular antigens such as antigens on cancer cells, pathogenic cells, viruses or cells infected with viruses. The present invention is useful in identifying particularly immunogenic antigens for immunotherapy. Furthermore, as a consequence, the present invention is useful in avoiding the need for expensive and time 15 consuming clinical trials. The present invention further provides a method for the treatment or prophylaxis of a disease or condition in a subject by generating T-cells reactive to an antigenic molecule and administering an effective amount of antigen-reactive T-cells to the subject or other compatible host. Furthermore, the present invention permits the generation of dendritic cell/T-cell populations for use in cellular immunotherapy. | 04-16-2009 |
| 20090098091 | Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis - The present disclosure teaches analogs of human chemokines and methods of using them in the prevention, treatment, and ameliorization of diseases that can benefit from therapeutic angiogenesis. The teachings are generally directed to compositions comprising SDF-1 mimetics, as well as methods that include the use of SDF-1 mimetics to induce neo-vessel formation. The disclosure also teaches articles of manufacture that can be useful in practicing the methods taught herein. | 04-16-2009 |
| 20090098092 | Composite Bone Material and Method of Making and Using Same - Bone composite implants and the method of constructing bone composite implants are disclosed which may be used in the repair, replacement, and/or augmentation of various portions of animal or human skeletal systems. Furthermore, the bone composite implants of the present invention may be considered load-bearing implants which are incorporated into the skeletal structure of the patient. | 04-16-2009 |
| 20090098093 | GENERATION OF INNER EAR CELLS - Methods for generating cells of the inner ear, e.g., hair cells and supporting cells, from stem cells, e.g., mesenchymal stem cells, are provided, as well as compositions including the inner ear cells. Methods for the therapeutic use of the inner ear cells for the treatment of hearing loss are also described. | 04-16-2009 |
| 20090098094 | SKELETAL MUSCLE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass. | 04-16-2009 |
| 20090104158 | Non-Embryonic Totipotent Blastomere-Like Stem Cells And Methods Therefor - Non-embryonic blastomere-like totipotent stem cells are disclosed. Most preferably, such cells are obtained from various tissues of postnatal mammals (e.g., using tissue biopsied from the mammal), are smaller than 1 μm, have normal karyotype, and do not spontaneously differentiate in serum-free medium without differentiation inhibitors. These non-embryonic blastomere-like totipotent stem cells typically express CD66e, CEA-CAM-1 and telomerase, but do not typically express CD10, SSEA-1, SSEA-3, and SSEA-4. Such blastomere-like totipotent cells can be differentiated into ectodermal, mesodermal, or endodermal tissues, including placental tissues and germ cells. Moreover, when implanted into a mammal, such cells will not be teratogenic. | 04-23-2009 |
| 20090104159 | Vascular/Lymphatic Endothelial Cells - The present invention provides methods to culture and use vascular endothelial cells, including lymphatic, venous and arterial endothelial cells. | 04-23-2009 |
| 20090104160 | Mobilization of Stem Cells After Trauma and Methods Therefor - Methods are presented in which release of stem cells from skeletal muscle is quantitated and correlated with severity of a disease or trauma, a future treatment option, prognosis, and/or anticipated time to recovery. Most preferably, the stem cell is a BLSC and/or an ELSC, and the stem cell isolation for the cell count is performed using sedimentation or filtration as principal separation step, thereby avoiding commonly used complicated, expensive, and time-consuming processes such as antibody-based separation and fluorescence-activated cell sorting. | 04-23-2009 |
| 20090104161 | METHOD FOR ACTIVATION TREATMENT OF ANTIGEN-PRESENTING CELL - Activated antigen-presenting cells that can induce immunocytes including disease antigen-specific CD8+ CTLs and/or γδ T cells efficiently in vivo and/or in vitro, a medical composition comprising the activated antigen-presenting cells, a treatment and prevention method using the activated antigen-presenting cells, and an induction method of immunocytes including disease antigen-specific CTLs and/or γδ T cells induced using the activated antigen-presenting cell, immunocytes induced by the above-noted method, a medical composition comprising the immunocytes, and a treatment and prevention method using the immunocytes are provided. By co-pulsing antigen-presenting cells with bisphosphonate in addition to the pulse with a disease antigen, the ratio of disease antigen-specific CD8+ CTLs and/or γδ T cells and the number of the disease antigen-specific CD8+ CTLs and the γδ T cells can be increased, compared with the case where the co-pulse with bisphosphonate is not carried out. | 04-23-2009 |
| 20090104162 | Attenuated reoviruses for selection of cell populations - The present invention relates to methods for killing neoplastic cells, such as ras-activated cancerous cells, in vitro. In particular embodiments, an attenuated reovirus (e.g., a reovirus lacking a wild-type S1 gene) may be administered to a mixed cellular composition comprising cancerous cells and stem cells such as adult stem cells and/or hematopoietic stem cells; in these embodiments, the attenuated reovirus may result in killing of the cancerous cells with little or no damage to the healthy stem cells. | 04-23-2009 |
| 20090104163 | Immunomodulatory Properties of Multipotent Adult Progenitor Cells and Uses Thereof - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described. | 04-23-2009 |
| 20090104164 | ANGIOGENIC CELLS FROM HUMAN PLACENTAL PERFUSATE - Provided herein are the production of vasculogenic or angiogenic cells from placental perfusate. Also provided are methods of treating an individual having a cardiac or vascular insufficiency, disease, disorder or condition comprising administering to said individual placental perfusate, placental perfusate cells, or combinations of placental perfusate or perfusate cells with placental or non-placental hematopoietic stem cells or adherent placental stem cells. | 04-23-2009 |
| 20090110666 | Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours - The invention described herein refers to derivatives of the long pentraxin PTX3 with the sequence indicated in the text, capable of binding to the membranes of inactivated tumour cells. The inactivated tumour cells, bearing on their surface a derivative of PTX3 are used to prepare an autologous vaccine for the treatment of tumours. | 04-30-2009 |
| 20090110667 | DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS - Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing the involving a PD1 ligand. | 04-30-2009 |
| 20090110668 | SUBPOPULATIONS OF BONE MARROW-DERIVED ADHERENT STEM CELLS AND METHODS OF USE THEREFOR - The presently disclosed subject matter provides an isolated subpopulation of bone marrow-derived adherent stem cells that are purified from bone marrow-derived adherent cells. Also provided are methods for isolating the subpopulation of bone marrow-derived adherent stem cells from bone marrow-derived adherent cells and for using the isolated subpopulation of bone marrow-derived adherent stem cells for treating tissue and/or organ damage in a subject. | 04-30-2009 |
| 20090110669 | METHODS FOR IMPROVING CELL LINE ACTIVITY IN IMMUNOISOLATION DEVICES - Methods for maintaining and improving the secretory activity of cells housed in immunoisolation devices. | 04-30-2009 |
| 20090117083 | IMMUNOMODULATORY ALKALOIDS - Immunotherapy comprises administration of an alkaloid at a dose sufficient to induce IL-2 production in dendritic cells in a patient. The alkaloid induces the production of IL-2 in dendritic cells. The alkaloids need not be naturally occurring, and may be synthetic analogues or derivatives of naturally occurring counterparts. Such analogues or derivatives are preferably pharmaceutically acceptable analogues, salts, isomers or derivatives as herein defined. However, preferred alkaloids are phytochemicals. Such phytochemicals may be isolated from natural sources or synthesised in vitro. Particularly preferred are alkaloids is selected from piperidine alkaloids; pyrrolin alkaloids; pyrrolidine alkaloids; pyrolizidine alkaloids: indolizidine alkaloids and nortropane alkaloids. | 05-07-2009 |
| 20090117084 | BACTERIOPHAGE AND PROPHAGE PROTEINS IN CANCER GENE THERAPY - The present invention relates to the use of a polypeptide having a proliferation inhibitory activity or a cell death inducing activity on animal cells. The invention provides further means and methods to use said polypeptide and the corresponding nucleic acids sequence containing the coding regions of said polypeptide. The invention further relates to vectors expressing said polypeptide, to pharmaceutical compositions and therapeutic methods for treating proliferative disorders or diseases like cancer. Last but not least the invention provides a method for a gene therapeutic approach using said polypeptide having a proliferation inhibitory activity or a cell death inducing activity on animal cells. | 05-07-2009 |
| 20090117085 | MNTF DIFFERENTIATION AND GROWTH OF STEM CELLS - The present invention provides methods for inducing differentiation of an embryonic stem cell into a motor neuron using a motoneuronotrophic factor (MNTF) or its peptide analogues. The present invention further provides a method for isolating a population of stem cell derived motor neurons and a population of cells comprising the differentiated neural cells. Additionally, the present invention is directed to a method of enhancing the survival of the differentiated neural cells in long term cell cultures. Finally, the present invention provides compositions containing MNTF or its peptide analogs for therapeutic use in conjunction with stem cells. | 05-07-2009 |
| 20090117086 | Preparation of replicating macrophages and use in diagnosis and therapy - Provided are methods for replicating macrophages in vitro and cell culture compositions comprising replicating macrophages. Also provided are methods for preparing replicating Kupffer cells from human liver. Further provided are methods for enhancing or extending immune function in an individual suffering from a deficiency relating to a reduced number of functional macrophages in a tissue or organ by administering a therapeutically effective amount of a replicating macrophages obtained by the methods of the invention. | 05-07-2009 |
| 20090117087 | METHODS AND COMPOSITIONS FOR PRINTING BIOLOGICALLY COMPATIBLE NANOTUBE COMPOSITES OF AUTOLOGOUS TISSUE - A method of carrying out an autologous tissue implant in a subject in need thereof is carried out by: (a) forming an autologous tissue implant from autologous cells collected from a subject (e.g., by ink-jet printing, the autologous cells and the scaffold, separately or together), and then (b) implanting the autologous tissue implant in said subject. | 05-07-2009 |
| 20090117088 | CELLULAR INTERVENTION TO TREAT DAMAGED MYOCARDIUM - A system and method for treating damage myocardial tissue includes delivering replacement cells to the myocardium of a patient and electrically stimulating the spinal column of the patient to affect a cellular environment within the myocardium. | 05-07-2009 |
| 20090123430 | METHOD FOR DIFFERENTIATION OF STEM CELLS - A method for the differentiation of mammalian pluripotent stem (PS) cells into a mortal multi-lineage progenitor cell population is provided which comprises culturing the pluripotent stem cells in the presence of Hyaluronan (HA). The mortal multi-lineage progenitor cell population may be a population of mesenchymal stem cells. The mortal multi-lineage progenitor cell population may form cells of the mesodermal lineage, suitably osteoblasts. Alternatively, the mortal multi-lineage progenitor cell population may form cells of the endodermal lineage or of the ectodermal lineage, which may be neuronal progenitors. | 05-14-2009 |
| 20090123431 | CELL/LIGAND MARKING SYSTEM, WHEREIN THE MARKER IS OF EPH TYPE, CELL MATERIAL COMPRISING SAID SYSTEM, METHOD FOR PREPARING SAME AND PROANGIOGENETIC USE - A cell/ligand specific marking system, the system being characterized in that it comprises: (a) an endothelial precursor cell (EPC) including a cell marker selected from among the group consisting of the Eph (in particular EphB4 or EphB1), and (b) a protein material of structure L-K, which consists of a ligand (L) specific of the marker and is associated or fused with a binding protein (K), the system being capable of providing a proangiogenetic cell material of structure EPC-Eph-L-K. The invention also concerns the cell material as product capable of stimulating angiogenesis, its preparation method and its therapeutic use, in particular with respect to vascular insufficiencies. | 05-14-2009 |
| 20090123432 | Novel population of hepatocytes derived via definitive endoderm (DE-hep) from human blastocysts derived stem cells - The present invention relates to a novel hepatocyte-like cell progenitor and/or a novel hepatocyte-like cell derived via definitive endoderm from human blastocyst-derived stem (hBS) cells, to a method for the preparation of such cells and to the potential use of such cells in e.g. pharmaceutical drug discovery and development, toxicity testing, cell therapy and medical treatment. | 05-14-2009 |
| 20090123433 | Compositions Comprising Human Embryonic Stem Cells and their Derivatives, Methods of Use, and Methods of Preparation - The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells. | 05-14-2009 |
| 20090123434 | Cellular upregulation of VEGF receptor expression using nanofibrillar articles - The invention provides methods and systems for selectively upregulating the expression of a VEGF receptor in a cell using a synthetic nanofibrillar article. Exemplary embodiments relate to the upregulation of the VEGF receptor Flk-1 in endothelial cells. Cells having the selectively-upregulated VEGF receptor can be used in processes such as cell culturing, tissue engineering, cellular therapy, and drug discovery. | 05-14-2009 |
| 20090123435 | CULTURED THREE-DIMENSIONAL TISSUES AND USES THEREOF - The present disclosure provides compositions of three dimensional tissue that can be administered into tissues and organs using minimally invasive methods. The three dimensional tissues elaborate a repertoire of growth factors that facilitate repair or regeneration of damaged tissues and organs. | 05-14-2009 |
| 20090123436 | CRYOPRESERVATIVE COMPOSITIONS AND METHODS - The invention relates to compositions for the cryogenic storage of biological materials and related methods. In an embodiment, the invention includes a cryopreservative composition including a chaotropic agent and a kosmotropic agent. In an embodiment, the invention includes a cryopreservative composition including urea and trimethylamine-N-oxide. In an embodiment, the invention includes a method of cryopreserving cells including contacting cells with a cryopreservative composition, the cryopreservative composition comprising a chaotropic agent and a kosmotropic agent. In an embodiment, the invention includes a method of transplanting cells into a subject, the method including administering a composition to the subject, the composition comprising an effective amount of a chaotropic agent, an effective amount of a kosmotropic agent, and cells. Other embodiments are also included herein. | 05-14-2009 |
| 20090123437 | METHODS FOR COLLECTING AND USING PLACENTA CORD BLOOD STEM CELLS - An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing. | 05-14-2009 |
| 20090130064 | DIFFERENTIATION OF STEM CELLS AND STABILIZATION OF PHENOTYPICAL PROPERTIES OF PRIMARY CELLS - Methods of inducing differentiation of stem cells and stem cells obtained are disclosed. A method for stabilizing the phenotype of isolated primary cells in vitro is disclosed. In both methods, a central role is played by histone deacetylase inhibitors. | 05-21-2009 |
| 20090130065 | Multipotent adult stem cells - Isolated human multipotent adult stem cell and isolated populations of cells that include human multipotent adult stem cells are disclosed. Human hair-follicle derived multipotent adult stem cells and methods of preparing isolated populations of cells that include human multipotent adult stem cells are disclosed. Isolated human hair-follicle derived multipotent adult stem cell that can differentiate in culture into a neuronal cell, a glial cell, a melanocyte cell, a muscle cell, an osteocyte, a chondrocyte, and a lymphocyte. Isolated human hair-follicle derived multipotent adult stem cell that can grow in cell culture in spheres are disclosed. Human pancreas derived multipotent adult stem cells, human liver derived multipotent adult stem cells, human kidney derived multipotent adult stem cells, human heart derived multipotent adult stem cells, human neural derived multipotent adult stem cells and methods of preparing isolated populations of cells that include such human multipotent adult stem cells are disclosed. Method of treating an individual who has diabetes, cardiac muscle damage, muscle damage and disease, neurodegenerative disease or nerve damage or injury, bone loss, damage and/or disease, cartilage loss, damage and/or disease, hair loss and immune disorders, are disclosed. | 05-21-2009 |
| 20090130067 | Cell Population Having Immunoregulatory Activity, Method for Isolation and Uses - The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues. | 05-21-2009 |
| 20090130068 | Oral Tissue Regeneration and Repair - A method for treating an oral condition of a subject by grafting cultured tissue constructs to the oral tissue. The cultured tissue constructs comprise cultured cells and endogenously produced extracellular matrix components without the requirement of exogenous matrix components or network support or scaffold members. Some tissue constructs of the invention are comprised of multiple cell layers or more than one cell type. The tissue constructs of the invention have morphological features and functions similar to tissues their cells are derived and their strength makes them easily handleable. Preferred cultured tissue constructs of the invention comprise cells derived from human tissue. | 05-21-2009 |
| 20090136456 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS - The present invention provides a selected population of neural cells, including neural stem cells, neural progenitor cells, neural precursor cells, and progeny thereof, which neural cells are selected for an apoE4 | 05-28-2009 |
| 20090136457 | Methods of treating spinal cord injury and minimizing scarring - The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents. | 05-28-2009 |
| 20090136458 | Renal Carcinoma Cell Line and Uses thereof - The present invention relates to a renal carcinoma cell line capable of activating the immune system in an antigen-specific manner. According to a further aspect, the invention also includes derivatives of the cell line that maintain said activation capacity. The invention also comprises a method for targeting and activating immune system cells against cells of clear cell renal carcinoma. Said method comprises the co-incubation of isolated immune system cells (dendritic cells, CD4+, CD8+ lymphocytes etc.) with cells of the RCC BA85#21 line in accordance with the invention in a suitable culture medium, for a time sufficient to obtain antigen specific cells. | 05-28-2009 |
| 20090136459 | COMPOSITIONS FOR PREVENTING OR TREATING SKIN DEFECTS AND METHODS OF USE THEREOF - Described herein are compositions and methods that treat or prevent skin defects in a subject. | 05-28-2009 |
| 20090136460 | USE OF ADENOSINE RECEPTOR LIGANDS TO PROMOTE CELL ADHESION IN CELL-BASED THERAPIES - Intracoronary delivery of endothelial progenitor cells (EPCs) is an emerging concept for the treatment of cardiovascular disease, and enhancement of EPC adhesion to vascular endothelium should improve cell retention within targeted organs, as well as vascular development. The present inventors have shown that stimulation of adenosine receptors (AdoR) in murine embryonic EPCs (eEPCs) and cardiac endothelial cells (cECs) rapidly, within minutes, increased eEPC adhesion to cECs. eEPCs and cECs were found to predominantly express functional A | 05-28-2009 |
| 20090136461 | Neuronal differentiation method of adult stem cells using small molecules - The present invention relates to a neuronal differentiation method of adult stem cells using small molecules, more particularly to a method for inducing differentiation of adult stem cells into nerve cells using small molecules, which enables effective differentiation into nerve cells and, thus, is useful in treating intractable CNS disorders such as Parkinson's disease, dementia, Alzheimer's disease and spinal cord injury. | 05-28-2009 |
| 20090136462 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES - The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules. | 05-28-2009 |
| 20090136463 | Schwann Cell Bridge Implants and Phosphodiesterase Inhibitors to Stimulate CNS Nerve Regeneration - The use of a composition that elevates intracellular levels of cyclic nucleotide cyclases in combination with phosphodiesterase inhibitors and cell grafts to restore function after CNS injury. | 05-28-2009 |
| 20090142305 | PEGYLATED FIBRINOGEN-BASED BIOMATRIX - The invention involves methods and materials related to fibrin-based biomatrices. | 06-04-2009 |
| 20090142306 | METHODS AND SYSTEMS FOR TREATING ISCHEMIC TISSUES - Methods and systems for regenerating damaged tissue rely on direct injection of selected therapeutic cells into a tissue at or near the site of tissue damage. Direct injection is accomplished using an intravascular catheter having a deployable needle, and injection is usually targeted into the adventitial and peri-adventitial tissues surrounding the blood vessel from which the needle is deployed. | 06-04-2009 |
| 20090142307 | Shape-Based Approach for Scaffoldless Tissue Engineering - Methods for forming tissue engineered constructs without the use of scaffolds and associated methods of use in tissue replacement. One example of a method may comprise providing a shaped hydrogel negative mold; seeding the mold with cells; allowing the cells to self-assemble in the mold to form a tissue engineered construct. | 06-04-2009 |
| 20090142308 | Methods for treating autoimmune disease by inducing autoantigen-specific regulatory CD4+ T cells - Described herein are methods and compositions for the treatment and monitoring the progress of autoimmune diseases. In some embodiments, the methods include the stimulation of regulatory T cells specific to autoantigens associated with the autoimmune disease. A specific embodiment relates to diabetes mellitus, and the prevention or delay of loss of residual β-cell mass, providing a longer remission period and delaying the onset of diabetes related, progressive, complications through immunotherapeutic induction of regulatory T cells specific for human insulin B chain. In addition, the methods described herein can be used to predict whether a subject, e.g., a subject with ongoing anti-insulin autoimmunity, will progress to T1DM, and to evaluate a subject's response to a therapeutic intervention. | 06-04-2009 |
| 20090142309 | Hydroxyphenyl cross-linked macromolecular network and applications thereof - A dihydroxyphenyl cross-linked macromolecular network is provided that is useful in artificial tissue and tissue engineering applications, particularly to provide a synthetic macromolecular network for a wide variety of tissue types. In particular, artificial or synthetic cartilage, vocal cord material, vitreous material, soft tissue material and mitral valve material are described. In an embodiment, the network is composed of tyramine-substituted and cross-linked hyaluronan molecules, wherein cross-linking is achieved via peroxidase-mediated dityramine-linkages that can be performed in vivo. The dityramine bonds provide a stable, coherent hyaluronan-based hydrogel with desired physical properties. | 06-04-2009 |
| 20090142310 | METHOD OF TREATING INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDES - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. | 06-04-2009 |
| 20090142311 | ENGINEERED INTERVERTEBRAL DISC TISSUE - Surgically implantable tissue engineered intervertebral disc tissues that effectively replicate the physicochemical properties of the corresponding in vivo tissues are provided. Methods for producing such tissues can involve culturing the intervertebral disc cells to produce cells surrounded by an extracellular matrix and culturing the cells and matrix on a semipermeable membrane to form a cohesive tissue. | 06-04-2009 |
| 20090148415 | Treatment for Chronic Myocardial Infarct - A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF). | 06-11-2009 |
| 20090148416 | ANGIOGENICALLY INDUCED TRANSPLANTS AND METHODS FOR THEIR USE AND MANUFACTURE - Angiogenically induced transplants and methods for their use and manufacture are disclosed. The angiogenic potential of the transplants is increased by contacting the transplants with donor mesenchymal cells such as hair follicle dermal papilla stem cells. Methods for treating disorders and diseases, such as disorders of the skin and angiopathies, are also disclosed. | 06-11-2009 |
| 20090148417 | CARBON NANOTUBES SERVING AS STEM CELL SCAFFOLD - The present invention relates to a scaffold for transplanting a stem cell comprising a carbon nanotube without cytotoxicity, and a composition for stem cell therapy comprising (a) a stem cell; and (b) a carbon nanotube serving as a stem cell scaffold without cytotoxicity. The scaffold for transplanting stem cells comprising carbon nanotubes show excellent effects without cytotoxicity on networking between differentiated stem cells and tissues present in transplantation sites, thereby showing significant cell therapy efficacy. | 06-11-2009 |
| 20090148418 | Skeletal Site-Specific Characterization of Orofacial and Illiac Crest Human Bone Marrow Stromal Cells in Same Individuals - The present invention relates to methods and compositions useful for the detection, enrichment, and use of orofacial-derived bone marrow stromal cells. In one aspect, the invention relates to the use of characteristics specific to orofacial-derived bone marrow stromal cells to distinguish orofacial-derived bone marrow stromal cells from other cells. | 06-11-2009 |
| 20090148419 | USE OF ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASE - The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation. | 06-11-2009 |
| 20090148420 | STEM CELLS - Stem cells obtained through in vitro culture with heparan sulphate are described. | 06-11-2009 |
| 20090148421 | COMPOSITIONS COMPRISING VASCULAR AND MYOCYTE PROGENITOR CELLS AND METHODS OF THEIR USE - The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed. | 06-11-2009 |
| 20090148422 | METHODS OF PROLIFERATING STEM CELLS - The invention relates to methods of proliferating stem cells. More particularly, the invention relates to the use of glycosaminoglycans or proteoglycans to promote the growth of stem cells in ex vivo culture, while preserving their multipotentiality. | 06-11-2009 |
| 20090148423 | ENDOTHELIAL PROGENITOR CELLS AND METHODS OF USE THEREOF - Endothelial progenitor cells immunoreactive for VEGFR-2 or Tie-2, and CD45 are provided. Optionally the cell is immunoreactive with CD14. The cells are capable of differentiating in vivo into an endothelial cell or a smooth muscle cells. The cultures integrate well after transplantation into adult vasculature. | 06-11-2009 |
| 20090155218 | COMPOSITIONS AND METHODS FOR GROWTH OF EMBRYONIC STEM CELLS - The present invention relates to methods, compositions, and kits for maintenance of the undifferentiated state and/or pluripotency in stem cells, including embryonic stem (ES) cells. It also relates to stem cells that have been maintained in an undifferentiated state. The present invention provides these aspects using culture medium enriched with a TGFβ family member protein, an FGF family member protein, and/or nicotinamide, without using fibroblast feeder layers, conditioned media, or leukemia inhibitory factor. | 06-18-2009 |
| 20090155219 | METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-GFRA1 ANTIBODIES - The present invention relates to the use of cytoxicity based on the effector function of anti-GFRA1 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-GFRA1 antibody as an active ingredient for damaging GFRA1-expressing cells using antibody effector function. Since GFRA1 is strongly expressed in breast, gastric, liver, renal or lung cancer cells, the present invention is useful in breast, gastric, liver, renal or lung cancer therapies. | 06-18-2009 |
| 20090155220 | Use of Bone-Marrow Derived Stem Cells to Treat Ischemia - Disclosed are cellular compositions and methods for preventing, treating or reducing the severity of tissue ischemia, particularly limb ischemia in a mammal. One inventive method includes administering a therapeutically effective amount of a cellular composition comprising a novel isolated multi-potent human bone marrow-derived stem cell (BMSC) having undetectable or negligible levels of markers of other known stem cells isolated from bone marrow. These cells can be expanded in vitro and formulated into cellular compositions and grafts capable of differentiating into components of functional new blood vessels when directly administered into ischemic limb tissue. | 06-18-2009 |
| 20090155221 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. | 06-18-2009 |
| 20090155222 | CELL CULTURE - There is provided a method of retarding differentiation of a biological cell, the method comprising culturing the cell in the presence of an inhibitor of E-cadherin activity. The method is particularly advantageous in retarding the differentiation of stem or progenitor cells, and allows suspension culture of such cells in a manner that enables large scale expansion of cell populations. There is also provided a stem or progenitor cell comprising a construct encoding an inhibitor of E-cadherin activity; and a cell culture medium, for use in the retardation of biological cell differentiation, comprising an inhibitor of E-cadherin activity. | 06-18-2009 |
| 20090155223 | CELL-BASED COMPOSITIONS AND METHODS FOR TREATING CONDITIONS OF THE NERVOUS SYSTEM - Disclosed herein are cell-based compositions for the treatment of conditions of the nervous system and methods for their use. In one embodiment, a cell-based composition comprises glial-restricted progenitors (GRPs) genetically modified to express a targeting ligand on their cell surface. Methods for the preparation of such cell-based compositions are disclosed. Also disclosed is a method for treating a subject suffering from a condition of the central nervous system by providing therapeutic cells (e.g., GRPs) through an intra-arterial route of administration. | 06-18-2009 |
| 20090155224 | Dimethyl amino ethyl ether psoralens and methods for their production and use - Water-soluble dimethyl amino ethyl ether psoralens useful in the treatment of proliferative skin disorders, microbial infections and diseases, disorders of the blood and bone marrow of mammals and in microbiocidal compositions for sterilization of blood and blood products and surgical implants and inhibition of microbial growth in industrial applications are provided. | 06-18-2009 |
| 20090155225 | USES AND ISOLATION OF VERY SMALL OF EMBRYONIC-LIKE (VSEL) STEM CELLS - The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject. | 06-18-2009 |
| 20090155226 | Regenerative Dot cells - Methods and compositions are provided for the isolation, culture and use of highly regenerative somatic mammalian cells. The cells are very small, and have an undefined nuclear structure. The cells may be isolated from fetal or adult tissues, and are found in tissue including, without limitation, fetal dermal tissue, blood, and bone marrow. The cells are characterized as expressing one or more markers selected from E-cadherin, integrin β1, CXCR4, CD90 and CD34, and may be selected on the basis of such expression patterns. | 06-18-2009 |
| 20090155227 | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease - Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according to the results of the echo-cardiogram or clinical status of the patient. Heart disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy. | 06-18-2009 |
| 20090155228 | COMPOUNDS, KITS AND METHODS FOR CONFERRING CYTOPROTECTION - hABCG2, a member of the ATP-Binding Cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells, and variably regulated during cell differentiation. It is demonstrated herein that functional ABCG2 is expressed in human monocyte-derived dendritic cells by the activation of a nuclear hormone receptor, PPARg. The present results uncovered a mechanism by which up-regulation of functional ABCG2 expression can be achieved via exogenous or endogenous activation of the lipid activated transcription factor, PPARg. Thus the invention relates to combined treatments by PPARg agonists and cytotoxic drugs transportable by ABCG2, various treatments in the field of neoplastic diseases as well as cell therapy, including autologous cell therapy, as well as kits and composition therefor. Method for protecting cells against cytotoxic drugs are also provided. | 06-18-2009 |
| 20090162325 | CELL IMPLANTATION TO PREVENT AND/OR TREAT AUTOIMMUNE DISEASE - The present invention is directed to the prevention or treatment of autoimmune diseases, and in particular, of type I diabetes, by administering a therapeutically effective amount of an implantable composition comprising living choroid plexus cells. | 06-25-2009 |
| 20090162326 | METHOD FOR ISOLATING STEM CELLS AND STEM CELLS DERIVED FROM A PAD-LIKE TISSUE OF TEETH - The invention relates to a method for isolating non-embryonic stem cells from a tissue that is located in immediate vicinity of immature, developing teeth or wisdom teeth. The invention further relates to non-embryonic stem cells derived from said tissue. The method according to the invention utilises a living soft tissue residing underneath the dental papilla 12 in immediate vicinity of the apical side of a developing tooth, which is clearly distinguished from other tooth tissue, such as dental papilla 12 or follicle. The pad-like tissue 16 can only be detected in a defined, specific developmental stage in an early phase of root formation. That is, identifying and separating the pad-like tissue 16 is only possible from the appearance of the bony alveolar fundus to the end of the formation of the root of the tooth. | 06-25-2009 |
| 20090162327 | BONE MARROW TRANSPLANTATION FOR TREATMENT OF STROKE - There is provided a treatment for patients suffering from neurodegenerative disease or neural injury including the steps of transplanting cultured bone marrow cells into the spinal cord or brain or injecting intravascularly bone marrow cells of a patient in need. Also provided is a method of activating the differentiation of neural cells in an injured brain including the steps of transplanting bone marrow cells adjacent to the injured brain cells and activating the endogenous central nervous system stem cells to differentiate into neurons. A method of treating injured brain or spinal cord cells is also provided including the steps of transplanting bone marrow cells near the injured brain cells and generating new neurons at the location of transplantation. A method of treating injured brain or spinal cord cells with a composite of MSCs and neurospheres. | 06-25-2009 |
| 20090162328 | IN VIVO ASSAY AND MOLECULAR MARKERS FOR TESTING THE PHENOTYPIC STABILITY OF CELL POPULATIONS AND SELECTED CELL POPULATIONS FOR AUTOLOGOUS TRANSPLANTATION - An in vivo assay to measure anchorage-independent growth and phenotypic stability of a certain cell population comprising subcutaneous or intramuscular injection in a mammal of a cell suspension of articular chondrocytes in an iso-osmotic liquid, the same suspension comprising articular chondrocytes in an amount equivalent to at least 1×10 | 06-25-2009 |
| 20090162329 | COMPOSITIONS COMPRISING HDAC INHIBITORS AND METHODS OF THEIR USE IN RESTORING STEM CELL FUNCTION AND PREVENTING HEART FAILURE - The invention provides compositions of histone deacetylase (HDAC) inhibitors and progenitor cells useful for treating heart failure in a subject. The invention also provides methods of restoring progenitor cell function to aged progenitor cells and methods for enhancing progenitor cell proliferation and/or differentiation using HDAC inhibitors. | 06-25-2009 |
| 20090162330 | Method of Isolating Human Neuroepithelial Precursor Cells from Human Fetal Tissue - A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided. | 06-25-2009 |
| 20090169520 | Compounds, Pharmaceutical Compositions and Therapeutic Methods of Preventing and Treating Diseases and Disorders Associated With Amyloid Fibril Formation - Compounds, pharmaceutical compositions and methods for prevention and/or reversal of amyloid fibril formation and treating amyloid-related disorders are provided. Also provided a method of limiting and/or reducing inflammation. | 07-02-2009 |
| 20090169521 | Vascularized cardiac tissue and methods of producing and using same - An isolated composition of matter is disclosed. The composition comprises a heterogeneous population of cells seeded on a scaffold, wherein the heterogeneous population of cells comprises cardiomyocytes, endothelial cells and fibroblast cells. Pharmaceutical compositions comprising same and uses thereof are also disclosed. | 07-02-2009 |
| 20090169522 | MESENCHYMAL STEM CELLS EXPRESSING TNF-A RECEPTOR - Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 | 07-02-2009 |
| 20090169523 | HSC SELF-RENEWAL - The invention is related to methods for culturing stem cells, more particularly hematopoietic stem cells (HSC). The invention relates to methods for HSC expansion and the use of RASSF8 to increase the retention and/or expansion of KLS cells in vitro. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of disorders or diseases (e.g. leukemia). The invention also relates to the development of small molecules that may increase HSC self renewal in vitro and in vivo. | 07-02-2009 |
| 20090169524 | COMPOSITES AND METHODS OF PREPARATION AND USE THEREOF - The invention provides composites, methods for their preparation, composites prepared according to the methods, and methods for using the composites. | 07-02-2009 |
| 20090169525 | METHODS OF REDUCING TRANSPLANT REJECTION AND CARDIAC ALLOGRAFT VASCULOPATHY BY IMPLANTING AUTOLOGOUS STEM CELLS - The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used. | 07-02-2009 |
| 20090169526 | BMP-6 ESTROGEN RESPONSIVE ELEMENT AND METHODS OF USE THEREOF - This invention is directed to a BMP-6 ERE nucleic acid sequence, vectors, cells and compositions comprising same. This invention also provides methods for identification of estrogen agonists, antagonists and therapeutic applications of same. This invention also provides methods of treating conditions, which are associated with estrogen insufficiency or with lack of response to external estrogen or agonists thereof utilizing sequences, vectors, cells and/or compositions described herein. | 07-02-2009 |
| 20090169527 | MATERIALS FROM BONE MARROW STROMAL CELLS FOR USE IN FORMING BLOOD VESSELS AND PRODUCING ANGIOGENIC AND TROPHIC FACTORS - A therapeutic for use in inducing angiogenesis and vasculogenesis, the therapeutic including angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharmaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of angiogenesis and vasculogenesis inducing factors. Angiogenesis and vasculogenesis inducing factors isolated and purified from stem cells for use in a therapy. A process for obtaining the angiogenesis and vasculogenesis inducing factors as set forth above, the process including the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture expanding the mesenchymal stem cells to produce a tool for neurological and musculoskeletal therapy. Isolated and culture expanded mesenchymal stem cells under the influence of a requisite compound, that are capable of differentiating and producing a desired cell phenotype needed for tissue repair. | 07-02-2009 |
| 20090169528 | KERATINOCYTES EXPRESSING EXOGENOUS ANGIOGENIC GROWTH FACTORS - The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1 or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue. | 07-02-2009 |
| 20090175832 | Isolated Embryonic-Like Stem Cells Derived From Human Umbilical Cord Blood - The present invention is related generally to embryonic-like stem cells isolated from human umbilical cord blood, designated herein as cord blood-stem cells (CB-SC's), which display the characteristics of embryonic stem cells and hematopoietic cells. These cells have the capability of proliferation and are able to differentiate to multiple types of cells. In addition, the CB-SC display low immunogenicity and immune regulation. These cells are, therefore, suitable for use in stem cell-based therapies for the treatment of diseases such as Parkinson's disease, diabetes, spinal cord damage, multiple sclerosis, cardiovascular disease, stroke and birth defects, and for preventing, treating and/or reducing an autoimmune disease in a mammalian subject. | 07-09-2009 |
| 20090175833 | PERICYTES FOR USE AS STEM CELLS - A method of promoting perictye differentiation by selectively culturing pericytes in an enriched environment containing a promoter specific to a type of differentiation. Isolated and purified multipotent pericytes or pericyte precursors are provided. A stem cell therapy replacement comprising isolated and purified multipotent pericytes. A treatment of disease comprising an effective amount of isolated and purified multipotent pericytes or pericyte precursors is provided. | 07-09-2009 |
| 20090175834 | NEURONAL PROGENITOR CELLS AND METHODS OF DERIVATION AND PURIFICATION OF NEURONAL PROGENITOR CELLS FROM EMBRYONIC STEM CELLS - The invention provides neuronal progenitor cells, populations and cultures of cells, cell compositions and methods of producing neuronal progenitor cells. Neuronal progenitor cells can be prepared from embryonic stem cells, such as human embryonic stem cells. | 07-09-2009 |
| 20090175835 | COMPOSITION FOR TREATING DAMAGE OF CENTRAL OR PERIPHERAL NERVE SYSTEM - The present invention provides a composition for treating damage of central or peripheral nerve system comprising neural precursor cell derived from subcutaneous tissue; neuron obtained by differentiating the neural precursor cell; or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell; a use of neural precursor cell derived from subcutaneous tissue, neuron obtained by differentiating the neural precursor cell, or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell, for the manufacture of an agent for treating damage of central or peripheral nerve system; a method for treating damage of central or peripheral nerve system which comprises administrating to a mammal a therapeutically effective amount of neural precursor cell derived from subcutaneous tissue, neurons obtained by differentiating the neural precursor cell, or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell. Further, the present invention provides a method of preparing the neural precursor cell, neurons, oligodendrocyte or Schwann cell of the present invention. | 07-09-2009 |
| 20090175836 | PRELAMIN A PRE PEPTIDE AS A UNIVERSAL STEM CELL DIFFERENTIATION SIGNAL - Disclosed is the use of prelamin A pre peptide and homologues or analogs thereof for the induction of cell differentiation and tissue or organ growth and repair processes. The invention extends to virtually any cell, including both embryonic and non-embryonic stem cells, such as stem cells that are progenitors for a wide variety of cell and tissue types. Also disclosed is the use of prelamin A pre peptide and prelamin A to determine and establish cell morphology and tissue architecture. Treatment of a variety of diseases and conditions, as well as cosmetic, general health, and anti-aging applications are described. | 07-09-2009 |
| 20090186004 | Method For Preparing An Organ For Transplantation - The present invention provides a method for preparing an organ, particularly a kidney, for transplantation into mammals. In detail, the present invention provides a method for preparing autotransplantation of autologous organs, particularly a kidney, wherein the isolated autologous mesenchymal stem cells are transplanted into an embryo inside a pregnant mammalian host or into an embryo dissected from a pregnant mammalian host at a desired site to induce differentiation, which is then transplanted into the individual. | 07-23-2009 |
| 20090186005 | Methods and Compositions For Treating Motor Neuron Diseases Comprising Mesenchymal Stem Cells - Disclosed herein are a composition for treating motor neuron diseases, particularly amyotrophic lateral sclerosis (ALS), using mesenchymal stem cells, and a method for treating motor neuron diseases using the composition. The composition and treatment method can provide effective therapy for motor neuron diseases, particularly for amyotrophic lateral sclerosis (ALS). | 07-23-2009 |
| 20090186006 | PLACENTAL VASCULAR LOBULE STEM CELLS - The present invention provides isolated populations of stem and progenitor cells from fetal vascular lobules of the placenta. The isolated populations of stem and progenitor cells of the invention express the markers CD144, CD105, and/or CD31 and lack expression of the hematopoietic-lineage marker CD45. Under specific conditions, cells of the invention may function as endothelial precursors and may provide therapeutic preparations, for example, in the treatment of ischemia. | 07-23-2009 |
| 20090191159 | Multipotent/pluripotent cells and methods - Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods. | 07-30-2009 |
| 20090191160 | Methods of producing pluripotent stem-like cells - The instant invention provides methods and compositions for the production and use of pluripotent stem-like cells from somatic cells, e.g., fibroblasts. | 07-30-2009 |
| 20090191161 | TENOCYTE CELL CULTURING METHOD - The present invention relates to a method for culturing tenocytes. In particular the present invention relates to a method for culturing tenocytes comprising the step of incubating tenocytes in a culture medium comprising insulin or functional derivative. | 07-30-2009 |
| 20090191162 | Catecholamine Receptor Modulation - The invention relates to receptors of catecholamines and their role in stem cell development and function. | 07-30-2009 |
| 20090191163 | Primed tissue for tissue engineering and methods of priming tissue - Provided is a composition comprising a primed engineered tissue construct, methods of making the composition, methods of using the composition in dermatologic surgery, and a kit for supplying surgical tissue graft components. | 07-30-2009 |
| 20090191164 | HUMAN HEMATOPOIETIC MULTIPOTENT PROGENITOR CELLS - A substantially enriched human multipotent progenitor cell population is provided, which is characterized as a progenitor cell capable of giving rise to the multipotent lineage but which lacks certain long-term self-renewal properties of the hematopoietic stem cell. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD34, CD38, CD90 and CD45RA, in conjunction with lineage specific markers. These cells give rise to all types of hematopoietic cells, e.g. myeloid and lymphoid cells, in vivo. | 07-30-2009 |
| 20090191165 | FIBRIN GLUE COMPOSITION FOR REPAIRING NERVE DAMAGE AND METHODS THEREOF - A fibrin glue composition is for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve which includes fibrin glue and an amount of bone marrow stem cells (BMSCs) effective for repairing the nerve damage and/or enhancing at least partially the functional recovery. A method is also for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve in a subject which includes topically applying to the damaged nerve the fibrin glue composition of the invention. | 07-30-2009 |
| 20090191166 | SCREENING AND THERAPY FOR LYMPHATIC DISORDERS INVOLVING THE FLT4 RECEPTOR TYROSINE KINASE (VEGFR-3) - The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects. | 07-30-2009 |
| 20090191167 | ADULT SERTOLI CELLS AND USES THEREOF - The invention relates, in part, to non-neonatal Sertoli cells derived from non-rodent animals, pharmaceutical compositions comprising such Sertoli cells, and uses thereof. The non-neonatal, non-rodent Sertoli cells express more FasL than neonatal Sertoli cells, and they provide greater immunoprivilege than neonatal Sertoli cells. In some embodiments the Sertoli cells are modified to express a biological factor. In other embodiments, the pharmaceutical compositions further comprise non-Sertoli cells. The invention also provides implantation devices comprising the pharmaceutical compositions, methods of making the pharmaceutical compositions, and methods of using the pharmaceutical compositions by administering an effective amount of the compositions. | 07-30-2009 |
| 20090191168 | Pregnancy-Induced Oligodendrocyte Precursor Cell Proliferation Regulated by Prolactin - The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent. | 07-30-2009 |
| 20090196855 | Artificial "arterio-venous" permeable hollow fiber capillary system - An artificial “arterio-venous” permeable hollow fiber capillary membrane system for wound treatment is described, that can be placed onto a wound, under the wound dressing, to enable fluid-/mass exchange, and thus enables pH- and electrolyte regulation, the supply of factors/mediators/medications, the removal of secretion- and/or waste material, and the support of therapeutically applied cells in the wound. | 08-06-2009 |
| 20090196856 | Method for Generating Dendritic Cells Employing Decreased Temperature - The invention relates in certain embodiments to a method for generating dendritic cells by employing temperatures below 37° C. during the development of progenitor cells and immature dendritic cells. In some embodiments the invention relates to populations of dendritic cells and its use. | 08-06-2009 |
| 20090196857 | Kidney-Derived Stem Cell Population, Identification and Therapeutic Use - A novel population of kidney-derived cells is described that exhibits surface co-expression of CD133 and CD24 markers; said cells possess stem cell capacity and are capable of undergoing tubulogenic, adipogenic, osteogenic and neurogenic differentiation. | 08-06-2009 |
| 20090196858 | AMELIORATING AGENT FOR BRAIN DAMAGE - The present invention provides a pharmaceutical composition for ameliorating brain damage induced by oxygen deficiency, comprising a chondroitin sulfate-degrading enzyme and at least one of a neural stem cell(s) and a neural progenitor cell(s), as active ingredients. | 08-06-2009 |
| 20090196859 | Oligodendrocyte Precursor Cell Composition and Methods of Use - The present invention provides a cell culture enriched for sphingolipid enhances neural stem cells (SENSe), particularly oligodendrocyte precursor cells (ODPCs), that do not form teratomas after transplanted in vivo. Methods for producing and use of the invention ODPCs or the cell culture enriched with these ODPCs for stem cell therapy are also provided. The invention method comprises culturing a stem cell culture with a cell culture medium comprising a ceramide compound and a S1P receptor agonist in sequence, overlapping intervals or concurrent manners. The present invention further provides a cellular or gene therapy using a composition comprising a ceramide compound in conjunction with a S1P | 08-06-2009 |
| 20090202494 | Combined use of glp-1 agonists and gastrin for regulating blood glucose levels - The invention relates generally to novel compositions and methods comprising a gastrin compound. The compositions and methods provide beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in particular sustained beneficial effects, in the treatment of diabetes. | 08-13-2009 |
| 20090202495 | Hyaluronic Acid Derivative and Neural Stem Cells for SCI and PNT Regeneration - A biomaterial for the treatment of spinal cord or of peripheral nerve injury injury, obtainable by: a) treating a hyaluronic acid derivative with a coating solution promoting Neuronal Stem Cells adhesion, branching and differentiation; b) contacting isolated Neuronal Stem Cells with the hyaluronic acid derivative obtained from step a) and culturing and expanding the absorbed cells in the presence of growth or neurotrophic factors selected from βFGF (basic fibroblast growth factor), CNTF (ciliary neurotrophic factor), BDNF (brain derived neurotrophic factor) and GDNF (glial derived neurotrophic factor) or mixtures thereof. | 08-13-2009 |
| 20090202496 | METHOD FOR REGENERATING AN IMMUNE SYSTEM - An isolated and purified cell line of hematopoeitic stem cells (HSC) that are incapable of expressing the CCR5 receptor on the cell surface (“the CCR5Δ32 cells” are used to regenerate the immune system in a subject in need thereof and especially to treat a subject infected with human immunodeficiency virus (HIV). The method is carried out by transplanting CCR5Δ32 into the recipient subject. Because mature immune cells derived from CCR5Δ32 cells cannot express functional CCR5 receptors, they will be resistant to infection by HIV and other pathogens that use the CCR5 receptor to infect cells. An embodiment of the invention includes administration of a nutritional regimen to the patient that optimizes conditions for CCR5Δ32 cell transplantation. Another embodiment of the invention includes co-transplanting mesenchymal cells along with the HSC in order to enhance the growth and development of the transplanted HSC. | 08-13-2009 |
| 20090202497 | USE OF GLP-1, GLP-1 DERIVATIVES OR GLP-1 FRAGMENTS FOR SKIN REGENERATION, STIMULATION OF HAIR GROWTH, OR TREATMENT OF DIABETES - The present invention relates to the use of GLP-I, GLP-I derivatives or GLP-I fragments for skin regeneration or hair growth in mammals. As used for skin regeneration, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to dermal wounds including burns, lacerations, cuts and scrapes. As used for hair growth, GLP-I, GLP-I derivatives or GLP-I fragments can be applied to humans suffering from alopecia, or baldness. GLP-I, GLP-I derivatives or GLP-I fragments can also be used to stimulate hair growth in animals raised for their pelts. GLP-I, GLP-I derivatives or GLP-I fragments can also be used in the redifferentiation of endothelial or skin cells into insulin producing cells, as a treatment for patients suffering from diabetes. | 08-13-2009 |
| 20090202498 | DIRECT DIFFERENTIATION OF CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS - The present invention relates to the induction of differentiation in stem cells to cardiomyocytes and factors such as prostaglandin alone or in combination with other factors including essential minerals selected from the group including transferrin and selenium, small molecules selected from the group including a p38 MAPK inhibitor such as SB203580 and protein growth factors of the FGF, IGF and BMP families such as but not limited to IGF1, FGF2, BMP2, BMP4 and BMP6. and insulin that influence the process of differentiation to cardiomyocytes. Media that is appropriate for the induction of differentiation of cardiomyocytes from stem cells is also provided wherein the media contains these factors. The use of cardiomyocytes and cardiac progenitors produced by the directed differentiation in transplantation and screening for cardiac compounds is also provided. | 08-13-2009 |
| 20090202499 | Human Telomerase Reverse Transcriptase Peptides - Tumor antigens can be categorized as tumor type specific or common. Telomerase reverse transcriptase (TRT) is the first bona fide common tumor antigen. While several 9mer peptides of the human TRT (hTRT) have been identified for HLA-A2, the most prevalent (˜50%) HLA type in humans, little information exists on peptides for the remaining HLA types. As described herein, a multi-step approach was taken to select and characterize a panel of HLA-B79mer peptides as candidate immunogens. Specifically, several of algorithm based predictions, in vivo immunization of HLA-B7 transgenic mice, in vitro immunization of human blood lymphocytes, in vivo processing and supertype binding were employed to identify HLA-B7-restricted epitopes in hTRT. A correlation between in vivo immunogenicity and actual HLA-B7 binding avidity was found for the seven predicted peptides. Furthermore, endogenous processing was found to correlate with in vitro immunogenicity in human PBMC and HLA-B7 supertype binding. | 08-13-2009 |
| 20090202500 | Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues - The present inventors revealed the following for the first time in the world:
| 08-13-2009 |
| 20090202501 | Chimeric NK receptor and methods for treating cancer - The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are further provided. | 08-13-2009 |
| 20090208462 | Methods of Treatment - The invention concerns the use of a nucleic acid encoding a photoactivator in the manufacture of a medicament for inducing photosensitivity in neuronal cells. In particular, the invention concerns the induction of photosensitivity in retinal ganglion cells (RGCs) for restoring sight and/or alleviating blindness in an individual. The invention further concerns vectors, cells and pharmaceutical compositions therefor. | 08-20-2009 |
| 20090208463 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting wound healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 08-20-2009 |
| 20090208464 | MESENCHYMAL STEM CELL ISOLATION AND TRANSPLANTATION METHOD AND SYSTEM TO BE USED IN A CLINICAL SETTING - A system and method for the percutaneous, autologous transplantation of mesenchymal stem cells and progenitor helper cells (PHC) from bone marrow to degenerated intervertebral discs or joints. This method is designed to be used by operating room staff in a clinical setting to isolate a mesenchymal stem cell population and PHC during the same surgical procedure as transplantation. The method can be used as a two step procedure where cells are harvested, then isolated, then reimplanted at a later time. In addition, experimental techniques are described to determine which bone marrow cells should be removed via negative selection to generate a PHC population most likely to regenerate certain tissue types in-vitro as well as which combination of fibrinogen and hyaluronic acid and which degree of gel maceration provides the best matrix for in-vitro and in-vivo regeneration of joints and intervertebral discs. | 08-20-2009 |
| 20090208465 | METHOD OF TREATING NEURAL DEFECTS - The present invention provides a therapeutic agent for a nerve injury and a method for treating a nerve injury. One aspect of the invention is the method for treating a nerve injury by administering to a patient with a nerve injury a therapeutic agent for a nerve injury containing a differentiated cell-derived pluripotent cell obtained by forced expression of reprogramming genes such as a combination of the Oct3/4 gene, Sox2 gene, Klf4, and c-myc gene. in a differentiated cell; or cells obtained by inducing the aforementioned differentiated cell-derived pluripotent cells to differentiate into an embryoid body or a neurosphere. | 08-20-2009 |
| 20090208466 | INK-JET PRINTING OF TISSUES - A method of forming an array of viable cells is carried out by ink-jet printing a cellular composition containing said cells on a substrate. At least two different types of viable mammalian cells are printed on the substrate, the at least two different types of viable mammalian cells selected to together form a tissue. In some embodiments at least three or four different viable mammalian cells are printed on the substrate, the cells selected to together form a tissue. In some embodiments one of the viable mammalian cell types is a stem cell. In some embodiments the method further comprises printing at least one support compound on the substrate, the support compound selected to form a tissue together with said cells. In some embodiments the method further comprises printing at least one growth factor on the substrate, the growth factor selected to cause the cells to form a tissue. | 08-20-2009 |
| 20090208467 | P27 AND P21 IN GENE THERAPIES - The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p21 | 08-20-2009 |
| 20090208468 | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to, an autoimmune disease, by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. Also disclosed are methods of suppressing an immune response in a subject by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide. | 08-20-2009 |
| 20090214480 | Novel cancer antigen peptide and the use thereof - Novel peptides useful as a therapeutic and/or prophylactic agent of cancers, as well as medical uses thereof, are described. Each of these peptides have a consecutive amino acid sequence within a specific region of YKL-40 antigen expressing on the cell surface of brain tumor cells, that is, within the region aa10-19, aa49-61, aa74-83, aa96-117, aa152-161, aa177-185, aa202-211, aa246-261 or aa326-354, which peptide has an immunity-inducing activity. These peptides are useful for therapy and/or prevention of cancers when administered to a living body, and are useful for inducing T cells which exert cytotoxic activity against cancer cells when used to stimulate the T cells in vitro. | 08-27-2009 |
| 20090214481 | TREATMENT OF ISCHEMIA USING STEM CELLS - The invention features a method for treating or preventing ischemia in a mammal by administering unrestricted somatic stem cells (USSCs) to the mammal. | 08-27-2009 |
| 20090214482 | Transgenic Mammals Expressing Human Preproinsulin - Transgenic mammals which express human preproinsulin, methods and reagents for producing the transgenic mammals, and therapeutic methods of providing patients with insulin and C-peptide using tissues and cells from the transgenic mammals. | 08-27-2009 |
| 20090214483 | Progenitor Cells and Uses Thereof - Methods for preparing progenitor cells are described where epithelial cells are induced to undergo epithelial-mesenchymal transition as a result of exposure to an inducing agent or introduction of a gene therein that induces epithelial-mesenchymal transition. Progenitor cells resulting therefrom have use in cell-based therapies, among other utilities. | 08-27-2009 |
| 20090214484 | STEM CELL THERAPY FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS - The invention provides a method for treating CNS disorders by administering a neural stem cell composition and a mesenchymal stem cell composition on opposing sides of the blood brain barrier. The neural stem cell composition is administered to the central nervous system, while the mesenchymal stem cell composition is administered to the circulatory system, such as by intravenous injection. The method finds use in the treatment of degenerative GNS disorders, as well as traumatic CNS disorders such as stroke and spinal cord injury. | 08-27-2009 |
| 20090214485 | STEM CELL THERAPY FOR THE TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC OPTIC NEUROPATHY - The invention comprises methods and stem cell compositions for the treatment of diabetic retinopathy and other degenerative diseases of the eye. The invention is practiced in two stages with the first stage comprising the administration of neural stem cells to the eye, and the second stage comprising the administration of mesenchymal cells intravenously. | 08-27-2009 |
| 20090214486 | Serum Response Factor and Myocardin Control Alzheimer Cerebral Amyloid Angiopathy - Cerebral amyloid angiopathy is involved in Alzheimer dementia through reduction in arterial blood flow that may impair protein synthesis, which is required for learning and memory, and lower the threshold for ischemic injury. Elevated serum response factor (SRF) or myocardin (MYOCD) activity in subjects afflicted by or at risk for development of Alzheimer's disease (AD) promotes a “vascular smooth muscle cell” (VSMC) hypercontractile phenotype in brain arteries and enhance accumulation of Aβ in the vessel wall. This, in turn, can initiate a disease process in cerebral arteries which can cause brain arterial hypoperfusion and neurovascular uncoupling, that are commonly seen in AD. Thus, SRF and MYOCD represent novel targets for treating arterial dysfunction associated with cognitive decline in AD. | 08-27-2009 |
| 20090214487 | USE OF MESENCHYMAL STEM CELLS FOR TREATING GENETIC DISEASES AND DISORDERS - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 08-27-2009 |
| 20090214488 | METHODS AND COMPOSITIONS FOR TREATING BASEMENT MEMBRANE DISORDERS - The invention features methods and compositions for the treatment of basement membrane diseases and disorders, such as Alport's syndrome. | 08-27-2009 |
| 20090214489 | PEPTIDES AND COMPOUNDS THAT BIND TO A RECEPTOR - Described are peptides and peptide mimetics that bind to and activate the thrombopoietin receptor. Such peptides and peptide mimetics are useful in methods for treating hematological disorders and particularly, thrombocytopenia resulting from chemotherapy, radiation therapy, or bone marrow transfusions as well as in diagnostic methods employing labeled peptides and peptide mimetics. | 08-27-2009 |
| 20090214490 | HUMAN EMBRYONIC STEM CELL METHODS AND PODXL EXPRESSION - A method of identifying an undifferentiated human embryonic stem cell in a sample which may contain such cells, the method comprising identifying the cell or cells within the sample that express podocalyxin-like protein (PODXL) on their surface. A method of isolating an undifferentiated human embryonic stem cell from a sample containing such cells, the method comprising isolating the cell or cells within the sample that express PODXL on their surface. Typically, the methods use an antibody which binds to PODXL. Undifferentiated human embryonic stem cells isolated by the method may be useful in cell therapy. Also, in particular, compositions of cells differentiated from a human embryonic stem cell but which composition has been depleted of undifferentiated human embryonic stem cells are provided which are useful in cell therapy. | 08-27-2009 |
| 20090214491 | Method Of Using Mitotically Inactivated Stem Cells For Damaged Tissue Repair - The present invention is directed to the use of mitotically and/or lethally inactivated stem cells for the repair of damaged organs and/or tissues. Stem cells are mitotically and/or lethally inactivated and transplanted into damaged tissue. Any form of ex vivo inactivation of stem cells may be used such that the stem cells cannot undergo mitosis or cell division before in vivo application. Mitotically and/or lethally inactivated stem may be used to ameliorate numerous disease, injury, traumatic, ischemic, aging, and/or degenerative conditions in different types of organs and/or tissues. | 08-27-2009 |
| 20090214492 | ISOLATED STROMAL CELLS FOR USE IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM - Methods of treating a human patient having a disease, disorder or condition of the central nervous system are disclosed. The methods include obtaining a bone marrow sample from a human donor, isolating stromal cells from the bone marrow sample, and administering the isolated stromal cells to the central nervous system of the human patient, wherein the presence of the isolated stromal cells in the brain effects treatment of the disease, disorder or condition. Stromal cells which are isolated may be cultured in vitro, they may be genetically engineered to produce therapeutic compounds, and/or they may be pre-differentiated prior to administration into the central nervous system. | 08-27-2009 |
| 20090214493 | Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectable or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 08-27-2009 |
| 20090220461 | Metastasis inhibition preparations and methods - Disclosed are compositions and pharmaceutical preparations suitable for inhibiting metastasis of a malignant cancer in an animal. Methods for inhibiting and/or eliminating metastasis in an animal are also provided. In some embodiments, the preparations and compositions comprise a whole cell tumor preparation comprising tumor tissue cells and tumor connective tissue stroma. The disclosure also provides methods for preparing the preparations and pharmaceutical preparations. Inhibition of metastasis of malignant prostate cancer to the lung is shown in vivo. | 09-03-2009 |
| 20090220462 | STEM CELLS - The present invention relates, in general, to stem cells and, in particular, to a method of expanding stem cells by inhibiting aldehyde dehydrogenase (ALDH). The invention further relates to methods of identifying compounds suitable for use in effecting expansion of stem cells. | 09-03-2009 |
| 20090220463 | Pharmaceutical Composition For Treating Vascular-Related Diseases Comprising Peptide - Disclosed is a composition for treating vascular diseases by acting on abnormal angiogenesis by means of secretion of angiopoietins. | 09-03-2009 |
| 20090220464 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 09-03-2009 |
| 20090220465 | METHODS AND COMPOSITIONS FOR MODULATION OF STEM CELL AGING - Methods are described for promoting or maintaining self-renewal of a stem cell expressing or expected to express p16 | 09-03-2009 |
| 20090220466 | VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS AND METHODS OF ISOLATING AND USING THE SAME - The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject. | 09-03-2009 |
| 20090232771 | Method of controlling cell functions - The present invention provides methods of screening genes associated with cell regeneration, growth and differentiation and regulators for cell regeneration, growth or differentiation; regulators for cell regeneration, growth or differentiation; and so on. More specifically, the present invention provides methods of screening genes associated with cell regeneration, growth and differentiation, which comprises the step of quantitatively analyzing expression levels of multiple genes collectively in a cell having a regeneration, differentiation or growth capability to thereby identify the genes associated with the regeneration, growth or differentiation of the cell; methods of screening genes associated with cell regeneration, growth and differentiation, which comprises the step of quantitatively analyzing expression levels of multiple genes collectively in a cell having a regeneration, differentiation or growth capability to thereby identify one or more genes that show higher expression levels in the cell or are specific in expression as compared to the other cells; and, the step of contacting at least one candidate substance capable of regulating the functions of the identified genes or their gene products with the cell and comparing changes before and after the contact; and so on. | 09-17-2009 |
| 20090232772 | HUMAN CORNEAL ENDOTHELIAL CELL-DERIVED PRECURSOR CELLS, CELLULAR AGGREGATES, METHODS FOR MANUFACTURING THE SAME, AND METHODS FOR TRANSPLANTING PRECURSOR CELLS AND CELLULAR AGGREGATES - Providing is cellular aggregates derived from corneal endothelial cells that, when transplanted, readily adhere to the parenchyma of cornea and function in a manner equivalent to corneal endothelial cells, and a method of transplantation of the cellular aggregates. Cellular aggregates derived from corneal endothelial cells. The cellular aggregates derived from corneal endothelial cells is prepared by culturing human corneal endothelial cells in a medium containing fetal bovine serum, growth factor and glucose; and then float culturing the cells obtained in a medium containing growth factor. A method of transplantation into the anterior chamber the cellular aggregate or the cellular aggregate prepared by the above method, comprising inserting a tube into the parenchyma of cornea, introducing the cellular aggregate into the anterior chamber through the inserted tube, and causing the cellular aggregate that has been introduced to adhere to Descemet's membrane by assuming in a downward-facing position. | 09-17-2009 |
| 20090232773 | Method for Distinguishing Mesenchymal Stem Cell Using Molecular Marker and Use Thereof - Disclosed is a method for distinguishing a mesenchymal stem cell comprising, using at least one gene selected from the genes having the nucleotide sequences indicated by the accession numbers shown in Table 1 as a distinguish marker, detecting the difference in expression of the distinguish marker between a mesenchymal stem cell and a connective tissue cell to distinguish the mesenchymal stem cell from the connective tissue cell. This method enables to distinguish an undifferentiated mesenchymal stem cell from other connective tissue cell such as fibroblasts, osteoblasts, chondrocytes and adipose cells with good accuracy. A mesenchymal stem cell given by this method or a composition comprising the mesenchymal stem sell can be used as a therapeutic for use in the regenerative medicine. | 09-17-2009 |
| 20090232774 | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance - The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject | 09-17-2009 |
| 20090232775 | Compounds and methods for increasing neurogenesis - The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis modulating agents. Novel methods for treating neurological disorders using neurogenesis modulating agents are disclosed. | 09-17-2009 |
| 20090232776 | USE OF IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION - Methods of treating, preventing or managing endothelial dysfunction and other disorders are disclosed. The methods encompass the administration of an immunomodulatory compound provided herein. Further described are methods of treatment using the immunomodulatory compounds in combination with a second active agent. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed. | 09-17-2009 |
| 20090232777 | Expansion and Differentiation of Mesenchymal Stem Cells - A cell culture system for expanding and differentiating mammalian mesenchymal stem cells to chondrocytes is provided. Said cell culture system comprises a subpopulation of isolated MSC selected for their expression of integrin alpha 10, as well as additives promoting expansion and differentiation to chondrocytes. Methods and uses of said expanded and differentiated cells with a chondrogen phenotype are also provided, as well as compositions comprising said expanded and differentiated chondrocyte cells. | 09-17-2009 |
| 20090232778 | Methods and Compositions for Hair Growth - Methods and compositions for identifying and isolating dermal papilla cells are described. DP cells can be identified based on corin expression. Isolated DP cells can be used, e.g., to modulate hair growth. | 09-17-2009 |
| 20090232779 | OLIGODENDROCYTES DERIVED FROM HUMAN EMBRYONIC STEM CELLS FOR REMYELINATION AND TREATMENT OF SPINAL CORD INJURY - This invention provides populations of neural cells bearing markers of glial cells, such as oligodendrocytes and their precursors. The populations are generated by differentiating pluripotent stem cells such as human embryonic stem cells under conditions that promote enrichment of cells with the desired phenotype or functional capability. Various combinations of differentiation factors and mitogens can be used to produce cell populations bearing markers of oligodendrocyte precursor cells. Upon further differentiation form complex processes characteristic of mature oligodendrocytes. The cells are capable of forming myelin sheaths, and can be used therapeutically improve function of the central nervous system. | 09-17-2009 |
| 20090232780 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION - This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation. | 09-17-2009 |
| 20090232781 | Treatment of liver diseases through transplantation of human umbilical mesenchymal stem cells - A method for treating liver diseases or liver damage, including but not limited to liver fibrosis, and/or aiding recovery from liver diseases, including but not limited to liver fibrosis, or liver damage in a subject, includes transplanting human umbilical mesenchymal stem cells (HUMSCs) obtained from Wharton's Jelly to the area of liver disease or damage of the subject. | 09-17-2009 |
| 20090232782 | Method for treating brain ischemic injury through transplantation of human umbilical mesenchymal stem cells - A method for treating or preventing an ischemic brain injury or neurological damage due to ischemia in a subject includes transplanting a therapeutically effective amount of human umbilical mesenchymal stem cells (HUMSCs) obtained from Wharton's Jelly to the ischemic areas of the brain injury or the neurological damage of the subject. Recovery from neurological behavior deficits also is improved according by the method. | 09-17-2009 |
| 20090232783 | Method for Regulating Production of Hemoglobin Beta Chains - A method is described for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell utilizing a ferritin-H protein, a vector encoding ferritin-H, or an exogenous ferritin-H inducer. | 09-17-2009 |
| 20090238798 | Nucleotide Sequences Encoding Insecticidal Proteins - The present invention provides nucleotide sequences encoding an insecticidal protein exhibiting lepidopteran inhibitory activity, as well as a novel insecticidal protein referred to herein as a Cry1A.105 insecticide, transgenic plants expressing the insecticide, and methods for detecting the presence of the nucleotide sequences or the insecticide in a biological sample. | 09-24-2009 |
| 20090238799 | Conditionally-Immortalised Pancreatic Cells - Conditionally immortalized pancreatic cells are produced which remain immortal in the presence of 4-hydroxytamoxifen (4-OHT) but express normal pancreatic cell markers when 4-OHT is not present. The cells therefore permit cell lines to be constructed to produce cells useful for transplantation or in screening assays. | 09-24-2009 |
| 20090238800 | ISOLATION AND THERAPEUTIC APPLICATION OF ADULT RETINAL STEM CELLS COLLECTED FROM EXTRA-RETINAL TISSUES - The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal suffering from persistent fetal vasculature. The present invention is further directed to a culture medium for growing or maintaining retinal stem cells, and methods of maintaining adult retinal cells in culture. The present invention is further directed to methods of treating a treating an eye with retinal dystrophy using retinal stem cells, and an eye with glaucomatous injury with retinal stem cells. The present invention is further directed to kits for harvesting extra-retinal ocular tissue comprising a sterile container and a harvesting solution, wherein the kit allows the survival of the tissue until later dissociation of cells from the tissue. | 09-24-2009 |
| 20090238801 | AMNION-DERIVED STEM CELLS AND USES THEREOF - The present invention relates to stem cells obtained from the amnion and their methods of obtaining and culturing. The present invention further relates to compositions comprising amnion-derived stems cells (ADSCs) and to methods of using ADSCs. | 09-24-2009 |
| 20090238802 | Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example. | 09-24-2009 |
| 20090238803 | HUMAN CORD BLOOD DERIVED UNRESTRICTED SOMATIC STEM CELLS (USSC) - A composition in human cord and placental blood which comprises unrestricted somatic stem cells is described here which can be amplified in vitro to large quantities sufficient for medical applications as regenerative medicines. Initiation and maintenance as well as ex vivo expansion protocols of such stem cells from cord blood is described. | 09-24-2009 |
| 20090246178 | CD56 POSITIVE HUMAN ADULT PANCREATIC ENDOCRINE PROGENITOR CELLS - The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates. | 10-01-2009 |
| 20090246179 | METHOD OF TREATING MYOCARDIAL INJURY - A method of treating a myocardial injury of a subject includes administering a population of at least one of mesenchymal stem cells (MSCs), multipotent adult progenitor cells (MAPCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSs), which have down-regulated expression of disabled-2 (Dab2), to the subject. | 10-01-2009 |
| 20090246180 | HYPOXIA INDUCING FACTORS AND USES THEREOF FOR INDUCING ANGIOGENESIS AND IMPROVING MUSCULAR FUNCTIONS - This invention provides HIF-3α nucleic acid and sequences. Also provided are methods for using HIF-3α nucleic acids, proteins, fragments, antibodies, probes, and cells, to characterize HIF-3α, modulate HIF-3α cellular levels, induce angiogenesis, improve muscular function, and treat coronary and cardiac diseases in mammals. | 10-01-2009 |
| 20090246181 | THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS - A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed. | 10-01-2009 |
| 20090252710 | TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS - Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. | 10-08-2009 |
| 20090252711 | Stem Cells And Methods Of Making And Using Stem Cells - The invention provides a method of making a pluripotent stem cell from a cell that is not pluripotent, such as from a differentiated stem cell or a lineage-restricted stem cell. The methods comprise culturing the starting cell in the presence of one or more epigenetic altering agents, such as a histone deacetylase inhibitor and/or a DNA methyltransferase inhibitor. Pluripotent stem cells are also provided, as are methods of treating or preventing a disease, disorder, or condition in a mammal using the cells. | 10-08-2009 |
| 20090252712 | CHIMERIC C3-LIKE RHO ANTAGONIST BONE THERAPEUTIC - Methods of treating bone disorders in a subject in need thereof by administering to said subject a therapeutically effective amount of a Rho antagonist are disclosed. | 10-08-2009 |
| 20090257985 | METHODS OF REGULATING EXPRESSION OF GENES OR OF GENE PRODUCTS USING SUBSTITUTED TETRACYCLINE COMPOUNDS - The present invention relates, at least in part, to the use of substituted tetracycline compounds for regulation of expression of nucleic acids operably linked to a tetracycline operator system. The invention pertains to compounds used in a regulatory system which utilizes components of the Tet repressor/operator/inducer system of prokaryotes to regulate gene expression in cells. Use of certain substituted tetracycline compounds, as featured in the methods of the invention, result in improved dose-response results when compared to those for e.g., tetracycline and doxycycline. Certain methods of the invention thus allow for enhanced control of the Tet repressor/operator/inducer system in regulating gene expression in cells. | 10-15-2009 |
| 20090257986 | EPIDERMAL AND DERMAL EQUIVALENTS - The present invention relates to the treatment of skin defects by organotypically-cultured autologous keratinocytes isolated from the outer root sheath of anagen or growing hair. Methods for primary, as well as subsequent organotypic cultures (i.e., epidermal equivalents) in fully-defined media supplemented by autologous human serum and substances isolated form blood components, with minimal allogeneic biological supplements, are disclosed herein. Techniques to prepare epidermal equivalents for transplantation by use of a biocompatible glue are also disclosed herein. | 10-15-2009 |
| 20090257987 | Method of generating dopamine-secreting cells - Methods of generating cells which secrete dopamine are disclosed. One method comprises incubating mesenchymal stem cells in a culture medium comprising brain derived neurotrophic factor (BDNF), wherein the culture medium comprises no more than 0.1 μM retinoic acid (RA). Another method comprises incubating mesenchymal stem cells in a culture medium comprising glial-derived neurotrophic factor GDNF, transforming growth factor β3 (TGFβ3) and retinoic acid (RA). Cells generated by the above-described methods are also disclosed as well as uses thereof. | 10-15-2009 |
| 20090257988 | METHODS AND COMPOSITIONS FOR ACCELERATING THE GENERATION OF REGULATORY T CELLS EX VIVO - The present invention is directed to generating regulatory T cells by treating a cell culture that includes non-regulatory T cells with a regulatory composition. The invention encompasses methods utilizing a regulatory composition that includes agents that prevent methylation of the locus for the FOXP3 transcription factor, agents that accelerate differentiation of T cells into suppressor cells, and agents that are histone deacetylase inhibitors. The invention also encompasses compositions of regulatory T cells generated by culturing non-regulatory T cells with a regulatory composition as well as the use of such regulatory T cells in the treatment of autoimmune diseases and aberrant immune responses. | 10-15-2009 |
| 20090257989 | Intraperitoneal Delivery Of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example. | 10-15-2009 |
| 20090263357 | Therapeutic Reprogramming, Hybrid Stem Cells and Maturation - Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells which have been matured such that they represent either a more differentiated state or a less differentiated state after contact with stimulatory factors. The therapeutically reprogrammed cells are suitable for cellular regenerative therapy and have the potential to differentiate into more committed cell lineages. Additionally, hybrid stem cells suitable for therapeutic reprogramming and cellular regenerative therapy are provided. | 10-22-2009 |
| 20090263358 | METHOD FOR TREATING MULTIPLE MYELOMA - The present invention relates to methods for the treatment of multiple myeloma. More particularly, the present invention relates to a method for inducing apoptosis in myeloma cells by administration of a K121-like antibody. | 10-22-2009 |
| 20090263359 | Particulate Delivery Vehicles for Embryoid Bodies - The present invention provides a vehicle for delivering various chemicals, compositions and proteins to stem cells and embryoid bodies. The vehicle may be biocompatible and biodegradable polymer microparticles. Typically the particles will contain at least a growth factor for delivery to the embryoid bodies, and generally the growth factor induces differentiation of the cells in the embryoid body along a specific lineage. The present invention also provides methods for directing differentiation of the cells in the embryoid body. | 10-22-2009 |
| 20090263360 | Neuronal progenitors from feeder-free human embryonic stem cell culture - The present invention relates to methods for producing feeder cell-free neuroprogenitor cells (preferably adherent) from embryonic stems cells, preferably human embryonic stem cells, the feeder cell-free neuroprogenitor cells, preferably human cells themselves, as well as methods for producing feeder cell-free samples of neuronal cells, preferably adherent human neuronal cells and the feeder cell-free neuronal cells themselves. Pharmaceutical compositions and methods of treating neurodegenerative diseases as well as the use of the described cells in assay systems is also described. | 10-22-2009 |
| 20090263361 | HUMAN TROPHOBLAST STEM CELLS AND USE THEREOF - Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies. | 10-22-2009 |
| 20090263362 | FERTILITY ENHANCEMENT USING LIPID CARRIERS AND BIOACTIVE MOLECULES - The invention relates to a composition and method for enhancing fertilization. Fertilization enhancement is achieved by effectively delivering bioactive molecules with a lipid anchor (GPI-linked proteins) to the surface of epididymal or ejaculated sperm. The process may be facilitated or promoted in the presence of Clusterin/APOJ, a well-known lipid carrier. The rate of delivery, or removal, of bioactive molecules is regulated by the concentration of lipid carrier present. The acquisition of these molecules, such as Sperm Adhesion Molecule 1 (SPAM1) can significantly impact sperm maturation and function. | 10-22-2009 |
| 20090263363 | Compositions and Methods For Treating Bone Formation Disorders - The present invention relates to compositions and methods for the detecting, treating, and empirically investigating disorders associated with bone formation (e.g., osteoporosis). In particular, the present invention provides compositions and methods for using maspin and targets of maspin in the diagnosis, treatment, and empirical investigation of disorders associated with bone formation (e.g., osteoporosis). | 10-22-2009 |
| 20090269309 | Retinoic acid stimulates differentiation of pancreatic progenitor cells into insulin producing cells - The invention relates to a method of forming pancreatic hormone-producing endocrine cells in vitro, wherein pancreatic stem cells are treated with one or more retinoids and/or retinoic acid in vitro and cultured. Especially the dorsal pancreatic bud is used and to the cells obtained by the method. Further, it relates to the use of the pancreatic hormone-producing endocrine cells, for the production of a pharmaceutical composition for transplantation and/or treatment of type 1 and type 2 diabetes. It also relates to a method for treatment of type 1 and type 2 diabetes by administrating the hormone-producing endocrine cells to individuals in need thereof. The invention also regards the use of one or more retinoids and/or retinoic acid for the differentiation, in vitro of pancreatic stem cells into pancreatic hormone-producing endocrine cells, such as glucagon producing cells, and in particular, insulin producing β-cells. | 10-29-2009 |
| 20090269310 | METHOD FOR OBTAINING HUMAN SMOOTH MUSCULAR CELLS AND USES THEREOF - The invention concerns a method for obtaining in vitro a population of cells comprising essentially human smooth muscular cells expressing calponin and SM-MHC from a sample of human muscular biopsy or from human muscular biopsies differentiated in vitro into skeletal muscle cells. The invention also concerns a composition comprising the isolated smooth muscular cells obtainable by said method as therapeutic principle designed for humans. The invention further concerns the use of the isolated smooth muscular cells for preparing a therapeutic composition designed to replace smooth muscular cells. In particular, the invention concerns the use of said isolated smooth muscular cells for treating ischemia, cancer or any disease requiring revascularization of damaged tissues. Finally, the invention concerns the use of said smooth muscular cells as vector for an active principle for preparing a therapeutic composition designed for humans requiring treatment with said active principle. | 10-29-2009 |
| 20090269311 | Method for treating multiple system atrophy - The present invention provides a method for treating multiple system atrophy, comprising administering a therapeutically effective amount of mesenchymal stem cells (MSCs) to a human in need thereof. Preferably, the administering is performed by an intra-arterial injection of said MSCs and one or more intravenous injections of said MSCs. | 10-29-2009 |
| 20090269312 | Methods, Systems, and Apparati for Cellular Therapeutic Agent Preparation and Delivery - Methods and devices for the preparation of a biological pharmaceutical composition outside of a classified environment, such as Biological Safety Cabinet type environment, are described. In one aspect of the present technology, a method is provided to prepare a biological pharmaceutical composition preferably in an area next to a patient's bedside or at a facility's pharmacy. The method comprises transferring an appropriate amount of a diluent from a diluent component into a mixing receptacle using a transfer device, connecting a pooling harness between a biological pharmaceutical component and the mixing receptacle, transferring a biological pharmaceutical composition through the pooling harness to the mixing receptacle, mixing the diluent and the biological pharmaceutical composition to form a biological pharmaceutical composition mixture and administering the biological pharmaceutical composition mixture to a patient for either flat based or weight based dosing needs. | 10-29-2009 |
| 20090269313 | ENCAPSULATION SYSTEM - An encapsulation system for use in the treatment of diabetes (Types 1 or 2, and LADA) are provided. The system has (1) a delivery vehicle comprising a selectively permeable membrane that allows passage of glucose, insulin and other nutrients through the membrane, but prevents large molecules such as antibodies or inflammatory cells from passing through the membrane; (2) a population of islet cells or insulin producing cells encapsulated by said membrane; and (3) a biological response modifier that may be in contact with the membrane or encapsulated by the membrane. Generally, the biological response modifier is a compound, including resolved enantiomers, diastereomers, tautomers, salts and solvates thereof, having the following formula: | 10-29-2009 |
| 20090269314 | HUMAN CARDIOVASCULAR PROGENITOR CELLS - The present invention provides populations of human cardiovascular progenitor cells, methods of making such cells, and methods of using the cells for production of populations of cardiovascular colonies and populations of cardiomyocytes. Methods of cardiomyocytes replacement therapy are also provided. | 10-29-2009 |
| 20090269315 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF CARDIOVASCULAR CONDITIONS - Cells present in processed lipoaspirate tissue are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit. | 10-29-2009 |
| 20090269316 | Methods for Using a Three-Dimensional Stromal Tissue to Promote Angiogenesis - The present invention relates to a method for promoting blood vessel formation in tissues and organs. In particular, the method relates to implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelialization and angiogenesis in the heart and related tissues. The three-dimensional stromal tissue of the present invention may be used in a variety of applications including, but not limited to, promoting repair of and regeneration of damaged cardiac muscle, promoting vascularization and healing during cardiac surgery, promoting blood vessel formation at anastomosis sites, and promoting vascularization and repair of damaged skeletal muscle, smooth muscle or connective tissue. | 10-29-2009 |
| 20090269317 | IRREVERSIBLE ELECTROPORATION TO CREATE TISSUE SCAFFOLDS - The present invention provides engineered tissue scaffolds, engineered tissues, and methods of using them. The scaffolds and tissues are derived from natural tissues and are created using non-thermal irreversible electroporation (IRE). Use of IRE allows for ablation of cells of the tissue to be treated, but allows vascular and neural structures to remain essentially unharmed. Use of IRE thus permits preparation of thick tissue scaffolds and tissues due to the presence of vasculature within the scaffolds. The engineered tissues can be used in methods of treating subjects, such as those in need of tissue replacement or augmentation. | 10-29-2009 |
| 20090269318 | PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD - Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC−/− progenitor cells, and is useful to grow and repair human tissues including bone. | 10-29-2009 |
| 20090269319 | ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery - ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic. | 10-29-2009 |
| 20090274663 | Materials and Methods Relating to Cell Based Therapies - The invention provides a novel multipotent cell population of adult origin that can be used to treat ageing and disease, particularly by transplantation to site of cellular damage. | 11-05-2009 |
| 20090274664 | Method of culturing vascular smooth muscle cells, culture device and medical material obtained by the culture - There is provided a method for culturing vascular smooth muscle cells while maintaining their normal function, and a culture device and regenerative medical material for the same. The method takes advantage of vascular smooth muscle cell recognition of elastin as an extracellular matrix. The invention provides a method for culturing vascular smooth muscle cells on elastin, a culture device having elastin anchored on the cell-growing surface, a culture device wherein the cell-growing surface is composed of an elastin molded article, and medical materials obtained by culturing vascular smooth muscle cells using such culture devices. | 11-05-2009 |
| 20090274665 | Stem Cells For Treating Lung Diseases - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow. | 11-05-2009 |
| 20090274666 | B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE - The invention provides novel polypeptides useful for co-stimulating T cells, isolated nucleic acid molecules encoding them, vectors containing the nucleic acid molecules, and cells containing the vectors Also included are methods of making and using these co-stimulatory polypeptides. | 11-05-2009 |
| 20090274667 | RETINAL PIGMENT EPITHELIAL STEM CELLS - The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment. | 11-05-2009 |
| 20090274668 | Combined Regulation of Neural Cell Production - This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells. | 11-05-2009 |
| 20090280092 | G-Protein Coupled Receptor 83 As a Molecular Switch for the Induction of Regulatory (immunosuppressive) T-cells - The present invention makes use of the role of the G-protein coupled receptor 83 (GPCR83) in the induction of regulatory T cells (Tregs) during the course of ongoing immune response. The present invention relates to means and methods for identifying compounds that are interacting with the GPCR83 polypeptide, and to compounds capable of functioning as immunomodulators in mammals, in particular humans. In addition, the present invention relates to methods of treatment of a subject, in particular a human, suffering from an undesired immunoreaction. | 11-12-2009 |
| 20090280093 | COMPOSITIONS AND POPULATIONS OF CELLS OBTAINED FROM THE UMBILICAL CORD AND METHODS OF PRODUCING THE SAME - The present invention relates to populations and compositions of stem and progenitor cells derived from the umbilical cord, and methods of obtaining the same. In some embodiments, one or more entire umbilical cords or sections thereof are subjected to a process where a cell population is derived without prior removal of any blood vessel. The population may be derived using mechanical and chemical means. The presently disclosed process may be applied to a single umbilical cord or to a plurality of umbilical cords, for example, as a batch process. Optionally, this process includes removing some or all cord blood before deriving the population. In some embodiments, presently disclosed cell populations include mesenchymal stem cells derived from Wharton's jelly and endothelial progenitor cells derived from a wall of a blood vessel of an umbilical cord. Optionally, the cell population includes stem cells derived from cord blood. The presently disclosed cell populations and compositions may be banked and/or used in a number of clinical or other applications. Exemplary applications include but are not limited to applications related to regenerative medicine, for screening compounds, for research, and for gene therapy. | 11-12-2009 |
| 20090280094 | Treatment of Ischemic Diseases Using Erythropoietin - Disclosed is a method for stimulating revascularization in a subject comprising the steps of:
| 11-12-2009 |
| 20090280095 | CELL CULTURE OF KERATINOCYTES UNDER NON-DIFFERENTIATING CONDITIONS - The present invention relates to a cell culture medium comprising (a) an inhibitor of bone morphogenetic protein-4 (BMP-4) and (b) an inhibitor of pigment epithelium-derived factor (PEDF, also known as SerpinF1). In one embodiment, the inhibitors are antibodies against BMP-4 and PEDF, respectively. The medium allows to culture keratinocytes under non-differentiating conditions. The invention also relates to corresponding methods and kits. As the media and methods disclosed allow for an improved manufacture of keratinocytes, the invention also relates to the treatment of skin wounds and to the manufacture of corresponding medicaments. This will be of advantage for treatment e.g. of burns, ulcers, etc., in which transplantation of keratinocytes or skin is required. | 11-12-2009 |
| 20090280096 | PANCREATIC ENDOCRINE PROGENITOR CELLS DERIVED FROM PLURIPOTENT STEM CELLS - The invention provides pluripotent cells modified to overexpress Pdx1 and Ngn3. Pluripotent cells include embryonic stem cells and induced pluripotent stem cells. Methods of producing pancreatic endocrine progenitor cells from ES cells or from iPS cells by forced expression of Pdx1 and Ngn3 are provided. Pancreatic endocrine progenitor cells are useful for drug discovery and cell replacement therapy. | 11-12-2009 |
| 20090280097 | PLURIPOTENT CELLS - Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration. | 11-12-2009 |
| 20090285785 | External Agent for Treatment of Skin Ulcer - [Problems] To provide a novel external agent for treatment of skin ulcer which has an excellent healing effect on intractable skin ulcer such as bedsore, diabetic skin ulcer and ischemic skin ulcer. | 11-19-2009 |
| 20090285786 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH - The present invention provides for compositions and methods for modulating hematopoietic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E2 (PGE2) and agents that stimulate the PGE2 pathway. Conversely, HSC modulators that prevent PGE2 synthesis decrease HSC numbers. HCS modulators may be used in vitro, in vivo, or ex vivo. | 11-19-2009 |
| 20090285787 | Intracoronary, intracardia, or intravenous infusion of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium - The present invention is a method for improving cardiac function and myocardial regeneration in living subjects after the occurrence of myocardial infarction. The method is a combination stem cell therapy involving a mixture of bone marrow-derived mesenchymal stem cells and bone marrow derived mononuclear cells surgically implanted by using either a direct or catheter-mediated injection into damaged myocardium. Studies have shown that the implant improves heart function and myocardial regeneration as assessed by MRI, SPECT and echocardiographic measurements. | 11-19-2009 |
| 20090291064 | Immortal unipotent porcine PICM-19H and PICM-19B stem cell lines - Two cell lines, PICM-19H and PICM-19B, were derived from the bipotent ARS-PICM-19 pig liver stem cell line and assessed for their potential application in artificial liver devices. The study included assessments of growth rate and cell density in culture, morphological features, and hepatocyte detoxification functions, i.e., inducible CYP450 activity, ammonia clearance, and urea production. The PICM-19H cells contain numerous mitochondria, Golgi apparatus, smooth and rough endoplasmic reticulum, vesicular bodies and occasional lipid vacuoles. PICM-19H cells display inducible CYP450 activity, clear ammonia, and produce urea in a glutamine-free medium. Ultrastructural analysis of the PICM-19B monolayers show that the roughly cuboidal cells display basal-apical polarization and are joined by tight junction-like complexes. Other ultrastructure features are similar to those of PICM-19H cells except that they possess numerous cell bodies resembling mucus vacuoles. The PICM-19B cells possess relatively high levels of GGT activity, but retain some inducible CYP450 activity, and some ammonia clearance and urea synthesis ability. These data indicate that both cell lines, either together or alone, may be useful as the cellular substrate for an artificial liver device. In vitro models of the liver are needed to replace animal models for the rapid assessment of drug biotransformation and toxicity. A unipotent porcine stem cell line PICM-19H differentiates exclusively into hepatocytes and can be induced to express CYP450 enzymes. These cells have many activities associated with xenobiotic phase I and phase II metabolism lacking in other liver cell lines. The PICM-19H cell line was also compared to the tumor-derived human HepG2 C3A cell line and to primary cultures of adult porcine hepatocytes. The results demonstrate the potential for the use of PICM-19H cells in drug biotransformation and toxicity testing and further support their use in artificial liver device technology. | 11-26-2009 |
| 20090291065 | COLLECTION AND SELECTION METHODS OF AN EMBRYONIC-LIKE STEM CELL POPULATION FROM HUMAN ADULT PERIODONTAL FOLLICULAR TISSUES - Methods for the isolation, expansion and storage of a population of stem cells belonging to human dental follicles, called FENC ( | 11-26-2009 |
| 20090291066 | COMPOSITION AND METHOD OF TREATING FACIAL SKIN DEFECT - This invention relates to a subcutaneous deliverable composition containing an agonist of the peroxisome proliferator-activated receptor-gamma, and a method for treating facial skin defects in a mammalian subject using the subcutaneous deliverable composition. | 11-26-2009 |
| 20090291067 | Composition for treating cancer comprising adult stem cell culture or its fraction - The present invention provides a pharmaceutical composition for treating cancer, comprising a culture of adult stem cells or a fraction of the culture as an active ingredient. The culture of adult stem cells and its fraction, especially a specific fraction of adult stem cell culture, inhibit proliferation of a variety of cancer such as melanoma, pancreatic cancer, breast cancer, hepatic cancer, gastric cancer, colon cancer, lung cancer, and cervical cancer, thereby having excellent cancer-treating activity. The composition according to the present invention includes, not stem cells, but a complex of active proteins secreted from the stem cells, and thus both pharmaceutical problems in formulation and individual variation, which usually occurred when using stem cells, can be minimized. And also, side effects caused by direct administration of cells into the human bodies can be thoroughly prevented. | 11-26-2009 |
| 20090297485 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC AND NEURODEGENERATIVE DISORDERS - Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue. | 12-03-2009 |
| 20090304639 | Method for preparing an organ for transplantation - The present invention provides a means for achieving generation of a complex organ such as kidney and the like through the use of hMSCs to generate the human organ. The method for preparing a desired organ for transplantation to human by transplanting an isolated human mesenchymal stem cell to the embryo of a pregnant mammal host to induce differentiation of the mesenchymal stem cell is a method wherein the mesenchymal stem cell is transplanted into the embryo at a corresponding site for differentiation into the desired organ in the host at a transplantation time when the host is still at an immunologically tolerant stage. | 12-10-2009 |
| 20090304640 | Transfection of Collagen-Producing Cells - A method is provided for introducing at least one polynucleotide of interest into an intervertebral disc cell, wherein the polynucleotide of interest is transfected with a lipid-based delivery agent. Also provided are methods for introducing polynucleotides encoding one or more telomerase catalytic subunits into collagen-producing cells and methods for increasing extracellular matrix formation in collagen-producing cells. | 12-10-2009 |
| 20090304641 | Methods and Compositions for Regulating Gene Expression - In certain embodiments, the disclosure relates to compositions and methods relating to a translation-based gene regulation system that functions in mammalian cells. In certain specific embodiments, the disclosure relates to methods of regulating gene expression via modulating translational termination. | 12-10-2009 |
| 20090304642 | METHODS OF SPECIFYING MESODERMAL, ENDODERMAL AND MESOENDODERMAL CELL FATES - We disclose a method for producing a mesodermal or a endodermal cell from a pluripotent stem cell, the method comprising activating a Wnt signalling pathway in the pluripotent stem cell. In some embodiments, the pluripotent stem cell is in a substantially 2 dimensional configuration, such as a monolayer, for at least a portion of the time when the Wnt signalling pathway is activated. | 12-10-2009 |
| 20090304643 | Methods of Preparing and Characterizing Mesenchymal Stem Cell Aggregates and Uses Thereof - The invention provides compositions and methods for preparing and characterizing multipotential mesenchymal stem cell aggregates. The invention further provides methods for using stem cell aggregates of the invention. | 12-10-2009 |
| 20090304644 | SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS SEPARATED AND CONCENTRATED FROM ADIPOSE TISSUE - The invention provides methods for manipulating regenerative cells from adipose tissue. Specifically, it provides methods for enrichment of desired cells and enhancement of their therapeutic effects. | 12-10-2009 |
| 20090304646 | Multipotent/Pluripotent Cells and Methods - Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods. | 12-10-2009 |
| 20090304647 | Production of Neural Stem Cells from Bone Marrow Tissue and Use Thereof - The invention provides reagents and methods for preparing mammalian mesenchymal-derived neural stem cells, especially autologous mesenchymal-derived neural stem cells, compositions thereof, and methods for using and administering the cells in a patient in need thereof. | 12-10-2009 |
| 20090304648 | Mast Cell Stabilizers to Prevent or Treat Laminitis - Provided herein are mast cell stabilizers used to prevent, treat, or mitigate severity of laminitis. Mast cell stabilizers can be combined with antihistamines and other medicaments to prevent, treat, or mitigate severity of laminitis. | 12-10-2009 |
| 20090311220 | Bone forming compound composed of a mixture of osteoblast and biomatrix and method for producing the same - A compound for bone forming and a method for producing the same are provided using a mixture of an osteoblast and a bio-matrix. The method comprises: isolating osteoblasts from bone tissue and culturing the isolated osteoblasts to prepare an osteoblast suspension; and mixing the resulting osteoblast suspension with a bio-matrix to prepare an osteoblast therapeutic agent. A bone formation method is provided that results in no clinical graft rejection, and is capable of achieving effective and rapid bone formation via injection of a compound which has been pre-shaped to a certain extent, so as to alleviate problems associated with bone tissue formation in unwanted regions resulting from escape of injected osteoblasts from the targeted site for bone formation and then propagation thereof to other sites via the blood stream, which are caused by injection of an osteoblast suspension. | 12-17-2009 |
| 20090311221 | BIOMATERIALS FOR REGENERATIVE MEDICINE - It was examined whether a cartilage-like tissue is formed under various reaction conditions using cartilage matrix components: glycosaminoglycan, proteoglycan, and collagen. The present inventors have discovered that proteoglycan bound to glycosaminoglycan through self-organization form an aggregate when the glycosaminoglycan was reacted with proteoglycan under specific concentrations and pH, and that a mesh structure composed of collagen fibers was constructed through self-organization using the aggregates as a skeleton when the aggregates were reacted with collagen molecules. | 12-17-2009 |
| 20090311222 | TRANSPLANTATION OF NEURAL CELLS - Restoration or increase of inhibitory interneuron function in vivo is achieved by transplantation of MGE cells into the brain. Compositions containing MGE cells are provided as are uses to treat various diseases characterised by abnormal inhibitory interneuron function or in cases where increase inhibition may ameliorate neural circuits that are abnormally activated. | 12-17-2009 |
| 20090317365 | SYSTEMS AND METHODS FOR MAKING HEPATOCYTES FROM EXTRAHEPATIC SOMATIC STEM CELLS AND USE THEREOF - A method for making hepatocytes from extrahepatic somatic stem cells comprises: a) culturing somatic stem cells in a medium comprising hepatic growth factor to cause the stem cells to differentiate toward hepatocytes; b) culturing cells from a) in a medium comprising HGF and oncostatin M to facilitate the cell differentiation toward hepatocytes; and c) culturing cells from b) in a medium comprising oncostatin M to cause the differentiated cells to mature into hepatocytes, thereby producing a cell population that has morphological features of hepatocytes and at least four of the following characteristics: i) antibody-detectable expression of albumin; ii) real-time reverse transcriptase-polymerase chain reaction-detectable expression of α-fetoprotein, HNF-1α, HNF-3β, HNF-4, HNF-6, α1-antitrypsin, alkaline phosphatase, tryptophan 2,3-dioxygenase, tyrosine aminotransferase, cytochrome P450 family 2 subfamily E polypeptide 1, glutamine synthetase, and/or low density lipoprotein receptor; iii) urea secretion; iv) cytochrome p450 enzyme activity; v) glycogen storage; and vi) low density lipoprotein uptake. | 12-24-2009 |
| 20090317366 | METHOD FOR TREATING PROGRESSIVE NEURODEGENERATIVE DISORDERS - A method for treating a progressive neurodegenerative disorder with bone marrow stem cells and a G-CSF receptor agonist. | 12-24-2009 |
| 20090317367 | METHODS OF PRODUCING PREADIPOCYTES AND INCREASING THE PROLIFERATION OF ADULT ADIPOSE STEM/PROGENITOR CELLS - The present invention describes preadipocytes and methods of differentiating macrophages into preadipocytes by co-culturing adipocytes and resident adipose tissue macrophages. Also described are methods of increasing the proliferative rate of adipose adult stem/progenitor cells. | 12-24-2009 |
| 20090324555 | Neural Stem Cells - Subject of the invention is a method for generating neural stem cells in vitro, wherein dental progenitor cells are isolated from soft tissue of tooth or wisdom tooth and cultivated until they form primary spheres which are then dissociated into single cells. These single cells are cultivated until they form spheroids and the spheroid-forming cells are separated to obtain neural stem cells. | 12-31-2009 |
| 20090324556 | Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof - The invention concerns the optimization of the wild R9M peptide and the use of the resulting peptides for therapeutic vaccination and/or preventive vaccination against leukaemia in humans. More particularly, the invention concerns mutated immunogenic peptides derived from the human TEL/AML1 fusion protein comprising the wild R9M peptide sequence Arg-Ile-Ala-Glu-Czs-Ile-Leu-Gly-Met. The invention also concerns polynucleotides coding for the mutated R9M immunogenic peptides, cellular expression vectors comprising nucleic acid sequences expressing the mutated R9M immunogenic peptides and polyclonal or monoclonal antibodies capable of being fixed on at least one of said peptides/polynucleotides. The invention further concerns the use of said peptides, polynucleotides and/or antibodies for preparing vaccines, anti-tumoral medicines and compositions and for in vitro and in vivo stimulation of the immune response in humans. | 12-31-2009 |
| 20090324557 | METHOD TO INDUCE AND EXPAND THERAPEUTIC ALLOANTIGEN-SPECIFIC HUMAN REGULATORY T CELLS IN LARGE-SCALE - Methods for inducing, expanding, and/or generating alloantigen-specific regulatory T cells. Alloantigen-specific regulatory T cells can be induced, expanded, and/or generated from naive CD4 | 12-31-2009 |
| 20090324558 | Transdiscal administration of cycline compounds - The present invention relates to administering a doxycycline compound into a diseased intervertebral disc. | 12-31-2009 |
| 20090324559 | METHODS AND PLATFORMS FOR DRUG DISCOVERY - The present invention involves methods for identifying an agent that corrects a phenotype associated with a health condition or a predisposition for a health condition. The invention also involves methods for identifying a diagnostic cellular phenotype, determining the risk of a health condition in a subject, methods for reducing the risk of drug toxicity in a human subject, and methods for identifying a candidate gene that contributes to a human disease. The invention also discloses human induced pluripotent stem cell lines. | 12-31-2009 |
| 20090324560 | METHOD FOR PREPARATION OF CARTILAGE CELL - Chondrocytes are prepared from perichondrocytes. | 12-31-2009 |
| 20090324561 | Cells exhibiting neuronal progenitor cell characteristics and methods of making them - Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells. | 12-31-2009 |
| 20100003222 | METHODS FOR BONE REGENERATION USING ENDOTHELIAL PROGENITOR CELL PREPARATIONS - The present invention relates in general to orthopedics and to a method for promoting repair of large bone defects, in particular non-union or delayed union fractures. Specifically the invention concerns the use of endothelial progenitor cell preparations for bone repair. | 01-07-2010 |
| 20100003223 | METHOD FOR THE PRODUCTION OF MULTICOMPONENT STEM CELLS, RELATIVE KITS AND USES IN THE MEDICAL FIELD - The invention relates to a method for the production of multipotent stem cells starting from highly differentiated adult somatic cells of mammals or their precursors comprising the demethylating treatment phase of highly differentiated cells with 5′ Aza 2′ cytidine and relative kits and uses in the medical field. | 01-07-2010 |
| 20100003224 | Combination Therapy - Methods to mobilize progenitor and/or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor and at least one VLA-4 inhibitor are described. The combinations may also be used to treat multiple myeloma. | 01-07-2010 |
| 20100008890 | MAPC Therapeutics Without Adjunctive Immunosuppressive Treatment - The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like with MAPCs, without the need for adjunctive immunosuppressive treatment. | 01-14-2010 |
| 20100008891 | Production of Pluripotent Cells Through Inhibition of Bright/Arid3a Function - The present invention involves the identification of Bright/ARID3a as involved in the regulation of pluripotency in cells, and the targeting of that function for the regulation of pluripotency. Thus, methods of de-differentiating cells into pluripotent cells are provided, as well as methods for re-differentiating such cells in a controlled fashion. | 01-14-2010 |
| 20100015099 | Materials and methods relating to treatment of injury and disease to the central nervous system - The application provides materials and methods for promoting myelination of neuronal axons in the CNS. These derive from the findings first that the molecules Nogo and Caspr interact with one another during establishment and maintenance of the axoglial junction, and secondly that the molecules F3 and NB-3 are capable of promoting oligodendrocyte maturation via interaction with Notch. The materials and methods provided may be used in the treatment of CNS damage, in particular the treatment of spinal cord injury, multiple sclerosis, epilepsy and stroke. | 01-21-2010 |
| 20100015100 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer. | 01-21-2010 |
| 20100015101 | NOVEL TUMOR ANTIGEN PEPTIDES - The invention relates to novel tumor antigen proteins and peptides derived therefrom and use of the same in the filed of cancer immunity. Specifically, the inventions relates to a peptide which comprises a partial peptide derived from Lengsin, BJ-TSA-9, C20orf42, BUB1, C10orf3 or HIFPH3 and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier. | 01-21-2010 |
| 20100015102 | Composition for treatment of cartilage disease - The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue. | 01-21-2010 |
| 20100015103 | Cell culture method and application thereof - The invention relates to a cell culture method, particularly to a co-culture method for human mesenchymal stem cells and target animal cells, in order to solve the problem that animal cells are not easy to survive alone upon culturing. The invention also provides a method for using a stem cell conditioned medium to culture animal cells. The invention also provides a method to induce the transformation of human fetal islet-like cell clusters from human stem cells and its application thereof. | 01-21-2010 |
| 20100015104 | GENERATION OF ADIPOSE TISSUE AND ADIPOCYTES - The invention provides novel methods by which adipose tissue, preadipocytes, and adipocytes can be generated for research purposes, and methods for identifying cell populations that can proliferate and differentiate into adipocytes in vivo. The invention further provides a means for the in vivo derivation of “designer” or “customized” adipose tissue, preadipocytes, and adipocytes. Also provided are methods for identifying agents that affect adipocytes and adipose tissue, as well as the agents themselves. In particular, the present invention allows for creation of tissues and cells that can be used to screen for agents useful for treating human disorders associated with adipose tissue, including obesity, metabolic syndrome, and diabetes. | 01-21-2010 |
| 20100015105 | METHOD OF TREATING SCHIZOPHRENIA - A method of treating schizophrenia in a subject in need thereof is provided. The method comprising, administering to the subject a therapeutically effective amount of cells expressing at least one exogenous polypeptide forming a connexin channel and/or a hyperpolarizing ion channel, thereby treating the schizophrenia in the subject. | 01-21-2010 |
| 20100015106 | Method and compositions for inhibiting tumorigenesis - The present invention discloses methods of producing neuronal cells from stem cells, particularly from adult brain stem cells. The use of such neuronal cells in the treatment and/or prevention of neurological diseases, conditions and/or injuries is also disclosed. In addition, the present invention provides a novel source of neuronal cells for use as a laboratory tool. | 01-21-2010 |
| 20100015107 | Expression elements - The invention relates to genetic elements capable of improving the levels of expression of operably-linked transcription units. In particular, said genetic elements are derived from the 5′ untranslated regions of ribosomal protein genes and may comprise a CpG island. Also provided are vectors and host cells comprising said genetic elements and methods of use to obtain high levels of recombinant gene expression. | 01-21-2010 |
| 20100021433 | Disease treatment via developing non-syngeneic graft transplantation - A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject. | 01-28-2010 |
| 20100021434 | Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases - Isolated human cells and populations thereof are provided comprising at least one oligodendrocyte phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an oligodendrocyte phenotype. Methods of generating and using same are also provided. | 01-28-2010 |
| 20100021435 | PANCREATIC ISLET-LIKE CELLS - The generation of pancreatic islet-like cells from isolated monocyte-derived stem cells (MDSCs) is provided. MD-SCs may be differentiated into pancreatic islet cells by contacting the MDSCs with a differentiation factor or factors. Compositions comprising pancreatic islet cells and methods of using them are also provided. | 01-28-2010 |
| 20100021436 | MULTIPOTENT ADULT STEM CELL DERIVED FROM CANINE UMBILICAL CORD BLOOD, PLACENTA AND CANINE FETUS HEART, METHOD FOR PREPARING THE SAME AND CELLULAR THERAPEUTICS CONTAINING THE SAME - The present invention relates to multipotent adult stem cells derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart, and a method for preparing the same as well as a cellular therapeutic agent containing the same, more specifically, to a multipotent adult stem cell isolated by culturing an eukaryotic cell derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart in a FBS-containing medium and a method for preparing the same. Adult stem cells according to the present invention are derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart. The adult stem cells have characteristics highly similar to human mesenchymal stem cells as well as remarkable cell growth at the initial step compared to human UCB-derived mesenchymal stem cells so that the cells are useful to treat canine incurable diseases and difficult-to-cure diseases. Furthermore, multipotent adult stem cells are effective to treat musculoskeletal diseases and neural diseases due to the ability to differentiate into osteogenic cells and neural cells. | 01-28-2010 |
| 20100021437 | NEURAL STEM CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS - The present invention provides novel populations of neural stem cells derived from induced pluripotent stem cells, and methods for making and using the same. | 01-28-2010 |
| 20100021438 | KIDNEY DERIVED STEM CELLS AND METHODS FOR THEIR ISOLATION, DIFFERENTIATION AND USE - The invention relates generally to methods for isolation and culture of kidney stem cells, cells isolated by the methods, and therapeutic uses for those cells. | 01-28-2010 |
| 20100021439 | METHODS AND COMPOSITIONS FOR TREATING INTERVERTEBRAL DISC DEGENERATION - A fluid matrix comprising cross-linked remodelable collagen from a donor vertebrate animal is useful for regenerating hydrodynamic function in damaged intervertebral discs in vivo. The matrix may be injectable and may comprise cells and a plurality of purified cell growth factors. The matrix promotes cell growth and elaboration of proteoglycans to facilitate regeneration of native tissues. The collagen in the matrix may be cross-linked using photooxidative catalysis and visible light, and purified cell growth factors are preferably at least partly bone-derived. | 01-28-2010 |
| 20100021440 | USE OF TROPOELASTIN FOR REPAIR OR RESTORATION OF TISSUE - The present invention relates to tropoelastin and to tissue repair and restoration using elastic materials. Disclosed is a process for producing an elastic material from tropoelastin including heating a solution of tropoelastin having an alkaline pH to form an elastic material from the tropoelastin in the solution. Also disclosed are elastic materials prepared according to this process and their applications. | 01-28-2010 |
| 20100021441 | MHC MOLECULE-BINDING TUMOR-ASSOCIATED PEPTIDES - The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I. The invention further relates to the use of the peptides for preparation of a drug and for the treatment of tumor diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described comprising at least one of the pepti | 01-28-2010 |
| 20100021442 | METHOD FOR PROMOTING IMMUNOTHERAPY USING AN AGENT FOR ELEVATING DENDRITIC CELL PRECURSOR LEVEL IN BLOOD - Although the fields of therapeutic applications of dendritic cells are now expanding, dendritic cell precursors exist only in a small amount in the peripheral blood and, therefore, it is still difficult to obtain them in a therapeutically useful amount even though they are proliferated in vitro. Therefore, it is a key point in performing a therapy with the use of dendritic cells in practice to elevate dendritic cell precursor level in the peripheral blood of a patient. The present invention provides an agent for elevating dendritic cell precursor level in the blood which comprises an agonist to a receptor expressed in immature dendritic cells or a functional derivative thereof as the active ingredient. | 01-28-2010 |
| 20100028305 | Methods for the treatment of lysosomal storage disorders - Provided herein are methods for the treatment of lysosomal storage disorders characterized by a missing or defective secreted lysosomal enzyme. Such lysosomal storage disorders include, but are not limited to neuronal ceroid lipofuscinoses. The disclosed methods involve the transplantation of human multipotent neural stem cells into the CNS of patients suffering from the lysosomal storage disorder. Also provided herein are methods of reversing or slowing the progression of neurodegeneration in patients suffering from or at risk of developing neuronal ceroid lipofuscinoses. | 02-04-2010 |
| 20100028306 | Amnion-Derived Cell Compositions, Methods of Making and Uses Thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies. | 02-04-2010 |
| 20100028307 | PLURIPOTENT STEM CELL DIFFERENTIATION - The present invention relates to the field of pluripotent stem cell differentiation. The present invention provides methods for the differentiation of pluripotent stem cells on a human feeder cell layer. In particular, the present invention provides an improved method for the differentiation of pluripotent stem cells into pancreatic endocrine cells using a human feeder cell layer. | 02-04-2010 |
| 20100028308 | METHODS TO MAINTAIN, IMPROVE AND RESTORE THE CARTILAGE PHENOTYPE OF CHONDROCYTES - The present invention relates to regulatory cells, which are capable of restoring, maintaining or improving the stable cartilage phenotype of expanded and passaged chondrocytes. These regulatory cells are also capable of directing precursor and stem cells into the chondrogenic lineage. An enriched population of regulatory cells can be obtained by harvesting the non-adherent cells in the culture medium of a monolayer culture of PO chondrocytes. | 02-04-2010 |
| 20100028309 | METHOD FOR DIRECTED CELL IN-GROWTH AND CONTROLLED TISSUE REGENERATION IN SPINAL SURGERY - The present invention relates to a method for directed cell in-growth and controlled tissue regeneration to prevent post-surgical or post-traumatic adhesion and fibrosis formation on the injured surface of a tissue selected from the group consisting of spinal column tissue, dura mater, and spinal nerves in a mammal, comprising the step of providing, covering and separating the tissue with a bioactive biofunctional, non-porous, microscopically multilayered collagen foil biomatrix, and to a method for treating a defect in a mammal comprising the step of providing, covering and separating said tissue with a bioactive biofunctional, non-porous, microscopically multilayered collagen foil biomatrix. | 02-04-2010 |
| 20100028310 | Composition for Transplantation Comprising Adipose Stem Cells or Adipocytes - The present invention relates to a composition for transplantation in a physiologically compatible buffer solution comprising, (a) a transplant-cell selected among an adipose stem cell, an adipocyte, adipose tissues (fat tissue) and a mixture thereof; and (b) a semi-solid substance derived from a living body or a biodegradable substance selected among a hyaluronic acid, collagen, elastin, thrombin, chondroitin sulfate, albumin and a mixture thereof. | 02-04-2010 |
| 20100028311 | USING OF SCAFFOLD COMPRISING FIBRIN FOR DELIVERY OF STEM CELLS - The invention generally relates to the field of delivery of cells to desired tissue sites, prolonged retention of the cells at the sites, and integration of cells into an area of interest for increased therapeutic effect. The invention provides, in part, compositions and methods for treating ischemia in a subject in need thereof. In some aspects, the methods of treatment comprise the administration of a fibrin scaffold or fibrin clot comprising stem cells. | 02-04-2010 |
| 20100034778 | STEM CELLS - The present invention relates, in general, to stem cells and, in particular, to a method of expanding human stem cells using a retinoic acid receptor modulator. | 02-11-2010 |
| 20100034779 | COMPOSITIONS AND METHODS FOR PRODUCING PLURIPOTENT CELLS FROM ADULT TESTIS - The present application describes a method of producing embryonic stem cell (ESC)-like cells derived from adult mammalian testis. Furthermore, the application describes to a method of producing embryoid bodies from ESC-like cells as well as a method of producing a tissue and/or a differentiated cell from the ESC-like cell or the embryoid body. In addition, an ESC-like cell, an embryoid body and/or differentiated cell and/or tissue obtainable by said methods and pharmaceutical preparations containing the same are provided. Finally, the application describes to the use of these products for medical treatments and the preparation of pharmaceutical compositions for medical treatments. | 02-11-2010 |
| 20100034780 | TUMOR ANTIGEN PEPTIDE DERIVED FROM AMACR - The present invention relates to a peptide which comprises a partial peptide derived from AMACR and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier, and the like. | 02-11-2010 |
| 20100034781 | Oxysterol Compounds and the Hedgehog Pathway - This invention relates, for example, to synthetic oxysterols. Also described are methods for using the compounds, including treating subjects in need thereof, and pharmaceutical compositions and kits for implementing methods of the invention. | 02-11-2010 |
| 20100034782 | Methods of Using Anti-Thymocyte Globulin and Related Agents - Uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-beta are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases. | 02-11-2010 |
| 20100034783 | Medical kit and using method thereof - An aseptic/sterile medical kits are comprising a cartilage regeneration kit, a bone regeneration kit or an umbilical cord blood storage kit in a configuration that each process performs according to functionally-specialized kit sets for each step, via division of overall processes into corresponding steps for isolation, culture, collection and storage of cells, and implantation of desired cells into target sites of the body. The cartilage is regenerated by cartilage tissue collection; chondrocyte isolation; chondrocyte medium change and subculture; preparation of chondrocyte therapy product; media for isolation/culture/preparation/cryopreservation of cells; and media for isolation/culture/cryopreservation of cells, using the cartilage regeneration kit. The bone is regenerated by bone marrow collection; osteoblast isolation; osteoblast medium change and subculture; and preparation of osteoblast therapy product, using the bone regeneration kit. Additionally, the umbilical cord blood is stored by umbilical cord blood collection; hematopoietic stem cell isolation; and cryopreservation of hematopoietic stem cells, using the umbilical cord blood storage kit. | 02-11-2010 |
| 20100034784 | USE OF FUSED NICOTINAMIDES TO PROMOTE NEUROGENESIS - The present invention provides a group of compounds found to increase the number of neurons derived from stem cells for use as a therapeutic agent in neurological conditions or diseases. In one embodiment of the present invention, the compounds are used to detect the mechanism by which the number of neurons is increased. | 02-11-2010 |
| 20100034785 | Differentiation of Pluripotent Cells into Primary Germ Layer Progenitors - This invention relates to the culture of pluripotent cells in a fully humanised chemically defined medium. Cells may be cultured over a prolonged period of time without losing their pluripotent status or may be controllably induced to differentiate into progenitor cells of the three primary germ layers by the addition of differentiation factors, for example differentiation factors which modulate one or more of the Activin/Nodal, FGF, Wnt or BMP signalling pathways. | 02-11-2010 |
| 20100034786 | Use of PI3K M-TOR and Akt Inhibitors to Induce FOXP3 Expression and Generate Regulatory T Cells - The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PBK alpha or PBK delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PBK inhibitors, PBK inhibitors for particular uses, and kits. | 02-11-2010 |
| 20100034787 | COMPOSITION AND METHODS FOR PROMOTING HAIR GROWTH - The present disclosure provides compositions and methods for promoting the growth of hair for cosmetic purposes as well as for treating disorders of hair growth. The compositions are conditioned media obtained from a three dimensional tissue that produces a combination of cellular factors effective to induce, promote, or enhance hair growth. | 02-11-2010 |
| 20100040581 | EPO DERIVATIVE-CONTAINING THERAPEUTIC AGENTS FOR BLOOD-RELATED DISEASES - Blood flow enhancers, vascular promoters or therapeutic agents for ischemic diseases containing an erythropoietin (EPO) derivative as an active ingredient. | 02-18-2010 |
| 20100040582 | Methods of selecting stem cells and uses thereof - A method of selecting stem cells from heterogeneous population of cells is disclosed. The method comprises contacting the population of cells with an apoptosis inducing agent under conditions which are apoptotic to non-stem cells and non-apoptotic to stem cells, thereby selecting the stem cells from the heterogeneous population of cells. The selected stem cells may then be used for a variety of applications including transportation and differentiation. | 02-18-2010 |
| 20100040583 | COMPOSITIONS AND METHODS USING STEM CELLS IN CUTANEOUS WOUND HEALING - Provided herein are compositions and methods using stem/progenitor cells in a therapeutic approach for the treatment of, or promotion of healing of, acute and chronic wounds. | 02-18-2010 |
| 20100040584 | METHODS FOR PROMOTING NEOVASCULARIZATION - The success of tissue engineering and therapeutic neovascularization depends on the development of a microvascular network. The present invention provides methods for promoting neovascularization in tissue engineering constructs, tissue repair, and wound healing comprising endothelial and mesenchymal progenitor cells. | 02-18-2010 |
| 20100040585 | METHODS FOR ISOLATING AND USING HEMATOPOIETIC AND EMBRYONIC STEM CELLS OF THE PERITONEAL CAVITY - The invention relates to the isolation and use of hematopoietic and embryonic stem cells. Additionally, the inventors identified the peritoneal cavity as a new source of hematopoietic stem cells. In one embodiment, the invention provides methods of isolating progenitor and/or stem cells from the peritoneal cavity. In another embodiment, the invention provides methods of transporting progenitor and/or stem cells from the peritoneal cavity to another organ. In another embodiment, the present invention provides methods of regenerating bioengineered tissues and/or reconstituting an hematopoietic system. | 02-18-2010 |
| 20100040586 | Treatment of Injuries to the Central Nervous System - The disclosure provides compositions and methods useful for treating injuries to the central nervous system (e.g., spinal cord injuries). The compositions and methods described herein can be optionally used in combination with a variety of techniques (e.g., surgical techniques) and/or therapies (e.g., physical therapy regimens) to affect treatment of injuries to the central nervous system. | 02-18-2010 |
| 20100040587 | CELLS FOR THERAPY OF THE HEART, METHOD OF OBTAINING A CELL PREPARATION, AND CELL PREPARATION - Fibroblast-like cells obtained from heart muscle biopsies, which are CD90 negative, CD105 positive, CD117 negative and/or CD166 positive as well as cell preparations of such cells for therapy of heart diseases, as well as a method for providing the latter. The cells are characterized by a good cultivability in cell culture. Furthermore a method for obtaining the cells and cell preparations according to the invention are disclosed. | 02-18-2010 |
| 20100040588 | Procurement, Isolation, and Cryopreservation of Endometrial/Menstrual Cells - Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefor are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II. | 02-18-2010 |
| 20100047210 | Systems and Methods for Positioning of Needles and Other Devices Within Body Tissue - Systems and methods for delivering a substance (e.g., a therapeutic or diagnostic substance, drug, biologic, cells, etc.) or device (e.g., implantable device, sensor, electrode, etc.) to a specific location within a tissue mass (e.g., an organ, tumor, other mass of body tissue, etc.) that is located a spaced distance from an open or fluid-filled space, body cavity or body lumen. | 02-25-2010 |
| 20100047211 | METHOD OF GROWTH OF MESENCHYMAL CELLS UNDER NON-ADHERENT CONDITIONS FOR CLINICAL APPLICATIONS - The invention provides methods for expanding mesenchymal stem cells (MSCs) in non-adherent cultures. The methods include the propagation of MSCs in or on non-adherent matrices. The invention further provides administration and the use of cells propagated by the method of the invention for administration and preparation of a therapeutic agent. The invention further provides kits including cells propagated by the methods of the inventions. | 02-25-2010 |
| 20100047212 | USE OF THE PEDF FACTOR TO INDUCE CELL REGENERATION - Use of the PEDF factor to induce cell regeneration. The present invention refers to the use of the molecule PEDF for the manufacture of medicines to activate processes included in the group of regenerative processes, such as skin regeneration, wound healing, cell therapy for cardiac, neural, or hematopoietic regeneration. It also refers to the manufacture/use of pharmaceutical compounds that contain an efficient quantity of the PEDF factor for stem cell self-renewal. | 02-25-2010 |
| 20100047213 | CELL COMPOSITION AND METHODS OF MAKING THE SAME - Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby. | 02-25-2010 |
| 20100047214 | Methods and Compositions for Treatment of Bone Defects with Placental Cell Populations - Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual. | 02-25-2010 |
| 20100047215 | STEM CELL TARGETING METHODS - The present invention is directed to methods for delivering stem cells to a target tissue in a mammal using glycoconjugate to traffic the stem cells to a desired organ in the mammal. The methods according to the present invention are especially applicable to administering stem cells such as those derived from the bone marrow or from umbilical cord tissue. The methods are also useful for targeting a gene of interest to a tissue in a mammal by introducing a cell containing the gene of interest and administering a glycoconjugate to the mammal. | 02-25-2010 |
| 20100055074 | Light as a Replacement for Mitogenic Factors on Progenitor Cells - The present invention generally relates to a method of using light treatment supporting specific cell types in a subject. Specifically, the present invention relates to methods for stimulating the proliferation, migration, differentiation and survival of cell using specific parameter of lights. These methods are particularly useful in the cellular regeneration and replacement in a tissue injury, such as CNS or PNS injury, and in transplantation of organs, tissues and cells. | 03-04-2010 |
| 20100055075 | METHODS OF TREATING ISCHEMIC SPASTITICY - The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord. | 03-04-2010 |
| 20100055076 | Mesenchymal stem cell-mediated autologous dendritic cells with increased immunosuppression - A method for preparing dendritic cells which have an enhanced potential to suppress immune responses, method for suppressing immune response by comprising administering them, dendritic cells carrying a potential to suppress immune responses, and a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses. The present dendritic cells having an enhanced potential to suppress immune responses can be utilized for treating or preventing various diseases or disorders through the suppression of immune responses. In addition, the enhanced immunotolerance potential of the dendritic cells ensures the cells to be effectively used as an immunosuppressive agent. | 03-04-2010 |
| 20100055077 | METHODS FOR INCREASING AND MOBILIZING HEMATOPOIETIC STEM CELLS - A method is provided for increasing the number of hematopoietic stem cells in the bone marrow, increasing the mobilization of these cells to migrate from the bone marrow to the bloodstream and elsewhere, and increasing the number of differentiating hematopoietic stem cells in the bloodstream. | 03-04-2010 |
| 20100055078 | METHODS OF MAKING A TRANSPLANTABLE BONE REPAIR SYSTEM USING MULTIPOTENT STEM CELLS - Methods are provided herein for making a biocompatible transplantable bone repair device. In some examples, the method includes culturing multipotent stem cells with a first medium containing a fibroblast growth factor (FGF), such as fibroblast growth factor-2 (FGF-2), in the substantial absence of dexamethasone, seeding a biologically compatible substrate including extracellular matrix (ECM) with the multipotent stem cells cultured with FGF, and inducing the cells to differentiate to osteoblast cells by culturing with a second medium containing a differentiation factor (such as bone morphogenetic protein, such as bone morphogenetic protein-2 (BMP-2)), in the substantial absence of dexamethasone. Also provided are methods for treating a bone defect by surgically implanting the biocompatible transplantable bone repair device at the site of a bone defect. | 03-04-2010 |
| 20100055079 | Method of Harvesting, Isolating, and Culturing Neural Stem Cells and Related Methods of Treating a Patient - The present invention provides a method of producing purified neural stem cells, comprising harvesting fluid containing neural stem cells from cerebrospinal fluid surrounding the spinal cord of an individual, isolating the neural stem cells from the fluid, culturing the neural stem cells in a culture medium effective to induce proliferation of the neural stem cells and purifying the cultured neural stem cells. Also provided is a method of treating a patient afflicted with a neurological condition, in which the purified neural stem cells are administered autologously into the same individual or heterologously to a patient other than the individual. Administration of the purified neural stem cells results in the purified neural stem cells propagating in the site of the brain region afflicted with the neurological condition. | 03-04-2010 |
| 20100061962 | Tissue Engineered Cartilage, Method of Making Same, Therapeutic and Cosmetic Surgical Applications Using Same - Cartilage has been constructed using biodegradable electrospun polymeric scaffolds seeded with chondrocytes or adult mesenchymal stem cells. More particularly engineered cartilage has been prepared where the cartilage has a biodegradable and biocompatible nanofibrous polymer support prepared by electrospinning and a plurality of chondocytes or mesenchymal stem cells dispersed in the pores of the support. The tissue engineered cartilages of the invention possess compressive strength properties similar to natural cartilage. Methods of preparing engineered tissues, including tissue engineered cartilages, are provided in which an electrospun nanofibrous polymer support is provided, the support is treated with a cell solution and the polymer-cell mixture cultured in a rotating bioreactor to generate the cartilage. The invention provides for the use of the tissue engineered cartilages in the treatment of cartilage degenerative diseases, reconstructive surgery, and cosmetic surgery. | 03-11-2010 |
| 20100061963 | Methods of Improving Stem Cell Homing and Engraftment - A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential. | 03-11-2010 |
| 20100061964 | METHOD FOR PREPARING PANCREATIC BETA CELLS STARTING FROM BETA CELL PROGENITORS AND BETA CELLS THEREBY OBTAINED - The present invention relates to a method for preparing pancreatic islet cells, and preferably pancreatic beta cells starting from progenitor cells obtained from the pancreas of an adult mammal. The invention also provides a method for isolating progenitor cells, and preferably beta cell progenitors, from the pancreas of an adult mammal. Other aspects of the invention comprise the pancreatic islet (beta) cells and the progenitor cells that can be obtained with the present invention and their use, e.g. in diagnostic, therapeutic or research applications. | 03-11-2010 |
| 20100061965 | RESPIRATORY SYNCYTIAL VIRUS RENDERS DENDRITIC CELLS TOLEROGENIC - The present invention includes compositions, methods and systems for inducing immune tolerance using antigen presenting cells by infecting isolated antigen presenting cells with an effective amount of respiratory syncytial virus (RSV) or portions thereof sufficient to infect the antigen presenting cells and contacting CD4 | 03-11-2010 |
| 20100061966 | Cardiac Stem Cells - Human cardiac stem cells can be isolated from endomyocardial biopsies. Such cells mediate cardiac regeneration and improve heart function in a mouse infarct model. The cells can be used for autologous, allogeneic, syngeneic, or xenogeneic therapeutic applications in patients. The stem cells can be genetically modified to enhance their therapeutic activity. | 03-11-2010 |
| 20100068186 | High affinity telomerase t cell receptors - The present invention provides T cell receptors (TCRs) having the property of binding to ILAKFLHWL-HLA-A*0201 and comprising at least one TCR α chain variable domain and/or at least one TCR β chain variable domain CHARACTERISED IN THAT said TCR has a K | 03-18-2010 |
| 20100068187 | TRANSCRIPTION FACTORS FOR DIFFERENTIATION OF ADULT HUMAN OLFACTORY PROGENITOR CELLS - A method of transplantation that includes lineage priming human progenitor cells, to form lineage primed cells and transplanting the lineage primed cells into a patient. The lineage primed cells are selected from the group consisting of oligodendrocytic lineage primed cells, dopaminergic lineage primed cells, and motoneuronal lineage primed cells, and lineage priming has an efficiency of at least 1%. | 03-18-2010 |
| 20100068188 | COMPOSITION FOR REGENERATION OF PERIODONTAL HARD TISSUE AND METHOD FOR REGENERATION OF PERIODONTAL HARD TISSUE - An object of the present invention is to provide technology of using a preadipocyte to restore comprehensively bone, cartilage and periodontal ligament, and cause a periodontal hard tissue to regenerate. By culturing a preadipocyte using a culture medium containing (i) at least one member selected from the group consisting of glycerophosphate and salts thereof, and (ii) at least one member selected from the group consisting of ascorbic acid, derivatives thereof and salts thereof and not containing an adrenal cortical hormone in such an amount that promotes differentiation of a preadipocyte into a periodontal hard tissue cell, differentiation of the cell into a periodontal hard tissue cell is induced efficiently. Furthermore, a scaffold is combined with the preadipocyte cultured with the above-mentioned culture medium to be transplanted into a periodontal tissue that requires regeneration. | 03-18-2010 |
| 20100068189 | Method for Expanding Adult Stem Cells from Blood and Compositions and Methods for Using the Same - A method for the expansion of adult stem cells from blood, particularly but not only peripheral blood, involves removing adult stem cells from blood of a mammal, immediately expanding the stem cells via in-vitro treatment with MCSF (Macrophage Colony Stimulating Factor) at a concentration of about 8-15 nM, and purifying the expanded stem cells. Compositions and methods of using the expanded adult stem cells are also described. | 03-18-2010 |
| 20100068190 | MESOANGIOBLAST-LIKE CELL AS WELL AS METHODS AND USES RELATING THERETO - The present invention relates to a medicament comprising a mesoangioblast-like cell obtained from a subject, a method of isolating a mesoangioblast-like cell, a method of producing a mesoderm-derived cell using a mesoangioblast-like cell, the use of a mesoangioblast-like cell for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease and a method of converting the mesoangioblast-like cell into a pluripotent stem cell. | 03-18-2010 |
| 20100068191 | PURIFIED MESENCHYMAL STEM CELL COMPOSITIONS AND METHODS OF PURIFYING MESENCHYMAL STEM CELL COMPOSITIONS - One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed. | 03-18-2010 |
| 20100074874 | SYNTHETIC MULTI-LAYER STRUCTURES COMPRISING BIOPOLYMER FIBRES - The invention relates to a method for the in vitro preparation of a synthetic multi-layer structure comprising biopolymer fibers, wherein the biopolymer fibers in each layer are unidirectionally and uniformly oriented, which comprises successive polymerisation of layers of a biopolymer fiber forming solution in the presence of a magnetic field, wherein the fiber orientation in at least one layer differs from that in at least one of its superior and/or inferior layer according to an angle alpha. The invention also relates to a biological tissue-like multi-layer structure comprising the synthetic multi-layer structure and cells inoculated therein, such as an orthogonal multi-layer collagen and/or fibrin tissue-like cornea, and the method for its preparation. The invention may be used for preventing or treating a damaged tissue, or for creating a model for biological testing, such as pharmacotoxicity testing. | 03-25-2010 |
| 20100074875 | COMPOSITION CONTAINING HUMAN UMBILICAL CORD BLOOD-DERIVED MESENCHYMAL STEM CELL FOR INDUCING DIFFERENTIATION AND PROLIFERATION OF NEURAL PRECURSOR CELLS OR NEURAL STEM CELLS TO NEURAL CELLS - A use of a composition comprising umbilical cord blood-derived mesenchymal stem cells for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells is provided, the composition being effective for the treatment of nerve injury diseases. | 03-25-2010 |
| 20100074876 | CALCIUM PHOSPHATE DELIVERY VEHICLES FOR OSTEOINDUCTIVE PROTEINS - A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also disclosed. | 03-25-2010 |
| 20100080777 | COMPOSITION CONTAINING AUTOLOGOUS MONONUCLEAR CELLS AND PIG COLLAGEN SCAFFOLD IN PASTE FORM AND ITS USE IN THE PREPARATION OF A MEDICAMENT FOR SURGICAL TREATMENT - Composition including autologous mononuclear cells supported on scaffold chosen from the group including lyophilized scaffold or pre-constituted scaffold in the form of membrane or tissue, with possible addition of platelet gel, as well as use of said composition for the preparation of medicaments for surgical treatments. | 04-01-2010 |
| 20100080778 | STEM CELL EXPANSION ENHANCING FACTOR AND METHOD OF USE - The present invention relates to a stem cell expansion factor, and to a method for enhancing hematopoietic stem cell expansion by direct delivery of a protein in the cell and which protein is able to cross cell membrane. The method comprises directly delivering in a HSC an amino acid sequence having the activity of a peptide encoded by a Hoxb4 nucleotide sequence. Once delivered, the amino acid sequence is functionally active in the hematopoietic stem cell and enhances expansion thereof. The amino acid sequence may is a HOXB4 or HOXA4 protein. | 04-01-2010 |
| 20100080779 | Methods related to wound healing - The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination. | 04-01-2010 |
| 20100080780 | PLURIPOTENT AUTOLOGOUS STEM CELLS FROM ORAL MUCOSA AND METHODS OF USE - The present invention provides a new readily accessible source of adult somatic stem cells from the gastrointestinal tract in general and oral mucosa in particular, methods for isolating pluripotent stem cells from oral mucosa, cells derived therefrom and uses thereof. | 04-01-2010 |
| 20100080781 | Preventing Transfusion Related Complications in a Recipient of a Blood Transfusion - This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood. | 04-01-2010 |
| 20100086523 | METHOD FOR GENERATING PLURIPOTENT STEM CELLS - The present invention relates to a method for generating pluripotent stem cells and to pluripotent stem cells generated from human testis. | 04-08-2010 |
| 20100086524 | CELLULAR PREPARATIONS FOR USE AS A REVASCULARIZATION STIMULATING AGENT - The invention relates to a cellular preparation containing endothelial cell precursors (EPCs) and smooth muscular cell precursors (SMCs), as a combination product for simultaneous, separated or time-spread administration, used as a revascularisation stimulating agent. The invention also relates to the use of such a cellular preparation. | 04-08-2010 |
| 20100086525 | Compositions and Methods for Altering Pancreas or Liver Function - Methods for altering pancreatic and liver cell function are provided, wherein the compositions and methods are based on use of osteopontin or on altering the activity of osteopontin. | 04-08-2010 |
| 20100092432 | CELL PREPARATION CONTAINING MULTIPOTENTIAL STEM CELLS ORIGINATING IN FAT TISSUE - [Problems] To provide a novel use of multipotential stem cells originating in a fat tissue. | 04-15-2010 |
| 20100092433 | VASCULARIZED ISLETS AND METHODS OF PRODUCING SAME - An isolated composition of matter is provided comprising a heterogeneous population of cells seeded on a surface of a scaffold, wherein the heterogeneous population of cells comprises at least one pancreatic islet, endothelial cells and fibroblast cells. Methods of generating same and uses thereof are also provided. | 04-15-2010 |
| 20100092434 | THROMBOPOIETIC ACTIVITY OF TYROSYL-TRNA SYNTHETASE POLYPEPTIDES - Thrombopoietic compositions are provided comprising tyrosyl tRNA synthetase polypeptides, including truncations and/or variants thereof. Also provided are methods of using such compositions in the treatment of conditions that benefit from increased thrombopoiesis, such as thrombocytopenia. | 04-15-2010 |
| 20100092435 | USE OF A VARICELLOVIRUS TAP-INHIBITOR FOR THE INDUCTION OF TUMOR-OR VIRUS-SPECIFIC IMMUNITY AGAINST TEIPP - The present invention provides a novel approach to the modulation of the immune response, directing it towards specific antigens, away from antigens against which no response is desired. The invention is based on the use of viral immune evasion proteins, such as UL49.5, which block antigen presentation to CD8+ T cells. The viral immune evasion proteins are used for: 1) the induction of tumor-specific or virus-specific immunity in cases where a conventional immune response is absent due to antigen processing defects; 2) the induction of empty MHC class I molecules at the cell surface that can be loaded with peptides of a desired specificity; 3) the inhibition of unwanted immune responses against transplanted tissues or organs, e.g. against islets of Langerhans in type 1 diabetes or allogeneic stem cells, or against self antigens in the case of autoimmunity. | 04-15-2010 |
| 20100092436 | COMPOSITIONS AND METHODS FOR RESTORING IMMUNE RESPONSIVENESS IN PATIENTS WITH IMMUNOLOGICAL DEFECTS - The present invention relates generally to methods for stimulating, activating, and maintaining or increasing the polyclonality of expressed TCRs in a population of T cells. In the various embodiments, cells are stimulated with a surface, wherein the surface has attached thereto one or more agents that ligate a cell surface moiety of at least a portion of the T cells and stimulates at least a portion of the T cells, yielding enhanced proliferation, cell signal transduction, and/or cell surface moiety aggregation. In certain aspects methods for stimulating a population of cells such as T-cells, by cell surface moiety ligation are provided by contacting the population of cells with a surface, that has attached thereto one or more agents that ligate a cell surface moiety thereby inducing cell stimulation, cell surface moiety aggregation, and/or receptor signaling enhancement. Also provided are methods for producing T-cells for the use in diagnostics and the treatment of a variety of indications, including cancer, viral infection, and immune related disorders. Compositions of cells having increased polyclonality produced by these processes are further provided. | 04-15-2010 |
| 20100098669 | USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA - Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae. | 04-22-2010 |
| 20100098670 | Autologous dental pulp stem cell-based bone graft substitute - The invention features methods and compositions for promoting the growth and differentiation of dental pulp stem cells and the use of the differentiated cells for the treatment of orthopedic conditions. | 04-22-2010 |
| 20100098671 | COMPOSITION FOR PREVENTION OR TREATMENT OF BONE MARROW DAMAGE - Disclosed herein are a composition for prevention or treatment of bone marrow damage comprising Substance-P as an active ingredient; a use of Substance-P for the preparation of a medicament for prevention or treatment of bone marrow damage; a method for prevention or treatment of bone marrow damage comprising administering a therapeutically effective amount of Substance-P to a mammal; an anticancer supplement comprising Substance-P as an active ingredient; a use of Substance-P for the preparation of an anticancer supplement; and a method for prevention or treatment of cancer comprising administering a therapeutically effective amount of Substance-P as an anticancer supplement to a mammal. | 04-22-2010 |
| 20100098672 | USE OF MESENCHYMAL STEM CELLS FOR TREATING GENETIC DISEASES AND DISORDERS - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 04-22-2010 |
| 20100098673 | BONE GRAFT COMPOSITES AND METHODS OF TREATING BONE DEFECTS - Bone graft compositions comprising demineralized bone matrix, calcium phosphate, collagen and bioinductive cellular solution. Methods to repair and heal defective and missing bone using the bone graft compositions are also described. | 04-22-2010 |
| 20100104539 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 04-29-2010 |
| 20100104540 | METHODS AND COMPOSITIONS FOR TREATMENT OF FIBROSIS - Treatment methods and compositions for the treatment of fibrosis are provided. In some embodiments, these methods include augmentation of dendritic cells for treatment of fibrosis. In some embodiments, fms-like tyrosine kinase 3 ligand (Flt3L) is used for the treatment of fibrosis and/or the augmentation of dendritic cells. In certain embodiments, the invention relates to methods for the treatment of fibrosis using Flt3L-expanded dendritic cells. In certain embodiments, the fibrosis is hepatic or pulmonary fibrosis. | 04-29-2010 |
| 20100104541 | Method for Preventing and Treating Cardiovascular Diseases with BRCA1 - Methods for inhibiting cardiomyocyte apoptosis and/or to improving cardiac function and inhibiting inflammation-induced apoptosis in endothelial cells by delivering BRCA1 are provided. Such methods are useful in treatment and prevention of cardiovascular diseases. | 04-29-2010 |
| 20100104542 | CELL TRANSPLANTATION - The present invention provides polymers for use in preventing damage to the membranes of cells in fat grafts. Mixing of a triblock copolymer such as poloxymer P188 with adipocytes or adipose tissue to be transplanted into a subject is thought to stabilize the membranes of the cells leading to more successful fat transplantation in soft tissue reconstruction or augmentation. Such methods may also be used in the transplantation of adult stem cells or other cells derived from fat tissue. Other agents such as lipoic acid may also be added to the polymer/cell compositions for cell transplantation. | 04-29-2010 |
| 20100104543 | CELLULAR COMPOSITIONS AND METHODS OF MAKING AND USING THEM - The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differentiation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and/or immunological features of non-hematopoietic cells; and uses of the cellular compositions. The invention also relates to a method for the expansion of hematopoietic stem and progenitor cells. | 04-29-2010 |
| 20100104544 | SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE - Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein the cells have been expanded in vitro. The kidney cells preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells express EPO in vivo in an oxygen tension-dependent manner. | 04-29-2010 |
| 20100111905 | METHODS FOR IMPROVED ENGRAFTMENT FOLLOWING STEM CELL TRANSPLANTATION - The present invention relates to methods repairing, regenerating, and reconstituting tissues by transplanting at least two stem cell populations, wherein the first and the second population of stem cells are introduced into a subject separated by a time interval of about 2 to about 24 hours. The stem cells can be derived from umbilical cord, mobilized peripheral blood, or bone marrow. The cells of at least the second population may be enriched for adult stem and progenitor cells. The methods of the invention are useful in accelerating hematopoeitic recovery in subjects following myeloablation or chemotherapy. | 05-06-2010 |
| 20100111906 | VOLUME MAINTAINING OSTEOINDUCTIVE/OSTEOCONDUCTIVE COMPOSITIONS - An osteoinductive/osteoconductive composition prepared from a quantity, of demineralized fibrous bone elements possessing an average surface area to volume ratio of about 100:1 to about 20:1, a quantity of mostly shaped regular non-fibrous bone elements possessing an average surface area to volume ratio of about 10:1 or less and a sufficient quantity of biocompatible fluid carrier sufficient to provide the composition as a deformable mass is provided herein. Also provided is a method of using the composition to repair a bone defect site. | 05-06-2010 |
| 20100111907 | Methods and compositions for gene inactivation - Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. | 05-06-2010 |
| 20100111908 | Induction of Renal Cells for Treatment of Kidney Disease - Methods and systems for the generation of induced renal cells are provided. For example, methods for inducing renal cells from lineage undifferentiated hematopoietic stem and/or progenitor cell incubated with growth factors are described. Furthermore, the invention provides methods for using induced renal cells for treating a renal disease and/or injury. | 05-06-2010 |
| 20100111909 | Dedifferentiation of Adult Mammalian Cardiomyocytes into Cardiac Stem Cells - Dedifferentiation is a mechanism whereby specialized cells regain properties of their ancestors, including, in the extreme, stemness. We found that highly-purified cardiomyocytes isolated from adult mammalian hearts dedifferentiated rapidly when cultured in mitogen-rich medium. Such myocytes reentered the cell cycle and proliferated, expressing stem cell surface markers such as c-kit and early cardiac transcription factors including GATA and NKx2.5. These myocyte-derived cells (MDC) were capable of re-differentiating into myocytes and endothelial cells. Contrary to prevailing dogma, cardiomyocyte dedifferentiation yields proliferative cells expressing stem cell markers and capable of multilineage differentiation. Cardiomyocyte dedifferentiation is a potential source of endogenous stem cells in the adult heart. | 05-06-2010 |
| 20100119489 | Stimulation of Pancreatic Beta Cell Proliferation - This invention provides a polypeptide, TMEM27, and secreted forms thereof, nucleic acids and constructs encoding the same, and cells comprising the same. The TMEM27 protein is expressed in hormone positive cells at early stages of pancreas development and pancreatic β-cells in the mature pancreas, whose expression promotes pancreatic β-cell replication and increased islet mass. Applications of the protein in diagnostics and therapeutics are described. | 05-13-2010 |
| 20100119490 | Therapeutic Use of CD31 Expressing Cells - As described below, the present invention features compositions and methods related to the isolation, culture and therapeutic use of CD31-expressing cells. | 05-13-2010 |
| 20100119491 | DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF - In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity. | 05-13-2010 |
| 20100119492 | Method and device for activating stem cells - Invention embodiments described herein include methods and devices for stimulating mesenchymal stem cells in a stem cell source to differentiate into osteoblasts capable of forming bone. Devices and methods described include exposing a stem cell source, such as bone marrow aspirate, adipose tissue and/or purified allogenic stem cells, to an active agent, in a manner effective to form activated stem cells. | 05-13-2010 |
| 20100119493 | Telencephalic Glial-Restricted Cell Populations and Related Compositions and Methods - Provided herein are telencephalic glial-restricted precursor cell populations and related compositions. Related compositions include, but are not limited to, any cell or cell population derived from a population of telencephalic glial-restricted precursor cells. Further provided are methods of using and producing telencephalic glial-restricted precursor cell populations and related compounds. | 05-13-2010 |
| 20100119494 | METHODS AND COMPOSITIONS RELATED TO MODULATING THE EXTRACELLULAR STEM CELL ENVIRONMENT - This invention relates, in part, to methods and compositions that modulate the stem cell environment. More specifically, the invention relates, in part, to methods and compositions for modulating stem cell differentiation. Therefore, methods and compositions are provided for modulating glycosaminoglycan moieties, e.g., heparan sulfate glycosaminoglycan (HSGAG) moieties, in the microenvironment of stem cells. Methods and compositions for promoting or inhibiting embryonic stem cell differentiation (e.g., differentiation into endothelial cells) are also provided. This invention also relates, therefore, in part, to cell populations (e.g., endothelial cell populations or impoverished endothelial cell populations) that can be produced with the methods and compositions provided. Furthermore, the invention relates, in part, to tissues, and uses thereof, formed by the methods and compositions provided. Moreover, the invention also relates, in part, to methods of treatment using the methods and compositions provided. | 05-13-2010 |
| 20100119495 | HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES - The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides. | 05-13-2010 |
| 20100124547 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VII GENES - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Factor VII gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a Factor VII gene using said pharmaceutical composition; and methods for inhibiting the expression of Factor VII in a cell. | 05-20-2010 |
| 20100129327 | METHOD OF TREATING HEARING LOSS - The present invention relates to a method of generating cochlear hair cell-like cells in the inner ear of a subject. Preferably, the subject is human and is suffering from sensorineural hearing loss. The invention also relates to a method of generating cochlear hair cell-like cells in vitro and use of the cochlear hair cell-like cells for treating or preventing sensorineural hair loss in a subject. | 05-27-2010 |
| 20100129328 | METHODS FOR PROMOTING HAIR GROWTH - The invention is directed to methods for promoting hair growth. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 05-27-2010 |
| 20100129329 | METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION - The present invention relates to methods repairing, regenerating, and reconstituting tissues by transplanting at least two stem cell populations, wherein the first and the second population of stem cells are introduced into a subject separated by a time interval of about 2 to about 24 hours. The first population comprises stem cells derived from umbilical cord. The second population comprises ALDHbr cells. These ALDHbr cells can be administered to a patient immediately after isolation or can be primed in culture using a combination of cytokines for about 2 to about 7 days prior to transplantation. The methods of the invention are useful in accelerating time to neutrophil and/or platelet engraftment and immune reconstitution following myeloablative therapy. | 05-27-2010 |
| 20100129330 | ADIPOCYTIC DIFFERENTIATED ADIPOSE DERIVED ADULT STEM CELLS AND USES THEREOF - The present invention is differentiated adipose tissue-derived stromal cells that exhibit the improved properties of increased extracellular matrix proteins and/or a lower amount of lipid than a mature isolated adipocyte. Methods for the expansion and differentiation of these cells are also provided. The cells of the invention are used for the treatment, repair, correction and/or regeneration of soft tissue cosmetic defects. | 05-27-2010 |
| 20100129331 | DISACCHRIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS, AND BONES - The present invention relates to the use of a series of disaccharides, as well as of compositions containing them, for the preparation of a medicament for the treatment or prevention of a tendon, ligament or bone disease, disorder or injury. The present invention also relates to the new compositions comprising a disaccharide in combination with inulin polysulphate, a glycosamino-glycan, a growth factor or cells. The glycosaminoglycan is preferably chondroitin sulphate or hyaluronic acid and the growth fact is IFG-1. | 05-27-2010 |
| 20100135963 | USE OF PAX4 IN PANCREATIC CELL PROLIFERATION - The present invention relates to an in vitro method for the generation and isolation of pancreatic β-cells, comprising the steps of (a) contacting an adult cell derived from mammalian pancreatic islets or an explant culture of adult pancreatic islets with functional, wild-type Pax4; and (b) detecting and isolating; from said adult cell or explant culture, β-cells that proliferate in response to the contact with Pax4. Furthermore, the use of functional; wild-type Pax4 for the preparation of a pharmaceutical composition for transplantation and/or tissue replacement is described. | 06-03-2010 |
| 20100135964 | TISSUE GRAFTING METHOD - The tissue grafting method relates to a tissue graft material, a method of preparing the material, and a method of using the material. The tissue graft material is made from the tunica serosa of the small intestine of a warm-blooded vertebrate, which has been delaminated from the tunica muscularis, tunica submucosa, and the tunica mucosa of the intestinal tissue. The tissue graft material may be perforated by discrete punctures. The tissue graft material is dehydrated by air drying or vacuum drying, sterilized with ethylene oxide, and stored in a hermetically sealed enclosure at room temperature until needed, having an indefinite storage life. When needed, the tissue graft material is rehydrated, cut to match the size of the wound, and applied to the wound. The graft may be overlaid with nylon mesh, or bandaged with an elastic tubular dressing. | 06-03-2010 |
| 20100135965 | METHOD OF CHONDROGENIC DIFFERENTIATION FROM MESENCHYMAL STEM CELL, AND COMPOSITION COMPRISING CHONDROGENIC CELL DIFFERENTIATED USING THE METHOD TO TREAT DISEASE CAUSED BY CARTILAGE DAMAGE - Provided are a method of chondrogenic differentiation from mesenchymal stem cells and a composition comprising chondrogenic cells differentiated using the method to treat diseases caused by cartilage damage. In the method, a centrifugal force is applied to human mesenchymal stem cells to be differentiated into chondrogenic cells. The chondrogenic differentiation may be achieved at moderate cost without using expensive cytokines or growth factors by periodically applying only a centrifugal force. According to the method of chondrogenic differentiation from mesenchymal stem cells in the present embodiment, chondrogenic cells may be also differentiated from human mesenchymal stem cells. | 06-03-2010 |
| 20100135966 | AGENTS FOR TREATING FLAVIVIRIDAE INFECTIONS - The invention relates to agents for the treatment, therapy and inhibition of Flaviviridae virus infections, which agents comprise proteasome inhibitors as the active component. The agents which are used for inhibiting the release, maturation and replication of Flaviviridae comprise, as the active component in pharmaceutical preparations, substance classes which share the common property of inhibiting the 26S proteasome in cells. These substance classes include, in particular, proteasome inhibitors which affect the activities of the ubiquitin/proteasome pathway, in particular the enzymic activities of the 26S and the 20S proteasome complex. The application of the invention lies in the antiviral therapy of Flaviviridae infections, especially in preventing the establishment and maintenance of a chronic hepatitis C virus infection and a hepatopathogenesis which is associated therewith. | 06-03-2010 |
| 20100135967 | CULTURED CARTILAGE/BONE CELLS/TISSUE, METHOD OF GENERATING SAME AND USES THEREOF - A method of generating cultured chondrocytes/endochondral bone cells is provided. The method comprising isolating chondrocytes from mandibular condyle tissue, and culturing the isolated chondrocytes. A method of isolating chondrocytes from mandibular condyle tissue is further provided. The method comprises isolating mandibular condyle tissue from a mammal and treating the mandibular condyle tissue so as to selectively remove fibroblast-like cells and/or myocytes therefrom, the modified mandibular condyle tissue including chondrocytes, and selectively collecting the chondrocytes from the modified mandibular condyle tissue. | 06-03-2010 |
| 20100135968 | Oligodendrocyte Production From Multipotent Neural Stem Cells - This invention relates to methods of producing oligodendrocytes from multipotent neural stem cells by using at least one oligodendrocyte promoting factor, particularly granulocyte-macrophage colony stimulating factor, granulocyte colony stimulating factor, interleukin 3 or interleukin 5. The neural stem cells may optionally be expanded prior to being subjected to the oligodendrocyte promoting factor. | 06-03-2010 |
| 20100135969 | METHOD OF TREATING CANCER USING PLATELET RELEASATE - Platelets are concentrated from the blood of a patient. The platelets are treated by a method such as ultrasound or agitation to obtain platelet releasate. This releasate as a whole or a component thereof is formulated into an injectable formulation which is administered to the same patient the platelets were extracted from in order to treat the patient's cancer. | 06-03-2010 |
| 20100143310 | SPINAL NERVE REPAIR PROMOTING THERAPEUTICS CONTAINING GHRELIN OR ITS DERIVATIVES OR SUBSTANCES THAT ACT ON GHS-R1a AS AN ACTIVE INGREDIENT - The invention provides a spinal neuron damage treating agent for use in the treatment of spinal neuron damage, or an agent for promoting the proliferation of spinal neuronal precursor cells in the culture of spinal neuronal precursor cells, or an agent for promoting the regeneration of spinal nerves after transplantation of cultured spinal neuronal precursor cells, and the like. | 06-10-2010 |
| 20100143311 | ANTICANCER THERAPY BY TRANSPLANTING VASCULAR ENDOTHELIAL PROGENITOR CELLS - It is intended to provide anticancer therapy using autologous cells or the like, which induces the regression of cancer or has favorable drug delivery effects and brings about reduction or withdrawal of a hypoxic region(s) in tumor. Transplantation of endothelial progenitor cells, via intravenously or other methods leads to tumor growth inhibition, an increase of the vascular density with an enlargement of the vascular diameter, and reduction of a hypoxic region(s) in the tumor. Allogeneic transplantation of endothelial progenitor cells may be achieved to secure the cells for the therapy, however, autologous transplantation of endothelial progenitor cells from cancer patients would be desirable in order to evade rejection. When the autologous cells are used, mononuclear cells are separated from the peripheral blood or bone marrow of the patient and cultured using an endothelial differentiation medium containing cytokines such as VEGF to obtain adherent cells, which can then be collected and advantageously used as endothelial progenitor cells. | 06-10-2010 |
| 20100143312 | TREATMENT OF DISEASES, DISORDERS OR CONDITIONS OF THE LUNG USING PLACENTAL CELLS - Provided herein are compositions and methods of treatment of individuals having a disease, disorder or condition of the lung, comprising administering a therapeutically-effective amount of placental cells, e.g., placental stem cells. | 06-10-2010 |
| 20100143313 | HOMOGENEOUS DIFFERENTIATION OF HEPATOCYTE-LIKE CELLS FROM EMBRYONIC STEM CELLS - One of the major hurdles of cellular therapies for the treatment of liver failure is the low availability of functional human hepatocytes. Although embryonic stem (ES) cells represent a potential cell source for therapy, current methods for differentiation result in mixed cell populations or low yields of the cells of interest. The present invention provides for a rapid, direct differentiation method that yields a homogeneous population of endoderm-like cells with 95% purity. In one embodiment, mouse ES cells cultured on top of collagen-sandwiched hepatocytes differentiate and proliferate into a uniform and homogeneous cell population of endoderm-like cells. The endoderm-like cell population was positive for Foxa2, Sox17 and AFP, and could further differentiate into hepatocyte-like cells that demonstrate hepatic morphology, functionality, and gene and protein expression. Incorporating the hepatocyte-like cells into a bioartificial liver device to treat fulminant hepatic failure improved animal survival, thereby underscoring the therapeutic potential of these cells. | 06-10-2010 |
| 20100150875 | INDEFINITE CULTURE OF HUMAN ADULT GLIA WITHOUT IMMORTALIZATION AND THERAPEUTIC USES THEREOF - Cell culture conditions for the isolation, maintenance, and indefinite expansion of human glia are established favoring the growth of neural precursor cells. Cultured cells proliferate indefinitely, express catalytic telomerase, and retain a non-immortalized phenotype. Compositions allow for the indefinite expansion of non-immortalized neural tissue for bioassay applications and restorative neuroscience. | 06-17-2010 |
| 20100150876 | ENDODERMAL PROGENITOR CELLS - The present invention relates to endodermal progenitor cells and methods of isolation, culture, differentiation and use thereof. | 06-17-2010 |
| 20100150877 | Osteopontin for the Prediction and Treatment of Cardiovascular Diseases - Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin. | 06-17-2010 |
| 20100150878 | DERMAL MICRO-ORGANS, METHODS AND APPARATUSES FOR PRODUCING AND USING THE SAME - Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells so as to minimize cellular toxicity and concomitant death due to insufficient nutrition and accumulation of waste in the DMO. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure. Other embodiments are described and claimed. | 06-17-2010 |
| 20100150879 | Methods for the detection, isolation, and use of lipid phosphate phosphatase-3-positive stem cells - The present invention embraces antibodies that bind Lipid Phosphate Phosphatase-3, and use thereof in the detection and isolation of stems cells for promoting wound healing, neovascularization, and/or angiogenesis. | 06-17-2010 |
| 20100150880 | Isolated mesenchymal cell population and method for isolating and using same - The present invention provides a novel isolated mesenchymal cell population of highly purified osteoprogenitors (HipOPs) that can be used in the formation of bone tissue and methods for isolating and using same. | 06-17-2010 |
| 20100150881 | Compositions and Methods for Use of Scar Tissue in Repair of Weight Bearing Surfaces - Compositions and methods are provided for weight bearing surface, i.e., intervertebral disc (‘disc’), between spinous processes and articular cartilage, repair. Compositions include fibrosis inducing agents for facilitating fibrosis in or on the site in need of repair in order to form fibrotic connective tissue. In addition, methods are provided for distracting the appropriate disc space during treatment of a disc in need of repair, and in particular treatment of the disc in need of repair with a fibrosis inducing agent. | 06-17-2010 |
| 20100150882 | HUCBC TREATMENT OF AMYLOID ASSOCIATED DISEASE - Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ | 06-17-2010 |
| 20100150883 | STEM CELLS TREATED BY IN VITRO FUCOSYLATION AND METHODS OF USE - A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy. | 06-17-2010 |
| 20100158872 | Cardiomyocyte Cell Populations - The present invention provides methods for inducing the differentiation of cardiac progenitor cells and cell populations produced by the methods of the invention. The invention further provides a method of screening for agents that affect cardiomyocytes, and a method of cardiomyocyte replacement therapy. | 06-24-2010 |
| 20100158873 | METHOD FOR EXTRACTING AND SELECTING CELLS - Method for selecting cells, comprising at least one at least partially combined step of enzymatic digestion and of selection in culture. | 06-24-2010 |
| 20100158874 | Compositions and Methods for Treating Peripheral Vascular Diseases - The invention relates to methods for producing endothelial cells, pericytes and/or muscle cells (in particular smooth muscle cells), cell preparations and pharmaceutical compositions comprising the cells or preparations, and the use of the cells, preparations and compositions in research or commercial applications. In aspects, the invention provides a method of treating a patient with a condition involving endothelial cells, endothelial precursor cells, pericytes and/or muscle cells, such as a peripheral vascular disease, comprising administering to the patient endothelial precursor cells, endothelial cells, pericytes and/or muscle cells obtained from multipotent CD45 | 06-24-2010 |
| 20100158875 | MUSCLE DERIVED CELLS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL PATHOLOGIES AND METHODS OF MAKING AND USING THE SAME - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux. | 06-24-2010 |
| 20100158876 | PROCESS FOR THE PREPARATION OF STEM CELLS FROM HUMAN MUSCLE TISSUE AND ADIPOSE TISSUE, AND STEM CELLS OBTAINABLE BY THIS PROCESS - The invention relates to a process for the preparation of the human stem cells from muscle tissue or adipose tissue. The process provides for the incubation of cells obtained from a sample of muscle tissue or adipose tissue in a medium comprising BSA, Bfgf, EGF, VEGF, LIF, heparin and usual inorganic salts, natural acids and vitamins necessary for the growth of mamalian cells. The invention relates also to the human muscle stem cells (hMSC) and human adipose tissue cells (hFSC) obtainable by this process. | 06-24-2010 |
| 20100158877 | TREATMENT OF LUNG AND PULMONARY DISEASES AND DISORDERS - Compositions and methods of using cells derived from umbilical cord tissue to stimulate and support lung tissue angiogenesis, to improve blood flow to lung tissue, to regenerate, repair, and improve lung tissue damaged by lung disease, disorder and/or injury, and to protect lung tissue from damage caused by lung disease, disorder and/or injury in a patient. | 06-24-2010 |
| 20100158878 | TARGET POPULATIONS OF OLIGODENDROCYTE PRECURSOR CELLS AND METHODS OF MAKING AND USING SAME - This application provides for enriched target populations oligodendrocyte precursor cells (OPCs) that can differentiate into oligodendrocytes. The target OPCs may be expanded and optionally subjected to conditions to induce their differentiation into oligodendrocytes. The target OPCs and their progeny are useful for the treatment of disease associated with demyelination of central nervous system axons. | 06-24-2010 |
| 20100166710 | Compositions and Methods for Inducing Neuronal Differentiation - The present invention provides compositions and methods for inducing neuronal cell differentiation. | 07-01-2010 |
| 20100166711 | METHOD FOR TREATING SKIN WOUNDS - The present invention relates to a method for treating a skin wound in an individual, comprising applying to the skin wound of the individual a therapeutically effective quantity of gingival fibroblasts. | 07-01-2010 |
| 20100166712 | BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AS A SOURCE OF NEURAL PROGENITORS - Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types. | 07-01-2010 |
| 20100166713 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) - The present invention relates to the production of multipotent migratory cell (MMCs) which can be differentiated into mesoderm or endoderm lineages. Multipotent Migratory Cells (MMC) are stable and robust and can be passaged at least 20 times (perhaps indefinitely), can be recovered after freezing, reamplified and differentiated into multiple lineages. They are therefore storage stable. The method of producing these cells points to a way to generate a multipotent cell type (mesendoderm) from blastocycts for the generation of therapeutically useful cell types without going through a classical hESC state. The production of multipotent migratory cells, mesendoderm cells and mesoderm cells (Isl1+) is also described. | 07-01-2010 |
| 20100166714 | CARDIOVASCULAR STEM CELLS, METHODS FOR STEM CELL ISOLATION, AND USES THEREOF - The present invention relates to isolation of cardiovascular stem cells, and more particularly to cardiovascular stem cells positive for markers isll | 07-01-2010 |
| 20100166715 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY - The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for providing improved bone marrow transplantation and in the treatment of other conditions wherein bone marrow depletion or suppression is involved. | 07-01-2010 |
| 20100166716 | Colony-forming unit cell of human chorion and method to obtain and use thereof - The present invention features colony-forming unit cells derived from the chorion of human placenta and describes compositions and methods for the uses of chorionic cells and their products for therapeutic purposes based upon production and release of multiple growth factors and cytokines by these cells stimulating tissue regeneration independent of engraftment, as well as differentiation into a specific cell type. | 07-01-2010 |
| 20100166717 | METHOD OF TREATING ISCHEMIC DISORDERS - A method of treating an ischemic disorders in a subject includes administering stromal cell derived factor-1 (SDF-1) to ischemic tissue of the subject in an amount effective to inhibit apoptosis of cells of the tissue. | 07-01-2010 |
| 20100166718 | LARGE SCALE PANCREATIC ISLET PURIFICATION - The present invention includes a method of isolating pancreatic islets by density centrifugation wherein the pancreatic islets are loaded in a solution comprising pancreatic islets with the density gradient and the islets are isolated by centrifuging the vessel wherein the pressure on the pancreatic islets is less than 50 Pa and wherein the pancreatic islets are isolated from the gradient, the improvement comprising creating a continuous density gradient in a vessel comprising at least 100 milliliters with a bend tube that reduces convection currents that disrupt the gradient. | 07-01-2010 |
| 20100166719 | Hair growth method - A method of enabling effective hair growth and furthermore, inducing hair growth closely similar to the natural hair state in the case of transplanting dermal papillae or cultured dermal papilla cells into the skin to regenerate the hair, characterized by comprising transplanting a composition containing the following components into an epidermis defect site: (a) dermal papillae or dermal papilla cells, (b) an epidermal tissue or epidermal cells and/or (c) a tissue constituting hair follicles or cells thereof. | 07-01-2010 |
| 20100166720 | GENERATION OF NEURONAL CELLS FROM PLURIPOTENT STEM CELLS - The invention relates to in vitro methods for differentiating mammalian pluripotent stem cells into cells displaying a neuronal phenotype, more particularly into cortical-type neurons including inter alia pyramidal neurons and cortical inhibitory interneurons. The invention further encompasses so-obtained neuronal cells and cell population, compositions comprising such, and further uses of said neuronal cells and cell population. | 07-01-2010 |
| 20100172878 | Polynucleotides encoding mhc class i-restricted htert epitopes, analogues thereof or polyepitopes - This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer. | 07-08-2010 |
| 20100172879 | AMYLOID BETA PEPTIDES AND METHODS OF USE - The application describes several mutant amyloid beta peptides and specific regions which are useful in the therapeutic and diagnostic of neurological diseases. The application further describes methods of using these mutant peptides as treatment and reagents for diagnosis of diseases. The application further describes diagnostic kits and pharmaceutical compositions for use in therapy to treat neurological diseases including but not limited to Alzheimer's disease and various forms of mild cognitive impairments. | 07-08-2010 |
| 20100172880 | DNA METHYLATION MARKERS BASED ON EPIGENETIC STEM CELL SIGNATURES IN CANCER - In particular aspects, stem-cell polycomb group (PcG) targets are more likely to have cancer-specific promoter DNA methylation than non-targets, indicating a stem-cell origin of cancer, where reversible gene repression is replaced by permanent silencing, locking the cell into a perpetual state of self-renewal and predisposition to subsequent malignant transformation. Exemplary aspects provide methods for identifying preferred DNA methylation markers for a cellular proliferative disorder and/or cancer and markers for developmental lineages and/or stages, based on identifying PcG protein or PcG repressive complex genomic target loci within a precursor cell (e.g., stem or progenitor cell) population, and determining, in cells of the proliferative disorder and/or cancer or cell of the particular developmental lineages and/or stages, a characteristic methylation status of the PcG target loci. Additional aspects provide methods for validating and/or monitoring a precursor cell (e.g., stem cell) population. Diagnostic and prognostic methods for ovarian and breast cancer are provided. | 07-08-2010 |
| 20100172881 | USE OF TAILORED RECOMBINASES FOR THE TREATMENT OF RETROVIRAL INFECTIONS - The present invention is directed to a method for preparing an expression vector encoding a tailored recombinase, wherein said tailored recombinase recombines asymmetric target sites within the LTR of proviral DNA of a retrovirus inserted into the genome of a host cell and is useful as means for excising the provirus from the genome of the host cell. The present invention further relates to an in vitro-method of optimising the treatment of a retroviral infection of a subject and to the use of tailored recombinases for the preparation of pharmaceutical compositions for reducing the viral load in a subjected infected by a retrovirus. | 07-08-2010 |
| 20100172882 | COMPOSITIONS AND METHODS FOR TARGETED INACTIVATION OF HIV CELL SURFACE RECEPTORS - Compositions for targeted mutagenesis of cell surface receptors for HIV and methods of their use are provided herein. The compositions include triplex-forming molecules that bind to duplex DNA in a sequence specific manner at target sites to form triple-stranded structures. The triplex-forming molecules can be triplex-forming oligonucleotides (TFOs) or peptide nucleic acids (PNAs). The triplex-forming molecules are useful to induce site-specific homologous recombination in mammalian cells when used in combination with donor oligonucleotides. The triplex-forming molecules target sites within or adjacent to genes that encodes cell surface receptors for human immunodeficiency virus (HIV). This binding stimulates homologous recombination of a donor oligonucleotide to cause mutations in HIV cell surface receptor genes that result in one or more deficiencies in the ability of the encoded receptor to bind to HIV and allow its transport into the cell. Methods for ex vivo and in vivo prophylaxis and therapy of HIV infection using the disclosed compositions are also provided. | 07-08-2010 |
| 20100172883 | METHODS OF GENERATING CARDIOMYOCYTES - The present invention provides methods of generating cardiomyocytes from a cell other than a cardiomyocyte, the methods generally involving contacting the cell with an agent that increases the level and/or activity of a protein that links a transcription factor to a chromatin remodeling complex. The present invention provides a population of cardiomyocytes generated using a subject method; and treatment methods involving introducing the cardiomyocyte population in or around diseased myocardial tissue. | 07-08-2010 |
| 20100172884 | Cardiac Muscle Repair Or Regeneration Using Bone Marrow-Derived Stem Cells - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 07-08-2010 |
| 20100172885 | Multipotent Adult Stem Cells And Uses of Multipotent Adult Stem Cells To Treat Inflammation - Disclosed are cell preparations comprising multipotent adult stem cells and methods for using multipotent adult stem cells to treat autoimmune diseases, treat allergic responses, treat cancer, treat inflammatory diseases, treat fibrotic disorders, reduce inflammation and/or fibrosis, promote would healing, repair epithelial damage, and/or promote angiogenesis. | 07-08-2010 |
| 20100178274 | APPLICATION OF SYNOVIUM-DERIVED MESENCHYMAL STEM CELLS (MSCS) FOR CARTILAGE OR MENISCUS REGENERATION - An object of the present invention is to provide a method for treating defects of articular cartilage or meniscus of a patient using in vivo chondrogenesis of synovium-derived MSCs. The present invention provides a method for treating a disease associated with defects of cartilage or meniscus. In the present invention, the method for treating a disease associated with defects of cartilage or meniscus comprises the following steps: culturing ex vivo autologous synovium-derived mesenchymal stem cells (MSCs); implanting the MSCs such that said cartilage defect site or meniscal defect site is covered by the MSCs; and regenerating cartilage tissue at the cartilage defect site or meniscal defect site in situ by differentiating the MSCs into cartilage cells. | 07-15-2010 |
| 20100178275 | METHODS AND MEANS FOR STEM CELL PROLIFERATION AND SUBSEQUENT GENERATION AND EXPANSION OF PROGENITOR CELLS, AS WELL AS PRODUCTION OF EFFECTOR CELLS AS CLINICAL THERAPEUTICS - The invention is related to methods for expanding and differentiating hemopoietic progenitor cells in a medium comprising a collection of cytokines, desulphated glycosaminoglycan and human serum. The invention further relates to a collection of cells obtainable by a method of the invention, use of the collection of cells, and a kit of parts for expanding and differentiating hemopoietic progenitor cells. | 07-15-2010 |
| 20100178276 | CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | 07-15-2010 |
| 20100178277 | METHODS AND COMPOSITIONS FOR STIMULATING CELLS - The invention provides compositions and methods for treating, preventing, delaying the onset, and/or delaying the development of a disease or condition for which the activation, differentiation, and/or proliferation of one or more cell types is beneficial. These compositions and methods include, for example, a hydrogenated pyrido[4,3-b]indole such as dimebon and/or a cell that has been incubated with a hydrogenated pyrido[4,3-b]indole such as dimebon. In some embodiments, the compositions and methods also include a growth factor and/or an anti-cell death compound. The invention also provides methods of activating a cell, promoting the differentiation of a cell, and/or promoting the proliferation of a cell by incubating the cell with one or more hydrogenated pyrido[4,3-b]indoles or pharmaceutically acceptable salts thereof. In some embodiments, the cell is also incubated with one or more growth factors and/or anti-cell death compounds. | 07-15-2010 |
| 20100178278 | FORMABLE BIOCERAMICS - A formable bioceramic including hydroxyapatite nanocrystals, gelatin, and sol-gel-containing material is described. Also described is a process for making and using the bioceramic. The formable bioceramic displays superior mechanical strength, elasticity, biocompatibility and forming capabilities and is targeted for bone repairs and template-assisted tissue engineering applications. | 07-15-2010 |
| 20100178279 | Beta-Glucan Enhances Hematopoietic Progenitor Cells Engraftment and Promotes Recovery from Chemotoxicity - Methods to use beta glucans in the culture of cell populations containing CD34+ cells in order to expand the numbers of CD34+ subsets of progenitor and stem cells are provided. Methods to improve homing and engraftment of stem and progenitor cells by first culturing the cells with beta glucans, or co-administering with beta glucans, are also provided. Additionally, methods to ameliorate chemotherapy toxicity and promote development of functionally active neutrophils by administering beta glucans are presented. The beta glucans are preferably extracted from maitake mushroom ( | 07-15-2010 |
| 20100183560 | Angiogenesis-modulating compositions and uses - Hedgehog agonists and antagonists can be used to regulate angiogenesis, and have utility in treating tissue repair and cancer, and to prevent angiogenesis driven pathologies. | 07-22-2010 |
| 20100183561 | Biological therapeutic compositions and methods thereof - Novel uses of Platelet Rich Plasma (PRP) for infection prevention, bone repair and transmyocardial vascularization is disclosed. The present disclosure is directed to methods for preparing concentrated mesenchymal or haematopoietic stem cells, and autologous platelet-rich plasma (PRP) from the blood utilizing the Magallen® System. The stem cells and/or PRP may be combined with secondary biological agents such as antibiotics, fibrinogen and thrombin, and appropriately used in variety of medical conditions, such as, cardiovascular, thoracic, transplantation, head and neck, oral, gastrointestinal, orthopedic, neurosurgical, and plastic surgery. | 07-22-2010 |
| 20100183562 | SUB -POPULATION OF HEMATOPOIETIC STEM CELLS THAT EXPRESS THE CRISP-1 PROTEIN - The subject of the present invention is a sub-population of isolated hematopoietic stem cells that express the CRISP-1 gene and produce the CRISP-1 protein on the cytoplasmic membrane of the cell, their isolation and their application in the therapeutic/diagnostic/prognostic field. | 07-22-2010 |
| 20100183563 | DENTINOGENESIS PROMOTER AND DENTINOGENIC PULP-CAPPING MATERIAL - The present invention provides a dentinogenesis inducer and dentinogenesis pulp-capping material, which are effectively used for formation (regeneration) of dentin. The present invention also provides a method of producing odontoblasts useful for dental regenerative therapy and the application of the obtained odontoblasts. The dentinogenesis inducer and the dentinogenesis pulp-capping material of the present invention are both characterized by the use of an HMG-CoA reductase inhibitor as an active ingredient. Additionally, odontoblasts can be produced by culturing cells capable of differentiating into odontoblasts in the presence of the HMG-CoA reductase inhibitor. | 07-22-2010 |
| 20100183564 | COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS - The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense. | 07-22-2010 |
| 20100183565 | INDUCTION OF HUMAN EMBRYONIC STEM CELL DERIVED CARDIAC PACEMAKER OR CHAMBER-TYPE CARDIOMYOCYTES BY MANIPULATION OF NEUREGULIN SIGNALING - The present invention is directed to methods of producing cardiomyocytes having a nodal/pacemaker phenotype and cardiomyocytes having an atrial/ventricular phenotype. Isolated populations of nodal/pacemaker and atrial/ventricular cardiomyocytes are also disclosed. Methods of treating a subject having cardiac arrhythmia and a subject in need of cardiac tissue repair using the isolated populations of nodal/pacemaker cardiomyocytes and atrial/ventricular cardiomyocytes, respectively, are also disclosed. | 07-22-2010 |
| 20100183566 | METHOD FOR EFFICIENT TRANSFER OF HUMAN BLASTOCYST-DERIVED STEM CELLS (hBS CELLS) FROM A FEEDER-SUPPORTED TO A FEEDER-FREE CULTURE SYSTEM - Technology is provided for the transfer of human blastocyst-derived stem cells (hBS cells) to a feeder-free culture system and propagation of the cells in such a feeder-free culture system, the method comprising the following steps of (a) transferring the blastocyst-derived stem cells from feeder to feeder free culture by mechanical treatment, (b) culturing the blastocyst-derived stem cells under feeder cell free growth conditions in a suitable growth medium and/or on a suitable support substrate, and (c) optionally passaging the blastocyst derived stem cell line every 3-10 days by enzymatic and/or mechanical treatment. The application of hBS cells cultured under a feeder-free condition in medicine (e.g., myocardial regeneration) and screening and toxicity testing also is provided. | 07-22-2010 |
| 20100183567 | Novel Mammalian Multipotent Stem Cells and Compositions, Methods of Preparation and Methods of Administration Thereof - This invention provides methods for preparing novel mammalian multipotent stem cells (MSCs), compositions thereof, and methods of preparing and administering the cells. | 07-22-2010 |
| 20100183568 | METHOD FOR PRODUCTION OF HEPATIC-LOBULE-LIKE CELL CLUSTER FROM ADIPOSE-TISSUE-DERIVED CELL - Disclosed are: a method for producing a hepatic-lobule-like cell mass from an adipose-tissue-derived cell, which is characterized by culturing the adipose-tissue-derived cell; a hepatic-lobule-like cell mass produced by the method; a method for the screening of a substance capable of promoting or inhibiting the formation of a hepatic-lobule-like cell mass, which is characterized by culturing an adipose-tissue-derived cell to produce the hepatic-lobule-like cell mass, wherein a candidate substance is added to a culture medium; and a kit for use in the screening method. | 07-22-2010 |
| 20100183569 | POROUS COMPOSITE MATERIAL, PREPARATION PROCESS THEREOF AND USE TO REALIZE TISSUE ENGINEERING DEVICES - The present invention refers to a porous composite material, wherein at least one interdispersed biopolymer is present, with a calcium-phosphate mineral component comprising from 50 w/% to 95 w/% of α-tricalcium phosphate (α-TCP, α-Ca | 07-22-2010 |
| 20100183570 | NON-EMBRYONIC STEM CELLS AND USES THEREOF - Disclosed are novel stem cells of non-embryonic origins and the uses thereof. | 07-22-2010 |
| 20100183571 | TREATMENT OF MULTIPLE SCLEROSIS USING PLACENTAL STEM CELLS - The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations. | 07-22-2010 |
| 20100189694 | Scar Tissue Treatment System - A treatment for hypertrophic scar tissue and methods for treatment of hypertrophic scar tissues utilizing viable fibroblast cells. | 07-29-2010 |
| 20100189695 | IRAK-1 AS REGULATOR OF DISEASES AND DISORDERS - The present invention provides methods and compositions for treatment of diseases and disorders. More specifically, the invention for the first time shows a link between IRAK-1 and phosphorylation of proteins involved in cardiovascular disease, diabetes, neurodegeneration, and associated diseases and disorders and complications. Typically, the diseases and disorders involve an inflammatory component. Assays for bioactive substances affecting IRAK-1 regulated progression of inflammation and diseases and disorders involving inflammation are also disclosed. | 07-29-2010 |
| 20100189696 | LITHIUM STIMULATION OF CORD BLOOD STEM CELL PROLIFERATION AND GROWTH FACTOR PRODUCTION - The present invention provides methods for expanding human umbilical cord blood stem cells and methods for stimulating growth factor production by cord blood stem cells using an in vitro cell culture system comprising a lithium salt. The present invention also provides in vivo methods for enhancing the survival and growth of transplanted cord blood stem cells by treating the cells with a lithium salt prior to transplantation. In vivo methods for reducing rejection of transplanted cord blood stem cells by administering a lithium salt after transplantation are also provided. | 07-29-2010 |
| 20100189697 | CARDIAC-SPECIFIC PROGENITOR CELLS - This document provides methods and materials related to treating cardiovascular tissue (e.g., heart tissue or vascular tissue). For example, stem cells (e.g., CXCR4+/Flk-1+ stem cells), compositions containing stem cells, methods for obtaining stem cells, and methods for repairing cardiovascular tissue are provided. | 07-29-2010 |
| 20100189698 | TREATMENT OR PROPHYLAXIS OF A NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION - A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function. | 07-29-2010 |
| 20100189699 | METHOD OF CONSTRUCTING MASSES OF MYOCARDIAL CELLS AND USE OF THE MYOCARDIAL CELL MASS - The object of the present invention is to improve the post-transplantation engraftment rate of cardiomyocytes that have been purified to such an extent that they are free from non-cardiomyocytes and any components derived from other species. | 07-29-2010 |
| 20100189700 | CULTURE FOR EXPANDING STEM CELLS EX-VIVO - The present invention relates to a culture including a growth medium and a combination of cytokines consisting of i) interleukin-6 (IL6); ii) flt3-ligand (FLT3); iii) stem cell factor (SCF) and iv) thrombopoi-etin (TPO); the use of the culture for expanding. ex vivo stem cells and/or parental cells and cells differentiated therefrom, and the use of said cells obtainable from said expansion. | 07-29-2010 |
| 20100196326 | METHOD AND SYSTEM FOR BIASING CELLULAR DEVELOPMENT - Compositions and methods comprising siRNA targeted to APP mRNA are advantageously used to transfect stem cells and bias the cells against differentiating into glial type neural cells. The siRNA of the invention causes RNAi-mediated silencing of the APP mRNA. The inventors have discovered that expression APP induces gliogenesis, i.e., promotes differentiation of potent cells into glial cells. The transfection of potent cells with the subject siRNA silences APP mRNA and thus increases probability of the cells to differentiate into non-glial neural cells. | 08-05-2010 |
| 20100196327 | METHODS FOR DIAGNOSING BIOLOGICAL SAMPLES CONTAINING STEM CELLS - The present invention relates to a method for diagnosing the compatibility of a biological sample containing stem cells from a donor with the immune system of a recipient. Furthermore, the present invention relates to a method for determining the quality of a stem cell preparation based on the inventive method, as well as methods of diagnosing an immune disorder affecting stem cell recognition. The present invention further relates to a method for producing an improved stem cell preparation, and an apparatus that is equipped for performing the method according to the invention. The invention can be used in the field of stem cell-based transplantation and respective diseases. The invention also includes a method for testing the efficacy of donor immune cells as treatments for disease such as cancer in a host patient. A method for testing the immune response of a patient to recall antigens is also disclosed. | 08-05-2010 |
| 20100196328 | ISCHEMIA-INDUCED NEOVASCULARIZATION IS ENHANCED BY hCNS-SC TRANSPLANTATION - The invention provides methods for inducing or enhancing neovascularization following ischemia by transplanting an effective amount of human central nervous system stem cells. The human central nervous system stem cells can be grown as neurospheres or in adherent culture. Also provided are methods for inducing the repair of ischemic tissue in a patient and methods for treating stroke in a patient suffering therefrom. | 08-05-2010 |
| 20100196329 | COMPOSITION FOR TREATING ISCHEMIC LIMB DISEASE COMPRISING STEM CELLS DERIVED FROM ADIPOSE TISSUE - Disclosed herein is a cell therapeutic composition for treating ischemic limb diseases, more specifically, disclosed is a cell therapeutic composition for treating ischemic diseases, which contains adipose tissue-derived mesenchymal stem cells and sucrose or mannose as an excipient. The composition induces angiogenesis around closed blood vessels in the ischemic limb lesions, and thus is useful to treat ischemic diseases. | 08-05-2010 |
| 20100196330 | PHARMACEUTICAL COMPOSITIONS COMPRISING UNACYLATED GHRELIN AND THERAPEUTICAL USES THEREOF - The present invention relates to compositions containing unacylated ghrelin and derivatives thereof and their uses in the control of glycemia in ageing patients, GH deficient patients, diabetic patients and obese patients. | 08-05-2010 |
| 20100196331 | COMPOSITIONS INCLUDING ANTHOCYANIN OR ANTHOCYANIDIN FOR THE PREVENTION OR TREATMENT OF ARTICULAR CARTILAGE-ASSOCIATED CONDITIONS - Methods of treating an arthritic joint of a subject, including administering a pharmaceutical composition by injection into the arthritic joint, wherein the composition includes an anthocyanin or anthocyanidin, glucose, and a pharmaceutically acceptable carrier. | 08-05-2010 |
| 20100196332 | Generation of brachial, thoracic and lumbar spinal motor neurons from embryonic stem cells in the absence of all-trans retinoic acid supplement - Disclosed are methods for generating a neuron expressing Hoxc8 transcription factor or a caudal motor neuron comprising culturing an embryonic stem cell in a composition which is essentially free of retinoids and comprises an isotonic salt solution, so as to generate the neuron which expresses Hoxc8 transcription factor or the caudal motor neuron. Disclosed are also methods for generating a caudal brachial motor neuron, a thoracic motor neuron, or a lumbar motor neuron from an embryonic stem cell in a composition essentially free of retinoids and comprising ADFNK medium, an amount of FGF-2, or Gdf11 respectively. Disclosed are also methods of transplanting a motor neuron into a subject comprising generating the motor neuron and transplanting the motor neuron into the subject. Disclosed is also a population of motor neuron cells enriched for motor neuron cells expressing Foxp1 and expressing a gene associated with Spinal Muscular Atrophy (SMA) or Amyotrophic Lateral Sclerosis (ALS). | 08-05-2010 |
| 20100196333 | Device and Process for Producing Fiber Products and Fiber Products Produced Thereby - The present invention is directed to a fiber, preferably bone fiber, having a textured surface, which acts as an effective binding substrate for bone-forming cells and for the induction or promotion of new bone growth by bone-forming cells, which bind to the fiber. Methods of using the bone fibers to induce or promote new bone growth and bone material compositions comprising the bone fibers are also described. The invention further relates to a substrate cutter device and cutter, which are effective in producing substrate fibers, such as bone fibers. | 08-05-2010 |
| 20100196334 | Cell Suspension Preparation Technique and Device - The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site. | 08-05-2010 |
| 20100203020 | METHODS OF GENERATING, REPAIRING AND/OR MAINTAINING CONNECTIVE TISSUE IN VIVO - This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue. | 08-12-2010 |
| 20100203021 | PROVISION OF NEW CARDIOMYOCYTE PROGENITOR CELLS AND CARDIOMYOCYTES DERIVED THEREFROM - The present invention relates to cardiomyocyte progenitor cells (CMPCs), to methods for their isolation and to the use of this CMPCs for the provision of cardiomyocytes, by way of differentiating the obtained CMPCs with a demethylating agent. The present invention also relates to pharmaceuticals compositions comprising cardiomyocytes for use in a cardiomyocyte replacement therapy and/or for the treatment in myocardial infarctation or for ameliorating the effects of myocardial infarctation. | 08-12-2010 |
| 20100203022 | METHODS AND COMPOSITIONS FOR DELIVERING THERAPEUTIC AGENTS TO THE CENTRAL NERVOUS SYSTEM - Methods are provided for targeting therapeutic agents to an injury site within the central nervous system. | 08-12-2010 |
| 20100203023 | ENHANCED COMPOSITIONS CONTAINING CELLS AND EXTRACELLULAR MATRIX MATERIALS - Described are medical graft materials and devices having improved properties relating to their component profiles. | 08-12-2010 |
| 20100209396 | Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells - The present invention provides methods for inducing differentiation of a stem cell, such as an embryonic stem cell, into a hematopoietic stem cell, by expressing a cdx gene and/or a hox gene. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. | 08-19-2010 |
| 20100209397 | METHOD FOR NON-AUTOLOGOUS CARTILAGE REGENERATION - The present invention relates in general to the field of tissue engineering, and in particular to methods for repair and regeneration of diseased and injured bone and cartilage tissue by allotransplantation or xenotransplantation of neonatal mandibular condyle-derived chondrocytes. The composition may comprise mandibular condyle-derived chondrocytes in the form of a chondrocyte film, per se, or in combination with a scaffold. | 08-19-2010 |
| 20100209398 | Compositions of stem cells and stem cell factors and methods for their use and manufacture - Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture. | 08-19-2010 |
| 20100209399 | BRAIN-DERIVED STEM CELLS FOR REPAIR OF MUSCULOSKELETAL SYSTEM IN VERTEBRATE SUBJECTS - The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair different types of damage in musculoskeletal system, with significantly greater efficacy than stem cells derived from adult tissues. These cells are hypoimmunogenic and can be used for allogeneic transplantation to vertebrate hosts having disease and/or damage in musculoskeletal and other tissues. The cells can be administered by direct injection to the site in need of repair or by systemic (e.g., intravenous) administration. The stem cells of the invention are capable of migrating to the sites in need of repair, and of adopting a phenotype most appropriate to the nature of the damage, injury or disease. | 08-19-2010 |
| 20100209400 | TAK1-Mediated Regulation of Osteogenesis - This invention is directed to methods, nucleic acids and compositions in TAK1-mediated regulation of SMAD activity. Promotion of TAK1 interaction with MH2 domains in SMADs negatively regulates SMAD biological activity. BMP-mediated SMAD activity is subject to TAK1 effects. | 08-19-2010 |
| 20100209401 | Use of SDF-1 to Improve Ischemic Myocardial Function - A method is provided for increasing trafficking of endothelial progenitor cells to an ischemic myocardium in a subject's heart comprising administering to the subject's heart an amount of Stromal-Derived Factor-1 (SDF-1). | 08-19-2010 |
| 20100209402 | AGENT FOR PROMOTING CORNEAL ENDOTHELIAL CELL ADHESION - The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium. | 08-19-2010 |
| 20100209403 | ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND USE THEREOF IN THERAPY - A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed. | 08-19-2010 |
| 20100209404 | ENHANCED METHOD FOR PRODUCING STEM-LIKE CELLS FROM SOMATIC CELLS - The instant invention provides methods and compositions for the production and use of pluripotent stem-like cells from low passage somatic cells, e.g., fibroblasts. | 08-19-2010 |
| 20100209405 | SERICIN EXTRACTED SILKWORM FIBROIN FIBERS - The present invention provides a novel silk-fiber-based matrix having a wire-rope geometry for use in producing a ligament or tendon, particularly an anterior cruciate ligament, ex vivo for implantation into a recipient in need thereof. The invention further provides the novel silk-fiber-based matrix which is seeded with pluripotent cells that proliferate and differentiate on the matrix to form a ligament or tendon ex vivo. Also disclosed is a bioengineered ligament comprising the silk-fiber-based matrix seeded with pluripotent cells that proliferate and differentiate on the matrix to form the ligament or tendon. A method for producing a ligament or tendon ex vivo comprising the novel silk-fiber-based matrix is also disclosed. | 08-19-2010 |
| 20100215622 | TREATMENT OF IMMUNOSUPPRESSION-RELATED DISORDERS - Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders. | 08-26-2010 |
| 20100215623 | BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. | 08-26-2010 |
| 20100215624 | Pharmaceutical Compositions for Treating Rheumatoid Arthritis Comprising Semi-Mature Dendritic Cell - The present invention relates to a pharmaceutical composition for treating rheumatoid arthritis, which comprises (a) a pharmaceutically effective amount of a semi-mature dendritic cell; and (b) a pharmaceutically acceptable carrier. The semi-mature dendritic cell of this invention has a safe and remarkably improved potential to treat or prevent rheumatoid arthritis through the activity of the suppression of auto-immune responses. | 08-26-2010 |
| 20100215625 | EFFICIENT PREPARATION OF NAPHTHOQUINONE ANTICANCER ACTIVE INGREDIENTS - One of the problems to be resolved by the present invention is to stably and sustainably produce active ingredients contained in Bignoniaceous plants of which a mass production is difficult in a conventional manner. The present invention relates to a method for efficiently preparing an anticancer active ingredient NQ | 08-26-2010 |
| 20100221229 | MODULATING BONE GROWTH IN TREATING SCOLIOSIS - The present specification provides, amongst other things, a method of treating scoliosis comprising delivering a therapeutically acceptable amount of a growth modulator to an epiphyseal growth plate to correct or compensate for disproportionate growth. | 09-02-2010 |
| 20100221230 | Elective Collection and Banking of Autologous Peripheral Blood Stem Cells - An elective healthcare insurance model using an individual's own peripheral blood stem cells for the individual's future healthcare uses. An individual can elect to have his or her own stem cells collected, processed and preserved, while he or she is in healthy or “pre-disease” state, for future distribution for his or her healthcare needs. The process includes methods of collection, processing, preservation and distribution of adult (including pediatric) peripheral blood stem cells during non-diseased state. The stem cells collected will contain adequate dosage amounts, for one or more transplantations immediately when needed by the individual for future healthcare treatments. The collected adult or non-neonate child peripheral blood stem cells can be aliquoted into defined dosage fractions before cryopreservation so that cells can be withdrawn from storage without the necessity of thawing all of the collected cells. | 09-02-2010 |
| 20100221231 | Skin replacement compositions and methods - The invention is directed to methods of making novel skin replacement compositions. The invention is further directed to the novel skin replacement compositions. The invention is also directed to methods for treating wounds, in particular burns and chronic, non-healing wounds, with such novel skin replacement compositions. | 09-02-2010 |
| 20100226893 | High Retention Cell Injectate - The present disclosure generally relates to high retention cell injectates, methods of producing the high retention cell injectates and further to methods of treating diseases or conditions by administering the cell injectates to patients in need thereof. To allow for cell rentention into a provided hyaluronic acid solution, the present disclosure provides pretreatment of cells with one or more substances that increases the number of CD44 receptors on their surfaces. Cells expressing CD44 ligands show increase in binding to hyaluronic acid. The pretreated cells are thus incorporated into hyaluronic acid. | 09-09-2010 |
| 20100226894 | Mobilization of a complete cells mixture with embryonic like stem cells from the peripheral blood - Disclosed is a method to recover a mixture cell population consisting of a complete profile of progenitor cells including embryonic like stem cells (a “complete progenitor cell mixture” or CPM) from the peripheral blood of an individual by administering to that individual a combination of at least one or more from the category of growth factors and hormones combining with at least one or more from the category of cell fusion inhibitor compounds, and then recovering peripheral blood progenitor cells from said individual. The hormones and growth factors group should include hGH (human growth hormone) with or without erythropoietin (EPO), but specifically without either G-CSF or GM-CSF. The cell fusion inhibitor group should include a CXCR4 antagonist. Also disclosed is a method for using or preserving such a complete progenitor cells mixture (CPM) for the treatment of diseases. | 09-09-2010 |
| 20100226895 | NEURAL SCAFFOLDS - Disclosed herein are compositions and methods useful for preparing neural scaffolds. The scaffolds comprise tissue taken from the spinal cord and/or dura mater of vertebrate and can be processed to form gels or sheets. Methods of treating patient with CNS injury are also presented. | 09-09-2010 |
| 20100226896 | METHOD FOR INTRATHECAL ADMINISTRATION OF AUTOLOGOUS STEM CELLS IN PREMATURE INFANTS - The invention provides a method of treating a premature infant at a statistical risk of sustaining an intraventricular hemorrhage. The method, or therapeutic protocol, can include at least one or more of the following steps: identifying premature infants at a statistical risk of having an intraventricular hemorrhage, collecting umbilical cord blood from the identified premature infant, separating totipotential stem cells (e.g., having the ability to proliferate and differentiate as neural stem cells) from the collected cord blood, storing the separated stem cells, establishing evidence of an intraventricular hemorrhage (preferably prior to Grade III/IV if possible) in the premature infant, and intrathecally administering the autologous cord blood derived stem cells to the premature infant. | 09-09-2010 |
| 20100226897 | METHOD FOR MODIFYING THE WETTABILITY AND/OR OTHER BIOCOMPATIBILITY CHARACTERISTICS OF A SURFACE OF A BIOLOGICAL MATERIAL BY THE APPLICATION OF GAS CLUSTER ION BEAM TECHNOLOGY AND BIOLOGICAL MATERIALS MADE THEREBY - The invention provides methods for surgical grafting of a tissue. The method comprises the steps of explanting a graft tissue from a donor, irradiating at least a first portion of the graft tissue with an ion beam, and surgically grafting the graft tissue into a recipient. | 09-09-2010 |
| 20100233130 | Method and Apparatus for Maintenance and Expansion of Hematopoietic Stem Cells From Mononuclear Cells - A method of expanding/maintaining undifferentiated hematopoietic stem cells by obtaining unselected mononuclear cells; and seeding the mononuclear cells into a stationary phase plug-flow bioreactor in which a three dimensional mesenchymal/stromal cell culture has been pre-established, thereby expanding/maintaining undifferentiated hematopoietic stem cells. | 09-16-2010 |
| 20100233131 | SELENIUM DEDIFFERENTIATED CELL, PREPARATION METHOD AND USAGE THEREOF - Provided are a cell therapeutic composition containing selenium, a method of dedifferentiating selenium-treated cells, a cell therapeutic composition containing cells dedifferentiated from the selenium-treated cells by the same method, and a cell therapeutic composition containing cells redifferentiated from the dedifferentiated cells. | 09-16-2010 |
| 20100233132 | FORMATION OF VASCULAR NETWORKS USING EMBRYONIC STEM CELLS - In various aspects, provided are methods for providing CD34 | 09-16-2010 |
| 20100233133 | TISSUE REPAIR - According to the invention there is provided a cosmetic method for the augmentation of subcutaneous or dermal tissue in a subject, which method comprises the steps of: (i) providing a suspension of autologous dermal fibroblasts; and (ii) injecting an effective volume of the suspension into tissue subadjacent to the subcutaneous or dermal tissue so that the tissue is augmented; wherein the fibroblasts are suspended in HypoThermosol®, preferably HypoThermosol® FRS. | 09-16-2010 |
| 20100233134 | Use of Adipose-Tissue Cell Fractions for Post-Irradiation Tissue Regeneration - The present invention concerns the use of cells derived from the cellular fraction of the vascular stroma of the extramedullary adipose tissue to promote the regeneration of tissue following lesions caused by irradiation. More specifically, the use according to the invention aims to prepare a drug for promoting regeneration of the skin, and in particular to repair the cutaneous wounds caused by irradiation. | 09-16-2010 |
| 20100233135 | COMPOSITIONS AND METHODS FOR HEMATOPOIETIC STEM CELL EXPANSION OR FOR MODULATING ANGIOGENESIS - The present invention provides compositions and methods featuring ZBP-89 polypeptides or nucleic acid molecules for expanding a hematopoietic stem cell population or for modulating angiogenesis. | 09-16-2010 |
| 20100233136 | ISOLATED POPULATIONS OF CELLS AND METHODS OF GENERATING AND USING SAME - An isolated homogeneous population of cells comprising a plurality of human ectodermal progenitor cells. Also provided are methods of generating and using the population of cells. | 09-16-2010 |
| 20100233137 | Compositions and Methods for Modification of Target Cells and to Their Uses Thereof - Methods and compositions are described for preparing modified cells useful in various therapeutic applications. | 09-16-2010 |
| 20100233138 | Vocal Cord Augmentation Utilizing Muscle-Derived Progenitor Compositions, and Treatments Thereof - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment vocal cord tissue following introduction (e.g. via injection, transplantation, or implantation) into the vocal cords. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, vocal cords in the treatment of various cosmetic or functional conditions, including vocal cord tissue weakness, voice and swallowing disorders. The invention also relates to the novel use of MDCs for the increase of vocal cord tissue mass in speakers, singers or other people in need of greater than average vocal cord tissue mass. | 09-16-2010 |
| 20100233139 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER - Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed. | 09-16-2010 |
| 20100233140 | COLLAGEN-CONTAINING CELL CARRIER - The present invention relates to the use of a collagen-containing composition for the cultivation of biological cells, a method for the cultivation of biological cells, a method for the implantation of biological material into an organism and a method for the improvement of a composition in its suitability for the cultivation of biological cells. | 09-16-2010 |
| 20100233141 | Compositions And Methods For The Delivery Of Biologically Active RNAs - The present invention provides novel compounds, compositions, and methods for the delivery of biologically active RNA molecules to cells. Specifically, the invention provides novel nucleic acid molecules, polypeptides, and RNA-protein complexes useful for the delivery of biologically active RNAs to cells and polynucleotides encoding the same. The invention also provides vectors for expressing said polynucleotides. In addition, the invention provides cells and compositions comprising the novel compounds and vectors, which can be used as transfection reagents. The invention further provides methods for producing said compounds, vectors, cells, and compositions. Additionally, vectors and methods for delivering biologically active RNA molecules to cells and/or tissues are provided. The novel compounds, vectors, cells, and compositions are useful, for example, in delivering biologically active RNA molecules to cells to modulate target gene expression in the diagnosis, prevention, amelioration, and/or treatment of diseases, disorders, or conditions in a subject or organism. | 09-16-2010 |
| 20100233142 | Stem Cells Derived from Uniparental Embryos and Methods of Use Thereof - Embryonic stem cells derived from uniparental embryos and methods of use thereof are disclosed. | 09-16-2010 |
| 20100233143 | Parthenogenic Activation of Human Oocytes for the Production of Human Embryonic Stem Cells - Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O | 09-16-2010 |
| 20100239538 | COMPOSITIONS COMPRISING VASCULAR AND MYOCYTE PROGENITOR CELLS AND METHODS OF THEIR USE - The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed. | 09-23-2010 |
| 20100239539 | Methods for promoting differentiation and differentiation efficiency - The invention is directed to methods for promoting differentiation of stem cells to hematopoietic cell lineages. The invention is further directed to increasing the differentiation efficiency of hematopoietic stem/progenitor cells. Such methods utilize novel compositions, including but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), each alone or in combination with each other or other agents. | 09-23-2010 |
| 20100239540 | Peptide Linked Cell Matrix Materials for Stem Cells and Methods of Using the Same - Biostructures that comprises modified alginates entrapping one or more stem cells are discloses. The modified alginates comprise at least one alginate chain section to which is bonded by covalent bonding at least one cell attachment peptide. Pluralities of stem cells are also disclosed. Methods of preventing death of stem cells and cells differentiated there from are disclosed. Methods of preparing a plurality of stem cells are disclosed. Methods of treating an individual who has a degenerative disease, such as a neurological disorder, or injury involving nerve damage by administering stem cells to said individual are disclosed. | 09-23-2010 |
| 20100239541 | TRANSPLANTATION OF HUMAN NEURAL CELLS FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS - A method of treating neurodegenerative conditions is provided. Neural stem cells may be implanted at and/or remote from a region of neuron degeneration. The methods can include isolating neural stem cells from regions where specific types of neurons corresponding to the neurons to be replaced are generated. The methods can include isolating neural stem cells secreting growth factors affecting the growth and/or regeneration of specific types of neuron. In this invention, we disclose a method of treating such disorders, including several neurodegenerative disorders arising from the lack of cells that produce particular neurotransmitters in neural circuitry by transplanting exogenously cultured and expanded neural progenitors which, upon transplantation into a neural tissue, differentiate into neurons capable of integrating and producing neurotransmitters in sufficient quantities and in a sufficient manner to overcome the symptoms associated with the neurodegeneration. | 09-23-2010 |
| 20100239542 | PLURIPOTENT EMBRYONIC-LIKE STEM CELLS, COMPOSITIONS, METHODS AND USES THEREOF - The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention. | 09-23-2010 |
| 20100239543 | PLURIPOTENT EMBRYONIC-LIKE STEM CELLS, COMPOSITIONS, METHODS AND USES THEREOF - The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention. | 09-23-2010 |
| 20100239544 | METHODS OF TREATMENT USING ELECTROMAGNETIC FIELD STIMULATED STEM CELLS - Methods of modifying stem cells and compositions of modified stem cells, in particular mesenchymal stem cells, using electric or electromagnetic fields. In various embodiments, the present invention's methods are for the treatment of a human or other mammal subject in need thereof, comprising providing an in vitro culture comprising mesenchymal stem cells, administering an electric stimulation to the in vitro culture, and implanting the mesenchymal stem cells into the subject. Methods also include treatment of a human or other mammal subject, comprising implanting mesenchymal stem cells into the subject, and administering an electric stimulation to the mesenchymal stem cells in situ. Other embodiments include methods of administering electric stimulation in conjunction with growth factors to stem cells. | 09-23-2010 |
| 20100247491 | Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure - The invention provides methods and compositions for the treatment of multi-organ failure or kidney dysfunction, such as acute renal failure, by mesenchymal stem cells and a CD26 inhibitor, where inhibition of CD26 increases homing of the mesenchymal stem cells to a target tissue. | 09-30-2010 |
| 20100247492 | METHODS FOR THE DETECTION OF CIRCULATING TUMOR CELLS - The present invention provides methods for revealing, detecting, and analyzing circulating tumor cells in the blood of a subject. Revealing detectable circulating tumor cells allows for early stage detection and diagnosis in addition to long term prognosis in subjects with cancer. Additionally, enrichment allows for robust detection and clinically meaningful analysis of low volume samples for use in clinical settings as well as innovative methods for the treatment of cancers. | 09-30-2010 |
| 20100247493 | Method for Identifying and Selecting Cardiomyocytes - The present invention relates to new and/or improved methods of identification and selection of cardiomyocytes from human embryonic stem (hES) cells. The method further comprises isolating the selected cardiomyocyte population. There is also provided method for the screening for cardiovascular compounds comprising subjecting the said cardiomyocyte population to test compound/s, and observing and/or interpreting a response of the cardiomyocytes to the test compound. | 09-30-2010 |
| 20100247494 | Compositions of Mesenchymal Stem Cells to Regenerate Bone - The present invention encompasses an osteogenic composition comprising mesenchymal stem cells pre-cultured in the presence of an agent that accelerates canonical Wnt signaling therein. Also, provided are osteogenic compositions incorporated into a biocompatible gel. The present invention provides methods for treating bone degeneration or injury associated with a pathophysiological condition in a mammal or for accelerating repair of a skeletal injury in a mammal by administering to the mammal or contacting the site of injury with the osteogenic composition. | 09-30-2010 |
| 20100247495 | Treatment of Muscular Dystrophy - The present invention provides mesenchymal stem cells and mesenchymal-like cells useful for treatment of muscular dystrophies including Duchenne Muscular Dystrophy (DMD), as well as, Becker, limb girdle, congenital, facioscapulohumeral, myotonic, oculopharyngeal, distal, and Emery-Dreifuss dystrophies. Also provided are protocols for administration of cells for treatment of the above dystrophies and adjuvant protocols. Futhermore, the invention teaches methods of manipulating mesenchymal and mesenchymal-like cells in vitro and in vivo for augmentation of therapeutic effects. Particularly, use of endometrial regenerative cells, alone or in combination with mesenchymal stem cells is provided for treatment of DMD and Becker muscular dystrophy. | 09-30-2010 |
| 20100254951 | Nerve Regeneration Promoting Agent - A neuronal differentiation promoting agent for neural stem cells comprising, as an active ingredient, at least one member selected from the group consisting of ω-3 unsaturated fatty acids and ω-6 unsaturated fatty acids having 18 to 22 carbon atoms, and derivatives thereof. The agent can be used for induction of differentiation of neural stem cells and is useful for treating and/or preventing a variety of neurological diseases, and in the fields of nerve transplantation and/or regenerative medicine for nerves. | 10-07-2010 |
| 20100254952 | Isolated myeloid-like cell populations and methods of treatment therewith - The present invention provides a method of rebuilding and stabilizing functional vasculature in hypoxic retinal tissue comprising contacting the hypoxic retinal tissue with an effective amount of cells from an isolated myeloid-like cell population comprising a majority of cells that express CD44 antigen, CD11b antigen, and hypoxia inducible factor 1α (HIF-1α). The isolated myeloid-like bone marrow cells optionally can be transfected with a gene encoding a therapeutically useful peptide, for delivering the gene to the retina. | 10-07-2010 |
| 20100254953 | CELL GROWTH METHOD AND PHARMACEUTICAL PREPARATION FOR TISSUE REPAIR AND REGENERATION - The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method. | 10-07-2010 |
| 20100254954 | Human Bone Stem Cells From Amniotic Mesenchymal Cell Layer - A bone stem cell which may be supplied stably and which is free from the problem about the compatibility in transplantation is disclosed. The bone stem cell according to the present invention is separated from human amniotic mesenchymal cell layer. The bone stem cell may be used for osteogenesis in a bone defect or the like. | 10-07-2010 |
| 20100254955 | SURGICAL DEVICE FOR SKIN THERAPY OR TESTING - A device, and method of making the device, capable of therapeutic treatment and/or for in vitro testing of human skin. The device may be used on skin wounds for burned, injured, or diseased skin, and provides structures and functions as in normal uninjured skin, such as barrier function, which is a definitive property of normal skin. The device contains cultured dermal and epidermal cells on a biocompatible, biodegradable reticulated matrix. All or part of the cells may be autologous, from the recipient of the cultured skin device, which advantageously eliminates concerns of tissue compatibility. The cells may also be modified genetically to provide one or more factors to facilitate healing of the engrafted skin replacement, such as an angiogenic factor to stimulate growth of blood vessels. The inventive device is easy to handle and manipulate for surgical transplant, can be made into large sheets to minimize the number of grafts required to cover a large surface area to be treated, and can be produced within the time frame to treat a burned individual requiring a skin graft. | 10-07-2010 |
| 20100260721 | Enrichment of Cells - The present invention relates to methods of isolating and enriching mesenchymal stem cells (MSCs) comprising treating a tissue sample comprising cells and extracellular matrix with an amount of a collagenase that is sufficient to free MSCs from the extracellular matrix in a liquid medium and then isolating a fraction of the medium containing MSCs. The isolated MSCs can be isolated in surprisingly large numbers such that the fraction can have immediate use in a number of clinical contexts. This represents an advance of prior art techniques that either require the pooling of large volumes of sample tissues from different sources or require MSCs to be expanded in culture. The invention therefore further concerns the clinical use of cells isolated according to the methods of the first aspect of the invention. | 10-14-2010 |
| 20100260722 | Material for ameliorating skin tissue and method for producing the same - A material for ameliorating skin tissue provided by the invention comprises, as a main component, a culture obtained by culturing cells or tissue fragments derived from human or other mammalian alveolar mucosa. Typically, 50% or more of the cells contained in the culture are fibroblasts, and having a high growth rate and a high productivity in vascular endothelial cell growth factor (VEDF) and/or keratinocyte growth factor (KGF). | 10-14-2010 |
| 20100260723 | IMPLANTABLE SYSTEM FOR AN INTERVERTEBRAL DISC AND INTERVERTEBRAL DISC IMPLANT - The present invention relates to an implantable system comprising a biologically acceptable bag comprising a cell carrier medium and a multi-component system, the use of such an implantable system for implanting into an intervertebral disc for the treatment of an annulus fibrosus and/or nucleus pulposus defect and/or for preventing an annulus fibrosus and/or nucleus pulposus defect, and an intervertebral disc implant. | 10-14-2010 |
| 20100260724 | METHOD FOR MEASURING THE PLASMINE ACTIVITY OF MICROPARTICLES PRESENT IN A SAMPLE OF A BIOLOGICAL FLUID AND USE THEREOF - The invention relates to a method for measuring the plasmine activity of microparticles, in particular circulating microparticles, in a sample of a biological fluid, particularly a biological fluid in a flow situation, wherein said method can be used as a diagnosis method or a method for following a treatment. | 10-14-2010 |
| 20100260725 | Materials and Methods for Treating Allergic and Inflammatory Conditions - The subject invention provides for the utilization of bone-marrow derived stem cells in the treatment of allergic and inflammatory diseases. In one embodiment, the invention provides for treatment of asthma. Bone-marrow derived stem cells can be used for decreasing inflammation and alter the course of immune response in the lung. | 10-14-2010 |
| 20100260726 | Methods for Producing a Non Human Model for Aortic Aneurysm - The present invention relates to methods for producing a non human animal model for aortic aneurysm which could provide insight into the diagnosis and treatment of said disease. Furthermore, the present invention relates to methods and compositions for the treatment or the prevention of aneurysm in a subject in need thereof. | 10-14-2010 |
| 20100260727 | METHOD TO AMPLIFY CARDIAC STEM CELLS IN VITRO AND IN VIVO - Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes. | 10-14-2010 |
| 20100260728 | METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy. | 10-14-2010 |
| 20100260729 | Corn Event PV-ZMIR13 (MON863) Plants and Compositions and Methods for Detection Thereof - The present invention provides compositions and methods for detecting the presence of the corn event MON863 DNA inserted into the corn genome from the transformation of the recombinant construct containing a Cry3Bb gene and of genomic sequences flanking the insertion site. The present invention also provides the corn event MON863 plants, progeny and seeds thereof that contain the corn event MON863 DNA. | 10-14-2010 |
| 20100260730 | SHIP-Deficiency to Increase Megakaryocyte Progenitor Production - The invention concerns a method for increasing megakaryocyte and megakaryocyte progenitor numbers in vitro or in vivo by suppressing SH2-containing inositol-5-phosphatase (SHIP) function in megakaryocytes or megakaryocyte progenitors expressing the SHIP gene. SHIP function can be suppressed by administering an interfering RNA, or other SHIP inhibitor, to the megakaryocytes or megakaryocyte progenitors in vitro or in vivo. | 10-14-2010 |
| 20100266552 | TREATMENT OF CHRONIC LUNG DISEASE - A method of cellular therapy for a lung disease or condition in a subject is disclosed, wherein the method involves the administration of multipotent epithelial stem cells derived from amnion tissue (AECs). In a particular application, the method is used for the treatment of lung diseases and conditions such as chronic lung diseases including chronic obstructive pulmonary disease (COPD), acute lung conditions such as acute respiratory distress syndrome (ARDS), and ventilator associated lung injury (VALI). | 10-21-2010 |
| 20100266553 | METHOD FOR ISOLATING AND CULTURING ADULT STEM CELLS DERIVED FROM HUMAN AMNIOTIC EPITHELIUM - The present invention relates to a method for isolating and culturing adult stem cells derived from human amniotic membrane in high yield, and more particularly to a method for obtaining a large amount of adult stem cells, the method comprising obtaining amniotic epithelial cells from human amniotic tissue in high yield by treatment with dithiothreitol (DTT) and a low concentration of trypsin and culturing the amniotic epithelial cells in a medium containing a Rho-associated kinase inhibitor. The human amniotic epithelial cell-derived stem cells are easily extracted compared to existing therapeutic stem cells such as umbilical cord blood stem cells and bone marrow stem cells, the yield and proliferation thereof are significantly increased by DTT treatment, the addition of the ROCK inhibitor or the replacement of medium. Thus, the method can be used to efficiently prepare adult stem cells. | 10-21-2010 |
| 20100266554 | METHODS AND COMPOSITION FOR TREATING NEURAL DEGENERATION - Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendents; e.g., bone marrow-derived neural regenerating cells; in the treatment of various neurodegenerative disorders. In certain embodiments, bone marrow-derived neural regenerating cells transplanted to sites of neural degeneration stimulate growth and/or survival of host neurons. | 10-21-2010 |
| 20100266555 | MICRO RNAS AS MARKERS OF THE FUNCTIONAL STATE OF A DENDRITIC CELL - The present invention relates to the use of specified micro RNAs as markers of the functional state of a dendritic cell. In one aspect the invention relates to a method for producing a quality-controlled therapeutic composition comprising dendritic cells. In another aspect the invention relates to a method of in vitro screening of immunomodulatory compounds. | 10-21-2010 |
| 20100266556 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND - An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various hematopoietic disorders is provided. | 10-21-2010 |
| 20100266557 | NOVEL PEPTIDE-BASED SCAFFOLDS FOR CARTILAGE REGENERATION AND METHODS FOR THEIR USE - Disclosed herein are novel peptide amphiphile molecules and compositions composed of a peptide sequence that non-covalently binds the growth factor TGF-β1. Also disclosed are methods of using these peptide amphiphiles to create a gel scaffold in situ that enhances articular cartilage regeneration when used in combination with microfracture. Significant improvement in tissue quality and overall O'Driscoll histological scores were observed in rabbits with full thickness articular cartilage defects treated with the TGF-binding peptide amphiphile. The gel can further serve as a delivery vehicle for recombinant TGF-β1 protein growth factor. Scaffolds that localize and retain chondrogenic growth factors may synergistically enhance cartilage repair when combined with microfracture, by inducing bone marrow mesenchymal stem cells into chondrogenic differentiation. This invention represents a promising new biomimetic approach to enhance current techniques of articular cartilage regeneration in the clinical setting. | 10-21-2010 |
| 20100266558 | METHOD AND ASSAY FOR GLYCOSYLATION PATTERN DETECTION RELATED TO CELL STATE OF STEM CELLS - A method and assay for characterizing populations of stem cells according to their glycosylation pattern, particularly for distinguishing between stem cell populations, for example with regard to state of differentiation. | 10-21-2010 |
| 20100266559 | STABILIZED, STERILIZED COLLAGEN SCAFFOLDS WITH ACTIVE ADJUNCTS ATTACHED - Bioimplants and methods of making the bioimplants are provided. The bioimplants comprise biological tissues having conjugated thereto adjunct molecules. The biological tissues are sterilized with a chemical sterilizing agent, such as a water soluble carbodiimide. The processes of making the bioimplants include a process in which an adjunct molecule is conjugated to a biological tissue during the sterilization process. | 10-21-2010 |
| 20100272692 | ANTICANCER COMPOSITION COMPRISING PLANT STEM CELL LINE DERIVED FROM TAXUS CAMBIUM OR PROCAMBIUM - The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a | 10-28-2010 |
| 20100272693 | BONE SCAFFOLDS, INJECTABLE BONE REPAIR MATERIALS AND METHODS FOR BONE REPAIR - A method of bone repair that includes applying to a subject a composite that comprises at least one calcium phosphate, at least one polyamine polymer material; and a linking structure covalently crosslinking the calcium phosphate to the polyamine polymer material, wherein the linking structure is covalently bonded to the calcium phosphate via a —O—Si— moiety or an isocyanato moiety and the linking structure is covalently bonded to the polyamine polymer material via amine groups of the polyamine polymer. Also disclosed is a combination of ingredients comprising at least one polyamine polymer; and calcium phosphate particles that are substantially coated with at least one functional group that is covalently reactive with amine groups on the polyamine polymer; wherein the ingredients are adapted for injection into a subject for forming a bone replacement material in vivo. | 10-28-2010 |
| 20100272694 | CLINIC COMPLIANT METHOD FOR BANKING HUMAN PLACENTAL MESENCHYMAL CELLS - The present invention relates to a method for processing human placental cell sample, a human placental cell sample obtained according to said method for processing human placental cell sample, a human placental cell bank, a method for banking human placental cells, a method for searching human placental cell sample in said human placental cell bank according to the present invention, a method for preparing human cord blood serum, use of human placental cells obtained by said method for processing human placental cell sample or human placental cell bank established by said method for banking human placental cells in treating human dysfunction and diseases due to cell injury or cell malfunction, as well as a method for treating human dysfunction and diseases due to cell injury or cell malfunction. | 10-28-2010 |
| 20100272695 | CELL COMPOSITIONS DERIVED FROM DEDIFFERENTIATED REPROGRAMMED CELLS - Methods and cell culture compositions, in particular, pancreatic cell culture methods and compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as, induced pluripotent stem (iPS) cells. | 10-28-2010 |
| 20100272696 | Human Bone-Forming Cells In The Treatment of Inflammatory Rheumatic Diseases - The invention relates to novel therapeutic uses of isolated bone-forming cells, particularly in the treatment of inflammatory rheumatic diseases. | 10-28-2010 |
| 20100278782 | DIFFERENTIATION OF RAT LIVER EPITHELIAL CELLS INTO HEPATOCYTE-LIKE CELLS - Methods for differentiation of cells of a rat liver epithelial (RLEC) cell line to hepatocyte-like cells are disclosed. In particular, methods involve sequential exposure of the RLEC to two or more differentiation agents. Cells obtained by the method are described as well as their uses in various pharmacological, toxicological, therapeutic, diagnostic and research applications. | 11-04-2010 |
| 20100278783 | Method of Preparing Autologous Cells and Method of Use for Therapy - A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy. | 11-04-2010 |
| 20100278784 | METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS - The invention features methods, kits, and compositions for treating aging-related skin conditions (e.g., wrinkles), pigmentation disorders, acne, and scar formation, as well as methods, kits, and compositions for preventing scar formation. | 11-04-2010 |
| 20100278785 | INJECTION DEVICE FOR INJECTION INTO BIOLOGICAL TISSUE AND INJECTION DEPOT - An injection device ( | 11-04-2010 |
| 20100278786 | USE OF THE OPPOSITE CELL DIFFERENTIATION PROGRAM (OCDP) FOR THE TREATMENT OF DEGENERATED ORGANS IN THE PATHOLOGICAL STATE - The present invention relates to a method for the treatment of organs which are degenerative and/or in the pathological state by means of the use of cells, which are phenotypically stably differentiating or differentiated but not necessarily ultimately predetermined with respect to development, from a donor organ selected according to the principles of the opposite cell differentiation program (OCDP) and also to the use of cells of this type for the treatment or for the production of a drug for treatment of the same. Furthermore, the present invention relates to pharmaceutical agents comprising suitable phenotypically stable cells, cells of a first organ which is different from the second organ with respect to organ type thereby being used, which, in the normal physiological state with respect to a predetermined set of expressed genes and/or phenotypical properties, have opposite properties to the second cells in the normal physiological state. | 11-04-2010 |
| 20100278787 | CARDIOMYOCYTE-LIKE CELL CLUSTERS DERIVED FROM HBS CELLS - A cluster is provided comprising cardiomyocyte-like cells, wherein the cluster has i) contracting cells, ii) cells that are electrically connected, and expresses iii) cardiac markers including Nkx.2.5, troponin and myosin, iv) markers for functional adrenergic receptors, v) markers for functional muscarinic receptors, vi) markers for functional ion-channels including hERG, Na+, Ca | 11-04-2010 |
| 20100278788 | Osteogenic Differentiation Of Bone Marrow Stem Cells And Mesenchymal Stem Cells Using A Combination Of Growth Factors - The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 11-04-2010 |
| 20100278789 | METHODS OF GENERATING EXPANDED AND RE-DIFFERENTIATED ADULT ISLET BETA CELLS CAPABLE OF PRODUCING INSULIN - A method of increasing insulin content in adult islet beta cells is disclosed. The method comprises contacting the adult islet beta cells with an agent capable of down-regulating activity and/or expression of at least one component participating in a NOTCH pathway, the component being up-regulated in beta cell dedifferentiation above a predetermined threshold, thereby increasing the insulin content in adult islet beta cells. Methods of labeling dedifferentiated adult islet beta cells are also disclosed. Cell populations generated using the methods of the present invention and uses thereof are also disclosed. | 11-04-2010 |
| 20100284976 | COMPOSITIONS FOR THE PREPARATION OF MATURE DENDRITIC CELLS - The invention relates to a method for in vitro maturation of at least one immature dendritic cell, comprising stimulating said immature dendritic cell with TNFα, IL-1β, IFNγ, a TLR7/8 agonist and prostaglandin E2 (PG). Furthermore, the invention relates to a composition comprising said factors as well as to mature dendritic cells produced by the method of the invention. | 11-11-2010 |
| 20100284977 | Expression of Anti-Nociceptive Compounds from Endogenously Regulated Promoters - Expression of anti-nociceptive compounds under the control of endogenously regulated promoters is disclosed. Methods and materials can be used to modify nociception, the process activated by detection of noxious stimuli. The activity of endogenous promoters employed is up-regulated following nociception in animal models of pain. Thus, expression of anti-nociceptive compounds, e.g., proteins, antisense RNAs or micro RNAs, under the control of these promoters can occur in an auto-regulatory, demand-driven manner. Delivery to neurons activated during pain transmission of disclosed expression cassettes containing up-regulated promoters to drive expression of anti-nociceptive compounds can be useful for pain management. | 11-11-2010 |
| 20100291042 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated the stem cells, are also provided. | 11-18-2010 |
| 20100291043 | IL-12 IMMUNOTHERAPY FOR CANCER - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as leukemia. | 11-18-2010 |
| 20100291044 | Lunasin-induced regulation of disease-related gene expression - Methods are provided for screening a test compound for anti-neoplastic activity by providing a test compound to a cancer cell and measuring the acetylation of Lysine 16 of the N-terminal tail of histone H4. Methods are also provided for using a test compound for staging a cancer tissue and for measuring the degree of the test compound's anti-neoplastic activity upon a cancer tissue by providing a test compound to a cancer tissue sample and measuring the degree of methylation of nucleotides within the 5′ region in the cancer tissue sample. | 11-18-2010 |
| 20100291045 | DYNAMIC VIBRATIONAL METHOD AND DEVICE FOR VOCAL FOLD TISSUE GROWTH - Dynamic vibrational methods and devices for inducing differentiation of stem cells into vocal fold fibroblast-like cells or for generating vocal fold-like tissue from cultured cells. Also provided are matrices providing sustained release of growth factors, and bioreactors generating and delivering a high frequency vibration with in-plane shear stress to cultured cells. | 11-18-2010 |
| 20100291046 | Equine Progenitor Cells - An isolated mammalian progenitor cell or its progeny, isolated from articular cartilage, is disclosed. Further is disclosed an equine progenitor cell isolated from the surface zone of equine articular cartilage tissue and uses thereof. Also disclosed are a method of tissue repair, a medicament, and a method of treating mammalian cartilage damage using such progenitor cells or progeny. | 11-18-2010 |
| 20100291047 | Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 11-18-2010 |
| 20100297087 | PLURIPOTENT STEM CELLS CHARACTERIZED BY EXPRESSION OF GERMLINE SPECIFIC GENES - The present invention relates to pluripotent or multipotent somatic stem cells characterized by the expression of the germline specific gene, DAZL. The somatic stem cells expressing the DAZL marker are further characterized by expression of additional markers and absence of expression of certain blood markers. In particular, the present invention discloses therapeutic and diagnostic uses, other than the germ cell potential use, of the DAZL pluripotent or multipotent stem cells isolated from adult or peripheral somatic sources such as peripheral blood, bone marrow or umbilical cord blood. | 11-25-2010 |
| 20100297088 | Methods for Culturing Minimally-Passaged Fibroblasts and Uses Thereof - The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times. | 11-25-2010 |
| 20100303765 | Scaffoldless Constructs for Tissue Engineering of Articular Cartilage - A process for culturing chondrocytes to form constructs which contain higher percentages of cells that retain the chondrocytic phenotype are disclosed. The tissue engineered constructs may be formed into neocartilage-containing compositions for a variety of in vitro and in vivo purposes. Methods of treating individuals in need of articular cartilage growth by implanting a new composition are disclosed. | 12-02-2010 |
| 20100303766 | CELL POPULATION WITH ENHANCED TRANSPLANTATION ACTIVITY - A cell having excellent migration ability and engraftment ability to tissues is required for the restoration and the like of damaged tissues making use of a hematopoietic stem cell transplantation or a stem cell transplantation. By the present invention, a cell population having excellent migration ability and engraftment ability to tissues, a pharmaceutical preparation comprising said cell and a transplantation method of said cell are provided. The cell of the present invention is useful for hematopoietic stem cell transplantation and restoration of damaged tissues using stem cell transplantation and the like. | 12-02-2010 |
| 20100303767 | METHODS FOR COMPACT AGGREGATION OF DERMAL CELLS - The invention provides for a method for aggregating dermal papilla cells or dermal sheath cells or a combination thereof, the method comprising: growing dermal papilla cells or dermal sheath cells or a combination thereof in suspension culture; and contacting the culture with an effective amount of an enzyme, wherein a substrate of the enzyme is an extracellular matrix molecule in the suspension culture, so as to aggregate dermal papilla cells or dermal sheath cells. The culture may be a hanging drop culture and the enzyme may be a hyaluronidase. | 12-02-2010 |
| 20100303768 | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith - Isolated, mammalian, adult bone marrow-derived, lineage negative hematopoietic stem cell populations (Lin | 12-02-2010 |
| 20100303769 | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease - Acute and chronic heart disease is treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The progress of treatment is continuously monitored by echo-cardiogram with growth factor treatment and/or stem cell administration adjusted according to the results of the echo-cardiogram or clinical status of the patient. Heart disease is also treated by a method that comprises administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy. | 12-02-2010 |
| 20100303770 | METHODS FOR CULTURING DERMAL CELLS FOR TREATMENT OF SKIN INJURIES SUCH AS BURNS - The present invention relates to novel methods of growing or otherwise producing unpassaged or minimally-passaged dermal cells from a small biopsy specimen for treating skin injuries significantly larger than the biopsy. | 12-02-2010 |
| 20100303771 | GABA NEURON PROGENITOR CELL MARKER 65B13 - The present inventors identified a selective marker 65B13 for GABA neuron progenitor cells of the spinal dorsal horn and cerebellum, and successfully isolated GABA neuron progenitor cells using antibodies that bind to a protein encoded by the gene. 65B13 was demonstrated to be useful as a marker to isolate GABA-producing neuron progenitor cells in the spinal dorsal horn and cerebellum. GABA neuron progenitor cells can be efficiently identified or isolated by using the identified marker as an indicator. | 12-02-2010 |
| 20100303772 | METHOD AND SYSTEM FOR DIRECTING A LOCALIZED BIOLOGICAL RESPONSE TO AN IMPLANT - The invention provides methods for directing a localized biological response of a mammalian body to an implant disposed within the body. In one embodiment, a delivery system is positioned outside the body and adjacent to the implant within the body. The delivery system comprises a first tissue response modifier effective for directing a localized biological response of the body to the implant. The tissue response modifier is nonsurgically delivered from the delivery system into the body in a quantity effective to direct the localized biological response of the body to the implant. The invention also provides an implant system for long-term use comprising an implant and nonsurgical means for delivering a tissue response modifier through the epidermis of the body, the tissue response modifier effective for directing a localized biological response of the body to the implant. | 12-02-2010 |
| 20100303773 | TSP-1, TSP-2, IL-17BR AND HB-EGF ASSOCIATED WITH STEM CELL ACTIVITY AND USE THEREOF - Thrombospondin 1 (TSP-1), TSP-2, interleukin 17B receptor (IL-17BR) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) associated with stem cell activity and use thereof. | 12-02-2010 |
| 20100303774 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS - Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit. | 12-02-2010 |
| 20100310523 | Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene - There is provided a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of a Notch gene. Specifically, the invention provides a method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells in vitro, which method comprises introducing a Notch gene and/or a Notch signaling related gene into the cells, wherein the finally obtained differentiated cells are the result of cell division of the bone marrow stromal cells into which the Notch gene and/or Notch signaling related gene have been introduced. The invention also provides a method of inducing further differentiation of the differentiation-induced neural cells to dopaminergic neurons or acetylcholinergic neurons. The invention yet further provides a treatment method for neurodegenerative and skeletal muscle degenerative diseases which employs neural precursor cells, neural cells or skeletal muscle cells produced by the method of the invention. | 12-09-2010 |
| 20100310524 | Compositions Suitable for Treatment of Spinal Disease, Disorder or Condition - The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronectin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration. | 12-09-2010 |
| 20100310525 | WNT PATHWAY STIMULATION IN REPROGRAMMING SOMATIC CELLS - The invention provides compositions and methods of use in reprogramming somatic cells. Compositions and methods of the invention are of use, e.g., for generating or modulating (e.g., enhancing) generation of induced pluripotent stem cells by reprogramming somatic cells. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a pluripotent state and/or enhances the speed and/or efficiency of reprogramming. Certain of the compositions and methods relate to modulating the Wnt pathway. | 12-09-2010 |
| 20100310526 | COSMETIC METHOD FOR INCREASING THE PIGMENTATION OF SKIN USING MELANOCYTE PRECURSOR CELLS - The present invention proposes a cosmetic method for increasing the pigmentation of skin with the steps application of melanocyte precursor cells from root sheaths collected from a first area of skin of a donor to a second area of skin of a recipient. Furthermore, the use of melanocyte precursor cells for increasing the pigmentation of skin as well as a method for producing a suspension having precursor cells from the root sheath is proposed. | 12-09-2010 |
| 20100310527 | LIPOSOME MEDIATED DELIVERY OF LINEAGE DETERMINING FACTORS - Methods and compositions are provided for lineage predetermination of cellular transplants including through liposome mediated transfection with aqueous protein extracts from populations of differentiated mammalian cells, or cellular fractions thereof, wherein the differentiated mammalian cells are enriched in one or more of adipocytes, chondrocytes, endothelial cells, hepatocytes, cardiomyocytes, smooth muscle cells, skeletal muscle cells, cardiac pacemaker cells, Schwann cells, pancreatic islet cells, hematopoietic cells, myeloblasts, neurons, and osteoblasts. | 12-09-2010 |
| 20100310528 | Vector System for Site-Specific Integration - The integration system comprises at least one vector capable of expressing at least one exogenous gene, the vector comprising a coding sequence for an attP gene region and a coding sequence for at least one therapeutic molecule and an integrase. The integration system has an application in bacterial metabolic engineering and in gene therapy. | 12-09-2010 |
| 20100310529 | EXTRACELLULAR MATRIX FROM PLURIPOTENT CELLS - Isolated extracellular matrix from marrow adherent stromal cells and their descendents, which stimulates the growth and survival of a number of different neural cell types, is provided, along with methods for preparation and uses. | 12-09-2010 |
| 20100310530 | Cell Therapy for Brain Tissue Damage - Disclosed are methods for conditioning stems cells and using the conditioned stems cells for treating brain tissue damage. | 12-09-2010 |
| 20100310531 | PEPTIDE-COATED CELL LOCALIZATION TO DISEASED OR DAMAGED TISSUES AND METHODS RELATED THERETO - Embodiments of the present invention are directed to a coated cell comprising a therapeutic cell and a plurality of targeting complexes coating the therapeutic cell and each of said targeting complexes comprising a homing molecule, a lipid moiety, and a spacer having from about 1 to about 10 amino acids and covalently linking the homing molecule to the lipid moiety and wherein the lipid moiety is non-covalently attached to the therapeutic cell. In some embodiments, the therapeutic cell is a stem cell. Embodiments of the invention are directed to methods of coating a therapeutic cell. Embodiments of the invention are directed to methods of treating diseases of the vasculature. | 12-09-2010 |
| 20100316612 | PRIMED CELL THERAPY - The subject invention is directed to a composition comprising primed connective tissue cells and a pharmaceutically acceptable carrier thereof. | 12-16-2010 |
| 20100316613 | FEEDER CELL-FREE CULTURE MEDIUM AND SYSTEM - A cell culture medium and system are provided which eliminates or at least reduces the need for feeder cells. The cell culture medium comprises one or more factors that are normally secreted and/or produced by a feeder cell and a synthetic chimeric protein comprising IGF-I and a portion of vitronectin. The cell culture medium is particularly suitable for propagating human embryonic stem cells and keratinocytes. This invention also relates to compositions and methods which utilize the cells cultured in the cell culture medium of the invention. | 12-16-2010 |
| 20100322906 | Method for Obtaining Pancreatic Endocrine Cells From Adipose Tissue-Origin Cells - A method of obtaining pancreatic endocrine cells from cells originating in an adipose tissue characterized by comprising culturing the adipose tissue-origin cells; the pancreatic endocrine cells that can be obtained thereby; a method of treating or preventing a disease caused by the hypofunction in pancreatic endocrine cells wherein the above-described pancreatic endocrine cells are used; a method of screening a substance capable of promoting or inhibiting the differentiation into pancreatic endocrine cells characterized by comprising adding a candidate substance to a medium in the course of culturing adipose tissue-origin cells to obtain the pancreatic endocrine cells; and so on. | 12-23-2010 |
| 20100322907 | Expansion of Hematopoietic Stem Cells - Described herein are methods, compositions and kits related to manipulating hematopoietic stem cells and more particularly to methods, compositions and kits related to increasing the number of hematopoietic stem cells in vitro and in vivo. Also described are methods, compositions and kits related to making an expanded population of hematopoietic stem cells (HSCs) and methods, compositions and kits related to using the expanded population of HSCs. | 12-23-2010 |
| 20100322908 | COMPOSITIONS AND METHODS FOR AUGMENTATION AND REGENERATION OF LIVING TISSUE IN A SUBJECT - The present invention provides for a composition, for augmentation and regeneration of living tissue in a subject, comprising a population of porous microparticles of a biodegradable polymer, one or more mammalian cell populations, and optionally, a biocompatible adhesive. | 12-23-2010 |
| 20100330042 | Use of Proinsulin for the Preparation of a Neuroprotective Pharmaceutical Composition, Therapeutic Composition Containing it and Applications Thereof - The present invention relates to the use of a compound that induces the activity of proinsulin, preferably human proinuslin, for the preparation of a medicinal product or pharmaceutical composition for the prevention and treatment of neurodegenerative conditions, disorders or diseases involving programmed cell death, preferably neurodegenerative pathologies of the central and peripheral nervous systems, and, more preferably, of the heredodegenerative diseases known as retinosis pigmentosa. The activator compound may consist of a chemical molecule, a peptide, a protein or a nucleotide sequence. | 12-30-2010 |
| 20100330043 | GPR125 AS A MARKER FOR STEM AND PROGENITOR CELLS AND METHODS USE THEREOF - The present invention relates to GPR1 25 as a marker of stem and progenitor cells, including multipotent adult spermatogonial-derived stem cells (MASCs), spermatogonial stem and progenitor cells, skin stem or progenitor cells, intestinal stem or progenitor cells, neural stem or progenitor cells, and cancer stem cells. The invention provides, inter alia, methods for enriching or isolating GPR125-positive stem or progenitor cells, methods for detecting GPR125-positive stem or progenitor cells, methods for culturing GPR125-positive stem or progenitor cells, purified GPR125-positive stem or progenitor cells, therapeutic compositions containing purified GPR125-positive stem or progenitor cells, methods for targeting therapeutic agents to GPR125-positive stem and progenitor cells, and methods of treatment comprising administering GPR125-positive stem and progenitor cells, or differentiated cells derived therefrom, to subjects in need thereof. The present invention also provides methods of detecting cancer cells based on GPR1 25 expression, and methods of targeting therapeutic agents to cancer cells to GPR125-positive cancer cells. | 12-30-2010 |
| 20100330044 | MESP1 AS A MASTER REGULATOR OF MULTIPOTENT CARDIOVASCULAR PROGENITOR SPECIFICATION AND USES THEREOF - A method for differentiating or promoting or inducing differentiation of stem cells into pluripotent cardiovascular progenitors (MCPs) by transiently inducing the expression of a single gene, namely Mesp1, is disclosed. Cells obtained by the method and their uses in research and clinical settings are also disclosed. Using genome wide transcriptional analysis, the inventors found that Mesp1 rapidly activates and represses a discrete set of genes, which form potential new targets for both therapy and for the identification of MCPs. Insights into the molecular mechanisms underlying the earliest step of cardiovascular specification and potential methods for dramatically increasing the number of cardiovascular cells for cellular therapy in humans are provided. | 12-30-2010 |
| 20100330045 | Mesenchymal precursor cell - A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilising MACS recognising expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilising two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1. | 12-30-2010 |
| 20100330046 | HUMAN SKIN SUBSTITUTES EXPRESSING IL-12 - The present invention relates generally to compositions for treating patients that have skin cancer or have recently had skin cancers removed. More specifically, the present invention provides human skin substitutes engineered to express exogenous IL-12 and compositions and methods for making human skin substitutes engineered to express exogenous IL-12. In addition, the present invention provides methods for treatment of sites on a patient where skin cancers have been removed with human skin substitutes engineered to express exogenous IL-12. | 12-30-2010 |
| 20100330047 | Mesenchymal Stem Cells Grown Under Hypoxic Conditions: Compositions, Methods and Uses Therefor - Methods of forming ex vivo cell cultures comprising differentiated mesenchymal lineage cells are disclosed. These methods comprise a) providing a cell culture comprising a plurality of mesenchymal stem cells (MSCs); b) subjecting the MSCs to hypoxic conditions; and c) subsequent to b), subjecting the MSCs to normoxic conditions. Enhanced differentiation of various mesenchymal lineage cells can be achieved for mammalian cells such as murine cells or human cells. | 12-30-2010 |
| 20100330048 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 12-30-2010 |
| 20100330049 | METHOD FOR GENERATING ISLET BETA CELLS FROM DEDIFFERENTIATED EXOCRINE PANCREATIC CELLS - The present invention relates to an in vitro method for generating insulin-producing beta cells from a population of mammalian cells comprising dedifferentiated exocrine pancreatic cells. The method comprises the step of culturing said dedifferentiated exocrine pancreatic cells in a culture medium in the presence of at least one agent that is able to inhibit the Notch 1 signaling pathway in said dedifferentiated exocrine pancreatic cells, and at least one ligand of the gp130 receptor and/or at least one ligand of the EGF receptor. The invention further provides a population of mammalian pancreatic cells comprising insulin-producing beta cells obtainable by the present method and uses thereof in a pharmaceutical composition for treating type 1 or type 2 diabetes. | 12-30-2010 |
| 20110002892 | MODULAR APTAMAR-REGULATED RIBOZYMES - An extensible RNA-based framework for engineering ligand-controlled gene regulatory systems, called ribozyme switches, that exhibit tunable regulation, design modularity, and target specificity is provided. These switch platforms typically contain a sensor domain, comprised of an aptamer sequence, and an actuator domain, comprised of a hammerhead ribozyme sequence. A variety of modes of standardized information transmission between these domains can be employed, and this application demonstrates a mechanism that allows for the reliable and modular assembly of functioning synthetic hammerhead ribozyme switches and regulation of ribozyme activity in response to various effectors. In some embodiments aptamer-regulated cis-acting hammerhead ribozymes are provided. | 01-06-2011 |
| 20110002893 | DIAGNOSIS AND TREATMENT OF CONGENITAL HEART DEFECTS USING NELL1 - The present invention provides diagnostic methods for detecting congenital heart defects, or increased risk thereof, based on the Nell1 gene, RNA and protein. The methods include obtaining a biological sample and assessing the presence of a mutation in the Nell1 gene, RNA or protein. The presence of a mutation in the Nell1 gene, RNA or protein can be assessed by determining the levels of Nell1 gene, RNA or protein in the biological sample. The present invention further provides therapeutic methods for treating congenital heart defects based on the Nell1 gene. RNA and protein. | 01-06-2011 |
| 20110002894 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HEART TISSUE DEGENERATION AND USES THEREOF - The present invention provides compositions useful for cardiac therapy comprising a cyclin-associated agent. The present invention also provides kits for use in delivering a cyclin-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter. The present invention additionally provides a methods for enhancing cardiac function; promoting regeneration of cardiac tissue; inducing endogenous myocardial regeneration; and preventing or treating heart failure in a subject in need thereof by augmenting cyclin in cells. | 01-06-2011 |
| 20110002895 | COMPOSITION FOR AUTOTRANSPLANTATION OR ALLOTRANSPLANTATION USING DENTAL PULP STEM CELL, AND USE OF THE COMPOSITION - The object is to provide a novel use application of a dental pulp stem cell collected from a deciduous tooth or a permanent tooth. Disclosed is a composition for autotransplantation or allotransplantation, which is characterized by comprising a dental pulp stem cell collected from a deciduous tooth or a permanent tooth. | 01-06-2011 |
| 20110002896 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT - Compositions and methods useful in the reduction of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating localized accumulations of fat including, for example, lower eyelid fat herniation, lipodystrophy and fat deposits associated with cellulite and do not require surgical procedures such as liposuction. | 01-06-2011 |
| 20110002897 | DIRECTED DIFFERENTIATION OF STEM CELLS - Disclosed are compositions and methods for producing neural cells from stem cells and uses thereof. | 01-06-2011 |
| 20110002898 | VACCINE COMPOSITIONS - The invention relates to tumour therapy. In particular, the present invention relates to vaccine compositions comprising allogenic cells modified with hypercytokines for the treatment of cancer in general and for the treatment of melanoma in particular. | 01-06-2011 |
| 20110002899 | Lymph Nodes as a Site for Regeneration - Methods of transplanting cells, such as hepatocytes, are presented herein. Such methods are useful for treating liver disease as well as other disorders. | 01-06-2011 |
| 20110008296 | MUSCLE-DERIVED CELLS HAVING DIFFERENTIATION CAPACITIES - The present application relates to cell populations having differentiation capacities, which are obtainable by isolation from a muscle tissue, more particularly from a skeletal and/or cardiac muscle tissue, preferably from endomysial and/or cardiac tissue, more preferably from endomysial tissue. The cell populations of the invention comprise ALDH-positive cells, and notably have myogenic and/or adipogenic and/or osteogenic differentiation capacities. | 01-13-2011 |
| 20110008297 | OXYSTEROLS FOR ACTIVATION OF HEDGEHOG SIGNALING, OSTEOINDUCTION, ANTIADIPOGENESIS, AND WNT SIGNALING - Synthetic oxysterols can be made and can be used for the treatment of bone disorders, obesity, cardiovascular disorders, and neurological disorders. | 01-13-2011 |
| 20110008298 | METHOD OF DERIVING PROGENITOR CELL LINE - We disclose a method comprising: (a) providing an embryonic stem (ES) cell; and (b) establishing a progenitor cell line from the embryonic stem cell; in which the progenitor cell line is selected based on its ability to self-renew. Preferably, the method selects against somatic cells based on their inability to self-renew. Preferably, the progenitor cell line is derived or established in the absence of co-culture, preferably in the absence of feeder cells, which preferably selects against embryonic stem cells. Optionally, the method comprises (d) deriving a differentiated cell from the progenitor cell line. | 01-13-2011 |
| 20110008299 | TREATMENT OF PELVIC FLOOR DISORDERS WITH AN ADIPOSE-DERIVED CELL COMPOSITION - A method for treating a pelvic floor disease comprises removing adipose tissue from a patient, processing a first portion of the adipose tissue to obtain a heterogeneous mixture of cells that includes adipose-derived stem cells, combining the heterogeneous mixture of cells with a second, unprocessed portion of the adipose tissue in a ratio of from approximately 1:1 to 1:4 to produce a cell composition, wherein the second portion of the adipose tissue is structured to provide a natural scaffold, and administering the cell composition to the patient to treat a pelvic floor disease. | 01-13-2011 |
| 20110008300 | Cryopreservation of Adipose Tissue for the Isolation of Mesenchymal Stem Cells - The present invention relates to a method and composition for the cryopreservation of adipose tissue with the intention to use this tissue in the culturing of stem and/or progenitor cells. The method uses a specific cryoprotection medium to prevent damage of the original tissue during the cryopreservation while still maintaining a high viability of the stem and/or progenitor cells obtained from the cryopreserved adipose tissue. Furthermore the cryoprotection medium of the present invention does not contain any kind of xenogeneic sera, a critical factor since it is the intention of that the cryopreserved tissue is used for obtaining stem and/or progenitor cells that can be used in medicine. The cryoprotection medium is characterized in that it is a solution of physiological water comprising glycerol and sucrose and/or trehalose and optionally serum albumin. | 01-13-2011 |
| 20110008301 | HUMAN ADIPOSE DERIVED INSULIN MAKING MESENCHYMAL STEM CELLS FOR TREATING DIABETES MELLITUS - The invention provides a novel therapeutic composition comprising of insulin producing mesenchymal stem cells obtained from human adipose tissue along with Hematopoietic stem cells for the treatment of diabetic patients especially insulinopenic patients. The invention also describes a simple and efficient process for the isolation, proliferation and differentiation of insulin producing mesenchymall stem cells from human adipose tissue. Unfiltered extract of adipose tissue is used in the process with a medium totally free from xenogenic material; the serial passages of the cells are avoided in the process. | 01-13-2011 |
| 20110014158 | COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS - The present invention relates to protein and nucleic acid mutants of chondroitinase ABCI. Such chondroitinase ABCI mutant enzymes exhibit altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using chondroitinase ABCI mutant enzymes are also provided. | 01-20-2011 |
| 20110014159 | METHOD FOR OBTAINING CHARACTERIZED MUSCLE-DERIVED CELL POPULATIONS AND USES - A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of the required cell population and collecting the selected culture stage for preparing a cell therapy product. The invention also concerns cell populations derived from muscular tissue obtained by implementing the method whereof the dominant cell type is CD34+, CD15+ or CD56+ or Class 1+HLA, or comprises a doubly negative CD56−/CD15− cell type or may comprise more minority CD10+, Stro-1+ and CD 117+ cell types. | 01-20-2011 |
| 20110014160 | DDR1-Mediated Cell Purification of Pancreatic Endocrine Cells Through Their Progenitors - The invention relates to a method of identifying, obtaining and/or quantifying a culture of pancreatic cells selected from the group consisting of ductal/endocrine progenitor cells, endocrine progenitor cells, early endocrine cells, and fully differentiated endocrine cells. Also contemplated is a method of expanding the numbers of such cells as well as sorting such cells. The invention further relates to a selective cell surface marker, DDR1, that permits the selection of a unique subset of cells with pancreatic endocrine progenitor phenotype. Furthermore, the invention relates to isolated cells selected from such cells and compositions thereof. | 01-20-2011 |
| 20110014161 | Cardiac Tissue-Derived Cells - The present invention is directed to methods and compositions for repairing damaged myocardium using human cardiac tissue-derived cells. In particular, the present invention provides methods and compositions for repairing damaged myocardium using expanded human cardiac tissue-derived cells that do not express telomerase. | 01-20-2011 |
| 20110014162 | Preserved Compositions of Activated NK Cells and Methods of Using the Same - Disclosed herein are activated NK cells that exhibit durable and prolonged activity in the absence of the activating agent and retain their activated state after preservation. Methods of administrating the NK cells to a patient do not require co-administration of the activating agent, and thus, pharmaceutical compositions comprising the NK cells may remain substantially free of the activating agent. | 01-20-2011 |
| 20110014163 | Differentiation of Human Embryonic Stem Cells - The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal. | 01-20-2011 |
| 20110014164 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS - The disclosure features a method of producing an induced pluripotent stem cell a somatic cell. The method includes contacting a somatic cell with a DNA methyl transferase inhibitor or a histone deacetylase (HDAC) inhibitor, or a combination thereof, to produce a pluripotent stem cell. | 01-20-2011 |
| 20110020291 | USE OF STEM CELLS FOR WOUND HEALING - Cells, compositions, and methods of cell therapy for administering a therapeutically effective amount of stem cells or cell concentrate to achieve accelerated wound healing of normal and chronic wounds, while minimizing the formation of scar tissue. | 01-27-2011 |
| 20110020292 | Use of Stem Cells to Reduce Leukocyte Extravasation - The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential. | 01-27-2011 |
| 20110020293 | Use of Stem Cells to Reduce Leukocyte Extravasation - The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential. | 01-27-2011 |
| 20110020294 | INDUCEMENT OF ORGANOGENETIC TOLERANCE FOR PANCREATIC XENOTRANSPLANT - Provided herein is an approach to establish organogenetic tolerance via prior transplantation of pig embryonic pancreas, thereby enabling subsequent implantation of porcine islets in a subject without the need for immune-suppression. In one aspect of the invention, porcine pancreatic primordia are implanted into a mammalian subject, and after a period of time sufficient to induce tolerance, porcine islet cells are implanted in the subject. | 01-27-2011 |
| 20110020295 | PRE-TRANSPLANT ACCOMMODATED ORGANS RESISTANT TO ANTI-DONOR IMMUNITY - This invention includes the composition of organ grafts accommodated prior to transplantation and therefore resistant to rejection by preformed antibodies. Accommodation is achieved within the donor animal by administration of sub-lethal levels of accommodation inducing factors derived from animals sensitized to the donor. | 01-27-2011 |
| 20110020296 | METHODS FOR TREATING DISEASES AND INCREASING LONGEVITY - Diseases such as cancer, HIV/AIDS, diabetes, infectious diseases, as well as diseases related to the immune and autoimmune systems, are treated through the formation and/or enhancement of the function of organs and suborgans of human patients. An important organ for such purpose is the thymus. Enhancement may be direct or indirect and utilizes energy, enhancement compositions, and/or living organisms to enhance the cells and/or cell products produced by organs and suborgans. | 01-27-2011 |
| 20110020297 | DNER-MEDIATED CELL PURIFICATION OF PANCREATIC ENDOCRINE PRE-PROGENITOR CELLS AND THEIR PROGENY - The invention relates to a method of identifying and obtaining a culture cells comprising cells selected from the group consisting of endocrine pre-progenitor cells, endocrine progenitor cells, early endocrine cells, and/or fully differentiated endocrine cells. Also contemplated is a method of expanding the number of such cells as well as sorting such cells. In some aspects the invention further relates to a selective cell surface marker, DNER, that permits the selection of a unique subset of cells with endocrine pre-progenitor, endocrine progenitor, early endocrine, and/or fully differentiated endocrine phenotype. In some aspects the selective cell surface marker is selected from the group consisting of DNER, DISP2, SEZ6L2, LRP1 1 and SLC30A8. Furthermore, the invention relates to isolated cells selected from such cells and compositions thereof. | 01-27-2011 |
| 20110020298 | COLLAGEN-BINDING SYNTHETIC PEPTIDOGLYCANS, PREPARATION, AND METHODS OF USE - This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use. | 01-27-2011 |
| 20110020299 | METHOD AND COMPOSITION FOR THE REGENERATION OF TISSUE WITH THE AID OF STEM CELLS OR BONE MARROW CELLS - The invention relates to a novel polymerisable composition essentially consisting of blood or blood plasma, and also stem cells or bone-marrow cells, and to a method for tissue regeneration with the aid of such compositions. Mixtures of this type are able to polymerise under the influence of endogenous or exogenous polymerisation factors, such as thrombin, calcium ions or cell detritus, to give viscous gels, which are very advantageous for the development and differntiation of the stem cells or bone-marrow cells into tissue-specific cells. Polymers of this type, which, in particular, additionally comprise erythropoietin (EPO), or growth factors with a similar action, exhibit excellent properties on use for tissue regeneration or in the regeneration of bone defects. | 01-27-2011 |
| 20110027234 | METHODS FOR IDENTIFICATION AND SELECTION OF HUMAN EMBRYONIC STEM CELL DERIVED CELLS - A nucleic acid construct is disclosed, the nucleic acid comprising a polynucleotide comprising a nucleic acid sequence encoding a detectable expression product, the nucleic acid sequence being operably linked to a human tissue specific promoter. A method of lineage tracing of human stem cells and isolated human embryonic stem cell comprising the nucleic acid construct are also disclosed. | 02-03-2011 |
| 20110027235 | Targeted integration into stem cells - Disclosed herein are methods and compositions for targeted integration of sequences of interest such as lineage-specific or cell fate reporter constructs or protein encoding sequences into stem cells. | 02-03-2011 |
| 20110027236 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF OSTEOARTICULAR DISEASES - A pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases includes an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells. | 02-03-2011 |
| 20110027237 | Intraperitoneal Delivery of Genetically Engineered Mesenchymal Stem Cells - A method of expressing at least one protein in an animal by intraperitoneal administration of mesenchymal stem cells genetically engineered with at least one polynucleotide encoding the at least one protein. The method may be employed in treating lysosomal storage disorders, such as Fabry Disease, or arthritic disorders, or hemophilia, for example. | 02-03-2011 |
| 20110027238 | Mesenchymal Stem Cells and Uses Therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 02-03-2011 |
| 20110033426 | USE OF MODIFIED CELLS FOR THE TREATMENT OF MULTIPLE SCLEROSIS - The present invention describes blood cells chemically coupled with immunodominant myelin peptides and their use in the treatment of Multiple Sclerosis. | 02-10-2011 |
| 20110033427 | Expansion Of Renewable Stem Cell Populations - Ex vivo and in vivo methods of expansion of renewable stem cells, expanded populations of renewable stem cells and their uses. | 02-10-2011 |
| 20110033428 | METHOD FOR ISOLATING SMOOTH MUSCLE STEM CELLS - This invention relates to a method for isolating smooth muscle stem cells derived from mammalian smooth muscle comprising bringing mammalian smooth muscle cells into contact with a fluorescence-labeled anti-CD45 antibody, anti-CD34 antibody, and anti-CD49f antibody, and isolating cells that would not bind to the anti-CD45 antibody but would bind to the anti-CD34 antibody and the anti-CD49f antibody. | 02-10-2011 |
| 20110044953 | Methods and Compositions for Localized Secretion of Anti-CTLA-4 Antibodies - The present invention provides compositions and methods for effectuating the localized expression of anti-CTLA-4 antibody proximal to a target tissue in a patient. | 02-24-2011 |
| 20110044954 | Methods of producing germ-like cells and related therapies - The present invention relates to methods of producing germ-like cells (GLCs) from embryonic stem cells and induced pluripotent stem cells, GLCs produced by such methods, gametes derived from such GLCs, pharmaceutical compositions and kits containing such GLCs, screens that use GLCs to identify agents useful in enhancing mammalian reproductive health, and methods of treatment that use GLCs to enhance mammalian reproductive health. | 02-24-2011 |
| 20110044955 | ALTERING MEMORY BY AFFECTING STAUFEN - The present invention provides cell-based screening methods for identifying pharmaceutical agents which are capable of modulating (have the ability to modulate) STAUFEN function by screening for STAUFEN function. | 02-24-2011 |
| 20110044956 | NELL-1 ENHANCED BONE MINERALIZATION - This invention pertains to the discovery that the human NELL-1 gene induces or upregulates bone mineralization. The NELL-1 gene or gene product thus provides a convenient target for screening for modulators of bone mineralization. In addition, NELL-1 can be used to facilitate repair of bone fractures and/or to generally increase bone density. | 02-24-2011 |
| 20110044957 | METHODS AND SYSTEMS FOR EXTENDED IN VITRO CULTURE OF NEURONAL CELLS - A cell culture system related to extended in vitro culture of mature neuronal cells and methods for preparing the cell culture system are provided. In a preferred embodiment the invention provides a cell culture system comprising a mixture of mature neuronal retinal cells and cells isolated from a ciliary body. Methods for identifying bioactive agents that alter neurodegeneration of neuronal retinal cells are also provided. | 02-24-2011 |
| 20110044958 | ACTIVATED MESENCHYMAL STEM CELLS FOR THE PREVENTION AND REPAIR OF INFLAMMATORY STATES - Inflammatory cytokines e.g. IFN-γ serve as initiating stimuli for MSC immunosuppressive activity in vivo. Other inflammatory cytokines, such as TNF alpha, the molecule hemoxygenase I, and TLR ligation of MSC may also provide such a response. | 02-24-2011 |
| 20110044959 | NOVEL COMPOSITION OF STEM CELLS FOR TRANSPLANTATION TOLERANCE - The present invention provides a simple, economical yet efficient method of creating transplant tolerance in organ transplant patients without the continuous need for costly immunosuppressive drugs with serious adverse effects. The invention essentially deals with the administration of a novel composition to the patient which consists of adipose tissue derived Mesenchymal Stem Cells (MSC) combined with bone marrow derived Haematopoietic Stem Cells(HSC) and MSC and peripheral blood stem cells (PBSC). This helps in creating transplant tolerance ie. Stable adequate allograft function with minimum/no rejection using very low dose of immunosuppressive medication. The invention also deals with a simple method of isolating Mesenchymal Stem cells from human adipose tissue without using any xenogenic material. | 02-24-2011 |
| 20110044960 | MEDICAMENT, DENTAL MATERIAL, AND METHOD OF SCREENING - The present invention provides a novel and creative dental materials for treatment of pulpitis and/or enhancement of dentinogenesis. The dental materials of the present invention contain at least one of a protein having matrix metalloprotease 3 activities or matrix metalloprotease 3 precursor protein as an active ingredient. The dental materials of the present invention contain a carrier having biocompatibility. The dental materials of the present invention can contain at least one cell type among pulp cells, pulp stem cells, pulp progenitor cells, odontoblasts or cells that can differentiate into odontoblasts. | 02-24-2011 |
| 20110052545 | Regeneration system, its production and use - The present invention relates to a tissue-maintaining colony-forming unit (TM-CFU), a method of preparing the same, a pharmaceutical composition comprising the TM-CFU, the use of the TM-CFU for the manufacture of a pharmaceutical composition, and a method of determining the effect of at least one stimulus on the TM-CFU or a cellular subpopulation thereof. | 03-03-2011 |
| 20110052546 | Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation - The instant invention teaches the inhibition of SHIP expression, or function for the increased efficacy of autologous stem cell transplants. In another embodiment, interference with SHIP function can be used to temporarily expand and mobilize the hematopoietic stem cell compartment to assist with leukapheresis, to promote hematopoietic recovery after myeloablation treatments, to deplete target stem cell clones (such as leukemic clones and other tumor stem cell types), and to deplete, or damage, the repopulating ability of the endogenous hematopoietic stem cell pool in order to allow transplanted hematopoietic stem cells to better home and engraft and to promote in vivo expansion and mobilization of other organ-specific stem cell populations (e.g., mesenchymal, mammary). | 03-03-2011 |
| 20110052547 | RAPAMYCIN-RESISTANT T CELLS AND THERAPEUTIC USES THEREOF - Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer. | 03-03-2011 |
| 20110052548 | CELL CULTURE MEDIA TO DIFFERENTIATE EMBRYONIC STEM CELLS INTO NEURONAL LINEAGES - This invention provides compositions for differentiating an isolated embryonic stem cell or an isolated embryoid body into neuronal progenitor cells and methods for using same. | 03-03-2011 |
| 20110052549 | CELL CULTURE DEVICE TO DIFFERENTIATE STEM CELLS IN A SPECIFIC ORIENTATION - Methods and compositions for aligning cell growth is provided by this invention by contacting at least one isolated cell with a device, wherein the device comprises a plurality of continuously orientating substantially parallel structures on the surface of the device, and culturing the cell under conditions that favor division of the at least one cell into a population of cells, thereby growing the population of cells in a substantially parallel orientation. | 03-03-2011 |
| 20110052550 | Therapeutic Uses of Allogeneic Myeloid Progenitor Cells - Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients. | 03-03-2011 |
| 20110052551 | CARDIAC MYOCYTE MORPHOGENIC COMPOSITIONS AND METHODS OF USE THEREFOR - Disclosed are methods for inducing cardiomyogenic differentiation in cells that are competent for differentiation along the cardiomyogenic lineage such as certain unfractionated bone marrow mononuclear cells (BMMNCs). In some embodiments, the methods include contacting a plurality of unfractionated, density gradient-separated BMMNCs with a cardiomyocyte differentiation-inducing amount of a Wnt11 gene product for a time and under conditions sufficient to induce cardiomyocyte differentiation in at least a subset of the BMMNCs. Also provided are methods for treating an injury to cardiac tissue in a subject using cells that have been induced to differentiate along the cardiomyogenic lineage, recombinant host cells comprising an expression vector that encodes a Wnt11 polypeptide or a functional fragment thereof, and systems for inducing cardiomyogenic differentiation in a cultured cell. | 03-03-2011 |
| 20110052552 | COMPOSITIONS TO EFFECT NEURONAL GROWTH - Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed | 03-03-2011 |
| 20110059050 | METHODS AND COMPOSITIONS RELATING TO STEM CELL TRANSPLANTATION - The invention relates to methods and compositions for stem cell transplantation. Aspects of the invention relate to administering hematopoietic stem cells and mesemchymal cells to a patient. | 03-10-2011 |
| 20110059051 | Molecular Control of Brown Fat Differentiation and Engergy Expenditure - The invention provides methods and compositions for inducing brown fat cell differentiation through modulation of Prdm 16 activity or expression. Also provided are methods for preventing or treating obesity or an obesity related disorder in a subject through stimulation of Prdm 16 expression or activity. Further provided are methods for identifying compounds that are capable of modulating Prdm 16 expression or activity. | 03-10-2011 |
| 20110059052 | CELLULAR THERAPEUTIC AGENT FOR INCONTINENCE OR URINE COMPRISING STEM CELLS ORIGINATED FROM DECIDUA OR ADIPOSE - The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence. | 03-10-2011 |
| 20110059053 | METHOD OF TREATING BIOCELLS - A method of treating biocells includes the steps of: a. providing biocells; b. applying at least one stressor to the biocells sufficient to cause nonlethal and reparable cell wall damage to the biocells, thereby putting the biocells in a catabolic state during which catabolic metabolic functions predominate over anabolic metabolic functions; and c. obtaining at least one product produced by the biocells during the catabolic state. In another embodiment, the method includes the steps of: a. providing biocells that are mammalian cells; b. applying at least one stressor to the biocells sufficient to cause nonlethal and reparable cell wall damage to the biocells, the reparable cell wall damage comprising openings that allow increased passage of materials through the cells walls; and c. inserting foreign DNA through the openings into the biocells. | 03-10-2011 |
| 20110059054 | ENHANCED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY - Described herein are methods of cancer immunotherapy, particularly methods of preparing a population of enhanced dendritic cells and methods of treating cancer using the enhanced dendritic cells. | 03-10-2011 |
| 20110059055 | TREATING MYELIN DISEASES WITH OPTIMIZED CELL PREPARATIONS - The disclosure relates to oligodendrocyte-biased glial progenitor cells and methods of making, isolating, and using such cells. | 03-10-2011 |
| 20110064700 | NEURAL STEM CELLS - The invention provides compositions and methods for obtaining neural stem cells from post-natal subjects and their use in treating neurological disorders. | 03-17-2011 |
| 20110064701 | Pluripotent embryonic-like stem cells, compositions, methods and uses thereof - The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting the pluripotent stem cells of the present invention in a mammalian host, such as human, comprising introducing the stem cells, into the host. The invention further relates to methods of in vivo administration of a protein or gene of interest comprising transfecting a pluripotent stem cell with a construct comprising DNA which encodes a protein of interest and then introducing the stem cell into the host where the protein or gene of interest is expressed. The present also relates to methods of producing mesodermal, endodermal or ectodermal lineage-committed cells by culturing or transplantation of the pluripotent stem cells of the present invention. | 03-17-2011 |
| 20110064702 | Methods and Kits for Enhancing Cell Survival, Stimulating Cell Proliferation, Treating Diabetic Patients, and/or Reinnervation - Methods for enhancing beta cell survival and/or for stimulating beta cell proliferation, comprise co-transplanting pancreatic islets, beta cells, and/or stem cells which can generate beta cells, with (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and/or (iii) pre-differentiated stem/progenitor neural cells. Methods for reinnervation in an organ or tissue transplant patient comprise co-transplanting with the organ or tissue (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and/or (iii) pre-differentiated stem/progenitor neural cells. Kits for conducting such methods employ at least one of (i) neural crest stem cells (NCSCs), (ii) tetracycline-regulated gene expression system (Tet-System)-containing neural stem/progenitor cells (TetStock neural stem/progenitor cells), and (iii) pre-differentiated stem/progenitor neural cells. | 03-17-2011 |
| 20110064703 | BONE SUBSTITUTE COMPOSITIONS, METHODS OF PREPARATION AND CLINICAL APPLICATIONS - The present invention relates to bone substitute compositions and methods of their preparation, and their use in a wide variety of clinical applications. The compositions include calcium phosphate, acidic calcium salt, basic calcium salt, sodium hydrogen phosphate and porogen. The compositions further include a mixing liquid. The compositions can optionally include biological signaling molecules and/or a growth compound. Further, the compositions can optionally include a plasticizer. | 03-17-2011 |
| 20110064704 | SHIP-DEFICIENCY TO INCREASE MEGAKARYOCYTE AND PLATELET PRODUCTION - A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced. | 03-17-2011 |
| 20110064705 | HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS - Methods of generating and expanding human hemangio-colony forming cells and non-engrafting hemangio cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells, non-engrafting hemangio cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Human non-engrafting hemangio cells are a novel progenitor cell population that is related to but distinct from the hemangioblast and human hemangio-colony forming cells. The invention also provides compositions, preparations, and solutions comprising hemangio-colony forming cells, non-engrafting hemangio cells or cells differentiated therefrom. The compositions, preparations, and solutions include cryopreserved preparations and substantially purified preparations, as well as mixed compositions formulated in combination with related hemangioblast progenitor cell types that can engraft into the bone marrow. | 03-17-2011 |
| 20110070201 | Mucosal or enteral administration of biologically active macromolecules - A method of systemically delivering a biologically active, recombinant biomolecule, in a biologically active form, to a subject in need thereof. , the method comprising, enterally or mucosally administering to the subject a therapeutically effective amount of plant cells expressing an exogenous biologically active recombinant biomolecule, thereby systemically delivering the biologically active recombinant biomolecule, in a biologically active form, to the subject. | 03-24-2011 |
| 20110070202 | Targeted delivery to the brain of magnetically labeled stem cells - Provided herein is a method of targeting stem cells to a specific region of the central nervous system of an individual in need of such treatment, comprising the steps of administering stem cells containing a superparamagnetic nanoparticles to said individual; and applying an external source of a magnetic field to the exterior of said individual's brain so as to advance and maneuver said stem cells. Also provided is a composition for targeting cells to a specific region of the central nervous system of an individual in need of such treatment, comprising stem cells containing a superparamagnetic nanoparticles. | 03-24-2011 |
| 20110070203 | MESENDODERM AND MESODERM CELL POPULATIONS - The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. | 03-24-2011 |
| 20110070204 | MEDIUM FOR HANDLING AND STORING BIOLOGICAL TISSUES OF THE MUSCULOSKELETAL SYSTEM OUTSIDE AN ORGANISM - The present disclosure relates to a medium for handling, including storing, cultivating, coating, impregnating and/or preserving musculoskeletal tissues such as bone, cartilage, tendon, muscle, nerve, ligament, blood vessel, skin, fascia, bursa and joint capsule tissue or cells, wherein the medium is an aqueous solution comprising hyaluronan and a first saccharide, polyol, or combination thereof. Further disclosed are methods of handling musculoskeletal tissue or cells or preserving the viability of these tissues or cells using this medium as well as the preserved tissues or cells. | 03-24-2011 |
| 20110070205 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49 | 03-24-2011 |
| 20110070206 | METHODS OF APPLYING PHYSICAL STIMULI TO CELLS - We describe herein methods for applying physical stimuli to cells, including mesenchymal stem cells, in culture or in vivo. These methods can be applied in, and are expected to benefit subjects in, a great variety of circumstances that arise in the context of, for example, traumatic injury (including that induced by surgical procedures), wound healing (of the skin and other tissues), cancer therapies (e.g., chemotherapy or radiation therapy), tissue transplantation (e.g., bone marrow transplantation), and aging. More generally, the present methods apply where patients would benefit from an increase in the number of cells (e.g., stem cells) within a given tissue and, ex vivo, where it is desirable to increase the proliferation of cells (e.g., stem cells) for scientific study, inclusion in devices bearing cells (e.g., polymer or hydrogel-based implants), and administration to patients. | 03-24-2011 |
| 20110070207 | THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS - A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed. | 03-24-2011 |
| 20110076253 | Defined Culture Conditions of Human Embryonic Stem Cells - The present invention relates to compositions and methods for culturing stem cells, particularly embryonic stem cells. Specifically, the invention relates to a culture medium that supports proliferation of substantially undifferentiated stem cells, while maintaining potency of the cells. An an embodiment, the culture medium is defined and supports proliferation of substantially undifferentiated embryonic stem cells in essentially serum free and feeder cell free conditions. Compositions for making the medium and methods using the culture medium are also provided. | 03-31-2011 |
| 20110076254 | POROUS SCAFFOLDS FOR STEM CELL RENEWAL - A method for expanding a population of stem cells using a porous scaffold, a porous scaffold populated with renewed stem cells, methods of administering stem cells using the porous scaffold and cells collected from the porous scaffold, and methods for tissue engineering and treating a condition treatable by administration of stem cells using the porous scaffold and cells collected from the porous scaffold. | 03-31-2011 |
| 20110076255 | COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE MYOCARDIAL INJURY DUE TO A VASCULAR INSUFFICIENCY - The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury—due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent. | 03-31-2011 |
| 20110076256 | Human Neural Stem Cell and Pharmaceutical Composition for the Treatment of Central or Peripheral Nervous System Disorders or Injuries Using Same - The present invention relates to a human neural stern cell, and to a pharmaceutical composition for the treatment of central or peripheral nervous system disorders and injuries using same. More particularly, the present invention relates to a human telencephalon-derived human neural stem cell effective in the treatment of nervous system disorders and injuries, and to a pharmaceutical composition for the treatment of nervous system disorders and injuries using same, to the use of the human neural stem cell for preparing therapeutic agents for the treatment of nervous system disorders and injuries, and to a method for treating nervous system disorders and injuries, capable of administrating an effective amount of the human neural stem cells into individuals that need the human neural stem cells. The human neural stem cell of the present invention has active effects for treating patients of neural system disorders and injuries, specifically for treating patients with a severe spinal cord injury, ischemic brain damage, epilepsy, and Alzheimer's disease, known to have no special treatment as of present and remain with permanent neurological aftereffects. Accordingly, the pharmaceutical composition containing the human neural stem cell of the present invention provides a novel method for treating neural system injuries. | 03-31-2011 |
| 20110081321 | OMENTUM AS A SOURCE OF STROMAL/STEM CELLS AND MEDICAL TREATMENTS USING STROMAL/STEM CELLS - Methods for generating and using omentum cells, and particularly stromal cells and/or omentum stem cells, in medical treatments such as tissue repair and regeneration to facilitate healing from traumatic injury to an abdominal organ, and immune modulation treatments such as suppression of immune responses and inflammation and prevention of tissue fibrosis. According to one aspect, a medical procedure is performed on a patient that involves harvesting omental tissue from the patient, and then transferring the omental tissue to an organ of the patient. At least a portion of the harvested omental tissue may be activated prior to transferring the omental tissue to the organ. Alternatively, the transferred omental tissue may comprise non-lymphoid cells isolated from the omentum tissue and obtained by homogenizing at least a portion of the harvested omental tissue. The invention also encompasses a medical procedure comprising the transfer of omental stem cells to a patient, and a procedure comprising in vitro activation of omental stem cells by T cells to enhance immunomodulatory functions of the omental stem cells. | 04-07-2011 |
| 20110081322 | ELASTIN PRODUCING FIBROBLAST FORMULATIONS AND METHODS OF USING THE SAME - The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention. | 04-07-2011 |
| 20110081323 | Methods and compositions for organ and tissue functionality - Materials and methods for treating tissue defects in human or animal tissues using implantable cells are described. Further, culture techniques and factors for enhancing these procedures, and cell survival and adaptation are described. Many of the tissue defects may be treated with autologous cells, while applications involving non-autologous cells or stem cells are also described. | 04-07-2011 |
| 20110081324 | COLLAGEN PEPTIDE CONJUGATES AND USES THEREFOR - Described herein are conjugates of collagen peptides and metal binding agents and compositions resulting therefrom, useful in various tissue engineering and regeneration applications, in cell culture, cell adhesion, cosmetic surgery, construction of artificial skin substitutes, management of severe burns and burn surgery, reconstruction of bone and a wide variety of dental, orthopedic and surgical purposes, as drug delivery vehicles and in delivering populations of cells to a site of disease or injury. | 04-07-2011 |
| 20110081325 | NOVEL TREATMENT OF HEART DISEASES - Provided is a novel therapeutic approach for the treatment of heart failure and diseases associated therewith. In particular, vinca alkaloids are used for improving the viability of cardiomyocytes and preventing myocardial infarction. | 04-07-2011 |
| 20110081326 | DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO FIBROBLASTS, COMPOSITIONS COMPRISING MESENCHYMAL STEM CELL-DERIVED FIBROBLASTS, AND METHODS OF USING THE SAME - Methods and compositions are provided for the differentiation and characterization of mammalian fibroblast from mesenchymal stem cells. The methods of the invention provide a means to obtain mesenchymal stem cell-derived fibroblast populations, e.g., seeded on a scaffold, which may be used in wound healing. | 04-07-2011 |
| 20110086007 | EPIDERMAL STIMULATION TO ENHANCE HAIR FOLLICLE FORMATION - The present invention features a method for improving the efficiency of hair formation by follicular cell implantation. The method includes the use of epidermal stimulation (ES) to stimulate keratinocytes in a subject's skin in order to make them more receptive to hair inductive signals originating from implanted follicular cells (e.g. dermal papilla cells, dermal sheath cells, and/or outer root sheath cells). | 04-14-2011 |
| 20110086008 | COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER TISSUES - The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention. | 04-14-2011 |
| 20110086009 | Cell line for the production of prostacyclin and uses thereof - Provided herein are methods for producing a biomolecule by converting or engineering a plurality of cells, e.g., mammalian cells, having an endogenous precursor of a biomolecule to cells transfected to contain a nucleic acid that stably overexpresses a hybrid enzyme effective to metabolized the precursor to the biomolecule in the cell, e.g., prostacyclin produced from arachidonic acid. Also provided are methods of treating a pathophysiological condition associated with at least a decrease in the biomolecule or treating a vascular disease by administering the engineered, stably transfected mammalian cells to a subject where production of the biomolecule treats the condition or vascular disease. Further provided are the recombinant hybrid enzymes and the engineered cell lines and pharmaceutical compositions thereof, the nucleic acids encoding the hybrid enzymes, and vectors comprising the nucleic acids. | 04-14-2011 |
| 20110086010 | Methods, Systems, and Apparati for Cellular Therapeutic Agent Preparation and Delivery - Methods and devices for the preparation of a biological pharmaceutical composition outside of a classified environment, such as Biological Safety Cabinet type environment, are described. In one aspect of the present technology, a method is provided to prepare a biological pharmaceutical composition preferably in an area next to a patient's bedside or at a facility's pharmacy. The method comprises transferring an appropriate amount of a diluent from a diluent component ( | 04-14-2011 |
| 20110091426 | Human brain endothelial cells and growth medium and method for expansion of primitive CD34+CD38- bone marrow stem cells - A novel co-culture system using human brain endothelial cells (HUBEC) which promotes the expansion of human CD34 | 04-21-2011 |
| 20110091427 | METHODS FOR TREATING A KIDNEY INJURY - Provided herein are methods of treating a kidney injury in a patient, comprising administering to the patient hematopoietic stem cells (HSCs) in an amount effective to treat the kidney injury. In some embodiments, administration of the HSCs is delayed, such that the HSCs are not administered immediately after the kidney injury. In certain aspects, the HSCs are administered to the patient during the beginning of the repair phase of the kidney. Further embodiments and aspects of the invention, including related methods and compositions for use therein, are described herein. | 04-21-2011 |
| 20110091428 | COMPOSITIONS OF ADULT ORGAN STEM CELLS AND USES THEREOF - Compositions of isolated adult organ stem cells, including hematopoietic stem cells, cardiac stem cells, and kidney stem cells, are disclosed. In particular, the present invention provides c-kit positive, lineage negative adult stem cells that can be isolated from adult organ tissue. Such stem cells are capable of generating all the cell lineages of the organ tissue from which they were isolated. Methods for repairing damaged organ tissue with the isolated organ stem cells are also disclosed. | 04-21-2011 |
| 20110091429 | Methods for Enhancing Stem Cell Engraftment During Transplantation - The present invention relates to the fields of hematopoietic stem cell transplantation and molecular biology. More specifically, methods for improving engraftment efficiency in stem cell transplants by improving stem cell homing to bone marrow are provided. | 04-21-2011 |
| 20110097308 | STEM CELLS TREATED BY IN VITRO FUCOSYLATION AND METHODS OF USE - A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy. | 04-28-2011 |
| 20110097309 | Pharmaceutical Agent for Promoting the Functional Regeneration of Damaged Tissue - The present inventors assessed the possibility that bone marrow-derived cells are mobilized to the grafted skin from nonskin tissues and contribute to skin tissue regeneration during the engraftment of grafted skin on biological tissues. As a result, the present inventors for the first time in the world demonstrated that: | 04-28-2011 |
| 20110097310 | ANTI-AGING OR ANTIOXIDANT COMPOSITION CONTAINING PLANT STEM CELL LINE DERIVED FROM CAMBIUM OF PANAX GINSENG - The present invention relates to an anti-aging or antioxidant composition which contains, as an active ingredient, a plant stem cell line derived from the cambium of | 04-28-2011 |
| 20110104122 | EFFICIENT PRODUCTION AND USE OF HIGHLY CARDIOGENIC PROGENITORS AND CARDIOMYOCYTES FROM EMBRYONIC AND INDUCED PLURIPOTENT STEM CELLS - This invention relates to a method for producing cardiomyocytes and/or cardiac progenitor cells, comprising culturing an induced pluripotent stem (iPS) cell or embryonic stem (ES) cell, which has been differentiated into a mesoderm cell, in the presence of cyclosporin-A. | 05-05-2011 |
| 20110104123 | THERAPEUTIC PROTOCOL USING STEM CELLS IN TISSUE AND NEURONAL REPAIR, MAINTENANCE, REGENERATION AND AUGMENTATION - The present invention relates generally to the field of tissue and neuronal repair, maintenance, regeneration and augmentation. More particularly, the present invention encompasses an improved stem cell therapeutic protocol. | 05-05-2011 |
| 20110104124 | MESODERMAL-LIKE CELL POPULATION FOR TREATING ISCHEMIA IN MAMMALS - Compositions containing an effective amount of mesodermal-like multipotent mammalian mononuclear cells that express both CD34 and M-cadherin cell surface markers are used for preventing, treating or reducing the severity of tissue ischemia or an ischemia associated disorder in a mammal. Such uses may include repopulating an in vivo site with new myocytes and/or vascularizing an ischemic or adjacent tissue. Detection of the level and/or distribution of CD34 | 05-05-2011 |
| 20110104125 | EPISOMAL REPROGRAMMING WITH CHEMICALS - Methods and composition of induction of pluripotent stem cells are disclosed. For example, in certain aspects methods for generating essentially vector-free induced pluripotent stem cells with cell signaling regulators are described. Furthermore, certain aspects of the invention provide novel compositions comprising induced pluripotent stem cells essentially free of exogenous retroviral vector elements in the presence of a medium comprising signaling inhibitors. In certain aspects, feeder-free episomal reprogramming methods may be provided. | 05-05-2011 |
| 20110104126 | Human Hepatic Stem Cell, Method for Preparation of the Same, Method for Induction of Differentiation of the Same, and Method for Utilization of the Same - The present invention provides a human hepatic stem cell which is sorted based on the presence or absence of the expression of at least one marker selected from the group consisting of CD318, CD90, CD66 and CD13. A method of preparing the human hepatic stem cell, a method of inducing differentiation of the same and a method of using the same are also provided. | 05-05-2011 |
| 20110110897 | Adult Human Cardiac-Derived Progenitor Cells - The present invention is based, in part, on the discovery that cardiac progenitor cells are present in and can be isolated from adult human heart. Accordingly, a cell of the present invention comprises a human adult cardiac-derived progenitor cell capable of differentiating into a cardiac myocyte where said cell is isolated according to the expression of specific biomarkers, identified elsewhere herein. The present invention also includes methods of use of an adult cardiac-derived progenitor cell in the treatment of heart disease. | 05-12-2011 |
| 20110110898 | Bioactive removal of hypertrophic scars - An embodiment of the invention includes methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus. Alternatively, the corrective application involves the cells placed in a matrix, preferably comprised of autologous extracellular matrix constituents as a three-dimensional structure or as a suspension, prior to placement into a position with respect to the subject's defect. In a further embodiment, the preferable autologous extracellular matrix constituents are collected from culture and placed in a position with respect to the subject's defect. | 05-12-2011 |
| 20110110899 | Combined Chemical and Genetic Approaches for Generation of Induced Pluripotent Stem Cells - The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency. | 05-12-2011 |
| 20110110900 | NOVEL ADULT PROGENITOR CELL - The invention relates to the isolation and use of a novel progenitor cell population from the lamina propria of the oral mucosa. The novel progenitor cell population is highly proliferative and can be differentiated into a range of cell lineages. Further, these novel progenitor cells possess immunomodulatory activity and so can be used in the allogeneic transfer of tissue or to help combat immune disorders. | 05-12-2011 |
| 20110110901 | METHODS OF LONG-TERM CULTURE OF EUKARYOTIC CELLS AND USES THEREOF - An immortalizing protein complex, comprises an internalizing molecule, a transforming polypeptide and an endosome releasing molecule; all molecule and/or polypeptides being operatively linked to one or more of the other polypeptides, and optionally one or more of a nuclear internalizing molecule and a telomere extending molecule. A method of producing immortalized cells or extending the life of primary cells, comprises contacting the immortalizing protein complex of the invention with a target cell under conditions and for a period of time effective for the protein complex to be internalized and the transforming polypeptide released, and allowing for the transforming polypeptide to extend the life of the cell and/or overcome cell arrest. Also provided are an immortalizing polynucleotide encoding the protein complex, a hybrid vector carrying an expression vector and the polynucleotide, a cell transformed with the hybrid vector, a cell expressing the protein complex, and a cell immortalization kit that comprises the protein complex and/or a polynucleotide encoding the protein and/or a hybrid expression vector carrying the polynucleotide, and instructions for its(their) use to practice the method for immortalizing cells. Cells and tissue transplants comprising the cell(s), and various uses for the immortalized cells and tissue thereof are also provided. | 05-12-2011 |
| 20110117061 | Ex Vivo Expansion of Human Hematopoietic Stem Cells - Methods and kits for expanding the number of hematopoietic stem cells are provided. The methods comprise incubating cells in medium comprising isolated IGFBP-2 and an angiopoietin-like protein (Angptl). Expanded HSCs are provided as well as culture media and kits for the expansion of human HSCs in a defined medium. Methods of administering expanded human HSCs to and individual are provided as well as methods of treating an individual by administering certain growth factors and cytokines. | 05-19-2011 |
| 20110117062 | Methods For Producing Enriched Populations of Human Retinal Pigment Epithelium Cells - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 05-19-2011 |
| 20110117063 | Methods For Producing Enriched Populations of Human Retinal Pigment Epithelium Cells For Treatment of Retinal Degeneration - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 05-19-2011 |
| 20110117064 | ASSAY FOR THE PREDICTION OF THERAPEUTIC EFFECTIVENESS OF MESENCHYMAL STROMAL CELLS, AND METHODS OF USING SAME - The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations. | 05-19-2011 |
| 20110117065 | COMPOSITIONS AND METHODS FOR USING CELLS TO TREAT HEART TISSUE - This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue. | 05-19-2011 |
| 20110117066 | ESTABLISHED HUMAN BROWN ADIPOCYTE LINE AND METHOD FOR DIFFERENTIATION FROM AN HMADS CELL LINE - The subject matter of the invention is a functional population of human brown adipocytes, in which the expression of UCP1, CIDEA, CPT1B and Bcl2 is higher, the expression of Bax is lower and the expression of PPAR-alpha, PGC-1alpha, PGC-1beta and PRDM16 is similar compared with the corresponding expressions of a population of human white adipocytes. The invention also relates to a method for differentiation of hMADS cells into the functional population of human brown adipocytes, to a method for conversion of a population of human white adipocytes into the functional population of human brown adipocytes, and also to a method of screening for molecules capable of modulating the bodyweight in an individual. | 05-19-2011 |
| 20110123497 | GRAFT COMPOSITION FOR NEURAL TISSUE REGENERATION, METHOD OF PRODUCTION AND USES THEREOF - The present invention provides a biocompatible, biodegradable graft composition for regeneration of neural tissue, comprising the following components: a) a gel scaffold formed from an isolated platelet containing fluid and an activating agent comprising calcium chloride, with or without thrombin, b) a nerve growth factor selected from BDNF, NGF, retinoic acid and combinations thereof, and c) a culture of at least 50,000 progenitor stem cells; the method of production and the uses thereof. | 05-26-2011 |
| 20110123498 | MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF USING SAME - The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders. | 05-26-2011 |
| 20110123499 | CELLULAR DIFFERENTIATION PROMOTION - Neural precursor cells can be encouraged to form mature neural cells twice as quickly in the absence, or reduced expression of, thymosin β4. | 05-26-2011 |
| 20110123500 | METHODS OF ISOLATING NON-SENESCENT CARDIAC STEM CELLS AND USES THEREOF - The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. In particular, a subset of adult cardiac stem cells with superior regenerative capacity is disclosed. Such cells were found to have immortal DNA. Compositions comprising the non-senescent stem cells are also described. In addition, the present invention provides methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells. | 05-26-2011 |
| 20110129447 | Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy - A method of cell expansion is provided. The method comprising culturing adherent cells from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion. | 06-02-2011 |
| 20110129448 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS - Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula | 06-02-2011 |
| 20110135610 | Multipotent stem cells from the extrahepatic biliary tree and methods of isolating same - The present invention relates to a multipotent stem cell, multipotent cell populations, and an enriched multipotent cell population, each found in fetal, neonatal, pediatric, and adult biliary tree tissue and up to 72 hours post mortem (although preferentially, within 10 hours post mortem) and capable of maturing into multiple endodermal tissues that include liver, biliary and pancreatic tissues. The multipotent stem/progenitor cell and cell populations are found in peribiliary glands, and progenitors descending from them are present throughout the biliary tree including in the gallbladder. High numbers of the peribiliary glands are found in the branching locations of the biliary tree such as hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder. Related multipotent cells, multipotent cell populations and their descendent progenitors are found throughout the biliary tree including in the gall bladder, which does not have peribiliary glands. Compositions comprising same, methods of identifying and isolating same, maintaining same in culture, expanding same in culture and differentiating or lineage restricting the same in vitro or in vivo to hepatic, biliary or pancreatic fates (e.g., as hepatocytes, cholangiocytes, and/or pancreatic islet cells) are also provided. Methods of using the multipotent cells and/or multipotent cell populations are also provided. | 06-09-2011 |
| 20110135611 | METHODS FOR TREATING APOLIPOPROTEIN E4-ASSOCIATED DISORDERS - The present disclosure provides methods of reducing apoE4 fragment-mediated toxicity of interneurons, e.g, GABAergic interneurons. The present disclosure provides methods of treating apoE4-mediated neurological disorders in an apoE4-positive individual. | 06-09-2011 |
| 20110142804 | NANOFIBER SCAFFOLD - The invention is directed to a device and method to prevent migration of Human Mesenchymal Stem Cells (hMSCs) from a delivery site while allowing communication between the stem cells and native cardiomyocytes. The device is characterized by scaffold pore size, fiber diameter and biomaterial selection. The invention includes a two part polyurethane scaffold that prevents migration of stem cells, allows gap junction formation through pores and is packaged for minimally invasive delivery. | 06-16-2011 |
| 20110142805 | METHOD OF RENAL REPAIR AND REGENERATION AND THE TREATMENT OF DIABETIC NEPHROPATHY - We have disclosed methods for treating chronic kidney disease. More specifically, we have disclosed methods for treating diabetic nephropathy with human kidney derived cells. | 06-16-2011 |
| 20110142806 | Electroactive Scaffold - A scaffold assembly and related methods of manufacturing and/or using the scaffold for stem cell culture and tissue engineering applications are disclosed which at least partially mimic a native biological environment by providing biochemical, topographical, mechanical and electrical cues by using an electroactive material. The assembly includes at least one layer of substantially aligned, electrospun polymer fiber having an operative connection for individual voltage application. A method of cell tissue engineering and/or stem cell differentiation uses the assembly seeded with a sample of cells suspended in cell culture media, incubates and applies voltage to one or more layers, and thus produces cells and/or a tissue construct. In another aspect, the invention provides a method of manufacturing the assembly including the steps of providing a first pre-electroded substrate surface; electrospinning a first substantially aligned polymer fiber layer onto the first surface; providing a second pre-electroded substrate surface; electrospinning a second substantially aligned polymer fiber layer onto the second surface; and, retaining together the layered surfaces with a clamp and/or an adhesive compound. | 06-16-2011 |
| 20110142807 | Mesenchymal Stem Cells and Uses Therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 06-16-2011 |
| 20110142808 | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells - Solutions and suspensions comprising polymerized hemoglobin derived from human blood are disclosed. The solutions and suspensions may comprise cell culture medium, an enzyme (such as a protease), and/or a buffer. Processes of preparing the solutions and suspensions are also disclosed. The solutions and suspensions may be employed in methods of isolating mammalian cells, such as pancreatic islets, methods of preserving mammalian tissue and organs, methods of aiding the recovery of mammalian cells following their isolation, methods of maintaining mammalian cells, methods of propagating mammalian cells, and methods of treating a mammal with diabetes. | 06-16-2011 |
| 20110142809 | METHOD FOR SEPARATING HIGHLY ACTIVE STEM CELLS FROM HUMAN STEM CELLS AND HIGHLY ACTIVE STEM CELLS SEPARATED THEREBY - The present invention relates to a method for separating highly active stem cells from human stem cells, the highly active stem cells separated by the method, a cell therapeutic agent containing the stem cells, and a medium for separating the highly active stem cells from stem cells containing a specific cytokine. According to the present invention, the method is useful for separating the highly efficient stem cells from mesenchymal stem cells of various origins. Further, the method is very useful in developing a cell therapeutic agent of high efficiency because the method can be applicable to stem cells of various origins which are cultured under different conditions. Senescent stem cells increased by several passage times in vitro can be effectively sorted out, so the method can be used for reactivating the stem cells. | 06-16-2011 |
| 20110142810 | CELL PREPARATION FOR BONE TISSUE REGENERATION - The present invention provides a cell preparation that can be prepared from cells collected from a patient of any age group, and that has an excellent bone tissue regenerative capacity and is effective for bone tissue regeneration. Undifferentiated osteoblasts obtained from alveolar bone, particularly those obtained by being cultured after the enzyme treatment of alveolar bone have a remarkable bone tissue regenerative capacity, and are therefore useful for a cell preparation for bone tissue regeneration. | 06-16-2011 |
| 20110150842 | Derivation of Embryonic Stem Cells - This present invention provides novel methods for deriving embryonic stem cells, those cells and cell lines, and the use of the cells for therapeutic and research purposes without the destruction of the embryo. It also relates to novel methods of establishing and storing an autologous stem cell line prior to implantation of an embryo, e.g., in conjunction with reproductive therapies such as IVF. | 06-23-2011 |
| 20110150843 | METHOD FOR THE THERAPEUTIC CORRECTION OF HEMOPHILIA A BY TRANSPLANTING BONE MARROW CELLS - The transdifferentiation of bone marrow cells (BMCs) into hepatocytes can be used for the development of cellular medicine for degenerative and genetic diseases. Since the liver is the primary site of factor VIII (FVIII) synthesis, the partial replacement of mutated liver cells by healthy cells in hemophilia A (HA) could manage the severity of the bleeding disorder. The use of BMCs could be used as a therapy for the bleeding phenotype of hemophilia A and other related disorders. | 06-23-2011 |
| 20110150844 | COMPOSITIONS AND METHODS FOR CONTROLLING PROLIFERATION AND DIFFERENTIATION OF CELLS - Methods and compositions for modulating cell differentiation, proliferation and morphology in vitro or in vivo are described. The methods include modifying the extracellular nanoenvironment of stem cells with a self-assembling peptide nanofiber scaffold. The extracellular nanoenvironment can be modified by changing the percentage of self-assembling peptides used to form the nanofiber scaffold, the concentration of cells in the nanofiber scaffold, the pH, or the amounts of serum. Modulating the extracellular nanoenvironment of cells in nanofiber scaffold allows for increased targeting of cell placement and therapeutic delivery, amplified by cell encapsulation and implantation. | 06-23-2011 |
| 20110150845 | METHODS AND COMPOSITIONS FOR MODULATING IMMUNOLOGICAL TOLERANCE - The invention provides compositions and methods for modulating immune responses using mesenchymal stem cells. The invention further provides methods for inducing tolerance to self antigens using mesenchymal stem cells. | 06-23-2011 |
| 20110150846 | COMPOSITIONS AND METHODS FOR TISSUE FILLING AND REGENERATION - Injectable compositions are provided which include both a living cellular component and a filler component conducive to cell growth. The compositions are capable of providing both immediate tissue filling and long term tissue regeneration. | 06-23-2011 |
| 20110150847 | METHOD OF THREE-DIMENSIONALLY CULTURING CHONDROCYTES - It is intended to provide a method of three-dimensionally culturing normal joint chondrocytes; the production and supply of chondrocytes; and a transplantation material to be used in an injured site in a joint tissue. | 06-23-2011 |
| 20110150848 | Cell Suspension Preparation Technique and Device - The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site. | 06-23-2011 |
| 20110158954 | METHOD FOR PRODUCING GAMMA DELTA T CELL POPULATION - A method for preparing a γδ T cell population, characterized in that the method includes the step of culturing a cell population containing γδ T cells, in the presence of (a) fibronectin, a fibronectin fragment or a mixture thereof and (b) an activating factor of γδ T cells. According to the present invention, a method for preparing a γδ T cell population is provided. The γδ T cell population obtained by the method is suitably used in, for example, immunotherapy. Therefore, the method of the present invention is expected to greatly contribute to a medical field. | 06-30-2011 |
| 20110158955 | METHOD FOR PRODUCING CELLS HAVING CHARACTERISTIC OF HEMATOPOIETIC STEM CELLS/PROGENITOR CELLS - Provided are a new method of producing cells having characteristics of hematopoietic stem/progenitor cells, for use in hematopoietic stem cell transplantation, and hematopoietic stem/progenitor cell-like cells produced by the method. Provided in particular are a method of producing hematopoietic stem/progenitor cell-like cells retaining differentiation pluripotency and self-replication potential, comprising (1) a step for providing a mammalian pro-B cell or progenitor cell thereof, and (2) a step for culturing the cell (1) above under conditions for induction of differentiation into B cells, wherein the function and/or expression of the transcription factor E2A is suppressed at least at the stage of pre-pro-B cells or pro-B cells in the process (2) above; a hematopoietic stem/progenitor cell-like cell produced by the method; and an immunotherapeutic agent comprising the hematopoietic stem/progenitor cell-like cell, and the like. | 06-30-2011 |
| 20110158956 | TREATING CANCER - Provided is a cyclic peptide which comprises:
| 06-30-2011 |
| 20110158957 | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases - Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided. | 06-30-2011 |
| 20110158958 | Methods for treating ophthalmic disorders, diseases and injuries - The invention is directed to methods for treating ophthalmic disorders, diseases and injuries. In particular, the invention is directed to treating disorders, diseases and injuries of the cornea and ocular surface. Such methods utilize novel compositions including, but not limited to, trophic factor secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents. | 06-30-2011 |
| 20110158959 | IMMUNOPHENOTYPE AND IMMUNOGENICITY OF HUMAN ADIPOSE DERIVED CELLS - The present invention encompasses methods and compositions for generating an isolated adipose tissue-derived stromal cell exhibiting a low level of immunogenicity. The present invention encompasses methods and compositions for reducing an immune response associated with transplantation by administering the recipient with an amount of adipose tissue-derived stromal cells effective to reduce or inhibit host rejection and/or host versus graft disease. | 06-30-2011 |
| 20110158960 | ISOLATION OF PRECURSOR CELLS AND THEIR USE FOR TISSUE REPAIR - Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor β having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body. | 06-30-2011 |
| 20110158961 | MATERIALS AND METHODS RELATING TO CELL BASED THERAPIES - The invention relates to the provision of a novel cell population that can be used for tissue regeneration and the treatment of disease states associated with cell degeneration for age related tissue changes. The cell population are derived from adult stem/progenitor cells which are characterised by being positive or negative to the Thy1.1 cell marker. | 06-30-2011 |
| 20110158962 | DENTAL PULP MARROW SIMILAR CELLS (DPMSC) AND METHODS OF ISOLATING AND USING - The invention provides for isolated population of pulp marrow similar cells (DPMSCs) and methods for isolating and using these cells. The population of DPMSCs are highly homogenous for CD1O, CD29, CD13, CD44, CD49a, CD49d, CD59, CD73, CDw90, CD105, Oct-4 Isoform A and B, Nanog, Sox-2, and SSEA-4. | 06-30-2011 |
| 20110158963 | THREE-DIMENSIONAL MATRICES OF STRUCTURED POROUS MONETITE FOR TISSUE ENGINEERING AND BONE REGENERATION, AND METHOD OF THE PREPARATION THEREOF - The present invention is comprised within tissue engineering and, specifically, within bone regeneration. The invention relates to a porous three-dimensional matrix of monetite which is biocompatible, has structured porosity and is predefined and reabsorbable, as well as to the method of synthesis capable of producing said material and the applications thereof. These matrices are a perfect base for cell colonization and proliferation, allowing the application thereof in tissue engineering and bone regeneration as a result of their advantageous properties of biocompatibility, reabsorption, osteoinduction, revascularization, etc. | 06-30-2011 |
| 20110158964 | Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 06-30-2011 |
| 20110158965 | Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 06-30-2011 |
| 20110158966 | STEM CELLS CHARACTERIZED BY EXPRESSION OF GERMLINE SPECIFIC GENES - The present invention relates to adult stem cells derived from somatic sources characterized by the expression of the germline specific gene, DAZL. The somatic stem cells expressing the DAZL marker are further characterized by expression of additional markers and absence of expression of certain blood markers. In particular, the present invention discloses therapeutic and diagnostic uses, other than the germ cell potential use, of the DAZL multipotent stem cells isolated from somatic sources such as peripheral blood, bone marrow or umbilical cord blood. | 06-30-2011 |
| 20110158967 | MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 06-30-2011 |
| 20110158968 | METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS - Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient. | 06-30-2011 |
| 20110165128 | HOMING IN MESENCHYMAL STEM CELLS - The present invention relates to expression of CXCR4 in mesenchymal stem cells (MSCs) and homing of MSCs to sites of injury. In particular, the invention provides expanded cultures of MSCs which maintain cell surface expression of CXCR4. The MSCs are capable of homing to sites of injury and are suitable for treatment of ischemic disorders, including cardiac disorders, bone and cartilage disorders, liver disorders, inflammatory disorders, and stroke. | 07-07-2011 |
| 20110165129 | Ameliorating Nervous Systems Disorders - The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition. | 07-07-2011 |
| 20110165130 | Methods for Preparing Human Skin Substitutes from Human Pluripotent Stem Cells - The present invention relates to an ex vivo method for obtaining a population of human keratinocytes derived from human pluripotent stem cells comprising a step of co-culturing human pluripotent stem cells with cells that support ectodermal differentiation in presence of an agent that stimulates epidermal induction and a agent that stimulates terminal differentiation of keratinocytes. A further object of the invention relates to a method for preparing a human skin substitute comprising a step of providing an organotypic culture of the substantially pure homogenous population of human keratinocytes derived from human pluripotent stem cells obtained according to the method of the invention. | 07-07-2011 |
| 20110165131 | METHODS FOR TREATING DISEASES AND INCREASING LONGEVITY - Diseases such as cancer, HIV/AIDS, diabetes, infectious diseases, as well as diseases related to the immune and autoimmune systems, are treated through the formation and/or enhancement of the function of organs and suborgans of human patients. An important organ for such purpose is the thymus. Enhancement may be direct or indirect and utilizes energy, enhancement compositions, and/or living organisms to enhance the cells and/or cell products produced by organs and suborgans. | 07-07-2011 |
| 20110165132 | Heparan Sulphate Which Binds BMP2 - The invention relates to heparan sulphate GAGs obtained by affinity chromatography using the heparin-binding domain of BMP2. The GAGs were obtained from osteoblast extracellular matrix and from a commercially available heparan sulfate (Celsus HS). | 07-07-2011 |
| 20110171179 | Method for Regulating Production of Hemoglobin Beta Chains - A method is described for repressing production of β-globin protein and increasing production of γ-globin protein in a human cell utilizing a ferritin-H protein, a vector encoding ferritin-H, or an exogenous ferritin-H inducer. | 07-14-2011 |
| 20110171180 | BIOENGINEERED SKIN SUBSTITUTES - A bioengineered skin substitute was developed that contains a microfabricated basal lamina analog that recapitulates the native microenvironment found at the dermal-epidermal junction (DEJ). | 07-14-2011 |
| 20110171181 | METHODS FOR MODIFYING VASCULAR VESSEL WALLS - This invention relates in one aspect to the treatment of a vascular vessel with a biomaterial. The biomaterial can be a remodelable material that strengthens and/or supports the vessel walls. Additionally the biomaterial can include a variety of naturally occurring or added bioactive agents and/or viable cellular populations. | 07-14-2011 |
| 20110171182 | METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY - Methods for treating a subject suffering from a compromised endogenous hematopoietic system are described that comprise administering to the subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described. | 07-14-2011 |
| 20110171183 | Markers of Induced Pluripotent Stem Cells - The disclosure relates to the expression of podocalyxin-like protein (PODXL) on the surface of induced pluripotent stem cells and particularly, although not exclusively, to the use of PODXL as a marker of induced pluripotent stem cells. | 07-14-2011 |
| 20110177038 | Inhibition of Tumor Growth via Peroxiredoxin 3 - Deregulated expression of the c-Myc transcription factor is found in a wide variety of human tumors. Because of this significant role in oncogenesis, considerable effort has been devoted to elucidating the molecular program initiated by deregulated c-myc expression. The primary transforming activity of Myc is thought to arise through transcriptional regulation of numerous target genes. Thus far, Myc target genes involved in mitochondrial function have not been characterized in depth. Here, we describe a nuclear c-Myc target gene, PRDX3, which encodes a mitochondrial protein of the peroxiredoxin gene family. Expression of PRDX3 is induced by the mycER system and is reduced in c-myc−/− cells. Chromatin immunoprecipitation analysis spanning the entire PRDX3 genomic sequence reveals that Myc binds preferentially to a 930-bp region surrounding exon 1. We show that PRDX3 is required for Myc-mediated proliferation, transformation, and apoptosis after glucose withdrawal. Results using mitochondria-specific fluorescent probes demonstrate that PRDX3 is essential for maintaining mitochondrial mass and membrane potential in transformed rat and human cells. These data provide evidence that PRDX3 is a c-Myc target gene that is required to maintain normal mitochondrial function. | 07-21-2011 |
| 20110177039 | ADULT BONE MARROW CELL TRANSPLANTATION TO TESTES CREATION OF TRANSDIFFERENTIATED TESTES GERM CELLS, LEYDIG CELLS AND SERTOLI CELLS - This invention pertains to the discovery that stem cells (e.g., bone marrow stem cells) transplanted directly into a testicular environment are transdifferentiated into bona fide Sertoli cells, and/or Leydig cells, and/or and germ cells. This provides a mechanism for the treatment of male infertility and/or testosterone deficiency. Thus, in one embodiment, this invention provides a method of treating infertility or testosterone deficiency in a male mammal. The method typically involves implanting stem cells into the testes of the mammal whereby the stem cells differentiate into germ cells and/or Sertoli cells and/or Leydig cells thereby reducing infertility and/or testosterone deficiency. | 07-21-2011 |
| 20110177040 | Cytokine Induction Of Selectin Ligands On Cells - Methods and compositions for treating cells with cytokines are provided herein. | 07-21-2011 |
| 20110177041 | MATERIAL FOR TREATMENT OF CEREBRAL INFARCTION AND BRAIN TISSUE REGENERATION METHOD - Disclosed is a therapeutic material for cerebral infarction, which can recover a vascular disorder in an area affected by cerebral infarction to improve the brain function. The therapeutic material for cerebral infarction includes a dental pulp stem cell comprising at least one member selected from a CD105-positive cell, an SP cell, a CD24-positive cell, a CD133-positive cell, a CD271-positive cell and a CD150-positive cell. The therapeutic material may additionally include a protein secreted from a dental pulp cell. A transplanted dental pulp stem cell cannot be differentiated directly into a neural progenitor cell or a neurocyte, but is involved indirectly in the promotion of differentiation to eliminate an area affected by cerebral infarction, thereby recovering the affected area into a normal area. | 07-21-2011 |
| 20110177042 | Method for Dedifferentiating Melanocytes - The present invention features a method for producing a dedifferentiated melanocyte. The method involves contacting a melanocyte with an agent that activates Notch1 and selecting for a dedifferentiated melanocyte which exhibits a premelanoma stem cell-like state. Agents for activating Notch1 and methods for using the cells and agents are also provided. | 07-21-2011 |
| 20110182866 | ISOLATION OF STEM CELL PRECURSORS AND EXPANSION IN NON-ADHERENT CONDITIONS - Stem cells and compositions thereof are isolated, cultured and expanded. Culture conditions and methods of culturing the isolated stem cells provide non-adherent stem cells which are prophylactically and therapeutically more effective in patients, diagnostics, screening assays and other stem cell uses. | 07-28-2011 |
| 20110182867 | MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES - The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies. | 07-28-2011 |
| 20110189135 | HUMAN STEM CELL-DERIVED NEURAL PRECURSORS FOR TREATMENT OF AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM - The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease. | 08-04-2011 |
| 20110189136 | USES AND ISOLATION OF VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS - The presently disclosed subject matter provides populations of stem cells that are purified from bone marrow, peripheral blood, and/or other sources. Also provided are methods of using the stem cells for treating tissue and/or organ damage in a subject. | 08-04-2011 |
| 20110189137 | METHOD FOR GENERATION AND REGULATION OF IPS CELLS AND COMPOSITIONS THEREOF - The present invention provides methods for generating induced pluripotent stem (iPS) cells having an increased efficiency of induction as compared with conventional methods. The method includes treating a somatic cell with a nuclear reprogramming factor in combination with an agent that alters microRNA levels or activity in the cell and/or a p21 inhibitor. The invention further provides iPS cells generated by such methods, as well as clinical and research uses for such iPS cells. | 08-04-2011 |
| 20110189138 | REPAIR AND/OR RECONSTITUTION OF INVERTEBRAL DISCS - This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1 | 08-04-2011 |
| 20110189139 | Hematopoietic Cell E-Selectin/L-Selectin Ligand Glycosylated CD44 Polypeptide - The invention feature methods and compositions for treating hematopoietic disorders, inflammatory conditions, and cancer and providing stem cell therapy in a mammal. | 08-04-2011 |
| 20110189140 | Compositions and Methods for Tissue Repair with Extracellular Matrices - Described herein are compositions comprising decellularized cardiac extracellular matrix and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damaged or ischemic cells, tissues or organs in a subject, preferably a human, using a decellularized cardiac extracellular matrix of the invention are provided. Methods of preparing cardiomyocyte culture surfaces and culturing cells with absorbed decellularized cardiac extracellular matrix are provided. | 08-04-2011 |
| 20110195054 | Preparation And Use Of Stromal Cells For Treatment Of Cardiac Diseases - This invention is directed to the preparation and use of stromal cells for treatment of cardiac tissue. | 08-11-2011 |
| 20110195055 | Method and apparatus for holding cells - The present invention pertains to an apparatus for holding cells. The apparatus comprises a mechanism for incubating cells having a dynamically controlled environment in which the cells are grown, which are maintained in a desired condition and in which cells can be examined while the environment is dynamically controlled and maintained in the desired condition. The apparatus also comprises a mechanism for determining the state of the cells. The determining mechanism is in communication with the incubating mechanism. The present invention pertains to a method for holding cells. The method comprises the steps of incubating the cells in a dynamically controlled environment which is maintained in a desired condition and in which the cells can be examined while the environment is dynamically controlled and maintained in the desired condition. Additionally, there is the step of determining the state of the cells. | 08-11-2011 |
| 20110200562 | Chimeric Cytokine of IL-7 and Beta Chain of HGF and Methods of Use - The present invention relates to a single-chain or chimeric polypeptide comprising a cytokine and a growth factor linked by at least one amino acid residue, and wherein the chimeric polypeptide enhances the proliferation and/or differentiation of hematopoietic precursor cells. In particular the invention relates to, a chimeric polypeptide comprising the beta-chain of hepatocyte growth factor, and IL-7 linked by at least one amino acid, and wherein the chimeric polypeptide demonstrates pre-pro-B proliferation and growth stimulating activity. | 08-18-2011 |
| 20110200563 | CALCIUM-MEDIATED EFFECTS OF CORAL AND METHODS OF USE THEREOF - This invention is directed to coral scaffolds seeded with precursor cells in culture in the presence of a chelator and uses thereof in inducing or enhancing bone and/or cartilage formation in a subject, and kits related thereto. This invention is also directed to use of cadherin-upregulating coral for treating cancer or inhibiting cancer progression. This invention is also directed to use of aragonite or calcite-producing species for in vivo calcium release, and its application to the treatment of skin diseases, disorders or conditions. | 08-18-2011 |
| 20110200564 | DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE (AD) - Disclosed herein are novel methods, assays and systems for detecting an increased risk for Alzheimer's disease (AD) in a subject by identifying at least one nuclei acid polymorphism described herein in a biological sample from the subject. Levels of the genes associated with the nucleic acid polymorphism described herein are also determined for detection of higher risk for AD. Disclosed herein further provides methods for treating AD by administering to a subject in need thereof with ATXN1. | 08-18-2011 |
| 20110200565 | VIRUS CLEARANCE OF NEOPLASTIC CELLS FROM MIXED CELLULAR COMPOSITIONS - The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention. | 08-18-2011 |
| 20110200566 | Compositions and Methods for the Treatment of Vitiligo - Compositions and methods for darkening skin and treating vitiligo are provided. | 08-18-2011 |
| 20110206643 | Automated Cell Therapy System - A method for automated cell processing is provided, including receiving at least one tissue containing a multiplicity of cells belonging to multiple cell types, and automatically increasing both the proportion of cells of at least one of said multiple cell types as compared with at least another of said multiple cell types and the absolute number of cells of said at least one of said multiple cell types. Other embodiments are also described. | 08-25-2011 |
| 20110206644 | METHODS FOR TRANS-DIFFERENTIATING CELLS - The present provides methods for affecting and/or altering the differentiation state of a cell. In certain embodiments, the present invention provides methods to transdifferentiate a cell into an endothelial cell or a hematopoietic cell. In the practice of the invention, a demethylating agent (e.g., 5-azacytidine) is used to affect and/or alter the differentiation state of a cell. The invention demonstrates the transdifferentiation of numerous cell types, including cell populations that are themselves somewhat differentiated (e.g., normal fibroblasts) into distinct cell types, including hematopoietic cells and endothelial cells, which transdifferentiation is effected further through the selection of particular growth factors which, together with the demethylating agents, directs the differentiation path. The invention provides a novel approach to providing useful cell types for many types of medical applications. | 08-25-2011 |
| 20110206645 | TREATMENT OF BONE-RELATED CANCERS USING PLACENTAL STEM CELLS - Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer. | 08-25-2011 |
| 20110206646 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE - Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration. | 08-25-2011 |
| 20110206647 | Modulation of Angiogenesis - The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors. | 08-25-2011 |
| 20110212061 | Mesoderm and Definitive Endoderm Cell Populations - The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. The present invention further provides a method of generating hepatocytes, cell populations enriched for hepatocytes, and a method of hepatocyte replacement therapy. | 09-01-2011 |
| 20110212062 | COMPOSITIONS AND METHODS USING STEM CELLS IN CUTANEOUS WOUND HEALING - Provided herein are compositions and methods using stem/progenitor cells in a therapeutic approach for treatment of or promotion of healing of acute and chronic wounds. | 09-01-2011 |
| 20110212063 | METHODS OF MANUFACTURE OF IMMUNOCOMPATIBLE CHORIONIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 09-01-2011 |
| 20110212064 | THERAPEUTIC PRODUCTS COMPRISING VITALIZED PLACENTAL DISPERSIONS - This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 09-01-2011 |
| 20110212065 | METHODS OF MANUFACTURE OF THERAPEUTIC PRODUCTS COMPRISING VITALIZED PLACENTAL DISPERSIONS - This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 09-01-2011 |
| 20110212066 | METHOD OF FOSTERING THE RESTORATION OF A BODY FUNCTION USING CELLS OF THE ROOT SHEATH, COMPOSITION AND PREPARATION METHOD - The present invention proposes a method for promoting the re-establishment of at least one function of the skin of a second skin area or of another area or part or tissue, comprising applying cells obtained from hair root sheaths of a first skin area of a donor onto a second skin area or another area or part or another tissue of a host. Furthermore, cells, a preparation, the use of cells and a method for preparing a preparation are proposed. | 09-01-2011 |
| 20110212067 | Methods for Purifying Cells Derived from Pluripotent Stem Cells - The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention provides methods of characterization of cells differentiated into cells expressing markers characteristic of the pancreatic endocrine lineage utilizing unique surface markers. The present invention also provides methods to enrich or sort cells expressing markers characteristic of the pancreatic endocrine lineage. The present invention also provides methods to deplete cells that may contaminate populations of cells expressing markers characteristic of the pancreatic endocrine lineage formed by the methods of the present invention, thereby reducing the incidence of tumor formation in vivo following transplantation. | 09-01-2011 |
| 20110212068 | METHODS AND COMPOSITIONS FOR TREATING CONGESTIVE HEART FAILURE - Compositions and methods for treating congestive heart failure are provided herein. | 09-01-2011 |
| 20110212069 | Modulation of Microglia Activation - The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component. The invention is generally directed to reducing inflammation by administering cells that modulate microglia activation. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to modulate microglia activation. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of potency to modulate microglia activation. | 09-01-2011 |
| 20110217269 | METHOD OF FOSTERING THE HEALING OF SKIN WOUNDS USING CELLS OF THE ROOT SHEATH, COMPOSITION AND PREPARATION METHOD - The present invention relates to a method for promoting the healing of skin wounds or the re-establishment of the function of the skin and/or its skin appendices of a second skin area, comprising the step of: applying cells obtained from hair root sheaths of a first skin area of a donor onto a second skin area of a host. It further relates to cells, a preparation, the use of cells as well as a method for preparing a preparation. | 09-08-2011 |
| 20110217270 | METHODS FOR TREATING TUMORS AND CANCEROUS TISSUES - The invention disclosed herein relates generally to immunotherapy and, more specifically, to therapeutic methods for treating tumors and cancerous tissues by first inducing necrosis or apoptosis (e.g., cryotherapy, chemotherapy, radiation therapy, ultrasound therapy, or a combination thereof applied against at least a portion of the tumor or cancerous tissue), and then delivering one or more se doses of antigen presenting cells (e.g., autologous dendritic cells) intratumorally or proximate to the tumor or cancerous tissue, but only after a selected period of time sufficient for the bioavailability of liberated cancer-specific antigens (monitored over the selected period of time) resulting from the necrosis or apoptosis to be at or near a maximum value. The present invention provides an alternative strategy to the ex vivo loading of target antigen to antigen presenting cells such as, for example, enriched autologous dendritic cells for purposes of enhancing an immune response. | 09-08-2011 |
| 20110217271 | TREATMENT OF DISEASES OR DISORDERS USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 09-08-2011 |
| 20110217272 | TREATMENT OF RADIATION INJURY USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 09-08-2011 |
| 20110217273 | Composition for Preventing or Treating AIDS Containing Plant Stem Cell Line Derived from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng as Active Ingredient - The present invention relates to a composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a homogenous cell line, and a lysate, an extract and a culture thereof as an active ingredient. The homogenous cell line, the lysate, the extract and the culture thereof, which are derived from a natural product, minimize adverse side effects of prior therapeutic agents and safe for the human body. Further, they effectively increase the count of T cells such as CD4+ T cells and decrease the number of HIVs, thereby preventing opportunistic infection, dysneuria, and neoplasia caused by immune incompetence, and ultimately the risk of death. Therefore, they are useful in preventing and treating AIDS, and relieving symptoms of AIDS. | 09-08-2011 |
| 20110223138 | Mesenchymal stem cells that express increased amounts of anti-apoptotic proteins - The invention includes a purified population of mesenchymal stromal cells that have been cultured under conditions, such as having been contacted with an apoptotic cell, to express increased levels of at least one anti-apoptotic protein. Such mesenchymal stem cells may be used to treat diseases, disorders, or conditions associated with apoptosis or with unresolved inflammation. | 09-15-2011 |
| 20110223139 | RAPID PREPARATION OF STEM CELL MATRICES FOR USE IN TISSUE AND ORGAN TREATMENT AND REPAIR - A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition. | 09-15-2011 |
| 20110223140 | METHOD FOR DIFFERENTIATION INTO RETINAL CELLS FROM STEM CELLS - Disclosed is a method for inducing stem cells to differentiate into retinal cells at high yield within a short period of time, without gene implantation and co-culture with retinal tissues, by implementing a differentiation process similar to the in vivo embryonic development in chemically defined conditions. Also, retinal cells including the photoreceptor cells and their progenitor cells, and various types of other retinal cells, generated according to the method, are disclosed. A composition comprising the retinal cells and a method are provided for treating retinal degeneration-related diseases. The differentiated photoreceptor cells, when transplanted into degenerated or injured retinas, can be engrafted and fused within the retinas to prevent or cure retinal degeneration. | 09-15-2011 |
| 20110223141 | TREATMENT OF BRAIN OR SPINAL CORD INJURY USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 09-15-2011 |
| 20110223142 | METHODS AND COMPOSITIONS FOR SOFT TISSUE REPAIR - Compositions and methods for tissue repair are provided including cell binding peptides and growth factor binding peptides. The cell binding peptides bind to one or more of stem cells, fibroblasts, or endothelial cells. The growth factor binding peptides include platelet derived growth factor (PDGF) binding peptides and growth differentiation factor (GDF) binding peptides. The tissue for repair includes tendon, muscle, connective tissue, ligament, cardiac tissue, vascular tissue, or dermis. Implantable devices for tissue repair are provided to which the cell and growth factor binding peptides are attached, such as acellular extracellular matrix having attached binding peptide. | 09-15-2011 |
| 20110223143 | STEM CELL FOR THERAPEUTIC USE WHICH IS DERIVED FROM HUMAN MONOCYTE, AND METHOD FOR INDUCING SAME - The present invention relates to stem cells obtained by culturing monocytes in the presence of (i) M-CSF and (ii) at least one member selected from the group consisting of ganglioside and water-soluble plant-derived extract, thereby dedifferentiating the monocytes; a therapeutic agent for treating damaged cells, tissues or organs; a cell drug agent; a method of producing stem cells, a culture medium for dedifferentiating monocytes; a dedifferentiation inducing agent; a cell drug kit; a kit for producing dedifferentiated cells; and a pharmaceutical composition. | 09-15-2011 |
| 20110229440 | Differentiation of Human Embryonic and Induced Pluripotent Stem Cells - The invention relates to culture systems, methods, and conditions that allow pluripotent undifferentiated hESCs or iPSCs to progressively and uniformly differentiate into cells of the chondrogenic lineage. | 09-22-2011 |
| 20110229441 | Method and Medium for Neural Differentiation of Pluripotent Cells - The invention relates to a culture medium comprising an inhibitor of the BMP signaling pathway; and an inhibitor of the TGF/activin/nodal signaling pathway and to a method for obtaining a population of neural precursors using said culture medium. | 09-22-2011 |
| 20110229442 | Cells exhibiting neuronal progenitor cell characteristics and methods of making them - Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells. | 09-22-2011 |
| 20110229443 | Composition for Cancer Prevention or Treatment Containing as Active Ingredient Plant Stem Cell Line Dervied from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng - The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a | 09-22-2011 |
| 20110229444 | Neuregulin And Cardiac Stem Cells - The present invention relates to compositions and methods for inducing cardiomyogenesis in mammalian cells, particularly embryonic stem cells in vitro and in vivo. | 09-22-2011 |
| 20110236355 | DIFFERENTIATION OF STEM CELLS INTO DOPAMINERGIC CELLS - Methods for differentiating stem cells are disclosed herein. These methods can be used to generate neurons, including, but not limited to, dopaminergic neurons. The disclosed methods include culturing stem cells in the absence of fibroblast growth factor-2 to generate embryoid bodies and culturing the embryoid bodies in the presence of an effective amount of at least one of stromal cell-derived factor 1, pleiotrophin, insulin-like growth factor 2, and ephrin B1 on an extracellular matrix for a period of time sufficient to produce dopaminergic neuronal cells. The differentiated cells can be used to study pharmaceutical agents that affect dopaminergic neurons and can be used in the treatment of neurodegenerative disorders such as Parkinson's disease. | 09-29-2011 |
| 20110236356 | METHODS OF ISOLATING AND USING STEM CELLS - Methods of isolating and using stem cells from neural crest, e.g. periodontal ligament, isolated stem cell and therapeutic cell cultures, and therapeutic applications for a variety of conditions. The cells and cell cultures are especially useful for autologous administration. | 09-29-2011 |
| 20110236357 | BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AS A SOURCE OF NEURAL PROGENITORS - Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types. | 09-29-2011 |
| 20110243898 | SOMATIC CELL-DERIVED PLURIPOTENT CELLS AND METHODS OF USE THEREFOR - Provided are methods for producing a reprogrammed fibroblast. The methods can include growing a plurality of fibroblasts in monolayer culture to confluency; and disrupting the monolayer culture to place at least a fraction of the plurality of fibroblasts into suspension culture under conditions sufficient to form one or more embryoid body-like spheres, wherein the one or more embryoid body-like spheres comprise one or more reprogrammed fibroblasts that express one or more markers not expressed by a fibroblast growing in the monolayer culture prior to the disrupting step. Also provided are reprogrammed fibroblasts produced by the disclosed methods, formulations that include reprogrammed fibroblasts, and methods for treating an injury to a tissue in a subject by administering to a subject in need thereof a composition of reprogrammed fibroblast cells in a pharmaceutically acceptable carrier. | 10-06-2011 |
| 20110243899 | Wnt Signaling Inhibitor Comprising Insulin-Like Growth Factor-Binding Protein - Provided is a novel soluble factor that modulates morphogenesis and cell proliferation, such as cardiac development and/or cardiomyocyte differentiation. Specifically provided are: an inhibitor of Wnt signalling, comprising an insulin-like growth-factor-binding protein (IGFBP), the protein being binding to a Wnt receptor, and/or a polynucleotide encoding the protein; a medicament for prevention and/or treatment of a disease due to enhanced Wnt signalling, comprising the inhibitor of Wnt signalling, and a medicament for induction of cardiomyocyte differentiation; and a method for prevention and/or treatment of a disease due to enhanced Wnt signalling and a method of inducing cardiomyocyte differentiation, the methods each comprising using the inhibitor of Wnt signalling, and a cardiomyocyte, which is obtained by the method of inducing cardiomyocyte differentiation, and a use thereof. | 10-06-2011 |
| 20110243900 | SOFT TISSUE AND BONE AUGMENTATION AND BULKING UTILIZING MUSCLE-DERIVED PROGENITOR CELLS, COMPOSITIONS AND TREATMENTS THEREOF - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction. | 10-06-2011 |
| 20110243901 | Compositions and Methods for the Treatment of Lysosomal Storage Disorders - The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells. | 10-06-2011 |
| 20110243902 | METHOD FOR TREATING OR PREVENTING A PANCREATIC DYSFUNCTION - The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1 | 10-06-2011 |
| 20110243903 | USE OF A ROCK INHIBITOR TO SUSTAIN PRIMARY HUMAN KERATINOCYTES IN A PROLIFERATIVE STATE - Disclosed herein is the finding that treatment with a ROCK inhibitor increases proliferation and induces immortalization of primary keratinocytes. Accordingly, provided is a method of immortalizing primary keratinocytes by exposure to a ROCK inhibitor. Also provided are immortalized primary keratinocytes produced by the described method, as well as organotypic tissue equivalents and cell cultures comprising the immortalized primary keratinocytes. Furthermore, ROCK inhibitor-treated cells show a greatly increased ability to support viral DNA replication of both “low risk” and “high risk” HPV genomes, indicating that ROCK inhibitors will be useful for studying the life cycles of a wide range of HPVs. | 10-06-2011 |
| 20110250179 | METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER - The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoKβ) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoKβ) for the treatment of cancer as well as to methods for determining the prognosis of a patient based on the determination of the ChoKβ expression levels as well as based on the determination of the relationship between the ChoKβ and ChoKα expression levels. Finally, the invention relates to methods for determining the response of a patient who suffers from cancer to ChoKα-inhibiting agents based on the determination of the PEMT and/or ChoKβ expression levels. | 10-13-2011 |
| 20110250180 | CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE - The present invention provides a CCN3 peptide for treating a subject in need thereof having an amino acid sequence identified as CCNp37, CCNp38 (human), CCNp38 (mouse), a cysteine-substituted CCNp37, cysteine-substituted CCNp38 (human) or a cysteine-substituted CCNp38 (mouse). | 10-13-2011 |
| 20110250181 | HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 10-13-2011 |
| 20110250182 | ANGIOGENESIS USING PLACENTAL STEM CELLS - Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells. | 10-13-2011 |
| 20110250183 | Combination Therapy for Treatment of Patients with Neurological Disorders and Cerebral Infarction - The present invention provides compositions and methods for treating stroke patients using TCM and a Western medicament used for the treatment of stroke patients. | 10-13-2011 |
| 20110250184 | METHODS FOR DETERMINING EFFICACY OF A THERAPEUTIC REGIMEN AGAINST DELETERIOUS EFFECTS OF CYTOTOXIC AGENTS IN HUMAN - The invention provides drug screening methods and methods for determining efficacy of a therapeutic regimen in humans. In particular, the invention provides screening methods to determine efficacy of a therapeutic regimen to protect human subjects from deleterious effects of cytotoxic agents. The inventive method comprises i) extracting target cells from the human subject prior to exposure to a cytotoxic agent, ii) treating the subject with a cytotoxic protective drug; iii) extracting the target cells from the subject after treatment with the cytotoxic protective drug of step ii); iv) exposing the target cells of steps i) and iii) to the cytotoxic agent; and v) analyzing and comparing one or more parameters indicative of viability and growth conditions in target cells of step i) and step iii), wherein a favorable viability and growth condition of the target cells of step iii) as compared to target cells of step i) is indicative of the efficacy of the therapeutic regimen in the human subject. | 10-13-2011 |
| 20110250185 | TUMOR SUPPRESSION USING PLACENTAL STEM CELLS - The present invention provides methods of suppression of tumor cell proliferation and tumor growth using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of tumor suppression, and compositions comprising such cells and cell populations. | 10-13-2011 |
| 20110256105 | CARDIAC STEM CELL AND MYOCYTE SECRETED PARACRINE FACTORS - The invention relates to secreted proteins from cardiac stem cells (cardiospheres and cardiosphere-derived cells) or myocytes for diagnostic and/or therapeutic use. | 10-20-2011 |
| 20110256106 | Methods and Compositions for Treating Intervertebral Disc Degeneration - A fluid matrix comprising cross-linked remodelable collagen from a donor vertebrate animal is useful for regenerating hydrodynamic function in damaged intervertebral discs in vivo. The matrix may be injectable and may comprise cells and a plurality of purified cell growth factors. The matrix promotes cell growth and elaboration of proteoglycans to facilitate regeneration of native tissues. The collagen in the matrix may be cross-linked using photooxidative catalysis and visible light, and purified cell growth factors are preferably at least partly bone-derived. | 10-20-2011 |
| 20110256107 | TREATMENT OF BRAIN DAMAGE USING UMBILICAL CORD BLOOD CELLS - The invention relates to the treatment of chronic stroke, traumatic brain injury, and neurodegenerative disorders using umbilical cord blood cells. | 10-20-2011 |
| 20110256108 | METHODS OF SELECTION OF CELLS FOR TRANSPLANTATION - A method of selecting a population of adherent cells of a placenta tissue suitable for transplantation is disclosed. The method comprising: (a) determining prior to transplantation in a candidate population of adherent cells of a placenta tissue at least one of the following parameters: (i) percentage of viable cells in the candidate population; (ii) immune phenotype of cells in the candidate population; (iii) xeno-contamination in the candidate population; (iv) sterility of the candidate population; and (v) immunosuppressive activity of cells in the candidate population; and (b) selecting or excluding the candidate population according to predetermined values of at least one of the parameters, thereby selecting a population of adherent cells of the placenta tissue suitable for transplantation. | 10-20-2011 |
| 20110256109 | CHONDROGENIC PROGENITOR CELLS, PROTOCOL FOR DERIVATION OF CELLS AND USES THEREOF - The present invention provides an isolated population of chondrocyte precursor cells wherein 1% or less of the cells express Oct4, Nanog and/or TRA-1-60, 7% or less of the cells express no collagen II, collagen X, CD105 or Stro-1 and 85% or more of the cells express CBFA1, methods for preparing such cells and uses of chondrocyte cells derived from said precursor cells. | 10-20-2011 |
| 20110256110 | AMNIOTIC FLUID CELLS AND USES THEREOF - The present invention relates generally to amniotic fluid derived renal progenitor cells positive for CD24 and OB-cadherin and subpopulations thereof, as well as methods of isolating and uses thereof. The invention is further directed to preventing and treating kidney damage with a population of amniotic fluid derived c-kit positive stem cells. | 10-20-2011 |
| 20110256111 | ISOLATED MULTIPOTENT MESENCHYMAL STEM CELL FROM HUMAN ADULT GLOMERULI (HGL-MSC), A METHOD OF PREPARING THEREOF AND USES THEREOF IN THE REGENERATIVE MEDICINE OF THE KIDNEY - The invention relates to an isolated multipotent glomerular mesenchymal stem cell derived from adult human kidney (hGL-MSC), which is characterised by the marker profile CD133 | 10-20-2011 |
| 20110262402 | THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS - Provided is a pharmaceutical composition and a method for the treatment and/or prophylaxis of arthritis, inter alia, rheumatoid arthritis. The pharmaceutical composition comprises human mesenchymal stem cells, and the method comprises administering an effective amount human mesenchymal stem cells to a patient. | 10-27-2011 |
| 20110262403 | Method of accelerating osteogenic differentiation and composition thereof - The invention discloses a method of accelerating osteogenic differentiation and a composition thereof. The method comprises a step of adding type II collagen into stem/progenitor cells or osteoblasts to accelerate the osteogenic differentiation of the added cells, and the composition comprises type II collagen, and stem/progenitor cells or osteoblasts. Type II collagen can accelerate osteogenesis of mesenchymal stem cells (MSCs) much faster than does type I collagen. The said composition is effective to facilitate bone repair upon introduction of the composition into various osseous defects. | 10-27-2011 |
| 20110262404 | Novel Mesenchymal Stem Cells and Bone-Forming Cells - The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 10-27-2011 |
| 20110262405 | APPARATUS, SYSTEM, AND METHOD FOR HARVESTING IMPROVED BONE GRAFT MATERIAL WITH REAMER-IRRIGATOR-ASPIRATOR (RIA) DEVICE - The present invention provides for the harvesting of specific materials in multiple stages of filtration of bone graft materials from a Reamer-Irrigator-Aspirator (RIA) Device, specifics of interconnected stages, related filtration materials, and techniques. The harvesting process collects large material in a first stage, and other materials of a limited geometric size in at least a second stage of filtration. Such material captured in the second stage may contain plasma, cellular elements including stem cells as well as growth factors and other particulate matter of a specific geometrically limited size, using various filtration approaches including centrifugation in some embodiments. Further embodiments of the invention provide for an improved tubing interface and management approach to ease use in the operating room. Filtration materials may include collagen based filters and may allow direct implant of small scale and larger scale matter in specific portions within the collagen itself. | 10-27-2011 |
| 20110262406 | COMPOSITIONS AND METHODS FOR TARGETED INACTIVATION OF HIV CELL SURFACE RECEPTORS - Compositions for targeted mutagenesis of cell surface receptors for HIV and methods of their use are provided herein. The compositions include triplex-forming molecules that displace the polypyrimidine strand of target duplex and form a triple-stranded structure and hybrid duplex in a sequence specific manner with the polypurine strand of the target duplex. The triplex-forming molecules include a mixed-sequence “tail” which increases the stringency of binding to the target duplex, improves the frequency of modification at the target site, and reduces the requirement for a polypurine:polypyrimidine stretch. Methods for using the triplex-forming molecules in combination with one or more donor oligonucleotides for targeted modification of sites within or adjacent to genes that encodes cell surface receptors for human immunodeficiency virus (HIV) are also disclosed. Methods for ex vivo and in vivo prophylaxis and therapy of HIV infection using the disclosed compositions are also provided. | 10-27-2011 |
| 20110262407 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS - The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic. | 10-27-2011 |
| 20110268706 | PREPARATION METHOD OF POROUS HYALURONIC ACID SPONGE FOR CELL DELIVERY SYSTEM - Provided is a preparation method of a porous hyaluronic acid sponge comprising the steps of: dissolving hyaluronic acid in an aqueous sodium hydroxide solution; adding an epoxy-based crosslinking agent to the resultant aqueous sodium hydroxide solution in which hyaluronic acid is dissolved and homogenizing the hyaluronic acid solution; hydrogelating the homogenized hyaluronic acid solution; washing the hydrogelated hyaluronic acid hydrogel with ultrapure water; swelling the washed hyaluronic acid hydrogel to attain porosity; and freeze-drying the hyaluronic acid hydrogel to obtain a porous hyaluronic acid sponge. | 11-03-2011 |
| 20110268707 | Ex-vivo treatment of peripheral blood leukocytes with IFN-lambda - The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-λ). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-λ in an effective amount to inhibit cytokine releases. The IFN-λ exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-λ treatment of pDC, in conjunction with co-administration of a composition comprising IFN-λ. | 11-03-2011 |
| 20110268708 | ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE - The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. | 11-03-2011 |
| 20110268709 | Generation of Histocompatible Tissues Using Nuclear Transplantation - Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy. | 11-03-2011 |
| 20110268710 | METHODS OF TREATING STROKE USING STEM CELL-LIKE MENSTRUAL BLOOD CELLS - A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats. | 11-03-2011 |
| 20110274662 | Methods of Producing RPE Cells and Compositions of RPE Cells - The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases. | 11-10-2011 |
| 20110274663 | PHARMACEUTICAL COMPOSITION CONTAINING HUMAN MESENCHYMAL STEM CELL - Disclosed are a method for producing a frozen pharmaceutical composition prepared from cultured human mesenchymal stem cells and a pharmaceutical composition containing human mesenchymal stem cells. This method is a method for producing a frozen pharmaceutical composition containing human mesenchymal stem cells, which comprises the following steps in this order: (a) adding trypsin to human mesenchymal stem cells in a culture vessel to detach the cells from the surface of the culture vessel; (b) adding a bicarbonate Ringer's solution containing human serum albumin to the detached cells to terminate the reaction with trypsin, and washing the cells with the bicarbonate Ringer's solution containing human serum albumin; (c) suspending the cells in a bicarbonate Ringer's solution containing human serum albumin and dimethyl sulfoxide; (d) putting the resulting suspension in a container which allows freezing of what is contained therein, and sealing the container; and (e) freezing the suspension put in the container. | 11-10-2011 |
| 20110274664 | HEPATIC PROGENITOR CELLS AND USES THEREOF - Disclosed are cells, compositions, and methods for treating liver diseases. | 11-10-2011 |
| 20110274665 | DOSAGE UNIT FORMULATIONS OF AUTOLOGOUS DERMAL FIBROBLASTS - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×10 | 11-10-2011 |
| 20110274666 | METHOD OF ENGRAFTING CELLS FROM SOLID TISSUES - A method of repairing diseased or dysfunctional organs or of establishing a model system of a disease state is provided. For repairing diseased organs, the method involves engraftment of cells from healthy tissue of the diseased or dysfunctional organ admixed with gel-forming biomaterials and nutrient medium, signaling molecules and extracellular matrix components that can be made insoluble rapidly upon transplantation to form a graft. In this way, the graft mimics the complexity of the native microenvironment with a minimum number of components that allow transplantation of cells to successfully engraft, expand and then rebuild part or the entirety of the diseased or dysfunctional organ. In the case of using grafting methods for establishing a disease model, diseased cells may be transplanted in the biomaterials and into experimental hosts. | 11-10-2011 |
| 20110274667 | METHODS FOR OBTAINING CELL POPULATIONS FROM ADIPOSE TISSUE - Provided herein are methods of efficiently obtaining large numbers of viable, freshly isolated cells from small amounts of adipose tissue, as well as methods of enriching or selecting for target cell populations found therein. In certain embodiments, the method of obtaining a population of cells from adipose tissue comprises incubating the adipose tissue in a solution comprising an enzyme at a concentration which is at least 200 U/ml solution and not more than about 319 U/ml solution. In some embodiments, the method is devoid of any steps which expand the population of cells obtained. In certain aspects, the method further comprises positive or negative selection steps for obtaining an enriched population of target cells from adipose tissue. Related methods of preparing a pharmaceutical composition comprising cells for administration to a patient and methods of treating a disease or medical condition in a patient are further provided herein. | 11-10-2011 |
| 20110274668 | VOLUME MAINTAINING OSTEOINDUCTIVE/OSTEOCONDUCTIVE COMPOSITIONS - An osteoinductive/osteoconductive composition prepared from a quantity, of demineralized fibrous bone elements possessing an average surface area to volume ratio of about 100:1 to about 20:1, a quantity of mostly shaped regular non-fibrous bone elements possessing an average surface area to volume ratio of about 10:1 or less and a sufficient quantity of biocompatible fluid carrier sufficient to provide the composition as a deformable mass is provided herein. Also provided is a method of using the composition to repair a bone defect site. | 11-10-2011 |
| 20110280841 | Electroprocessing in Drug Delivery and Cell Encapsulation - The invention is directed to novel compositions comprising an electroprocessed material and a substance, their formation and use. The electroprocessed material can, for example, be one or more natural materials, one or more synthetic materials, or a combination thereof. The substance can be one or more therapeutic or cosmetic substances or other compounds, molecules, cells, vesicles. The compositions can be used in substance delivery, including drug delivery within an organism by, for example, releasing substances or containing cells that release substances. The compositions can be used for other purposes, such as prostheses or similar implants. | 11-17-2011 |
| 20110280842 | METHODS OF REPROGRAMMING CELLS - The present invention provides methods of reprogramming cells, for example, directly reprogramming a somatic cell of a first cell type into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics. The present invention also relates to an isolated population comprising reprogrammed cells, compositions and their use in the treatment of diabetes mellitus. In particular, the present invention relates to reprogramming a cell of an endoderm origin to a cell having pancreatic β-cell characteristics by increasing the protein expression of at least one transcription factor selected from Pdx1, Ngn3 or MafA in the cell of endoderm origin to reprogram the cell of an endoderm cell to a cell which exhibits at least one or at least two characteristics of an endogenous pancreatic β-cell. | 11-17-2011 |
| 20110280843 | TREATMENT OF DISEASES AND DISORDERS USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells. | 11-17-2011 |
| 20110286973 | METHODS FOR INTRODUCING HETEROLOGOUS CELLS INTO FISH - The invention provides methods of introducing heterologous cells into fish. After introduction cells remain viable, and in some instances proliferate, for sufficient time to conduct a variety of analyses on the heterologous cells or the fish or both. Such methods are useful for screening potential drugs for toxicity toward introduced cells or for capacity to stimulate differentiation and/or proliferation of introduced cells. Such methods are also useful for diagnosing the presence of small quantities of cancerous cells or pathogens in patient tissue samples. Such methods are also useful for culturing cells for subsequent use in cell or tissue engineering. | 11-24-2011 |
| 20110286974 | Method for treating diabetes and other glucose regulation disorders using stem cells - Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. | 11-24-2011 |
| 20110286975 | SYSTEMS AND METHODS FOR MAGNETIC GUIDANCE AND PATTERNING OF MATERIALS - Systems and methods generally useful in medicine, cellular biology, nanotechnology, and cell culturing are discussed. In particular, at least in some embodiments, systems and methods for magnetic guidance and patterning of cells and materials are discussed. Some specific applications of these systems and methods may include levitated culturing of cells away from a surface, making and manipulating patterns of levitated cells, and patterning culturing of cells on a surface. Specifically, a method of culturing cells is presented. The method may comprise providing a plurality of cells, providing a magnetic field, and levitating at least some of the plurality of cells in the magnetic field, wherein the plurality of cells comprise magnetic nanoparticles. The method may also comprise maintaining the levitation for a time sufficient to permit cell growth to form an assembly. | 11-24-2011 |
| 20110286976 | BI-SPECIFIC FUSION PROTEINS - Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network. | 11-24-2011 |
| 20110286977 | G6PC2-Encoded Beta Cell Surface Tags - The invention relates to G6PC2-encoded beta cell surface markers, methods of identifying and obtaining a culture cells comprising fully differentiated beta cells. Also contemplated is a method of sorting such cells, isolated cells and compositions thereof. | 11-24-2011 |
| 20110293572 | INCREASING THE PLASTICITY OF STEM CELLS - The invention relates to methods of culturing non-embryonic cells to increase their plasticity and their potential to differentiate into multi-lineage cell types. | 12-01-2011 |
| 20110293573 | METHOD AND APPARATUS FOR CULTURING TISSUE - A method for culturing microtissue is provided. The method includes steps of: (a) forming a pattern microarray on a hydrophobic film; (b) adhering the hydrophobic film to a carrier; (c) disposing a plurality of cells on the hydrophobic film for culturing depending on the pattern microarray, and forming a plurality of hair follicle microtissues. | 12-01-2011 |
| 20110293574 | Hematopoietic stem cell growth factor - The present invention relates, in general, to stem cells and, in particular, to a hematopoietic stem cell (HSC) growth factor and to methods of using same. | 12-01-2011 |
| 20110293575 | PHOTOCHEMICAL INTERNALISATION OF KINASE INHIBITORS - The present invention relates to a method for enhancing the activity of kinase inhibitors in target cells, and more specifically for enhancing the activity of tyrosine kinase inhibitors (TKIs), said method comprising contacting a cell with a kinase inhibitor and a photosensitizing agent and irradiating said cell with light of a wavelength effective to activate the photosensitizing agent, and to the use of this method for enhancing the effects of kinase inhibitors or kinase inhibitor-based drugs in particular to achieve cell death, for example, in cancer treatment and other diseases or conditions in which kinase inhibitors, such as TKIs, have a beneficial effect. | 12-01-2011 |
| 20110293576 | MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF ISOLATING AND USING SAME - The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders. | 12-01-2011 |
| 20110293577 | Therapeutic Methods Using Adipose Tissue-Derived Cell Suspensions Comprising Adipocytes - Provided herein is a use of an adipose tissue-derived cell suspension which comprises adipocytes for the preparation of a pharmaceutical composition for use in the treatment of an inflammatory disorder, a cartilage or bone disorder and/or the alleviation of pain associated with an inflammatory disorder in a mammalian subject. Also provided herein is a method of treating an inflammatory disorder, a cartilage or bone disorder or alleviating pain associated with an inflammatory disorder in a mammalian subject, comprising administering to the subject a pharmaceutical composition which comprises: (i) an adipose tissue-derived cell suspension which comprises adipocytes; or (ii) a cell-free extract which is prepared from an adipose tissue-derived cell suspension, wherein the adipose tissue-derived cell suspension comprises adipocytes, together with a pharmaceutically-acceptable carrier or diluent. | 12-01-2011 |
| 20110293578 | Use of Stem Cells to Prevent Neuronal Dieback - The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons. | 12-01-2011 |
| 20110293579 | Bi-specific fusion proteins - Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration. | 12-01-2011 |
| 20110293580 | GYNOGENETIC OR ANDROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES - Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs. | 12-01-2011 |
| 20110293581 | BONE-REGENERATING COMPOSITION CONTAINING ANGIOGENIN - The present invention relates to a bone-regenerating composition containing angiogenin and to a bone-generating scaffold comprising the composition. Angiogenin has a superior ability to induce initial angiogenesis and bone regeneration as compared to the platelet rich plasma (PRP) which is used as a conventional element for stimulating bone regeneration, thus improving the speed of bone regeneration | 12-01-2011 |
| 20110293582 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using farnesyl compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation. | 12-01-2011 |
| 20110293583 | METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY - Methods for treating a subject suffering from a compromised endogenous hematopoietic system are described that comprise administering to the subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described. | 12-01-2011 |
| 20110293584 | Tissue Regeneration - The present invention relates to a method of treating a tissue defect in a human or animal body comprising the steps of implanting into said body an unseeded scaffold; allowing or effecting a wound healing response at the site of said defect; allowing said scaffold to be vascularized until a substantially sufficient fluid flow through said scaffold is assured for the transport of nutrients and/or waste products, and seeding said vascularised scaffold with a suitable population of tissue-regenerating cells. | 12-01-2011 |
| 20110300111 | GENERATION OF INDUCED PLURIPOTENT STEM CELLS WITHOUT THE USE OF VIRAL VECTORS - Presented herein, generally, are methods for generating reprogrammed mammalian cells, e.g., induced pluripotent stem cells, from differentiated mammalian cells without the use of viral or plasmid vectors. In one aspect, the methods involve contacting a differentiated cell with transducible polypeptides comprising a reprogramming factor polypeptide linked to a cell penetration peptide so that a reprogrammed mammalian cell that exhibits at least one characteristic of pluripotency is generated. Also presented herein are methods for cardiac differentiation of a mammalian cell without the use of viral or plasmid vectors. In one aspect, such methods involve contacting a mammalian cell exhibiting at least one characteristic of pluripotency with a transducible polypeptide, so that cardiac differentiation of the cell occurs. | 12-08-2011 |
| 20110300112 | METHODS FOR ENHANCING YIELD OF STEM CELL CULTURES AND ENHANCING STEM CELL THERAPY - The present application relates to methods and compositions for the generation of therapeutic cells having reduced incidence of karyotypic abnormalities. In several embodiments cardiac stem cells are cultured in an antioxidant-supplemented media that reduces levels of reactive oxygen species, but does not down regulate DNA repair mechanisms. In several embodiments, physiological oxygen concentrations are used during culture in order to increase the proliferation of stem cells, decrease the senescence of the cells, decrease genomic instability, and/or augment the functionality of such cells for cellular therapies. | 12-08-2011 |
| 20110305672 | COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME - The present invention relates to inter alia, methods for the generation and maintenance of Mesoderm-derived ISL1+ Multipotent Progenitors (IMPs), the production of a number of pluripotent cells including and epicardial pluripotent cells (EPCs) and using these cells to produce endothelial cells, cardiomyocytes, smooth muscle cells, vascular cells and other cells and related methods as otherwise disclosed herein. The invention also relates to compositions comprising a population of cells. | 12-15-2011 |
| 20110305673 | COMPOSITIONS AND METHODS FOR TISSUE REPAIR - The invention features compositions comprising mesenchymal stem cells or multipotent stromal cells, agents secreted by such cells in culture, and methods featuring such cells for the repair or regeneration of a damaged tissue or organ. The present invention is based, at least in part, on the discovery that agents secreted by bone marrow mesenchymal stem cells or multipotent stromal cells (MSCs) were useful for the treatment or prevention of tissue damage related to ischemic injury (e.g., cerebral or cardiac ischemia). | 12-15-2011 |
| 20110305674 | Pathways to Generate Hair Cells - This disclosure relates to methods and compositions for modulating (e.g., increasing) Atoh1 activity (e.g., biological activity) and/or expression (e.g., transcription and/or translation) in vivo and/or in vitro, e.g., in a biological cell and/or in a subject. The methods and compositions described herein can be used in the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression in a biological cell. | 12-15-2011 |
| 20110305675 | METHODS FOR EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS - Described herein are methods and compositions for expanding hematopoietic stem and progenitor cells (HSPC) ex vivo and in vivo, and methods and compositions for transplanting HSPCs and treatment of anemia in a human subject. HSPCs are expanded in the presence of an inhibitor of serine threonine kinase 38 (STK38), wherein said inhibitor is preferably an RNAi agent. | 12-15-2011 |
| 20110305676 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation. | 12-15-2011 |
| 20110305677 | HUMAN EMBRYONIC STEM CELL CULTURES, AND COMPOSITIONS AND METHODS FOR GROWING SAME - Human pluripotential embryonic stem cell cultures are provided, as are human feeder cells useful for growing the human embryonic stem cells, conditioned medium obtained from cultures of the human feeder cells, and factors derived from the conditioned medium. Also provided are methods of growing human embryonic stem cells in the presence of the human feeder cells, the conditioned medium, the factors derived from the conditioned medium, or a combination thereof. In addition to the human embryonic stem cell cultures grown according to such methods, isolated human embryonic stem cells obtained from such human embryonic stem cell cultures are provided, as are methods of using such isolated cells. | 12-15-2011 |
| 20110305678 | USE OF MESENCHYMAL STEM CELLS FOR TREATING GENETIC DISEASES AND DISORDERS - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 12-15-2011 |
| 20110311491 | TREATMENT OF SARCOIDOSIS USING PLACENTAL STEM CELLS - Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof. | 12-22-2011 |
| 20110311492 | MAINTENANCE/EXPANSION OF HSC's - The invention is related to methods for culturing stem cells, more particularly hematopoietic stem cells (HSC). The invention relates to methods for HSC maintenance and/or expansion through the use of soluble factors. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of disorders or diseases (e.g. leukemia). The invention also relates to the development of small molecules that may increase HSC self renewal in vitro and in vivo. | 12-22-2011 |
| 20110311493 | METHODS FOR STABILIZING A BIOPROSTHETIC TISSUE BY CHEMICAL MODIFICATION OF ANTIGENIC CARBOHYDRATES - Methods are provided herein for modifying antigenic carbohydrate epitopes within a xenographic bioprosthetic tissue by oxidation of vicinal diols to form aldehydes or acids and subsequence reductive amination of aldehydes to form stable secondary amines, or amidation or esterification of acids to form stable amides or esters. Advantageously, methods provided herein mitigate the antigenicity of the bioprosthetic tissue while leaving the overall tissue structure substantially undisturbed, and thereby enhance the durability, safety and performance of the bioprosthetic implant. | 12-22-2011 |
| 20110311494 | METHODS OF REPROGRAMMING RENAL CELLS - A method of reprogramming a differentiated renal cell towards a progenitor phenotype is disclosed. The method comprises up-regulating in the differentiated renal cell an expression of at least one pluripotency associated gene and/or at least one renal stem cell associated gene, thereby reprogramming the differentiated renal cell towards a progenitor phenotype. Cell populations generated thereby and uses thereof are also disclosed. | 12-22-2011 |
| 20110311495 | ISOLATED POPULATIONS OF RENAL STEM CELLS AND METHODS OF ISOLATING AND USING SAME - Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells. | 12-22-2011 |
| 20110311496 | MESENCHYMAL STEM CELLS AND USES THEREFOR - The present technology provides compositions of mesenchymal stem cells for promoting wound healing or fracture healing and methods of promoting wound healing or fracture healing comprising the steps of administering mesenchymal stem cells in an effective amount. | 12-22-2011 |
| 20110311497 | Cell Suspension Preparation Technique and Device - The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site. | 12-22-2011 |
| 20110318312 | Rejuvenation or preservation of germ cells - Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of germ cells or gametes. Certain embodiments disclosed herein include, but are not limited to, methods of modifying germ cells or gametes, or methods of administering modified germ cells or gametes to at least one biological tissue. | 12-29-2011 |
| 20110318313 | Modulation of Splenocytes in Cell Therapy for Traumatic Brain Injury - The invention provides methods for treating traumatic brain injury. The invention is generally directed to treating traumatic brain injury by administering cells that have one or more of the following effects in an injured subject: interact with splenocytes, preserve splenic mass, increase proliferation of CD4 | 12-29-2011 |
| 20110318314 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount. | 12-29-2011 |
| 20110318315 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Methods of treating graft versus host disease, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 12-29-2011 |
| 20120003186 | METHOD FOR DEDIFFERENTIATING ADIPOSE TISSUE STROMAL CELLS - A method for dedifferentiating adipose tissue stromal cells (ATSC) is provided. When the ATSC is treated under hypoxia condition and with a 4-(3,4-Dihydroxy-phenyl)-derivative (DHP-derivative), expression of stemness genes, cellular growth-related genes and cellular mobility-related genes increase, and expression of histone and DNA methylation-related genes decrease so that cell proliferation increases and pluripotency for differentiating into adipocytes, osteocytes, myocytes, beta cells and cartilage cells is acquired. When the dedifferentiated ATSC is implanted into animal model with spinal cord injury and diabetic animal model, effects of nerve regeneration and increased blood surge level are confirmed. As a result, the method for dedifferentiating the ATSC can be effectively used in the stem cell research, tissue regeneration and development of cytotherapeutic medicines. | 01-05-2012 |
| 20120003187 | BIOLOGICAL MEDIUM FOR PRESERVING A PREPARATION OF INSULIN-SECRETING CELLS - A method for preserving a preparation of insulin-secreting cells includes the step of placing the preparation of insulin-secreting cells in contact with a biological medium, the biological medium including a nutritive product including albumin, and further includes a peptone or a mixture of peptones in sufficient quantity to preserve the insulin-secreting cells. | 01-05-2012 |
| 20120003188 | Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived from Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 01-05-2012 |
| 20120003189 | Materials and Methods to Enhance Hematopoietic Stem Cells Engraftment Procedures - This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE | 01-05-2012 |
| 20120003190 | LATERAL VENTRICLE CELL COMPOSITIONS AND USE FOR TREATING NEURAL DEGENERATIVE DISEASES - A pluripotent stem cell isolated from the lateral ventrical of the brain or choroid plexus is provided. Compositions and methods of isolating and using the cell also is provided. | 01-05-2012 |
| 20120003191 | VALPROIC ACID, DERIVATIVES, ANALOGUES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE - The present disclosure includes methods and compositions for treating any condition or disorder that benefits from activation of the Akt signaling pathway. These methods and compositions involve the use of valproic acid, derivatives, analogs and compositions including the same for treating muscular disorders, such as muscular dystrophy. | 01-05-2012 |
| 20120003192 | HYDROGEL-FORMING COMPOSITION COMPRISING PROTEIN AND NON-PROTEIN SEGMENTS - A hydrogel-forming composition is formed from a protein polymer derivative having a plurality of cross-linkable units depending therefrom, and a non-protein polymer derivative having a plurality of cross-linkable units depending therefrom, said non-protein polymer derivatives having hydrolysable units disposed between the polymer backbone of said derivative and at least some of said cross-linkable units. The use of a combination of protein and non-protein polymers provides for biodegradability of the hydrogel by hydrolysis of the hydrolysable units and/or enzymatic degradation of the proteins, along with mechanical properties such as strength and elasticity. | 01-05-2012 |
| 20120003193 | Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided. | 01-05-2012 |
| 20120009156 | GERMLINE STEM CELL BANKING SYSTEM - Methods and systems are provided for the isolation, characterization, cryopreservation and banking of human germline stem cells and gonadal tissue. Also disclosed are methods for the transplanting of the cryopreserved cells to repopulate a sterile reproductive organ. | 01-12-2012 |
| 20120009157 | CULTURE METHOD OF EMBRYOID BODIES AND/OR NEURAL STEM CELLS DERIVED FROM HUMAN DIFFERENTIATED CELL-DERIVED PLURIPOTENT STEM CELLS - A method for differentiating a human differentiated cell-derived pluripotent stem cell into a neural stem cell is provided, which includes the steps of: making an embryoid body from the human differentiated cell-derived pluripotent stem cell; and culturing the embryoid body in a medium containing LIF to differentiate into a neural stem cell, so that, when the neural stem cell is allowed to differentiate in vitro after multiple subculturing of the neural stem cell, it differentiate mainly into neurons but substantially not into glial cells. | 01-12-2012 |
| 20120009158 | VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF - The present invention generally relates to methods and compositions to generate a secondary iPS (2iPS) cell to produce somatic cells of a rare differentiation cell type fate. In some embodiments, the method relates to an increase in efficiency of differentiation and production of high yields of somatic cells of a rare differentiation cell type fate produced from secondary iPS (2iPS) cells as compared to their differentiation from other pluripotent stem cell sources such as ES cells or primary iPS cells. In some embodiments, the present invention relates to compositions, methods and systems for reprogramming a first somatic cell into a primary iPS cell, where the primary iPS cell is then differentiated along a selected linage to produce a second somatic cell, which is then reprogrammed to a secondary iPS cell (2iPS) cell. The 2iPS cell has a high efficiency of differentiating into a cell of the same cell type as the second somatic cell, e.g., a somatic cells of a rare differentiation cell type fate such as but not limited to a ventricular cardiomyocyte, a pancreatic β-cell or a hepatic cell. In some embodiments, the first somatic cell is a fibroblast, or a cardiac cell, but is not limited to cardiac fibroblast cells. In some embodiments, the present invention relates to compositions, methods and systems to produce ventricular cardiomyocytes from secondary induced pluripotent stem cells (iPSC), where the iPSC are themselves generated from ventricular cardiomyocytes. The secondary iPS (2iPS) cell generated from ventricular cardiomyocytes have a higher cardiomyogenic potential and high cardiomyogenic yield as compared to primary iPSC, and are useful in drug discovery, disease modeling and cell-based therapy. | 01-12-2012 |
| 20120009159 | BIOCOMPATIBLE SUBSTRATE FOR FACILITATING INTERCONNECTIONS BETWEEN STEM CELLS AND TARGET TISSUES AND METHODS FOR IMPLANTING SAME - Disclosed herein are substrates for cell delivery to target tissues requiring treatment for various diseases that induce cell death, damage or loss of function. The substrates are configured to provide seeded cells, including stem cells, with a structural support that allows interconnection with and transmission of biological signals between the cells and the target tissue. | 01-12-2012 |
| 20120014924 | Compositions and Methods for Improving the Functional Efficacy of Stem Cell-Derived Cardiomyocytes - This invention provides an isolated stem cell modified to provide, enhance or contain the functional characteristics of the sarcoplasmic reticulum (SR) The isolated stem cells are modified by expressing a calcium channel protein, by expressing a calcium pump protein such as the sarcro/endoplasmic reticulum Ca2+-ATPase (SERCA) protein, by inhibiting or downregulating expression of the Na+/Ca2+ exchanger (NCX) protein, by expressing a calcium handling protein, by expressing a transverse (t)-tubule, and/or by expressing a transverse (t)-tubule biogenic protein The modified cells may be expanded to a substantially homogenous population of these cells or differentiated to a more mature cell type Compositions are also provided The cells and compositions can be administered to a host and used to regenerate cardiac tissue, improve cardiac function, restore action potential of cardiac tissue, and treat or prevent cardiac malfunction Use for diagnostic screening of therapeutic candidates is also provided | 01-19-2012 |
| 20120014925 | Self-Assembling Peptides Incorporating Modifications and Methods of Use Thereof - The invention relates to a novel class of self-assembling peptides, compositions thereof, methods for the preparation thereof and methods of use thereof. The invention also encompasses methods for tissue regeneration, increasing the production of extracellular matrix proteins, and methods of treatment comprising administering self-assembling peptides. | 01-19-2012 |
| 20120014926 | Activation of Precursor Cells for Cell Therapy - This invention relates to a method and compositions for activation of precursor cells via upregulation of CXCR4 surface receptor expression, to give the activated cells a better homing capability and higher viability. The method for activation involves incubation of the target cells with an isotonic activation solution containing an activation-effective amount of calcium. Such activated cells have a better ability to engraft into target tissues to execute the therapeutic function. | 01-19-2012 |
| 20120014927 | METHODS AND KITS FOR DETERMINING PREDISPOSITION TO CANCER - Provided are methods and kits for determining predisposition to cancer by determining the presence or absence in a heterozygote form of the KLOTHO functional variant. Also provided are methods of designing treatment and treating cancer based on the increased predisposition to the cancer, and to determine the prognosis of a subject diagnosed with cancer. | 01-19-2012 |
| 20120014928 | METHODS AND COMPOSITIONS FOR TARGETED CLEAVAGE AND RECOMBINATION - Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. | 01-19-2012 |
| 20120014929 | STEM CELLS FOR TREATING LUNG DISEASES - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow. | 01-19-2012 |
| 20120014930 | STEM CELLS FOR TREATING LUNG DISEASES - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow. | 01-19-2012 |
| 20120014931 | HUMAN LATE STAGE MOTOR NEURON PROGENITOR CELLS - Motor neuron progenitor (MNP) cells and populations of MNP cells, are provided, in particular, populations of human late stage MNP cells having a purity of greater than about 65% late stage MNP cells and high-purity populations of MNP cells having greater than 95% viable cells, as well as method of making and using the same, including deriving late stage MNP cells from pluripotent embryonic stem cells, producing high-purity populations of late stage MNP cells, producing populations of viable MNP cells, transporting viable MNP cells, and transplanting MNP cells. | 01-19-2012 |
| 20120020929 | METHODS AND COMPOSITIONS RELATING TO NEURONAL CELL AND TISSUE DIFFERENTIATION - The invention relates to methods for isolating and purifying specific types of neurons, such as cortical or other projection neurons including corticospinal motor neurons, subcerebral projection neurons, and callosal projection neurons. The invention also relates to genes that are specific for particular neuronal subtypes, and the use of such genes in genetic/molecular control of cell development. The isolated cells and subtype-specific genes also have uses in diagnostics, therapeutics, and screening assays for pharmaceutical molecules. | 01-26-2012 |
| 20120020930 | METHODS FOR THE PREPARATION OF ADIPOSE DERIVED STEM CELLS AND UTILIZING SAID CELLS IN THE TREATMENT OF DISEASES - The present invention provides a method for the preparation of adipose derived stem cells for use in cellular therapy. In further aspects the present invention provides cells produced by the method of the invention, pharmaceutical compositions and kits suitable for use in treatment of patients. | 01-26-2012 |
| 20120020931 | THERAPEUTIC ENCAPSULATED EMBRYONIC STEM CELLS AND MESENCHYMAL STROMAL CELLS - This application discloses alginate microencapsulation-mediated differentiation of embryonic stem cells and use of the stem cell differentiation method for the development of effective treatment of various diseases and disorders. The microencapsulation of embryonic stem (ES) cells results in decreased cell aggregation and enhanced neural lineage differentiation through incorporating the soluble inducer retinoic acid (RA) into the permeable microcapsule system. This application also discloses a micro-encapsulation system for immobilizing mesenchymal stromal cells (MSCs) while sustaining the molecular communication. Thus, the invention provides the use of encapsulated mesenchymal stromal cells in the cellular transplantation therapies. Moreover, the invention provides methods for delivery of encapsulated MSCs into the central nervous system and therapies derived therefrom, such as, the treatment of spinal cord injury (SCI) and other inflammatory conditions. | 01-26-2012 |
| 20120020932 | THERMOSENSITIVE HYDROGEL COMPOSITION AND METHOD - A hydrogel-forming composition is provided that comprises an extracellular matrix protein, hyaluronic acid, and a thermosensitive biocompatible polymer such as methylcellulose. The hydrogels can provide a therapeutic effect; further, the hydrogels may comprise an optional therapeutic agent such as cells or a pharmaceutical composition. The composition may be injected to an area in need of treatment by the therapeutic agent. The composition may form a gel at about 37° C., such that the gel maintains the therapeutic agent in the area of the body in need of such treatment. | 01-26-2012 |
| 20120020933 | METHOD OF NERVE REPAIR WITH AMNION AND CHORION CONSTRUCTS - Improved methods for the surgical repair of a damaged or severed nerve are described. The improvement includes covering the surgically repaired nerve or a damaged neurilemma with at least one of an amniotic fluid and a construct, or replacing the damaged neurilemma with the construct prior to wound closing during the surgery. The construct contains an allograft having at least one layer of amnion and chorion tissues, and a shape adapted for enclosing a damaged or severed nerve or for covering or replacing the damaged neurilemma during the surgical repair. The products and methods improve the performance of the nerve surgery, e.g., by reducing inflammation, inhibiting fibrosis, scarring, fibroblast proliferation, post-operative infection while also promoting more rapid healing of damaged or traumatized nerve structures. | 01-26-2012 |
| 20120020934 | MATERIALS AND METHODS FOR CRYOPRESERVED BONE CONSTRUCTS - The subject invention concern materials and methods for cryopreservation of HCG-cell constructs. In one embodiment, porous HCG scaffolds are provided in a perfusion bioreactor having perfusion chambers that can contain the HCG scaffolds, cells are then seeded in the HCG scaffolds in the perfusion bioreactor, cell culture media is perfused through and the bioreactor operated so as to allow for cell seeding and growth in the HCG scaffold. After a suitable period of time, the cell culture media is removed and the HCG containing cells (HCG-cell constructs) can be washed with a suitable buffer, such as phosphate-buffered saline (PBS). The HCG-cell constructs are then perfused in the bioreactor with a suitable cryopreservation fluid. The cryopreservant can comprise one or more of the following: DMSO, trehalose, glycerol, ethylene glycol, and serum for cell culture (e.g., fetal bovine serum (FBS)). In one embodiment, the HCG-cell constructs are perfused for a suitable period of time with cryopreservant fluid using transverse flow of the fluid in the bioreactor at a suitable flow rate. The HCG-cell constructs (or the perfusion chambers containing them) are then removed from the bioreactor and placed in a cryopreservant media and maintained at increasingly colder temperatures until temperatures reach about −80° C. The frozen HCG-cell constructs (or the chambers containing them) can then be stored at a suitable cryogenic temperature (e.g., in liquid nitrogen) until needed. When needed, frozen HCG-cell constructs can be removed from cold storage and thawed using suitable means (e.g., 37° C. water bath). Cells contemplated for use in the present invention include stem cells, such mesenchymal stem cells. Cells can be animal cells, such as mammalian cells. In one embodiment, the cells are human cells. | 01-26-2012 |
| 20120020935 | CARDIAC STEM CELLS AND METHODS FOR ISOLATION OF SAME - Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs. | 01-26-2012 |
| 20120020936 | TREATMENT OF NEURODEGENERATIVE DISEASE USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 01-26-2012 |
| 20120020937 | AUTOLOGOUS AND ALLOGENIC ADIPOSE-DERIVED STROMAL STEM CELL COMPOSITION FOR TREATING FISTULAS - The present invention relates to a method for producing clinically effective quantities of human adipose tissue-derived stromal cells for treating fistulas and a composition made with the same. The method of the present invention can efficiently produce clinically effective number of adipose tissue-derived stromal cells within a short period by improving conventional standard culturing methods. The adipose stem cells composition containing the adipose tissue-derived stromal cells obtained by the method of the present invention exhibit superior multipotency and immunomodulatory activity over those of a cell composition produced by conventional methods, and thus is more suitable for treating fistulas. The cell composition of the present invention has excellent clinical usages especially since immune response is suppressed in allogenic adipose-derived stem cells. | 01-26-2012 |
| 20120027729 | METHODS FOR TREATING DIABETES - Transplantation of multipotent stromal cells (MSCs) into diabetic mice lowers blood sugar, increases blood insulin levels, increases the number and size of islets, and improves renal pathology. Accordingly, the invention provides methods for treating or preventing diabetes by administering isolated MSCs. The invention also provides methods for treating or preventing complications which arise from diabetes, including diabetic nephropathy, by transplanting isolated MSCs. | 02-02-2012 |
| 20120027730 | USES OF MESENCHYMAL STEM CELLS - The invention relates to the use of mesenchymal stem cells (MSCs) for treating systemic inflammatory response syndrome (SIRS) in a subject. The invention provides compositions, uses and methods for the treatment of SIRS. | 02-02-2012 |
| 20120027731 | HEMANGIO-COLONY FORMING CELLS - Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. | 02-02-2012 |
| 20120027732 | THERMOREVERSIBLE COLLAGEN - This invention relates to collagen formulations. More particularly, this invention relates to thermoreversible collagen formulations and methods of their use and preparation. | 02-02-2012 |
| 20120027733 | COMPOSITIONS TO EFFECT NEURONAL GROWTH - Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed. | 02-02-2012 |
| 20120034191 | EXTRACELLULAR MATRIX COMPOSITIONS FOR TISSUE REGENERATION - The invention is compositions of extracellular matrix that comprise mammalian extracellular matrix from two or more tissue sources in a mammal. The invention also includes methods of using these compositions to regenerate tissue or generate new tissue at sites of defects or wounds in mammals. | 02-09-2012 |
| 20120034192 | COMPOSITIONS AND METHODS FOR ENHANCING CELL REPROGRAMMING - The invention provides compositions and methods of use to enhance reprogramming of mammalian cells. Certain compositions and methods of the invention are of use to enhance generation of induced pluripotent stem cells by reprogramming somatic cells. Certain compositions and methods of the invention are of use to enhance reprogramming of pluripotent mammalian cells to a differentiated cell type. Certain compositions and methods of the invention are of use to enhance reprogramming of differentiated mammalian cells of a first cell type to differentiated mammalian cells of a second differentiated cell type. The reprogrammed somatic cells are useful for a number of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that enhances or contributes to reprogramming mammalian cells. Certain of the inventive compositions and methods relate to inhibiting histone methylation. | 02-09-2012 |
| 20120034193 | TREATMENT OF NEUROTROPHIC FACTOR MEDIATED DISORDERS - An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health. | 02-09-2012 |
| 20120034194 | Somatic Stem Cells - A population of somatic stem cells and a method of preparing same. Also disclosed are two subpopulations thereof and their various uses. | 02-09-2012 |
| 20120034195 | PLACENTAL STEM CELLS DERIVE FROM POST-PARTUM MANMALIAN PLACENTA, AND USES AND METHODS OF TREATMENT USING SAID CELLS - The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. | 02-09-2012 |
| 20120034196 | GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7P15-21 AND USES THEREOF (FRANK) - The invention relates to an MDR family P-glycoprotein located on human chromosome 7p15-21, polynucleotide sequences encoding this P-glycoprotein and fragments thereof. This gene is utilized in methods for assessing cancer cell susceptibility to therapies directed against multidrug resistance, and for the design of diagnostic and therapeutic methods relating to cancer multidrug resistance. The invention also relates to methods for determining whether a test compound may inhibit multidrug resistance. | 02-09-2012 |
| 20120039854 | Nanoparticle Targeted Drug Delivery to the Lungs Using Extra-Testicular Sertoli Cells - A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the of the injected nanoparticle to load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection. | 02-16-2012 |
| 20120039855 | FIBRIN BASED SCAFFOLD, PREPARATION AND USE THEREOF - The invention relates to a fibrin-based scaffold suitable for supporting a population of cells comprising mesenchymal stem cells (MSC) and/or umbilical tissue derived cells (UTC) at the site of administration for a prolonged period of time. The scaffold is capable of supporting at least 1×10 | 02-16-2012 |
| 20120039856 | COMPOSITION FOR TREATING BALDNESS WITH STEM CELL DERIVED FROM UMBILICAL CORD BLOOD - Provided is a therapeutic technique for treating baldness, using an umbilical cord blood-derived mesenchymal stem cell. Transplantation of a composition for treating baldness into a bald area of a patient can make great contributions to treatment for baldness, wherein the composition comprises stem cells isolated and cultured from umbilical cord blood in which 6 HLA (Human Leukocyte Antigen) are identical with a patient, or one or two HLA are not identical with the patient. | 02-16-2012 |
| 20120039857 | SYSTEMS AND METHODS FOR CARDIAC TISSUE REPAIR - The present application relates to cardiac stem cells and a method of using cardiac stem cells to repair damaged heart tissue. In one embodiment, cardiac stem cells, such as cardiosphere-derived cells and/or cardiospheres, can be seeded, embedded and/or cultured in a biomaterial or matrix made from, for example, a hydrogel, that is subsequently administered to a subject to repair damaged heart tissue. | 02-16-2012 |
| 20120045417 | METHODS AND COMPOSITIONS FOR ISLET CELL PRESERVATION - Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In particular, the present invention relates to compositions and methods for inhibition of graft rejection and promotion of graft survival. Thus, the invention relates to modulation of cellular activities, including graft rejection, promotion of graft survival, graft versus host rejection and conditions commonly associated with graft rejection. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease and inducers of other alpha 1-antitrypsin activities. | 02-23-2012 |
| 20120045418 | PHARMACEUTICAL PREPARATION COMPRISING SUPERNATANT OF BLOOD MONONUCLEAR CELL CULTURE - The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h. | 02-23-2012 |
| 20120045419 | METHODS AND USES OF HYPOXIC COMPARTMENT CELLS - The disclosure relates to methods of maintaining and/or expanding an in vitro population of hypoxia compartment cells comprising culturing said population of cells optionally in an oxygen controlled environment, wherein the population of hypoxia compartment cells is exposed to an oxygen concentration of between about 1.5% and about 10%, preferably between about 2% and about 5%, and uses of cells expanded according to these methods. | 02-23-2012 |
| 20120045420 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual. | 02-23-2012 |
| 20120045421 | METHODS FOR THE ISOLATION OF CARDIAC STEM CELLS - Method for the isolation, expansion and preservation of cardiac stem cells from human or animal tissue biopsy samples to be employed in cell transplantation and functional repair of the myocardium or other organs. Cells may also be used in gene therapy for treating cardiomyopathies, for treating ischemic heart diseases and for setting in vitro models to study drugs. | 02-23-2012 |
| 20120058088 | Resveratrol-Containing Compositions And Methods Of Use - A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, and one or more additional antioxidants such as phenolic antioxidants or vitamin D. | 03-08-2012 |
| 20120058089 | TREATMENT OF ORGAN INJURIES AND BURNS USING PLACENTAL STEM CELLS - The present invention provides a method of extracting and recovering embryonic-like stem cells, including, but not limited to pluripotent or multipotent stem cells, from an exsanguinated human placenta. A placenta is treated to remove residual umbilical cord blood by perfusing an exsanguinated placenta, preferably with an anticoagulant solution, to flush out residual cells. The residual cells and perfusion liquid from the exsanguinated placenta are collected, and the embryonic-like stem cells are separated from the residual cells and perfusion liquid. The invention also provides a method of utilizing the isolated and perfused placenta as a bioreactor in which to propagate endogenous cells, including, but not limited to, embryonic-like stem cells. The invention also provides methods for propagation of exogenous cells in a placental bioreactor and collecting the propagated exogenous cells and bioactive molecules therefrom. | 03-08-2012 |
| 20120064040 | SERUM FREE CULTURE MEDIUM AND SUPPLEMENT - Provided herein is a chemically defined method of endothelial cell (EC) derivation from embryonic stem cells (ESC). These progenitor cells are capable of low-density lipoprotein uptake, an important function of EC, and also express EC specific markers. By using chemically defined culture conditions, the reproducibility of the derivation as well as eliminate the possibility of unknown contaminants such as undefined growth factors and sundry animal proteins is improved. The differentiated cells can then be applied to a myriad of potential therapies such as tissue engineered vascular grafts, cardiac patches, and pre-vascularized tissue transplants. | 03-15-2012 |
| 20120064041 | Efficient Generation of Neurally-Induced Mesenchymal Stem Cells and Applications Thereof - The present invention provides methods and compositions for reprogramming mammalian mesenchymal stem cells, as well as to methods for using such cells, for example, to prevent or treat various injuries, diseases, and disorders in human and non-human animals. | 03-15-2012 |
| 20120064042 | XENO-FREE GENERATION OF TISSUE-SPECIFIC PROGENITOR CELLS - The invention relates to purified, tissue-specific progenitors, methods of making and using such tissue-specific progenitors. | 03-15-2012 |
| 20120064043 | TISSUE ENGINEERING SCAFFOLDS AND METHODS OF USE - Provided herein are methods of producing a meniscus scaffold to remove material and increase the pore size and porosity therein. In some embodiments, methods include seeding the tissue with allogeneic or autogeneic cells. Bioscaffolds produced by the processes described herein are also provided, as are methods of treating a subject in need of a bioscaffold implant. | 03-15-2012 |
| 20120064044 | METHODS OF TREATING EDEMA RELATED TO ISCHEMIA-REPERFUSION - Methods are described for preventing or reducing edema related to ischemia-reperfusion by treating the organ or tissue being transplanted with an aminoalkyl glucosaminide phosphate. | 03-15-2012 |
| 20120064045 | COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE MYOCARDIAL INJURY DUE TO A VASCULAR INSUFFICIENCY - The described invention provides methods and regimens for treating adverse consequences of a persistent and progressive myocardial injury-due to a vascular insufficiency that occurs early or late in a subject in need thereof, and progressive myocardial injury-preventing compositions that contain a chemotactic hematopoietic stem cell product, and, optionally, an additional active agent. | 03-15-2012 |
| 20120064046 | MAINTENANCE AND PROPAGATION OF MESENCHYMAL STEM CELLS - Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same. | 03-15-2012 |
| 20120064047 | Use of Multipotent Adult Stem Cells in Treatment of Myocardial Infarction and Congestive Heart Failure - The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells in cardiac indications. | 03-15-2012 |
| 20120064048 | TREATMENT OF REPROGRAMMING FACTOR RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A REPROGRAMMING FACTOR - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Reprogramming factor, in particular, by targeting natural antisense polynucleotides of a Reprogramming factor. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Reprogramming factors. | 03-15-2012 |
| 20120064049 | USE OF STEM CELLS FROM HAIR ROOT SHEATHS AND KERATINOCYTE PRECURSOR CELLS FOR THE REGENERATION OF AGED SKIN - The present invention relates to the use of stem cells from hair root sheaths and/or keratinocyte precursor cells for the regeneration of aged but otherwise healthy and non-injured skin for the cosmetic purposes and for the prevention of skin diseases. In addition, the invention is directed to a cosmetic method for the regeneration of aged skin. | 03-15-2012 |
| 20120070418 | STEM CELLS FOR MUSCULOSKELETAL TISSUE REPAIR - The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair different types of damage in musculoskeletal system, with significantly greater efficacy than stem cells derived from adult tissues. These cells are hypoimmunogenic and can be used for allogeneic transplantation to vertebrate hosts having disease and/or damage in musculoskeletal and other tissues. The cells can be administered by direct injection to the site in need of repair or by systemic (e.g., intravenous) administration. The stem cells of the invention are capable of migrating to the sites in need of repair, and of adopting a phenotype most appropriate to the nature of the damage, injury or disease. | 03-22-2012 |
| 20120076759 | TRANSPLANTATION OF BONE MARROW STROMAL CELLS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS). | 03-29-2012 |
| 20120076760 | COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR CROSS-REFERENCE TO RELATED APPLICATIONS - The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium. | 03-29-2012 |
| 20120082649 | PERIVASCULAR MESENCHYMAL PRECURSOR CELLS - Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1 | 04-05-2012 |
| 20120087898 | COMPOSITIONS COMPRISING FEMALE GERMLINE STEM CELLS AND METHODS OF USE THEREOF - The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof. | 04-12-2012 |
| 20120087899 | Heparan Sulphate - Heparan sulphate from bone marrow stroma is disclosed together with the use of heparan sulphate from bone marrow stroma in the differentiation and/or lineage commitment of stem cells. | 04-12-2012 |
| 20120093781 | HUMAN MAST CELL LINE AND USES THEREOF - The subject invention pertains to the development of a novel human mast cell line, USF-MC1. USF-MC1 is a mast cell precursor present in human umbilical cord blood (HUCB) that may be sustained in culture in the absence of exogenous cytokines to serve as a convenient experimental model of human mast cell activation. The SCF-independent human mast cell line USF-MC1 responds to IgE-mediated and IgE-independent stimuli in a way comparable to that of LAD2. USF-MC1 cells are useful for investigation of IgE-mediated activation mechanisms of human mast cells, contributing to the development of effective treatments for allergic disorders and other disorders. The subject invention provides a ready source of human mast cells for research, including pharmacological studies for the screening of various agents, and toxicologic, e.g., for the cosmetic and pharmaceutical industries. The mast cells can also be used as biofactories, for the large-scale production of biomolecules. | 04-19-2012 |
| 20120093782 | Enhanced Hematopoietic Stem Cell Engraftment - The invention relates to improved products, processes, and therapeutic methods relating to hematopoietic stem cells and hematopoietic stem cell transplantation. Included are methods for improving transplant efficiency of cord blood units comprising use of mixtures of expanded CD34 | 04-19-2012 |
| 20120093783 | USE ADIPOSE TISSUE-DERIVED REGENERATIVE CELLS IN THE MODULATION OF INFLAMMATION IN THE PANCREAS AND IN THE KIDNEY - Aspects of the present invention relate to the field of medicine, specifically, the effect of adipose tissue and its components on modulating inflammation. | 04-19-2012 |
| 20120093784 | COMPOSITIONS AND METHODS FOR CONTROLLING STEM CELL AND TUMOR CELL DIFFERENTIATION, GROWTH, AND FORMATION - The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers. | 04-19-2012 |
| 20120100110 | PHYSIOLOGICAL METHODS FOR ISOLATION OF HIGH PURITY CELL POPULATIONS - The disclosure provides methods for isolating a pure or enriched population of differentiated cells derived from stem cells, comprising differentiating the population of stem cells; and migrating the differentiated cells through a porous membrane in a differentiation device to isolate the pure or enriched population of differentiated cells. The disclosure also provides a differentiation device for isolating a pure or enriched population of differentiated cells derived from stem cells, the device comprising a porous membrane; and an extracellular matrix. | 04-26-2012 |
| 20120100111 | METHOD FOR TREATING CANCER - The present invention relates to a method for preventing or treating cancer in an individual comprising administering the individual with a prophylactically or therapeutically effective quantity of a gingival fibroblast-derived product. | 04-26-2012 |
| 20120100112 | MATERIALS AND METHODS FOR USING ADIPOSE STEM CELLS TO TREAT LUNG INJURY AND DISEASE - The present invention provides methods for treating patients with acute or chronic lung disease or injury to the lungs including injury caused by exposure to cigarette smoke other irritants or another cause of pulmonary distress. Typical conditions that can be treated include conditions that cause inflammation in the lung or the death of lung endothelial cells. Treatment of other conditions such as compromised bone marrow function and cachexia can also be treated by the inventive methods disclosed herein. These methods including contacting Adipose Stem Cells (ASC) or media conditioned by contact with ASC (ASC-CM) or various factors secreted by the same including the media or components of the media with lung tissue and cells. In some instances the ASC used is harvested from the patient's own adipose tissue while in other instances the source is an exogenous donor. | 04-26-2012 |
| 20120100113 | DIFFERENTIATION METHOD FOR PRODUCTION OF GLIAL CELL POPULATIONS - The present invention provides methods for generating oligodendrocyte progenitor cells from pluripotent cells, as well as methods for sustaining these oligodendrocyte progenitor cells in relatively pure cultures for long periods of time. The present invention also provides methods for further differentiating these oligodendrocyte progenitor cells into various glial cells. | 04-26-2012 |
| 20120100114 | MESENCHYMAL STEM CELLS AND SUPPORTS FOR TISSUE REGENERATION, REPAIR AND RECONSTRUCTION - Materials and methods for preparing mesenchymal stem cells are described such that the mesenchymal stem cells remain for a longer period of time than would normally be found at a site of tissue healing. The mesenchymal stem cells are pretreated to exhibit osteogenic characteristics and, when combined with extracellular matrix components produced from the pretreated cells, improve tissue healing. Co-administration of the pretreated cells and their secreted extracellular matrix components at an injured site or defect allowed the mesenchymal stem cells to co-localize at or near the injured or defect site for a longer period. The combination improves overall repair of the tissue by extending the retention signal of mesenchymal stem cells. A three-dimensional scaffold containing the pretreated cells with or without addition of the secreted extracellular matrix is also described. The conditioned scaffold is suitable for use in vivo and may be preserved cryogenically prior to use. | 04-26-2012 |
| 20120107281 | COMPOSITIONS AND METHODS FOR MODIFYING CELL SURFACE GLYCANS - Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein. | 05-03-2012 |
| 20120107282 | NEURAL STEM CELL COMPOSITION CAPABLE OF TREATING CANCER AND METHOD OF TREATMENT - Disclosed is a method of treatment of an individual suffering from primary brain tumors (glioma and medulloblastoma) and brain metastases of extracranial cancers using human stem cells encoding therapeutic genes. The method includes giving the individual a clinically acceptable therapeutic reagent by intravascular injection of a pharmaceutical composition. The pharmaceutical composition includes neural stem cells (NSCs) genetically engineered to express a suicide gene (cytosine deaminase) and a cytokine gene (IFN-β) and a pharmaceutical carrier suitable for injection. The NSCs migrate selectively to tumor site in the brain, target tumor cells, kill tumor cells, inhibit tumor growth and thus treat the tumor. | 05-03-2012 |
| 20120107283 | HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES - The present invention relates generally to compositions for wound closure. More specifically, the present invention provides human skin equivalents engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compositions and methods for making human skin equivalents engineered to express exogenous polypeptides. In addition, the present invention provides methods for treatment of wounds with human skin equivalents engineered to express exogenous polypeptides. | 05-03-2012 |
| 20120114613 | DEFINITIVE ENDODERM CELL POPULATIONS - The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. | 05-10-2012 |
| 20120114614 | METHODS AND COMPOSITIONS FOR LONG TERM HEMATOPOIETIC REPOPULATION - Methods for isolating a CD133 | 05-10-2012 |
| 20120114615 | HYDROLYTICALLY DEGRADABLE POLYSACCHARIDE HYDROGELS - Provided are polysaccharide compositions capable of controllable hydrolytic degradation and suitable for controlled release of therapeutic agents. Also provided are methods for synthesizing such compositions and a variety of applications in which the compositions may be used. | 05-10-2012 |
| 20120114616 | OLFACTORY STEM CELLS AND USES THEREOF - Some aspects of this invention are based, at least in part, on the discoveries (i) pluripotent stem cell populations can be obtained from olfactory mucosa, (ii) that various regions of the olfactory mucosa contain pluripotent stem cells, (iii) that cells from these olfactory mucosa derived stem cell populations can be maintained in cultures containing EGF and/or bFGF, (iv) that cells from these olfactory mucosa derived stem cell populations are able to form neurospheres, and/or (v) that cells from these olfactory mucosa derived stem cell populations can differentiate into various lineages, including mesenchymal and neuronal lineages. | 05-10-2012 |
| 20120114617 | PEPTIDE PROMOTING CELL ADHESION AND MIGRATION - Synthetic peptide including the sequence KKLRIKSKEK (SEQ ID 1) or a sequence of identical size, in which the K residue (in position 1) and the R residue (in position 4) are conserved, the sequence being able to bind to the syndecan-1 receptor. | 05-10-2012 |
| 20120114618 | Mesenchymal Stem Cells Producing Inhibitory RNA for Disease Modification - Compositions and methods for delivering a siRNA, dsRNA, or miRNA polynucleotide into a target cell comprising contacting the target cell with a mesenchymal stem cell, which mesenchymal stem cell comprises an exogenous DNA sequence expressing the siRNA or dsRNA polynucleotide, thereby delivering the siRNA, dsRNA, or miRNA polynucleotide to the target cell through a cellular protrusion or a microvesicle. | 05-10-2012 |
| 20120121544 | Method for Efficiently Proliferating and Differentiating Natural Killer Cells from Umbilical Cord Blood - The present invention relates to a method for efficiently proliferating and differentiating natural killer cells (NK cells) from umbilical cord blood, more precisely a method for efficiently proliferating and differentiating natural killer cells from umbilical cord blood comprising the following steps: 1) preparing CD3 negative cells by eliminating CD3 positive T-cells from umbilical cord blood derived mononuclear cells; and 2) culturing the CD3 negative cells after treating various cytokines thereto. The present invention is advantageous in obtaining high purity NK cells in a short period of time by inducing NK cells from CD3 negative cells, compared with the conventional method inducing NK cells from haematopoietic stem cells, and in promoting NK cell proliferation and differentiation by treating different cytokines together, for example by the co-treatment of IL-15 and IL-21. That is, the method of the present invention can induce NK cells with increased anti-cancer cytotoxicity, so that it can be effectively used for anti-cancer cell therapy. | 05-17-2012 |
| 20120121545 | Pharmaceutical Composition For Bone Disease Treatment Or Countering Inflammation, Comprising Cartilage Stem Cells As An Active Principle - Disclosed is a pharmaceutical composition for treating bone disease or countering inflammation containing cartilage stem cells as an active ingredient. The present disclosure provides a novel cell treatment regimen for bone disease and inflammatory disease using the cartilage stem cells as an active ingredient. When the cartilage stem cells of the present disclosure are administered into the articular capsule, the administered cartilage stem cells are highly effective in treating bone disease and inflammatory bone disease since they grow or differentiate into chondrocytes and exhibit an anti-inflammatory activity. Since the cartilage stem cells of the present disclosure do not express histocompatibility antigens which give rise to rejection in tissue or organ transplants, autologous cells or exogenous cells can be used during cell transplantation for treatment of bone disease and inflammation. | 05-17-2012 |
| 20120121546 | Method of Producing Progenitor Cells from Differentiated Cells - The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and/or tissue or organ repair and/or regeneration and/or building are also provides. Methods of using progenitor cells in treatment and prophylaxis of conditions alleviated by administering stem cells or tissue or organ derived from stem cells to a subject or by grafting stem cells or tissue or organ derived from stem cells into a subject or by transplanting stem cells or tissue or organ derived from stem cells into a subject are also provided. Also included are progenitor cells and differentiated cells and/or tissues and/or organs derived therefrom, and kits comprising same. | 05-17-2012 |
| 20120121547 | Methods and compositions for treating chronic wounds - The invention is directed to novel methods for treating wounds, in particular, chronic wounds such as diabetic ulcers. Such methods utilize novel cell and cell-product compositions in combination with insulin. | 05-17-2012 |
| 20120121548 | PRODUCTION OF REPROGRAMMED PLURIPOTENT CELLS - The present invention provides a method of producing a reprogrammed cell, said method comprising exposing Stro-1 | 05-17-2012 |
| 20120121549 | INDUCED PLURIPOTENT STEM CELLS AND METHODS OF USE - The invention relates to the field of stem cells and, specially, to the reprogramming of adult somatic cells; to obtain pluripotent cells by the transfection of specific genes. Thus, the invention provides induced pluripotent stem cells (iPS) and methods of obtaining and using them. | 05-17-2012 |
| 20120121550 | PRODUCTION OF OLIGODENDROCYTES FROM PLACENTA-DERIVED STEM CELLS - The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis. | 05-17-2012 |
| 20120121551 | COMPOSITIONS AND METHODS FOR IMMUNOSTIMULATORY RNA OLIGONUCLEOTIDES - The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-α-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes. | 05-17-2012 |
| 20120121552 | METHODS FOR PURIFYING HEMATOPOIETIC STEM CELLS - Described herein are methods for purifying hematopoietic stem cells. Also described herein are methods for purifying EPCR+ cells. The invention also provides substantially pure isolated hematopoietic stems cells, including EPCR+ hematopoietic stem cells. | 05-17-2012 |
| 20120121553 | SELECTION AND PROPAGATION OF PROGENITOR CELLS - A population of progenitor cells and methods for obtaining and culturing the progenitor cells, that are useful in fields including regenerative medicine (tissue regeneration), transplantation, and cancer research. | 05-17-2012 |
| 20120121554 | HMG-COA SECONDARY METABOLITES AND USES THEREOF - The present invention is directed, among other things, to using secondary metabolites in the mevalonate pathway (such as, for example, HMG) and/or structurally related compounds to mediate biological activities (e.g., for therapeutic applications) and/or as diagnostic agents. In some embodiments, the biological activities comprise one or more pleiotropic effects of statins (such as, for example, angiogenesis, promoting vascular function, anti-inflammatory action, immunomodulation, etc.). Also provided are methods of screening for mevalonate pathway secondary metabolites, methods of producing HMG, and methods of diagnosing comprising measuring amount of mevalonate pathway secondary metabolites. | 05-17-2012 |
| 20120121555 | Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived From Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 05-17-2012 |
| 20120121556 | METHODS OF USING REGENERATIVE CELLS TO PROMOTE WOUND HEALING - Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit. | 05-17-2012 |
| 20120121557 | NEUREGULIN INDUCED PROLIFERATION OF CARDIOMYOCYTES - The present invention provides methods for inducing division of postmitotic mammalian differentiated cardiomyocytes. The invention can be used to repair heart tissue damaged by, for example, myocardial ischemia, hypoxia, stroke, myocardial infarction or chronic ischemic heart disease in vivo. In addition, the methods of the invention can be used to induce heart muscle cells to divide in vitro, in vivo and/or ex vivo, which can then be used in heart tissue repair. | 05-17-2012 |
| 20120128636 | Gingiva Derived Stem Cell And Its Application In Immunodulation And Reconstruction - The present invention relates to gingiva derived messenchymal stem cells (GMSCs). More specifically, the invention provides compositions and methods of using GMSCs to regulate inflammatory response in the setting of normal versus pathological wound healing and to treat inflammatory and/or autoimmune diseases. | 05-24-2012 |
| 20120128637 | Cellular Seeding and Co-Culture of a Three Dimensional Fibroblast Construct - The present invention provides methods for cellular seeding onto three-dimensional fibroblast constructs, three-dimensional fibroblast constructs seeded with muscle cells, and uses therefore. | 05-24-2012 |
| 20120128638 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEART DISEASES - The present invention is related to a pharmaceutical composition comprising cells committed to the generation of heart tissue and at least one pharmaceutically acceptable excipient produced according to internationally recognized standards for pharmaceutical product manufacture, a process for the manufacture of such a pharmaceutical composition and a kit for the administration of said pharmaceutical composition which comprises a container containing said pharmaceutical composition. | 05-24-2012 |
| 20120128639 | In Vitro Production Of Oligodendrocytes From Human Umbilical Cord Stem Cells - The invention provides a method of producing oligodendrocytes by in vitro differentiation of human multi-potent progenitor cells (MLPCs). The method comprises culturing isolated MLPCs on a first surface in a serum-free defined culture medium; replacing the culture medium with serum-free culture medium supplemented with bFGF, EGF and PDGF-AA for approximately 24 hours; changing the cultured MLPCs into the supplemented serum-free culture medium further supplemented with differentiation factors norepinephrine, forskolin. and K252a; establishing a 3D environment by covering the culture with a second surface opposite and spaced apart from the first surface, so as to contain the MLPCs therebetween; and continuing to culture until a majority of the MLPCs have differentiated into oligodendrocytes. Additionally included is a method of treatment for a subject afflicted by a disease characterized by central or peripheral nervous system demyelination, the method comprising transplanting into the subject oligodendrocytes produced according to the method disclosed. | 05-24-2012 |
| 20120128640 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS - An expansion agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy useful for treatment of various disorders is provided. | 05-24-2012 |
| 20120128641 | METHODS AND COMPOSITIONS FOR IMPROVING THE VIABILITY OF CRYOPRESERVED CELLS - The present invention provides polymers and methods for increasing the viability of cryopreserved cells after thawing. Thawing cryopreserved cells in the presence of a polymer such as poloxymer P1 88 or other non-ionic polymers is thought to stabilize the membranes of the cells leading to increased post-thaw viability. Such methods may be used in the processing of cells and tissues for transplantation or for research purposes. Other agents such as antioxidants, vitamins, or osmotic protectants may also be added to cells to improve viability. | 05-24-2012 |
| 20120128642 | POTENCY MARKERS - Methods for identifying trichogenic dermal cells, including dermal papilla cells and dermal sheath cells, capable of inducing hair follicle formation when injected into skin are provided. Biomarkers have been discovered that can be used to detect, identify, and distinguish trichogenic dermal cells, i.e., that are able to induce hair follicle formation, from non-trichogenic skin cells. Populations of enriched trichogenic dermal cells can be produced by selecting for and enriching for dermal cells that the disclosed biomarkers. These enriched trichogenic dermal can be used for inducing hair follicle formation. | 05-24-2012 |
| 20120134965 | METHOD FOR DIFFERENTIATION OF STEM CELLS INTO VASCULAR CELLS AND THE INDUCTION OF ANGIOGENESIS USING THE SAME - The present invention relates to a method for differentiating stem cells into vascular cells by culturing them in the form of a three-dimensional cell cluster and the use of the three-dimensional cell cluster for angiogenesis. Specifically, the present invention teaches a method for differentiating stem cells into vascular cells comprising culturing stem cells by adhering them onto a culture plate with a surface having a hydrophobic property or a culture plate onto which a growth factor is immobilized, wherein the cultured stem cells are later detached from the culture plate as their density increases to form a three-dimensional cell cluster and grown in the form of a three-dimensional cell cluster while differentiating into vascular cells. Also disclosed is the use of a three-dimensional cell cluster composed of the vascular cells differentiated from stem cells by the above method as a cell therapy agent for angiogenesis. | 05-31-2012 |
| 20120134966 | EMBRYONIC STEM CELL SPECIFIC MICRORNAS PROMOTE INDUCED PLURIPOTENCY - The methods of the present application describe that introduction of physiologically relevant miRNAs can enhance or modulate somatic cell reprogramming, generating induced pluripotent stem cells (iPS cells). These miRNAs did not further enhance reprogramming in the presence of cMyc. Furthermore, unlike previously described methods of generating iPS cells, such as through the introduction of genetic elements using viruses, the methods of the present invention reduce the risk of activating oncogenes in the iPS cells. The methods of the invention generate iPS cells that can be free of genetic modifications and thus have greater potential for use as therapeutic agents than those generated by existing methods. | 05-31-2012 |
| 20120134967 | Scaffolds For Cell Transplantation - A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and/or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material. | 05-31-2012 |
| 20120134968 | Composition for manufacturing a scaffold for tissue engineering, and a method of making it - The invention relates to a composition comprising a mixture of at least one degradable hydrogel and at least one kind of degradable and surface cross-linked particle. The at least one kind of degradable and surface cross-linked particle comprises a material which degrades faster than the degradable hydrogel. The composition can further comprise one or more species of living cells. The invention relates also to a method of manufacturing the composition, as well as to a method of manufacturing a scaffold for tissue engineering using the composition. | 05-31-2012 |
| 20120134969 | PHARMACEUTICAL COMPOSITION CONTAINING NUCLEAR FACTOR INVOLVED IN PROLIFERATION AND DIFFERENTIATION OF CENTRAL NEURONAL CELLS - With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided. | 05-31-2012 |
| 20120141428 | MUSCLE-DERIVED CELLS (MDCS) FOR TREATING MUSCLE- OR BONE-RELATED INJURY OR DYSFUNCTION - The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-1, transforming growth factor-a, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins. | 06-07-2012 |
| 20120141429 | Method for stimulating osteogenesis - Nanostructures such as nanowires, nanosprings, nanorods, and nanoparticles, when maintained in contact with a source of bone cells, enhance the proliferation of the bone cells and integration bone into the nanostructures. The nanostructures may or may not be coated with a metal or metal oxide coating and preferably are textured. Such coated or non-coated nanostructures may be utilized on the surface of bone implants to enhance osseointegration of the implants. | 06-07-2012 |
| 20120141430 | Tissue Regeneration Membrane - The present invention relates to a membrane comprising at least one positively charged, synthetic, hydrophobic polymer, at least one hydrophilic polymer and at least one plasticizer; wherein said membrane is flexible and is capable of supporting at least one of cell adherence, cell proliferation or cell differentiation. The invention further relates to use of a membrane of the invention in the preparation of an implantable devices including cell delivery systems, cell growing surfaces and scaffolds. The invention further provides methods for promoting tissue regeneration in a defected tissue region applying membranes of the invention. | 06-07-2012 |
| 20120141431 | METHODS FOR IDENTIFYING, ISOLATING, AND UTILIZING ENDOCRINE PROGENITOR CELLS FROM ADULT HUMAN PANCREAS - The presence of the cell surface marker CD133 or the presence of a glycosylated form of the prominin- | 06-07-2012 |
| 20120141432 | USE OF CATALYTIC ANTIOXIDANT TO PRESERVE STEM CELL PHENOTYPE AND CONTROL CELL DIFFERENTIATION - Methods are disclosed herein for maintaining stem cells in an undifferentiated state in vitro. The methods include contacting the stem cells with an effective amount of a catalytic antioxidant. Also disclosed are methods for the increasing the number of stem cells in vitro while maintaining the stem cells in an undifferentiated state. The methods include contacting the stem cells with an effective amount of a catalytic antioxidant and an effective amount of one or more growth factors that promotes the expansion of the stem cells. | 06-07-2012 |
| 20120141433 | Vaporized Stem Cell Derivatives for Topical and Other Therapeutic Uses - The invention provides compositions of vaporized stem cell derivatives and methods for their use and manufacture in the treatment of skin conditions and other therapeutic applications. Stem cell derivatives comprising vaporized stem cells, stem cell factors and/or stem cell microvesicles are disclosed and contemplated as being within the scope of the invention. The invention finds use in medical, rejuvenative and cosmetic applications. | 06-07-2012 |
| 20120141434 | Methods for Selecting Expanded Stem Cell Populations - A method and criteria are provided for selecting expanded hematopoietic stem cell populations for allogenic transplantation, the selected cell populations having high probability of engraftment and positive clinical outcome. | 06-07-2012 |
| 20120141435 | USE OF OLIVE LEAF EXTRACTS IN A PHARMACEUTICAL COMPOSITION FOR INDUCING ANGIOGENESIS AND VASCULOGENESIS - The invention relates to the use of olive leaf extracts for producing a pharmaceutical composition capable of inducing angiogenesis and vascularization. In general, the composition can be used for therapeutic applications in order to promote the differentiation of stem cells into endothelial progenitor cells (EPCs) and/or mature endothelial cells, as well as to induce the vessel formation from said endothelial cells. The vascularization-inducing angiogenic composition of the invention is intended for, inter alia, cardiovascular disease, ischemic processes in general, ulcers, and wound healing in both human and veterinary medicine. | 06-07-2012 |
| 20120141436 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY - Compositions and methods for providing an enriched population of mature, glucose-responsive insulin secreting cells, and for modulating insulin expression, activity and secretion in a subject. | 06-07-2012 |
| 20120141437 | Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 06-07-2012 |
| 20120141438 | CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 06-07-2012 |
| 20120141439 | BIOARTIFICAL LUNG - Presented is an airway organ bioreactor apparatus, and methods of use thereof, as well as bioartificial airway organs produced using the methods, and methods of treating subjects using the bioartificial airway organs. | 06-07-2012 |
| 20120148536 | METHODS AND STORAGE AND RETRIEVAL OF FUNCTIONAL MATURE RETINAL CELLS - A method for the isolation, storage and retrieval of mature retinal cells is disclosed. The Method is applicable to adult mammalian cone cells, and more particularly human cone cells, and to healthy as well as pathological or otherwise altered cone cells. A kit for the isolation, storage and retrieval of mature retinal cells is also described. | 06-14-2012 |
| 20120148537 | METHODS TO ENHANCE CELL MIGRATION AND ENGRAFTMENT - A method is provided to functionally select cells with enhanced characteristics relevant to cell engraftment, including both spontaneous migration and directional migration towards specific chemo-attractants. The cells are preferably undifferentiated cells, such as mesenchymal stem cells. The method involves entrapping or encapsulating the cells in a biomaterial barrier, optionally inducing cell migration, and selecting cells that migrated through the barrier. The cells selected by this method have better migratory activities and enhanced in vivo engraftment to injured tissues when they are supplemented systemically. | 06-14-2012 |
| 20120148538 | COMPOSITION FOR HARD TISSUE FORMATION AND, DENTIN OR PULP REGENERATION CONTAINING AMELOBLAST, APICAL BUD CELL OR ITS CULTURE FLUID AS AN ACTIVE INGREDIENT - The present invention relates to a composition for hard tissue formation and dentin, or dental pulp regeneration comprising ameloblasts, apical bud cells, or its culture fluid as an active ingredient. The ameloblasts, apical bud cells, or its culture fluid promotes the differentiation of odontoblasts, human dental pulp stem cells and osteoblasts, increases DSPP promoter activity, induces dental pulp regeneration of dental pulp stem cells, and induces hard tissue formation significantly in vivo, so that they can be effectively used for a composition for promoting hard tissue formation and dentin or dental pulp regeneration. | 06-14-2012 |
| 20120148539 | Methods and Compositions for Tissue Engineering - Disclosed herein are methods and compositions for promoting endochondral bone formation. The invention includes methods of promoting endochondral bone formation by down-regulating the expression of the DIO2 gene or the activity of the deiodinase protein. The invention also includes methods of up-regulating the activity of the FGFR3, ADAMTS9, HEY1, HAS3, and/or MFI2 genes and/or the activity of the expression products of those genes to promote endochondral bone formation. The invention also includes compositions of BMP-7 and agonists of FGFR3, ADAMTS9, HEY1, HAS3, and/or MFI2 proteins. Compositions can further include mesenchymal stem cells. | 06-14-2012 |
| 20120148540 | PROLIFERATED CELL LINES AND USES THEREOF - The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferating cells in culture by contacting cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation. The proliferated cells of the subject invention are useful for cell therapy, cell/gene therapy, biological production of molecules, and as in vitro models for research, toxicity testing, and drug development. | 06-14-2012 |
| 20120148541 | COMPOSITIONS AND METHODS TO GENERATE PILOSEBACEOUS UNITS - The disclosure describes compositions and methods to generate pilosebaceous units. In one aspect, a biocompatible scaffold and an effective amount of dermal and epidermal precursor cells is described. | 06-14-2012 |
| 20120148542 | MACHINE PERFUSION WITH COMPLEMENT INHIBITORS - Methods for perfusing one or more organs, tissues or the like (hereinafter “organs”) with a composition comprising at least one complement inhibitor to sustain, maintain or improve the viability of the organs before and/or during transplantation. | 06-14-2012 |
| 20120148543 | SYNTHETIC GRAFT - The present invention relates to the use of a plastically-compacted collagen gel as a substrate for the growth of corneal cells, particularly limbal corneal epithelial stem cells. Cells grown on such a substrate can be cultured to produce artificial ocular epithelia which can be used in ocular toxicity testing or for transplantation. | 06-14-2012 |
| 20120148544 | Treatment of Diseases and Disorders Using Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 06-14-2012 |
| 20120148545 | CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 06-14-2012 |
| 20120148546 | PERICYTE PROGENITOR CELLS AND METHODS OF GENERATING AND USING SAME - Provided are methods of isolating pericyte progenitor cells from pluripotent stem cells such as embryonic stem cells and induced pluripotent stem cells, by isolating CD105+, CD73+ and/or CD105+/CD73+ cells from embryoid bodies and optionally by enriching the cells with CD31− cells. Also provided are methods of isolating endothelial cells and co-derivation of pericyte and endothelial cells progenitor cells from embryoid bodies, and methods of differentiating same for various therapeutic applications. In addition, the invention provides an isolated pericyte progenitor cell having an expression marker signature of CD105+/CD73+CD31−/alpha SMA−/CD133−/Flk-1−. | 06-14-2012 |
| 20120148547 | COMBINATION OF VITAMIN E AND BETA-GLYCOSPHINGOLIPIDS IN COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING HEPATIC DISORDERS - The present invention relates to combined compositions comprising a combination of at least one natural or synthetic beta-glycolipid and at least one tocopherol (vitamin E). The invention further provides methods and kits using said combined compositions for treating and preventing hepatic disorders, specifically, liver insult cause by hepatotoxic drugs or caused by any one of infectious, metabolic, toxic, immune, or perfusion or blood flow related hepatic injury. | 06-14-2012 |
| 20120148548 | Joint Repair Using Mesenchymal Stem Cells - A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue. | 06-14-2012 |
| 20120156175 | COMPOSITION FOR INDUCING MIGRATION OF NEURAL STEM CELLS CONTAINING PERIOSTIN AS EFFECTIVE INGREDIENT - A novel use of periostin, and more particularly a composition for inducing the migration of neural stem cells, which contains periostin or a periostin-secreting cell as an active ingredient, based on the discovery of a novel function of periostin that induces the migration of neural stem cells. Periostin induces the migration of neural stem cells, and thus the composition for inducing the migration of neural stem cells, which contains periostin or periostin-secreting cells as an active ingredient, can be used in various applications based on neural stem cells. A pharmaceutical composition containing suicide gene-expressing neural stem cells and periostin allows the neural stem cells to effectively migrate to tumor tissues, and thus can be used as a cell therapeutic agent for treating cancer. Also, the pharmaceutical composition containing neural stem cells and periostin has improved effects on the stimulation of regeneration of nerve cells and the treatment of neural diseases. | 06-21-2012 |
| 20120156176 | THERMORESPONSIVE, BIODEGRADABLE, ELASTOMERIC MATERIAL AND USES THEREFOR - Provided are novel biocompatible copolymers and compositions comprising the copolymers. The copolymers are non-toxic and typically have an LCST below 37° C. Compositions comprising the copolymers can be used for wound treatment, as a cellular growth matrix or niche and for injection into cardiac tissue to repair and mechanically support damaged tissue. The copolymers comprise numerous ester linkages so that the copolymers are erodeable in situ. Degradation products of the copolymers are soluble and non-toxic. The copolymers can be amine-reactive so that they can conjugate with proteins, such as collagen. Active ingredients, such as drugs, can be incorporated into compositions comprising the copolymers. | 06-21-2012 |
| 20120156177 | METHODS AND DEVICES FOR HARVESTING AND PROCESSING CONNECTIVE TISSUE PRECURSOR CELLS FROM AUTOLOGOUS FAT - Methods and devices are disclosed for repairing injured, infected, or otherwise damaged connective tissues. Such repairs use injectable combinations of: (i) stromal precursor cells, which can be obtained from a patient via liposuction, and which can mature rapidly into muscle, ligament, tendon, or other types of connective tissue cells that are needed at a repair site; and (ii) platelets, which will accelerate and promote a repair process, and which can be obtained from the patient's blood. When mixed together, stromal precursor cells and platelet cells will act synergistically, to generate new tissue which can replace or repair damaged tissue. Devices and methods are disclosed for processing an already-centrifuged layer of “spun fat”, obtained from a liposuction extract, to remove unhelpful materials and concentrate the stromal precursor cells, before the stromal cells are mixed with platelet cells for injection into a patient. | 06-21-2012 |
| 20120156178 | TREATMENT OF PEYRONIES DISEASE - The invention relates to systems and therapeutic methods to reduce plaque causing Peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque. Plaque disruption is enhanced by the mechanical force of the high pressure, followed by the enzymatic action of collagenase. Another approach uses collagenase as a pretreatment, followed by addition of adipose-derived stem cells ADSCs. The initial collagenase injection breaks down collagen (often more type III than type I in Peyronie's) to provide short term benefit. The longer-term benefit is provided by introduction of ADSCs to the plaque, which can produce cytokines and other signals for revascularization and restoration of normal penile tissue. The resulting combination advantageously reduces the bulk of the plaque early on with ongoing reduction through the revascularization of the tissue. In addition, the treatment provides an advantageous shift of elastin and collagen ratios. | 06-21-2012 |
| 20120156179 | METHOD FOR INDUCING EXTENDED SELF-RENEWAL OF FUNCTIONALLY DIFFERENTIATED SOMATIC CELLS - The present invention relates to a method for inducing proliferation of functionally differentiated somatic cells comprising a step of activating expression of a Myc family gene and a KIf family gene in said cells or contacting said cells with a Myc family protein and a KIf family protein. | 06-21-2012 |
| 20120156180 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRABBE AND OTHER NEURODEGENERATIVE DISEASES - Provided are compositions and methods for the treatment of Krabbe and other neurodegenerative diseases, including storage diseases such as GM1 gangliosidosis, Niemann-Pick disease, Tay-Sachs disease, Sandhoff disease, metachromatic leukodystrophy, Canavan disease, Pelizaeus-Merzbacher disease, and storage conditions facilitated by aging of lysosomal functions, which are associated with psychosine (and/or other storage material)-mediated axonal degeneration. Compositions and methods employ (1) one or more inhibitor of a phos-photransferase activity of one or more kinase(s) such as, for example, CDK5, P38, jnk, src, CK2, PKC, GSK3α and β; (2) one or more inhibitor of a phosphotransferase activity of one or more phosphatase(s) such as, for example, the Ser/Thr protein phosphatase PP1 and Tyr protein phosphatase PP2; one or more inhibitor of a caspase/calpain activity of one or more caspases such as caspase 3 and calpains such as calpain 1 and 2; and (4) one or more inhibitor of a sodium/calcium exchange protein such as, for example, NCX1. Inhibitors include small molecules, including the GSK3β inhibitor L803 and the NCX1 inhibitor flecainide, and siRNA molecules that downmodulate cellular levels of one or more mRNA, including siRNA that are capable of downmodulating the cellular expression of PP1. Inhibitors disclosed can cross the blood-brain barrier and, thus, are available to the central nervous system (CNS) and effective in reducing psychosine-mediated axonal degeneration. | 06-21-2012 |
| 20120156181 | THERAPEUTIC AGENT FOR LIVER-RELATED DISEASES - The present invention relates to a therapeutic agent for liver-related diseases, comprising adipose tissue-derived multilineage progenitor cells; and others. | 06-21-2012 |
| 20120164110 | DIFFERENTIALLY METHYLATED REGIONS OF REPROGRAMMED INDUCED PLURIPOTENT STEM CELLS, METHOD AND COMPOSITIONS THEREOF - Provided herein are differentially methylated regions (DMRs) of reprogrammed iPS cells (R-DMRs) and methods of use thereof. The invention provides methods for detecting and analyzing alterations in the methylation status of DMRs in iPS cells, somatic cells and embryonic stem (ES) cells as well as methods for reprogramming somatic cells to generate an iPS cell. | 06-28-2012 |
| 20120164111 | NOVEL POST-TRANSLATIONAL FIBRINOGEN VARIANTS - Provided are novel post-translationally modified variants of fibrinogen, in particular human fibrinogen, a method for producing and isolating said variants, as well as methods of using the variant, in particular in systemic and local/topical treatment and prophylaxis of excessive bleeding. | 06-28-2012 |
| 20120164112 | EXPANDING HEMATOPOIETIC STEM CELLS - A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome. | 06-28-2012 |
| 20120164113 | ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USE THEREOF - Methods of treating using adipose tissue using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within adipose tissue and thereby obtain mesenchymal or stromal vascular fractions for use in human subjects are provided. These methods preferably do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased numbers of the cells which constitute the mesenchymal or stromal vascular fractions (about 10-fold greater) than methods which use collagenase to isolate these cells. | 06-28-2012 |
| 20120164114 | TREATMENT OF IMMUNE-RELATED DISEASES AND DISORDERS USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of using amnion derived adherent cells, and populations of, and compositions comprising, such cells, in the modulation of an immune response. In various embodiments, the immune response is graft-versus-host disease, an allergy, asthma, or an immune-related disease or disorder, e.g., an autoimmune disease. | 06-28-2012 |
| 20120164115 | Methods related to surgery - The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 06-28-2012 |
| 20120164116 | COMPOSITIONS AND METHODS FOR TISSUE FILLING AND REGENERATION - Injectable compositions are provided which include both a living cellular and a filler conducive to cell growth. The compositions are capable of providing both immediate tissue filling and long term tissue regeneration. | 06-28-2012 |
| 20120164117 | METHODS OF GENERATING HUMAN CARDIAC CELLS AND TISSUES AND USES THEREOF - A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting the cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, and culture, medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype. | 06-28-2012 |
| 20120171168 | METHOD FOR TREATING PANCREATITIS WITH MESENCHYMAL STEM CELLS - The present application discloses a method of treating pancreatitis by administering to the patient mesenchymal stem cells that are obtained by manipulating a biological sample of cells, which includes multi-lineage stem cells, progenitor cells, other marrow stromal cells: allowing the sample of cells to settle in a container; transferring supernatant from the container to another container; and isolating cells from the supernatant, which has comparatively lower density in the sample. | 07-05-2012 |
| 20120171169 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING, OR ALLEVIATING BONE OR CARTILAGE DISEASES - The present invention provides pharmaceutical compositions, methods of preparations, and uses for treatments, preventions or alleviation of bone and cartilage diseases. The present invention discloses methods and pharmaceutical compositions comprising adipose tissue-derived stem cells, platelet rich plasma, calcium chloride, and hyaluronic acid for the treatments, preventions, or alleviation of bone diseases; methods and a pharmaceutical compositions further comprising of dexamethasone for treatments, preventions, or alleviation of cartilage diseases. | 07-05-2012 |
| 20120171170 | TREATMENT OF COLLAGEN GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A COLLAGEN GENE - The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Collagen gene, in particular, by targeting natural antisense polynucleotides of a Collagen gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Collagen genes. | 07-05-2012 |
| 20120171171 | Methods and Compositions for In Vitro and In Vivo Chondrogenesis - Aspects of the present invention include methods and compositions related to the production, identification and use of embryonic progenitor cell lines that are capable of undergoing chondrogenesis. A number of exemplary chondrogenic cell lines derived from primordial stem cells are disclosed. The chondrogenic cell lines described herein are robust, can expand for >40 passages, and have site-specific purity, thus providing for compositions and methods of producing diverse cartilage types with unique molecular compositions for use in research and therapy. | 07-05-2012 |
| 20120171172 | Methods Of Engineering Neural Tissue - In one aspect, the invention is a method of generating a neural conduit comprising neurotrophic factors and angiogenic factors ex vivo comprising introducing cells that enhance nerve regeneration into an isolated, naturally occurring epineural sheath, thereby producing a combination. The combination is maintained under conditions in which neurotrophic factors and angiogenic factors are expressed in the epineural sheath, thereby generating a neural conduit comprising neurotrophic factors and angiogenic factors ex vivo. In another aspect, the invention is directed to neural conduits such as a neural conduit produced by the methods provided herein. In other aspects, the invention is directed to an article of manufacture. | 07-05-2012 |
| 20120171173 | PROCESS FOR PRODUCTION OF NATURAL KILLER CELLS - A process for producing a cell mass containing natural killer cells, characterized by involving a step of carrying out the expansion culture of a cell mass containing natural killer cells and/or cells capable of being differentiated into natural killer cells in the presence of a biological response modifier and cells that has been so treated as to lose a proliferation capability, and others. | 07-05-2012 |
| 20120171174 | Methods of Inducing Tissue Regeneration - Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from postmitotic tissues derived from patients with diseases allows for a characterization of pathways that have gone awry in these diseases and for screening of drugs that will ameliorate or correct the defects as a means of novel drug discovery. Also provided are kits for performing these methods. | 07-05-2012 |
| 20120171175 | METHODS FOR TREATING REFRACTORY INFECTIONS IN NEUTROPENIC INDIVIDUALS - The invention is based, in part, on the discovery of a novel cell-based immunotherapy that can recapitulate neutrophil functions in neutropenic individuals afflicted with a microbial infection. The therapeutic methods of the invention are broadly applicable to treat any infection in a neutropenic individual, including infections caused by bacteria, fungi, protozoa, and viruses. The methods of the invention represent a practical, rapid cell-based immunotherapy for refractory infections comprising compositions of activated, irradiated HL-60 cells. | 07-05-2012 |
| 20120177610 | Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins - Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health. | 07-12-2012 |
| 20120177611 | Elastic substrates and methods of use in cell manipulation and culture - Methods are provided for the ex vivo manipulation of cells, stem cells and other reproductive cells, by manipulating the cells in a container or device comprising an elastic substrate, wherein the substrate has an elasticity that mimics the elasticity of a native microenvironment of the cell. | 07-12-2012 |
| 20120177612 | METHODS FOR TREATING AND/OR REVERSING NEURODEGENERATIVE DISEASES AND/OR DISORDERS - The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder. | 07-12-2012 |
| 20120177613 | USE OF GINGIVAL FIBROBLASTS FOR VASCULAR CELL THERAPY - The invention relates to the use of gingival fibroblasts for obtaining a cellular composition for treating arterial-remodelling pathology, for example an aneurysm, post-cryoplasty stenosis and restenosis, an aortic dissection or atherosclerosis. | 07-12-2012 |
| 20120177614 | CULTURE METHOD TO OBTAIN AND MAINTAIN A PURE OR ENRICHED POPULATION OF MAMMALIAN NEURAL STEM CELLS AND/OR NEURAL/PROGENITOR CELLS THAT ARE PRONE TO DIFFERENTIATE INTO OLIGODENDROCYTE-LINEAGE CELLS IN VITRO - An isolated expandable human neural stem or progenitor cell wherein the cell is a progenitor cells or stem cell, maintains its capability to differentiate into neurons, astrocytes, and oligodendrocytes, maintains its ability to differentiate into oligodendrocyte lineage cells efficiently throughout subsequent passages, and the cell expresses at least cell surface antigens CD133 and CD140α. Also provided is a method of in vitro culturing an expandable neural progenitor or stem cell isolated from a mammalian central nervous system, and the culture itself, wherein said cell maintains its capability to differentiate into neurons, astrocytes, and oligodendrocytes and its ability to differentiate into oligodendrocyte-lineage cells efficiently. In addition, a method of treating a condition caused by a loss of myelin or a loss of oligodendrocytes is provided as is a composition comprising an isolated expandable neural stem cell or one cultured by the methods of the invention. | 07-12-2012 |
| 20120177615 | TISSUE PRESERVATION SYSTEM - The present invention provides a method and apparatus for tissue, such as an allograft, storage and preservation for extended periods of time at room temperature in a sterile tissue culture chamber. The invention further provides a process for maintaining the sterility of tissue using the apparatus as described. | 07-12-2012 |
| 20120177616 | Methods for augmentation collection of placental hematopoietic stem cells and uses thereof - The subject matter of this invention is a novel method to augment the process of obtaining populations of placental hematopoietic stem and progenitor cells for use in medical practices. A method of augmentation of stem cells collection from placenta is claimed comprising the steps of (a) infusing placental vessels cell preservation compound and a with a composition containing blockers of cell adhesion receptors, (b) incubating said placenta for a sufficient period of time, (c) placing placenta in a containment with sufficient intensity of electromagnetic or ultrasound field for a sufficient period of time; (d) eluting cell suspension from placental vessels, (e) collecting cell suspension and harvesting cells. Invention further claims a method of treatment a disease by means of administering therapeutic composition containing said placental-derived hematopoietic stem cells. | 07-12-2012 |
| 20120177617 | Composition for Providing Relief of Undesired Body Odours - The present invention relates to a composition suitable for providing relief of undesired body odours caused by consumption of food and/or drink, comprising chlorella, parsley and a mouth refreshing agent. In particular, the food and/or drink comprises a plant, or part thereof, which belongs to the Allium genus. More in particular, the food and/or drink comprises onion, shallot, leek, bunching onion, chive, preferably garlic, any part thereof, or any combination thereof. The composition according to the invention comprises an amount of chlorella between 2 and 30, preferably between 4 and 25, more preferably between 5 and 20 percent by weight of the total composition. | 07-12-2012 |
| 20120177618 | HEMATOPOIETIC STROMAL PROGENITOR CELLS AND USES THEREOF - The invention provides compositions and methods for modulating disease using hematopoietic stromal progenitor cells derived from hematopoietic tissues. The invention further provides methods for isolating, storing and culturing hematopoietic stromal progenitor cells. | 07-12-2012 |
| 20120177619 | COMPOSITION COMPRISING A HAEMATIC COMPONENT AND ITS USE FOR THE TREATMENT OF DEGENERATIVE JOINT DISEASE - A composition including a haematic component, including blood cell components and heat shock protein, also including PDRN, alternatively including a thickener or mesenchymal stem cells, the process for preparing it, as well as its use for the treatment of degenerative joint disease. | 07-12-2012 |
| 20120183509 | MICROGLIAL PRECURSOR CELLS FOR THE TREATMENT OF MALIGNANT NEOPLASMS OF THE CENTRAL NERVOUS SYSTEM - Microglial precursor cells for use in the treatment of malignant neoplasms of the central nervous system. A method of treating malignant neoplasms of the central nervous system comprising administering a pharmaceutically effective amount of microglial precursor cells to a subject in need thereof. | 07-19-2012 |
| 20120183510 | HIGH-THROUGHPUT CULTURE AND TRANSFER DEVICE AND METHOD - A method and device for creating hanging drop cell aggregates. The method and device includes a plurality of pegs that allow for high throughput culture of aggregates. Also disclosed are means of transferring formed aggregates to various destinations, such as well plates, scaffolding, tissues, or wounds. Use of the device permits aggregates to be prepared or created in larger quantities than current methods, and allows for them to be transferred more efficiently. | 07-19-2012 |
| 20120189583 | PLACENTAL OR UMBILICAL CORD TISSUE COMPOSITIONS - The present invention encompasses compositions, including solutions, gels, and pastes, manufactured from amniotic membrane, umbilical cord membrane, or both. The present invention also encompasses methods of making such compositions, and methods of using the compositions to treat conditions of the eye. | 07-26-2012 |
| 20120189584 | GENIPIN CROSS-LINKED FIBRIN GELS - The invention provides a genipin cross-linked fibrin gel. The ratio of genipin to fibrin in the gel ranges from about 0.1:1 to about 10:1 (genipin:fibrin). The gel can be hydrogel. Also provided is method for repairing tissue defects by administering the gel to site of tissue defect. | 07-26-2012 |
| 20120189585 | METHOD AND COMPOSITION FOR RESTORATION OF AGE-RELATED TISSUE LOSS IN THE FACE OR SELECTED AREAS OF THE BODY - This application relates to stem cell compositions and methods for restoring age-related tissue loss in the face and other selected areas of the body. In a first embodiment, a composition includes stem cells and hyaluronic acid as a carrier wherein the stem cells are peripheral blood stem cells, bone marrow-derived blood stem cells, or mesenchymal stem cells. | 07-26-2012 |
| 20120189586 | Human Placental Derived Extracellular Matrix and Uses Therof - The invention provides a composition for use in tissue augmentation of a human. More specifically, the composition comprises collagen extracted from human placenta and a bulking agent. Furthermore, the invention discloses methods of augmenting soft tissue comprising the use of the compositions described herein. | 07-26-2012 |
| 20120189587 | CELL SHEET FOR TISSUE REPAIR AND BIO-ARTIFICIAL TISSUE ENGINEERING, METHOD OF PRODUCING THE SAME AND METHOD OF USING THE SAME - Disclosed is a cell sheet for tissue repair and bio-artificial tissue engineering. The cell sheet comprises treated stem cell embedded in its self-secreted extracellular matrix (ECM) and formed a cell sheet. The cell sheet is formed by isolating the stem cell, expanding the stem cell and treating the stem cell with biological factors or factors leading to the production of biological factors, to induce its differentiation, production of extracellular matrix and formation of a cell sheet in vitro. The cell sheet is used as a bioactive material or as an acellular material for the promotion of tissue repairs or used to form a bio-artificial organ for tissue replacement. The cell sheet of the present invention eliminates the need to use scaffolds for cell delivery. The cell sheet facilitates in vivo cell transplantation and provides some tensile mechanical strength for bearing early mechanical load during tissue repair. | 07-26-2012 |
| 20120189588 | Compositions and Methods for Implantation of Processed Adipose Tissue and Processed Adipose Tissue Products - The invention provides compositions and methods for the preparation of processed adipose tissue. The invention further provides methods of use of the processed adipose tissue. | 07-26-2012 |
| 20120189589 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 07-26-2012 |
| 20120189590 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 07-26-2012 |
| 20120189591 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 07-26-2012 |
| 20120189592 | METHODS FOR PROMOTING HEMATOPOIETIC RECONSTITUTION - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 07-26-2012 |
| 20120189593 | METHODS FOR PROMOTING HSC ENGRAFTMENT - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 07-26-2012 |
| 20120189594 | METHODS FOR PROMOTING HSC SELF-RENEWAL - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 07-26-2012 |
| 20120195860 | LATENT NEURAL STEM CELL POPULATION - The present invention relates to a latent neural stem cell population which is capable of activation by membrane depolarization of a neural cell population, isolation and culture of same, and uses thereof. | 08-02-2012 |
| 20120195861 | METHODS AND COMPOSITIONS FOR PRODUCING GERM CELLS FROM PERIPHERAL BLOOD DERIVED GERMLINE STEM CELLS - Described herein are the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof. | 08-02-2012 |
| 20120195862 | BIOMECHANICAL INDUCTION OF HEMATOPOIESIS - The present invention provides methods and compositions for increasing the hematopoietic potential of a population of hematopoietic progenitor cells, vascular cells, and or hemogenic endothelium, by exposing the cells to at least one external biomechanical stimulus. More specifically, the application of shear stress to hematopoietic progenitor cells or endothelial cells stimulates hematopoiesis, with or without concurrent application of other extrinsic modulators of hematopoiesis. | 08-02-2012 |
| 20120195863 | METHODS AND APPARATUS FOR ENHANCED RECOVERY OF CELLS AND OF CELL-ENRICHED MATRIX FROM TISSUE SAMPLES - This document describes methods and an apparatus for recovery of a cell-enriched matrix and cells (e.g., regenerative cells) from a tissue sample. In some embodiments, at least two rounds of acceleration and deceleration are performed. | 08-02-2012 |
| 20120201786 | METHODS FOR THE USE OF STEM CELLS AND STEM CELL FACTORS IN THE TREATMENT OF SKIN CONDITIONS - The invention provides a method for treating a skin condition in a patient through the administration of stem cells, stem cell factors or a combination thereof. The invention finds use in medical (i.e. healing) and cosmetic applications. Disclosed herein are methods for making and using compositions of stem cells and stem cell factors, and methods for their use in the treatment of skin conditions. | 08-09-2012 |
| 20120201787 | TREATMENT OF SPINAL CORD INJURY AND TRAUMATIC BRAIN INJURY USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of treating spinal cord and traumatic brain injuries using cells from amnion, and populations of such cells, referred to herein as “amnion derived adherent cells” (“AMDACs”). | 08-09-2012 |
| 20120201788 | METHODS AND COMPOSITIONS FOR CELL THERAPY - Improved methods of cell therapy are provided using cells and tissues that are histocompatible with a human or non-human transplant recipient. The cells and tissues for transplant produced by the present invention exhibit a youthful state and can be committed to specific cell lineages to better infiltrate and proliferate at a desired target, e.g., a tissue, or organ in need of cell replacement therapy. For providing cells and tissues for transplant to a non-human mammal, the cells and tissues can be isolated from a gastrulating embryo produced by same-species nuclear transfer. | 08-09-2012 |
| 20120201789 | GENERATION OF CHOROID PLEXUS EPITHELIAL CELLS FROM HUMAN EMBRYONIC STEM CELLS - Choroid plexus epithelial cells are generated in a culture medium using embryonic stem cells and adding an effective amount of bone morphogenetic protein and/or other members of the transforming growth factor beta (TGF-beta) superfamily. Generation of such choroid plexus epithelial cells are confirmed using a combination of genetic markers, antibodies, histology inspection, functional assays, and integration into the endogenous choroid plexus in mice. | 08-09-2012 |
| 20120201790 | PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME - An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells. | 08-09-2012 |
| 20120201791 | METHODS OF TREATING DISEASES OR CONDITIONS USING MESENCHYMAL STEM CELLS - The present invention provides a method of treating or preventing a disease or condition in a patient comprising intravenously administering a therapeutically effective amount of mesenchymal stem cells to the patient, wherein the disease or condition is osteoarthritis, rheumatoid arthritis, multiple sclerosis, stroke, ulcerative colitis, psoriasis, Hashimoto's thyroiditis, atopic dermatitis, allergic rhinitis, chronic obstructive pulmonary disease with bronchial asthma or hearing loss. | 08-09-2012 |
| 20120207714 | COMPOSITIONS COMPRISING VASCULAR AND MYOCYTE PROGENITOR CELLS AND METHODS OF THEIR USE - The invention provides compositions of adult cardiac vascular progenitor cells (VPCs) and adult cardiac myocyte progenitor cells (MPCs) useful for the treatment of various cardiac conditions. The invention also encompasses methods of generating a biological bypass, repairing damaged myocardium, and treating or preventing hypertensive cardiomyopathy and heart failure with the compositions of the invention. Methods of isolating the cardiac progenitor cells are also disclosed. | 08-16-2012 |
| 20120207715 | METHODS AND SYSTEMS FOR STORING AND PROLONGING VIABILITY OF MATRIX DEPENDENT CELLS - The present invention relates to systems, methods and storage media for preserving and prolonging viability of cultured matrix dependent cells including multipotent progenitor cells, such as mesenchymal stem cells. The system and method of the invention are effective in ambient room temperature and apply during storage and shipment of said cells. The storage medium of the invention comprises fibrin microbeads and culture medium, and is suitable for the maintenance and storage of matrix dependent cells. The methods of the invention comprise use of said system, for attaching matrix dependent cells to fibrin microbeads in culture so as to form cell-fibrin microbead complexes. | 08-16-2012 |
| 20120207716 | Cardiac Muscle Regeneration Using Mesenchymal Stem Cells - Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 08-16-2012 |
| 20120207717 | Methods for treating inhalation injury - The invention is directed to methods for treating inhalation injuries. Such methods utilize novel cell compositions such extraembryonic cytokine secreting (ECS) cells and Amnion-derived Multipotent Progenitor (AMP) cells and novel cellular factor-containing solution compositions such as extraembryonic cell-derived cellular cytokine solution, Amnion-derived Cellular Cytokine Solution (ACCS), and physiologic cytokine solution (PCS) compositions. The compositions may be used alone or in combination with each other and/or other agents. | 08-16-2012 |
| 20120207718 | THIN SHELL GRAFT FOR CARTILAGE RESURFACING - An articular cartilage shell graft is designed to treat the arthritic population for which current biologic treatments are insufficient and as a biological-stage repair for intervention before prosthetic knee arthroplasty. | 08-16-2012 |
| 20120207719 | PANCREATIC ISLET-LIKE CELLS - The generation of pancreatic islet-like cells from isolated monocyte-derived stem cells (MDSCs) is provided. MDSCs may be differentiated into pancreatic islet cells by contacting the MDSCs with a differentiation factor or factors. Compositions comprising pancreatic islet cells and methods of using them are also provided. | 08-16-2012 |
| 20120207720 | LAMININS, DERIVATIVES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE - In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The method, in yet another embodiment, is used to prevent or reduce muscle damage or injury. In specific implementations of these methods, the laminin or composition that includes laminin is administered in a therapeutically effective amount. In some implementations, the laminin is a complete laminin protein. In other implementations, the laminin is a laminin fragment, a laminin derivative, or a laminin analogue. | 08-16-2012 |
| 20120213743 | TREATMENT OF PERIPHERAL VASCULAR DISEASE USING UMBILICAL CORD TISSUE-DERIVED CELLS - Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease with umbilical derived cells and fibrin glue are disclosed. | 08-23-2012 |
| 20120213744 | COMPOSITIONS AND METHODS FOR MODULATING STEM CELLS AND USES THEREOF - There are provided compositions and methods for modulating stem cell division decisions, in particular, division symmetry. It has been demonstrated that wnt7a acts through frizzled-7 receptor expressed on the surface of adult stem cells, e.g. satellite stem cells, to activate the planar cell polarity (PCP) pathway, thereby promoting symmetrical expansion of stem cells. The compositions and methods of the invention are useful, for example, in modulating stem cell division symmetry in vitro and in vivo, in replenishing and expanding the stem cell pool, and in promoting the formation, maintenance, repair and regeneration of tissue. | 08-23-2012 |
| 20120213745 | SERUM-FREE MEDIA AND THEIR USES FOR CHONDROCYTE EXPANSION - The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential. | 08-23-2012 |
| 20120213746 | METHOD AND COMPOUNDS FOR GENERATION OF iPSCs - The present invention is based on the seminal concept of combining genomics and chemical biology to identify new agents useful for induced pluripotent stem cell (iPSC) generation. The invention provides a method of generating an iPSC utilizing agents that antagonize a cell specific gene or upregulate expression or activity of a nuclear reprogramming gene, as well as a method of screening for such agents. | 08-23-2012 |
| 20120213747 | METHODS OF REDUCING TRANSPLANT REJECTION AND CARDIAC ALLOGRAFT VASCULOPATHY BY IMPLANTING AUTOLOGOUS STEM CELLS - The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively, bone marrow progenitor cells (BMPCs) isolated from the recipient may also be used. | 08-23-2012 |
| 20120213748 | CARDIOMYOCYTES AND METHODS OF PRODUCING AND PURIFYING CARDIOMYOCYTES - The invention provides methods for producing a culture of cardiomyocytes and cultures of cardiomyocytes. Exemplary methods of producing and cultures of cardiomyocytes include a population of cells including cells having spontaneous and periodic electrical activity, and/or including nodal, sino-atrial or pacemaker cells; immature cardiomyocytes (cardiomyoblasts); mature contractile cardiomyocytes; or a mixed population of two or more of such cells. | 08-23-2012 |
| 20120213749 | CARDIAC MUSCLE REGENERATION USING MESENCHYMAL STEM CELLS - Disclosed is a method for repairing or regenerating blood vessels in the heart of an individual, method of stimulating or promoting angiogenesis in the heart of an individual, or method of stimulating or promoting vascular endothelial growth factor (VEGF) expression in a heart of an individual by administering to the individual an effective amount of mesenchymal stem cells. These cells can be administered as a liquid injectable. | 08-23-2012 |
| 20120213750 | USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA - Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae. | 08-23-2012 |
| 20120219529 | Silver ion compositions of pectins - The invention described herein relates to the preparation of silver compounds prepared from pectin and pectin derivatives and the process for preparing them. The silver derivatives thus prepared are amenable for use in the preparation of medical and/or veterinary dressings or implants. | 08-30-2012 |
| 20120219530 | COMPOSITIONS AND METHODS OF GENERATING REPROGRAMMED ADIPOCYTE CELLS AND METHODS OF USE THEREFORE - The invention provides therapeutic compositions comprising reprogrammed adipocyte cells for use as disease models, therapeutic compositions comprising reprogrammed adipocyte cells for the treatment of conditions characterized by a reduction in cell number or tissue mass, and methods of generating such cells. | 08-30-2012 |
| 20120219531 | Microcarriers for Stem Cell Culture - The present application discloses a method of generating bone tissue in vivo comprising implanting cells into a human or animal at a location where bone growth is required, wherein the cells have been obtained by the in vitro suspension culture of mesenchymal stem cells attached to microcarriers. | 08-30-2012 |
| 20120219532 | METHODS AND COMPOSITIONS FOR INCREASED SAFETY OF STEM CELL-DERIVED POPULATIONS - The invention provides methods and compositions relating to differentiated cell populations that derive from pluripotent stem cells. The methods relate to reducing the number of residual stem cells present in such populations. The compositions include differentiated cell populations that contain reduced number of stem cells or that contain no stem cells. Pluripotent stem cells may be reduced in number and/or function through exposure to low oxygen levels. | 08-30-2012 |
| 20120219533 | METHOD FOR THE PRODUCTION OF INTERVERTEBRAL DISK CELL TRANSPLANTS AND THEIR USE AS TRANSPLANTATION MATERIAL - The invention relates to a method for the in vitro production of intervertebral disk cartilage cell transplants from affected intervertebral disk tissue from patients and to the use thereof as transplantation material for the treatment of affected intervertebral disks. The invention also relates to a three-dimensional, vital, and mechanically stable intervertebral disk cartilage tissue and to the use thereof as transplantation material for the treatment of affected intervertebral disks and in testing active substances. Furthermore, the invention is directed to the surgical technique for incorporating the transplants, to the intervertebral disk cell transplants and intervertebral disk cartilage tissues produced, and to therapeutic formulations, e.g. injection solutions, which include said tissue and said cell transplants. | 08-30-2012 |
| 20120219534 | FREEZE-DRIED FIBRIN MATRICES AND METHODS FOR PREPARATION THEREOF - Methods for treating diseased or injured tissue by implanting into the tissue at a site of the disease or injury a porous freeze-dried fibrin matrix formed from plasma proteins. The proteins include fibrinogen cleaved by the action of thrombin at varying concentrations sufficient to cleave the fibrinogen and Factor XIII. The matrix has less than 10% residual moisture and is devoid of exogenous anti-fibrinolytic agents, plasminogen and of organic chelating agents. Alternatively, the plasma proteins comprise partially purified plasma proteins that are devoid of plasminogen. | 08-30-2012 |
| 20120219535 | CRANIAL NEURAL CREST STEM CELLS AND CULTURE CONDITION THAT SUPPORTS THEIR GROWTH - Provided herein is a method to isolate a cranial neural crest stem cell and novel compositions containing the cell. Also provided are compositions and methods to clonally expand the population and differentiate the cells into various phenotypes. Therapeutic methods for the compositions are further provided. | 08-30-2012 |
| 20120225038 | MYELOID-DERIVED SUPPRESSOR CELLS GENERATED IN VITRO - A population of myeloid-derived suppressor cells and the culture procedure to obtain these in vitro starting with bone marrow cells of mice, other animals and human beings, in the presence of specific cytokine combinations used to determine concentrations, is provided. | 09-06-2012 |
| 20120225039 | TISSUE ENGINEERED CARTILAGE, METHOD OF MAKING SAME, THERAPEUTIC AND COSMETIC SURGICAL APPLICATIONS USING SAME - Cartilage has been constructed using biodegradable electrospun polymeric scaffolds seeded with chondrocytes or adult mesenchymal stem cells. More particularly engineered cartilage has been prepared where the cartilage has a biodegradable and biocompatible nanofibrous polymer support prepared by electrospinning and a plurality of chondocytes or mesenchymal stem cells dispersed in the pores of the support. The tissue engineered cartilages of the invention possess compressive strength properties similar to natural cartilage. Methods of preparing engineered tissues, including tissue engineered cartilages, are provided in which an electrospun nanofibrous polymer support is provided, the support is treated with a cell solution and the polymer-cell mixture cultured in a rotating bioreactor to generate the cartilage. The invention provides for the use of the tissue engineered cartilages in the treatment of cartilage degenerative diseases, reconstructive surgery, and cosmetic surgery. | 09-06-2012 |
| 20120225040 | METHODS AND COMPOSITIONS FOR TREATING TISSUE USING SILK PROTEINS - Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications. | 09-06-2012 |
| 20120225041 | METHODS AND COMPOSITIONS FOR TREATING TISSUE USING SILK PROTEINS - Compositions for forming a self-reinforcing composite biomatrix, methods of manufacture and use therefore are herein disclosed. Kits including delivery devices suitable for delivering the compositions are also disclosed. In some embodiments, the composition can include at least three components. In one embodiment, a first component can include a first functionalized polymer, a second component can include a second functionalized polymer and a third component can include silk protein or constituents thereof. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition can include a biologic encapsulated, suspended, disposed within or loaded into a biodegradable carrier. In some embodiments, the composition(s) of the present invention can be delivered by a dual lumen injection device to a treatment area in situ, in vivo, as well as ex vivo applications. | 09-06-2012 |
| 20120230959 | ENHANCEMENT OF PLACENTAL STEM CELL POTENCY USING MODULATORY RNA MOLECULES - Provided herein are methods of producing enhanced placental stem cells by modulatory RNA molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response. Further provided herein are compositions comprising said enhanced placental stem cells. | 09-13-2012 |
| 20120230960 | PHARMACEUTICAL KITS COMPRISING MESENCHYMAL STEM CELLS - A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse. | 09-13-2012 |
| 20120230961 | MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 09-13-2012 |
| 20120230962 | GP100-SPECIFIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein. | 09-13-2012 |
| 20120230963 | Methods and Compositions for Expanding, Identifying, Characterizing and Enhancing Potency of Mammalian-Derived Glial Restricted Progenitor Cells - Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided. | 09-13-2012 |
| 20120230964 | THE ISOLATION AND CHARACTERISATION OF HEPARAN SULPHATES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT AND STEM CELL CULTURE MEDIA SUITABLE FOR CONDITIONS ASSOCIATED WITH BONE REPAIR - Heparan sulphates isolated from male and female murine liver, their characterisation and use in pharmaceutical compositions, methods of treatment and in stem cell culture media suitable for conditions associated with bone repair. | 09-13-2012 |
| 20120237484 | Generation of Functional Basal Forebrain Cholinergic Neurons From Stem Cells - The present invention provides method, compositions, and systems for generating basal forebrain cholinergic neurons (BFCNs) using FGF8, SHH, LXH8, GBX1, or vectors encoding these ligands, as well as using such BFCNs to treat neurological disorders such as Alzheimer's disease. | 09-20-2012 |
| 20120237485 | Trabecular Meshwork Stem Cells - Provided herein are isolated populations of multipotent stem cells capable of differentiating into trabecular meshwork (TM) cells, methods of obtaining an isolated population of TM cells, and isolated populations of TM cells obtained therefrom. Compositions, kits, and devices comprising the isolated populations of multipotent stem cells or TM cells are also provided herein. Further provided are methods of using the compositions, kits, and devices for decreasing intraocular pressure in an eye, increasing cell density in a trabecular meshwork of an eye, increasing outflow of aqueous humor from an eye, or treating or preventing a medical condition in a subject. | 09-20-2012 |
| 20120237486 | MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 09-20-2012 |
| 20120237487 | MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 09-20-2012 |
| 20120237488 | LSC AND HSC SIGNATURES FOR PREDICTING SURVIVAL OF PATIENTS HAVING HEMATOLOGICAL CANCER - A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis. | 09-20-2012 |
| 20120244128 | Perivascular Stem Cell Composition For Bone - Embodiments of the present invention provide an osteogenic composition comprising perivascular stem cells or induced pluripotent cells (iPS) and an osteogenic agent and methods of making and using the same. | 09-27-2012 |
| 20120244129 | PLURIPOTENT STEM CELL THAT CAN BE ISOLATED FROM BODY TISSUE - Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue. | 09-27-2012 |
| 20120251504 | PLURIPOTENT STEM CELLS OBTAINED FROM DENTAL PULP - The present invention relates to pluripotent stem cells obtained from the dental pulp of patients of different ages, the invention furthermore comprises cultures of said cells, means for obtaining them and pharmaceutical compositions comprising them, as well as their application in tissue regeneration. | 10-04-2012 |
| 20120251505 | HUMAN LYMPHOID TISSUE INDUCER (LTi) CELL COMPOSITIONS AND METHODS OF USE - The invention provides human lymphoid tissue inducer (LTi) cells, methods of producing human lymphoid tissue inducer (LTi) cells, and methods of using human lymphoid tissue inducer (LTi) cells. Such methods include treatment of a subject that would benefit from human lymphoid tissue inducer (LTi) cells, for example, an immunocompromised or immunosuppressed subject. | 10-04-2012 |
| 20120251506 | METHODS AND COMPOSITIONS RELATING TO NEURONAL CELL AND TISSUE DIFFERENTIATION - The invention relates to methods for isolating and purifying specific types of neurons, such as cortical or other projection neurons including corticospinal motor neurons, subcerebral projection neurons, and callosal projection neurons. The invention also relates to genes that are specific for particular neuronal subtypes, and the use of such genes in genetic/molecular control of cell development. The isolated cells and subtype-specific genes also have uses in diagnostics, therapeutics, and screening assays for pharmaceutical molecules. | 10-04-2012 |
| 20120251507 | COMPOSITIONS FOR PREVENTING CARDIAC ARRHYTHMIA - Disclosed herein are compositions and methods for treating or preventing a cardiac arrhythmia in a subject. | 10-04-2012 |
| 20120251508 | CYTOCOMPATIBLE ALGINATE GELS - The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy. | 10-04-2012 |
| 20120258081 | METHODS OF TREATING PROLIFERATIVE DISEASES - Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided. | 10-11-2012 |
| 20120258082 | PRODUCTION OF IFN-LAMBDA BY CONVENTIONAL DENDRITIC CELLS AND USES THEREOF - In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and/or eCD8+ cDCs in the prevention and/or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and/or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and/or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and/or eCD8+ cDCs in a subject suffering from an infectious disease or cancer. | 10-11-2012 |
| 20120258083 | PLACENTAL VASCULAR LOBULE STEM CELLS - The present invention provides isolated populations of stem and progenitor cells from fetal vascular lobules of the placenta. The isolated populations of stem and progenitor cells of the invention express the markers CD144, CD105, and/or CD31 and lack expression of the hematopoietic-lineage marker CD45. Under specific conditions, cells of the invention may function as endothelial precursors and may provide therapeutic preparations, for example, in the treatment of ischemia. | 10-11-2012 |
| 20120263681 | COMPOSITION COMPRISING CELL AND BIOCOMPATIBLE POLYMER - It is an object of the present invention to provide a cell-containing composition capable of suppressing the outflow of the cells after transplantation and improving the survival rate of the cells. The present invention provides a composition which comprises any of bone marrow stromal cell-derived neural precursor cells, bone marrow stromal cell-derived Schwann cells, or bone marrow stromal cell-derived skeletal muscle cells; and a biocompatible polymer. | 10-18-2012 |
| 20120263682 | CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 10-18-2012 |
| 20120263683 | PREPARATION FOR REPAIRING CARTILAGE TISSUE, ESPECIALLY ARTICULAR CARTILAGE DEFECTS - Provided herein are preparations for repairing enchondral or osteochondral defects ( | 10-18-2012 |
| 20120263684 | Novel methods for modulating inflammatory and/or immune responses - The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents. | 10-18-2012 |
| 20120263685 | ANTI-TUMOR COMPOSITION COMPRISING HUMAN-DERIVED ADULT STEM CELLS - The present invention relates to a composition for preventing or treating cancer, which contains one or more selected from the group consisting of human adult stem cells and their secretory products, and to a method of preventing or treating cancer using the same. Particularly, the invention relates to the use of adult stem cells that exhibit the effect of preventing or treating cancer by activating the immune system. The human adult stem cells of the invention are administered by a simple method such as intravenous injection and are highly valuable as a cell therapeutic agent for treating various cancer (tumor) diseases. Thus, the adult stem cells will be highly useful in anticancer studies. | 10-18-2012 |
| 20120263686 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual. | 10-18-2012 |
| 20120263687 | Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 10-18-2012 |
| 20120269774 | ALLOGENEIC STEM CELL TRANSPLANTS IN NON-CONDITIONED RECIPIENTS - Methods, cells, and compositions of matter are disclosed for performing stem cell transplants in patients that have not been previously immunosuppressed. Specific disclosed are methods of matching, methods of treating the stem cell graft, and use of engraftment-assisting cells and agents. | 10-25-2012 |
| 20120269775 | Adipose Stromal Stem Cells For Tissue And Vascular Modification - Methods are provided for promoting angiogenesis in a mammal, such methods including the administration of therapeutic quantity of adipose-derived stromal cells to a mammal such that therapeutic angiogenesis occurs. | 10-25-2012 |
| 20120269776 | PRODUCTIONS OF ARTIFICIAL TISSUES BY MEANS OF TISSUE ENGINEERING USING AGAROSE-FIBRIN BIOMATERIALS - The present invention is encompassed in the field of biomedicine and more specifically tissue engineering. It relates specifically to an in vitro method for preparing an artificial tissue, to the artificial tissue obtainable by said method and to the use of this artificial tissue to partially or completely increase, restore or replace the functional activity of a damaged tissue or organ. | 10-25-2012 |
| 20120269777 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 10-25-2012 |
| 20120269778 | METHODS OF GENERATING NEURAL STEM CELLS - The present disclosure provides methods of generating neural stem cells from differentiated somatic cells. The present disclosure also provides induced neural stem cells generated using a subject method, as well as differentiated cells generated from a subject induced neural stem cell. A subject neural stem cell, as well as differentiated cells derived from a subject neural stem cell, is useful in various applications, which are also provided in the present disclosure. | 10-25-2012 |
| 20120269779 | MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF USING SAME - The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders. | 10-25-2012 |
| 20120269780 | Method For Preparing an Acellular Organic Tissue of Human or Animal Origin For Revitalization - The invention concerns a method for the preparation of an acellular organic tissue for revitalization, in particular for the introduction of living cells, comprising a stage in which the acellular organic tissue ( | 10-25-2012 |
| 20120269781 | METHOD FOR PROLIFERATING HAIR FOLLICLE STEM CELLS - The present invention relates to a method of proliferating follicular stem cells in high yield, and more particularly, to a method of proliferating follicular stem cells in large amounts by culturing the cells using a specific medium containing a specific concentration of a Rho-associated kinase (ROCK) inhibitor and to a medium which is used in the method. | 10-25-2012 |
| 20120269782 | MATERIALS AND METHODS FOR GENERATING PLURIPOTENT STEM CELLS - The present invention relates to a method of reprogramming a somatic cell to produce an induced pluripotent stem (iPS) cell which is capable of differentiating into somatic cells derived from ectoderm, mesoderm or endoderm. The present invention also relates to the aforementioned iPS cells, methods of generating and maintaining iPS cells, and methods of using iPS cells. | 10-25-2012 |
| 20120269783 | COMPOSITION CONTAINING AUTOLOGOUS MONONUCLEAR CELLS AND PIG COLLAGEN SCAFFOLD IN PASTE FORM AND ITS USE IN THE PREPARATION OF A MEDICAMENT FOR SURGICAL TREATMENT - Composition including autologous mononuclear cells supported on scaffold chosen from the group including lyophilized scaffold or pre-constituted scaffold in the form of membrane or tissue, with possible addition of platelet gel, as well as use of said composition for the preparation of medicaments for surgical treatments. | 10-25-2012 |
| 20120269784 | CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for method of treating a subject having reduced cardiac function or cardiac disease by administering adult bone marrow-derived stem cells to an individual. In some embodiments, the subject is a myocardial infarction patient or congestive heart failure patient. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 10-25-2012 |
| 20120269785 | SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN CANINES - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection. | 10-25-2012 |
| 20120269786 | SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN FELINES - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection. | 10-25-2012 |
| 20120269787 | SYSTEMIC, ALLOGENIC STEM CELL THERAPIES FOR TREATMENT OF DISEASES IN EQUINES - A method for treating preselected diseases comprising the steps of providing a therapeutic dose of a mesenchymal stem cell composition, the mesenchymal stem cell composition comprising mesenchymal stem cells harvested from at least one tissue selected from the group consisting of placental tissue, bone marrow, dental tissue, testicle tissue, and dermal tissue; and systemically administering the mesenchymal stem cell composition to the patient suffering from a preselected disease or diseased state through an intravenous injection. | 10-25-2012 |
| 20120276061 | CD117+ Cells and Uses Thereof - The present invention provides compositions comprising CD117+ cells and methods for using the same in allograft. In some aspects of the invention, methods are provided for prolonging allograft survival in a subject by administering CD117+ cells. | 11-01-2012 |
| 20120276062 | METHODS FOR TREATING ISCHEMIC TISSUE - Compositions and methods for treating ischemic tissue are provided herein. | 11-01-2012 |
| 20120276063 | PRIMING OF PLURIPOTENT STEM CELLS FOR NEURAL DIFFERENTIATION - Methods and composition for differentiation of pluripotent stem cells are provided. For example, in certain aspects methods including priming stem cells for neural differentiation in a culture medium essentially free of growth factors such as FGF and TGFβ. As an advantage, the neural cells may be provided with improved consistency and purity. | 11-01-2012 |
| 20120276064 | METHODS AND COMPOSITIONS FOR REJUVENATION AND EXPANSION OF STEM CELLS - The regenerative potential of stem cells is enhanced in vitro and in vivo by inhibition of the p38 MAPK signaling pathway. | 11-01-2012 |
| 20120276065 | Dendritic Cell Populations that are Enriched for Cells that Bear the BDCA-1 Antigen - The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby. | 11-01-2012 |
| 20120276066 | Peptide Linked Cell Matrix Materials for Stem Cells and Methods of Using the Same - Biostructures that comprises modified alginates entrapping one or more stem cells are discloses. The modified alginates comprise at least one alginate chain section to which is bonded by covalent bonding at least one cell attachment peptide. Pluralities of stem cells are also disclosed. Methods of preventing death of stem cells and cells differentiated there from are disclosed. Methods of preparing a plurality of stem cells are disclosed. Methods of treating an individual who has a degenerative disease, such as a neurological disorder, or injury involving nerve damage by administering stem cells to said individual are disclosed. | 11-01-2012 |
| 20120276067 | Assay for the Prediction of Therapeutic Effectiveness of Mesenchymal Stromal Cells, and Methods of Using Same - The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations. | 11-01-2012 |
| 20120276068 | METHOD FOR TREATING CHRONIC NERVE TISSUE INJURY USING A CELL THERAPY STRATEGY - A method for treating a degenerative or traumatic injury to a nerve tissue or the brain by administering at or near the injury site a composition containing adherent bone marrow stem cells suspended in a pharmaceutically acceptable liquid in an amount effective to elicit axonal regeneration or re-myelination at the site of injury. | 11-01-2012 |
| 20120276069 | HYDROGELS BASED ON POLYMERS OF DEXTRAN TYRAMINE AND TYRAMINE CONJUGATES OF NATURAL POLYMERS - The invention relates to composition comprising a dextran-tyramine conjugate and a conjugate selected from the group consisting of chondroitin sulphate-tyramine, collagen-tyramine, chitosan-tyramine, chitosan-phloretic acid, gelatine-tyramine, heparan sulphate-tyramine, keratin sulphate-tyramine, hyaluronic acid-tyramine and heparin-tyramine. | 11-01-2012 |
| 20120276070 | Induced Pluripotent Stem Cells and Related Methods - The present invention provides materials and methods to reprogram adult stem cells without transfection of foreign genes through the employment of appropriate environmental factors. Cells made via these processes are also provided. Methods to use the pluripotent cells are also provided. | 11-01-2012 |
| 20120282226 | Tissue Products Derived From Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase - The present invention provides tissues derived from animals, which lack any expression of functional alpha 1,3 galactosyltransferase (alpha-1,3-GT). Such tissues can be used in the field of xenotransplantation, such as orthopedic reconstruction and repair, skin repair and internal tissue repair or as medical devices. | 11-08-2012 |
| 20120282227 | METHODS AND COMPOSITIONS FOR THE INDUCTION OF HYPOTHERMIA - Provided herein are methods for the induction of hypothermia and the treatment of clinical insults in a subject through the administration of a regulated hypothermic multidrug combination. The compositions or multidrug combinations of the invention comprise a regulated hypothermic compound or a dopamine receptor agonist; a vasoactive compound; and an antiarrhythmic compound or a serotonin 5-HT3 receptor antagonist. Additional agents can be included in the composition including at least one of an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. The invention further recognizes that a two phase delivery of multidrug combinations, a rapid infusion of the composition to induce hypothermia followed by a period of slow infusion to maintain the hypothermic state for a sustained period of time. Using the two phase delivery method of the invention, the composition may comprise ethanol and, optionally, at least one of a vasoactive compound, an antiarrhythmic compound, a serotonin 5-HT3 receptor antagonist, an antioxidant, a vitamin, N-acetylcysteine, and an antihyperglycemic compound. This two phase delivery method can be used to deliver any of the compositions of the invention and provides significant benefits to a patient. | 11-08-2012 |
| 20120282228 | METHOD OF PRODUCING PROGENITOR CELLS FROM DIFFERENTIATED CELLS - The present invention provides a method of producing progenitor cells, such as cells capable of being differentiated into a plurality of different cell types, from differentiated cells. Methods of using progenitor cells in differentiation and/or tissue or organ repair and/or regeneration and/or building are also provides. Methods of using progenitor cells in treatment and prophylaxis of conditions alleviated by administering stem cells or tissue or organ derived from stem cells to a subject or by grafting stem cells or tissue or organ derived from stem cells into a subject or by transplanting stem cells or tissue or organ derived from stem cells into a subject are also provided. Also included are progenitor cells and differentiated cells and/or tissues and/or organs derived therefrom, and kits comprising same. | 11-08-2012 |
| 20120288480 | CELL POPULATION COMPRISING ORBITAL FAT-DERIVED STEM CELLS (OFSCS) AND THEIR ISOLATION AND APPLICATIONS - The invention relates to a cell population comprising minimal volume of orbital fat-derived stem cells (OFSCs) and its isolation, purification, characterization and application. The OFSCs of the invention are capable of multilineage development and express at least CD90 and CD 105 but not hematopoietic and epithelial markers. The OFSCs have colony formation ability and multi-lineage differentiation ability. They possess at least osteogenic, chondrogenic and adipogenic differentiation capacity; besides mesodermal tri-linage differentiation, the OFSCs have corneal epithelial differentiation potential. Taking together, orbital fat tissues are a novel source for multi-potent stem cells which possess multiple therapeutic potential. Therefore, the OFSCs can be used in cell therapy and tissue engineering. | 11-15-2012 |
| 20120288481 | TREATMENT OF HEART DISEASE - Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy. | 11-15-2012 |
| 20120288482 | THERAPEUTIC AGENT (Y-39983) FOR CORNEAL ENDOTHELIAL DYSFUNCTION - The present invention aims to provide a means for effectively and conveniently treating diseases wherein corneal endothelial cells poor in proliferative capacity in vivo are damaged. The present invention provides a therapeutic agent for corneal endothelial dysfunction containing (R)-(+)-N-(1H-pyrrolo [2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide or a pharmacologically acceptable salt thereof (compound (Ia)) as active ingredient, an agent for promoting adhesion of corneal endothelial cells, containing compound (Ia), a culture medium for corneal endothelial cells, containing the agent for promoting adhesion, an implant for corneal endothelial keratoplasty, containing corneal endothelial cells, scaffold and compound (Ia), and a production method of a corneal endothelial preparation, including a step of cultivating corneal endothelial cells using the culture medium. | 11-15-2012 |
| 20120294834 | REGENERATION OF, REESTABLISHING FUNCTION IN AND REPLACING MICROVASCULATURE IN ORGANS AND TISSUES - The invention provides compositions and methods involving the use of endothelial progenitor cells (EPC) to re-generate and/or reestablish a functioning microvasculature in damaged or ischemic organs and tissue. The invention also provides compositions and methods using EPC for replacing lost function in organ and tissue that is damaged, ischemic, or scarred. Such compositions and methods may find utility in, for instance, organs or tissues that have been damaged due to lack of vasculature. | 11-22-2012 |
| 20120294835 | SUBSTITUTED PYRIDINES AND PYRIMIDINES - Provided is a compound of formula (I), and/or salt thereof, | 11-22-2012 |
| 20120294836 | HIGH YIELD METHOD AND APPARATUS FOR VOLUME REDUCTION AND WASHING OF THERAPEUTIC CELLS USING TANGENTIAL FLOW FILTRATION - The present invention provides processes for aseptically processing live mammalian cells in an aqueous medium to produce a cell suspension having a cell density of at least about 10 million cells/mL and cell viability of at least about 90%. These methods comprise a step of reducing the volume of the medium using a tangential flow filter (TFF) having a pore size of greater than 0.1 micron, during which step the trans-membrane pressure (TMP) is maintained at less than about 3 psi and the shear rate is maintained at less than about 4000 sec | 11-22-2012 |
| 20120294837 | METHODS OF ISOLATING AND CULTURING MESENCHYMAL STEM CELLS - Provided herein is a relatively pure population of mesenchymal stem cells (MSCs) expressing the Notch 2 receptor (Notch 2+ a MSCs). Also provided is a method of isolating from a subject a population of Notch 2+ MSCs and a method of culturing the population of Notch 2+ MSCs. Also provided is a method of treating a subject with a disorder associated with a deficiency or defect in cells of mesenchymal lineage comprising administering a population of Notch 2+ MSCs to the subject. | 11-22-2012 |
| 20120301436 | POLYELECTROLYTE COMPLEX GELS AND SOFT TISSUE AUGMENTATION IMPLANTS COMPRISING THE SAME - The invention provides a polyelectrolyte complex gel comprising a chitosan and a γ-polyglutamic acid (γ-PGA) having a molecular weight from about 1 kDa to about 400 kDa or the salt thereof, wherein the chitosan and the γ-PGA are swollen with an aqueous solution. Also provided is a soft tissue augmentation implant, comprising a polyelectrolyte complex gel of the invention as a carrier or a filler and an optional additive. The polyelectrolyte complex gel and the soft tissue augmentation implant containing the same has long degradation time and better supportability so as to provide good maintenance for soft tissue. | 11-29-2012 |
| 20120301437 | Technologies, Methods, and Products of Small Molecule Directed Tissue and Organ Regeneration from Human Pluripotent Stem Cells - Pluripotent human embryonic stem cells (hESCs) hold great potential for restoring tissue and organ function, which has been hindered by inefficiency and instability of generating desired cell types through multi-lineage differentiation. This instant invention is based on the discovery that pluripotent hESCs maintained under defined culture conditions can be uniformly converted into a specific lineage by small molecule induction. Retinoic acid induces specification of neuroectoderm direct from the pluripotent state of hESCs and triggers progression to neuronal progenitors and neurons efficiently. Similarly, nicotinamide induces specification of cardiomesoderm direct from the pluripotent state of hESCs and triggers progression to cardiac precursors and cardiomyocytes efficiently. This technology provides a large supply of clinically-suitable human neuronal or cardiac therapeutic products for CNS or myocardium repair. This invention enables well-controlled efficient induction of pluripotent hESCs exclusively to a specific clinically-relevant lineage for tissue and organ engineering and regeneration, cell-based therapy, and drug discovery. | 11-29-2012 |
| 20120301438 | Reprogramming Blood Cells to Pluripotent and Multipotent Stem Cells - The present invention is based on the seminal discovery that cord blood (CB) and adult bone marrow (BM) CD34+ cells can be reprogrammed to early stem cells. The invention provides the reprogramming of CB and adult bone marrow (BM) CD34+ cells from subjects without any pre-treatment. Provided are methods for reprogramming blood cells of a subject. Also provided are methods of disease modeling and methods of generating subject-specific differentiated cells. In addition, the invention provides methods of identifying an agent that alters a function of subject-specific differentiated cells as well as isolated pluripotent or multipotent stem cells reprogrammed from blood cells. | 11-29-2012 |
| 20120301439 | INHIBITION OF CHOROIDAL NEOVASCULARIZATION - Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration. | 11-29-2012 |
| 20120301440 | METHODS AND MATERIALS FOR INCREASING POTENCY OF CELLS - Disclosed herein are methods and materials for producing a more developmentally potent cell from a less developmentally potent cell. Specifically exemplified herein are methods that comprise introducing an expressible dedifferentiating polynucleotide sequence into a less developmentally potent cell, wherein the transfected less developmentally potent cell becomes a more developmentally potent cell capable of differentiating to a less developmentally potent cell of its lineage of origin or a different lineage. | 11-29-2012 |
| 20120301441 | DEXTRAN-HYALURONIC ACID BASED HYDROGELS - The invention provides a copolymer of hyaluronic acid (HA) grafted with a dextran-tyramine (Dex-TA) conjugate. | 11-29-2012 |
| 20120301442 | TREATMENT OF BONE FRACTURE - The use of mesenchymal stem cells cultured in the presence of HS-2 for the treatment of bone fracture. Repair of bone fracture using such cells is enhanced compared with the treatment of bone fracture using mesenchymal cells cultured without HS-2. These mesenchymal stem cells may be formulated in a pharmaceutical composition and injected directly into tissues surrounding the fracture or used in a biocompatible implant or prosthesis. | 11-29-2012 |
| 20120301443 | METHODS FOR DEVELOPING ENDOTHELIAL CELLS FROM PLURIPOTENT CELLS AND ENDOTHELIAL CELLS DERIVED - Disclosed herein is a method for developing human endothelial cells (ECs) from human embryonic stem cells (ESCs). The method is based on inhibition of TGF signaling following mesoderm induction and during vascular differentiation of hESC-derived cells. Also disclosed herein is a substantially pure and stable population of ECs that maintains a high degree of proliferation and phenotypic homogeneity for extended culture periods. Related pharmaceutical compositions and therapeutic methods are also disclosed. A reporter hESC line useful for tracking the development of ECs is also provided. | 11-29-2012 |
| 20120301444 | Amnion-derived cell compositions, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies. | 11-29-2012 |
| 20120301445 | TOOLS FOR ISOLATING AND FOLLOWING CARDIOVASCULAR PROGENITOR CELLS - The present invention provides new methods and tools for isolating pluripotent cardiovascular progenitors (MCPs), by transiently detecting the cell-surface expression of genes upregulated by Mesp1. Cells obtained by the method and there uses in research and clinical settings are also part of the invention. Using genome wide transcriptional analysis, the inventors found upstream and downstream members of the Mesp1 signaling pathway, which form potential new targets for both therapy and for the identification of MCPs and differentiation of MCPs into cardiovascular cells. This invention provides novel and important insights into the molecular mechanisms of cardiovascular specification and provides potential novel methods for dramatically increasing the number of cardiovascular cells for cellular therapy in humans. | 11-29-2012 |
| 20120301446 | COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION FOR TREATMENT OF NEUROLOGICAL DISORDERS - The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as glial cells) into neurons without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the transducible compositions thereof. | 11-29-2012 |
| 20120308528 | Methods and Compositions for Gene Inactivation - Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. | 12-06-2012 |
| 20120308529 | COMPOSITIONS COMPRISING ADIPOSE STEM CELLS - The present invention relates to adipose stem cell compositions, methods for making said compositions, kits comprising said compositions and uses of said compositions in the therapy of diseases. | 12-06-2012 |
| 20120308530 | Materials Composition and Methods to Control Neural Progenitor and Stem Cell Attachment, Proliferation and Guide Cell Differentiation - This invention disclosure provides culture surface compositions and methods that control the NPCs and NSCs, and/or MSCs to either largely maintain their phenotypes, or differentiate on these culture surfaces in guided lineage. The culture surface composition can be constructed to contain either OH functional groups, or —NH | 12-06-2012 |
| 20120308531 | Expansion of Stem Cells in Hollow Fiber Bioreactors - The invention is directed to producing large numbers of cells using hollow fiber bioreactor technology. The cells are non-embryonic stem, non-germ cells that can be characterized by one or more of the following: extended replication in culture and markers of extended replication, such as telomerase, markers of pluripotentiality, and broad differentiation potential, without being transformed. | 12-06-2012 |
| 20120308532 | COMPOSITION FOR THE TREATMENT OF A BONE FRACTURE - There is disclosed a composition formed by a reaction of at least one component A and at least one component B, wherein component A is selected from the group consisting of a compound comprising at least two thiol-groups and a disulfide derivative of a compound comprising at least two thiol groups, and wherein component B is a compound comprising at least two vinyl groups, for the manufacture of an implant for the treatment of a bone fracture. Advantages include that the adhesive patch formed by the composition will be solid in body fluid upon curing and will exhibit excellent mechanical strength. Advantages include that the composition is biocompatible, the material can be applied in small and inaccessible areas, the process requires less surgeon training, it solves drawback with open surgery, and it is possible to use cost effective materials and methods in the process. | 12-06-2012 |
| 20120308533 | ADIPOCYTE SHEET, THREE-DIMENSIONAL STRUCTURE THEREOF, AND METHOD FOR PRODUCING THE SAME - The present invention aims to provide an artificial tissue that can efficiently reproduce myocardial tissue function and that can be used in an actual implantation and produced by culturing. The present invention relates to a graft material for treating myocardial disease, the graft material including a cell sheet containing adipocytes. | 12-06-2012 |
| 20120308534 | NEURAL PROGENITOR CELL POPULATIONS - This invention provides populations of neural progenitor cells, differentiated neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural progenitor population. The progenitors can be further differentiated in culture into a variety of different neural phenotypes, including dopaminergic neurons. The differentiated cell populations or the neural progenitors can be generated in large quantities for use in drug screening and the treatment of neurological disorders. | 12-06-2012 |
| 20120308535 | Pharmaceutical Composition Containing Expanded Adult Stem Cells and Methods of Using Same for Treatment - A method for the expansion of adult stem cells from blood, particularly but not only peripheral blood, involves removing adult stem cells from blood of a mammal, immediately expanding the stem cells via in-vitro treatment with MCSF (Macrophage Colony Stimulating Factor) at a concentration of about 8-15 nM, and purifying the expanded stem cells. Compositions and methods of using the expanded adult stem cells are also described. | 12-06-2012 |
| 20120308536 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN AUGMENTING AUTOLOGOUS FAT TRANSFER - Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed. | 12-06-2012 |
| 20120315251 | POSTPARTUM CELLS DERIVED FROM UMBILICAL TISSUE AND METHODS OF MAKING AND USING THE SAME - Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described. | 12-13-2012 |
| 20120315252 | Methods of Reducing Teratoma Formation During Allogeneic Stem Cell Therapy - The present application relates to methods and compositions for treating diseased or damaged cardiac tissue comprising regenerative cells harvested from donor cardiac tissue. In one embodiment, regenerative cells are harvested from an allogeneic source and after administration result in increased viability and/or functional improvement of damaged or diseased cardiac tissue. | 12-13-2012 |
| 20120315253 | METHODS TO ENHANCE DELIVERY AND ENGRAFTMENT OF STEM CELLS INCLUDING THE IDENTIFICATION OF SPECIFIC PROSTAGANDIN E2 RECEPTORS - The receptor EP | 12-13-2012 |
| 20120315254 | METHODS AND COMPOSITIONS FOR ENHANCING FAT GRAFT SURVIVAL - A method of enhancing fat cell survival in a subject in need thereof is disclosed. The method comprising (a) implanting a population of fat cells into the subject; and (b) administering Erythropoietin to the subject, thereby enhancing fat cell survival in the subject. | 12-13-2012 |
| 20120321593 | LOW OXYGEN CULTURE CONDITIONS FOR MAINTAINING RETINAL PROGENITOR CELL MULTIPOTENCY - The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration. | 12-20-2012 |
| 20120321594 | METHODS OF CONTROLLING AXON OR DENDRITE DEVELOPMENT OF NEURONAL CELLS - One aspect of the present invention relates to a method of controlling axon or dendrite development in a neuronal cell population. This method involves providing a neuronal cell population and contacting the neuronal cell population with a modulator of R-type Ca | 12-20-2012 |
| 20120321595 | TREATMENT OF HEART DISEASE - Disclosed herein are methods, compositions and kits for treating cardiac stem cells to be administered to a subject in need thereof, e.g., with a damaged myocardium. The methods, composition and kits of the invention can be used to treat cardiovascular diseases such as heart failure, myocardial infarction and an age-related cardiomyopathy. | 12-20-2012 |
| 20120321596 | KIT FOR ADHERING BIOLOGICAL HARD TISSUES - A kit for bonding to biological hard tissues, containing a phosphorylated polysaccharide, a polyvalent metal salt other than phosphates, and a solvent. The adhesive composition for biological hard tissues provided by the kit for bonding to biological hard tissues is suitably used in for medical uses, such as cement for bones or dental cement. In addition, since the adhesive composition has excellent bio-absorbability, it is useful as fusion materials for artificial joint prosthesis, fusion materials for spine fracture, fusion materials for extremity fracture, filling materials for bone tumors in the region of orthopedics, filling materials and restorative materials at dental caries-defective sites, luting materials for prosthetic restorative materials such as inlay and crown, pulp-capping and lining materials, implant surface treatment materials, periodontal disease therapeutic materials, hyperesthesia preventive materials, dental pulp capping materials, substrates for DDS, substrates for systems engineering, and tissue bonding materials in the dental region. | 12-20-2012 |
| 20120321597 | METHODS AND COMPOSITIONS FOR REGENERATING CONNECTIVE TISSUE - Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament. | 12-20-2012 |
| 20120328578 | PRIMED STEM CELLS AND USES THEREOF TO TREAT INFLAMMATORY CONDITIONS IN JOINTS - Disclosed are methods of treating inflammation within a synovial joint, comprising administering to the joint a composition comprising primed stem or progenitor cells in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier. | 12-27-2012 |
| 20120328579 | HUMAN TROPHOBLAST STEM CELLS AND USE THEREOF - Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could be apply to human cell differentiation and for gene and cell-based therapies. | 12-27-2012 |
| 20120328580 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION - This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation. | 12-27-2012 |
| 20120328581 | TISSUE REPAIR - According to the invention there is provided a cosmetic method for the augmentation of subcutaneous or dermal tissue in a subject, which method comprises the steps of: | 12-27-2012 |
| 20120328582 | Primate Embryonic Stem Cells - A purified preparation of primate embryonic stem cells is disclosed. This preparation is characterized by the following cell surface markers: SSEA-1 (−); SSEA-4 (+); TRA-1-60 (+); TRA-1-81 (+); and alkaline phosphatase (+). In a particularly advantageous embodiment, the cells of the preparation are human embryonic stem cells, have normal karyotypes, and continue to proliferate in an undifferentiated state after continuous culture for eleven months. The embryonic stem cell lines also retain the ability, throughout the culture, to form trophoblast and to differentiate into all tissues derived from all three embryonic germ layers (endoderm, mesoderm and ectoderm). A method for isolating a primate embryonic stem cell line is also disclosed. | 12-27-2012 |
| 20130004464 | MULTIPOTENT ADULT STEM CELL POPULATION - The present invention relates to the identification, isolation, expansion and characterization of a specific type of adult stem cell. These adult stem cells are characterised in that they naturally express many of the markers of totipotency, which have hitherto generally been limited to embryonic cell populations. The cells of the invention display an unprecedented capacity for multipotency; they are able to differentiate into cell types of mesodermal, endodermal and ectodermal origin. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium. | 01-03-2013 |
| 20130004465 | ADHERENT CELLS FROM PLACENTA AND USE OF SAME IN DISEASE TREATMENT - Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta. | 01-03-2013 |
| 20130004466 | MYOGENIC DIFFERENTIATION OF STEM CELLS AND AND USES THEREOF - Disclosed are methods of differentiating stem cells into muscle cells by growing the cells in a myogenic culture medium. The differentiated cells can be used as a source of cells for transplantation in a patient in need thereof. | 01-03-2013 |
| 20130004467 | MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS - One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. | 01-03-2013 |
| 20130004468 | METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF - The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation. | 01-03-2013 |
| 20130004469 | ENGINEERED LUMENIZED VASCULAR NETWORKS AND SUPPORT MATRIX - Disclosed herein are capillary fabrication devices comprising living cells within a support medium. Culture of the cells produces viable lumenized capillary networks with natural or pre-determined geometries and ECM and basement membrane associated with the capillary networks. The capillary networks and the ECM and basement membrane detachable from the capillary networks are useful for tissue engineering applications. | 01-03-2013 |
| 20130011371 | ESTABLISHMENT OF PATIENT- OR PERSON- SPECIFIC CARDIAC MYOCYTE CELL LINES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS (iPSCs) - A composition and method for generating patient- or person-specific proliferative and substantially pure cardiac myocyte cell lines from pluripotent stem cells (iPSCs) is described herein. The patient-specific cardiac myocyte cell lines of the present invention find applications in research, drug screening and autologous cell-based therapy. The method of the present invention is simple and reproducible and generates cardiac myocyte cells having high purities and proliferating capacities. | 01-10-2013 |
| 20130017175 | ACTIVATED MESENCHYMAL STEM CELLS FOR WOUND HEALING AND IMPAIRED TISSUE REGENERATION - Inflammatory cytokines e.g. IFN-γ, serve as initiating stimuli for mesenchymal stem cell (MSC) immunosuppresive activity in vivo. Other inflammatory cytokines, such as TNF alpha, the molecule hemoxygenase I, and TLR ligation of MSC, may also provide such a response. Activated MSC's promote tissue regeneration in conditions such as aging, where regeneration is impaired. Wound healing in aged mammals was enhanced by restoring tensile strength to the levels of younger mammals. Activated MSCs were useful in treating wounds in diabetic primates. | 01-17-2013 |
| 20130017176 | COMPOSITIONS COMPRISING CARDIAC STEM CELLS OVEREXPRESSING SPECIFIC MICRORNAS AND METHODS OF THEIR USE IN REPAIRING DAMAGED MYOCARDIUM - The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed. | 01-17-2013 |
| 20130017177 | PHOTO-CROSSLINKED GELLAN GUM-BASED HYDROGELS: PREPARATION METHODS AND USES THEREOFAANM Da Silva Correia; Joana CatarinaAACI BragaAACO PTAAGP Da Silva Correia; Joana Catarina Braga PTAANM Antunes De Oliveira; Joaquin MiguelAACI Ponte GMRAACO PTAAGP Antunes De Oliveira; Joaquin Miguel Ponte GMR PTAANM Teixeira De Oliveira; Joao ManuelAACI MatosinhosAACO PTAAGP Teixeira De Oliveira; Joao Manuel Matosinhos PTAANM Amandi Romero De Sousa; Rui PedroAACI MatosinhosAACO PTAAGP Amandi Romero De Sousa; Rui Pedro Matosinhos PTAANM Goncalves Dos Reis; Ruic LuisAACI PortoAACO PTAAGP Goncalves Dos Reis; Ruic Luis Porto PT - This invention refers to photo-crosslinked hydrogel materials based in gellan gum suitable for tissue engineering and regenerative medicine applications or as drug delivery systems. Formulations of gellan gum with different degrees of acylation serve as precursor material for insertion of a polymerizable moiety. The materials are capable of free radical polymerization with a photo-initiator at mild temperatures and exposure to ultraviolet light, enabling control of reticulation and withstanding the encapsulation of human and animal cells and/or drugs, and any combination thereof. The physicochemical and biological properties can be adjusted by combining different formulations of gellan gum and reaction conditions. The matrix can be used either as an acellular or cellular system, dispensed manually or automatically by injection and crosslinked directly at the site of application, and can be processed using manual or automated systems in different types of scaffolds, such as hydrogels, fibres, | 01-17-2013 |
| 20130017178 | PREPARATION CREATED FROM AN IN VITRO CULTURE OF DEDIFFERENTIATED, NON-ELICITED CELLS OF THE ARGANIA TREE, USE THEREOF FOR TREATING SKIN AGEING, INFLAMMATION AND SCARRING, AND PRODUCTION THEREOFAANM Steward; NicolasAACI Pins-JustaretAACO FRAAGP Steward; Nicolas Pins-Justaret FRAANM Mandeau; AnneAACI ToulouseAACO FRAAGP Mandeau; Anne Toulouse FRAANM Castex-Rizzi; NathalieAACI ColomiersAACO FRAAGP Castex-Rizzi; Nathalie Colomiers FR - The invention relates to a preparation created from an in vitro culture of dedifferentiated, non-elicited cells of the Argania tree. | 01-17-2013 |
| 20130022580 | PREPARATION AND USE OF MERISTEMATIC CELLS BELONGING TO THE DENDROBIUM PHALAENOPSIS, ANISELLIA, POLYRRHIZA, VANILLA, CATTLEYA AND VANDA GENERA WITH HIGH CONTENT OF PHENYLPROPANOIDS, HYDROSOLUBLE POLYSACCHARIDES AND EXTENSINS - The present invention relates to the preparation of plant cell cultures belonging to the | 01-24-2013 |
| 20130022581 | PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 01-24-2013 |
| 20130022582 | MULTIPOTENT NESTIN-POSITIVE CELLS - The present invention relates to the use of at least one isolated multipotent stem cell for maintaining haematopoiesis in vitro, in which said multipotent stem cell is preferably a mesenchymal stem cell or, more preferably, said mesenchymal stem cell is a mesenchymal stem cell capable of expressing the nestin protein. The present invention also relates to an isolated cell population of adult nestin-positive mesenchymal cells from a mammal, including humans, to the use thereof for producing a drug for maintaining haematopoiesis in a mammal, for the prevention and/or treatment of at least one disease associated with a malfunction in maintaining haematopoiesis in a mammal, and for maintaining and expanding adult haematopoietic stem cells of said mammal, including a human. Furthermore, the present invention also relates to a method for maintaining haematopoiesis in vitro or to a method for evaluating the haematopoietic capacity of a mammal. | 01-24-2013 |
| 20130022583 | Direct Conversion of Cells to Cells of Other Lineages - Methods, compositions and kits for producing functional neurons, astroctyes, oligodendrocytes and progenitor cells thereof are provided. These methods, compositions and kits find use in producing neurons, astrocytes, oligodendrocytes, and progenitor cells thereof for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the CNS. Also provided are methods, compositions and kits for screening candidate agents for activity in converting cells into neuronal cells, astrocytes, oligodendrocytes, and progenitor cells thereof. | 01-24-2013 |
| 20130022584 | METHODS AND COMPOSITIONS FOR THE REPAIR AND/OR REGENERATION OF DAMAGED MYOCARDIUM USING CYTOKINES AND VARIANTS THEREOF - Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are disclosed and claimed. In addition, methods, compositions, and kits for forming coronary vasculature including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed. | 01-24-2013 |
| 20130028870 | PLURIPOTENT STEM CELLS AND METHOD OF STIMULATING AND EXTRACTING NON-EMBRYONIC PLURIPOTENT STEM CELLS FROM MAMMAL BLOOD AND USING RECONSTITUTED PLURIPOTENT STEM CELLS TO TREAT DISEASES INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Stimulating tissue resident pluripotent stem cells in a manner that the respective subject (e.g., human) acts as its own sterile bioreactor for in vivo stem cell proliferation thus eliminating the need to isolate, cultivate, maintain, proliferate and release stem cells ex vivo. The stimulation mobilizes excess pluripotent stem cells into the peripheral vasculature where the pluripotent stem cells can either migrate to damaged tissues and/or be harvested by simple venipuncture, thus eliminating potential morbidity and mortality elicited from harvesting tissue from solid tissue sites. The pluripotent stem cells are separated from the blood by gravity sedimentation, after which the pluripotent stem cells can easily be aspirated from the white blood cells and red blood cells. Billions of pluripotent stem cells can be generated in this fashion for infusion/injection into the body, via the vasculature, and into the organ(s) in need of tissue repair and regeneration. | 01-31-2013 |
| 20130028871 | PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 01-31-2013 |
| 20130028872 | COMPOSITION AND METHOD FOR DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS - Described are methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a cell or population of cells characteristic of the definitive endoderm, the method comprising incubating the cell or population of cells with a GSK-3 inhibitor. Also described are methods for inducing differentiation of a cell or population of cells, characteristic of the definitive endoderm, towards a hepatocyte-like cell or a population of hepatocyte-like cells, and methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a hepatocyte-like cell or a population of hepatocyte-like cells. Further described are cells obtained by the methods and uses thereof in therapy and toxicity screening. | 01-31-2013 |
| 20130028873 | METHOD FOR INCREASING ACTIVITY IN HUMAN STEM CELL - Provided are a method for preparing a highly active human mesenchymal stem cell, which includes forming a spherical cell aggregate by cultivating human mesenchymal stem cells against gravity; a highly active stem cell prepared thereby; a cell therapeutic agent including the stem cell aggregate; and a method for forming a spherical cell aggregate by cultivating human mesenchymal stem cells, wherein the amount of E-cadherin in the mesenchymal stem cell is increased during the cultivation. | 01-31-2013 |
| 20130028874 | METHODS, PHARMACEUTICAL COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ADMINISTERING THERAPEUTIC CELLS TO THE ANIMAL CENTRAL NERVOUS SYSTEM - Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury. | 01-31-2013 |
| 20130034524 | Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate - The present disclosure relates generally to processes, devices and systems for separating and concentrating stem and stromal cells from adipose tissue using a combination of mechanical disruption and filtration-centrifugation to obtain a highly enriched population of stem cells. | 02-07-2013 |
| 20130034525 | BETA ISELETS-LIKE CELLS DERIVED FROM WHOLE BONE MARROW - The invention provides for methods of producing pancreatic precursor cells and insulin-producing cells from bone marrow. In various embodiments, bone marrow derived stem cells are differentiated into pancreatic precursor cells and insulin-producing cells. In various embodiments, bone marrow derived stem cells are artificially induced to express VEGF and/or PDX-1. These cells can be used to treat or ameliorate diabetes or symptoms of diabetes. | 02-07-2013 |
| 20130034526 | POPULATIONS OF PANCREATIC PROGENITOR CELLS AND METHODS OF ISOLATING AND USING SAME - A method of generating pancreatic progenitor cells is disclosed. The method comprises:
| 02-07-2013 |
| 20130039892 | ADHERENT STROMAL CELLS DERIVED FROM PLANCENTAS OF MULTIPLE DONORS AND USES THEREOF - Pharmaceutical compositions comprising adherent stromal cells (ASCs) are provided. The ASCs are obtained from at least two donors. Articles of manufacture comprising the pharmaceutical compositions together with a delivery device for administering the ASCs to a subject are also provided. Also provided are methods of treating various diseases and conditions that are treatable by administering ASCs to a subject in need of treatment. | 02-14-2013 |
| 20130039893 | ISOLATION AND CULTIVATION OF STEM/PROGENITOR CELLS FROM THE AMNIOTIC MEMBRANE OF UMBILICAL CORD AND USES OF CELLS DIFFERENTIATED THEREFROM - The present invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells. | 02-14-2013 |
| 20130045187 | METHODS AND COMPOSITIONS OF PRODUCING PATIENT-SPECIFIC MULTIPOTENT NEURONAL STEM CELLS - The present invention relates to the seminal discovery of compositions and a method of producing NSC obtained from stem cells derived from parthenogenically activated human oocytes (phNSC). The phNSC of the invention maintain proliferative and differentiation potential during cultivation and expansion. | 02-21-2013 |
| 20130045188 | REDUCTION OF TGF BETA SIGNALING IN MYELOID CELLS IN THE TREATMENT OF CANCER - Methods of inhibiting metastasis in cancer patients are provided, wherein the methods comprise reducing TGFβ signaling, for example, by reducing TGF receptor II expression in myeloid cells. Vectors comprising a TGFβ receptor II RNAi nucleic acid sequence operably linked to a myeloid specific promoter also are provided. A method of diagnosing cancer in an individual by determining TGFβ receptor II expression in myeloid cells in the individual is provided. Additionally, a method of modulating TGFβ activity in myeloid cells in a cancer patient comprising administering a regulator of at least one of the GSK | 02-21-2013 |
| 20130045189 | METHODS OF TREATING STROKE THROUGH ADMINISTRATION OF CTX0E03 CELLS - The subject invention pertains to methods to enhance the therapeutic effects of cellular or drug treatment in various diseases and disorders. More particularly, the present invention provides methods of treating disorders by administering CTX0E03 cells to the patient, intravenously or intraarterially. The treatment is useful for neurodegenerative diseases, such as stroke. The CTX0E03 cells may be cryopreserved and/or passaged before administration into the patient. Administration of the CTX0E03 cells into stroke rat models was at or within 48 hours after stroke. Testing of the rat models through elevated body swing test to measure of neurobehavioral status at the time of transplant and repeated triphenyltetrazolium chloride (TTC) staining as a measure of infarct volume showed short term survival that provided significant protection from the stroke. | 02-21-2013 |
| 20130052166 | MATERIALS AND METHODS FOR MINIMALLY-INVASIVE ADMINISTRATION OF A CELL-CONTAINING FLOWABLE COMPOSITION - The disclosed invention is based on the discovery that a cell-based therapy can be used to treat, ameliorate, manage and/or reduce the progression of clinical sequelae associated with vascular interventions or cardiovascular diseases, particularly occlusive thrombosis, restenosis, intimal hyperplasia, inflammation and vasodilation. The invention further benefits from the additional discovery that a heretofore undescribed implantable flowable composition is capable of sustaining a confluent population of sufficiently viable cells which can be effectively administered via a minimally-invasive surgical procedure without diminishing the clinical effectiveness or the viability of the cells. The disclosed invention can be used to treat vasculature as well as non-vascular tubular structures such as a fallopian tube. | 02-28-2013 |
| 20130052167 | Methods and Apparatus for Creating Particle Derivatives of HDL with Reduced Lipid Content - The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction. | 02-28-2013 |
| 20130052168 | METHODS AND COMPOSITIONS FOR TISSUE REGENERATION - A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, IL-6, IL-8, TGFα, and TNFα, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial. | 02-28-2013 |
| 20130058900 | Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells - The invention is concerned with producing differentiated cells, tissues and organs from pluripotent and mutlipotent cells. The methods of the invention are particularly useful for producing differentiated cells from pluripotent cells wherein communication between the cells of more than one embryonic germ layer or more than one organ system are required for development along a specific cell lineage. The invention methods are effected by in vivo or in vitro culturing of embryonic and developing or developed allogeneic or xenogeneic cells. | 03-07-2013 |
| 20130058901 | TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE - Disclosed are transplantable graft-specific induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods. | 03-07-2013 |
| 20130058902 | DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS - Disclosed are induced tolerogenic dendritic cells (itDCs) produced from dendritic cell subsets that possess a desired physiological characteristic, as well as related compositions and methods. | 03-07-2013 |
| 20130058903 | Stem-Cell Material and Method of Use - Provided herein are mesenchymal stem cells which have been modified by the introduction of polynucleotides encoding for a mammalian Cdk1 protein. These cells do not sense in culture and are non-tumorigenic thereby providing an ongoing source of cells as well as conditioned medium. The conditioned medium from these cells can be used for tissue repair. Also provided is a method of modifying mesenchymal stem cells which can be continuously propagated in culture and are non-tumorigenic. | 03-07-2013 |
| 20130058904 | Method and system for treatment of biological tissue - A composition for reconstruction, replacement or repair of damaged or diseased biological tissue comprising an extracellular matrix (ECM) composition that includes an ECM scaffold component derived from a mammalian source and at least one additional bioactive component selected from the group consisting of a statin and a chitin derivative. | 03-07-2013 |
| 20130058905 | Angiohematopoietic Progenitor Cells - A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a. | 03-07-2013 |
| 20130058906 | PROCESS, TUBE AND DEVICE FOR THE PREPARATION OF WOUND HEALANT COMPOSITION - The present invention is related to the field of tissue regeneration. It concerns more particularly new processes, tubes and devices for thrombin, platelet concentrate and wound healant preparations, alone or in combination with cell extracts, cell compositions and uses thereof. | 03-07-2013 |
| 20130058907 | METHOD AND SYSTEM FOR THE PRODUCTION OF CELLS AND CELL PRODUCTS AND APPLICATIONS THEREOF - A cell culture system for the production of cells and cell derived products includes a reusable instrumentation base device incorporating hardware to support cell culture growth. A disposable cultureware module including a cell growth chamber is removably attachable to the instrumentation base device. The base device includes microprocessor control and a pump for circulating cell culture medium through the cell growth chamber. The cultureware module is removably attached to the instrumentation base device. Cells are introduced into the cell growth chamber and a source of medium is fluidly attached to the cultureware module. Operating parameters are programmed into the microprocessor control. The pump is operated to circulate the medium through the cell growth chamber to grow cells or cell products therein. The grown cells or cell products are harvested from the cell growth chamber and the cultureware module is then disposed. | 03-07-2013 |
| 20130064797 | COMPOSITION FOR MUCOSALLY DELIVERING FRUIT CELL CULTURES AND/OR PREPARATIONS DERIVED THEREFROM AND METHODS OF USING SAME - A pharmaceutical or nutraceutical composition comprising a cell line callus culture of grape berry cells grown in vitro, whereby the cell line callus culture of grape berry cells is derived from one or more of grape-berry cross section, grape-berry skin, grape-berry flesh, grape seed, grape embryo of seeded or seedless cultivars or grape seed coat. | 03-14-2013 |
| 20130064798 | METHODS AND COMPOSITIONS FOR TREATING CONGESTIVE HEART FAILURE - Compositions and methods for treating congestive heart failure are provided herein. | 03-14-2013 |
| 20130064799 | METHODS FOR PROMOTING CELL REPROGRAMMING - The present invention is based on the seminal discovery that several kinases play important roles in barrier pathways in somatic cell reprogramming. The present invention provides that modulating expression or activity of these kinases can significantly promote or enhance cell reprogramming efficiency. Key kinases are identified and key regulation networks involving such kinases are also identified that may be advantageously targeted to significantly increase reprogramming efficiency as well as direct differentiation of induced pluripotent stem (iPS) cells. | 03-14-2013 |
| 20130064800 | Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair - Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair. | 03-14-2013 |
| 20130064801 | Cellular Compositions and Methods of Making and Using Them - The invention relates to cellular compositions comprising hematopoietic cells with the potential or increased potential to form non-hematopoietic cells; methods for producing such cellular compositions; methods for differentiation of cells of cellular compositions of the invention into cells that exhibit morphological, physiological, functional, and/or immunological features of non-hematopoietic cells; and uses of the cellular compositions. The invention also relates to a method for the expansion of hematopoietic stem and progenitor cells. | 03-14-2013 |
| 20130071357 | IDENTIFICATION, PROLIFERATION IN SITU, HARVESTING, SEPARATION, AND TRANSPLANTATION OF ADULT-DERIVED REGENERATIVE PLURIPOTENT TRANSITIONAL BLASTOMERE-LIKE STEM CELLS AND METHODS OF TREATMENT THEREOF - Non-embryonic transitional blastomere-like stem cells are disclosed. Most preferably, such cells are obtained from the blood after induction by a plant-based compound to proliferate and reverse diapadese into the vasculature or from various tissues of postnatal mammals or humans (using tissue biopsied from the mammal or human), are in the range of 3-5 microns, have a normal karyotype, and do not spontaneously differentiate in situ (in vivo) or in serum-free medium without differentiation inhibitors. These non-embryonic transitional blastomere-like stem cells typically express CD66e, CEA-CAM-1, CD10, SSEA (SSEA-1, SSEA-3, and SSEA-4), telomerase, Sonic hedgehog, but do not typically express Nanog, Nanos, BCl-2 or CXCR-4. Such transitional blastomere-like pluripotent stem cells can be differentiated into epiblast-like stem cells, ectodermal, mesodermal, and endodermal tissues, but NOT placental tissues or germ cells. Moreover, when implanted into a mammal or human, such cells will not be teratogenic. | 03-21-2013 |
| 20130071358 | ALLOGENEIC MICROVASCULAR TISSUE FOR SOFT TISSUE TREATMENTS - Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries. | 03-21-2013 |
| 20130071359 | METHODS AND COMPOSITIONS FOR BONE AND CARTILAGE REPAIR - Biologically active extract of | 03-21-2013 |
| 20130071360 | Brown Fat Cell Compositions and Methods - Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes. | 03-21-2013 |
| 20130071361 | METHODS OF TREATMENT OF HEMOPHILIA - The present invention provides methods of treating hemophilia in a subject, the methods comprising transplanting a therapeutically effective amount of bone marrow, cord blood, cord blood or bone marrow fraction expressing Factor VIII, mononuclear cells, or mesenchymal stromal cells from a donor to the subject with hemophilia. The present invention also provides compositions for treating hemophilia. | 03-21-2013 |
| 20130071362 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME - The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal. | 03-21-2013 |
| 20130071363 | Amnion-derived cells, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies. | 03-21-2013 |
| 20130071364 | Amnion-derived cells, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies. | 03-21-2013 |
| 20130078220 | DOPAMINERGIC NEURONAL SURVIVAL-PROMOTING FACTORS AND USES THEREOF - In general, the invention features substantially purified MANF and substantially purified nucleic acids encoding the same. The invention also features a pharmaceutical composition that includes MANF and a pharmaceutically-acceptable excipient, methods for treatment of a neurodegenerative disease, methods for improving dopaminergic neuronal survival during or following cell transplantation, methods for production of neurons for transplantation, and methods for identifying compounds that modulate or mimic MANF's biological activity. | 03-28-2013 |
| 20130078221 | MULTIPOTENT ADULT STEM CELL DERIVED FROM CANINE UMBILICAL CORD BLOOD, PLACENTA AND CANINE FETUS HEART, METHOD FOR PREPARING THE SAME AND CELLULAR THERAPEUTICS CONTAINING THE SAME - The present invention relates to multipotent adult stem cells derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart, and a method for preparing the same as well as a cellular therapeutic agent containing the same, more specifically, to a multipotent adult stem cell isolated by culturing an eukaryotic cell derived from canine umbilical cord blood, placental blood and blood sample from canine fetal heart in a FBS-containing medium and a method for preparing the same. Adult stem cells according to the present invention have characteristics highly similar to human mesenchymal stem cells as well as remarkable cell growth at the initial step compared to human UCB-derived mesenchymal stem cells so that the cells are useful to treat canine incurable diseases and difficult-to-cure diseases. Furthermore, multipotent adult stem cells are effective to treat musculoskeletal diseases and neural diseases. | 03-28-2013 |
| 20130078222 | Intervertebral Disc Nucleus Pulposus Stem Cell/Progenitor Cell, The Cultivation Method And Intended Use Thereof - Provided are intervertebral disk nucleus pulposus stem cells or progenitor cells that may be used for treatment of intervertebral disk disorders. An intervertebral disk nucleus pulposus cell is characterized by being isolated from the intervertebral disk nucleus pulposus of a vertebrate and is positive for at least one surface marker from among Tie2 and GD2. That is, the intervertebral disk nucleus pulposus stem cell is characterized by being at least Tie2-positive for the surface marker and) possesses a self-renewal ability as well as multipotency capable of differentiating into adipocytes, osteocytes, chondrocytes and neurons. Also provided is an intervertebral disk nucleus pulposus progenitor cell characterized by being at least Tie2-negative and GD2-positive for the surface marker and capable of differentiating into any of adipocytes, osteocytes, chondrocytes and neurons. | 03-28-2013 |
| 20130078223 | Method And Composition For Inducing Human Pluripotent Stem Cells - The present invention provides pluripotent stem cell like (PSCL) cells or clones, a culture medium therefore, and a supernatant thereof, and methods of making and using the same. | 03-28-2013 |
| 20130084266 | METHODS FOR GENERATING PANCREATIC TISSUE - This document provides methods and materials related to tissue generation. For example, methods for generating pancreatic tissue and providing a population of hormone-secreting cells, e.g., insulin-producing cells in a human subject are provided. | 04-04-2013 |
| 20130084267 | METHOD FOR STEM CELL DIFFERENTIATION - The present invention relates generally to a method for generating mesenchymal stem cells from pluripotent cells, the method comprising (i) differentiating a population of pluripotent stem cells in the presence of an inhibitor of endogenous activin and TGF-β signalling and (ii) passaging the cells differentiated in step (i) in the presence of a mesenchymal stem cell medium for a time and under conditions sufficient to produce mesenchymal stem cells. The present invention also relates to mesenchymal stem cells produced by the methods of the present invention and uses thereof. | 04-04-2013 |
| 20130084268 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT AND/OR THE PREVENTION OF OSTEOARTICULAR DISEASES - An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells. | 04-04-2013 |
| 20130084269 | Methods and Compositions for Expanding and Stabilizing Natural Regulatory T Cells - The present invention is directed to methods and compositions for expanding and stabilizing the phenotype of natural regulatory T cells. In particular, the present invention provides methods and compositions for treating natural regulatory T cells that renders the cells resistant to factors present in the inflammatory milieu and stabilizes the suppressive properties of the cells. | 04-04-2013 |
| 20130084270 | STEM CELLS FROM ADIPOSE TISSUE, AND DIFFERENTIATED CELLS FROM SAID CELLS - The invention concerns adult multipotent human stem cells, characterized in that they have:
| 04-04-2013 |
| 20130089526 | Methods for Using Synthetic Triterpenoids in the Treatment of Bone or Cartilage Diseases or Conditions - The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions. | 04-11-2013 |
| 20130089527 | METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF - The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation. | 04-11-2013 |
| 20130089528 | COMPOSITIONS AND METHODS FOR PRESERVING INSULIN-PRODUCING CELLS AND INSULIN PRODUCTION AND TREATING DIABETES - Nuclear Transport Modifiers such as cSN50 and cSN50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (NOD) mice, a widely used model of Type 1 diabetes (T1D), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. cSN50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of T and B lymphocytes derived from NOD mice. cSN50 attenuated pro-inflammatory cytokine and chemokine production in immune cells in this model of human T1D. cSN50 also provides cytoprotection of beta cells, therefore preserving residual insulin-producing capacity. Because intracellular delivery of a Nuclear Transport Modifier peptide such as cSN50 and cSN50.1 can result in lowering of blood glucose levels and may reducing insulin resistance, the compositions, methods and cells described herein can also be used for treating Type 2 diabetes (T2D). | 04-11-2013 |
| 20130089529 | AGENT FOR OSTEOGENESIS USING SUBSTANCE-P AND PREPARATION PROCESS THEREOF - The present invention relates to an agent for osteogenesis containing as an active ingredient mesenchymal stem cells (MSCs) that have been mobilized from bone marrow into blood by administration of Substance-P; and a process of preparing the agent. | 04-11-2013 |
| 20130095075 | BONE MORPHOGENIC PROTEIN BINDING PEPTIDE - A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the overall osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis. | 04-18-2013 |
| 20130095076 | Methods For Increasing Blood Flow And/Or Promoting Tissue Regeneration - Methods for increasing blood flow and/or regenerating tissue using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula | 04-18-2013 |
| 20130095077 | Somatic Stem Cells - A somatic stem cell that is CD10+, CXCR4+, and CD31+ and another somatic stem cell that is CD 105+, CD44+, and nestin+. Also disclosed are both a method of preparing these stem cells and a method of using them to treat degenerative diseases, e.g., a muscle-degenerative disease. The invention further includes making and using liver cells derived from the somatic cell that is CD105+, CD44+, and nestin+. | 04-18-2013 |
| 20130095078 | METHODS FOR REGENERATING SKELETAL MUSCLE - An engineered muscle construct in the form of a braided collagen microthread scaffold is provided. The microthread scaffold can be used with or without cells as engineered skeletal muscle. The microthread scaffold can also be used to promote cell attachment and growth to deliver cells to a large muscle defect to stimulate muscle regeneration. Methods for making a muscle construct, seeding cells onto microthread scaffolds and treating muscle defects are also provided. | 04-18-2013 |
| 20130095079 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION WITHOUT HLA MATCHING - The present invention relates to methods and compositions for providing hematopoietic function in immunodeficient human patients, by selecting an expanded human umbilical cord blood stem/progenitor cell sample without taking into account the HLA-type of the expanded human cord blood stem/progenitor sample or the HLA-type of the patient; and administering the selected expanded human cord blood stem/progenitor cell sample to the patient. Methods for obtaining the expanded human cord blood stem/progenitor cell samples, banks of frozen expanded human cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein. | 04-18-2013 |
| 20130095080 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION - The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/pro-genitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein. | 04-18-2013 |
| 20130095081 | COMPOSITIONS AND METHODS OF TREATMENT WITH STEM CELLS - The disclosure of the present application provides compositions and methods of treatment with stem cells. In at least one embodiment of a method for treating a patient with an insulin-related disorder, the method comprises the step of administering a cell-based composition to a patient with an insulin-related disorder to treat the insulin-related disorder, the cell-based composition comprising at least one mammalian stem cell and optionally at least one islet cell, the at least one mammalian stem cell capable of prolonging an effective life of the at least one islet cell. | 04-18-2013 |
| 20130095082 | USE OF DES-ASPARTATE-ANGIOTENSIN I IN INFLAMMATION-RELATED PATHOLOGIES AND DISEASES - The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions. | 04-18-2013 |
| 20130095083 | Method For Controlling And Accelerating Differentiation Of Stem Cells Using Graphene Substrates - The invention relates to methods for directing differentiation of stem cells comprising graphene. In additional embodiments, the invention relates to methods for repairing and improving bone tissue functions comprising accelerating differentiation in stem cell growth by exposing stem cells to graphene and transplanting the graphene with the exposed stem cells in the tissue at the site of repair. | 04-18-2013 |
| 20130101561 | CLOSED SYSTEM SEPARATION OF ADHERENT BONE MARROW STEM CELLS FOR REGENERATIVE MEDICINE APPLICATIONS - A method for isolating and processing bone marrow derived stem cells, including the steps of: (a) collecting a biological sample containing adherent bone marrow stem cells in a receptacle with interior walls coated with a cell-adherent substrate; (b) incubating the bone marrow cells on the adherent substrate so that a layer of adherent bone marrow stem cells adheres to the substrate; (c) washing any non-adherent cells from the substrate; and (d) collecting the bone marrow stem cell layer. Isolation kits and use of bone marrow cells harvested for cell therapies are also described. | 04-25-2013 |
| 20130101562 | Methods for handling biological drugs containing living cells - The present invention includes methods for handling live cell compositions in non-nutritive buffer. The cells in the compositions maintain their identity and functional characteristics after being stored in non-nutrititive media up to about | 04-25-2013 |
| 20130101563 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 04-25-2013 |
| 20130101564 | METHOD FOR PREPARING DERMIS TISSUE CELLS AGGREGATION AND USES THEREOF - Dermis tissue cell aggregation, which comprises isolated dermis tissue cells with biological activity, is provided. The isolated dermis tissue cells are preserved in a mixed solution consisting of an isotonic saline solution for medical use, an anticoagulant, a nutrient for cells and a cell growth promoter, and a non-fluidity dermis tissue cell aggregation with adhesion is formed after several processes. A method for preparing the dermis tissue cell aggregation and the use thereof in preparing medicines for repairing scars are provided. | 04-25-2013 |
| 20130108588 | MULTIPOTENT STEM CELL CULTURES | 05-02-2013 |
| 20130108589 | Method of Producing Neurons from Stem Cells, the Neurons and Uses Thereof | 05-02-2013 |
| 20130108590 | METHOD FOR PRODUCING CELL SHEET | 05-02-2013 |
| 20130108591 | METHODS FOR COLLECTING AND USING PLACENTA CORD BLOOD STEM CELLS | 05-02-2013 |
| 20130108592 | USE ADIPOSE TISSUE-DERIVED REGENERATIVE CELLS IN THE MODULATION OF INFLAMMATION IN THE PANCREAS AND IN THE KIDNEY | 05-02-2013 |
| 20130108593 | Mesenchymal Stem Cell Isolation And Transplantation Method And System To Be Used In A Clinical Setting | 05-02-2013 |
| 20130115196 | HYBRID HYDROGEL SCAFFOLD COMPOSITIONS AND METHODS OF USE - The present invention includes new hybrid hydrogel scaffolds comprised of a polyoxyethylene-polyoxypropylene (block) copolymer (a “poloxamer”) and a self-assembling peptide, which maintain the mechanical and bioactive properties of its individual constituents (as compared to when the individual constituents are scaffolds or hydrogels by themselves). The hydrogels of the invention can include a combination of materials from different origins or with different properties that provides a hybrid material that meets the multiple needs of a scaffold for tissue engineering. | 05-09-2013 |
| 20130115197 | Amnion-derived cell compositions, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies. | 05-09-2013 |
| 20130115198 | HAIR FOLLICLE MESENCHYMAL STEM CELLS AND USE THEREOF - The present invention relates to a method for isolating hair follicle mesenchymal stem cells and to the use thereof for therapy and prophylaxis as well as for cosmetic treatments. | 05-09-2013 |
| 20130121969 | BIODEGRADABLE POLYURETHANE/UREA COMPOSITIONS - The present invention relates to biocompatible, biodegradable polyurethane/urea polymeric compositions that are capable of in-vivo curing with low heat generation to form materials suitable for use in scaffolds in tissue engineering applications such as bone and cartilage repair. The polymers are desirably flowable and injectable and can support living biological components to aid in the healing process. They may be cured ex-vivo for invasive surgical repair methods, or alternatively utilized for relatively non-invasive surgical repair methods such as by arthroscope. The invention also relates to prepolymers useful in the preparation of the polymeric compositions, and to methods of treatment of damaged tissue using the polymers of the invention. | 05-16-2013 |
| 20130121970 | METHOD FOR ELIMINATION OF SPACE THROUGH TISSUE APPROXIMATION - Acellular tissue matrix compositions for use in tissue approximation are provided. Also provided are methods for making and using the compositions to approximate tissue. | 05-16-2013 |
| 20130121971 | COMPOSITIONS AND METHODS OF VASCULAR INJURY REPAIR - The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium. | 05-16-2013 |
| 20130121972 | NATIVE WHARTON'S JELLY STEM CELLS AND THEIR PURIFICATION - Noncultured Wharton's Jelly stem cells and methods of their purification, storage and use are provided. | 05-16-2013 |
| 20130121973 | DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO FIBROBLASTS, COMPOSITIONS COMPRISING MESENCHYMAL STEM CELL-DERIVED FIBROBLASTS, AND METHODS OF USING THE SAME - Methods and compositions are provided for the differentiation and characterization of mammalian fibroblast from mesenchymal stem cells. The methods of the invention provide a means to obtain mesenchymal stem cell-derived fibroblast populations, e.g., seeded on a scaffold, which may be used in wound healing. | 05-16-2013 |
| 20130121974 | METHODS OF MAKING ENHANCED, AUTOLOGOUS FAT GRAFTS - Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient. | 05-16-2013 |
| 20130121975 | USE OF MESENCHYMAL STEM CELLS FOR COMPLETELY REPOPULATING HOST TISSUE - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 05-16-2013 |
| 20130129686 | Reducing Inflammation Using Cell Therapy - The invention provides methods for treating pathological conditions associated with an undesirable inflammatory component, including graft-versus-host disease. The invention is generally directed to reducing inflammation by administering cells that express and/or secrete prostaglandin E2 (PGE2). The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete PGE2, such as PGE2 receptor agonists. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of PGE2 expression and/or secretion. The invention is also generally directed to delivering cells directly to lymphohematopoietic tissue, such as spleen, lymph nodes, and bone marrow. The invention is, thus, also directed to a method for treating inflammation by administering cells directly into sites of lymphohematopoiesis, such as spleen, lymph nodes, and bone marrow. The administered cells include those that reduce the activation and/or proliferation of T-cells. Such cells may or may not express and/or secrete PGE2. | 05-23-2013 |
| 20130129687 | Generation of Lineage-Restricted Progenitor Cells from Differentiated Cells - Method for reprogramming differentiated cells into lineage restricted progenitor cells is provided. The method may include contacting differentiated cells with inhibitors of tyrosine phosphatases and apoptosis to de-differentiate differentiated cells into lineage restricted progenitor cells. | 05-23-2013 |
| 20130129688 | Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same - The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stem cell (MSC) populations by determining the number of GT repeats in the heme oxygenase-1 (HO-1) promoter region of both alleles. | 05-23-2013 |
| 20130129689 | AGENT DERIVED FROM TORTOISE SPLEEN STIMULATING MAMMALIAN HEMOPOIESIS - The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them. | 05-23-2013 |
| 20130129690 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 05-23-2013 |
| 20130129691 | Compositions For The Treatment Of Skin Conditions, Disorders Or Diseases And Methods Of Making And Using The Same - The present invention includes methods and compositions designed for treating a subject suffering from a skin condition, disorder or disease. The compositions include undifferentiated fetal skin cells that are either integrated with a collagen matrix or a carrier. | 05-23-2013 |
| 20130129692 | PLURIPOTENT CELLS - Pluripotent cells that are immunopositive for both the neural progenitor marker nestin and a pluripotent cell marker are provided. The cells exhibit rapid doubling times and can be maintained in vitro for extended periods. Also provided are cell cultures containing the pluripotent cells, a method of transplanting human pluripotent cells to a host, and a method of reducing seizure activity in a subject. These pluripotent cells, when transplanted into the ventricle of a host animal, migrate to the site of damage and adopt a suitably corrective phenotype, resulting in both structural and functional restoration. | 05-23-2013 |
| 20130136721 | Compositions and Methods of Generating a Differentiated Mesodermal Cell - The invention features a culture system, culture system components and culture methods that are useful for the rapid and reliable generation of differentiated mesodermal cells, including cardiac myocytes, from stem cells, such as human embryonic stem cells and human induced pluripotent stem cells differentiated mesodermal cells, including differentiated cardiac myocytes. | 05-30-2013 |
| 20130136722 | Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts - This invention provides methods and compositions of hematopoietic progenitor cells and hematopoietic stem cells, particularly methods for expanding populations of these cells types from biological sources. | 05-30-2013 |
| 20130136723 | CONNECTIVE TISSUE REPAIR - The invention concerns a homogenous population of human stem cells isolated from the full depth of human cartilage tissue and/or isolated from aged human cartilage; and uses thereof. | 05-30-2013 |
| 20130142761 | Method of Enhancing Hematopoietic Cell Transplantation - The invention relates to a method for enhancing the transplantation of hematopoietic cells to supplement or fully reconstitute the hematopoietic system. The method involves administering cells expressing CD34 and co-expressing HoxB4, wherein the HoxB4 is expressed at levels that provide therapeutically effective amounts of self-renewal of the administered cells. The method also involves administering cells expressing CD34 but not co-expressing HoxB4 or co-expressing HoxB4 in amounts so as to provide therapeutically effective amounts of differentiation of the administered cells into the various progeny cells of the hematopoietic system. To provide such cells to a subject, the invention relates to detecting such cells prior to treatment to ascertain whether such cells are present in clinically relevant amounts. | 06-06-2013 |
| 20130142762 | METHODS OF CARDIAC REPAIR - Provided herein is a new method to isolate and expand cardiac progenitor/stem cells from a placenta, which produces a cell population enriched in multipotent functional progenitor/stem cells. Cardiac progenitor/stem cells isolated by this method maintain their self-renewal character in vitro and differentiate into normal cells in myocardium, including cardiomyocytes, endothelial cells, and smooth muscle cells, after transplantation into ischemic hearts. Also provided in this application are substantially pure populations of multipotent cardiac progenitor/stem cells, and their use to treat and prevent diseases and injuries, including those resulting from myocardial infarction. A model for assessing the potential of cardiac stem cells for treatment of myocardial infarction is also provided. | 06-06-2013 |
| 20130142763 | CROSSLINKED CELLULOSIC POLYMERS - Crosslinked cellulosic polymers, crosslinked cellulosic polymer hydro-gels, and methods for their synthesis and use are described. The crosslinked cellulosic polymers include one or more cellulosic polymers and a one or more crosslinkers that crosslinks the one or more cellulosic polymers together. The crosslinking can be facilitated with a crosslinking agent capable of linking with a monomer the cellulosic polymer and crosslinking the cellulosic polymer intermoleculerly and/or intramolecularly. Crosslinked cellulosic polymers are well adapted for use in cell and tissue growth in vivo and in vitro. The crosslinked cellulose polymers may also be used as wound care devices. | 06-06-2013 |
| 20130149284 | METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS - The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration. | 06-13-2013 |
| 20130149285 | ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE - The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures, and for treatment of “dry eye” conditions, acute renal failure, and chronic renal failure in non-human mammals. | 06-13-2013 |
| 20130149286 | METHODS FOR OBTAINING STEM CELLS - The present invention relates to methods for obtaining stem cells from mammalian cadavers, methods for obtaining or purifying stem cells from a sample likely to contain non-stem cells, methods of regeneration of injured tissues and methods of treatment. | 06-13-2013 |
| 20130149287 | Corticogenesis of Human Pluripotent Cells - This invention relates to in vitro methods for the induction of corticogenesis in human pluripotent cells, such as iPS cells, by culturing the cells under conditions which stimulate retinoid signalling and inhibit TGFβ superfamily signalling. This may be useful in production of cortical neurons, in particular patient-specific cortical neurons; the modelling of juvenile and adult-onset neurological diseases; and the development of therapeutics. | 06-13-2013 |
| 20130149288 | METHODS OF GENERATING OLIGODENDROCYTES AND CELL POPULATIONS COMPRISING SAME - A method of generating a population of cells useful for treating a brain disorder in a subject is disclosed. The method comprises contacting mesenchymal stem cells (MSCs) with at least one exogenous miRNA having a nucleic acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 15-19 and 27-35, thereby generating the population of cells and/or generating neurotrophic factors that may provide important signals to damaged tissues or locally residing stem cells. MSCs differentiated by miRs may also secrete miRs and deliver them to adjacent cells and therefore provide important signals to neighboring endogenous normal or malignant cells. | 06-13-2013 |
| 20130156741 | Bone Augmentation Utilizing Muscle-Derived Progenitor Compositions, And Treatments Thereof - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone). Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. | 06-20-2013 |
| 20130156742 | Scaffold-Free Three Dimensional Nerve Fibroblast Constructs - The invention relates to scaffold-free three dimensional nerve fibroblast constructs and method of generating the nerve fibroblast constructs. The invention also relates to methods or repairing nerve transection and replacing damaged nerve tissue using the nerve fibroblast constructs of the invention. | 06-20-2013 |
| 20130156743 | VITRO HEPATIC DIFFERENTIATION - This invention relates to the induction of hepatic differentiation by culturing induced pluripotent stem (iPS) cells in an endoderm induction medium to produce a population of anterior definitive endoderm (ADE) cells and then culturing the population of ADE cells in a hepatic induction medium to produce a population of hepatic progenitor cells, which may be optionally differentiated into hepatocytes. The endoderm induction medium is a chemically defined medium which has fibroblast growth factor activity, stimulates SMAD2 and SMAD3 mediated signalling pathways and SMAD1, SMAD5 and SMAD9 mediated signalling pathways, and inhibits phosphatidylinositol 3-kinase (PI3K) and glycogen synthase kinase 3β (GSK3β); and the hepatic induction medium is a chemically defined medium which stimulates SMAD2 and SMAD3 mediated signalling pathways. These methods may be useful, for example, in producing hepatocytes and hepatic progenitor cells for cell-based therapies or disease modelling. | 06-20-2013 |
| 20130156744 | METHODS OF RECELLULARIZING A TISSUE OR ORGAN FOR IMPROVED TRANSPLANTABILITY - Described herein are methods of recellularizing an organ or tissue matrix. | 06-20-2013 |
| 20130164265 | SKIN CARE COMPOSITIONS - This invention provides compositions and methods of manufacturing such compositions that employ GRAS compounds which can act to promote the generation of stem, epidermal or other skin cells in the epidermis, activation of collagen synthesis, activation of hyaluronic acid synthesis, enhanced skin hydration, and dermal healing by stimulating stem cell and fibroblast migration to sites of needed repair. These compositions and methods are useful for rejuvenating the skin and for treating some skin-related aging or other dermal damaging conditions, including wrinkle reduction and treatment of minor dermal wounds. | 06-27-2013 |
| 20130164266 | 3-DIMENSIONAL SCAFFOLDS FOR IMPROVED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HEPATOCYTES - The present invention relates to the use of 3-dimensional (3D) synthetic or animal-derived bioscaffolds as substrates for the improved growth and differentiation of hPS (Human pluripotent stem cells); these scaffolds being adapted for use in conjunction with existing cell culture lab plastic-ware. More specifically, it relates to the seeding of these scaffolds, either alone or in conjunction with various biologic matrix coatings, with hPS cells for the improved differentiation of said hPS cells into hepatocyte or hepatocyte-like cell types. The invention also relates to the seeding of partially-differentiated hepatocyte progenitors onto scaffolds for further differentiation into more mature hepatocyte-cell types. | 06-27-2013 |
| 20130164267 | ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE - The invention provides for compositions and methods for making and using adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures, and for treatment of “dry eye” conditions, acute renal failure, and chronic renal failure in non-human mammals. | 06-27-2013 |
| 20130164268 | REGULATION OF GLYPICAN 4 ACTIVITY TO MODULATE THE FATE OF STEM CELLS AND USES THEREOF - The present invention thus relates to stem cells or progenitor cells wherein the expression and/or activity of a member of the glypican family is reduced or abolished for use for the treatment of a pathological condition selected from the group consisting of a degenerative disease, a cardiac disorder, a metabolic disease and an injury by stem cell-based therapy. | 06-27-2013 |
| 20130164269 | CELL CULTURE SYSTEM FOR BIOREACTOR SCALE-UP OF CELLS - The present invention relates to growing stem cells, for e.g., MSCs, in large-scale under GMP-compliance, using media and reagents that satisfy GMP requirements, while maintaining stemness, for effective downstream therapeutic use, which include but are not limited to, stem cell therapy, production of products, such as beneficial factors, recombinant proteins, etc. obtained from such stem cells. | 06-27-2013 |
| 20130171110 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING PLURIPOTENT STEM CELLS INTO PRIMITIVE BLOOD CELLS AND USES THEREOF - Compositions and methods that employ various combinations of such factors as retinoic acid signaling inhibitors, antioxidants, BMP4, VEGF, prostaglandin E | 07-04-2013 |
| 20130171111 | METHOD OF MANUFACTURING A SCAFFOLD FOR TISSUE ENGINEERING OR REPAIR - The invention relates to a method of manufacturing a scaffold for tissue engineering or repair. The method includes providing a mixture comprising a degradable hydrogel, a degradable particle, and living cells. The mixture is then incubated under conditions which allow proliferation of the living cells and degradation of the degradable particle in the hydrogel. The degradable hydrogel of the incubated mixture is then degraded at least partially, followed by adding further living cells to obtain the scaffold. | 07-04-2013 |
| 20130171112 | Methods for promoting hair growth - The invention is directed to methods for promoting hair growth. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 07-04-2013 |
| 20130171113 | METHOD OF TREATING GRAFT VERSUS HOST DISEASE - A method for preventing the development of or treating GvHD complications in a mammalian patient which comprises administering to the mammal a population of cells enriched for STRO-1 | 07-04-2013 |
| 20130171114 | ISLETS OF LANGERHANS TRANSPLANT USING ISLETS OF LANGERHANS AND ADIPOSE TISSUE DERIVED STEM CELLS - An object of the present invention is to provide a pancreatic islet transplantation technique that enables increase of graft survival rate of pancreatic islets after pancreatic islet transplantation, to maintain survival of pancreatic islets, and to reduce the number of transplanted pancreatic islets required for normalizing blood glucose level. When performing pancreatic islet transplantation, by transplanting pancreatic islets and adipose tissue-derived stem cells together, it is possible to significantly improve graft survival rate of transplanted pancreatic islets, and reduce by half the number of transplanted pancreatic islets required for normalizing blood glucose level. | 07-04-2013 |
| 20130177535 | WNT INHIBITORS FOR HUMAN STEM CELL DIFFERENTIATION - Methods and small molecule compounds for stem cell differentiation and treatment of animals with diseases are provided. One example of a class of compounds that may be used is represented by the compound of Formula I and II: | 07-11-2013 |
| 20130177536 | Enhancement Of Skeletal Muscle Stem Cell Engraftment By Dual Delivery Of VEGF And IGF-1 - An improved device and method for extended repair and regeneration of muscle tissue. An exemplary device comprises (a) a scaffold comprising an ECM component; (b) a combination of growth factors such as VEGF and IGF; and (c) a population of myogenic cells. Implantation of the device leads to muscle regeneration and repair over an extended period of time. | 07-11-2013 |
| 20130177537 | STEM CELLS AND METHODS FOR INCORPORATING ENVIRONMENTAL FACTORS AS A MEANS FOR ENHANCING STEM CELL PROLIFERATION AND PLASTICITY - Disclosed are methods for expanding stem cells that use a unique combination of environmental factors and cell culture conditions to produce stem cells having enhanced proliferation and differentiation characteristics. Also disclosed are methods for enhancing the engraftment and/or migratory potential of stem cells for therapeutic uses. Stem cells having unique proliferation, differentiation, migratory and engraftment characteristics are also disclosed. | 07-11-2013 |
| 20130183272 | MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO - The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and method sof treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies. | 07-18-2013 |
| 20130183273 | NATIVE WHARTON'S JELLY STEM CELLS AND THEIR PURIFICATION - Noncultured Wharton's Jelly stem cells and methods of their purification, storage and use are provided. | 07-18-2013 |
| 20130183274 | MAINTENANCE AND PROPAGATION OF MESENCHYMAL STEM CELLS - Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same. | 07-18-2013 |
| 20130183275 | Novel Use of Cryptotanshinone - Provided are a composition for stimulating differentiation of MSCs into osteoblasts, which includes cryptotanshinone, and an osteogenesis stimulator including cryptotanshinone and MSCs. | 07-18-2013 |
| 20130189230 | INJECTABLE POLYMER COMPOSITION FOR USE AS A CELL DELIVERY VEHICLE - This invention provides a polymer composition comprising at least one thermal gelling polymer and at least one anionic polymer for cell delivery applications. These injectable polymer compositions are shear-thinning, thixotropic and resorbable. More specifically there is described a hyaluronan (HA) and methylcellulose (MC) based thermogelling cell delivery system (HAMC) that promotes cell survival both in vitro and in vivo. Importantly, HAMC (relative to media alone) enhances survival of transplanted stem/progenitor cells in the injured CNS. HAMC provides a minimally-invasive cell delivery strategy where the microenvironment can be further defined and the differentiation and regenerative capacity further explored. This hydrogel system has applications for minimally-invasive cell delivery to other tissues/organs in the body as well. | 07-25-2013 |
| 20130189231 | COMPOSITION FOR TREATMENT OF CARTILAGE DISEASE - The present invention provides a composition for regenerating cartilage or treating a cartilage disease containing a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is possible to provide a composition for regenerating cartilage that improves cartilage regenerative action and ease of application to a cartilage injury lesion, and a composition for treating a cartilage disease, which has the effects of protecting cartilage from mechanical irritation, inhibiting degenerative changes in cartilage caused by wear and inflammation, repairing a cartilage injury lesion, and inhibiting inflammation and pain of joint tissue. | 07-25-2013 |
| 20130189232 | CELLULAR THERAPEUTIC AGENT FOR INCONTINENCE OR URINE COMPRISING STEM CELLS ORIGINATED FROM DECIDUA OR ADIPOSE - The present invention relates to a cellular therapeutic agent for treating urinary incontinence, and more particularly to a cellular therapeutic agent for treating urinary incontinence, which contains stem cells derived from the decidua of the placenta or menstrual fluid or stem cells derived from adipose. The decidua-derived stem cells or adipose-derived stem cells show the effects of increasing leak point pressure and urethral sphincter contractility, and thus are useful as an agent for treating urinary incontinence. | 07-25-2013 |
| 20130189233 | METHOD FOR USING DIRECTING CELLS FOR SPECIFIC STEM/PROGENITOR CELL ACTIVATION AND DIFFERENTIATION - A method is provided, including obtaining a population of isolated immature antigen-presenting cells; enriching a population of isolated stem/progenitor cells within a larger population of cells; activating the population of immature antigen-presenting cells; and following the activating, inducing at least one process selected from the group consisting of: differentiation, expansion, activation, secretion of a molecule, and expression of a marker, by exposing the enriched stem/progenitor cell population to the population of activated antigen-presenting cells. Inducing the at least one process includes generating a lineage specific precursor/progenitor population (LSP) from the enriched stem/progenitor cell population. In addition, (1) obtaining the population of immature antigen-presenting cells includes obtaining the population of immature antigen-presenting cells from umbilical cord blood, and/or (2) enriching the population of stem/progenitor cells includes obtaining the population of stem/progenitor cells from umbilical cord blood. Other applications are also described. | 07-25-2013 |
| 20130189234 | ULTRASONIC CAVITATION DERIVED STROMAL OR MESENCHYMAL VASCULAR EXTRACTS AND CELLS DERIVED THEREFROM OBTAINED FROM ADIPOSE TISSUE AND USE THEREOF - Methods of treating using adipose tissue using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within adipose tissue and thereby obtain mesenchymal or stromal vascular fractions for use in human subjects are provided. These methods preferably do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased numbers of the cells which constitute the mesenchymal or stromal vascular fractions (about 10-fold greater) than methods which use collagenase to isolate these cells. | 07-25-2013 |
| 20130189235 | Methods of treating spinal cord injury and minimizing scarring - The invention is directed to methods of promoting the healing of spinal cord injury. The invention is further directed to methods of minimizing the extent of scarring following spinal cord injury. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents. | 07-25-2013 |
| 20130195805 | MODIFICATION OF REACTIVITY OF BONE CONSTRUCTS - A method of enhancing the binding of growth factors and cell cultures to a demineralized allograft bone material which includes applying ex vivo an effective quantity of an ionic force change agent to at least a portion of the surface of a demineralized allograft bone material to produce a binding-sensitized demineralized allograft bone material and implanting the binding-sensitized demineralized allograft bone material into a host bone. The ionic force change agent may include at least one of enzymes, pressure, chemicals, heat, sheer force, oxygen plasma, supercritical nitrogen, supercritical carbon, supercritical water or a combination thereof. A molecule, a cell culture, or a combination thereof is administered to the binding-sensitized demineralized allograft bone material. | 08-01-2013 |
| 20130195806 | PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF - This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients. | 08-01-2013 |
| 20130195807 | AGONISTS OF GROWTH HORMONE RELEASING HORMONE AS EFFECTORS FOR SURVIVAL AND PROLIFERATION OF PANCREATIC ISLETS - Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists. | 08-01-2013 |
| 20130195808 | MESENCHYMAL STEM CELL AND A METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 08-01-2013 |
| 20130195809 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided. | 08-01-2013 |
| 20130195810 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided. | 08-01-2013 |
| 20130195811 | Biomatrix Scaffolds - The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same. | 08-01-2013 |
| 20130195812 | INDUCED PLURIPOTENT STEM CELLS - Described herein is a major breakthrough in nuclear reprogramming and induced pluripotent stem cell (iPSC) technology. Fusion of the powerful transcription activation domain (TAD) of MyoD to the Oct4 protein makes iPSCs generation faster, more efficient, purer, safer and feeder-free. Also, disclosed herein is the first report of the use of a TAD fused to a transcription factor as a method for making iPSCs. By combining transcription factors and TADs, this approach to nuclear reprogramming can have a range of applications from inducing pluriopotency to inducing transdifferentiation without transitioning through iPSCs. | 08-01-2013 |
| 20130195813 | METHOD FOR PRODUCING CELLS HAVING CHARACTERISTICS OF HEPATOCYTES - The present invention relates to a method of producing cells having at least one characteristic of human hepatocytes as well as to cells produced by said method and uses of these cells. | 08-01-2013 |
| 20130195814 | TISSUE-SPECIFIC DIFFERENTIATION MATRICES AND USES THEREOF - In some aspects, this invention provides a method of making a bone marrow-derived tissue-specific stem cell proliferation, expansion, isolation and rejuvenation extracellular matrix. In other aspects, this invention provides a method of making a tissue-specific fibroblast-derived stem cell differentiation extracellular matrix. Also provided are methods of using such a cell-derived preservation or differentiation matrices to induce tissue-specific differentiation of pluripotent cells, repair damaged tissue, and treat a subject having a physiologic deficiency using the same. | 08-01-2013 |
| 20130202563 | DECELLULARIZED ADIPOSE CELL GROWTH SCAFFOLD - Provided herein are methods of making a cell growth scaffold from adipose tissue, cell growth scaffolds having low lipid content and methods of using the cell growth scaffold. | 08-08-2013 |
| 20130202564 | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration - This invention provides a composition for controlled-release of polypeptide growth factors useful in tissue repair or engineering. The composition include a polypeptide growth factor covalently cross-linked to a biocompatible substrate by a transgultaminase. The cross-linking tethers the growth factor to a substrate so that it will not diffuse away from the desired site of application. It also concomitantly inactivates the growth factor. Release and reactivation of the growth factor can be achieved by endogenously produced metalloproteinase (MMPs) or exogenously provided proteases such as collagenases. Also provided are scaffolds, transplant devices, methods for using the same and methods for making the same, | 08-08-2013 |
| 20130202565 | METHOD FOR INDUCING DIFFERENTIATION OF ADULT STEM CELLS AND NERVE CELLS USING ELECTROMAGNETIC FIELD - The present invention relates to a method for differentiation of mesenchymal stem cells or dental pulp stem cells. More specifically, the invention relates to a method for differentiating stem cells to neural cells by applying mesenchymal stem cells or dental pulp stem cells with a low-frequency electromagnetic field. The differentiation method according to the present invention can induce differentiation even with low-cost mediums rather than induced neural differentiation mediums which are expensive due to addition of growth factors, and the neural cells differentiated according to the present invention may be useful for treatment of neurological brain diseases. | 08-08-2013 |
| 20130202566 | METHOD FOR INDUCING DIFFERENTIATION OF MESENCHYMAL STEM CELLS TO NERVE CELLS USING SOUND WAVES - The present invention relates to a method for differentiation of mesenchymal stem cells. More specifically, the invention relates to a method for differentiating mesenchymal stem cells to neural cells by treating the mesenchymal stem cells with low-frequency sound waves. The differentiation method of the present invention can induce differentiation even with low-cost media rather than induced neural differentiation mediums which are expensive due to addition of growth factors, and the neural cells differentiated according to the present invention may be useful for treatment of neurological diseases. | 08-08-2013 |
| 20130202567 | TISSUE CULTURE MEDIA CONTAINING TRIMETHYLAMINE N-OXIDE - The present disclosure provides cell culture medium comprising trimethylamine N-oxide (TMAO). Progenitor cells cultured with such medium can form connective tissue with enhanced mechanical properties. Also provided are methods of forming connective tissue and methods of treatment for connective tissue defects. | 08-08-2013 |
| 20130202568 | Ameliorating Nervous Systems Disorders - The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition. | 08-08-2013 |
| 20130209414 | Expansion Of Stem/Progenitor Cells By Inhibition Of Enzymatic Reactions Catalyzed By The Sir2 Family Of Enzymes - Provided are ex vivo and in vivo methods of expanding renewable stem cells using agents capable of down-regulating Sir2 protein activity and/or expression, expanded populations of renewable stem cells, and uses thereof. | 08-15-2013 |
| 20130209415 | PURIFIED COMPOSITIONS OF CARDIOVASCULAR PROGENITOR CELLS - Composition and methods are provided for the prospective enrichment of human cardiovascular progenitor cells, which can be differentiated into cardiomyocytes, from in vitro cultures of stem cells. The stem cells are cultured in conditions permissive for differentiation into cardiovascular progenitor cells, and cardiovascular progenitor cells are sorted for expression of one or more of the markers ROR2, CD13, KDR and PDGFαR, where the progenitor cells positively express these markers. Highly enriched populations of cardiomyocyte lineage cells can be obtained. | 08-15-2013 |
| 20130209416 | METHODS AND COMPOSITIONS FOR PREPARING CARDIOMYOCYTES FROM STEM CELLS AND USES THEREOF - The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries. | 08-15-2013 |
| 20130209417 | ISOLATION OF ADULT MULTIPOTENTIAL CELLS BY TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE - The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells. | 08-15-2013 |
| 20130209418 | METHODS AND COMPOSITION RELATED TO BROWN ADIPOSE-LIKE CELLS - Methods and therapeutics are provided for treating diseases, including metabolic diseases and other weight-related disorders. Generally, methods for making brown adipose-like including culturing a population of artery-derived cells in adipogenic induction medium for a period of time and under conditions sufficient to increase expression of at least one adipocyte marker at a higher level as compared to untreated artery-derived cells are disclosed. Isolated artery-derived, ex vivo differentiated brown adipose-like cells are also provided, including pharmaceutical compositions and cell delivery systems thereof. In another embodiment, a method of treating a subject is disclosed that includes obtaining a population of artery-derived brown adipose-like cells and administering the brown adipose-like cells into a target region in the subject. | 08-15-2013 |
| 20130209419 | Methods of Engraftment - Methods and compositions for improving the engraftment of stem cells are described. The method involves administering an effective amount of hemoglobin. The methods and compositions are useful in stimulating hematopoiesis and may be used to boost human hematopoietic re-engraftment for use in transplant recipients or in patients with bone marrow injury. | 08-15-2013 |
| 20130209420 | Mixed Cell Populations for Tissue Repair and Separation Technique for Cell Processing - The present invention provides a fluid exchange cell culture technique and tissue repair cells (TRCs) made by these methods, as well as methods using these cells. The method includes a new wash step which increases the tissue repair properties of the TRCs of the invention. This wash step allows for the production of TRC populations with greater tissue repair and anti-inflammatory capabilities. Embodiments of the present invention include a post-culture process for cultured cells that preferably includes the steps of: a wash process for removing unwanted residual culture components, a volume reduction process, and a harvesting process to remove cultured cells. Preferably, all these steps are performed within a aseptically closed cell culture chamber by implementing a separation method that minimizes mechanical disruption of the cells and is simple to automate. The harvested cells may then be concentrated to a final volume for the intended use. In such embodiments, the final composition is a substantially purified and concentrated cell mixture suspended in a physiologic solution suitable for immediate use in humans without further washing, volume reduction, or processing. Embodiments are also applicable to harvesting (and/or washing) particles within a liquid or solution within a chamber. | 08-15-2013 |
| 20130209421 | INDUCED PLURIPOTENT STEM CELLS DERIVED FROM HUMAN PANCREATIC BETA CELLS - A method of generating pluripotent stem cells is described. The method comprises:
| 08-15-2013 |
| 20130209422 | "Pharmaceutical Composition Comprising Stem Cells Treated with NOD2 Agonist or Culture Thereof for Prevention and Treatment of Immune Disorders and Inflammatory Diseases" - The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a method for preparing PGE | 08-15-2013 |
| 20130209423 | METHODS FOR PROMOTING HEMATOPOIETIC RECONSTITUTION - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 08-15-2013 |
| 20130209424 | COMPOSITIONS FOR PROMOTING HEMATOPOIETIC STEM CELL GROWTH - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 08-15-2013 |
| 20130209425 | ENCAPSULATION OF PANCREATIC CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS - The present invention relates to methods for encapsulating pancreatic progenitors in a biocompatible semi-permeable encapsulating device. The present invention also relates to production of human insulin in a mammal in response to glucose stimulation. | 08-15-2013 |
| 20130216502 | Methods of Treating Intestinal Injury Using Heparin Binding Epidermal Growth Factor and Stem Cells - The invention provides for methods of treating, abating and reducing the risk for intestinal injury by administering a combination heparin binding epidermal growth factor (HB-EGF) and stem cells, such as mesenchymal stem cells or intestinal stem cells, in an amount effective to reduce the onset or severity of intestinal injury. The invention also provides for methods of promoting engraftment of stem cells, such as mesenchymal stem cells or intestinal stem cells, within the intestine of a patient suffering from intestinal injury. | 08-22-2013 |
| 20130216503 | Methods for Generating Cardiomyocytes - The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes. | 08-22-2013 |
| 20130216504 | CCN3 AND CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTEC USES - The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof. | 08-22-2013 |
| 20130216505 | METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF AN ALLOGENIC CELL AND THERAPEUTIC USES - Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR. | 08-22-2013 |
| 20130216506 | Bioreactor for Isolation of Rare Cells and Methods of Use - The present invention relates to a bioreactor apparatus, and methods of use, for the isolation of rare blood cells, including hematopoietic stem cells and megakaryocytes. The apparatus includes a soft substrate and an anti-contractility agent, thereby providing a soft microenvironment to cultured cells. The apparatus of the invention is permissive for the survival of non-dividing cells while dividing cells are eliminated. This unique property allows for the simple isolation of rare blood cells without the use of costly equipment and antibodies. | 08-22-2013 |
| 20130216507 | METHODS FOR PROMOTING HSC ENGRAFTMENT - The present invention provides for compositions and methods for modulating hematopoetic stem cell populations by using HCS modulators, which are agents that either increase HSC numbers or decrease HSC numbers as desired by a particular indication. For example, HSC modulators found to increase HSC numbers include prostaglandin E | 08-22-2013 |
| 20130216508 | HUMAN LUNG STEM CELLS AND USES THEREOF - Embodiments of the invention relate to human stem cells and their therapeutic use in the treatment and/or prevention of lung diseases. Provided herein are compositions comprising c-kit positive human lung stem cells and methods of preparing and using c-kit positive human lung stem cells for the treatment and/or prevention of lung diseases. | 08-22-2013 |
| 20130224156 | METHOD OF PRODUCING HUMAN RETINAL PIGMENT EPITHELIAL CELLS - The invention relates to a method of producing a retinal pigment epithelial cell from a human pluripotent stem cell, and a method of treating or preventing a retinal disease by using the produced cell. The retinal pigment epithelial cell is prepared by (a) inducing differentiation of a human pluripotent stem cell into a pigment cell by adhesion cultivation of a human pluripotent stem cell in a medium containing a Nodal signal inhibitor and a Wnt signal inhibitor in the absence of a feeder cell to give a culture containing the pigment cell, (b) subjecting the obtained culture to further adhesion culture to give a culture containing a pigment cell colony, and (c) isolating the pigment cell from the obtained culture and culturing the cell to give a retinal pigment epithelial cell. | 08-29-2013 |
| 20130224157 | STEM CELLS FOR TREATING LUNG DISEASES - The invention is compositions and methods for treating lung diseases and conditions using mesenchymal stem cells. The preferred stem cells are those derived from a human umbilical cord, or from bone marrow. | 08-29-2013 |
| 20130224158 | TISSUE REPAIR USING ALLOGENEIC DERMAL FIBROBLASTS - The present invention provides a method for the repair of subcutaneous or dermal tissue in a subject, comprising in one aspect the injection of a suspension of allogeneic dermal fibroblasts into the subject. By injecting a suspension of allogeneic cells, the invention provides, for example, long-term augmentation of the subadjacent tissue without the disadvantages that accompany the preparation and/or use of presently available materials such as autologous fibroblasts cells or collagen. | 08-29-2013 |
| 20130224159 | PLACENTAL TISSUE GRAFTS AND IMPROVED METHODS OF PREPARING AND USING THE SAME - Described herein are tissue grafts derived from the placenta. The grafts are composed of at least one layer of amnion tissue where the epithelium layer has been substantially removed in order to expose the basement layer to host cells. By removing the epithelium layer, cells from the host can more readily interact with the cell-adhesion bio-active factors located onto top and within of the basement membrane. Also described herein are methods for making and using the tissue grafts. The laminin structure of amnion tissue is nearly identical to that of native human tissue such as, for example, oral mucosa tissue. This includes high level of laminin-5, a cell adhesion bio-active factor show to bind gingival epithelia-cells, found throughout upper portions of the basement membrane. | 08-29-2013 |
| 20130224160 | Treatment of Vocal Cords with Autologous Dermal Fibroblast Formulation - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×10 | 08-29-2013 |
| 20130224161 | METHODS FOR ORGAN REGENERATION - A method of enhancing or initiating regeneration of an organ in a subject in need thereof comprising the administration of endothelial cells specific to said organ, or inductive endothelial cells specific to said organ, into the area of the body in which organ regeneration is desired in said subject. | 08-29-2013 |
| 20130230493 | PHOTOCROSSLINKED BIODEGRADABLE HYDROGEL - A photocrosslinked biodegradable hydrogel includes a plurality of natural polymer macromers cross-linked with a plurality of hydrolyzable acrylate cross-links. The hydrogel is cytocompatible and produces substantially non-toxic products upon degradation. | 09-05-2013 |
| 20130230494 | Cellular Preparations For Wound Management - Disclosed herein are methods of preserving or preparing cell-based compositions for use in wound management. The methods can be carried out by steps including: (a) providing skin cells; (b) treating the skin cells with a monosaccharide; (c) treating the skin cells with a disaccharide; and (d) lyophilizing the skin cells. | 09-05-2013 |
| 20130230495 | AMPHIPHILIC CHITOSAN NANOGEL AS AN INJECTABLE DELIVERY SYSTEM FOR STEM CELL THERAPY - The present invention relates to a novel injectable delivery system for stem cell therapy, which comprises a thermo-sensitive amphiphlic chitosan nanogel. Therefore, the invention provides a method for repairing a tissue damage of a subject using the amphiphlic chitosan nanogel served as a carrier for delivering the stem cells to the damaged tissue. This invention also provides a method for sustaining the growth of stem cells using the amphiphlic chitosan nanogel served as a niche or scaffold. | 09-05-2013 |
| 20130230496 | GRAPHENE HYDROGEL AND METHOD FOR USING THE SAME - Provided herein is a hydrogel composition comprising a graphene, a chitosan, and a polyethylene (glycol) diacrylate (PEGDA) (PCG hydrogel). In some embodiments, the hydrogel further comprises a N-isopropylacrylamide (NIPAM) (TPCG hydrogel). Also provided is a method for differentiating a mesenchymal stem cell comprising contacting the cell with the PCG hydrogel. Further provided herein is a method for delivering a pharmaceutical composition to a cell comprising administering to the cell a TPCG hydrogel and the pharmaceutical composition. | 09-05-2013 |
| 20130230497 | Renovation And Repopulation Of Decellularized Tissues And Cadaveric Organs By Stem Cells - A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed. | 09-05-2013 |
| 20130236425 | COMPOSITIONS AND METHODS FOR CXCR4 SIGNALING AND UMBILICAL CORD BLOOD STEM CELL ENGRAFTMENT - The present invention provides for enhancing engraftment by co-infusing at least two partially HLA matched umbilical cord blood (“UCB”) units. The invention further provides for positive C3a mediated priming on responsiveness to doses of SDF-1 and C3a induced incorporation of CXCR4 in membranes in HSC and progenitors. The invention further provides for enhancing the homing of UCB HSC and progenitors via the SDF-1/CXCR4 pathway and that C3a and LL-37 are useful for this method. It is also disclosed herein that fragments of C3a (e.g., des-Arg) are effective in the methods of the invention, including enhancing homing of HSPCs to BM. The invention further encompasses the disclosure herein of NFAT1 regulation post-transcriptionally by both mir-184 and IFN-γ. The present invention further provides for measuring and using differences between UCB and adult CD4+/45RA+ T-cells as a means of defining strategies to enhance optimal allogeneic stem cell transplantation outcomes. The present invention further provides methods for maintaining IL-2 production in the absence of NFAT1 normal protein levels. | 09-12-2013 |
| 20130236426 | USE OF DECORIN FOR INCREASING MUSCLE MASS - The invention concerns decorin for increasing muscle mass, particularly in the treatment of muscular dystrophies. | 09-12-2013 |
| 20130236427 | Topical Dermal Formulations and Methods of Personalized Treatment of Skin - Personalized skin-specific topical formulations containing conditioned medium obtained from cultures of fibroblasts has been developed. Unlike other topical formulations, these formulations are specific for the recipient-skin type specific, and conditioned medium is obtained from a subject with desired skin characteristics. For example, since African American skin is known to wrinkle less and later than Caucasian skin, conditioned medium may be obtained from African American skin for application to pale skin. In another embodiment, the fibroblasts are obtained from young skin for administration to older skin. In still another embodiment, the fibroblasts are obtained from skin that does not suffer from acne or discoloration, for application to skin that is prone to acne or discoloration. Examples of skin donor selection criteria include delayed wrinkling, small pores, resistance to sunburn, resistance to acne, uniform coloration or lack of blotching or age spots and good moisture retention. | 09-12-2013 |
| 20130236428 | Reprogramming of Aged Adult Stem Cells - Reprogramming of mammalian stem cells including aged human adult stem cells of all types with young adult stem cell's supernatant-intracellular matrix, bioactive lipids and or microvesicules in a single step or as a secondary two step process using oocyte supernatant, its intracellular matrix and/or cellular components are disclosed to accomplish a gene erasure and reprogramming. This invention focuses on reprogramming and/or reactivating genes that are active and involved in youthful adult stem cell function, within aged adult stem cells that have been previously collected by and/or stored for patients who are 40 years and older. The process is accomplished by using the natural unaltered young adult stem cell fluid and its cellular components. | 09-12-2013 |
| 20130236429 | ENGINEERED VASCULAR ADIPOSE TISSUE - Embodiments of the invention relate to methods, compositions and kits for the in vivo formation of vascularized new adipose tissue in a subject. Combination of endothelial progenitor cells (EPCs) and mesenchymal progenitor cells (MPCs) implanted in vivo in a subject work synergistically to promote the formation vascularized new adipose tissue. | 09-12-2013 |
| 20130236430 | PROLIFERATION, SEPARATION AND TRANSPLANTATION OF INHIBITORY NEURON PROGENITORS AND PROLIFERATION PROMOTING SUBSTANCES FOR THE PROGENITORS - Those provided here are an Activin A-containing solution for making inhibitory neuron progenitors proliferate, a method for culturing the inhibitory neuron progenitors using this solution, a method for separating the inhibitory neuron progenitors and the inhibitory neurons using an Activin A receptor Acvr1 expression as an index, a method for transplanting thus separated cells to the brain surface, and a method for screening a factor for making the inhibitory neuron progenitors proliferate. | 09-12-2013 |
| 20130236431 | Compositions and Methods for Tissue Engineering, Tissue Regeneration and Wound Healing - In accordance with certain embodiments of the present disclosure, a kit is described. The kit includes primed living cells joined to and at least partially within a three-dimensional hydrogel structure and an isolated polypeptide having the carboxy-terminal amino acid sequence of an alpha Connexin, or a conservative variant thereof, wherein the polypeptide does not include the full length alpha Connexin protein. | 09-12-2013 |
| 20130236432 | METHOD AND DEVICE FOR MULTIPLYING AND DIFFERENTIATING CELLS IN THE PRESENCE OF GROWTH FACTORS AND OF A BIOLOGICAL MATRIX OR OF A SUPPORTING STRUCTURE - The invention relates to an in-vitro and in-vivo method for multiplying and differentiating cells, during which the growth process of the cells is initiated or terminated and structurally directed by the use of growth factors thrombopoietin (TPO) and/or erythropoietin (EPO), and/or growth hormone (GH), particularly human growth hormone (HGH), and/or somatostatin and/or leukemia inhibitory factor (LIF) and/or ciliary neurotropic factor (CNTF). The invention also relates to a biological matrix or supporting structure containing the aforementioned growth factors, and to a method and device for the production thereof and for carrying out the inventive method. | 09-12-2013 |
| 20130236433 | METHODS, COMPOSITIONS, CELLS, AND KITS FOR TREATING ISCHEMIC INJURY - The methods, compositions, cells and kits described herein are based on the discovery that stem cells, when injected into ischemic tissue of mammals, can be protected by preconditioning of the ischemic tissue with hypoxia-regulated human VEGF and human IGF-1. Methods, compositions, cells and kits for treating tissue injured by ischemia or at risk of ischemic injury in a subject are thus described herein. | 09-12-2013 |
| 20130236434 | AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS - A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal. | 09-12-2013 |
| 20130236435 | Somatic Stem Cells - A method of treating brain tissue damage or a neurodegenerative disease in a subject by obtaining from a subject a bodily fluid sample containing a plurality of cells, incubating the sample with EDTA or heparin in a container until the sample is separated into an upper layer and a lower layer, collecting the upper layer, isolating from the upper layer a population of somatic stem cells that are 0.3-6.0 micrometers in size, and administering to a subject in need thereof an effective amount of the somatic stem cells. | 09-12-2013 |
| 20130243733 | COMPOSITIONS AND METHODS FOR REGULATING ANGIOGENESIS - In accordance with the present invention, EC progenitors can be used in a method for regulating angiogenesis, i.e., enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g. anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation. | 09-19-2013 |
| 20130243734 | METHODS AND COMPOSITIONS FOR WOUND HEALING - Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair. | 09-19-2013 |
| 20130243735 | PRODUCTION OF INSULIN PRODUCING CELLS - The invention provides methods for differentiating stem cells along the pancreatic lineage as well as large scale culture methods. The present invention further provides pancreatic progenitor cells derived from stem cells to provide pancreatic cells to a subject. | 09-19-2013 |
| 20130243736 | REPLACEMENT OF BONE MARROW NICHE CELLS FOR TREATMENT OF VARIOUS DISEASES - In vitro 2-dimensional co-culture systems of LT-HSCs and osteoblastic niche cells and methods of establishing them are provided. For example, in certain aspects methods of screening people suffering from a disorder caused by dysfunction of osteoblastic niche cells, using said co-culture systems are described. In further aspects, methods for screening a candidate substance for treatment of a disorder caused by dysfunction of osteoblastic niche cells are provided. The present invention also concerns methods and therapeutic compositions of treating a patient suffering from a disorder caused by dysfunction of osteoblastic niche cells. | 09-19-2013 |
| 20130243737 | CALCIUM-CONTAINING STRUCTURES AND METHODS OF MAKING AND USING THE SAME - The present invention generally relates to calcium-containing structures and methods of making and using the structures. In one aspect, hollow calcium containing microstructures are used in conjunction with bone tissues/by-products to augment bone defects and extend the supply of bone tissues/by-products for bone augmentation. Bonding agents, such as calcium cements, are also used in the preparation of the hollow calcium microstructures combined with bone tissues/by-products or for use in preparing the hollow microstructures. The calcium-containing microstructures of the present invention are also useful as delivery vehicles of nitric oxide and/or nitric oxide containing or producing compounds for a variety of in vitro and in vivo uses. Calcium containing contoured substrates upon which cells/tissues can be grown in vitro for replacement and repair of tissues in vivo that conform in size and shape to the tissue surface to be replaced are also provided. | 09-19-2013 |
| 20130243738 | SOLUBILIZATION OF ANTIGEN COMPONENTS FOR REMOVAL FROM TISSUES - The present invention relates to methods for removing antigens from tissues by sequentially destabilizing and/or depolymerizing cytoskeletal components and removing and/or reducing water-soluble antigens and lipid-soluble antigens. The invention further relates to tissue scaffolding and decellularized extracellular matrix produced by such methods. | 09-19-2013 |
| 20130243739 | Methods And Compositions For Regenerating And Repairing Damaged Or Aged Tissue Or Organs Using Nonviable Irradiated Or Lyophilized Pluripotent Stem Cells - Compositions and methods are provided herein for regenerating and repairing damaged or aged tissue or organs using nonviable lethally irradiated or lyophilized pluripotent stem cells. In one aspect, the compositions and methods described herein provide anti-aging benefits to the skin by increasing the hydration reducing fine lines, wrinkles, and pores of the skin. Compositions and methods are also provided for promoting wound healing using lyophilized pluripotent stem cell powder. A method is provided for inducing cardiac muscle regeneration in a primate comprising delivering nonviable lethally irradiated pluripotent stem cells to damaged or aged areas of the heart. The compositions and methods include nonviable lethally irradiated or lyophilized pluripotent stem cells. In one aspect, the compositions and methods utilize nonviable pluripotent stem cells in the form of a powder, such as lyophilized stem cells. | 09-19-2013 |
| 20130243740 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS - The present specification discloses compositions and methods of transplanting tissue, for example, in breast augmentation procedures. The compositions include adipose tissue and compounds that reduce tissue volume loss and increase survival rate of the adipose tissue when the composition is introduced into breast tissue. | 09-19-2013 |
| 20130251684 | METHODS OF ISOLATING AND CULTURING STEM CELLS - Provided herein are methods of isolating and expanding a plurality of multipotent stem cells. Also described are methods of expanding stem cells on a substrate comprising an HC-HA complex. Also described are isolated and expanded stem cells produced by the methods and uses thereof, including stem cell therapy, as niche cells for supporting other types of stem cells, or as bioreactors for the production of HC-HA complexes. Also described are uses of HC-HA complexes as a carrier for stem cells. | 09-26-2013 |
| 20130251685 | Injectable Cross-Linked Polymeric Preparations and Uses Thereof - A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue. | 09-26-2013 |
| 20130251686 | METHODS OF TREATING ISCHEMIC SPASTICITY - The invention relates generally to methods of treating spasticity, rigidity, or muscular hyperactivity conditions by introducing a portion of an expanded population of neural stem cells into an area of a recipient spinal cord. | 09-26-2013 |
| 20130251687 | Compositions and Methods for Tissue Repair with Extracellular Matrices - Described herein are compositions comprising decellularized cardiac extracellular matrix and therapeutic uses thereof. Methods for treating, repairing or regenerating defective, diseased, damaged or ischemic cells, tissues or organs in a subject, preferably a human, using a decellularized cardiac extracellular matrix of the invention are provided. Methods of preparing cardiomyocyte culture surfaces and culturing cells with absorbed decellularized cardiac extracellular matrix are provided. | 09-26-2013 |
| 20130251688 | CELLS TREATED BY IN VITRO FUCOSYLATION AND METHODS OF PRODUCTION AND USE THEREOF - A population of cells possesses enhanced selectin binding based upon a fucosylated selectin ligand present on a surface thereof. Methods of producing the population of cells, along with therapeutic methods of using the cells, are also disclosed. | 09-26-2013 |
| 20130251689 | KERATIN COMPOSITIONS FOR TREATMENT OF BONE DEFICIENCY OR INJURY - A bone graft composition is described, with one or more of: (a) keratose; (b) kerateine; (c) optionally, particulate filler; (d) optionally, an antibiotic; and (e) water or saline. The composition may be provided in sterile form in a container, and optionally lyophilized. Methods of treating a bone deficiency or fracture making use of such compositions are also described. | 09-26-2013 |
| 20130251690 | STEM CELL DIFFERENTIATION USING KERATIN BIOMATERIALS - Provided are methods and keratin compositions useful for modulation of cell differentiation, both in vitro and in vivo, for example, in cell therapy applications. | 09-26-2013 |
| 20130251691 | Embryonic Stem Cell-Derived Cardiomyocytes and a Cellular Therapeutic Agent Comprising the Same as an Active Ingredient - The present invention relates to a method for producing embryonic stem cell-derived cardiomyocytes, cardiomyocytes produced by the method, a method for producing cardiomyocyte bodies from the cardiomyocytes, cardiomyocyte bodies produced by the method, a cellular therapeutic agent comprising the cardiomyocyte bodies as an active ingredient for the treatment of cardiac diseases, a method for treating cardiac diseases using the cellular therapeutic agent, and use of cardiomyocytes or cardiomyocyte bodies for the preparation of the cellular therapeutic agent. The method for producing cardiomyocytes of the present invention can be used to easily purify differentiated cardiomyocytes from embryonic stem cells. Further, the purified cardiomyocytes can be used to produce cardiomyocyte bodies, which can be used as a cellular therapeutic agent for treating cardiac diseases. Therefore, the cardiomyocyte bodies can be widely applied to the development of prophylactic or therapeutic agents for cardiac diseases. | 09-26-2013 |
| 20130251692 | METHODS OF GENERATING CORNEAL CELLS AND CELL POPULATIONS COMPRISING SAME - A method of generating a population of corneal epithelial cells is disclosed. The method comprises culturing human pluripotent stem cells in corneal fibroblast-conditioned medium on a solid surface comprising an extracellular matrix component thereby generating the population of corneal epithelial cells. Isolated cell populations and corneal tissues are also disclosed, as well as uses thereof. | 09-26-2013 |
| 20130259836 | MATURE HEPATOCYTE CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELLS, A GENERATING METHOD THEREOF, AND USE THEREOF FOR TREATMENT OF LIVER DISEASES - The present invention describes an efficient and rapid protocol to generate hepatocyte cells from human induced pluripotent stem cells (iPSCs). According to the method, the iPS cells can be differentiated into functional hepatocyte cells in a short time course (less than 15-20 days). The iPSC-derived hepatocyte cells of the invention have a similar gene expression profile to mature hepatocytes. Moreover, the iPSC-derived hepatocyte cells is proved to rescue lethal fulminant hepatic failure in a non-obese diabetic severe combined immunodeficient mouse model. The rapid and efficient differentiation protocol for generation of iPSC-derived hepatocyte cells may offer an alternative option for treatment of liver diseases. | 10-03-2013 |
| 20130259837 | Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived From Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 10-03-2013 |
| 20130259838 | CULTURED CARTILAGE TISSUE MATERIAL - Provided is a cultured cartilage tissue material which enables formation of cartilage tissue being substantially the same as the cartilage tissue actually in the living body, and which is large in volume. The cultured cartilage tissue material is to be used for cartilage regeneration and comprises chondrocytes, and is a mixed body of chondrocytes in a concentration of 1×10 | 10-03-2013 |
| 20130259839 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF TISSUE OF ORIGIN OF TUMOR SAMPLES - The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy. | 10-03-2013 |
| 20130259840 | PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD - Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC−/− progenitor cells, and is useful to grow and repair human tissues including bone. | 10-03-2013 |
| 20130259841 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors - Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 | 10-03-2013 |
| 20130266541 | HUMAN INDUCED PLURIPOTENT STEM CELLS - The present invention relates generally to the field of stem cells and, more particularly, to reprogramming blood cells to pluripotent stem cells. In a specific embodiment, a method for producing an induced pluripotent stem cell from a human myeloid progenitor cell comprising the steps of (a) activating the human myeloid progenitor cell by incubation with hematopoietic growth factors; (b) transfecting the activated progenitor cells with a non-viral vector expressing one or more pluripotency factors; and (c) co-culturing the transfected cells with irradiated mesenchymal bone marrow stromal cells. | 10-10-2013 |
| 20130266542 | Compositions and Methods of Using Living and Non-Living Bioactive Devices with Components Derived From Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro - The invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 10-10-2013 |
| 20130266543 | Multipotent Adult Stem Cell Population - The present invention relates to the identification, isolation, expansion and characterization of a specific type of adult stem cell. These adult stem cells are characterized in that they naturally express many of the markers of totipotency, which have hitherto generally been limited to embryonic cell populations. The cells of the invention display an unprecedented capacity for multi potency; they are able to differentiate into cell types of mesodermal, endodermal and ectodermal origin. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium. | 10-10-2013 |
| 20130266544 | Osteogenic Differentiation Of Bone Marrow Stem Cells And Mesenchymal Stem Cells Using A Combination Of Growth Factors - The invention relates to methods for osteogenic differentiation of human bone marrow stem cells (BMSC) or mesenchymal stem cells (MSC), in particular using human plasma or serum and FGF and TGFB growth factors. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 10-10-2013 |
| 20130266545 | METHODS FOR IMPROVED WOUND CLOSURE EMPLOYING OLIVAMINE AND HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS - The present disclosure relates to compositions for and methods of improving wound healing, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The methods for wound healing administer one or more compositions including hydroxytyrosol and oleuropein with cells derived from umbilical cord blood. | 10-10-2013 |
| 20130266546 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 10-10-2013 |
| 20130266547 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 10-10-2013 |
| 20130266548 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 10-10-2013 |
| 20130266549 | HIGHLY BIOCOMPATIBLE DUAL THERMOGELLING CHITOSAN/GLUCOSAMINE SALT COMPOSITION - The present disclosure relates to a chitosan solution neutralized with amino-sugar carbonate buffering solution or amino-sugar phosphate buffering solution or phosphorylated aminosugar buffering solution. The resulting themogelling chitosan composition is highly biocompatible, isotonic and has the ability to rapidly turn into gel upon heating to the body temperature. It provides a novel chitosan-based composition to suitable for drug delivery, cell delivery and repair or regeneration of tissues and organs as well as other clinical treatment. | 10-10-2013 |
| 20130266550 | DIAGNOSTIC METHOD FOR CONNECTIVE TISSUE AND ITS APPLICATION - The present invention relates to medicine and is used to evaluate conditions and to detect connective tissue pathology (and/or organ) by clonal analysis. The present invention relates to aesthetic medicine and is used for correction of aging skin changes. The method includes: cultivation of substrate-dependent cell colonies of analyzed tissue and/or organ, at conditions which provide formation of discrete colonies applicable for visualization, statistically reliable analysis of derived colonies, determination of at least one parameter which characterizes regenerative potential of population of substrate dependent cells, determination of at least one parameter which characterizes proliferative potential of population of substrate dependent cells, and processing of obtained results which allows to evaluate regenerative ability of patient's tissue and/or organ. The method provides objective qualitative characteristics of both the proliferative and regenerative potential which allows evaluating the regenerative potential of primary tissue (and/or organ) without complex and expensive instrumental studies. A computer based system for performing the present method is also provided. | 10-10-2013 |
| 20130273008 | Platelet Rich Plasma/Stem Cell Dispensing System and Methods Thereof - A method and apparatus is provided to separate Platelet Rich Plasma (PRP) utilizing standard whole blood harvesting techniques and separating the solution via centrifugation preparation. A pump is provided to pump PRP/Stem Cell solution from a centrifugation reservoir in to a nebulizer to aerosolize the PRP/Stem Cell solution in the nebulizer with oxygen. A patient will then inhale the aerosolized or vaporized PRP/Stem Cell solution into their respiratory system. Removal of any waste PRP/Stem Cell solution is provided by trapping the PRP/Stem Cells and any other biological matter other in a HEPA filter and allowing exhaled gasses to safely exit the from the Semi-Rebreathing Chamber. | 10-17-2013 |
| 20130273009 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS - Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula | 10-17-2013 |
| 20130273010 | SERUM-FREE MEDIA AND THEIR USES FOR CHONDROCYTE EXPANSION - The present invention provides defined serum-free cell culture media useful in culturing fibroblasts, especially articular chondrocytes, that avoid problems inherent in the use of serum-containing media. The defined media comprise platelet-derived growth factor (PDGF), chemically defined lipids, oncostatin M (OSM), interleukin-6 (IL-6), leukemia inhibitory factor (LIF), or combinations of these compounds. In another aspect, the present invention also provides tissue culture methods that comprise incubating chondrocytes in the defined serum-free media. The methods enhance attachment and proliferative expansion of chondrocytes seeded at low density while maintaining their redifferentiation potential. | 10-17-2013 |
| 20130273011 | STEM CELLS AND STEM CELL GENERATED NANOPARTICLES FOR TREATMENT OF INFLAMMATORY CONDITIONS AND ACUTE RADIATION SYNDROME - Disclosed are stem cells and nanoparticles derived from said stem cells, useful for the treatment of acute radiation syndrome (ARS) and other inflammatory conditions. In one embodiment, Endometrial Regenerative Cells (ERC) are administered to patients having been exposed to radiation to augment recovery of endogenous hematopoietic stem cells. In another embodiment, exosomes, nanoparticles that are generated by various stem cells are used as a drug for treatment of inflammatory conditions. | 10-17-2013 |
| 20130273012 | VIRUS CLEARANCE OF NEOPLASTIC CELLS FROM MIXED CELLULAR COMPOSITIONS - The present invention relates to a method for removing neoplastic cells from a mixed cellular composition, which is outside of a living organism, by using a virus which selectively infect and kill neoplastic cell. A variety of viruses can be used in this method to remove neoplastic cells for different purposes, for example, to purge hematopoietic stem cells prior to transplantation. Also provided are compositions prepared according to this method, and kits comprising a combination of viruses which are useful in this invention. | 10-17-2013 |
| 20130273013 | INSULIN PRODUCING CELLS DERIVED FROM PLURIPOTENT STEM CELLS - A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof. | 10-17-2013 |
| 20130280218 | METHODS OF OBTAINING CELL POPULATIONS ENRICHED WITH DESIRED CELLS - Provided is a method including providing a population of cells including a target type of differentiated cells having a pre-identified cytoskeletal profile and at least one cell selected from undifferentiated cells, differentiating cells and differentiated cells being different from the target type of differentiated cells; and incubating the population of cells with a cytotoxic agent, in an amount and for a time period effective to form a modified population of cells including predominantly or consisting essentially of the target type of differentiated cells. The pre-identified cytoskeletal profile can include the presence of class III β-tubulin on neuronal cells and the population of cells includes neural cells and neuronal cells. | 10-24-2013 |
| 20130280219 | MATERIALS AND METHODS RELATING TO CELL BASED THERAPIES - The invention relates to the provision of a novel cell population that can be used for tissue regeneration and the treatment of disease states associated with cell degeneration for age related tissue changes. The cell population are derived from adult stem/progenitor cells which are characterised by being positive or negative to the Thy1.1 cell marker. | 10-24-2013 |
| 20130287741 | FLOWABLE MATRIX COMPOSITIONS AND METHODS - Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies. | 10-31-2013 |
| 20130287742 | SILK FIBROIN AND POLYETHYLENE GLYCOL-BASED BIOMATERIALS - This invention relates to methods and compositions for preparation of silk-PEGs based biomaterials through crosslinking by chemically reacting active polyethylene glycols (PEGs) possessing different chemical groups (e.g., thiols and maleimides functionalized PEGs) that are additionally stabilized by the beta-sheet formation of silk fibroin. The crosslinked silk-PEGs biomaterials present strong adhesive properties, which are comparable to or better than the current leading PEG-based sealant, depending on the silk concentration in the silk-PEGs biomaterials. In addition, the silk-PEGs based biomaterials are cytocompatible, show decreased swelling behavior and longer degradation times, which make them suitable for hemostatic applications where the current available tissue sealant products can be contraindicated. | 10-31-2013 |
| 20130287743 | METHOD FOR DIFFERENTIATING HUMAN EMBRYONIC STEM CELLS INTO -CELLS FOR THE TREATMENT OF TYPE I DIABETES - The invention provides inter alia methods for differentiating embryonic stem cells into insulin producing cells, as well as compositions comprising such cells, and therapeutic uses of such compositions. | 10-31-2013 |
| 20130287744 | Biocomposites And Methods Of Making The Same - In general, the present invention is related to biopolymer and biocomposite materials and structures, and methods of making and using the same. In some embodiments, the present invention is directed to oriented collagen based biocomposite materials and structures, and methods of making. | 10-31-2013 |
| 20130287745 | COMPOSITIONS AND METHODS TO STIMULATE VASCULAR STRUCTURE FORMATION - Cell based compositions and methods are provided for inducing the formation of vascular structures in a warm blooded vertebrate. In one embodiment the composition comprises purified endothelial progenitor cells and adipose stromal cells and the method of stimulating the formation of vascular structures comprises the steps of implanting the composition in a host organism. | 10-31-2013 |
| 20130287746 | RADIATION CROSS-LINKED COLLAGEN GEL, AND PREPARATION METHOD AND USAGE METHOD THEREOF - The present invention relates to radiation cross-linked collagen gel, and a preparation method and usage method thereof. To this end, the present invention comprises a cross-linked collagen material made by irradiating liquid collagen with radioactive rays, wherein the concentration of said collagen is specifically 0.1-10% (W/V), and the radiation dose (dose rate×time) is 0.1-40 kGy on the basis of 1 kGy/hr. The present invention configured as above can prepare a formulated collagen gel using a physical cross-linking method instead of a chemical cross-linking method, specifically carries out the formulation by mixing biocompatible materials, and provides a method capable of using a cross-linked collagen hydrogel in wound dressings, graft materials, cell cultures and the like. Therefore, the present invention provides an industrially convenient and safe preparation method, thereby instilling a good image to a customer by greatly improving the quality and confidence in the products. | 10-31-2013 |
| 20130295056 | Generation of Histocompatible Tissues Using Nuclear Transplantation - Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy. | 11-07-2013 |
| 20130295057 | EN VIVO GENERATED TISSUE SYSTEM - The present invention relates to methods of generating an ex vivo tissue-like system in a bioreactor system capable of supporting continuous production of, and output of cells and tissues and an ex vivo tissue system made therefrom. | 11-07-2013 |
| 20130295058 | Pharmaceutical Compositions Comprising Gingiva A-Derived Mesenchymal Stem Cells and Methods of Treating Inflammation, Wound Healing and Contact Hypersensitivity - Disclosed are methods of polarizing macrophages to exhibit M2 phenotype, including introducing an effective amount of gingiva-derived mesenchymal stem cells to an environment comprising a population of macrophages such that the macrophages are in fluid communication with the gingiva-derived mesenchymal stem cells. Also disclosed are methods of promoting cutaneous wound healing including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells, thereby resulting in at least one of accelerated wound closure, rapid re-epithelialization, improved angiogenesis and improved tissue remodeling relative to untreated controls. Also disclosed are methods for attenuating contact hypersensitivity in a patient, the methods including administering to a patient an effective amount of human gingiva-derived mesenchymal stem cells at a time at least timeframe selected from the group consisting of before sensitization, after sensitization and before challenge and after challenge, thereby attenuating contact hypersensitity. | 11-07-2013 |
| 20130295059 | RHODAMINE DERIVATIVES FOR PHOTODYNAMIC DIAGNOSIS AND TREATMENT - Compositions and methods for reducing or preventing graft-versus-host disease associated with allogeneic stem cell transplantation are described. A method includes harvesting hematopoietic cells from a patient with an immunologic disorder and harvesting hematopoietic cells from a donor. The harvested hemaptopoietic cells from the patient and the donor are mixed ex vivo for a period of time sufficient to activate lymphocytes within the hematopoietic cells harvested from the donor such that an immune reaction occurs and an activated portion and an unactivated portion is produced. A rhodamine B derivative is then added to the mixture of cells and the mixture is irradiated at a suitable wavelength and intensity for the selective destruction and/or inactivation of the activated portion without substantially affecting the unactivated portion or causing systemic toxicity in said patient. The irradiated cells are then infused into the patient. | 11-07-2013 |
| 20130295060 | METHOD FOR CULTURING CARDIAC PROGENITOR CELLS AND USE OF CARDIAC PROGENITOR CELLS - Disclosed is a method for culturing myocardium-resident cardiac progenitor cells, comprising: embedding myocardial fragments into hydrogel; culturing the myocardial fragment into hydrogel; degrading only the hydrogel to recover cardiac progenitor cells grown out of the myocardial fragment to the hydrogel; and amplifying the cardiac progenitor cells in vitro. Also, the cardiac progenitor cells, a method for differentiating the same, and the use thereof as cell therapeutic agent for heart diseases are provided. In addition to possessing the potential to differentiate into cardiomyocytes, osteoblasts, adipocytes, chondrocytes, vascular endothelial cells, smooth muscle cells, neural cells, and skeletal muscle cells, the myocardium-resident cardiac progenitor cells can spontaneously differentiate into cardiomyocytes even in the absence of a special differentiation inducing agent. Thus, the cardiac progenitor cells can be used to produce bio-active medicines such as cell therapeutics and tissue engineering therapeutics with high industrial applicability. | 11-07-2013 |
| 20130295061 | Dosage Unit Formulations of Autologous Dermal Fibroblasts - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×10 | 11-07-2013 |
| 20130295062 | METHODS AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to methods and compositions for use in the treatment of neurological disorders, such as Alzheimer's disease and dementia. In one embodiment, the present invention provides a method of treatment of Alzheimer's disease in an individual by administering a composition overexpressing ACE to the individual. In another embodiment, the method of treatment comprises administering a composition comprising a therapeutically effective dosage of ACE. | 11-07-2013 |
| 20130302285 | Wharton's Jelly Mesenchymal Stem Cells and Uses Thereof - In one aspect, the invention is directed to methods of expanding hematopoietic stem cells (HSCs) comprising culturing the HSCs with Wharton's Jelly mesenchymal stem cells (WJSCs), a cell culture medium that has been conditioned with WJSCs, or a combination thereof, thereby producing a HSC culture; and maintaining the HSC culture under conditions in which the HSCs expand in the culture, thereby expanding the HSCs. In another aspect, the invention is directed to a method of transplanting the expanded HSCs in an individual in need thereof. In yet another aspect, the invention is directed to compositions comprising HSCs and Wharton's Jelly mesenchymal stem cells (WJSCs). The composition can further comprise a cell culture medium that has been conditioned with WJSCs. | 11-14-2013 |
| 20130302286 | Modalities for the treatment of degenerative diseases of the retina - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 11-14-2013 |
| 20130302287 | COMPOSITION FOR ANTI-AGING OR ANTIOXIDANT COMPOSITION CONTAINING PLANT STEM CELL LINE DERIVED FROM CAMBIUM OR PANAX GINSENG INCLUDING WILD GINSENG AND GINSENG AS ACTIVE COMPONENTS - The present invention relates to an anti-aging or antioxidant composition which contains, as an active ingredient, a plant stem cell line derived from the cambium of | 11-14-2013 |
| 20130302288 | Modalities for the treatment of degenerative diseases of the retina - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 11-14-2013 |
| 20130302289 | Methods for Modulating Immune Responses - The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents. | 11-14-2013 |
| 20130302290 | METHODS FOR TREATING A KIDNEY INJURY - Provided herein are methods of treating a kidney injury in a patient, comprising administering to the patient hematopoietic stem cells (HSCs) in an amount effective to treat the kidney injury. In some embodiments, administration of the HSCs is delayed, such that the HSCs are not administered immediately after the kidney injury. In certain aspects, the HSCs are administered to the patient during the beginning of the repair phase of the kidney. Further embodiments and aspects of the invention, including related methods and compositions for use therein, are described herein. | 11-14-2013 |
| 20130302291 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION - The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one antithrombin activator, preferably unfractionated heparin, as well as at least one thrombin inhibitor, preferably bivalirudin. | 11-14-2013 |
| 20130309206 | GYNOGENETIC OR ANDROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES - Methods for obtaining pluripotent (embryonic stem) cells from parthenogenetic embryos, especially primates, are provided. These cells are useful for producing differentiated cells, tissues and organs, especially human and non-human primate cells, tissues and organs. | 11-21-2013 |
| 20130309207 | COMPOSITIONS COMPRISING PERIVASCULAR STEM CELLS AND NELL-1 PROTEIN - Embodiments of the present invention provide a population of purified perivascular stem cells (PSC) or induced pluripotent stem cells (iPS) and a supernatant of stem cell free from the stem cell, a composition comprising any of these, and a method of using and making them. | 11-21-2013 |
| 20130309208 | Enhanced Medical Implant - A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Pluripotent stem cells, other cells, and biologic constituents of the dental pulp may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the pluripotent stem cells, other cells, and biologic constituents of the dental pulp can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair. | 11-21-2013 |
| 20130309209 | FORMATION OF HEMATOPOIETIC PROGENITOR CELLS FROM MESENCHYMAL STEM CELLS - There are provided, inter alia, methods for forming (e.g. transgeneration of) hematopoietic stem cells from mesenchymal stem cells. | 11-21-2013 |
| 20130309210 | ACCELERATION OF HEMATOPOIETIC RECONSTITUTION BY PLACENTAL ENDOTHELIAL AND ENDOTHELIAL PROGENITOR CELLS - Compositions useful for treatment of patients needing hematopoietic stimulation. In one embodiment patients are administered a cellular mixture derived from allogeneic placenta, said cellular mixture comprising substantially of endothelial cells and endothelial progenitor cells. | 11-21-2013 |
| 20130315875 | AMNION DERIVED ADHERENT CELLS - Provided herein are novel angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of, and compositions comprising, such cells. Further provided herein are methods of obtaining such cells and methods of using the cells in the treatment of individuals. | 11-28-2013 |
| 20130315876 | DIFFERENTIATION OF HUMAN EMBRYONIC AND INDUCED PLURIPOTENT STEM CELLS - The invention relates to culture systems, methods, and conditions that allow pluripotent undifferentiated hESCs or iPSCs to progressively and uniformly differentiate into cells of the chondrogenic lineage. | 11-28-2013 |
| 20130315877 | ANTICANCER COMPOSITION COMPRISING PLANT STEM CELL LINE DERIVED FROM TAXUS CAMBIUM OR PROCAMBIUM - The present invention relates to a composition for preventing or treating cancer, which contains, as an active ingredient, a | 11-28-2013 |
| 20130315878 | Methods and Compositions Comprising Hyaluronan for Enhancing Bone Marrow Cell Therapy - Disclosed herein are methods and compositions for treating cardiovascular disease and damaged cardiac tissue which employ at least one hyaluronan (HA) compound and one or more cells selected from the group consisting of stem cells, precursor cells, progenitor cells, committed cells, mature somatic cells, and recombinant cells. | 11-28-2013 |
| 20130315879 | METHOD FOR EXPANSION OF STEM CELLS AND THE USE OF SUCH CELLS - The present invention demonstrates that SALL4A and SALL4B are strong positive regulators of hematopoetic stem cell expansion. HSCs receiving expression of SALL4A or SALL4B are able to achieve a high-level of expansion. Cultures of SALL4-transduced cells results in extensive HSC expansion with over 1000-fold higher levels than controls within 2 to 3 weeks and expanded HSCs show no or very little maturation. Moreover, the expansion occurs quite rapidly with significant HSC growth in just a few days. In addition, SALL4-induced HSC expansion exhibits no impairment of hematopoietic cell differentiation. SALL4 appears to function in the maintenance of an undifferentiated proliferation state and block cell differentiation for HSCs. | 11-28-2013 |
| 20130315880 | ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS - The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. | 11-28-2013 |
| 20130315881 | METHOD AND ASSAY FOR GLYCOSYLATION PATTERN DETECTION RELATED TO CELL STATE OF STEM CELLS - A method and assay for characterizing populations of stem cells according to their glycosylation pattern, particularly for distinguishing between stem cell populations, for example with regard to state of differentiation. | 11-28-2013 |
| 20130315882 | Stem Cell Aggregates and Methods for Making and Using - The invention is directed to compositions of cell aggregates and methods for making and using the cell aggregates where the aggregates comprise cells that are not embryonic stem cells but can differentiate into cell types of at least two of ectodermal, undo dermal, and mesodermal embryonic germ layers, e.g., stem cells. | 11-28-2013 |
| 20130323211 | SHORT RNA MOLECULES - The present invention provides a short RNA capable of upregulating MafA expression in a human cell, wherein said short RNA includes a first strand which is 19 to 25 nucleotides in length and comprises the sequence AUCUGUACUGGAUGAGCGG or UUUCCCGCAGGAGAUUGAC. Also provided are uses thereof, particular medical uses, and induced cells and uses thereof. | 12-05-2013 |
| 20130323212 | Treatment for Chronic Myocardial Infarct - A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF). | 12-05-2013 |
| 20130323213 | ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND USE THEREOF IN THERAPY - A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed. | 12-05-2013 |
| 20130330300 | High Telomerase Activity Bone Marrow Mesenchymal Stem Cells, Methods of Producing the Same and Pharmaceuticals and Treatment Methods Based Thereon - Disclosed are isolated human bone marrow mesenchymal stem cells having high telomerase activity (tBMMSCs). Also disclosed are isolated human CD34 | 12-12-2013 |
| 20130330301 | Enhanced Medical Implant - A medical implant comprising in components from a tooth and stem cells harvested from at least one tooth. Pluripotent stem cells, other cells, and biologic constituents of the dental pulp may be harvested from the dental pulp of mammalian teeth, such as unerupted third molars in humans. After the stem cells are removed and isolated from the other teeth tissue, the hard tooth may be ground into a base material for the manufacture of a porous matrix into which the pluripotent stem cells, other cells, and biologic constituents of the dental pulp can be added. Additionally, soft tissue from the harvested tooth may be used as a carrier scaffold for soft tissue applications such as meniscal or cartilage repair. | 12-12-2013 |
| 20130330302 | RETINAL PIGMENT EPITHELIAL STEM CELLS - The present invention relates to a retinal pigment epithelial stem cell isolated from a posterior region of the retinal pigment epithelium of an adult mammal. The invention also relates to a method of inducing differentiation of retinal epithelial stem and progenitor cells in vitro, wherein the cells of the invention are highly plastic, multipotential stem cells. The invention also includes methods for the treatment of retinal diseases and vision loss involving the transplantation of retinal pigment epithelial stem cells or cells differentiated from retinal pigment epithelial stem cells to the retina of a patient in need of treatment. | 12-12-2013 |
| 20130330303 | BRAIN TISSUE REGENERATION METHOD - A material for treatment of cerebral infarction ameliorates angiopathy at a cerebral infarction region and improves brain function. The material for treatment of cerebral infarction according to the present invention comprises a dental pulp stem cell including at least one of a CD105-positive cell, an SP cell, a CD24-positive cell, a CD271-positive cell, and a CD150-positive cell. The material for treatment of cerebral infarction according to the present invention may contain a secretory protein of the dental pulp stem cell. Transplanted dental pulp stem cells do not directly differentiate into neural progenitor cells or neural cells and indirectly participate in the promotion of differentiation to restore and cure a cerebral infarction region such that the region becomes normal. | 12-12-2013 |
| 20130336933 | 3-DIMENSIONAL SCAFFOLDS FOR IMPROVED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO HEPATOCYTES - The present invention relates to the use of 3-dimensional (3D) synthetic or animal-derived bioscaffolds as substrates for the improved growth and differentiation of hPS (Human pluripotent stem cells); these scaffolds being adapted for use in conjunction with existing cell culture lab plastic-ware. More specifically, it relates to the seeding of these scaffolds, either alone or in conjunction with various biologic matrix coatings, with hPS cells for the improved differentiation of said hPS cells into hepatocyte or hepatocyte-like cell types. The invention also relates to the seeding of partially-differentiated hepatocyte progenitors onto scaffolds for further differentiation into more mature hepatocyte-cell types. | 12-19-2013 |
| 20130336934 | MULTIPOTENT STEM CELLS AND USES THEREOF - The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1 and TWIST but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105 and CD90. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and the differentiated stem cells, are also provided. | 12-19-2013 |
| 20130336935 | Compositions and Methods for Restoring or Rejuvenating Stem/Progenitor Cell Function - This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal. Also provided are methods of treating, delaying, preventing or reversing progeria or related syndromes in a mammal using isolated autologous or allogeneic stem/progenitor cells and/or regulatory factors secreted or released therefrom. | 12-19-2013 |
| 20130336936 | CELL TRANSPLANTATION - The present invention provides polymers for use in preventing damage to the membranes of cells in fat grafts. Mixing of a triblock copolymer such as poloxymer P188 with adipocytes or adipose tissue to be transplanted into a subject is thought to stabilize the membranes of the cells leading to more successful fat transplantation in soft tissue reconstruction or augmentation. Such methods may also be used in the transplantation of adult stem cells or other cells derived from fat tissue. Other agents such as lipoic acid may also be added to the polymer/cell compositions for cell transplantation. | 12-19-2013 |
| 20130336937 | CHONDROGENIC DIFFERENTIATION MEDIA AND METHODS FOR INDUCING CHONDROGENIC DIFFERENTIATION OF CELLS - The invention provides chondrogenic differentiation media comprising chondrogenic growth factors and low-molecular-weight sulfated polysaccharide derivatives of marine native exopolysaccharides (EPS) excreted by mesophilic marine bacteria from deep-sea hydrothermal environments. The invention relates to methods for inducing chondrogenic differentiation in pluripotent or multipotent cells, to cartilage tissues obtained by such methods, and to the use of such cartilage tissues for therapeutic purposes. | 12-19-2013 |
| 20130344035 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF RENAL DISEASES AND DISORDERS - Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit. | 12-26-2013 |
| 20130344036 | PLANT DERIVED CELL CULTURE MATERIAL - The present invention relates material that is useful in culturing and transferring cells as well as delivering cells. The material comprises plant derived cellulose nanofibers or derivatives thereof, wherein the cellulose nanofibers are in a form of a hydrogel or membrane. The invention also provides methods for producing these materials and compositions and uses thereof. | 12-26-2013 |
| 20130344037 | TREATMENT OF INFLAMMATORY DISEASES USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells. | 12-26-2013 |
| 20130344038 | METHOD FOR ENHANCING ENGRAFTMENT OF HAEMATOPOETIC STEM CELLS - The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analogue to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analogue for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided. | 12-26-2013 |
| 20140004085 | Method of Enhancing Hematopoietic Cell Transplantation | 01-02-2014 |
| 20140004086 | FORMATION OF CELL AGGREGATES | 01-02-2014 |
| 20140004087 | ENDOMETRIAL REGENERATIVE CELLS FOR TREATMENT OF TRAUMATIC BRAIN INJURY | 01-02-2014 |
| 20140004088 | IDENTIFICATION AND USE OF TARGET GENES FOR CONTROL OF PLANT PARASITIC NEMATODES | 01-02-2014 |
| 20140010790 | CELL CULTURE MATERIAL BASED ON MICROBIAL CELLULOSE - The present invention relates material based on microbial cellulose that is useful in culturing and transferring cells as well as delivering drugs. The material comprises cellulose nanofibers and/or derivatives thereof, based on microbial cellulose, wherein the cellulose nanofibers are in a form of a hydrogel or membrane. The invention also provides methods for producing these materials and compositions and uses thereof. | 01-09-2014 |
| 20140017206 | Methods for Improved Treatment of Adipose Tissue - The present disclosure relates generally to methods of treatment of tissue prior to implantation. In one aspect, the methods of treatment include washing adipose tissue with detergents to improve the viability of adipose cells for implantation and/or to increase the amount of viable adipose cells per volume of tissue for implantation. | 01-16-2014 |
| 20140017207 | ISOLATION, EXPRESSION AND GUIDED DIFFERENTIATION OF SELF-RENEWING PROGENITOR CELLS FROM ADULT HUMAN PANCREAS - The present invention relates to the field of pancreatic progenitor cells. More specifically, the present invention provides methods for isolating self-renewing centroacinar and terminal ductal progenitors from adult human pancreas. In a specific embodiment, the method comprises the steps of (a) providing a population of pancreatic cells; and (b) selecting for high expression of CD133, EpCAM, and CD44 on the pancreatic cells to isolate self-renewing centroacinar and terminal ductal progenitors. | 01-16-2014 |
| 20140017208 | GLP-1 RECEPTOR AGONISTS FOR ISLET CELL TRANSPLANTATION - The disclosure provides methods for treating diabetes by promoting graft survival and improved graft function in a patient receiving an islet transplant by treating the patient with a GLP-1 receptor agonist compound prior to the islet transplant. The methods may also comprise treating the islets with a GLP-1 receptor agonist compound prior to transplanting them in a patient. The methods may eliminate the need for immunosuppressive therapy in islet transplants. Any GLP-1 receptor agonist compound know in the art can be used in the methods described herein. | 01-16-2014 |
| 20140017209 | METHODS FOR TREATING RADIATION OR CHEMICAL INJURY - Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described. | 01-16-2014 |
| 20140017210 | METHODS FOR REGULATING GELATION OF POLYSACCHARIDE SOLUTIONS AND USES THEREOF - The present invention provides a method for preparing chitosan solutions to allow regulating the conditions in which the chitosan solution will gel. The present invention also provides methods for using chitosan solutions as compositions and for using chitosan solutions in vitro and in vivo. | 01-16-2014 |
| 20140017211 | METHODS AND COMPOSITIONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONS - Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells. | 01-16-2014 |
| 20140023621 | BONE MARROW DERIVED CD271 PRECURSOR CELLS FOR CARDIAC REPAIR - Methods for the isolation of CD271 | 01-23-2014 |
| 20140023622 | Brown Fat Cell Compositions and Methods - Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes. | 01-23-2014 |
| 20140023623 | Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby - A method of culturing mesenchymal stem cells (MSCs) is provided. The method comprising culturing a population of the MSCs in a medium comprising an aryl hydrocarbon receptor antagonist, thereby culturing MSCs. | 01-23-2014 |
| 20140023624 | DECELLULARIZED LIVER TRANSPLANTATION COMPOSITION AND METHODS - This disclosure provides an isolated or purified decellularized liver extracellular matrix (DLM) composition containing an isolated or purified cell capable of differentiating into a hepatocyte and/or liver tissue, and methods for its use in vitro and in vivo. | 01-23-2014 |
| 20140030231 | METHODS AND COMPOSITIONS FOR PRESERVING TISSUES AND ORGANS - The present invention generally relates to methods and compositions to determine viability of an organ for transplantation and other medical purposes. One aspect of the invention relates to a method for assessing the viability of an organ by measuring the energy parameters to determine the energy level of the organ by determining the stored cellular energy (e.g., ATP levels), and/or energy consumption over a particular time period of viability. The energy parameters can be compared to reference energy parameters as a highly accurate and reliable prediction of viable cell yield, and organ viability. Another aspect of the invention relates methods to preserve or extend the time period of viability of an organ any combination of (i) preservation perfusion of the organ to prevent ischemic damage, (ii) chemical metabolic suppression of the organ e.g., using metabolic suppressants, (iii) metabolic suppression by physical or environmental conditions, e.g., sub-zero non-freezing storage. | 01-30-2014 |
| 20140030232 | HEMATOPOIETIC STEM AND PROGENITOR CELL THERAPY - The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of modified hematopoietic stem and/or progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic composition. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution. | 01-30-2014 |
| 20140030233 | Therapeutic Compositions and Methods - This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy. | 01-30-2014 |
| 20140030234 | METHODS AND COMPOSITIONS FOR MODULATING ISLET BETA CELL DEVELOPMENT - Methods and compositions are provided for modulating pancreatic islet β-cell development. Aspects of the methods include promoting β-cell development by providing agents that promote calcineurin/N FAT signaling, and inhibiting β-cell development by providing agents that inhibit calcineurin/NFAT signaling. These methods find a number of uses, including, for example, in the treatment of diabetes and human islet diseases. In addition, reagents, devices and kits thereof that find use in practicing the subject methods are provided. | 01-30-2014 |
| 20140030235 | Use of Mesenchymal Stem Cells for Treating Genetic Disease and Disorders - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 01-30-2014 |
| 20140030236 | DERIVATION AND MATURATION OF SYNTHETIC AND CONTRACTILE VASCULAR SMOOTH MUSCLE CELLS FROM HUMAN PLURIPOTENT STEM CELLS - Embryonic vascular smooth muscle cells (vSMCs) have a synthetic phenotype (Syn-vSMC), but in adults, they commit to the mature contractile phenotype (Con-vSMC). Con-vSMCs differ from Syn-vSMC derivatives in condensed morphology, prominent filamentous cytoskeleton proteins, elastin production and assembly elastin, low proliferation, numerous active caveolae, enlarged endoplasmic reticulum, ample stress fibers and bundles, as well as high contractility. The human pluripotent stem cell-derivatives can differentiate into a desired phenotype. Differentiation can be controlled by appropriate concentrations of relevant factors. Growth in high serum with platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor-β1 induces the Syn-SMC phenotype with increased extracellular matrix protein expression and reduced expression of contractile proteins. Serum starvation and PDGF-BB deprivation causes maturation towards the Con-vSMC phenotype. When transplanted subcutaneously into nude mice, the human Con-vSMCs aligned next to the host's growing functional vasculature, with occasional circumferential wrapping and vascular tube narrowing. | 01-30-2014 |
| 20140030237 | TREATMENT OF IMMUNOSUPPRESSION-RELATED DISORDERS - Disclosed are methods of using blastomere-like stem cells to treat a number of immunodeficiency disorders. | 01-30-2014 |
| 20140037589 | NOVEL MAMMALIAN MULTIPOTENT STEM CELLS AND COMPOSITIONS, METHODS OF PREPARATION AND METHODS OF ADMINISTRATION THEREOF - This invention provides methods for preparing novel mammalian multipotent stem cells (MSCs), compositions thereof, and methods of preparing and administering the cells. | 02-06-2014 |
| 20140037590 | Isolation and Characterization of Progenitor Cells From Mesothelium - Populations enriched for smooth muscle progenitors are obtained by selection on the basis of expression of specific cell surface markers. | 02-06-2014 |
| 20140037591 | Methods for reducing and/or preventing excessive cellular apoptosis - The invention is directed to novel methods for reducing the number of apoptotic cell deaths in a population of cells undergoing excessive cellular apoptosis. The invention is also directed to novel methods for preventing apoptotic cell death in a population of cells at risk for developing excessive cellular apoptosis. In particular, the invention is directed to novel methods for reducing or preventing excessive cellular apoptosis comprising exposing cells exhibiting or at risk for developing excessive cellular apoptosis to a novel cellular factor-containing composition called Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS), which is obtained from the culturing of Amnion-derived Multipotent Progenitor (AMP) cells, or AMP cells. | 02-06-2014 |
| 20140037592 | METHOD FOR PRODUCING REGENERATIVE ORGAN PRIMORDIUM PROVIDED WITH GUIDE FOR TRANSPLANTATION, COMPOSITION CONTAINING REGENERATIVE ORGAN PRIMORDIUM PROVIDED WITH GUIDE FOR TRANSPLANTATION PRODUCED THEREBY, AND METHOD FOR TRNSPLANTING REGENERATIVE ORGAN PRIMORDIUM PROVIDED WITH GUIDE FOR TRANSPLANTATION - A method for producing a regenerative organ germ for transplantation includes using regenerative organ germ for transplantation ensuring continuity with a recipient after transplantation and facilitating transplantation procedures. A method for producing a regenerative organ germ provided with a guide for transplantation includes preparing a regenerative organ germ by closely contacting a first cell mass, which substantially consists of mesenchymal cells, and a second cell mass, which substantially consists of epithelial cells, culturing these cell masses within a support, and inserting the guide into the regenerative organ germ. | 02-06-2014 |
| 20140037593 | Tricalcium Phosphate Binding Peptides And Uses Thereof - The invention is directed to a composition comprising all or a portion of a beta-tricalcium phosphate (β-TCP) bound to all or a portion of a β-TCP binding peptide and methods of use thereof. | 02-06-2014 |
| 20140037594 | COMPOSITIONS AND METHODS FOR TREATING BONE FORMATION DISORDERS - The present invention relates to compositions and methods for the detecting, treating, and empirically investigating disorders associated with bone formation (e.g., osteoporosis). In particular, the present invention provides compositions and methods for using maspin and targets of maspin in the diagnosis, treatment, and empirical investigation of disorders associated with bone formation (e.g., osteoporosis). | 02-06-2014 |
| 20140037595 | TISSUE GRAFTING METHOD - The tissue grafting method relates to a tissue graft material, a method of preparing the material, and a method of using the material. The tissue graft material is made from the tunica serosa of the small intestine of a warm-blooded vertebrate, which has been delaminated from the tunica muscularis, tunica submucosa, and the tunica mucosa of the intestinal tissue. The tissue graft material may be perforated by discrete punctures. The tissue graft material is dehydrated by air drying or vacuum drying, sterilized with ethylene oxide, and stored in a hermetically sealed enclosure at room temperature until needed, having an indefinite storage life. When needed, the tissue graft material is rehydrated, cut to match the size of the wound, and applied to the wound. The graft may be overlaid with nylon mesh, or bandaged with an elastic tubular dressing. | 02-06-2014 |
| 20140037596 | Use of Stem Cells to Reduce Leukocyte Extravasation - The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to the endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential. | 02-06-2014 |
| 20140037597 | Sulfated Depolymerized Derivatives of Exopolysaccharides (EPS) From Mesophilic Marine Bacteria, Method For Preparing Same, And Uses Thereof In Tissue Regeneration - The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 μg (m) g/ml. | 02-06-2014 |
| 20140037598 | THERAPEUTIC PRODUCTS COMPRISING VITALIZED PLACENTAL DISPERSIONS - This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 02-06-2014 |
| 20140044681 | Cathepsin K As A Marker For Cartilage Production, Repair and Regeneration - Ctsk is used as a marker to identify, track, and manipulate Ctsk positive cartilaginous stem cells for cartilage repair and regeneration in vitro and in vivo. | 02-13-2014 |
| 20140044682 | GENERATION OF CARTILAGE EX VIVO FROM FIBROBLASTS - Embodiments of the invention encompass the ex vivo production of cartilage from chondrocytes differentiated from fibroblasts or stem cells. In particular embodiments, fibroblasts are subjected to conditions to produce chondrocytes in the form of cartilage tissue, for example cartilage having a desired shape. In at least some embodiments, a mold for the desired shape of the cartilage is produced from imaging of a body region of an individual in need thereof, and the fibroblasts are seeded in the mold with particular conditions. | 02-13-2014 |
| 20140044683 | CELL FUSION PROMOTER AND UTILIZATION OF THE SAME - The present invention provides a regeneration promoter for regenerating tissue with the use of somatic stem cells. The invention also provides a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation. | 02-13-2014 |
| 20140050704 | STEM CELL CULTURE METHOD - Methods for culturing pluripotent stem cells on fiber scaffolds are provided which result in the expansion of the number of stem cells without loss of pluripotency. Cells obtained by such methods, implants containing such cells and medical methods using such cells are also disclosed. | 02-20-2014 |
| 20140050706 | Compositions Comprising Human Embryonic Stem Cells and Their Derivatives, Methods of Use, and Methods of Preparation - The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells. | 02-20-2014 |
| 20140056855 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT - The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α | 02-27-2014 |
| 20140056856 | IMMUNOSUPPRESSIVE CELLS AND METHODS OF MAKING AND USING THEREOF - This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine. | 02-27-2014 |
| 20140056857 | Cancellous Bone Treated with Collagenase and Essentially Free of Blood Cells - A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying our their osteogenic function and to provide for an increased rate of bone formation. | 02-27-2014 |
| 20140056858 | CELL SHEET HAVING HYALURONIC ACID PRODUCTION ABILITY AND METHOD FOR PREPARING THE SAME - A cell sheet having a high hyaluronic acid production ability can be typically prepared by a method in which, on a cell culture support having a surface coated with a polymer which changes a hydration ability in a temperature range of 0-80° C., cells with increased stem cell content are cultured in a temperature range where the polymer exhibits a weak hydration ability, and then the temperature of a culture solution is changed to a temperature at which the polymer exhibits a strong hydration ability, so that the cultured cells are detached in the form of sheet. | 02-27-2014 |
| 20140056859 | METHOD FOR PRODUCING MYOCARDIAL SHEET FROM EMBRYONIC STEM CELLS - The present invention provides a method for producing a myocardial sheet using a group of cells derived from embryonic stem cells. This method is characterized by mixing Flk/KDR positive cells, cardiomyocytes, endothelial cells, and mural cells, all derived from embryonic stem cells, and culturing the mixed cells. Furthermore, the myocardial sheet can be used as a therapeutic agent for heart diseases since VEGF is released from the sheet. | 02-27-2014 |
| 20140065106 | Blood Plasma Based Hydrogels for Tissue Regeneration and Wound Healing Applications - The present disclosure generally relates to tissue engineering and wound healing. More particularly, the present disclosure relates to the modification of plasma with a stability conferring agent to create a hydrogel for use in regenerative medicine and other tissue engineering applications. | 03-06-2014 |
| 20140065107 | DEVICES, SYSTEMS, AND METHODS FOR MODULATING UTERINE FUNCTION - One aspect of the present disclosure relates to a method for modulating uterine function in a mammal. One step of the method includes placing a therapy delivery device into direct contact with a spinal cord target associated with uterine function. Next, the therapy delivery device is activated to deliver a therapy signal to the spinal cord target in an amount and for a time sufficient to effect a change in sympathetic and/or parasympathetic activity in the mammal and thereby modulate uterine function. | 03-06-2014 |
| 20140065108 | Tendon Stem Cells - The invention relates to tendon stem cells useful for treating a variety of diseases and condition, including tendon repair and attachment of tendon to bone. The invention is also directed to treatment and/or inhibition of bone formation by use of biglycan and/or fibromodulin. | 03-06-2014 |
| 20140065109 | USE OF SUBSTANCE P FOR MOBILIZATION OF MESENCHYMAL STEM CELLS OR PROLIFERATION OF MESENCHYMAL STEM CELLS AND FOR WOUND HEALING OR FACILITATING WOUND HEALING - The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing. | 03-06-2014 |
| 20140072536 | METHODS OF TREATING MUSCULAR DYSTROPHY - Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed. | 03-13-2014 |
| 20140072537 | MESENCHYMAL STROMAL CELLS AND USES RELATED THERETO - The present invention generally relates to novel preparations of mesenchymal stromal cells (MSCs) derived from hemangioblasts, methods for obtaining such MSCs, and methods of treating a pathology using such MSCs. The methods of the present invention produce substantial numbers of MSCs having a potency-retaining youthful phenotype, which are useful in the treatment of pathologies. | 03-13-2014 |
| 20140072538 | TREATMENT OF RADIATION INJURY USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of, and compositions comprising, such cells. | 03-13-2014 |
| 20140072539 | USE OF ADIPOSE TISSUE-DERIVED STROMAL STEM CELLS IN TREATING FISTULA - Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae. | 03-13-2014 |
| 20140072540 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRABBE AND OTHER NEURODEGENERATIVE DISEASES - Provided are compositions and methods for the treatment of Krabbe and other neurodegenerative diseases associated with psychosine (and/or other storage material)—mediated axonal degeneration. Compositions and methods employ one or more inhibitor(s) of (1) a phosphotransferase activity of one or more kinase(s) such as CDK5, P38, jnk, src, CK2, PKC, GSK3α and β; (2) a phosphotransferase activity of one or more phosphatase(s) such as PP1 and PP2; (3) a caspase/calpain activity of one or more caspases such as caspase 3 and calpains such as calpain 1 and 2; and/or (4) a sodium/calcium exchange protein such as NCX1. Inhibitors include small molecules (e.g., the GSK3β inhibitor L803 and the NCX1 inhibitor flecainide) and siRNA molecules that downmodulate cellular levels of one or more mRNA, such as PP1 mRNA. Inhibitors disclosed can cross the blood-brain barrier and, thus, are available to the CNS and effective in reducing psychosine-mediated axonal degeneration. | 03-13-2014 |
| 20140079673 | TREATMENT OF ISCHEMIA USING STEM CELLS - The invention features a method for treating or preventing ischemia in a mammal by administering unrestricted somatic stem cells (USSCs) to the mammal. | 03-20-2014 |
| 20140079674 | SPIDER SILK PROTEINS AND METHODS FOR PRODUCING SPIDER SILK PROTEINS - The invention provides an isolated major ampullate spidroin protein, which consists of from 150 to 420 amino acid residues and is defined by the formula REP-CT. REP is a repetitive, N-terminally derived protein fragment having from 80 to 300 amino acid residues. CT is a C-terminally derived protein fragment having from 70 to 120 amino acid residues. The invention further provides an isolated fusion protein consisting of a first protein fragment, which is a major ampullate spidroin protein, and a second protein fragment comprising a fusion partner and a cleavage agent recognition site. The first protein fragment is coupled via said cleavage agent recognition site to the fusion partner. The invention also provides a method of producing a major ampullate spidroin protein and polymers thereof. | 03-20-2014 |
| 20140086881 | GOOD HEALTHY CELLS FOUND IN PROTEINS, THEIR APPLICATIONS, AND PROCESS OF MAKING A MEDIUM TO HARVEST THE CELLS - GOOD HEALTHY DRAGON, SNAKE, DIFFERENT SIZE DOUBLE RINGS, LIGHTNING, SQUARE PIXEL, BEAMING RAYS, RECONSTRUCTION BACKGROUND, FACET, CRATER, YELLOW, LEER CELLS were found in New Proteins (among them 27 new ones and their sequences (Under a different patent application) or in the existing discovered proteins and their applications. The process of making the medium derived from any source to harvest any cell—named KH cells—KH cells are good healthy cells in which the RNA synthesizes good proteins that: 1—Send signal to the DAMAGED, SICK, AND BAD CELLS that triggers that synthesis of good proteins that transform these cells to become GOOD healthy cells. 2—Send signal to the other currently undamaged cells to synthesis of good proteins to protect them from being DAMAGED, INFECTED and PRONE to DNA and other cellular alterations. 3—Send signal to the body to produce new cells that are healthy and forbid them from being affected by intra- and extracellular damaging signals to increase the protein yield for the application of the cell expression of human healthcare, animal healthcare and plant healthcare including fertilizer and maximize production of medicine, food, fruit, juice, meat, seafood and plants. | 03-27-2014 |
| 20140086882 | STEM CELL PREPARATIONS AND METHODS OF USE - The present invention relates to a method of preparing cells and in particular to a method of preparing breastmilk stem cells (BSCs) by isolation from breastmilk and subsequent culture. The invention further relates to BSCs prepared by the methods of the invention and to methods and uses thereof. The invention has been developed primarily as a method for preparing and culturing BSC. | 03-27-2014 |
| 20140086883 | Compositions and Methods for the Generation of Platelets and Methods of Use Thereof - Compositions and methods for generating platelets and methods of use thereof are disclosed. | 03-27-2014 |
| 20140086884 | TREATMENT OF DISEASES AND DISORDERS USING SELF-RENEWING COLONY FORMING CELLS CULTURED AND EXPANDED IN VITRO - The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries. | 03-27-2014 |
| 20140093480 | Novel Mensenchymal Stem Cells And Bone-Forming Cells - The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy. | 04-03-2014 |
| 20140093481 | PRODUCTION OF DENTIN, CEMENTUM AND ENAMEL BY CELLS - One aspect provides a method of forming a mineralized material by co-culturing a epithelial cell, such as ameloblasts, and mesenchymal cells, such as osteoblasts or odontoblasts, in a mineral-stimulating medium. Another aspect provides matrix seeded with epithelial cells and mesenchymal cells and infused with a mineral-stimulating medium capable of forming a mineralized material in the matrix. Methods of manufacturing such compositions and methods of treating mineralization-related conditions are also provided. | 04-03-2014 |
| 20140093482 | METHODS AND APPARATUSES FOR ISOLATING AND PREPARING STEM CELLS - The present invention relates to a method of preparing a population of stem cells for autologous implantation to a subject. The cells are activated by irradiating the cells with one or more wavelengths of yellow and red and/or green light. In particular, the cells are irradiated with 575-595 nm (5-20 mW), and 630-635 nm or 660-670 nm (10-100 mW) and/or 510-540 nm (10-60 mW) of monochromatic light for 30-60 mins. Preferably the stem cells are adipose-derived stem cells. Also the invention relates to therapeutic applications of the activated stem cells. | 04-03-2014 |
| 20140093483 | COMPOSITION OF CULTURED GRAPE CELLS - A pharmaceutical or nutraceutical composition comprising a cell line callus culture of grape berry cells grown in vitro, whereby the cell line callus culture of grape berry cells is derived from one or more of grape-berry cross section, grape-berry skin, grape-berry flesh, grape seed, grape embryo of seeded or seedless cultivars or grape seed coat. | 04-03-2014 |
| 20140093484 | Use of Dextran Sulfate - A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof. | 04-03-2014 |
| 20140099285 | COMPOSITION FOR PREVENTING OR TREATING AIDS CONTAINING PLANT STEM CELL LINE DERIVED FROM CAMBIUM OF PANAX GINSENG INCLUDING WILD GINSENG OR GINSENG AS ACTIVE INGREDIENT - The present invention relates to a composition for preventing or treating acquired immunodeficiency syndrome (AIDS), comprising one or more of the following: a homogenous cell line, and a lysate, an extract and a culture thereof as an active ingredient. The homogenous cell line, the lysate, the extract and the culture thereof, which are derived from a natural product, minimize adverse side effects of prior therapeutic agents and safe for the human body. Further, they effectively increase the count of T cells such as CD4+ T cells and decrease the number of HIVs, thereby preventing opportunistic infection, dysneuria, and neoplaia caused by immune incompetence, and ultimately the risk of death. Therefore, they are useful in preventing and treating AIDS, and relieving symptoms of AIDS. | 04-10-2014 |
| 20140099286 | CELL THERAPY FOR CHRONIC STROKE - A method of treating stroke in a patient who has undergone a stroke comprising administering at least 2 million suitable neuronal cells in at least one brain area involved in the stroke. The method comprises the step of using a twist drill or a burr to form a hole in the skull through which the cells could be administered. Exemplary cells are hNT neuronal cells, HCN-1 cells, fetal pig cells, neural crest cells, neural stem cells, or a combination thereof. Also disclosed herein is a pharmaceutical composition of 95% pure hNT neuronal cells, which composition further includes a vial containing PBS and human neuronal cells. This vial is provided in a container with liquid nitrogen, whereby the composition is frozen and maintained at −170° C. before use. Also disclosed are methods of improving speech, cognitive, sensory, and motor function in a person who has experienced brain damage which interferes with function by administering a sterile composition of a sufficient number of neuronal cells or neural stem cells to the damaged area. Also disclosed is a method of replacing central nervous cells lost to neurodegenerative disease, trauma, ischemia or poisoning. | 04-10-2014 |
| 20140099287 | PLASMA PROTEIN CONCENTRATE FOR CELL DELIVERY IN REGENERATIVE APPLICATIONS - The invention is directed to concentrating autologously-derived plasma, using the concentrated plasma fluid to dilute the patient's cells and applying the combination of concentrated fluid with cells at a site of pathology or mixing the combination of concentrated fluid with cells with a particulate material like a bone void filler prior to placing the mixture at a site of pathology. | 04-10-2014 |
| 20140099288 | METHODS AND DEVICES FOR OBTAINING AND PROVIDING COMBINATION CELL THERAPY - The invention is directed to a method for isolating stromal cells to form a therapeutic composition; and administering said therapeutic composition to the subject. A further embodiment of the invention is directed to therapeutic compositions comprising isolated stromal cells. | 04-10-2014 |
| 20140099289 | Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair - Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair. | 04-10-2014 |
| 20140099290 | ENDOTHELIAL SCAFFOLDS - Provided herein is an endothelial scaffold comprising, consisting of, or consisting essentially of decellularized corneal stroma. In some embodiments, the scaffold has cultured endothelial cells seeded thereon. Methods of treating a patient in need of corneal endothelial transplant are also provided, including implanting the scaffold as described herein onto a cornea of the patient (e.g., by deep keratectomy). | 04-10-2014 |
| 20140105867 | BLOCKAGE OF PAI-1 IN DIABETIC CD34+ STEM CELLS CORRECTS CELLULAR DYSFUNCTION - Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which PAI-1 expression and/or activity has been transiently blocked. Other methods involve the administration of a PAI-1 blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a PAI-1 blocking agent and treated cells are co-administered to a subject in need thereof. | 04-17-2014 |
| 20140105868 | METHOD FOR TREATING VASCULAR-RELATED DISEASE - A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis. | 04-17-2014 |
| 20140105869 | Compositions and Methods for Treating Musculoskeletal Diseases and Disorders - Compositions and methods for modulating miRNAs up-regulated or down-regulated in aged individuals and their downstream targets are disclosed. Methods of treating musculoskeletal disorders are also provided. | 04-17-2014 |
| 20140105870 | Differentiation of Human IPS Cells to Human Alveolar Type II Via Definitive Endoderm - The present invention relates to compositions and methods for generating populations of tissue precursor cells from pluripotent cells, and preferably induction of stem cells into definitive endoderm to generate anterior foregut endoderm from pluripotent cells. The anterior foregut endoderm cells can then be differentiated into an alveolar epithelial type II cell. | 04-17-2014 |
| 20140105871 | Use Of Mesenchymal Stem Cells For The Improvement Of Affective And Cognitive Function - Disclosed is the use of mesenchymal stem cells (MSCs) and in particular MSCs pretreated with pituitary adenylate cyclase-activating polypeptide (PACAP) or analogs and fragments of PACAP, for treatment of neurodegenerative and psychiatric diseases, and for the improvement of affective and cognitive function in a normal individual or in an individual suffering from a neurodegenerative or neuropsychiatric disease. | 04-17-2014 |
| 20140105872 | PURIFIED MESENCHYMAL STEM CELL COMPOSITIONS AND METHODS OF PURIFYING MESENCHYMAL STEM CELL COMPOSITIONS - One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed. | 04-17-2014 |
| 20140112890 | INTRAOPERATIVE AND BLOOD DERIVED ADHESIVES - The invention features the production of an amine-reactive proteoglycan, specifically chondroitin sulfate or hyaluronic acid. This material can be provided in powder (solid) or liquid form and combined with blood derivatives including serum, platelets, platelet rich plasma, bone marrow, or with other tissue products to form hydrogels. The properties (physical and biological) are different for each of these hydrogels and can be further manipulated by controlling the conditions under which the hydrogels are formed. Such properties include the biodegradability of the hydrogel, the compressibility, the adhesive strength, the presence of pharmaceutical agents or therapeutic cells, and resiliency. | 04-24-2014 |
| 20140112891 | AUTOLOGOUS HUMAN ADULT PLURIPOTENT VERY SMALL EMBRYONIC-LIKE (hVSEL) STEM CELL REGENERATION OF BONE AND CARTILAGE - The invention provides methods and compositions for the repair or regeneration of osteochondral tissue. The methods and compositions provide an effective amount of isolated differentiable human Very Small Embryonic Like Stem Cells (hVSELs) sufficient for regeneration or repair of an osteochondral tissue. The compositions can be administered directly to the tissue or administered systemically. | 04-24-2014 |
| 20140112892 | SYNTHESIS AND ANALYSIS OF NOVEL COMPOUND CAPABLE OF INDUCING DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELL INTO HEPATOCYTE - The purpose is to select low-molecular-weight compounds which are effective in inducing differentiation of mesenchymal stem cell into hepatocyte and to develop a safe differentiation-inducing method having excellent efficiency of differentiating mesenchymal stem cell into hepatocyte. Provided are at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; a differentiation inducer comprising at least one compound selected from the group consisting of compounds represented by formulae (1) and (2), a salt thereof, or a solvate of them; and a differentiation inducer comprising a compound represented by formula (8), a salt thereof, or a solvate of them. | 04-24-2014 |
| 20140112893 | ENHANCED MSC PREPARATIONS - The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof. | 04-24-2014 |
| 20140112894 | AUTOLOGOUS CELLS ON A SUPPORT MATRIX FOR TISSUE REPAIR - The present invention relates to a method for the effective treatment of tissue defects and for tissue regeneration. The method includes seeding autologous cells on a support matrix and implanting the cell-seeded support matrix into a site of transplantation. The present invention also relates to various tissue repair structures that include cells seeded onto a cell-free membrane. The present invention also provides methods for cultivation, seeding, and implantation of autologous cells. | 04-24-2014 |
| 20140120064 | GENERATION OF NEW PANCREATIC BETA CELLS - The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue. This invention identifies a specific binding region of the Reg Receptor from which peptidomimetics and stimulating antibodies have been developed for the generation of new beta cells which may be administered directly to patients with said conditions including type 1 diabetes, type 2 diabetes, PreDiabetes and other conditions of beta cell deficiency, and provides specific methodology for protecting new beta cells generated for usage in type 1 diabetes and Latent Autoimmune Diabetes of Adulthood. This invention also provides for ex-vivo generation and delivery of beta cells utilizing the inventions described within. | 05-01-2014 |
| 20140120065 | PROTECTION FROM LETHAL IRRADIATION WITH MESENCHYMAL STROMAL CELLS - The present invention relates to the use of mesenchymal stromal cells (MSCs) for the treatment of supralethal radiation injury. | 05-01-2014 |
| 20140120066 | Cardiosphere Derived Cell Population and Methods of Use - Provided herein are compositions and methods for isolating and culturing cardiac progenitor cells, and for improved transplantation. | 05-01-2014 |
| 20140120067 | MUSCLE STEM CELL THERAPY FOR TREATMENT OF DYSPHAGIA - Described herein is a method for the treatment of dysphagia, comprising administering a therapeutically effective dose of an isolated muscle-derived stem cell population into a muscle involved in swallowing, such as tongue, pharynx, palate, and strap muscles. | 05-01-2014 |
| 20140120068 | SOLUTIONS, SYSTEMS AND METHODS FOR CELL, TISSUE AND ORGAN PRESERVATION - This disclosure provides solutions, systems, and methods for cell, tissue, and/or organ preservation. Some preservation solutions may include any combination of a balanced salt solution, electrolytes, antibiotic agents, antimycotic agents, protease inhibitors, anti-oxidants, simple sugars, starches impermeant ions, uric acid and/or amino acids. Some preservation solutions may also include hydrolyzed collagen. The preservation solutions including hydrolyzed collagen may be used alone or as part of a kit to preserve cells, tissue, or organs. The solution may also be used in connection with one or more medical procedures, for example organ transplantation. | 05-01-2014 |
| 20140120069 | Amphoteric Materials Based on Crosslinked Hyaluronic Acid, Method of Preparation Thereof, Materials Containing Entrapped Active Agents, Method of Preparation Thereof, and Use of Said Materials - The present invention describes novel amphoteric materials based on crosslinked hyaluronic acid, according to the general formula (I), and a method of preparation of said materials. Further, the invention relates to the material containing entrapped active agents (e.g. drugs, growth factors etc.) and a method of preparation thereof. Moreover, the present invention relates to the use of said materials for controlled release systems, in tissue engineering, wound dressing or tissue regeneration. | 05-01-2014 |
| 20140120070 | TESTIS SOMATIC CELL-DERIVED PLURIPOTENT STEM CELLS, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION FOR IMPOTENCE TREATMENT INCLUDING SAME - The present invention relates to testis somatic cell-derived pluripotent stem cells, and more particularly, to pluripotent adult stem cells which exhibit a positive immune reaction to both CD34 and CD73 and which are derived from testis somatic cells. The present invention further relates to a method for producing the testis somatic cell-derived pluripotent stem cells, and to a pharmaceutical composition including same for the treatment of erectile dysfunction. | 05-01-2014 |
| 20140127169 | INDUCED PRESOMITIC MESODERM (IPSM) CELLS AND THEIR USE - The invention relates to a method for reprogramming target cells to multipotent progenitor cells capable of differentiating into muscular, skeletal or dermal cell lines. In particular, the invention relates to an ex vivo method for preparing induced presomitic mesoderm (iPSM) cells, said method comprising the steps of: a) providing target cells to be reprogrammed, and, b) culturing said target cells under appropriate conditions for reprogramming said target cells into iPSM cells, wherein said appropriate conditions comprises increasing expression of at least one T-Box transcription factor in said target cells. The invention further relates to the use of said iPSM cells, for example, for regenerating skeletal, muscle, dermal and cartilage tissues. | 05-08-2014 |
| 20140127170 | Method and Composition for Skin Grafts - A chimeric skin comprising immortalized human keratinocyte cells cocultured with donor keratinocytes is disclosed. | 05-08-2014 |
| 20140127171 | TREATMENT OF CHRONIC POST-TRAUMATIC ENCEPHALOPATHY - Methods of treating chronic post-traumatic encephalopathy (PTE) using regenerative approaches is described. In one embodiment, molecules with capability of stimulating endogenous neural stem cells is provided. In another embodiment, cell therapeutics are provided capable of addressing angiogenic deficits in patients suffering from PTE. In another embodiment, cells are utilized to induce activation of endogenous progenitor cells in the central nervous system of PTE patients. Furthermore, low level laser irradiation is disclosed as a means of treatment of PTE either through direct administration to CNS tissue for stimulation of endogenous progenitor cells and reparative processes, or together with administration of exogenous stem cells, whether autologous or allogeneic. In a further embodiment exogenous stem cells are pretreated with laser prior to administration. | 05-08-2014 |
| 20140127172 | METHODS OF PRESERVING FUNCTIONALITY OF AN ORGAN, PRESERVING FERTILITY OF A PATIENT UNDERGOING A TREATMENT EXPECTED TO CAUSE STERILITY AND ASSURING A SUPPLY OF VIABLE GAMETES FOR FUTURE USE - A method of preserving functionality of an organ is disclosed herein, including removing a whole organ including vasculature from a donor, cryo-preserving the whole organ including vasculature, thawing the whole organ including vasculature so that at least a portion of cells contained therein resume biological activity, and introducing the whole organ including vasculature into a recipient so that a blood vessel in the vasculature is supplied with blood. Further disclosed herein is a method of preserving fertility of a patient undergoing a treatment expected to cause sterility, including removing at least one whole gonadal organ including vasculature from the patient, preserving functionality of the gonadal organ as described herein, conducting the treatment and waiting for an effect thereof to subside, and introducing the gonadal organ into the patient. | 05-08-2014 |
| 20140127173 | POPULATIONS OF SMOOTH MUSCLE CELLS OF SPECIFIC EMBRYONIC LINEAGES - This invention relates to the production of populations of Smooth Muscle Cells (SMCs) of specific embryonic lineages, such as neuroectodermal and mesodermal SMCs. Pluripotent stem cells are cultured in one or more lineage induction media to produce progenitor cells of a defined embryonic lineage, which are then cultured in an SMC induction medium to produce a population of SMCs of the embryonic lineage. Populations of SMCs of defined lineages may be useful, for example, in in accurately modelling vascular disease. | 05-08-2014 |
| 20140134137 | Use of Stem Cells to Reduce Leukocyte Extravasation - The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expression of cellular adhesion molecules reduces leukocyte adhesion to endothelial cells such that extravasation is reduced. The end result is a reduction of inflammation. The cells are non-embryonic non-germ cells that have pluripotent characteristics. These may include expression of pluripotential markers and broad differentiation potential. | 05-15-2014 |
| 20140134138 | Novel Use of Cryptotanshinone - Provided are a composition for stimulating differentiation of MSCs into osteoblasts, which includes cryptotanshinone, and an osteogenesis stimulator including cryptotanshinone and MSCs. When the cryptotanshinone is treated to the MSCs, the differentiation into osteoblasts is stimulated, and thus osteogenesis of a patient may be stimulated by directly transplanting the differentiation-induced MSCs to the patient. Accordingly, the composition or osteogenesis stimulator may be used to treat patients having disability requiring stimulation of osteogenesis such as osteoporosis, bone fracture, bone grafting including alveolar bone grafting for implant placement, or other bone defects. | 05-15-2014 |
| 20140134139 | CD34+ CELLS AND METHODS OF USE - Disclosed herein is a reprogrammed endothelial progenitor cell, said cell comprises a bone marrow-derived cell expressing the CD34+ marker and at least one cardiomyocyte-specific gene, as well as methods for preparing and using the same for cardiac regenerative medicine. | 05-15-2014 |
| 20140134140 | MESENCHYMAL STEM CELL COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTIONS - A method of treating a microbial infection in a subject includes administering to the subject a therapeutically effective amount of MSCs and an antimicrobial agent, wherein the MSCs potentiate the therapeutic activity of the antimicrobial agent, and the therapeutically effective amount is the amount effective to inhibit microbial growth and suppress microbial infection associated inflammation in the subject. | 05-15-2014 |
| 20140134141 | HUMAN FACILITATING CELLS - The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs. | 05-15-2014 |
| 20140140963 | Preservation of the biological activity of undenatured type II collagen - The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis in mammals. The instant invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water. | 05-22-2014 |
| 20140140964 | COMPOSITIONS AND METHODS FOR RECRUITING AND LOCALIZING STEM CELLS - Described herein are compositions and methods of using modified placental tissue to achieve endogenous and exogenous therapeutic effects. When applied to an injured or diseased organ or body part, the modified placental tissue elicit stem cell recruitment and/or localization directly to or proximate to the site of application. Also described is a novel vacuum drying device and the use thereof. | 05-22-2014 |
| 20140140965 | LOW OXYGEN CULTURE CONDITIONS FOR MAINTAINING RETINAL PROGENITOR CELL MULTIPOTENCY - The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration. | 05-22-2014 |
| 20140140966 | Methods of Manufacture of Immunocompatible Chorionic Membrane Products - Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 05-22-2014 |
| 20140140967 | PLURIPOTENT STEM CELL-DERIVED BROWN ADIPOCYTES, PLURIPOTENT STEM CELL-DERIVED CELL AGGREGATE, METHOD FOR PRODUCING SAME, AND CELL THERAPY AND MEDICAL THERAPY THEREFOR - Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine. | 05-22-2014 |
| 20140140968 | MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES - An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed. | 05-22-2014 |
| 20140147419 | COMPOSITIONS AND METHODS FOR FORMATION OF BONE TISSUE - Provided is a step-wise method of forming an engineered construct. Various embodiments include inducing differentiation of progenitor cells, such as embryonic stem cells; expanding the differentiated progenitor cells; combining the expanded progenitor cells and a biocompatible scaffold comprising a matrix material; and incubating the progenitor cells and the biocompatible scaffold so as to form a bone tissue module. | 05-29-2014 |
| 20140147420 | COMPOSITION AND METHOD TO IMPROVE THE THERAPEUTIC EFFECT OF STEM CELLS - The invention relates to a composition and method used for injuries treatment with a surprisingly therapeutic effect. This composition comprises a population of cells derived from human umbilical cord blood which expresses one of the following markers: CD34, CD45, and CD31; a population of CD34 | 05-29-2014 |
| 20140147421 | C1Q/TNF-RELATED PROTEIN 12 AND COMPOSITIONS AND METHODS OF USING SAME - The present invention provides substantially purified peptide portions of adipokine polypeptides, including, for example, Clq/TNF-related protein-12 (CTRP12), a functional homologue or function fragment of CTRP12, and a fusion polypeptide comprising any of the above. Methods for treating Type 2 diabetes mellitus by administering to a patient any of the following; CTRP12, a functional homologue of CTRP12, a functional fragment of CTRP12 or its functional homologue, a fusion polypeptide comprising any of the above, a substantially purified nucleic acid molecule encoding a polypeptide of any of the above, a vector comprising such nucleic acid molecule, a host cell transformed with such vector, a ligand that specifically binds to a polypeptide mentioned above, a compound that modifies the level of expression or activity of the amino acid sequence according to any of the above, a pharmaceutical composition comprising any one the above and a pharmaceutically acceptable carrier, and any combination of the above are also provided. | 05-29-2014 |
| 20140147422 | METHOD OF DERIVING STEM CELLS, STEM CELLS, AND USE OF STEM CELLS FOR WOUND HEALING - A method of deriving isolated stem cells including: implanting a matrix in a wound site of a living organism; allowing cells to infiltrate the matrix; removing the matrix containing the infiltrated cells from the wound site; and removing the infiltrated cells from the matrix to provide isolated stem cells. Stem cells produced by this process, stem cells with certain characteristics, and methods for treating wounds using these stem cells are provided. | 05-29-2014 |
| 20140154219 | METHODS AND COMPOSITIONS FOR LARGE-SCALE ISOLATION OF VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS - Methods for purifying very small embryonic-like (VSEL) stem cells from populations of cells suspected of including VSEL stem cells are provided. In some embodiments, the methods include (a) providing a population of cells suspected of including a VSEL stem cell; and (b) isolating a CD45 | 06-05-2014 |
| 20140154220 | Methods and Compositions for Improved Tissue Regeneration by Suppression of Interferon-Gamma and Tumor Necrosis Factor-Alpha - The present invention discloses methods, compositions and devices for improving tissue regeneration by suppressing the effects of several proinflammatory cytokines such as TNF-α and IFN-γ. Compositions and devices of this invention will generally include one or more anti-inflammatory agent(s) capable of reducing the level of TNF-α, IFN-γ, or both. Methods for improving tissue regeneration in accordance with this invention will generally have the step of applying a composition or device of the invention to a site in need of the composition or device. Also disclosed are methods for forming composition and devices of the invention and pharmaceutical compositions comprising one or more anti-inflammatory agent(s) effective of inhibiting or reducing the levels of TNF-α, IFN-γ, or both. | 06-05-2014 |
| 20140154221 | TREATMENT METHOD FOR MESENCHYMAL STEM CELLS AND THEIR APPLICATION AS A TREATMENT OF OXIDATIVE STRESS RELATED DISEASES - The present invention relates to a method of treatment of mesenchymal stem cells, preferably from adipose origin, comprising mainly two stages, firstly the collection and isolation of mesenchymal stem cells, and secondly, a period of growth and specific treatment of cells in a conditioning or treatment medium with an oxidizing agent. The invention also comprises the cells obtained directly through the method and its use in treating diseases caused by or associated with oxidative stress. | 06-05-2014 |
| 20140154222 | ISOLATED CELLS AND POPULATIONS COMPRISING SAME FOR THE TREATMENT OF CNS DISEASES - An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype. | 06-05-2014 |
| 20140161773 | USE OF AN AGENT THAT RESTORES TISSUE PERFUSION AND OXYGENATION - The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods. | 06-12-2014 |
| 20140161774 | Lgr5+ SOMATIC STEM CELLS - Described is an isolated somatic stem cell that is 2 to less than 6 micrometer in size and Lgr5+. Methods of preparing and using the cell are also described. | 06-12-2014 |
| 20140161775 | SILYLATED BIOMOLECULE-BASED HYDROGEL FOR CULTURING CARDIOMYOCYTES AND STEM CELLS, AND USE OF THE HYDROGEL THEREOF FOR TREATING HEART FAILURE - The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction. | 06-12-2014 |
| 20140161776 | MESENCHYMAL STEM CELLS AND USES THEREFOR - Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount. | 06-12-2014 |
| 20140161777 | METHODS AND COMPOSITIONS FOR TREATING BRAIN DISEASES - The present disclosure provides targeting peptides and vectors containing a sequence that encodes targeting peptides that deliver agents to the brain. | 06-12-2014 |
| 20140170116 | METHOD OF TREATING ISCHEMIC DISORDERS - A method of treating an ischemic disorders in a subject includes administering stromal cell derived factor-1 (SDF-1) to ischemic tissue of the subject in an amount effective to inhibit apoptosis of cells of the tissue. | 06-19-2014 |
| 20140170117 | Fabrication Of Bone Regeneration Scaffolds And Bone Filler Material Using A Perfusion Flow System - The present disclosure is directed at a process to form bone grafting material. One may provide a porous collagen scaffold and insert the scaffold into a perfusion chamber of a perfusion flow system. This may then be followed by continuously providing a mineralization perfusion fluid flow through the scaffold at a flow rate to provide dynamic intrafibrillar mineralization of the scaffold and form a collagen/hydroxyapatite composite scaffold. One may optionally provide the scaffold with bone tissue forming cells and then deliver a perfusion fluid including oxygen and one or more nutrients through the collagen/hydroxyapatite composite scaffold and to the bone tissue forming cells at a flow rate such that the bone tissue forming cells remodel the collagen/hydroxyapatite composite scaffold and form a bone tissue extracellular matrix. The bone tissue extracellular matrix may then be decellularized to form an acellular bone repair scaffold. | 06-19-2014 |
| 20140170118 | METHODS OF DIFFERENTIATING STEM CELLS BY MODULATING MIR-124 - Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells. | 06-19-2014 |
| 20140170119 | MULTI-CHAMBER APPLICATOR FOR GELATIN SOLUTION - Disclosed is a multi-chamber applicator comprising an aqueous gelatin solution and an aqueous cross-linking agent solution in separate chambers. | 06-19-2014 |
| 20140170120 | CYTOKINE INDUCTION OF SELECTIN LIGANDS ON CELLS - Methods and compositions for treating cells with cytokines are provided herein. | 06-19-2014 |
| 20140170121 | Neural Scaffolds - Disclosed herein are compositions and methods useful for preparing neural scaffolds. The scaffolds comprise tissue taken from the spinal cord and/or dura mater of vertebrate and can be processed to form gels or sheets. Methods of treating patient with CNS injury are also presented. | 06-19-2014 |
| 20140170122 | ADULT STEM CELLS DERIVED FROM HUMAN SKIN DERMIS - Provided in the present invention are adult stem cells derived from human skin dermis, and a method for isolating same. Further provided in the present invention are osteoblastic cells and adipocytes differentiated from the adult stem cells derived from human skin dermis, and a differentiation method therefor. Further provided in the present invention is a composition for osteogenesis or lipogenesis containing the stem cells, osteoblastic cells, or adipocytes. The isolation method of the present invention enables the adult stem cells derived from human skin dermis to be obtained in an easy and simple manner at a high yield rate. Genes and growth factors which are specifically expressed in the adult stem cells derived from human skin dermis isolated using the method can be separated, identified, and used later. | 06-19-2014 |
| 20140178343 | SUPPORTS AND METHODS FOR PROMOTING INTEGRATION OF CARTILAGE TISSUE EXPLANTS - The present disclosure provides tissue supports and methods for preparing a cartilage composition for repairing cartilage defects, which is prepared by expanding and integrating small cartilage tissue pieces derived from donor or engineered tissue. The methods and supports described herein promote cell migration and integration of neighboring tissue pieces in culture to form the cartilage composition. Methods of cartilage repair using the cartilage composition are also described. | 06-26-2014 |
| 20140178344 | ACRYLAMIDE HYDROGELS FOR TISSUE ENGINEERING - Disclosed are acrylamide hydrogels prepared from derivatives of (tetrahydropyranyl)methyl- and (tetrahydrofuranyl)methyl-acrylamide, methods of making the same, and methods of wound healing or tissue generation with acrylamide hydrogels. | 06-26-2014 |
| 20140186304 | Compositions for Regenerating Defective or Absent Myocardium - Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. | 07-03-2014 |
| 20140186305 | Culturing of Human Embryonic Stem Cells At The Air-Liquid Interface For Differentiation Into Pancreatic Endocrine Cells - The present invention provides methods, cell cultures and differentiation media to promote differentiation of pluripotent stem cells to pancreatic endocrine cells expressing PDX1, NKX6.1, and HB9 by culturing in a culture vessel at the air-liquid interface. The invention also provides for in vivo maturation of cells cultured at the air-liquid interface. | 07-03-2014 |
| 20140186306 | NOVEL AMPK AGONIST COMPOSITIONS AND METHODS OF USE - The invention relates to novel AMPK agonist containing compositions that are adapted for localised use in treating inflammation and/or pain due to disease or injury in a human or animal. The novel compositions of the invention are useful in the treatment of a variety of conditions including osteoarthritis (OA), synovitis, tendonitis, desmitis; cystitis, osteitis and laminitis. Routes of administration include intra-articular, direct injection into tissues, instillation, retrograde perfusion and topical. AMPK agonists which can be used include AICAR, metformin, phenformin, A-769662, resveratrol, berberine and polyphenols. | 07-03-2014 |
| 20140186307 | Use of Stem Cells to Prevent Neuronal Dieback - The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons. | 07-03-2014 |
| 20140186308 | COMPOSITIONS FOR DIRECTING ADIPOSE-DERIVED STEM CELLS TO A CHONDROGENIC DIFFERENTIATION AND METHODS OF USE THEREFOR - Composition and methods are provided to stimulate the proliferation and differentiation of pluripotent stem cells into chondrocytes. The method comprises the steps of contacting the pluripotent stem cells with an AB2 chimeric polypeptide under conditions suitable for grown and proliferation of the cells. | 07-03-2014 |
| 20140186309 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DISEASES - Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolation thereof. | 07-03-2014 |
| 20140186310 | METHOD OF EX VIVO CELLULAR GROWTH - The present invention relates generally to an ex vivo method of producing a population of cells and materials for use therewith. More particularly, the present invention is directed to an ex vivo method of generating the growth of a population of blood-derived cells and materials for use therewith. The method of the present invention facilitates cell growth by virtue of the migration of blood-derived cells from the vasculature of a vascularised receptacle to the acellular tissue support matrix of said receptacle. These findings have now facilitated the design of means for reliably and efficiently deriving cellular populations from blood-derived cells, such as the generation of bone marrow cells including haemopoietic stem cells and mesenchymal stem cells, for use in a wide variety of clinical and research settings. The method of the present invention is particularly useful for the therapeutic or prophylactic treatment of a range of conditions via the administration of the cells generated in accordance with the method of the present invention. | 07-03-2014 |
| 20140186311 | TRANSIENT IMMORTALIZATION - The invention relates to a method for transiently immortalizing cells according to which immortalization proteins are introduced into the cells from outside. The invention also relates to a method for producing cells according to which organ-related cells are transiently immortalized by the exogenous supply of immortalization proteins and are remortalized after their expansion. The invention further relates to the cells produced according to the inventive method, to the use of said cells for producing a transplant and to the immortalization proteins used in the method. | 07-03-2014 |
| 20140186312 | Method Comprising Contacting Tissue With a Cross-Linkable Polyester Prepolymer - The present inventions in various aspects provide elastic biodegradable polymers. In various embodiments, the polymers are formed by the reaction of a multifunctional alcohol or ether and a difunctional or higher order acid to form a pre-polymer, which is cross-linked to form the elastic biodegradable polymer. In preferred embodiments, the cross-linking is performed by functionalization of one or more OR groups on the pre-polymer backbone with vinyl, followed by photopolymerization to form the elastic biodegradable polymer composition or material. Preferably, acrylate is used to add one or more vinyls to the backbone of the pre-polymer to form an acrylated pre-polymer. In various embodiments, acrylated pre-polymers are co-polymerized with one or more acrylated co-polymers. | 07-03-2014 |
| 20140186313 | BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING - There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure. | 07-03-2014 |
| 20140186314 | PURE POPULATIONS OF ASTROCYTE RESTRICTED PRECURSOR CELLS AND METHODS FOR ISOLATION AND USE THEREOF - An isolated, pure homogeneous population of mammalian astrocyte restricted precursor cells which is CD44 immunoreactive and which generate astrocytes but not oligodendrocytes is provided. Methods for isolating and using these mammalian astrocyte restricted precursor cells are also provided. | 07-03-2014 |
| 20140186315 | COSMETIC COMPOSITION CONTAINING GREEN TEA COMPONENT - The present invention provides a cosmetic composition containing one or more selected from a group consisting of green tea saponin and green tea polyphenol as active ingredients. The cosmetic composition of the invention is very safe to the skin and can greatly enhance biological mechanisms in the skin, and thus can serve as an anti-aging cosmetic composition. | 07-03-2014 |
| 20140193373 | METHODS FOR ESTABLISHING AND IMPROVING THE SURVIVAL OF A POPULATION OF PANCREATIC PROGENITOR OR STEM CELLS - In some embodiments, methods for improving the survival of pancreatic β-cell progenitors in culture are provided. Such methods may include contacting a population of pancreatic progenitor cells with an amino acid (aa) sequence comprising IKVAV (SEQ ID NO:1). In other embodiments, methods for (i) verifying the establishment of a population of pancreatic progenitor or stem cells and (ii) methods for generating or establishing a population of pancreatic endocrine progenitor cells in vitro are provided. | 07-10-2014 |
| 20140193374 | METHODS AND COMPOSITIONS FOR CULTURING CELLS - The invention provides, among other things, methods and compositions for expanding stem cells. The invention further provides methods, devices and systems for directing differentiation of expanded stem cells. The invention further provides methods, devices and systems for treating a subject with differentiated cells in a subject in need thereof. | 07-10-2014 |
| 20140193375 | Mesenchymal Stromal Cell Populations and Methods of Making Same - The present invention provides compositions of mesenchymal stromal cells which express B7-H3, their subsequent use in tissue repair, improved methods of producing tissue repair cells and method of producing a substantially pure population of CD14+ autofluorescent macrophages. | 07-10-2014 |
| 20140193376 | COMBINED CHEMICAL MODIFICATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND CXCR4 SIGNALLING PATHWAYS FOR HEMATOPOIETIC STEM CELL (HSC) MOBILIZATION AND ENGRAFTMENT - The present embodiments provide for combinations of modulators that increase hematopoietic stem cell engraftment or increase mobilization in vivo. Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood are disclosed. One aspect of the invention relates to the use of a CXCR4 antagonist that act in concert with specific molar ratios of S1P receptor 1 (S1PR1) modulator agents to promote HSC mobilization. The invention also relates to methods of using these combinations of CXCR4 antagonists and S1PR1 modulator agents for enhancing the mobilization of hematopoietic stem cells when harvesting of the stem cells, for example for the treatment of diseases, disabilities or conditions whereby transplantation of such cells would be beneficial in ameliorating a symptom associated with such diseases, disabilities or conditions. Another aspect of the invention relates to the use of a CXCR4 antagonist that act in concert with different, but specific molar ratios of S1P receptor 1 (S1PR1) modulator agents to promote HSC engraftment and methods for promoting HSC engraftment in a subject in need thereof, e.g., a recipient subject of a bone marrow or HSC transplant. Methods of screening for novel agents and pharmaceutical compositions comprising these agents are also disclosed. | 07-10-2014 |
| 20140193377 | PREPARATION OF PARENTAL CELL BANK FROM FOETAL TISSUE - The present invention relates to methods of in vitro preparation of a parental cell bank (PCB) from foetal tissue consisting of foetal epiphyseal tissue, foetal Achilles tendon tissue and foetal skin tissue, using a rapid mechanical primary cell culture selection of cell type to be used in methods for wound and tissue repair. | 07-10-2014 |
| 20140193378 | GHRH AGONISTS FOR ISLET CELL TRANSPLANTATION AND FUNCTION AND THE TREATMENT OF DIABETES - Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat diabetes. In one embodiment, a method of promoting survival of grafted cells and/or tissues may involve exposing the cells and/or tissues to an effective amount of at least one agonist of GHRH. In some embodiments, the grafted cells and/or tissues may be pancreatic cells. In some embodiments, the grafted cells may be islet cells co-cultured with non-pancreatic cells. In a further embodiment, a method of treating a patient diagnosed with diabetes involves transplanting and/or grafting the islet cells and/or tissues comprising islet cells into a patient, and administering a therapeutically effective amount of at least one agonist of GHRH to the patient. In some embodiments, the islet cells and/or tissues comprising islet cells may be optionally exposed to GHRH and/or at least one agonist of GHRH prior to transplantation into a patient. In some embodiments, the at least one agonist of GHRH is administered pre-transplantation, concurrently with transplantation, post-transplantation or any combinations thereof. | 07-10-2014 |
| 20140193379 | TREATMENT OF VASCULOPATHY WITH PROSTACYCLIN AND MESENCHYMAL STEM CELLS - Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided. | 07-10-2014 |
| 20140193380 | Technologies, Methods, and Products of Small Molecule Directed Tissue and Organ Regeneration from Human Pluripotent Stem Cells - Pluripotent human embryonic stem cells (hESCs) hold great potential for restoring tissue and organ function, which has been hindered by inefficiency and instability of generating desired cell types through multi-lineage differentiation. This instant invention is based on the discovery that pluripotent hESCs maintained under defined culture conditions can be uniformly converted into a specific lineage by small molecule induction. Retinoic acid induces specification of neuroectoderm direct from the pluripotent state of hESCs and triggers progression to neuronal progenitors and neurons efficiently. Similarly, nicotinamide induces specification of cardiomesoderm direct from the pluripotent state of hESCs and triggers progression to cardiac precursors and cardiomyocytes efficiently. This technology provides a large supply of clinically-suitable human neuronal or cardiac therapeutic products for CNS or myocardium repair. This invention enables well-controlled efficient induction of pluripotent hESCs exclusively to a specific clinically-relevant lineage for tissue and organ engineering and regeneration, cell-based therapy, and drug discovery. | 07-10-2014 |
| 20140193381 | Fluid Exchange Methods and Devices - Methods and devices for exchanging therapeutic agents, such as cells, from one liquid medium to another liquid medium are provided. Aspects of embodiments of the methods include transferring a therapeutic agent from a first medium, such as a freezing, storage or shipping buffer, into a second medium, such as a sterile physiologically compatible buffer. In certain aspects, the transfer of the therapeutic agent from a first medium to a second medium involves the use of acoustic-focusing, or acoustophoresis. Embodiments of the subject methods may facilitate the transfer of a therapeutic agent from a storage medium to an infusion medium, and in certain embodiments include administering the therapeutic agent contained in the infusion medium to the subject. Also provided by the present disclosure are devices for practicing the subject methods. | 07-10-2014 |
| 20140199273 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell population. | 07-17-2014 |
| 20140199274 | NEURONAL PROGENITOR CELLS AND USES - Provided are methods of isolating a novel cell population of midbrain dopaminergic neuronal progenitor cells derived from stem cells using a novel combination markers. The cell population may be used for cell therapies for the treatment of Parkinson's disease and as substrates in pharmacological assays. | 07-17-2014 |
| 20140199275 | TREATING TEAR FILM DISORDERS WITH MESENCHYMAL STEM CELLS - This invention provides methods of preventing, reducing or inhibiting one or more symptoms of a tear film disorder by administration to a subject mesenchymal stem cells. | 07-17-2014 |
| 20140199276 | INKJET PRINTING OF TISSUES AND CELLS - Provided herein is an apparatus for printing cells which includes an electrospinning device and an inkjet printing device operatively associated therewith. Methods of making a biodegradable scaffold having cells seeded therein are also provided. Methods of forming microparticles containing one or more cells encapsulated by a substrate are also provided, as are methods of forming an array of said microparticles. | 07-17-2014 |
| 20140199277 | Methods of Treatment of Retinal Degeneration Diseases - The methods comprise administering cells having properties of stem cells or progenitor cells, to the retina and reprogramming of retinal cells mediated by cell fusion of said cells with said retinal cells, said reprogramming being mediated by activation of the Wnt/β-catenin signalling pathway. | 07-17-2014 |
| 20140205574 | USE OF STEM CELLS OR PROGENITOR CELLS TO TREAT, DELAY, PREVENT, OR REPAIR TEARING OF CRUCIATE LIGAMENTS - Methods for treating a partial or complete rupture of cranial cruciate ligament (CrCL) damage and for preventing or delaying CrCL damage with or without synovitis in dogs are disclosed. For example, this document provides methods for using stem cells and/or progenitor cells to prevent or reduce the likelihood of CrCL rupture in the contralateral leg of mammals, especially dogs, diagnosed with CrCL rupture, as well as methods for using stem cells and/or progenitor cells to treat, delay or prevent complete CrCL rupture in mammals, especially dogs, diagnosed as having a partial CrCL rupture. | 07-24-2014 |
| 20140205575 | In Vivo Iron Labeling of Stem Cells and Tracking these Labeled Stem Cells after their Transplantation - Intravenous ferumoxytol is used to effectively label mesenchymal stem cells (MSCs) in vivo and is used for in vivo tracking of stem cell transplants with magnetic resonance (MR) imaging. The method eliminates risk of contamination and biologic alteration of MSCs associated with ex-vivo-labeling procedures. | 07-24-2014 |
| 20140205576 | METHODS AND COMPOSITIONS FOR INCREASED TRANSGENE EXPRESSION - Described herein are methods of expressing nucleic acids in T cells pre-exposed to a co-stimulatory signal and then transduced with adenoviral vectors. In some embodiments, the co-stimulation is provided by anti-CD3 and anti-CD28 antibodies and the adenoviral vector is pseudotyped for T-cell entry. The invention also relates to compositions for carrying out these methods, provided as kits or pharmaceutical compositions that can be used to treat diseases including immunological conditions and hematological malignancies. | 07-24-2014 |
| 20140205577 | Treatment of Cardiovascular Disorders Using the Cell Differentiation Signaling Protein Nell1 - It has been identified in accordance with the present invention that Nell1 is essential for normal cardiovascular development by promoting proper formation of the heart and blood vessels. The present invention therefore provides therapeutic methods for treating cardiovascular disorders by employing a Nell1 protein or nucleic acid molecule. | 07-24-2014 |
| 20140212390 | Placental Membrane Preparation and Methods of Making and Using Same - This disclosure relates to placental membrane preparations and the methods of preparing and using thereof. In some embodiments, the disclosure relates to a placental membrane preparation. In some embodiments, the disclosure relates to methods of producing a placental membrane preparation. In some embodiments, the disclosure relates to methods of treating cartilage using placental membrane preparations. | 07-31-2014 |
| 20140212391 | VAGINAL LAXITY THERAPY UTILIZING CELL-BASED BULKING COMPOSITIONS - The invention provides methods for the treatment of vaginal laxity which include delivering a cell-containing composition to the vagina. The composition can include fat tissue to provide a bulking effect to reduce the size of the vaginal opening. The cells can provide healing and revascularization of the vaginal treatment area to sustain the bulking provided by the fat. The invention also provides systems and compositions useful for performing the method, and can include instruments and devices for removal of autologous adipose tissue from a patient (e.g., by liposuction), equipment for the enrichment of cells from adipose tissue, mechanical processing of adipose tissue, and the mixing of cells and processed adipose tissue. Devices for the delivery of the cell compositions to the vagina can also be included in the system. | 07-31-2014 |
| 20140212392 | METHOD OF ISOLATING HUMAN NEUROEPITHELIAL PRECURSOR CELLS FROM HUMAN FETAL TISSUE - A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided. | 07-31-2014 |
| 20140219969 | CELL THERAPY FOR THE TREATMENT OF NEURODEGENERATION - Methods are described for the isolation and selection of a heterogeneous bone marrow cell population, called NCS-01, that is effective at treating neurodegeneration. For example, NCS-01 cells are shown to treat neurodegeneration caused by ischemia. In vivo studies demonstrate that selected NCS-01 cell populations treat neurodegeneration in a standard rat middle cerebral artery occlusion (MCAO) animal model under conditions of transient or permanent total arterial occlusion. These studies also disclose that when the neurodegeneration is caused by ischemic stroke, combining the administration of a selected NCS-01 cell population with thrombolytic agents and/or mechanical methods of clot removal leads to a decrease in the volume of infarction caused by acute onset neurodegeneration. The disclosed cell therapy promises to make a significant clinical impact on patient survival after stroke. | 08-07-2014 |
| 20140219970 | TREATMENT OF SARCOIDOSIS USING PLACENTAL STEM CELLS - Provided herein are compositions and methods of treating individuals having sarcoidosis or a sarcoidosis-related disease or disorder, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein. Also provided herein are kits comprising said cells or a composition thereof. | 08-07-2014 |
| 20140219971 | ALGAL PRODUCED MALARIAL TRANSMISSION BLOCKING VACCINES - The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus | 08-07-2014 |
| 20140219972 | TISSUE ENGINEERING USING PROGENITOR CELLS TO CATALYZE TISSUE FORMATION BY PRIMARY CELLS - Methods of regenerating tissue using progenitor cells in combination with primary cells from a target tissue are disclosed. In particular, progenitor cells catalyze proliferation and tissue production by primary cells allowing the use of fewer primary cells from a target tissue for effective tissue regeneration. Cell-based therapies combining progenitor cells and primary cells can be used for repair and regeneration of damaged tissue and organs for treating bodily injuries and degenerative diseases. For example, adipose-derived stem cells and neonatal articular chondrocytes, co-encapsulated in mixed or bilayered cultures in a hydrogel comprising chondroitin sulfate methacrylate and poly(ethylene)glycol diacrylate, generated cartilage that could be used for treatment of traumatic injuries or diseases involving cartilage degeneration. Moreover, the inventors showed that progenitor cells could be used to stimulate cartilage formation with a minimal number of primary cells, as few as 1% or less, in mixed cultures containing primary cells and progenitor cells. | 08-07-2014 |
| 20140219973 | Composite Hydrogel-Clay Particles - A nanocomposite hydrogel formed from free radical dissociation of an initiator and polymerisation of a water soluble monomer. The resulting hydrogel finds particular application within the medical field for both soft and hard tissue repair in human and animals. The hydrogel is particularly advantageous for spinal disc repair. | 08-07-2014 |
| 20140234263 | CELLULAR AND MOLECULAR THERAPIES - The present invention provides, among other things, improved compositions and methods for the treatment of tissue damage (e.g., acute or chronic) and related diseases, disorders or conditions based on the use of pathfinder cells, extracellular secretomes thereof, and/or pathfinder cell-associated microRNAs. In some embodiments, the present invention provides a method for treating tissue damage (e.g., acute or chronic) comprising a step of administering a population of cells to an individual suffering from a disease, disorder or condition characterized by acute damage to one or more tissues, wherein the cells are originated from an adult tissue and wherein the cells induce tissue repair, regeneration, remodeling, reconstitution or differentiation. In some embodiments, the present invention provides a method for treating inflammation comprising a step of administering a population of cells, or extracellular secretomes thereof, to an individual suffering from a disease, disorder or condition characterized by inflammation of one or more tissues, wherein the cells are originated from an adult tissue and wherein the cells induce an anti-inflammatory response. | 08-21-2014 |
| 20140234264 | INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING A PPI IN COMBINATION WITH AN IMMUNE TOLERANCE AGENT - To date, no immune tolerance agent or combination of immune tolerance agents has been able to sustain insulin-independence among type 1 diabetes patients. This patent provides methods and pharmaceutical compositions for providing insulin independence among newly diagnosed and existing type 1 diabetes. Methods include utilization of PPIs, which increase gastrin resulting in the transformation of human ductal tissue into insulin-secreting new beta cells, used in combination with an immune tolerance agent to protect the new insulin-producing beta cells generated by the PPI from immune destruction. Compositions and methods are provided for beta cell generation therapy comprising at least one member from a group of PPIs with formulations selected from immune tolerance agents, when used in combination result in insulin-independence among new and existing type 1 patients whom currently require insulin to sustain life. Compositions and methods are provided for insulin-independence among type 2 patients using PPIs when combined with therapeutic agents utilized for the treatment of type 2 diabetes. | 08-21-2014 |
| 20140234265 | COMPOSITIONS AND METHOD FOR MANIPULATING PIM-1 ACTIVITY IN CIRCULATORY SYSTEM CELLS - The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart. | 08-21-2014 |
| 20140234266 | Cultured Hematopoietic Stem Cells and Method for Expansion and Analysis Thereof - Hematopoietic stem cells and methods for ex vivo expansion of hematopoietic stem cells are provided. The methods comprise culturing the cells in a media containing an effective amount insulin-like growth factor (IGF), fibroblast growth factor (FGF), thrombopoietin (TPO), and stem cell factor (SCF), under conditions sufficient for expansion of said cells. Methods for identifying expanded hematopoeitic stem cells and kits for ex vivo expansion of hematopoietic stem cells are also provided. | 08-21-2014 |
| 20140234267 | MAPC Generation of Lung Tissue - The present invention relates to methods of improving function in lung tissue by administering a population of multipotent adult progenitor cells (“MAPCs”) or differentiated progeny thereof. | 08-21-2014 |
| 20140234268 | TREATMENT USING REPROGRAMMED MATURE ADULT CELLS - A method of treating various diseases, disorders, or conditions in patient using reprogrammed cells such as retrodifferentiated, transdifferentiated, or redifferentiated cells. The method comprises obtaining committed cells from the patient, retrodifferentiating the committed cells to obtain retrodifferentiated target cells, and administering the retrodifferentiated cells to the patient. In certain embodiments, the method comprises obtaining committed cells from the patient, transdifferentiating the committed cells to obtain transdifferentiated target cells, and administering the transdifferentiated target cells to the patient. The retrodifferentiated or transdifferentiated target cells repair or replenish tissue or cells in the patient. | 08-21-2014 |
| 20140234269 | Endometrial Derived Stem Cells and Their Methods of Use - The present invention provides a method of making an insulin-producing cell derived from an endometrial stromal stem cell (ESSC). The invention includes the progeny of ESSC, including any cell type generated during the differentiation of ESSC towards cells that produce insulin and exhibit cell markers characteristic of insulin producing cells. The cells of the invention can be used to treat various diseases such as diabetes type I, diabetes type II and gestational diabetes. | 08-21-2014 |
| 20140234270 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS - The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic. | 08-21-2014 |
| 20140234271 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS - We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject. | 08-21-2014 |
| 20140234272 | Therapeutics Using Adipose Cells and Cell Secretions - The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells. | 08-21-2014 |
| 20140234273 | DIAGNOSTIC ASSAY FOR TISSUE TRANSPLANTATION STATUS - The present disclosure relates generally to tissue, including organ, transplantation. Taught herein is a genetic-based diagnostic assay to ascertain the status of a tissue transplantation procedure in a recipient based on a characterization of circulating or other cell free nucleic acid material. The instant disclosure enables kits, primers and protocols for ascertaining the status of a transplantation procedure. | 08-21-2014 |
| 20140242038 | METHOD FOR GENERATING BETA CELLS - The invention is directed to methods for generating pancreatic progenitor cells, insulin producing cells or endoderm cells using embryonic stem cells and induced pluripotent stem cells. The present invention also relates to an isolated population comprising pancreatic progenitor cells or a insulin-producing cells, compositions and their use in the treatment of diabetes | 08-28-2014 |
| 20140242039 | ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND USE THEREOF IN THERAPY - A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed. | 08-28-2014 |
| 20140242040 | Methods for preventing and/or treating nasal polyps and rhinosinusitis - The invention is directed to methods for preventing and/or treating nasal polyps. The invention is further directed to methods for preventing and/or treating rhinosinusitus. The invention is further directed to reducing inflammation of the paranasal sinuses. The invention is further directed to methods for preventing and/or treating nasal polyps and/or rhinosinusitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel immediate-release, targeted-release, and sustained-release (SR) cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions) | 08-28-2014 |
| 20140242041 | Methods for preventing or treating necrotizing enterocolitis - The invention is directed to methods for preventing and/or treating necrotizing enterocolitis. The invention is further directed to reducing inflammation of the intestinal mucosa associated with necrotizing enterocolitis. The invention is further directed to methods for preventing and/or treating necrotizing enterocolitis and/or inflammation of the intestinal mucosa associated with necrotizing enterocolitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). | 08-28-2014 |
| 20140242042 | Methods for preventing and treating hemorrhoids - The invention is directed to methods for treating hemorrhoids. The invention is also directed to methods for preventing hemorrhoids. The invention is further directed to reducing inflammation associated with hemorrhoids. The invention is further directed to methods for preventing hemorrhoids and/or treating hemorrhoids and/or reducing inflammation associated with hemorrhoids by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). | 08-28-2014 |
| 20140242043 | Methods for preventing or treating optic neuritis - The invention is directed to methods for preventing and/or treating optic neuritis. The invention is further directed to reducing inflammation associated with the development of optic neuritis. The invention is further directed to methods for preventing and/or treating optic neuritis and/or inflammation associated with the development of optic neuritis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel immediate-release, targeted-release, and sustained-release (SR) cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions) and/or and Amnion-derived Multipotent Progenitor (AMP) cell compositions. | 08-28-2014 |
| 20140242044 | Devices and methods for treating defects in the tissue of a living being - An implant for deployment in select locations or select tissue for regeneration of tissue is disclosed. The implant includes collagen and or other bio-resorbable materials, where the implant may also be used for therapy delivery. Additionally, the implant may include, or have blended in, an additive, such as an osteoinductive factor, for example biocompatible ceramics and glass. | 08-28-2014 |
| 20140242045 | Methods And Compositions For Delivering Interleukin-1 Receptor Antagonist - Methods and compositions generating and using an interleukin-1 receptor antagonist (IL-1ra)-rich solution. Methods for generating and isolating interleukin-1 receptor antagonist include incubating adipose tissue and/or adipocytes with polyacrylamide beads to produce interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist is isolated from the polyacrylamide beads to obtain the solution rich in interleukin-1 receptor antagonist. Methods for treating a site of inflammation in a patient include administering to the site of inflammation the solution rich in interleukin-1 receptor antagonist. | 08-28-2014 |
| 20140242046 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES - Methods and compositions are provided for the production of stem cells and induced pluripotent stem cells, and for uses thereof. | 08-28-2014 |
| 20140248244 | Mesenchymal Stem Cells Expressing TNF-alpha Receptors - Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/10 | 09-04-2014 |
| 20140248245 | DIAGNOSTIC METHOD FOR CONNECTIVE TISSUE AND ITS APPLICATION - The present invention relates to medicine and is used to evaluate conditions and to detect connective tissue pathology (and/or organ) by clonal analysis. The present invention relates to aesthetic medicine and is used for correction of aging skin changes. The method includes: cultivation of substrate-dependent cell colonies of analyzed tissue and/or organ, at conditions which provide formation of discrete colonies applicable for visualization, statistically reliable analysis of derived colonies, determination of at least one parameter which characterizes regenerative potential of population of substrate dependent cells, determination of at least one parameter which characterizes proliferative potential of population of substrate dependent cells, and processing of obtained results which allows to evaluate regenerative ability of patient's tissue and/or organ. The method provides objective qualitative characteristics of both the proliferative and regenerative potential which allows evaluating the regenerative potential of primary tissue (and/or organ) without complex and expensive instrumental studies. A computer based system for performing the present method is also provided. | 09-04-2014 |
| 20140255354 | BARRIER CELL TREATMENT FOR MALIGNANT OR BENIGN TUMORS - A method for administering a barrier cell treatment for malignant or benign tumor cells. The method includes preparing a material including chondrocytes and placing the material around the tumor cells. Preparing the material can include harvesting and culturing chondrocytes from the patient. | 09-11-2014 |
| 20140255355 | Methods for treating blepharitis - The invention is directed to methods for treating blepharitis. The invention is further directed to reducing inflammation associated with blepharitis. The invention is further directed to methods for treating blepharitis and/or reducing inflammation associated with blepharitis by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). | 09-11-2014 |
| 20140255356 | ISOLATION OF STROMAL VASCULAR FRACTION FROM VASCULAR TISSUES - Methods of isolating stromal vascular fractions for use in human subjects from a tissue comprising a blood vessel using mechanical, optionally ultrasonic cavitation, enzymatic, and/or chemical methods are provided. These methods yield an increased number of the cells which constitute the stromal vascular fractions (about 10-fold greater) than methods which use collagenase to isolate these cells. The stromal vascular fraction may be isolated from any tissue that comprises blood vessels, for example, muscle and adipose tissue. Additionally, the tissue may be isolated obtained from nonliving sources and animals (e.g., postmortem). | 09-11-2014 |
| 20140255357 | Methods And Compositions For Regenerating And Repairing Damaged Or Aged Tissue Or Organs Using Nonviable Irradiated Or Lyophilized Pluripotent Stem Cells - Compositions and methods are provided herein for regenerating and repairing damaged or aged tissue or organs using nonviable lethally irradiated or lyophilized pluripotent stem cells. In one aspect, the compositions and methods described herein provide anti-aging benefits to the skin by increasing the hydration reducing fine lines, wrinkles, and pores of the skin. Compositions and methods are also provided for promoting wound healing using lyophilized pluripotent stem cell powder. A method is provided for inducing cardiac muscle regeneration in a primate comprising delivering nonviable lethally irradiated pluripotent stem cells to damaged or aged areas of the heart. The compositions and methods include nonviable lethally irradiated or lyophilized pluripotent stem cells. In one aspect, the compositions and methods utilize nonviable pluripotent stem cells in the form of a powder, such as lyophilized stem cells. | 09-11-2014 |
| 20140255358 | GENERATION OF IMMUNOSUPPRESSIVE MYELOID CELLS USING PGE2 - Therapies effective for the treatment and prevention of autoimmune diseases, chronic inflammatory diseases, transplant rejection or Graft versus Host Disease (GvH), using prostaglandin (PG), alternative agonists of PG receptors, EP2 or EP4, or other activators of adenylate cyclase/cAMP/PKA/CREB signaling pathway are disclosed herein. These methods include the administration of a therapeutically effective amount of myeloid cells pre-treated ex vivo with the above-mentioned factors, or the in vivo administration of such agents in combination with the factors attracting myeloid precursor cells, such as myeloid cell-attracting chemokines or their inducers. Such therapies can be applied for the prevention or treatment of autoimmune diseases, spontaneous and specific pathogen-induced inflammatory diseases (including some infectious diseases), premalignant and malignant lesions, and for prevention and treatment of transplant rejection and GvH. | 09-11-2014 |
| 20140255359 | METHODS, KITS, AND COMPOSITIONS FOR STEM CELL SELF-RENEWAL - Methods and kits for expanding a stem cell population, particularly a hematopoietic stem cell population, in the presence of a DNA methyltransferase modulator and a Wnt pathway modulator are disclosed. | 09-11-2014 |
| 20140271565 | FLUORAPATITE GLASS-CERAMICS - The present invention provides a highly-sintered fluorapatite glass-ceramic comprising a high Ca/Al or Sr/Al mole-ratio, that possesses a microstructure that induces apatite/bone deposition. | 09-18-2014 |
| 20140271566 | IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS - A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation. | 09-18-2014 |
| 20140271567 | METHODS OF TREATING OR PREVENTING RHEUMATIC DISEASE - The present disclosure provides a method for treating or preventing a rheumatic disease, comprising administering a population of cells enriched for STRO-1 | 09-18-2014 |
| 20140271568 | METHOD AND KIT FOR PROVIDING AN INCREASED EXPRESSION OF TELOMERASE, BRAIN-DERIVED NEUROTROPHIC FACTOR, STROMAL CELL-DERIVED FACTOR-1, CXC CHEMOKINE RECEPTOR 4, AND/OR IMMUNE REGULATORY FACTOR OF STEM CELL - A method for providing an increased expression of at least one of telomerase, brain-derived neurotrophic factor (BDNF), stromal cell-derived factor-1 (SDF1), CXC chemokine receptor 4 (CXCR4), and an immune regulatory factor of a stem cell in a subject is provided. The method comprises simultaneously or separately administering to the subject an effective amount of (a) a phthalide and (b) a stem cell. | 09-18-2014 |
| 20140271569 | KITS AND METHODS FOR PROCESSING STEM CELLS FROM BONE MARROW OR UMBILICAL CORD BLOOD - Provided herein are kits for processing stem cells from bone marrow or umbilical cord blood, comprising: a) a precipitation reagent comprising an aqueous solution of 0.1-30% hydroxyethyl starch or 0.1-30% methyl cellulose, and 0.1-20% of cerebroprotein hydrolysate; and b) a separation reagent comprising an aqueous solution comprising Ficoll and diatrizoate and having a density of 1.0-1.2 g/ml, and methods of use. Further provided herein is a collection of stem cells obtained by the kits and methods disclosed herein comprising stem cells from bone marrow or umbilical cord blood, and uses thereof. | 09-18-2014 |
| 20140271570 | PERFORATED OSTEOCHONDRAL ALLOGRAFT COMPOSITIONS - Osteochondral graft composition comprising a cartilage component and a bone component, and further comprising one or more perforations in the bone component and/or the cartilage component, are provided. Methods of manufacturing and using osteochondral graft compositions comprising one or more perforations in the bone component and/or the cartilage component are also provided. | 09-18-2014 |
| 20140271571 | Cell Culture Cassettes and Incubator - The invention relates to cassettes for culturing cells. The invention also relates to analytical and preparative incubators for housing the cassettes. The invention also relates to methods of using the cassettes, for example, to culture cells wherein the processes of feeding and passaging cells are automated. | 09-18-2014 |
| 20140271572 | ADIPOSE TISSUE MESENCHYMAL STEM CELLS AND METHODS OF USE TO TREAT OR INHIBIT UTERINE DISORDERS - There is a high stem cell therapy potential in the field of reproductive disorders. Endometriosis is a common finding in women with infertility. In addition endometriosis is the major problem in the veterinary field. In the disclosed invention we provide a method of application and use of adipose tissue derived stem cell to treat fertility and pregnancy related disorders, especially endometriosis in mammalian objects. | 09-18-2014 |
| 20140271573 | PHARMACO-CELLULAR THERAPEUTIC METHOD FOR THE TREATMENT OF MUSCULAR DYSTROPHIES - A method of treating a muscular dystrophy disease in a patient includes administering an effective amount of a botanical drug isolated from | 09-18-2014 |
| 20140271574 | METHODS AND COMPOSITIONS FOR TREATING CONGESTIVE HEART FAILURE - Compositions and methods for treating congestive heart failure are provided herein. | 09-18-2014 |
| 20140271575 | ADULT CARDIAC STEM CELL POPULATION - The present invention relates to the identification, isolation, expansion and characterization of a specific type of adult cardiac stem cell. These adult stem cells are characterised in that they naturally express a specific pattern of markers, which can be used to assist with their isolation and expansion. The cells of the invention display an unprecedented capacity for providing, activating and/or inducing repair of damaged cardiac tissue. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium. | 09-18-2014 |
| 20140271576 | Self-Gelling Alginate Systems and Uses Thereof - Kits and compositions for producing an alginate gel are disclosed. The kits and compositions comprise soluble alginate and insoluble alginate/gelling ion particles. Methods for dispensing a self-gelling alginate dispersion are disclosed. The methods comprise forming a dispersion of insoluble alginate/gelling ion particles in a solution containing soluble alginate, and dispensing the dispersion whereby the dispersion forms an alginate gel matrix. The methods may include dispensing the dispersion into the body of an individual. An alginate gel having a thickness of greater than 5 mm and a homogenous alginate matrix network and homogenous alginate gels free of one or more of: sulfates citrates, phosphates, lactatates, EDTA or lipids are disclosed. Implantable devices comprising a homogenous alginate gel coating are disclosed. Methods of improving the viability of pancreatic islets, or other cellular aggregates or tissue, following isolation and during storage and transport are disclosed. | 09-18-2014 |
| 20140271577 | HUMAN LYSOSOMAL PROTEINS FROM PLANT CELL CULTURE - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 09-18-2014 |
| 20140271578 | RENAL STEM CELLS ISOLATED FROM KIDNEY - A novel renal precursor cell is identified from kidney tissue. The cell is multipotent capable of forming renal epithelial and endothelial tissues. The cell can be amplified in culture and maintains stemness over multiple passages. This cell fulfills a major unmet need as a cell-based source for kidney regeneration or repair. Treatment of kidney diseases and disorders (e.g., glomerularpathies and acute tubular necrosis) may be improved thereby. | 09-18-2014 |
| 20140286910 | STEM CELLS AND METHODS INCORPORATING ENVIRONMENTAL FACTORS AS A MEANS FOR ENHANCING STEM CELL PROLIFERATION AND PLASTICITY - Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture. The invention also contemplates the use of such stem cells in the treatment of neurodegenerative disorders including Alzheimer's disease and stroke. | 09-25-2014 |
| 20140286911 | CELL REPOPULATED COLLAGEN MATRIX FOR SOFT TISSUE REPAIR AND REGENERATION - The present invention provides compositions for treating soft tissue injuries comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix. Methods of making and using compositions comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix are also provided. | 09-25-2014 |
| 20140286912 | ISOLATED DISCOGENIC CELLS, METHODS OF USING, AND METHODS OF PREPARING SAME FROM MAMMALIAN TISSUE - The present disclosure relates to discogenic cell populations, methods of deriving, and methods of using them. The presently described discogenic cell populations may be used to restore or regenerate damaged, diseased, or missing intervertebral discs of a subject. The presently described discogenic cell populations can be derived from and administered or implanted into a subject, or may be derived from an unrelated donor. | 09-25-2014 |
| 20140286913 | COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME - The invention provides compositions that increase the mobilization, homing, expansion, and/or differentiation of stem cells and methods of using the same for the treatment of mammals. | 09-25-2014 |
| 20140286914 | PROTEIN THERAPY FOR TREATMENT OF EYE DISEASES - The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein. | 09-25-2014 |
| 20140286915 | METHOD FOR THE EX VIVO EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS - The present invention relates to hematopoietic cells, and more specifically to methods for long-term in vitro culturing and ex vivo expansion of hematopoietic cells. The present invention also provides compositions useful for culturing cells, such as media for culturing hematopoietic cells, specifically haematopoietic stem cells (HSC) and haematopoietic progenitor cells (HPC). The present invention further provides compositions including growth factor combinations and methods utilising altered growth and environmental conditions that are applicable in vitro culturing and to ex vivo expansion of HSC and/or HPC. | 09-25-2014 |
| 20140286916 | Uses of Growth and Differentiation Factor 8 (GDF-8) - The present invention relates to uses of growth and differentiation factor 8 (GDF-8) in vitro or in vivo for reducing the immunogenicity or risk of rejection of cells such as in particular mesenchymal stem cells (MSC), tissues or materials. The present invention further relates to methods for differentiating MSC in vitro or ex vivo into osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells using FGF-2 and GDF-8. In addition, the present invention relates to osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells obtainable by such methods and to the osteoprogenitors or osteoblastic cells or a cell population comprising osteoprogenitors and/or osteoblastic cells for use in the treatment of musculoskeletal diseases. | 09-25-2014 |
| 20140294775 | METHODS FOR TREATING OBESITY AND/OR METABOLIC SYNDROME - The present disclosure provides methods of treating or preventing obesity or causing weight loss or treating or preventing metabolic syndrome comprising administering to a subject a population of cells enriched for STRO-1 | 10-02-2014 |
| 20140294776 | Isolated populations of female germline stem cells and cell preparations and compositions thereof - The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof. | 10-02-2014 |
| 20140294777 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 10-02-2014 |
| 20140294778 | PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS - Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells. | 10-02-2014 |
| 20140294779 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 10-02-2014 |
| 20140294780 | COMPOSITIONS AND METHODS FOR INDUCTION AND MODULATION OF ANGIOGENESIS AND METHODS AND ASSAYS FOR IDENTIFYING ANGIOGENESIS MODULATORS - The present disclosure provides methods and compositions, including a placental extract, for inducing and/or modulating angiogenesis; methods of identifying modulators of angiogenesis, and assays for identifying modulators of angiogenesis. The present disclosure also provides methods of making a composition, including a placental extract that can induce and/or modulate angiogenesis. | 10-02-2014 |
| 20140294781 | Method to formulate T-cells - A method for formulating T-cells for use as a medicant comprises suspending T-cells with cross-linked surface moieties in a media suitable for infusion. The cross-linked T-cells are packaged in a container suitable for administration to a patient. | 10-02-2014 |
| 20140294782 | Reprogramming of Cellular Adhesion - Disclosed are membrane-anchored polynucleotides, and compositions comprising the membrane-anchored polynucleotides. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds and compositions in research and therapeutic applications. | 10-02-2014 |
| 20140294783 | IMPLANTABLE SCAFFOLDS AND METHODS OF USE - Inventive concepts relate general to the field of implantable three-dimensional scaffolds. More particularly, methods of preparing and using implantable nanofibrous tissue scaffolds are described. Inventive scaffolds can be used for treatment of defects in a living organism, such as hard or soft tissue defects including bone. | 10-02-2014 |
| 20140301985 | METHOD OF TREATING PANCREATIC AND LIVER CONDITIONS BY ENDOSCOPIC-MEDIATED (OR LAPAROSCOPIC-MEDIATED) TRANSPLANTATION OF STEM CELLS INTO/ONTO BILE DUCT WALLS OF PARTICULAR REGIONS OF THE BILIARY TREE - A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted. The cells are specifically introduced to the hepato-pancreatic common duct of the subject for treatment of pancreatic conditions or to the bile duct wall near to the liver for treatment of liver conditions and allowed to migrate to the pancreas or to the liver and expand and then rebuild part or the entirety of the diseased or dysfunctional organ. | 10-09-2014 |
| 20140301986 | IMMUNOCOMPATIBLE CHORIONIC MEMBRANE PRODUCTS - Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment. | 10-09-2014 |
| 20140301987 | STRUCTURE FOR TISSUE REGENERATION AND A PRODUCTION METHOD THEREFOR - The present invention relates to a structure for tissue regeneration and to a production method therefor. The structure for tissue regeneration according to the present invention allows autologous tissue to be used, makes stable transplantation possible and can be produced without additional materials such as biopolymers. Also, it can be produced to a diameter of any desired size from a number of microns to a number of centimeters and can easily be produced in volume, and it contains large amounts of the extracellular matrix GAG, collagen and the like and can be used in tissue regeneration or filling in various fields including dermatology, plastic surgery, dentistry, surgery, orthopaedic surgery, urology, otolaryngology or in obstetrics and gynaecology. | 10-09-2014 |
| 20140301988 | VASCULAR PROGENITOR CELL SHEET DERIVED FROM INDUCED PLURIPOTENT STEM CELLS, AND PRODUCTION METHOD THEREFOR - The present invention addresses the problem of providing a vascular progenitor cell sheet derived from induced pluripotent stem cells, which has the strength to tolerate practical applications and exhibits a high treatment effect. This vascular progenitor cell sheet derived from induced pluripotent stem cells is prepared by performing: (1) a step for preparing magnetically labeled Flk-1 positive cells derived from induced pluripotent stem cells; (2) a step for preparing a mixture of the Flk-1 positive cells and a gel material including type I collagen, laminin, type IV collagen and entactin as active ingredients, and then disseminating the mixture in a culture vessel; (3) a step for drawing the Flk-1 positive cells in the mixture to the culture surface of the culture vessel by application of a magnetic force to form a multi-layered cell layer; and (4) a step for gelling the gel material. | 10-09-2014 |
| 20140308250 | CELL PREPARATIONS DEPLETED OF TCR ALPHA/BETA - The invention relates to a composition, comprising a cell population that can be obtained from bone marrow or from blood, when the cell population is depleted of cells that express TCR alpha/beta and cells that express CD19. Such a pharmaceutical composition makes the reconstitution of the immune defense of a person as part of a bone marrow transplantation possible. By means of the invention, the time until the immune reconstitution is considerably shortened and the immune response after treatment are considerably reduced, in particular the occurrence of GvHD. The survival rate of the patient is considerably increased. | 10-16-2014 |
| 20140308251 | INTERVERTEBRAL DISC REPAIR, METHODS AND DEVICES THEREFOR - The present application discloses compositions, methods and devices for treatment of a degenerative intervertebral disc. A composition can comprise chondrocytes expressing type II collagen. These chondrocytes can be obtained from human cadavers up to about two weeks following death, and can be grown in vitro. The compositions can further comprise one or more biocompatible molecules. Treatment of a degenerative disc can comprise injecting or implanting a composition comprising the chondrocytes into a degenerative disc through an aperture or incision. If the aperture or incision is closed with a suture or a glue after introduction of the chondrocytes, the closure can withstand over 400 N of compression force. | 10-16-2014 |
| 20140308252 | Organs for Transplantation - The invention provides methods and compositions that improve the success of organ transplantation. The methods and compositions are directed to exposing a desired organ to stem cells prior to, during, and/or after transplantation. In one embodiment, the stem cells reduce the deleterious effects of ischemia on an organ designated to be harvested for transplantation or that has been harvested for transplantation. In another embodiment in which an organ designated for transplantation is perfused ex vivo, the method involves reducing ischemic reperfusion injury by perfusing the organ with a medium that contains stem cells. | 10-16-2014 |
| 20140308253 | ISOLATED POPULATIONS OF FEMALE GERMLINE STEM CELLS AND CELL PREPARATIONS AND COMPOSITIONS THEREOF - The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof. | 10-16-2014 |
| 20140308254 | METHODS AND COMPOSITIONS FOR TREATING DIABETES AND OTHER DEGENERATIVE NEUROENDOCRINE DISEASES OR DISORDERS - The present application describes the use of adult human olfactory neuroepithelium (ONe) stem cells in the treatment of diabetes. | 10-16-2014 |
| 20140308255 | Methods and Compositions for Regulation of Cell Aging, Carcinogenesis and Reprogramming - Compositions and methods described herein include somatic cells that are competent for reprogramming and malignant transformation and are characterized by a reduction of the levels of Sp100 in the cells, cells having markers of pluripotent stem cells, and methods for preparing same. Methods for reversably regulating aging or reprogramming to pluripotency in a somatic cell involve modulating the expression of Sp100 therein. Methods and compositions for retarding the growth of or suppressing unwanted cell proliferation involve expressing, inducing expression of, or upregulating, Sp100 in a targeted cell that is undergoing unrestricted proliferation or replication or increasing exposure to Sp100 in the environment or microenvironment of the targeted cell. Also disclosed are methods for treating a proliferative disease or condition by increasing expression or levels of Sp100 in the targeted cell or its environment. | 10-16-2014 |
| 20140308256 | Methods for Use of Neural Stem Cell Compositions for Treatment of Central Nervous System Lesions - Methods for inducing non-embryonic lesioned central nervous system neurons to survive, integrate, extend axons over long distances, induce intra-lesion ingrowth of neurons into the lesion from host tissue and form synapses in vivo. Pluripotent neural stem cells are grafted into the lesioned CNS tissue within a tissue adhesive suspension, optionally in the presence of growth factors. No modification of the neuronal regenerative inhibitory environment of the CNS is necessary. | 10-16-2014 |
| 20140314720 | HALOGENATED RHODAMINE DERIVATIVES AND APPLICATIONS THEREOF - Methods for treating an infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with either bacteria or a virus. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. The rhodamine compounds may be 2′-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl)4′,5′-dichloro-benzoic acid methyl ester hydrochloride. | 10-23-2014 |
| 20140314721 | USE OF NEURAL CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention is based in part methods for treating neurodegenerative diseases and disorders. Specifically, the present invention disclose methods for treating neurodegenerative disorders suing neural stem cells (NSCs) and/or pluripotent stem cell (PSC) derived neurons or neuron precursor cells. The present invention also discloses methods to induce endogenous dopaminergic neurons to release dopamine and increase the levels of dopamine in a subject. | 10-23-2014 |
| 20140314722 | MATRICES COMPRISING A MODIFIED POLYSACCHARIDE - The present invention discloses a matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid group. | 10-23-2014 |
| 20140314723 | ENDOTHELIAL CELL CULTURE - The disclosure relates to cell culture vessels comprising fabricated cell culture surfaces providing means for efficient corneal endothelial cell growth and the use of the cultured cells in the repair of corneal tissue damage. | 10-23-2014 |
| 20140314725 | METHOD FOR PREPARING MESENCHYMAL STEM CELL-LIKE CELLS AND CARDIOMYOCYTE-LIKE CELLS - The present invention provides a method for preparing mesenchymal stem cell-like cells and cardiomyocyte-like cells from induced pluripotent stem cells. With the method, embryoid bodies are first formed from induced pluripotent stem cells in a non-adherent substrate. The embryoid bodies are then contacted with a serum-free and insulin-free medium comprising a p38-MAPK inhibitor to form aggregates of contracting embryoid bodies. The contracting embryoid body aggregate(s) are then induced to form mesenchymal stem-cell-like cells and aggregates of cardiomyocyte-like stem cells with a medium comprising ≦5% serum in a cell-culture treated substrate. The cardiomyocyte-like cells and the mesenchymal stem-cell like cells may be separated to give isolated populations of each cell type. The population of cardiomyocyte-like cells and mesenchymal stem-cell like cells and the isolated population of each cell type may be used for replacing cells. In particular, the cells may be used for replacing cells in cardiac repair and/or cardiac therapy. | 10-23-2014 |
| 20140314726 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE - The present invention concerns methods and compositions for differentiating cells, including human fibroblasts, into chondrocyte-like cells via in vivo mechanical strain. In particular aspects, fibroblasts are delivered to a joint, such as an intervertebral disc, following which the fibroblasts differentiate into chondrocyte-like cells to treat dysfunction of cartilage therein, including to repair degenerated discs, for example. The fibroblasts that do not differentiate to chondrocytic cells because of the location of the cells, as in the fissures of annulus, or other biomechanical and biochemical micro-environment factors, may produce fibrous matrix molecule(s) in aiding tissue repair and regeneration in both nucleus pulposus and annulus fibrosus. In certain aspects, the fibroblasts prior to delivery to the individual are managed in the absence of growth factors, in vitro mechanical strain, and/or matrix molecules, for example. | 10-23-2014 |
| 20140322175 | Use Of Umbilical Cord Blood To Treat Individuals Having A Disease, Disorder Or Condition - The present invention provides methods of using cord blood and cord blood-derived stem cells in high doses to treat various conditions, diseases and disorders. The high-dose cord blood and cord blood-derived stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. In particular, the cord blood or cord blood-derived stem cells are delivered in high doses, e.g., at least 3 billion nucleated cells per treatment, where treatment may comprise a single or multiple infusions. The invention also provides for the use of cord blood or cord blood-derived stem cells from multiple donors without the need for HLA typing. | 10-30-2014 |
| 20140322176 | METHODS OF USING ZSCAN4 FOR REJUVENATING HUMAN CELLS - The present disclosure relates to methods for increasing telomere length in one or more human adult cells and/or increasing genome stability of one or more human adult cells, for example by contacting one or more human adult cells with an agent that increases expression of Zscan4 in the one or more human adult cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a telomere abnormality, of rejuvenating one or more human adult cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human adult cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 is also provided. | 10-30-2014 |
| 20140322177 | METHODS AND COMPOSITONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONS - Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual. | 10-30-2014 |
| 20140322178 | EXPANDING HEMATOPOIETIC STEM CELLS - A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome. | 10-30-2014 |
| 20140322179 | METHODS OF GENERATING GLIAL AND NEURONAL CELLS AND USE OF SAME FOR THE TREATMENT OF MEDICAL CONDITIONS OF THE CNS - A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity. | 10-30-2014 |
| 20140322180 | USE OF MESENCHYMAL STEM CELLS FOR COMPLETELY REPOPULATING HOST TISSUE - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 10-30-2014 |
| 20140322181 | USE OF HUMAN CORD BLOOD-DERIVED PLURIPOTENT CELLS FOR THE TREATMENT OF DISEASE - The present invention features methods of organ tissue regeneration using pluripotent cells derived from umbilical cord blood, compositions of these pluripotent cells, methods for further transforming these cells, and uses for these transformed cells. | 10-30-2014 |
| 20140322182 | Canine Amniotic Membrane-Derived Multipotent Stem Cells - The present invention relates to canine amniotic membrane-derived multipotent stem cells (cAM-MSCs) and preparation method thereof. More particularly, the present invention relates to canine amniotic membrane-derived multipotent stem cells, which show negative immunological properties on human markers CD3, CD11c, CD28, CD34, CD38, CD41a, CD45, and CD62L and positive immunological properties on human markers CD90 and CD105, and have the ability to be maintained in an undifferentiated state for 20 passages or more and the ability to be differentiated into fat, bones, nerves, cartilage, etc. | 10-30-2014 |
| 20140328804 | Method for Treating or Preventing Graft Versus Host Disease - A method of treating or preventing graft versus host disease (GVHD) in a subject receiving a graft comprising hematopoietic cells is provided. The method comprises contacting the graft ex vivo with an amount of a Myxoma Virus effective to inhibit proliferation of T lymphocytes in the graft and to treat or prevent GVHD in the host subject following infusion of the graft into the subject. After the contacting of the graft with the Myxoma Virus, the method comprises transplanting the virus-treated graft into the subject. | 11-06-2014 |
| 20140328805 | BIHETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R | 11-06-2014 |
| 20140328806 | ENERGETIC THREE-DIMENSIONAL ARTIFICIAL CARDIAC PATCH AND USES THEREOF - In some embodiments, the present disclosure provides a method for fabricating a three-dimensional artificial cardiac patch construct. In some embodiments, such method includes the steps of coating a substrate with an organic polymer; allowing the organic polymer coating to air dry; mounting anchors on the organic polymer coating; and sterilizing the organic polymer coating and the anchors. In further embodiments, the method includes the steps of forming a biodegradable gel-based support scaffold on top of the organic polymer coating and seeding the biodegradable gel-based support scaffold with neonatal cardiac cells. In yet further embodiments, the method comprises culturing the neonatal cardiac cells in vitro to form a real cardiac layer, under culture conditions that are suitable for the cells to self-organize into a monolayer and detach from the substrate to form the three-dimensional cardiac patch. In some embodiments, the present disclosure pertains to a method of treatment of cardiac tissue injury in a subject in need thereof. In some embodiments, the method includes implanting the three-dimensional artificial cardiac patch described above in the injured area of the subject. In another embodiment the present disclosure provides a composition comprising the three-dimensional artificial cardiac patch described above. Additional embodiments of the present disclosure pertain to a medicament including the three-dimensional artificial cardiac patch described above. | 11-06-2014 |
| 20140328807 | Mesenchymal Stem Cells and Uses Therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 11-06-2014 |
| 20140328808 | TECHNIQUE FOR ISOLATING/CULTURING COLORECTAL EPITHELIAL STEM CELL, AND TECHNIQUE FOR TRANSPLANTING COLORECTAL EPITHELIUM EMPLOYING SAID TECHNIQUE - It is an object of the present invention to provide a culture medium for in vitro culture of a colorectal epithelial stem cell or the like, a method of in vitro culturing a colorectal epithelial stem cell or the like using the culture medium, a prophylactic or therapeutic agent for a bowel disease containing a colorectal epithelial stem cell or the like cultured by the method, a method of administrating, i.e., transplanting a colorectal epithelial stem cell or the like cultured by the method to a bowel disease patient, and a method of isolating a colorectal epithelial stem cell or the like. The culture medium for in vitro culture of a colorectal epithelial stem cell and/or a colorectal epithelial cell characteristically contains serum albumin, Wnt3a, and r-spondin-1. | 11-06-2014 |
| 20140328809 | METHODS OF INDUCING CHONDROGENESIS IN MESENCHYMAL STEM CELLS USING SYNTHETIC TRITERPENOIDS - The present invention relates to methods for enhancing differentiation of mesenchymal stem cells into chondrocytes and/or inducing chondrogenesis. The invention also relates to applications in the treatment of diseases which can affect cartilage (chondrodystrophies). The present invention also relates to methods of treatment comprising establishing a population of chondrocytes from a population of mesenchymal stem cells, which have been induced to differentiate with a synthetic triterpenoid, and administering the population of cells to a patient. | 11-06-2014 |
| 20140335055 | REGENERATIVE AUTOLOGOUS CELL THERAPIES AND METHODS OF USE - The present novel technology relates to an autologous cell therapy that comprises a pre-determined amount of a processed bone marrow cellular matrix with a pre-determined amount of pre-mixture, where the pre-mixture includes quantities of anticoagulant solution, dextrose and phosphate buffered saline, and methods for production. The present novel technology further relates to a method of using the composition to reduce discogenic pain in humans. | 11-13-2014 |
| 20140335056 | SUSTAINED RELEASING PHARMACEUTICAL COMPOSITION - The present invention relates to a formulation made from a chitosan, a gelatin, and a phosphate salt can provide a sustained release/maintenance of a therapeutic agent, wherein the phosphate salt is selected from the group consisting of disodium phosphate and ammonium hydrogen phosphate. | 11-13-2014 |
| 20140335057 | Methods For Culturing Minimally-Passaged Fibroblasts And Uses Thereof - The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is needed directly into a large tissue culture flask, and passaged so more than three times. | 11-13-2014 |
| 20140335058 | ASSAY FOR THE PREDICTION OF THERAPEUTIC EFFECTIVENESS OF MESENCHYMAL STROMAL CELLS, AND METHODS OF USING SAME - The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations. | 11-13-2014 |
| 20140335059 | STEM CELL-DERIVED NEURAL CELLS FOR CELL THERAPY IN NEUROLOGICAL DISORDERS - The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided. | 11-13-2014 |
| 20140335060 | Equine Amniotic Membrane-Derived Mesenchymal Stem Cells - The present invention relates to equine amniotic membrane-derived mesenchymal stem cells (eAM-MSCs) and a preparation method thereof. More specifically, the present invention relates to equine amniotic membrane-derived mesenchymal stem cells, which show negative immunological responses to all of the human markers CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P and CD200, and positive immunological responses to all of the human markers CD44, CD90 and CD105, and have the ability to be maintained in an undifferentiated state for 14 passages or more and the ability to differentiate into ectoderm, mesoderm and endoderm-derived cells. | 11-13-2014 |
| 20140335061 | SUPPLEMENTED OIL COMPOSITIONS AND METHODS FOR IMPROVED HEALTH - Disclosed are compositions and methods comprising supplemented oils for improving health, reducing cardiovascular risk factors, or treating certain conditions. | 11-13-2014 |
| 20140335062 | CO-CULTURED MESENCHYMAL STEM CELLS AND MYOCYTES - Co-culturing of mesenchymal stem cells or tissues comprising mesenchymal stem cells with myocytes or myocyte containing tissues provide for the long term culture and expansion of myocytes. The co-culture gives rise to three-dimensional functioning cardiac tissue grafts or constructs. | 11-13-2014 |
| 20140341859 | METHOD FOR TREATMENT OF DAMAGED SITE OF BONE - Provided is a treatment method which enables regeneration of bone tissue even when the size of a damaged site of bone is large. The treatment method comprises the steps of: culturing chondrocytes which have been seeded onto a porous body, or differentiating stem cells having chondrogenic differentiation potential which have been seeded onto a porous body into chondrocytes and culturing the chondrocytes; and implanting the porous body having the cultured chondrocytes. | 11-20-2014 |
| 20140341860 | Methods for treating cartilage disorders, diseases, and injuries - The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. | 11-20-2014 |
| 20140341861 | RAPID INFUSION OF AUTOLOGOUS BONE MARROW DERIVED STEM CELLS - The present invention relates to a method and composition for the aspiration, processing, testing and infusion of bone marrow derived stem cells, as an adjuvant treatment in cardiovascular disorders. More specifically, the invention provides for the methods and compositions for the aspiration, analysis, processing, infusate preparation and infusion of bone-marrow derived stem cells, particularly in a rapid point-of-care environment, wherein a centrifugal fractionation and optically monitored separation of the bone marrow yield desired cellular product in the desired concentration and viscosity. | 11-20-2014 |
| 20140341862 | METHOD FOR PRODUCING A BIOLOGICAL TISSUE CONSTRUCT AND USE OF SPECIFICALLY OBTAINED AUTOLOGOUS CELLS - The method for preparing a tissue construct for medical purposes uses endothelial progenitor cells (EPC) which have not been passaged multiple times and have a content of EOEC (early outgrowth endothelial progenitor cells) and LOEC (late outgrowth endothelial progenitor cells). These cells and fibroblasts and/or muscle cells, viz. myoblasts, myofibroblasts, smooth muscle cells or the progenitors thereof, are, in the form of living cells, seeded onto a matrix or introduced into a matrix in order to yield the tissue construct following further treatment steps. The matrix is preferably a protein preparation, more particularly a fibrinogen preparation. Both the cells and the fibrinogen preparation can be obtained from a single blood sample from a patient. Apart from the preparation of bypass materials, prosthetic vascular graft, tissue patches, conduits and the like, the EOEC-containing EPC culture or suspension is suitable as means for cell transplantation. | 11-20-2014 |
| 20140341863 | ADULT MESENCHYMAL STEM CELL (MSC) COMPOSITIONS AND METHODS FOR PREPARING THE SAME - The described invention provides a composition comprising mesenchymal progenitor cells (MPC) and processes for isolating or enriching the mesenchymal progenitor cells (MPCs) having a cell surface antigenic profile of CD34(−)/CD133(−)/CD45(−)/CD73(+)/CD90(+)/CD105(+)/CD44(−). The described invention also provides methods for differentiating the mesenchymal progenitor cells (MPCs) into various cell types. | 11-20-2014 |
| 20140341864 | METHODS FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELL - The invention provides a method for producing a retinal tissue by (1) subjecting pluripotent stem cells to floating culture in a serum-free medium containing a substance inhibiting the Wnt signal pathway to form an aggregate of pluripotent stem cells, (2) subjecting the aggregate to floating culture in a serum-free medium containing a basement membrane preparation, and then (3) subjecting the aggregate to floating culture in a serum-containing medium. The invention also provides a method for producing an optic-cup-like structure, a method for producing a retinal pigment epithelium, and a method for producing a retinal layer-specific neural cell. | 11-20-2014 |
| 20140341865 | Dressing Material With Cell Components For Wound Healing - There is provided a dressing for treating a wound. The dressing for healing a wound can be useful in maintaining a moisture environment at a wound site using a biocompatible polymer scaffold, and effectively promoting healing of a wound by various growth factors secreted by skin cells or stem cells attached to the biocompatible polymer scaffold as well. | 11-20-2014 |
| 20140341866 | CELL TISSUE GEL CONTAINING COLLAGEN AND HYALURONAN - Described herein is a cell tissue gel containing collagen and hyaluronan at a weight ratio of 0.01-100:1. | 11-20-2014 |
| 20140341867 | TREATMENT OF STROKE USING ISOLATED PLACENTAL CELLS - Provided herein are methods for the treatment of stroke comprising administering to a stroke victim placental stem cells, populations of cells comprising placental stem cells, and/or compositions comprising placental stem cells. | 11-20-2014 |
| 20140341868 | TREATMENT OF LIMB ISCHEMIA - The present invention uses neural stem cells in the manufacture of a medicament for the treatment of a patient suffering peripheral arterial disease. The invention is particularly suited for treating limb ischemia or Buerger's disease. | 11-20-2014 |
| 20140348800 | MODIFIED TWO-COMPONENT GELATION SYSTEMS, METHODS OF USE AND METHODS OF MANUFACTURE - A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. A treatment agent, such as a cell type or a growth factor, can be added to either the first mixture or the second mixture. In some embodiments, the treatment agent is not added to either mixture. The first mixture can be co-injected with the second mixture to form a bioscaffolding in an infarct region for treatment thereof. | 11-27-2014 |
| 20140348801 | Treatment of Vocal Cords With Autologous Dermal Fibroblast Formulation - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three tunes approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×10 | 11-27-2014 |
| 20140348802 | METHODS OF TREATING ISCHEMIA - The invention provides compositions comprising stem and/or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and/or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia. | 11-27-2014 |
| 20140348803 | COMPOSITIONS AND METHODS FOR USING CELLS TO TREAT HEART TISSUE - This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue. | 11-27-2014 |
| 20140348804 | AGENT DERIVED FROM TORTOISE SPLEEN STIMULATING MAMMALIAN HEMOPOIESIS - The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them. | 11-27-2014 |
| 20140356331 | INJECTABLE CNS-DERIVED ECM FOR TISSUE RECONSTRUCTION - Methods useful for preparing central nervous system (CNS) derived extracellular matrix (ECM) materials, including powders and gels are provided. Also provided are CNS ECM preparations prepared according to those methods, and methods of treating a patient or mammal with CNS injury. | 12-04-2014 |
| 20140356332 | ENHANCING VESSEL LESION HOMING AND REPAIR POTENTIAL OF STEM CELLS - Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-β expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-β blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-β blocking agent and treated cells are co-administered to a subject in need thereof. | 12-04-2014 |
| 20140356333 | NAIL STEM CELLS AND METHODS OF USE THEREOF - The present invention is directed to an in vitro method for promoting proliferation, survival, and/or differentiation of K14+, K17+ nail stem cells (NSCs). The instant methods may be used to generate an expanded population of K14+, K17+ NSCs in vitro and expanded NSC populations in which a Wnt pathway is activated are envisioned as therapeutic agents. Methods for screening to identify agents capable of modulating K14+, K17+ NSC proliferation, survival, and/or differentiation are also encompassed herein, as are isolated, pure populations of homogeneous K14+, K17+ NSCs. | 12-04-2014 |
| 20140356334 | METHODS FOR IMPROVED WOUND CLOSURE EMPLOYING OLIVAMINE AND ENDOTHELIAL CELLS - The present disclosure relates to compositions for and methods of improving wound healing, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The methods for wound healing administer one or more compositions including hydroxytyrosol and oleuropein with cells derived from umbilical cord blood. | 12-04-2014 |
| 20140356335 | MAMMALIAN FETAL PULMONARY CELLS AND THERAPEUTIC USE OF SAME - A pharmaceutical composition comprising as an active ingredient an isolated population of cell suspension from a mammalian fetal pulmonary tissue is disclosed. The fetal pulmonary tissue is at a developmental stage corresponding to that of a human pulmonary organ/tissue at a gestational stage selected from a range of about 20 to about 22 weeks of gestation. Methods of using the pharmaceutical composition are also disclosed. | 12-04-2014 |
| 20140356336 | METHOD FOR INDUCING DIFFERENTIATION ENABLING TUMORIGENESIS OF IPS CELLS TO BE SUPPRESSED - The object of the invention is to provide a technique of suppressing tumorigenesis in IPS cells and inducing differentiation into target differentiated cells. In use of a statin and a differentiation inducer, iPS cells are differentiated into target differentiated cells, whereby iPS cells can be differentiated into differentiated cells in which tumorigenesis is suppressed. | 12-04-2014 |
| 20140363402 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION - The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RARγ agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue. | 12-11-2014 |
| 20140363403 | APPARATUS FOR HARVESTING IMPROVED BONE GRAFT MATERIAL UTILIZING AN IMPLANTABLE BIODEGRADABLE FILTER - The present invention provides for the harvesting of specific materials in multiple stages of filtration of bone graft materials from a reaming device, specifics of interconnected stages, related filtration materials, and techniques. The harvesting process collects large material in a first stage, and other materials of a limited geometric size in at least a second stage of filtration. Such material captured in the second stage may contain plasma, cellular elements including stem cells as well as growth factors and other particulate matter of a specific geometrically limited size, using various filtration approaches including centrifugation in some embodiments. Further embodiments of the invention provide for an improved tubing interface and management approach to ease use in the operating room. Filtration materials may include biodegradable-material based filters and may allow direct implantation of small scale and larger scale matter in specific portions within the biodegradable-material itself. | 12-11-2014 |
| 20140363404 | METHODS FOR INCREASING OSTEOBLASTIC FUNCTION - The present disclosure provides methods of increasing osteoblastic function in a subject, the method comprising systemically administering to the subject a population of stem cells and/or progeny thereof and/or soluble factors derived therefrom. | 12-11-2014 |
| 20140363405 | METHOD FOR OBTAINING MAB-LIKE CELLS AND USES THEREOF - The invention relates to the derivation of mesoangioblast-like (MAB-like) cells from pluripotent cells such as induced pluripotent (IPS) and embryonic stem (ES) cells, to cells obtained thereby and to medical uses of such cells, in particular in the treatment of muscular dystrophies. | 12-11-2014 |
| 20140363406 | ESTROGEN METABOLITE LEVELS AND CYP1B1 POLYMORPHISMS IN LUNG CANCER DIAGNOSIS, PROGNOSIS, AND RISK ASSESSMENT - Systems and methods for determining the prognosis of a patient having CYP1B1-mediated lung cancer and for diagnosing a risk of developing CYP1B1-mediated lung cancer are provided. The systems and methods comprise determinations of the concentration of estrogen metabolites in the lung tissue or a proxy thereof, or polymorphisms in the gene encoding the CYP1B1 protein, which metabolite concentrations or CYP1B1 polymorphisms are associated with a probability of surviving and/or a risk of developing lung cancer. | 12-11-2014 |
| 20140369967 | METHOD OF EXPANDING HEMATOPOIETIC STEM CELLS - Described is a method of expanding hematopoietic stem or progenitor cells. The invention further includes a method of treating primary or secondary bone marrow failure syndrome. | 12-18-2014 |
| 20140369968 | GENERATING VASCULOGENIC CELL POPULATIONS - The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitors, and methods and compositions for clinical applications in the field of regenerative medicine. | 12-18-2014 |
| 20140369969 | METHODS FOR TREATING CONDITIONS BY RESTORING CENTRAL NERVOUS SYSTEM ENDOCRINE GLAND FUNCTION, AND COMPOSITIONS AND DEVICES FOR PRACTICING THE SAME - Methods of improving a condition in a subject are provided herein. Aspects of the methods include at least partially restoring normal function of a central nervous system endocrine gland in a manner sufficient to improve the condition in the subject. In some instances, the condition is an aging associated condition. Aspects of the invention further include compositions, systems and devices for practicing the methods. | 12-18-2014 |
| 20140369970 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE - Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration. | 12-18-2014 |
| 20140369971 | METHOD AND COMPOSITION FOR INDUCING HUMAN PLURIPOTENT STEM CELLS - The present invention provides a fibromodulin (FMOD) reprogrammed (FReP) cell and a method of making therefor, a culture medium therefor, and a supernatant thereof, and methods of making and using these. | 12-18-2014 |
| 20140369972 | ENHANCED STEM CELL COMPOSITION - The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution. | 12-18-2014 |
| 20140369973 | COMPOSITIONS AND METHODS FOR ENHANCED GENERATION OF HEMATOPOIETIC STEM/PROGENITOR CELLS - The present invention relates to methods, kits and compositions for expansion of hematopoietic stem/progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem/progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem/progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem/progenitor cells, placental cord blood stem/progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem/progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and/or long-term in vivo repopulation benefits. | 12-18-2014 |
| 20140369974 | COMBINATION THERAPY FOR A STABLE AND LONG TERM ENGRAFTMENT USING SPECIFIC PROTOCOLS FOR T/B CELL DEPLETION - A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The methos comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject. | 12-18-2014 |
| 20140369975 | BIOMATERIALS COMPRISING HYALURONIC ACID BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMER MOLECULES FOR HYALURONIC ACID RETENTION AND TISSUE ENGINEERING APPLICATIONS - The present invention provides novel biomaterial compositions and methods having a technology to improve retention of hyaluronic acid (HA). The biomaterial compositions utilize small HA binding peptides that is tethered to synthetic biocompatible polymers. When tethered to the polymers, the peptide region allows the polymers to bind to HA. The biocompatible polymers are modified to contain a crosslinking group so that the HA can be incorporated into a scaffold and retained in place. The novel biomaterial | 12-18-2014 |
| 20140369976 | METHOD TO AMPLIFY CARDIAC STEM CELLS IN VITRO AND IN VIVO - Compositions comprising stem cells delivered into infarcted myocardium by endocardial injection, engraft and differentiate into myocytes, endothelial cells, and vascular smooth muscle, and do so without the requirement for survival enhancing modification. These cells engraft whether injected acutely (days) or late (months) after myocardial infarction, and the efficiency of engraftment correlates with the functional recovery of the heart. The stem cells also recruit endogenous cardiac precursor cells, reconstitute myocardial stem cell niches, and enhance endogenous cell differentiation into myocytes. | 12-18-2014 |
| 20140377226 | Tissue Transplantation Involving, and Tissues Modified by Decellularization And Recellularization Of Donor Tissues For Minimized Or Obviated Rejection Reactions - The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (PRP), the growth factors having increased weight. | 12-25-2014 |
| 20140377227 | Tissue Transplantation Involving, and Tissues Modified by Decellularization And Recellularization Of Donor Tissues For Minimized Or Obviated Rejection Reactions - The method of tissue transplantation involving recellularizing of a donor organ with the utilization of the recipient's cytokines collected from the recipient's blood plasma at less than systemic pressure, and at the temperature greater than freezing and less than normal systemic temperature of the recipient's blood. Specifically, a method of harvesting a platelet-derived growth factors from platelet rich plasma (PRP), the growth factors having increased weight. | 12-25-2014 |
| 20140377228 | Bone Marrow-Derived Cells Ameliorates The Pathological Consequences Of The Liver In Case Of Alpha1-Antitrypsin Deficiency - The present invention is based on the findings that bone marrow (BM)-derived progenitor cells more specifically mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs) and uncommitted hematopoietic cells (lin | 12-25-2014 |
| 20140377229 | METHODS AND COMPOSITIONS FOR TISSUE REGENERATION - A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vile, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGFβ, angiopoietin, EGF, IL-Iβ, TGFα, and TNFα, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second vial. | 12-25-2014 |
| 20140377230 | Placental Stem Cell Populations - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 12-25-2014 |
| 20140377231 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS - The present disclosure concerns methods and compositions for differentiating cells, including adipose cells, into chondrocyte-like cells via in vitro, ex vivo, and/or in vivo mechanical strain. In particular aspects, adipose cells or re-differentiated adipose cells that are chondrocyte-like cells, are delivered to a joint or are shaped into cartilage. In some embodiments, the adipose cells may be delivered to a joint, such as an intervertebral disc, following which the cells differentiate into chondrocyte-like cells to treat dysfunction of cartilage therein, including to repair degenerated discs, for example. In certain aspects, the cells prior to delivery to the individual are managed in the absence of growth factors, in vitro mechanical strain, and/or matrix molecules, for example. | 12-25-2014 |
| 20140377232 | INNERVATION OF ENGINEERED STRUCTURES - Methods of generating an innervated muscle structures are disclosed as well as bioengineered structures for tissue repair or regeneration. The methods can include the steps of obtaining populations of smooth muscle cells and neuronal progenitor cells and then seeding the cells together onto a matrix material, followed by culturing the seeded cells to form an innervated smooth muscle cell construct of directionally oriented smooth muscle cells. In one embodiment, the neuronal progenitor cells can be seeded first as neurospheres in a biocompatible solution, e.g., a collagen/laminin solution, and allowed to gel. Next, a second suspension of smooth muscle cells can be deposited as separate layer. Multiple layer structures of alternating muscle or neuron composition can also be formed in this manner. Differentiation of the neuronal progenitor cells can be induced by exposure to a differentiation medium, such as Neurobasal A medium and/or exposure to a differentiating agent, such as B-27 supplement. The innervated muscle structures can be disposed around a tubular scaffold, e.g., a chitosan-containing tube and further cultured to form tubular, bioengineered structures and two or more innervated muscle structures can be joined together to form an elongate composite structure. | 12-25-2014 |
| 20140377233 | METHOD OF PREPARING AN ARTIFICIAL TOOTH PRIMORDIUM IN VITRO AND ARTIFICIALTOOTH PRIMORDIUM DERIVED THEREFROM - The present invention is directed to a method of preparing an artificial tooth primordium in vitro, comprising the steps: a) providing isolated mesenchymal dental pulp cells; and b) culturing the mesenchymal dental pulp cells under non-adherent conditions to form a cell aggregate representing an artificial tooth primordium; as well as to an artificial tooth primordium derived therefrom. | 12-25-2014 |
| 20140377234 | METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF - The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation. | 12-25-2014 |
| 20140377235 | METHODS FOR USING SYNTHETIC TRITERPENOIDS IN THE TREATMENT OF BONE OR CARTILAGE DISEASES OR CONDITIONS - The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions. | 12-25-2014 |
| 20150010512 | Disease treatment via developing non-syngeneic graft transplantation - A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject. | 01-08-2015 |
| 20150010513 | Human Brown Adipose Derived Stem Cells and Uses - An isolated human brown adipose tissue stem cell line. In one embodiment, the isolated human brown adipose tissue stem cell line expresses the markers CD9, SSEA4, CD44, CD90, CD166, CD73, but not CD14, CD34, CD45 or STRO-1. In another embodiment, the isolated human brown adipose tissue stem cell line expresses the genes UCP1, PPARGC1A, NRF1, FOXC2, CREB1, SIRT3, and WNT5A (REFX). In still another embodiment, the isolated human brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes. | 01-08-2015 |
| 20150010514 | MIDBRAIN DOPAMINE (DA) NEURONS FOR ENGRAFTMENT - The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons using novel culture conditions. The midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons made using the methods of the present invention are further contemplated for various uses including, but not limited to, use in in vitro drug discovery assays, neurology research, and as a therapeutic to reverse disease of, or damage to, a lack of dopamine neurons in a patient. Further, compositions and methods are provided for differentiating midbrain fate FOXA2+LMX1A+TH+ dopamine (DA) neurons from human pluripotent stem cells for use in disease modeling, in particular Parkinson's disease. Additionally, authentic DA neurons are enriched for markers, such as CD142, and A9 type neuronal cells. | 01-08-2015 |
| 20150010515 | MAMMALIAN NEURAL PLATE BORDER STEM CELLS CAPABLE OF FORMING NEURAL TUBE AND NEURAL CREST CELL LINEAGES INCLUDING CENTRAL AND PERIPHERAL NEURONS - The present invention relates to a method for producing mammalian neural plate border stem cells (NPBSCs), comprising: (a) differentiation of mammalian pluripotent stem cells by (a-i) culturing mammalian pluripotent stem cells in pluripotent stem cell medium for about 24 to about 96 hours, wherein the pluripotent stem cell medium comprises: (i) an inhibitor of the activin/TGF-β signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-ii) culturing the cells obtained in step (a-i) for about 24 to about 96 hours in a neural medium, wherein the neural medium comprises: (i) an inhibitor of the Activin/TGF-β signalling pathway; (ii) an inhibitor of the BMP signalling pathway; (iii) an activator of the canonical WNT signalling pathway; and (iv) an activator of the Hedgehog signalling pathway; subsequently (a-iii) culturing the cells obtained in step (a-ii) for about 24 to about 96 hours in a neural medium, wherein the neural medium comprises: (i) an activator of the canonical WNT signalling pathway; (ii) an activator of the Hedgehog signalling pathway; and (iii) an inhibitor of oxidation; and (b) plating the obtained differentiated mammalian pluripotent stem cells in NPBSCs expansion medium, wherein the NPBSCs expansion medium comprises (i) an activator of the canonical WNT signalling pathway; (ii) an activator of the Hedgehog signalling pathway; and (iii) an inhibitor of oxidation; and expanding the cells in the NPBSCs expansion medium for about 24 to about 96 hours; (c) splitting the cells obtained in (b) and further expanding the cells in the NPBSCs expansion medium; and (d) repeating step (c) at least two times. The present invention further relates to neural plate border stem cells obtainable by the method of the invention and the use of the cells of the invention in medicine. | 01-08-2015 |
| 20150010516 | Novel MSC Surface Marker - The present invention relates to the use of at least one antibody which binds to the SUSD2 antigen, or to functional fragments of the antibody, in combination with at least one of the following: an antibody which binds to CD140b, an antibody which binds to CD56, and/or an antibody which binds to TNAP, or functional fragments thereof, for isolation of mesenchymal stem cells, especially those having particularly chondrocytic and osteogenic differentiation potential. The invention further relates to processes for isolating such stem cells using these antibodies | 01-08-2015 |
| 20150010517 | Apparatus for Preconditioning of Cell Suspensions - An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway. | 01-08-2015 |
| 20150017129 | Preservation of the biological activity of undenatured type II collagen - The instant invention is the storage of Type II collagen containing tissue in carbonated water. Such Type II collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals. Such Type II collagen is also useful for the prevention of arthritis in mammals. The instant invention is also a method for the preparation of a nutritional supplement that includes the steps of: (a) separating water-insoluble undenatured Type II collagen containing animal tissue from animal tissue not containing Type II collagen; (b) subdividing and sterilizing said tissue under conditions which do not change the original structure of the Type II collagen to produce a subdivided and sterilized product; (c) packaging the subdivided and sterilized product in carbonated water. | 01-15-2015 |
| 20150017130 | METHODS AND COMPOSITIONS FOR INHIBITION OF IMMUNE RESPONSES - Methods and compositions for modulating immune responses are provided herein. | 01-15-2015 |
| 20150017131 | HAIR FOLLICLES MADE EX VIVO THAT CAN BE INSERTED INTO A RECIPIENT FOR HAIR RESTORATION - The present invention recognizes that there exists a long felt need for reliable hair growth methods and compositions that do not suffer from side effects and limitations of current technologies, such as surgery using a subject's own hair and pharmaceutical compositions. A first aspect of the present invention is a method of making at least one three dimensional collection of cells capable of forming a functional hair follicle. A second aspect of the present invention is a product produced by the method of making at least one three dimensional collection of cells capable of forming a functional hair follicle of the present invention. A third aspect of the present invention is a method of making at least one functional hair follicle. A fourth aspect of the present invention is a product produced by the method of making at least one functional hair follicle of the present invention. A fifth aspect of the present invention is a method of hair growth in a subject using at least one three dimensional collection of cells capable of forming a functional hair follicle of the present invention. A sixth aspect of the present invention is a method of hair growth in a subject using at least one functional hair follicle of the present invention. | 01-15-2015 |
| 20150017132 | Mesenchymal Stem Cells and Uses Therefor - Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount. | 01-15-2015 |
| 20150017133 | PHENOTYPE PROFILE OF HUMAN RETINAL PROGENITOR CELLS - The present invention relates to substantially homogenous populations of human retinal progenitor cells having the following positive surface markers: SSEA4, CD73, PTK7 and PSA-NCAM. The invention also relates to method for preparing such substantially homogeneous cell populations from human tissue using cell sorting techniques. | 01-15-2015 |
| 20150017134 | EMT-INDUCING TRANSCRIPTION FACTORS COOPERATE WITH SOX9 - In some aspects, compositions and methods useful for generating stem cells from epithelial cells are disclosed. | 01-15-2015 |
| 20150017135 | IN VITRO DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO PANCREATIC ENDODERM CELLS (PEC) AND ENDOCRINE CELLS - A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation. | 01-15-2015 |
| 20150023926 | TREATMENT OF RADIATION INJURY USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of treating individuals having suffered exposure to radiation, e.g., individuals having radiation injury, by administering to the individuals angiogenic cells from amnion, referred to as amnion derived adherent cells, or populations of and compositions comprising, such cells. | 01-22-2015 |
| 20150023927 | CONVERSION OF SOMATIC CELLS INTO FUNCTIONAL SPINAL MOTOR NEURONS, AND METHODS AND USES THEREOF - The present invention provides methods of transdifferentiation of somatic cells, for example, directly converting a somatic cell of a first cell type, e.g., a fibroblast into a somatic cell of a second cell type, are described herein. In particular, the present invention generally relates to methods for converting a somatic cell, e.g., a fibroblast into a motor neuron, e.g., an induced motor neuron (iMN) with characteristics of a typical motor neuron. The present invention also relates to an isolated population comprising induced motor neurons (iMNs), compositions and their use in the treatment of motor neuron diseases such as ALS and SMA. In particular, the present invention relates to direct conversion of a somatic cell to an induced motor neuron (iMN) having motor neuron characteristics by increasing the protein expression of at least three motor-neuron inducing (MN-inducing) factors selected from Lhx3, Ascl1, Brn2, Myt1l, Isl1, Hb9, Ngn2 or NeuroD1 in a somatic cell, e.g., a fibroblast to convert the fibroblast to an induced motor neuron (iMN) which exhibits at least two characteristics of an endogenous motor neuron. | 01-22-2015 |
| 20150023928 | STEM CELL PREPARATIONS AND METHODS OF USE - The present invention relates to a method of preparing cells and in particular to a method of preparing breastmilk stem cells (BSCs) by isolation from breastmilk and subsequent culture. The invention further relates to BSCs prepared by the methods of the invention and to methods and uses thereof. In one aspect, the invention has been developed as a method for preparing and culturing BSC. | 01-22-2015 |
| 20150023929 | ORAL UNIT DOSAGE FORMS AND USES OF SAME FOR THE TREATMENT OF GAUCHER DISEASE - A method of treating Gaucher's disease in a subject in need thereof is provided. The method comprising orally administering to the subject a therapeutically effective amount of recombinant glucocerecbrosidase (GCD) comprised in plant cells, wherein said therapeutically effective amount of GCD corresponds to 1-1920 units/Kg/14 days, thereby treating Gaucher's disease. Also provide unit dosage forms which comprise the glucocerecbrosidase (GCD) comprised in plant cells. | 01-22-2015 |
| 20150023930 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF - Described herein are aminoquinoline and aminoacridine based hybrids, pharmaceutical compositions and medicaments that include such aminoquinoline and aminoacridine based hybrids, and methods of using such compounds for diagnosing and/or treating infections, neurodegerative diseases or disorders, inflammation, inflammation associated diseases and disorders, and/or diseases or disorders that are treatable with dopamine agonists such as the restless leg syndrome. | 01-22-2015 |
| 20150023931 | METHODS OF USING REGENERATIVE CELLS IN THE TREATMENT OF MUSCULOSKELETAL DISORDERS - Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit. | 01-22-2015 |
| 20150030568 | Use of Stem Cells to Generate Inner Ear Cells - This invention relates generally to methods and compositions for inducing stem cell or progenitor cell differentiation, and more particularly to methods and compositions for inducing differentiation of stem cells and/or progenitor cells into cells that function within the inner ear. | 01-29-2015 |
| 20150030569 | METHODS FOR INDUCING IMMUNE TOLERANCE TO ORGAN TRANSPLANTS - The present invention is directed to methods of treating an organ or a tissue prior to transplantation thereof into a recipient, comprising ablating the cells composing the blood vessels of said organ or tissue, preferably the cells lining the lumen surface of the blood vessels, thereby obtaining a treated viable organ or tissue having reduced immunogenicity. The invention is also directed to treated viable organs or tissues having reduced immunogenicity and uses thereof. | 01-29-2015 |
| 20150030570 | Culture medium for preparing neural stem cells and use thereof - Provided are a culture medium for preparing neural stem cell and use thereof, the culture medium for preparing neural stem cell comprising: a basic culture medium suitable for the growth of stem cell, and a cell signal pathway inhibitor selected from at least one of GSK inhibitor, MEK inhibitor, TGF-β inhibitor, ROCK inhibitor and BMP inhibitor. | 01-29-2015 |
| 20150030571 | Preparation and method for producing a preparation comprising mesenchymal stem cells - Preparation and method for producing a preparation or a tissue derivative that include mesenchymal stem cells, to be used in cellular therapy, for cosmetic treatments, for replacing a tissue or an organ, or inducing or accelerating tissue repair or regeneration. The method includes the steps of extracting tissue containing mesenchymal stem cells, such as adipose tissue, from a cadaveric donor by liposuction or by surgical removal of parts of adipose tissue, and mechanically treating tissue to provide a fluid component, having an oily component, a blood component and/or a sterile solution, and a solid component having cell fragments, cells and one or more cell macro-agglomerates of heterogeneous sizes, thereby separating and removing the fluid component from the solid component, which generates an emulsion of fluid components. | 01-29-2015 |
| 20150030572 | IDENTIFICATION OF MOLECULAR PATHWAYS AND METHODS OF USE THEREOF FOR TREATING RETINAL NEURODEGENERATION AND OTHER NEURODEGENERATIVE DISORDERS - Drug targets, pathways, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. | 01-29-2015 |
| 20150037289 | ACTIVATING ADIPOSE-DERIVED STEM CELLS FOR TRANSPLANTATION - A method of preparing a stem cell preparation is provided. The method includes steps of collecting adipose tissue from a mammal, contacting that adipose tissue with an enzyme preparation to digest fat and connective tissue and preserve stem cells and collecting those stem cells. In addition a kit is provided for preparing a stem cell preparation. | 02-05-2015 |
| 20150037290 | Methods of Modulating Smooth Muscle Cell Proliferation and Differentiation - The present disclosure provides methods of inducing smooth muscle cell differentiation. The present disclosure provides genetically modified cells comprising exogenous miR-143 and/or miR-145 nucleic acids; and artificial tissues comprising the genetically modified cells. The present disclosure provides methods and compositions for reducing pathological angiogenesis. The present disclosure provides methods of inducing therapeutic angiogenesis. The present disclosure provides methods, compositions, and devices for inhibiting vascular smooth muscle cell proliferation. | 02-05-2015 |
| 20150037291 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION - The present invention relates to compositions and methods for cell transplantation. In particular, the present invention provides a composition comprising procoagulant cells and at least one factor Xa inhibitor, preferably rivaroxaban, as well as at least one thrombin inhibitor, preferably bivalirudin. | 02-05-2015 |
| 20150037292 | STROMAL STEM CELLS - Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2. | 02-05-2015 |
| 20150037293 | TECHNOLOGIES FOR PANCREATIC ISLET TRANSPLANTATION - Biocompatible nanomatrices composed of peptide amphiphiles are provided for the embedding of cell populations for their implantation into a recipient animal or human. To confine the nanomatrix to a site of implantation, the nanomatrix can be encapsulated in a nanofiber sack formed from an electrospun nanofiber sheet. The nanofiber sheets are porous and have surface indentations that promote the vascularization of the implant, thereby maintain the viability and biofunctions of the cells, as wells as delivering cell-product products to the circulatory system to the benefit of the recipient subject. The implants may further include cell growth factors that can be beneficial to the survival of the cells as to promote angiogenesis and infiltration of the implant by new blood vessels. | 02-05-2015 |
| 20150037294 | Methods for Promoting Wound Healing and Muscle Regeneration with the Cell Signaling Protein Nell1 - The present invention provides methods for promoting wound healing and treating muscle atrophy in a mammal in need. The method comprises administering to the mammal a Nell1 protein or a Nell1 nucleic acid molecule. | 02-05-2015 |
| 20150037295 | METHODS OF INDUCING TISSUE REGENERATION - Methods are provided for producing cells within a lineage (lineage restricted cells) from post-mitotic differentiated cells of the same lineage ex vivo and in vivo, and for treating a subject in need of tissue regeneration therapy by employing these lineage-restricted cells. In addition, the production of lineage restricted cells from postmitotic tissues derived from patients with diseases allows for a characterization of pathways that have gone awry in these diseases and for screening of drugs that will ameliorate or correct the defects as a means of novel drug discovery. Also provided are kits for performing these methods. | 02-05-2015 |
| 20150044176 | STEM CELL CULTURE MEDIA AND METHODS OF ENHANCING CELL SURVIVIAL - The invention provides improved methods for preparing hematopoietic cells for transplantation and the resulting improved hematopoietic cell compositions. The invention further relates to improved culture media and methods of culturing, processing, modulating, and expanding blood cell products for hematopoietic transplantation. | 02-12-2015 |
| 20150044177 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of an individual having amyotrophic lateral sclerosis, comprising administering to the individual a therapeutically effective amount of placental stem cells, e.g., tissue culture surface-adherent placental stem cells (PDACs). In one aspect, provided herein is a method of treating amyotrophic lateral sclerosis (ALS) comprising administering to an individual having ALS a therapeutically effective amount of placental stem cells. In certain embodiments, “therapeutically effective” means an amount effective to reduce or ameliorate one or more symptoms of ALS. | 02-12-2015 |
| 20150044178 | NORMALIZATION OF CULTURE OF CORNEAL ENDOTHELIAL CELLS - The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) β signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention. | 02-12-2015 |
| 20150044179 | CELL PREPARATION INCLUDING FAT CELL - A main objective of the present invention is to provide a cell preparation useful for treatment of diseases in bone joints and repairing muscles which have been degenerated or damaged. The present invention provides a cell preparation for treatment of diseases in bone joints which comprises a fat cell, and a cell preparation for repairing muscles which comprises a fat cell and a mesodermal stem cell. | 02-12-2015 |
| 20150044180 | ISOLATION AND USE OF PLURIPOTENT STEM CELL POPULATION FROM ADULT NEURAL CREST-DERIVED TISSUES - The present invention relates to methods of isolating a substantially homogeneous population of pluripotent stem cells from adult neural crest tissue (e.g., periodontal ligament) as well as pharmaceutical compositions comprising such isolated pluripotent stem cells. Methods of inducing the isolated pluripotent stem cells into specific cell lineages, such as neurogenic and retinogenic lineages, are also described. The isolated pluripotent stem cells find use in various regenerative medicine applications and the treatment of degenerative diseases. | 02-12-2015 |
| 20150044181 | IDENTIFICATION OF CHANNELRHODOPSIN-2 (CHR2) MUTATIONS AND METHODS OF USE - The invention provides compositions and kits including at least one nucleic acid or polypeptide molecule encoding for a mutant ChR2 protein. Methods of the invention include administering a composition comprising a mutant ChR2 to a subject to preserve, improve, or restore phototransduction. Preferably, the compositions and methods of the invention are provided to a subject having impaired vision, thereby restoring vision to normal levels. | 02-12-2015 |
| 20150044182 | DEVICES AND METHODS FOR SELECTING APOPTOSIS-SIGNALING RESISTANT CELLS, AND USES THEREOF - The present invention discloses a device and a kit adapted for selection of cells that are resistant to receptor-mediated apoptosis and a method for using the device and kit. The device enables negative selection of mature immune cells which induce graft versus host disease (GvHD) out of a heterogeneous cell population which is introduced into the device. The device enables an efficient cell selection in simplified and cheaper setting by an off the shelf product—a solution that currently do not exist. The present invention further discloses uses for the device. | 02-12-2015 |
| 20150044183 | STEM CELL BASED ANTI-CANCER COMPOSITIONS AND METHODS - The present invention provides compositions and methods for target radiotherapeutic treatment of cancer. Freshly isolated or culture expanded ELA stem cells are loaded with at least one of a diagnostic agent and a therapeutic agent, and the stem cells are then introduced into a subject. The loaded ELA stem cells migrate to location of cancer and form the basis both of diagnostic imaging and of directed Neutron Capture Therapy. Treatment of a subject may include ELA stem cell-based NCT radiotherapy as an adjunct to traditional therapies. An ELA stem cell-based diagnostic preparation can be used directly, or as a further addition to current imaging agents and methods. | 02-12-2015 |
| 20150044184 | SIRT1 INHIBITORS AND STEM CELL REJUVENATION - Provided herein are, inter alia, methods and compositions for treating or preventing diseases using SIRT1 inhibitors. The methods provided herein are particularly useful for treating or preventing age-related hematological diseases as well as cancerous hematological diseases. Further provided herein are hematopoietic cells useful for treating or preventing hematological diseases. | 02-12-2015 |
| 20150044185 | Bone Augmentation Utilizing Muscle-Derived Progenitor Compositions in Biocompatible Matrix, and Treatments Thereof - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. | 02-12-2015 |
| 20150044186 | REPAIR AND/OR RECONSTITUTION OF INVERTEBRAL DISCS - This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1 | 02-12-2015 |
| 20150044187 | Brain-Specific Enhancers for Cell-Based Therapy - Herein are described a set of novel specific human enhancers for specific forebrain cell types used to study and select for human neural progenitor cells. This approach enables the ability to generate interneurons from human ES, iPS and iN cells, making them available for human transplantation and for molecular/cellular analyses. These approaches are also directly applicable to generating other neuronal cell types, such as cortical and striatal projection neurons, which have implications for many human diseases. | 02-12-2015 |
| 20150050247 | Natural Tissue-Derived Decellularized Matrix and Methods of Generating and Using Same - Decellularized tissue-derived extracellular matrices (ECM) and methods of generating and using same are provided. The method of generating a decellularized matrix includes the steps of: (a) subjecting the tissue to washes and a hypertonic buffer; (b) subjecting the tissue to an enzymatic proteolytic digestion with an enzyme such as trypsin; and (c) removing all cellular components from the tissue using a detergent solution which includes Triton-X-100 and ammonium hydroxide. Specifically, there is provided a decellularized myocardium-derived matrix which is completely devoid of all cellular components and hence non-immunogenic in a subject, exhibits suitable structural and mechanical properties for cardiac tissue engineering or replacement therapy of damaged cardiac tissue, and is capable of remodeling upon seeding of cells. | 02-19-2015 |
| 20150050248 | MULTIFUNCTIONAL IMMATURE DENTAL PULP STEM CELLS AND THERAPEUTIC APPLICATIONS - The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes. | 02-19-2015 |
| 20150050249 | ENHANCEMENT OF OSTEOGENIC POTENTIAL OF BONE GRAFTS - The present invention concerns the enhancement of the osteogenic potential of bone graft by ex vivo treatment with a Wnt polypeptide, such as a liposomal Wnt polypeptide. | 02-19-2015 |
| 20150050250 | CELL THERAPY TECHNOLOGY TO DELIVER RADIO-PROTECTIVE PEPTIDES - A method of reducing a symptom of radiation exposure in a subject is provided. The method includes a step of introducing mammalian cells into the subject, the mammalian cells having been treated ex vivo to insert therein a polynucleotide encoding polypeptide that is protective against radiation. The mammalian cells express in vivo in the subject a therapeutically effective amount of the polypeptide thereby reducing a symptom of radiation exposure. | 02-19-2015 |
| 20150050251 | Cosmetic Preparations - The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination. | 02-19-2015 |
| 20150050252 | PLURIPOTENT STEM CELLS AND METHOD OF STIMULATING AND EXTRACTING NON-EMBRYONIC PLURIPOTENT STEM CELLS FROM MAMMAL BLOOD AND USING RECONSTITUTED PLURIPOTENT STEM CELLS TO TREAT DISEASES INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Stimulating tissue resident pluripotent stem cells in a manner that the respective subject (e.g., human) acts as its own sterile bioreactor for in vivo stem cell proliferation thus eliminating the need to isolate, cultivate, maintain, proliferate and release stem cells ex vivo. The stimulation mobilizes excess pluripotent stem cells into the peripheral vasculature where the pluripotent stem cells can either migrate to damaged tissues and/or be harvested by simple venipuncture, thus eliminating potential morbidity and mortality elicited from harvesting tissue from solid tissue sites. The pluripotent stem cells are separated from the blood by gravity sedimentation, after which the pluripotent stem cells can easily be aspirated from the white blood cells and red blood cells. Billions of pluripotent stem cells can be generated in this fashion for infusion/injection into the body, via the vasculature, and into the organ(s) in need of tissue repair and regeneration. | 02-19-2015 |
| 20150056170 | PLACENTAL STEM CELLS, METHODS FOR ISOLATING SAME AND USE THEREOF - The present description relates to an isolated population of human placental pluripotent stem cells or an isolated human placental pluripotent stem cell, positive for human leucocyte antigen-G (HLA-G), a migration marker and at least one pluripotent stem cell marker. The present description further provides a method for isolating human placental pluripotent stem cells. The method comprising: extracting cells from a human placenta; and isolating cells positive for human leucocyte antigen-G (HLA-G), a migration marker and at least one pluripotent stem cell marker and use thereof. On the other hand, it is likely that this present description is applicable to primates and other animals. | 02-26-2015 |
| 20150056171 | Methods of Predicting Clinical Outcome of Chronic Lymphocytic Leukemia - Provided are methods of predicting the outcome of a chronic lymphocytic leukemia (CLL) in a subject. The methods comprise performing a polymerase chain reaction assay for an IGH locus on a nucleic acid from a biological sample from a subject with CLL, wherein the PCR assay amplifies a non-coding region of the IGH locus, sequencing a product from the PCR assay, and determining a level of mutation in the non-coding region of the IGH locus. An increased level of mutation in the non-coding region as compared to a control indicates a positive outcome for the subject with CLL. A decreased level or no mutation in the non-coding region as compared to a control indicates a poor outcome for the subject with CLL. | 02-26-2015 |
| 20150056172 | METHODS AND COMPOSITIONS USING FGF-8 TO ENHANCE CARDIAC REGENERATION AND ATTENUATE ADVERSE CARDIAC REMODELING - In an aspect, the invention relates to compositions and methods for enhancing cardiac tissue and/or cell regeneration. In an aspect, the invention relates to compositions and methods for attenuating adverse cardiac tissue and/or cell remodeling. In an aspect, the invention relates to compositions and methods for inhibiting apoptosis. In an aspect, the invention relates to compositions and methods for identifying a myocardial injury. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 02-26-2015 |
| 20150056173 | BETA CELL GROWTH AND DIFFERENTIATION - The invention includes methods that can be used to increase β cell populations in vivo and in vitro, useful in the treatment of diabetes and related disorders. | 02-26-2015 |
| 20150064139 | CELL POTENCY ASSAY FOR THERAPEUTIC POTENTIAL - The invention provides cell potency assays for measuring, determining, identifying, confirming, or validating the therapeutic potential of a cell population. Cell potency assays may be performed with various types of cells, including stem or progenitor cells, such as, for example, hematopoietic stem or progenitor cells. Cell potency assays may also be performed on stem or progenitor cells that have been treated with one or more agents to enhance therapeutic potential. Hematopoietic cells having therapeutic potential are useful in downstream clinical applications for increasing engraftment, reconstitution, homing, and proliferation in vivo. | 03-05-2015 |
| 20150064140 | METHODS AND USES OF BIOLOGICAL TISSUES FOR VARIOUS STENT AND OTHER MEDICAL APPLICATIONS - Methods and uses of biological tissues for various stent and other medical applications. In an exemplary embodiment of a method of processing a tissue of the present disclosure, the method comprises the steps of acquiring a mammalian tissue comprising at least a portion of a pulmonary region tissue, selecting a sample of pulmonary region tissue from the at least a portion of a pulmonary region tissue, and fixing the sample of pulmonary region tissue using a fixative, resulting in a fixed sample. In at least one embodiment, the step of selecting a sample of pulmonary region tissue comprises selecting a sample of pulmonary ligament tissue from the mammalian tissue. | 03-05-2015 |
| 20150064141 | REGENERATIVE SERA CELLS AND MESENCHYMAL STEM CELLS - Disclosed herein are three types of skin-derived cells. One type of the cells is mesenchymal stem cells characterized by expression of the cell surface biomarker cluster of differentiation (CD) 146, the second type expresses CD271. The third type of cells is regeneration-associated cells characterized by expression of the cell surface biomarkers stage-specific embryonic antigen 3 (SSEA3) and CD 105 (clone 35). Also disclosed are methods of isolating, purifying, culturing, storing, and using these cells. | 03-05-2015 |
| 20150064142 | ELASTIC SCAFFOLDS FOR TISSUE GROWTH - According to some aspects, tissue scaffolds are provided that comprise one or more types of nanofibers. In some embodiments, one or more design features are incorporated into a tissue scaffold (e.g., an electrospun tissue scaffold) to control the elasticity of the scaffold in at least one direction, making the scaffold suitable for withstanding mechanical forces when implanted in the body of a subject | 03-05-2015 |
| 20150064143 | IONICALLY CROSS-LINKABLE ALGINATE-GRAFTED HYALURONATE COMPOUND - The present invention provides an ionically cross-linkable alginate-grafted hyaluronate compound containing alginate and hyaluronate, the alginate and the hyaluronate forming a covalent linkage. The use of the compound can easily provide a cross-linked hyaluronate by adding a divalent cation without using a chemical cross-linking agent. The present invention also provides a method for cell transplantation that includes preparing a composition comprising the compound of claim | 03-05-2015 |
| 20150064144 | Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes - The present invention provides novel drug discovery platforms and methods for treating type I diabetes. | 03-05-2015 |
| 20150064145 | BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AS A SOURCE OF NEURAL PROGENITORS - Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types. | 03-05-2015 |
| 20150064146 | Blood Brain Barrier Device - Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects. | 03-05-2015 |
| 20150064147 | CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION - Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component. | 03-05-2015 |
| 20150064148 | METHOD FOR TREATING OR PREVENTING A PANCREATIC DYSFUNCTION - The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1 | 03-05-2015 |
| 20150071885 | OSTEOTOMY BELOW THE TIBIAL TUBEROSITY BY MULTIPLE DRILLING - Surgical devices, kits and methods of using thereof are described. Generally, the surgical kit includes an osteotomy guide device and/or a bone spacer guide device. The surgical kit can be used in a surgical method for correcting a malalignment of the knee joint that involves performing a fibular osteotomy and/or a tibial osteotomy, and/or administering stem cells. Generally, the osteotomy guide device is configured to allow drilling to occur around the tibia and across a horizontal cross-sectional plane of the tibia so that a direction of each of the drill holes that are formed in the tibia is substantially parallel to or on the same horizontal cross-sectional plane of the tibia. The osteotomy guide device allows drilling to be conducted efficiently and accurately. | 03-12-2015 |
| 20150071886 | PROGENITOR CELLS OF MESODERMAL LINEAGE - The invention relates to progenitor cells of mesodermal lineage and their use in therapy. | 03-12-2015 |
| 20150071887 | Soft Tissue and Bone Augmentation and Bulking Utilizing Muscle-Derived Progenitor Cells, Compositions and Treatments Thereof - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction. | 03-12-2015 |
| 20150071888 | Pouch-like Construct for Preventing Heart Distension - The invention is directed to a pouch-like construct comprising mammalian tissue which can be used for preventing distension and/or resisting dilation of the heart in a mammal. Preferably, the pouch-like tissue construct has contractile properties. The invention further relates to a method for the preparation of a pouch-like construct comprising mammalian tissue which can be used for the above purposes. | 03-12-2015 |
| 20150071889 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS - Disclosed herein are methods, compositions, and kits for high efficiency, site-specific genomic editing of cells. | 03-12-2015 |
| 20150079044 | USE OF GROWTH HORMONE FRAGMENTS - The invention provides a method for treating a condition in which growth hormone administration is beneficial, for treating osteoarthritis, for increasing chondrocyte, proteoglycan or collagen production or quality or repair or promoting cartilage tissue formation or repair, for promoting or improving muscle, ligament or tendon mass, repair, form or function, or for treating inflammatory, traumatic or genetic diseases of muscle or connective tissue, comprising administering to a subject an effective amount of a peptide comprising a carboxyl-terminal sequence from a growth hormone and not the IGF-1 domain of growth hormone. It also provides a method of treating a condition involving insufficient functional chondrocytes or insufficient functional cartilage tissue, the method comprising administering to a subject in need thereof a peptide comprising a carboxyl-terminal sequence from a growth hormone and not the domain of growth hormone responsible for IGF-1 production. | 03-19-2015 |
| 20150079045 | NPRCPS, PFDNCS AND USES THEREOF - Identification of a group of novel particle termed “non-platelet RNA-containing particles (NPRCP)” provides novel compositions, downstream products and therapeutic tools. In addition a group of mixed NPRCPs were identified that contain RNAs and proteins. NPRCPs do not have a nucleus and their membrane is not the typical eukaryotic cell membrane. Methods for isolation and enrichment are also provided. | 03-19-2015 |
| 20150079046 | STEM CELL MICROPARTICLES - This invention relates to stem cell microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601). | 03-19-2015 |
| 20150079047 | OCULAR THERAPEUTICS USING EMBRYONIC STEM CELL MICROVESICLES - Disclosed is a therapeutic composition comprising human embryonic stem cell-derived micro vesicles, and methods of their use, including treatment of eye pathologies and of obtaining retinal neural cells and retinal stem cells. | 03-19-2015 |
| 20150079048 | Method for In Vivo, Ex Vivo and In Vitro Repair and Regeneration of Cartilage and Collagen and Bone Remodeling - A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure. The application of external interval loading consisting of repeated periods of applied hydrostatic pressure followed and interrupted by periods of recovery. The application of the intermittent hydrostatic pressure at physiological levels 5-10 MPA for an interval of 4 hours followed by a recovery period up to about 20 hours, said pressure applied to the cartilage cells in vitro, explants of cartilage ex vivo and in vivo to cartilage that remains intact within to joint space of diarthrotic joints. The interval loading results in the selective inhibition of matrix degrading enzymes, pro-inflammatory cytokines and chemokines that attract inflammatory cells into the joint cavity and in selective decrease of gene expression of growth factors that are inhibitory to type II collagen expression. | 03-19-2015 |
| 20150086511 | SURVIVAL, DIFFERENTIATION AND STRUCTURAL INTEGRATION OF HUMAN NEURAL STEM CELLS GRAFTED INTO THE ADULT RAT SPINAL CORD - The present invention provides methods and compositions for treating spinal cord diseases and injuires. The methods involve transplanting neural stem cells which have been previously expanded in vitro into a patient such that the cells can ameliorate the disease or injury. The stem cells to be transplanted are derived from spinal cord tissue. | 03-26-2015 |
| 20150086512 | METHODS OF PRODUCING RPE CELLS AND COMPOSITIONS OF RPE CELLS - The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases. | 03-26-2015 |
| 20150086513 | METHOD FOR DERIVING MELANOCYTES FROM THE HAIR FOLLICLE OUTER ROOT SHEATH AND PREPARATION FOR GRAFTING - The present invention relates to the field of biology and medicine, and more specifically, to the field of stem-cell biology, involving producing or generating melanocytes from stem-cells and precursors derived from human hair root. Additionally, the present invention relates to the materials and method for producing autografts, homografts or allografts comprising melanocytes in general, as well as the materials and methods for producing autografts, homografts and allografts comprising melanocytes for the treatment of diseases related to depigmentation of the skin and for the treatment of scars. | 03-26-2015 |
| 20150086514 | MESENCHYMAL STEM CELL INJECTION AND PREPARATION METHOD THEREOF, AND APPLICATION THEREOF IN PREPARING DIABETES DRUG - The present invention provides a mesenchymal stem cell injection, a preparation method thereof, and application thereof in preparing diabetes mellitus drug. Mesenchymal stem cells used by the present invention come from the human umbilical cord and the human placenta. The ingredients of the mesenchymal stem cell injection are: mesenchymal stem cells, human albumin, low molecular weight heparin, a compound amino acid, vitamin C, and a solution medium. The solution medium is a compound electrolyte solution, glucose water, or a normal saline solution. | 03-26-2015 |
| 20150086515 | IMAGING-AIDED GENE THERAPY USING MESENCHYMAL STEM CELLS AS TARGET-DELIVERY VEHICLE - Compositions and methods of use thereof encompass engineered mesenchymal stem cells as a vehicle to deliver secreted tissue necrosis factor-RGD4C fusion polypeptides for tumor treatment, thereby reducing side effects of TNF. A reporter gene can be included in vector constructs to monitor the localization and viability of engineered MSCs after administration into a recipient animal. The genetically modified mesenchymal stem cell can comprise an expression cassette comprising a nucleic acid sequence operably linked to a gene expression promoter and encoding the heterologous fusion polypeptide comprising a tissue necrotic factor region and an integrin-binding region. Another aspect of the disclosure encompasses embodiments of a method of modulating the proliferation of a targeted population of tumor cells by delivering a population of the genetically modified mesenchymal stem cells to tumor cells, allowing the mesenchymal stem cells to express the heterologous polypeptide, thereby reducing the proliferative capacity of the tumor cells. | 03-26-2015 |
| 20150086516 | Methods, Compositions, and Devices to Induce Mobilization and Recruitment of Progenitor Cells - Methods, compositions and systems are provided for mobilizing and recruiting progenitor, progenitor-like cells, and/or stem cells to a target site, such as an in vivo site in a patient in need of treatment. In embodiments, the methods include embedding cells in a matrix material having a three-dimensional structure capable of contacting the cells in a non-planar manner to alter the secretome of the cells and/or miRNA expression in a manner effective to recruit progenitor, progenitor-like, or stem cells. | 03-26-2015 |
| 20150086517 | MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES - An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed. | 03-26-2015 |
| 20150086518 | METHODS FOR GENERATING PANCREATIC TISSUE - This document provides methods and materials related to tissue generation. For example, methods for generating pancreatic tissue and providing a population of hormone-secreting cells, e.g., insulin-producing cells in a human subject are provided. | 03-26-2015 |
| 20150093361 | HUMAN DISC TISSUE - This invention provides disc stem cells, processes for obtaining and culturing disc stein cells, and methods for repairing damaged or diseased disc tissue comprising the use of the disc stem cells of the invention. | 04-02-2015 |
| 20150093362 | FAT PROCESSING SYSTEM - Methods and devices for treating lipoaspirate for use in fat grafting procedures are provided and generally include a canister for containing lipoaspirate, a separation mechanism structured to separate both oils and other materials from cellular components of lipoaspirate contained in the canister. The separation mechanism includes filters having different filtering capacities, for example, different pore sizes. | 04-02-2015 |
| 20150093363 | OSTEOGENIC DIFFERENTIATION OF MESENCHYMAL STEM CELLS - The present invention relates to a method for inducing and/or promoting osteogenic differentiation using extracellular vesicles and the use thereof. | 04-02-2015 |
| 20150093364 | USE OF STEM CELLS TO PREVENT NEURONAL DIEBACK - The invention is generally directed to treatment of neuronal injury. In particular, the invention is directed to reducing axonal retraction (“dieback”) that occurs as a result of the interaction of activated macrophages with dystrophic axons that are produced during nervous system acute or chronic injury. The invention is also directed to promoting axonal growth/regeneration. The invention is specifically directed to using stem cells or their secreted cellular factors, such as would be produced in conditioned cell culture medium, to ameliorate or prevent axonal dieback and/or promote growth/regeneration of axons. | 04-02-2015 |
| 20150104427 | ENZYME-ASSISTED SPATIAL DECORATION OF BIOMATERIALS - A method of producing a hydrogel compromising a spatially-controlled, three-dimensional distribution of one or more bioactive signals is provided. The method compromises illuminating the hydrogel, wherein the hydrogel compromises a polymer bound to a peptide comprising a photolabile protected amino acid, wherein at least one portion of the hydrogel is illuminated to deprotect the protected amino acid, thereby converting the protected amino acid to a deprotected amino acid. Preferably, the deprotected amino acid is a substrate for an enzyme in at least one portion of the hydrogel. The method further comprises the step of contacting the hydrogel with the enzyme and a peptide comprising a bioactive signal, wherein the enzyme can form a bond between the substrate and the peptide comprising the bioactive signal, thereby producing a hydrogel compromising a plurality of bioactive signals occupying three dimensions of the hydrogel within at least one portion of the hydrogel subjected to illumination. | 04-16-2015 |
| 20150104428 | Compositions and Treatment Methods for Mesenchymal Stem Cell-Induced Immunoregulation - Mesenchymal Stem Cells (MSCs), including bone marrow-derived MSCs (BMMSCs) expressing Fas and FasL, and secreting MCP-1 are disclosed. Also disclosed are methods for upregulating regulatory T cells in a subject by administering MSCs, including BMMSCs. Also disclosed are methods for treating systemic sclerosis or colitis in a subject by administering MSCs, including BMMSCs. | 04-16-2015 |
| 20150104429 | SYNTHETIC TRITERPENOIDS AND METHODS FOR MODULATING STEM/PROGENITOR CELL GENE EXPRESSION - Synthetic triterpenoids and methods of using the same to induce gene expression and differentiation of stem or progenitor cells are provided. Furthermore, the present invention provides methods for producing a cell, such as a stem or progenitor cell, with induced gene expression by contacting a stem or progenitor cell with an effective amount of a synthetic triterpenoid to induce the expression of one or more of SOX9 (Sex determining region Y-box 9), COL2A1 (Type II Collagen (alpha1)), TGF-βI, TGF-p2, TGF-33, BMP2, BMP4, BMPRII (Bone Morphogenic Protein Receptor II), SMAD (Small Mothers Against Decapentaplegic) 3, SMAD4, SMAD6, SMAD7, TIMP (Tissue Inhibitor of Metalloproteinase)-1 or TIMP-2 in the stem or progenitor cell, wherein the stem or progenitor cell is not a mesenchymal stem cell, periosteium cell or osteoprogenitor cell. In one embodiment, the stem or progenitor cell is multipotent. | 04-16-2015 |
| 20150104430 | Methods and Compositions for Generating Pancreatic Progenitors and Functional Beta Cells from hPSCs - Methods and compositions for producing NKX6-1+ pancreatic progenitor cells and/or insulin producing cells from an endodermal cell population, the method comprising contacting the endodermal cell population with an EGF component, a Nicotinamide component and/or a Noggin component, optionally a combination of at least one EGF component and at least one nicotinamide component to induce the differentiation of at least one endodermal cell into a NKX6-1+ pancreatic progenitor cell, the combination optionally further comprising at least one Noggin component. | 04-16-2015 |
| 20150104431 | CARDIAC MUSCLE REPAIR OR REGENERATION USING BONE MARROW-DERIVED STEM CELLS - Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation. | 04-16-2015 |
| 20150104432 | COMPLETE HUMAN SKIN ORGAN GENERATED FROM CULTURE-EXPANDED CELLS - Systems and methods can support generation of a full-thickness, human skin organ from tissue culture expanded cells. Human dermal and epidermal progenitor cells can be isolated from human tissues. Isolated cells may be cultured as epidermal cells while other isolated cells may be separately cultured as dermal cells. The cultured epidermal cells and dermal cells may be combined for co-culturing. The co-cultured cells may be suspended within a slurry. The co-cultured cells may be implanted onto a recipient organism for generation of a full-thickness skin organ comprising fully cycling hair follicles, adipose tissue, and other skin organ structures. | 04-16-2015 |
| 20150104433 | TAILORED RECOMBINASE FOR RECOMBINING ASYMMETRIC TARGET SITES IN A PLURALITY OF RETROVIRUS STRAINS - The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them. | 04-16-2015 |
| 20150104434 | ARTIFICIAL KIDNEY PRECURSOR AND PROCESS FOR PRODUCTION THEREOF - The present invention provides an artificial kidney precursor containing a non-human mammalian metanephros separated out from a living body, wherein the metanephros has been subjected to freezing and thawing treatments outside a living body, and contains mammalian mesenchymal stem cells transferred outside a living body, and a method of production thereof. | 04-16-2015 |
| 20150104435 | METHODS AND COMPOSITIONS FOR PROVISION OF ANGIOGENIC FACTORS - Disclosed herein are methods and compositions for the use of marrow adherent stem cells and their descendents; e.g., bone marrow-derived neural regenerating cells; for provision of angiogenic factors to cells. In certain embodiments, provision of angiogenic factors to sites of neural degeneration stimulates growth and/or survival of host neurons. | 04-16-2015 |
| 20150110747 | Bone Grafts Including Osteogenic Stem Cells, and Methods Relating to the Same - Bone grafts and constructs including stem cells are provided. Example bone grafts include osteogenic stem cells seeded on a scaffold of osteoconductive cortico-cancellous chips and/or osteoinductive demineralized bone. Example constructs include extracellular matrix on a synthetic scaffold, in which the ECM is secreted from MSCs seeded onto the synthetic scaffold. Also provided are methods of making the present bone grafts and scaffolds. Further provided are methods of promoting bone healing and treating wound healing, by administering the present bone grafts and constructs to a mammal in need thereof. Also provided are kits that include the present bone grafts and/or constructs, or components thereof. | 04-23-2015 |
| 20150110748 | Bone Grafts Including Osteogenic Stem Cells, and Methods Relating to the Same - Bone grafts and constructs including stem cells are provided. Example bone grafts include osteogenic stem cells seeded on a scaffold of osteoconductive cortico-cancellous chips and/or osteoinductive demineralized bone. Example constructs include extracellular matrix on a synthetic scaffold, in which the ECM is secreted from MSCs seeded onto the synthetic scaffold. Also provided are methods of making the present bone grafts and scaffolds. Further provided are methods of promoting bone healing and treating wound healing, by administering the present bone grafts and constructs to a mammal in need thereof. Also provided are kits that include the present bone grafts and/or constructs, or components thereof. | 04-23-2015 |
| 20150110749 | GENERATING PLURIPOTENT CELLS DE NOVO - The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material. | 04-23-2015 |
| 20150110750 | METHODS FOR USING AUTOLOGOUS FIBROBLASTS TO ALTER SKIN IDENTITY - The present invention relates to the field of autologous fibroblasts. More specifically, the present invention provides methods and compositions comprising autologous fibroblasts and uses thereof to alter skin identity. In certain embodiments, volar fibroblasts can be expanded for the ability to induce volar skin at the stump site in amputees. In other embodiments, fibroblasts from haired scalp can be expanded to ameliorate alopecias. | 04-23-2015 |
| 20150110751 | STEM CELLS AS AN INDIVIDUALIZED MATERNAL THERAPY FOR PREVENTION OF PREMATURITY - The present invention relates to the field of premature birth. More specifically, the present invention provides methods and compositions useful for preventing premature birth. In one embodiment, a method for preventing preterm birth in a patient comprises the step of administering to the patient an effective amount of autologous mesenchymal stem cells (MSCs) during the first or second trimester. | 04-23-2015 |
| 20150110752 | MAGNETIC EXTRACELLULAR MATRIX - Methods of making and using a magnetic ECM are disclosed. The ECM comprises positively and negatively charged nanoparticles, wherein one of said nanoparticles contains a magnetically responsive element. When the magnetic ECM is seeded with cells, the cells will be magnetized and can be levitated for 3-D cell culture. | 04-23-2015 |
| 20150110753 | BIOMATRIX SCAFFOLDS - The present invention provides biomatrix scaffolds, a tissue extract enriched for extracellular matrix components and bound growth factors, cytokines and hormones, and methods of making and using same. | 04-23-2015 |
| 20150110754 | High Resolution Allele Identification - Provided herein are methods for accurately determining the alleles present at a locus that is broadly applicable to any locus, including highly polymorphic loci such as HLA loci, BGA loci and HV loci. Embodiments of the disclosed methods are useful in a wide range of applications, including, for example, organ transplantation, personalized medicine, diagnostics, forensics and anthropology. | 04-23-2015 |
| 20150110755 | ELASTIN PRODUCING FIBROBLAST FORMULATIONS AND METHODS OF USING THE SAME - The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests of mammalian elastin, chemically digested plant extracts comprising elastin-like peptides, and synthetic elastogenic peptides. The invention further comprises cosmetic and pharmaceutical treatment methods using the therapeutic fibroblast compositions of the invention. | 04-23-2015 |
| 20150110756 | THREE-DIMENSIONAL TISSUE STRUCTURE - The present invention provides a prosthetic tissue or sheet capable of withstanding implantation operations, which can be used in actual operation and can be produced by culture. The present invention also provides a novel therapy which can substitute for cell therapy. Particularly, the present invention provides a method for producing a prosthetic tissue comprising a cell derived from a part other than myocardium and capable of withstanding implantation operation. The above-described objects of the present invention were partially achieved by finding that by culturing cells under specific culture conditions, the cells are unexpectedly organized into a tissue, and the resultant prosthetic tissue is capable of being detached from culture dishes. The present invention also provides a three-dimensional structure applicable to heart, comprising a cell derived from a part other than the myocardium of an adult. | 04-23-2015 |
| 20150118193 | IMMUNOMODULATORY PROPERTIES OF MULTIPOTENT ADULT PROGENITOR CELLS AND USES THEREOF - Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described. | 04-30-2015 |
| 20150118194 | METHOD AND COMPOSITION FOR PREVENTING STEM CELL DISRUPTION AND AGGREGATION - There is provided a method for preventing disruption and aggregation of stem cells. In addition, there is provided a stem cell composition for intravascular administration, in which stem cells are suspended in a solution containing aspirin. Further, there is provided a composition for preventing disruption or aggregation of stem cells, in which stem cells are suspended in a solution containing aspirin. | 04-30-2015 |
| 20150118195 | Electro-Mechanically Stretched Micro Fibers and Methods of Use Thereof - The presently disclosed subject matter provides a scalable and electrostretching approach for generating microfibers exhibiting uniaxial alignment from polymer solutions. Such microfibers can be generated from a variety of natural polymers or synthetic polymers. The hydrogel microfibers can be used for controlled release of bioactive agents. The internal uniaxial alignment exhibited by the presently disclosed fibers provides improved mechanical properties to microfibers, contact guidance cues and induces alignment for cells seeded on or within the microfibers. | 04-30-2015 |
| 20150118196 | TREHALOSE-CONTAINING MAMMALIAN CELL SUSPENSION FOR PREVENTION OF PULMONARY EMBOLISM FORMATION - A mammalian cell suspension prevents pulmonary embolism formation during administration of mammalian cells, such as mammalian stem cells, through a blood vessel, and a preventive agent against pulmonary embolism formation during administration of mammalian cells through a blood vessel. suspending mammalian cells, such as mammalian stem cells, are suspended in a physiological aqueous solution containing trehalose or its derivative, or a salt thereof as an active ingredient to prepare a mammalian cell suspension for preventing pulmonary embolism formation during administration of the mammalian cells through a blood vessel, including the mammalian cells and trehalose or its derivative, or a salt thereof as active ingredients. Examples of the mammalian cells can include pancreatic islet cells, dendritic cells, natural killer cells, alpha/beta T cells, gamma/delta T cells, and cytotoxic T lymphocytes in addition to mammalian stem cells. Preferred mammalian stem cells can include mammalian mesenchymal stem cells and mammalian pluripotent stem cells. | 04-30-2015 |
| 20150118197 | SCAFFOLD - The invention provides a method for producing an electrospun scaffold, comprising electrospinning a polymer or co-polymer onto a template comprising a conductive collector having a three dimensional pattern thereon, wherein said electrospun polymer or co-polymer preferentially deposits onto said three dimensional pattern. | 04-30-2015 |
| 20150118198 | BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AS A SOURCE OF NEURAL PROGENITORS - Methods are provided for treating and/or reducing the severity of multiple sclerosis in a human, by administering autologous mesenchymal stem cell-derived neural precursors. Also described is an in vitro method for differentiating mesenchymal stem-cell derived neural precursor oligodengroglial and neuronal cell types. | 04-30-2015 |
| 20150118199 | METHODS OF MEASURING POTENTIAL FOR THERAPEUTIC POTENCY AND DEFINING DOSAGES FOR AUTOLOGOUS CELL THERAPIES - Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC. | 04-30-2015 |
| 20150118200 | PRODUCTION OF EXTRACELLULAR MATRIX, CONDITIONED MEDIA AND USES THEREOF - Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided. Also provided are conditioned media, related compositions, related methods, and related packaging products. | 04-30-2015 |
| 20150125427 | NOVEL STEM CELLS, NUCLEOTIDE SEQUENCES AND PROTEINS THEREFROM - The present invention provides novel stem cells, nucleotide sequences and proteins therefrom. More specifically, the present invention provides Pax7+/Myf5− stem cells and methods for identifying and isolating them. Also provided is a MEGF10 nucleotide sequence and protein. | 05-07-2015 |
| 20150125428 | Multipotent Vascular Stem Cells and Methods of Use Thereof - A substantially enriched mammalian multipotent vascular stem cell (MVSC) population is provided, as well as compositions comprising the population. Methods are provided for the isolation, purification, and culture of the MVSCs. The MVSCs are useful in various applications, which are also provided. | 05-07-2015 |
| 20150125429 | GENE TARGETING METHODS AND TOOLS - Provided herein is a general method of correcting a gene, for example a gene with many known mutations, such as a gene with mutations in many different exons which could vary from subject to subject (e.g., patient), as well as a set of tools (TALENs and gene targeting vectors) to accomplish such method. | 05-07-2015 |
| 20150125430 | COMPOSITIONS AND METHODS FOR INDUCING THROMBOPOIESIS - Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject. | 05-07-2015 |
| 20150132265 | Methods and Compositions for Treating Disease - The present invention relates to methods and compositions for treating a subject comprising destroying diseased cells in the subject. The methods comprise obtaining a population of cells from a subject and determining the activity of at least one disease marker gene within the population of the obtained cells. A polynucleotide molecule that encodes a polypeptide that is lethal to the cells is then introduced into the cells, where the expression of the lethal polypeptide is controlled by the promoter of at least one of the disease marker genes previously identified. After introduction of the polynucleotide, the cells are treated with conditions to induce expression of the lethal polypeptide to destroy the cells that are expressing the disease marker gene(s). After destruction of the diseased cells, the remaining live cells, which did not express the lethal polypeptide to an extent necessary to kill the cells, are separated from the dead cells, and the live cells are restored to the subject. | 05-14-2015 |
| 20150132266 | NON-EXPANDED POST-NATAL MULTILINEAGE-INDUCIBLE CELLS - A method of isolating non-expanded post-natal multilineage-inducible cells has the steps of obtaining a biological sample from an animal; isolating bone marrow from the biological sample, isolating total nuclear cells (TNCs) obtained from the bone marrow, incubating the total nuclear cells in the presence of an antibody or a cell adhesion substrate, separating the cells to isolate non-expanded post-natal multilineage-inducible cells and isolating the non-expanded post-natal multilineage-inducible cells in the absence of expansion. | 05-14-2015 |
| 20150132267 | FIBROBLAST MIXTURES AND METHODS OF MAKING AND USING THE SAME - The present disclosure provides a non-autologous product that is a mixture of two or more cells or tissue cultures of fibroblast, or extracts from cultures, or media cultures, isolated from separate individuals, either homogeneous or heterogeneous. The cells or factors are blended together in a product that imparts desired characteristics to the skin of a recipient who is not a source of the mixture. The present disclosure also relates to methods of making and using and/or culturing the fibroblasts including to optimize the potency of the mixture to impart one or more the desired characteristics to the skin of a recipient. | 05-14-2015 |
| 20150139960 | SKIN PRINTING AND AUTO-GRAFTING - An apparatus and method for the production of substitute skin that advantageously reduces the amount of donor dermal cells needed from non-wound areas of a patient having a wound to be auto-grafted is reduced by using all of the harvested skin cells. A 3D printer is used to construct a wound graft product from the harvested skin cells without wasting any of the harvested skin cells. In a case of an irregularly shaped wound, wastage of harvested skin associated with trimming is avoided. | 05-21-2015 |
| 20150139961 | Reprogramming Blood Cells to Pluripotent and Multipotent Stem Cells - The present invention is based on the seminal discovery that cord blood (CB) and adult bone marrow (BM) CD34+ cells can be reprogrammed to early stem cells. The invention provides the reprogramming of CB and adult bone marrow (BM) CD34+ cells from subjects without any pre-treatment. Provided are methods for reprogramming blood cells of a subject. Also provided are methods of disease modeling and methods of generating subject-specific differentiated cells. In addition, the invention provides methods of identifying an agent that alters a function of subject-specific differentiated cells as well as isolated pluripotent or multipotent stem cells reprogrammed from blood cells. | 05-21-2015 |
| 20150139962 | COMPOSITION AND METHOD OF STEM CELLS FOR PRESERVATION OF CARDIAC TISSUE - The present disclosure describes a method and composition for enhancing the survival of hematopoietic stem cells, preferably CD34+ derived from human umbilical cord or peripheral blood, in hypoxic and serum-deprived conditions by cultivating the cells in medium containing lysophosphatidic acid, preferably further comprising a gel, namely a biomimetic gel. | 05-21-2015 |
| 20150139963 | ISOLATED POPULATIONS OF RENAL STEM CELLS AND METHODS OF ISOLATING AND USING SAME - Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells. | 05-21-2015 |
| 20150139964 | BODY FLUID EXPANDERS COMPRISING N-SUBSTITUTED AMINOSULFONIC ACID BUFFERS - A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein. | 05-21-2015 |
| 20150139965 | MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES - The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes. | 05-21-2015 |
| 20150147299 | GENERATION OF FUNCTIONAL AND DURABLE ENDOTHELIAL CELLS FROM HUMAN AMNIOTIC FLUID-DERIVED CELLS - This disclosure is directed to methods for reproducibly generating substantial amounts of endothelial cells from amniotic cells. The endothelial cells generated in accordance with the present methodology, as well as therapeutic methods utilizing these cells, are also disclosed. | 05-28-2015 |
| 20150147300 | Methods Of Mediating Macrophage Phenotypes - Methods of inducing a polarization of macrophages. The method includes obtaining a blood fraction, fractionating the blood fraction to produce a blood fraction, and contacting the blood fraction with a source of macrophages. A blood fraction including platelet-poor plasma polarizes the source of macrophages into M1 macrophages. A blood faction including a protein solution polarizes the source of macrophages into M2 macrophages. | 05-28-2015 |
| 20150147301 | METHODS AND COMPOSITIONS OF PRODUCING PATIENT-SPECIFIC MULTIPOTENT NEURONAL STEM CELLS - The present invention relates to the seminal discovery of compositions and a method of producing NSC obtained from stem cells derived from parthenogenically activated human oocytes (phNSC). The phNSC of the invention maintain proliferative and differentiation potential during cultivation and expansion. | 05-28-2015 |
| 20150289501 | HUMAN AND LARGE-MAMMAL LUNG BIOREACTOR - The present invention provides a bioreactor for large-mammal lung tissue. The bioreactor is capable of hydraulic driven negative-pressure and positive-pressure perfusion and ventilation. Perfusion and ventilation is delivered at physiological rates and is easily controllable. In one embodiment, the bioreactor comprises a support scaffold to support the size of a large-mammal lung tissue. In another embodiment, the bioreactor comprises a pleural sack that provides a small isolated fluid chamber which surrounds an engineered lung, thereby minimizing the amount of culture media needed. The present invention also provides an in vitro model for examining the function of a test agent and compositions and methods for alleviating a lung defect in a large-mammal. | 10-15-2015 |
| 20150290249 | Differentiation of Human Embryonic Stem Cells - The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer. | 10-15-2015 |
| 20150290327 | SULFATED ALGINATE HYDROGELS FOR CELL CULTURE AND THERAPY - The present invention relates to a method for providing an embedded mammalian cell, comprising the steps of providing an alginate sulfate in aqueous solution; reacting the alginate sulfate to form a hydrogel in a gelation step, providing a precursor cell, and embedding the precursor cell in the sulfated alginate hydrogel in an embedding step, thus yielding an sulfated alginate hydrogel embedded cell. The invention further relates to sulfated alginate hydrogels, and cellular grafts comprising a mammalian cell embedded in sulfated alginate hydrogel. | 10-15-2015 |
| 20150290333 | PROCESS AND MATERIALS FOR MEDICAL APPLICATIONS - This disclosure relates to a fully or partially biodegradable carrier for the delivery of biologically active agents which are associated, either directly or indirectly, with the carrier via a biodegradable linking agent and the use of the carrier in the delivery of bioactive molecules for therapy and imaging, in particular the delivery of agents to mitochondria. | 10-15-2015 |
| 20150290362 | HYBRID FIBRIN-MICROGEL CONSTRUCTS FOR TISSUE REPAIR AND REGENERATION - Composite constructs of polymer matrices and polymeric microgels, and methods of making and using thereof, are described. The addition of the microgels to polymeric matrices retains the overall mechanical properties of the matrices and enables cell spreading, invasion and vascularization. Using fibrin as a model system, composite fibrin constructs with microgels are described, in which microgels form unique interconnected pockets within the fibrin matrix. The microgel assembly is driven by the polymerization dynamics of fibrin, and the architecture of these interconnected pockets can be tuned. The composite constructs support cell spreading, migration and infiltration more efficiently than do control matrices. The composite constructs can be used attract cells and/or to deliver therapeutic, diagnostic, nutraceutical, prophylactic and cosmetic agents to a desired site. | 10-15-2015 |
| 20150291571 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS - A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal. | 10-15-2015 |
| 20150291934 | CELL PREPARATION CONTAINING MYOCARDIUM-COMMITTED CELL - The present invention relates to a method for producing a cell population comprising myocardium-committed cells that differentiate into and survive as myocardial cells under a myocardial tissue environment. Specifically, the method is characterized in that adipose-tissue-derived multi-lineage/multi-potent progenitor cells are cultured in the presence of a polyamine. The present invention further relates to a cell population comprising the myocardium-committed cells, a cell preparation comprising the cell population, or a cell sheet. The present invention further relates to a method for treating a heart disease, which comprises administering the cell population to a subject. | 10-15-2015 |
| 20150297563 | REJUVENATION OF PRECURSOR CELLS - The present invention relates generally to methods and pharmaceutical compositions for rejuvenating hematopoietic stem cells and progenitor cells from blood, intestinal tissue and dermal tissue by administration of at least one inhibitor of a GT-Pase, such as Cdc42 GTPase. | 10-22-2015 |
| 20150297638 | CHEMICALLY INDUCED PLURIPOTENT STEM CELLS FOR SAFE THERAPEUTIC APPLICATIONS - This disclosure provides a chemically modified induced pluripotent stem (iPS) cells characterized by DNA hypomethylation and methods for generating the cells. The cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue in a patient in need thereof and to treat cardiac disease. | 10-22-2015 |
| 20150297640 | Method of Controlling Administration of Cancer Antigen - The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases. | 10-22-2015 |
| 20150297686 | TISSUE REGENERATION PROMOTING AGENT - The purpose of the present invention is to provide a novel tissue regeneration accelerator and tissue regeneration method. The present invention relates to: a composition for accelerating tissue regeneration, accelerating cell differentiation and/or accelerating cell multiplication comprising a component selected from the group consisting of activated stellate cells, the decomposition product of activated stellate cells, MMP14, collagen that has been treated with MMP14, and the secretion product of activated stellate cells; a composition for suppressing cell multiplication comprising MMP14 suppressing material; and a cell cultivation substrate comprising collagen that has been treated with MMP14. | 10-22-2015 |
| 20150299652 | COMPOSITIONS AND METHODS FOR GENERATING NEURAL CREST STEM CELLS AND SENSORY NEURONS - In an aspect, the invention relates to compositions, methods, and kits for generating neural crest stem cells, sensory neurons, and Schwann cells. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 10-22-2015 |
| 20150299653 | METHODS OF PRODUCING RPE CELLS - The present disclosure relates to the use of laminin-521 in obtaining retinal pigment epithelium (RPE) cells. Pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in totally defined and xeno-free conditions. A first cell culture medium contains a growth factor, and a second cell culture medium does not contain growth factor. The stem cells are first exposed to the first cell culture medium, then exposed to the second cell culture medium for a longer time period. After a number of weeks, clinical grade RPE cells are obtained from the stem cells. | 10-22-2015 |
| 20150299658 | METHOD FOR INDUCING PLURIPOTENT STEM CELLS TO DIFFERENTIATE INTO VENTRICULAR MYOCYTES IN VITRO - Provided in the present invention is a method for inducing pluripotent stem cells to differentiate into ventricular myocytes in vitro, which is achieved by maintaining, amplifying and culturing pluripotent stem cells in vitro, adding a substance capable of activating the Smad1/5/8 signaling pathway directly or indirectly into the culture medium when pluripotent stem cells are in the middle stage of myocardial differentiation, i.e. the period of differentiating into cardiac muscle cells from mesoderm cells or myocardial precursor cells, which enables stem cells to differentiate into ventricular myocytes directionally. Ventricular myocytes with biological activity and function are obtained successfully by means of the method of the present invention, which reveals the regulatory mechanism during differentiation of myocardial precursor cells into ventricular myocytes; moreover, the human ventricular myocytes obtained via differentiation can be widely used in treating myocardial infarction by cell transplantation, in toxicological analysis of the heart and in the development of heart-related drugs. | 10-22-2015 |
| 20150299659 | MUSCLE CELL PRODUCTION - The present disclosure relates to production of muscle cell precursors. In particular, the present disclosure relates to an in vitro method of producing skeletal muscle precursor cells from pluripotent stem cells. The present disclosure also further relates to the production of skeletal muscle cells (myoblasts and myocytes) from differentiated stem cells. The present disclosure also relates to the use of these cells in various research applications as well as their use in the treatment of skeletal muscle diseases or disorders. | 10-22-2015 |
| 20150299661 | PLURIPOTENT STEM CELLS OBTAINED FROM DENTAL PULP - The present invention relates to pluripotent stem cells obtained from the dental pulp of patients of different ages, the invention furthermore comprises cultures of said cells, means for obtaining them and pharmaceutical compositions comprising them, as well as their application in tissue regeneration. | 10-22-2015 |
| 20150299687 | FUSION PROTEINS FOR THE TREATMENT OF CNS - This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules. | 10-22-2015 |
| 20150306140 | INDUCED ACTIVATION IN DENDRITIC CELLS - The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide. | 10-29-2015 |
| 20150306146 | METHODS OF TREATING OR PREVENTING RESPIRATORY CONDITIONS - The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1 | 10-29-2015 |
| 20150306150 | TREATMENT OF BONE-RELATED CANCERS USING PLACENTAL STEM CELLS - Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer. | 10-29-2015 |
| 20150307568 | Medicament for atrophy treatment or increasing cell growth - The present invention provides SERF2, a nucleic acid encoding said SERF2 or a cell expressing SERF2 for use as a medicament, in particular for use for use in treating or preventing an atrophy disease or condition or for increasing cellular growth in a patient such as sarcopenia, cachexia, dystrophy, hypoplasia, hypotonia, or muscle loss, as well as in vitro methods suitable for cell culture proliferation and pharmaceutical compositions. | 10-29-2015 |
| 20150307608 | MONOCLONAL ANTIBODY STRO-4 - The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such as mesenchymal precursor cells (MPCs). | 10-29-2015 |
| 20150307840 | ENDOTHELIAL AND ENDOTHELIAL LIKE CELLS PRODUCED FROM FIBROBLASTS AND USES RELATED THERETO - This disclosure relates to endothelial or endothelial like cells cultured from fibroblasts exposed to transcription factor ETV2. In certain embodiments, the disclosure relates to methods of producing endothelial or endothelial like cells comprising exposing fibroblasts with ETV2 under conditions such that the fibroblasts are modified to form a pool of cells expressing increased levels of endothelium surface markers compared to the fibroblasts. In certain embodiments, the disclosure relates to using endothelial like cells reported herein for the treatment of vascular, cardiac, and wound healing indications. | 10-29-2015 |
| 20150307844 | CELL CULTURE METHOD - The present invention is directed towards methods for producing cell and tissue compositions suitable for therapeutic applications to a mammal in need of a therapeutic cell or tissue treatment. In particular, the invention is directed towards a method of culturing cells for use in therapy, which method comprises (i) culturing a sample of cells in a first cell culture medium and (ii) prior to harvesting cells for use in therapy culturing the cells in a second cell culture medium. | 10-29-2015 |
| 20150307845 | Apparatus for Enhanced Recovery of Regenerative cells From Tissue Samples - This document describes methods and an apparatus for recovery of a cell-enriched matrix and cells (e.g., regenerative cells) from a tissue sample. In some embodiments, at least two rounds of acceleration and deceleration are performed. | 10-29-2015 |
| 20150307846 | GROWTH FACTOR COCKTAIL TO ENHANCE OSTEOGENIC DIFFERENTIATION OF MESENCHYMAL CELLS - The present invention relates to methods and compositions for osteogenic differentiation of human periosteum derived cells, in particular using a growth medium containing a specific combination of growth factors and formulations thereof. The invention also relates to the differentiated cells and cell populations, as well as further products comprising such cells and uses thereof in bone therapy. | 10-29-2015 |
| 20150307867 | TARGETING BCL11A DISTAL REGULATORY ELEMENTS FOR FETAL HEMOGLOBIN REINDUCTION - Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels. | 10-29-2015 |
| 20150313947 | TREATMENT OF SCHIZOPHRENIA USING AMNION DERIVED ADHERENT CELLS - Provided herein are methods of treatment of individuals having schizophrenia, or schizophreniform disorder, using angiogenic cells from amnion, referred to as amnion derived adherent cells, and populations of and compositions comprising, such cells. A need exists for therapies that can ameliorate or palliate schizophrenia, or a schizophreniform disorder, or symptoms of the same. Provided herein are methods of treating individuals who have schizophrenia, or schizophreniform disorder, comprising administration of therapeutically-effective amounts (numbers) of AMDACs. | 11-05-2015 |
| 20150313948 | TREATING ORAL LESIONS USING PLACENTAL EXTRACELLULAR MATRIX - Provided herein are uses of compositions comprising extracellular matrix (ECM) and compositions comprising ECM components in the treatment of non-dental oral lesions. | 11-05-2015 |
| 20150314041 | Apparatus for enhanced recovery of regenerative cells from tissue samples - This document describes methods and an apparatus for recovery of a cell-enriched matrix and cells (e.g., regenerative cells) from a tissue sample. In some embodiments, at least two rounds of acceleration and deceleration are performed. | 11-05-2015 |
| 20150314044 | METHOD FOR IN VIVO HAIR MULTIPLICATION - Cosmetic methods providing a significant improvement over existing hair transplantation methods by providing greater hair density per hair implant, which is achieved through the process of an enhanced hair multiplication in vivo (e.g. in the scalp of a subject). The cosmetic methods also provide improved aesthetic results, particularly, more realistic and natural looking results, relative to the results obtained by traditional methods. The cosmetic methods are particularly suitable for hair transplantation in recipient areas of a subject experiencing baldness or lack of hair, optionally due to Androgenic alopecia, burn injuries, cancer chemotherapy, or other genetic or environmental factors or scarring. | 11-05-2015 |
| 20150315626 | MUCOPOLYSACCHARIDOSIS IVA/VII SCREENING AND TREATMENT METHOD - Provided is a rapid screening method for detecting mucopolysaccharidosis IVA and mucopolysaccharidosis VII. Biological samples containing glycosaminoglycans are enzymatically digested to converts chondroitin 6-sulfate into ΔDi-6S. ΔDi-6S is assayed by liquid chromatography-tandem mass spectroscopy analysis. Elevated ΔDi-6S, and thus elevated chondroitin 6-sulfate present in the sample, indicates a likelihood that the test subject is afflicted with mucopolysaccharidosis IVA or mucopolysaccharidosis VII. | 11-05-2015 |
| 20150320801 | USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS - Disclosed herein is that the systemic administration of ASC conditioned media diminished LPS-induced lung injury by inhibiting epithelial permeability, neutrophil inflammatory response, and secretion of pro-inflammatory TNFα. It is also shown that ARDS lung is able to retain IV-delivered ASC for a substantial amount of time, with no evidence of the significant cell distribution to other organs at this time point. These findings provide optimization of cell-based and cell-free therapy for the treatment of ARDS, including occurrences of ARDS caused by upper respiratory tract infections such as SARS and MERS. | 11-12-2015 |
| 20150320804 | Bandage Containing Foetal Fibroblasts and Keratinocytes - The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer). | 11-12-2015 |
| 20150320836 | CRYOPRESERVATION OF CELLS INSIDE A MACRO-ENCAPSULATION DEVICE - Embodiments disclosed herein relate to methods and compositions to simplify creation, storage, distribution, and Encapsulation Technology use of encapsulated cell based therapeutics, particularly cell-based therapeutics comprising islet-like cell clusters. | 11-12-2015 |
| 20150320840 | METHOD FOR INDUCING CELLS TO LESS MATURE STATE - The present application describes a method for inducing or maintaining pluripotency in a cell by contacting the cell with a biological or chemical species that increases MUC1* activity. | 11-12-2015 |
| 20150322406 | METHOD FOR REPROGRAMMING SOMATIC CELLS TO PANCREATIC BETA CELLS - The present invention relates to a method for reprogramming a somatic cell (e.g. a pancreatic ductal cell, a skin fibroblast or a keratinocyte) to a pancreatic β-cell. This method involves decreasing expression or activity of Fbw7 and/or decreasing phosphorylation-mediated degradation of NGN3 in the somatic cell. The method may be carried out ex vivo or in vivo. The invention also relates to a method of treating a subject with a metabolic disorder (e.g. diabetes) or a subject at risk of a metabolic disorder by administering somatic cells that have been re-programmed to pancreatic β-cells using methods described herein to the subject. In addition, the invention relates to screening methods for identifying a candidate agent for reprogramming a somatic cell to a pancreatic β-cell. | 11-12-2015 |
| 20150322407 | PRODUCTION OF INSULIN PRODUCING CELLS - The invention provides methods for differentiating stem cells along the pancreatic lineage as well as large scale culture methods. The present invention further provides pancreatic progenitor cells derived from stem cells to provide pancreatic cells to a subject. | 11-12-2015 |
| 20150328176 | COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISEASE - A composition of matter comprising an α-ketoglutarate (AKG) or an α-ketoglutaric acid or a salt of an α-ketoglutarate may be used to treat patients having a neurodegenerative disease, such as amyotrophic lateral sclerosis. The composition may be administered hourly or may be administered once a day depending on the size and activity of the patient and the release coating or mechanism provided. In addition to AKG, a core composition may comprise GABA and a source of coenzyme Q10. Other substances may be provided either orally or intravenous in addition to the core composition, as required to control symptoms, or in order to stimulate stem cells to add motor neurons. | 11-19-2015 |
| 20150328261 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 11-19-2015 |
| 20150328262 | COMPOSITIONS AND METHODS FOR TREATING RETINAL DISEASES - Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolation thereof. | 11-19-2015 |
| 20150328263 | CARDIAC STEM CELLS FOR CARDIAC REPAIR - Embodiments of the disclosure concern compositions and methods of use related to particular c-kit+ mesenchymal cells, including cardiac stem cells, obtained from a pediatric or neonatal individual. In specific embodiments, the cells, or conditioned medium or partial or total secretomes thereof, are provided in an effective amount to an individual in need thereof. | 11-19-2015 |
| 20150328366 | Process For Demineralization of Bone Matrix With Preservation of Natural Growth Factors - A demineralized bone matrix is produced by a process in which a bone body is placed in a first processing solution comprising an acid to demineralize the bone body. The bone body is periodically removed from the first solution at specific time intervals to perform at least one test, such as a compression test, on a mechanical property of the bone body. When the test yields a desired result, the bone body is exposed to a second processing solution that is less acidic than the first, thus minimizing the exposure of the bone body to the harsh acidic conditions of the demineralization phase of the process. | 11-19-2015 |
| 20150329823 | CO-DIFFERENTIATION OF MONOCYTES FROM ALLOGENEIC DONORS - Disclosed is a method of producing non-exhausted immature dendritic cells (DCs) originating from at two different, allogeneic donors. In the method, a mixture of allogeneic leukocytes, which allogeneic leukocytes have been obtained from at least two different, allogeneic donors is provided. Subsequently, allogeneic monocytes are isolated from the mixture of allogeneic leukocytes. Thereafter, non-exhausted immature DCs are generated from said isolated allogeneic monocytes. | 11-19-2015 |
| 20150335647 | Methods of Increasing Liver Proliferation - The present invention is directed to methods of enhancing liver repair after injury, resection or transplantation using antagonists of the bone morphogenetic protein (BMP) signaling pathway in the liver. | 11-26-2015 |
| 20150335679 | Methods and Compositions for Treating Malignancies with Dendritic Cells - This invention provides methods and compositions for the treatment and/or prevention of cancer, including solid malignancies and hematologic malignancies. In particular, the present invention relates to immunotherapy using antigen-presenting cells loaded with tumor associated peptide antigens (TAPAs). If a subject expresses at least one tumor-associated antigen, the subject can be treated by antigen-presenting cells (e.g., dendritic cells) loaded with at least one tumor-associated peptide antigen derived from the tumor-associated antigen (s) expressed by the subject. This personalized immunotherapy induces or enhances immune responses to cells that express tumor-associated antigen(s). | 11-26-2015 |
| 20150335683 | METHODS FOR PRODUCING DOPAMINERGIC NEURONS AND USES THEREOF - The present application relates to a stem cell, a precursor or progenitor cell in which Plexin C1 has been inactivated, a dopaminergic (DA) neuron in which Plexin C1 has been inactivated, methods of preparing same and uses thereof for the treatment of Parkinson's disease. | 11-26-2015 |
| 20150335684 | ORTHOPEDIC USE OF A HYDROGEL COMPOSITION - A method for augmentation of a soft tissue in a subject, comprising: introducing to the subject a hydrogel composition comprising a porous bio-absorbable ceramic carrier and a hyaluronic acid gel. The porous bio-absorbable ceramic carrier is made of a material selected from the group comprising hydroxyapatite, β-tricalcium phosphate, or calcium polyphosphate. The hydrogel composition further comprises a cell positioned in a pore of the porous bio-absorbable ceramic carrier. The hydrogel composition is introduced into the subject in the form of an injection thereby eliminating the need for a surgical procedure. | 11-26-2015 |
| 20150335685 | ENGINEERED STEM CELL THERAPY FOR CARDIAC REPAIR - This disclosure relates to compositions and methods of cardiac repair. In certain embodiments, the disclosure relates to a composition comprised of peptide amphiphiles and cardiac and/or cardiac precursor cells, and administering such a composition to a subject for the treatment of a cardiac condition. In certain embodiments, the peptide amphiphiles comprise a cell adhesive sequence and a metalloprotease degradable sequence. | 11-26-2015 |
| 20150337020 | CCN3 AND CCN3 PEPTIDES AND ANALOGS THEREOF FOR THERAPEUTIC USE - The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof. | 11-26-2015 |
| 20150337260 | Hybrid Matrix - The present invention relates to poly(caprolactone)-oligonucleotide surfaces for cell ware, and methods of use thereof for culturing, and differentiating cells. | 11-26-2015 |
| 20150337265 | MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 11-26-2015 |
| 20150342997 | SOMATIC STEM CELLS - Described herein is a method of generating muscle cells in a subject. The method includes isolating a population of somatic stem cells that are CD133− and 0.3-6.0 micrometers in size and administering to a subject in need thereof an effective amount of the somatic stem cells, whereby the somatic stem cells differentiate into muscle cells in the subject. | 12-03-2015 |
| 20150342999 | METHODS AND COMPOSITIONS FOR TREATING DIABETES WITH IPS DERIVED PANCREATIC BETA-LIKE CELLS - Diabetes mellitus is characterized by either the inability to produce insulin (Type 1 diabetes) and or as insensitivity to insulin secreted by the body (Type 2 diabetes). In either case, the body is unable to efficiently move blood glucose across cell membranes to be utilized. This leads to a variety of local and systemic detrimental effects. Current treatments for diabetes focus on exogenous insulin administration and dietary control. Provided herein are treatments of diabetes using a cellular therapy to ameliorate symptoms associated with both reduced insulin secretion and insulin sensitivity. Using induced-pluripotent stem (iPS) cells, beta-like (β-like) cells similar to the endogenous insulin secreting cells were derived. These β-like cells secreted insulin in response to glucose, and corrected a hyperglycemic phenotype in a mouse model of Type 2 diabetes via an iPS cell transplant. Within the Type 2 diabetes mouse model, a long term correction of hyperglycemia was achieved as measured by blood glucose and hemoglobin Alc measurements. Reduction of hyperglycemia was also seen in a chemically-induced mouse model for Type 1 diabetes. | 12-03-2015 |
| 20150344541 | PLATELET TARGETED TREATMENT - The present disclosure relates to compositions and methods for targeting expression of exogenous genes to platelets. In particular, the present disclosure relates to treatment of hemophilia and other diseases and conditions by targeting expression of exogenous agents (e.g., clotting factors) to platelets. | 12-03-2015 |
| 20150352083 | Mast Cell Stabilizers to Prevent or Treat Laminitis - Provided herein are mast cell stabilizers used to prevent, treat, or mitigate severity of laminitis. Mast cell stabilizers can be combined with antihistamines and other medicaments to prevent, treat, or mitigate severity of laminitis. | 12-10-2015 |
| 20150352153 | REPAIR OF PERIPHERAL NERVE INJURY - The invention relates to methods and compositions for maintaining the pro-regenerative capacity of distal nerve segments following nerve injury. | 12-10-2015 |
| 20150352154 | INDUCED PLURIPOTENT CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF MYELIN DISORDERS - The present invention relates to preparations of induced pluripotent cell-derived oligodendrocyte progenitor cells, and methods of making, isolating, and using these preparations. | 12-10-2015 |
| 20150352155 | USE OF ANTI-AGING GLYCOPEPTIDES TO ENHANCE PANCREATIC CELL HEALTH, SURVIVAL AND IMPROVE TRANSPLANT OUTCOME - The present disclosure relates to an in vitro method for enhancing engraftment of isolated pancreatic cells comprising the step of contacting an isolated pancreatic cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I: | 12-10-2015 |
| 20150352157 | Wound Dressing Nanomesh Impregnated with Human Umbilical Cord Wharton's Jelly Stem Cells - The invention is directed to a method of treating a wound (e.g., to suppress scar formation) in an individual in need thereof comprising contacting the wound with an effective amount of a composition comprising (i) Wharton's jelly stem cells (WJSCs). (ii) a cell culture medium that has been conditioned with WJSCs. (iii) a lysate of WJSCs. (iv) a cell culture medium that has been conditioned with WJSCs exposed to apoptotic skin cells and keloid cells, or (v) a combination thereof. The invention is directed to a medical dressing (e.g., pharmaceutical compositions) comprising Wharton's jelly stem cells (WJSCs), a cell culture medium that has been conditioned with WJSCs, a lysate of WJSCs, a cell culture medium that has been conditioned with WJSCs exposed to apoptotic skin cells and keloid cells, or a combination thereof. | 12-10-2015 |
| 20150352183 | LAMININS, DERIVATIVES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE - In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The method, in yet another embodiment, is used to prevent or reduce muscle damage or injury. In specific implementations of these methods, the laminin or composition that includes laminin is administered in a therapeutically effective amount. In some implementations, the laminin is a complete laminin protein. In other implementations, the laminin is a laminin fragment, a laminin derivative, or a laminin analogue. | 12-10-2015 |
| 20150352256 | TISSUE PROCESSING APPARATUS WITH MIXING DEVICE AND METHOD FOR PROCESSING ADIPOSE TISSUE - A portable apparatus for collection and processing of human biological material, such as containing adipose extracted during a lipoplasty procedure, is useful for multi-step processing to prepare a concentrated product (e.g., stromal vascular fraction) or a fat graft composition. The apparatus has a container with a containment volume with a tissue retention volume and a filtrate volume separated by a filter and with a tapered portion to a collection volume for collecting concentrate product. The apparatus includes a mixing device disposed at least in part within the tissue retention volume, and wherein the mixing device has a rotatable shaft extending from outside of to inside of the internal containment volume and has at least one mixing member that is disposed in the tissue retention volume with at least a portion disposed in the tapered portion of the internal containment volume and that is connected with the shaft to move through the tissue retention volume when the shaft is rotated. | 12-10-2015 |
| 20150353890 | COMPOSITIONS AND METHODS FOR EXPANSION OF EMBRYONIC HEMATOPOIETIC STEM CELLS - The present invention relates to methods, kits and compositions for expansion of embryonic hematopoietic stem cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGFp pathway. Also provided herein are methods for expanding embryonic hematopoietic stem cells using kits and compositions comprising a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TOPβ pathway. The embryonic hematopoietic stem cells expanded using the disclosed kits, compositions and methods include cells derived from an embryo (e.g., aorta-gonad-mesonephros region of the embryo), embryonic stem cells, induced pluripotent stem cells, or reprogrammed cells of other types. The present invention also relates to administering the embryonic hematopoietic stem cells expanded using a combination of a Notch agonist, one or more growth factors, and, optionally, an inhibitor of the TGFp pathway to a patient for short-term and/or long-term in vivo repopulation benefits. | 12-10-2015 |
| 20150359822 | METHODS TO REBALANCE THE HYPOTHALAMIC-PITUITARY-GONADAL AXIS - A hypothalamic-pituitary-gonadal (HPG) axis of a patient in need thereof is rebalanced by administering a therapeutically effective amount of at least one donor cell. | 12-17-2015 |
| 20150359823 | MULTIPOTENT ADULT STEM CELLS AND METHODS FOR ISOLATION - The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells. | 12-17-2015 |
| 20150359845 | TRANSCRIPTION FACTOR-BASED GENERATION OF PACEMAKER CELLS AND METHODS OF USING SAME - Several embodiments disclosed herein relate generally to methods and compositions for the generation of biological pacemakers. In some embodiments, the methods comprise contacting non-pacemaker cells with one or more transcription factors (in vivo or in vitro) and inducing pacemaker functionality in the cells. | 12-17-2015 |
| 20150359931 | Calcium-Mediated Effects of Coral and Methods of Use Thereof - This invention is directed to coral scaffolds seeded with precursor cells in culture in the presence of a chelator and uses thereof in inducing or enhancing bone and/or cartilage formation in a subject, and kits related thereto. This invention is also directed to use of cadherin-upregulating coral for treating cancer or inhibiting cancer progression. This invention is also directed to use of aragonite or calcite-producing species for in vivo calcium release, and its application to the treatment of skin diseases, disorders or conditions. | 12-17-2015 |
| 20150359940 | METHODS, SUBSTRATES, AND SYSTEMS USEFUL FOR CELL SEEDING OF MEDICAL GRAFTS - Described are methods, cell growth substrates, and devices that are useful in preparing cell-containing graft materials for administration to patients. Tubular passages can be defined in cell growth substrates to promote distribution of cells into the substrates. Also described are methods and devices for preparing cell-seeded graft compositions, methods and devices for preconditioning cell growth substrates prior to application of cells, and cell seeded grafts having novel substrates, and uses thereof. | 12-17-2015 |
| 20150361390 | COMPOSITION AND METHOD FOR GENERATING A DESIRED CELL TYPE AND/OR TISSUE TYPE FROM HAIR FOLLICULAR STEM CELLS - The present invention is concerned with a composition and in vitro method for generating a desired cell type and/or tissue type from hair follicular stem cells. The composition and in vitro method are particularly suitable for generating an autologous desired cell type and/or tissue type. Furthermore, the composition and method are especially efficient and suitable for use in the context of cosmetic cell and/or tissue transplantation in recipient areas of a subject experiencing cell and/or tissue loss caused by, for example, a wound, scar, burn injury, tissue degeneration, and aging. The composition and in vitro method are also suitable to circumvent complications related to infections and/or immune rejection of a cosmetic cell and/or tissue implant or graft. | 12-17-2015 |
| 20150361398 | REPROGRAMMING OF HUMAN ENDOTHELIUM INTO HEMATOPOIETIC MULTI-LINEAGE PROGENITORS BY DEFINED FACTORS - The invention is directed to generation of hematopoietic multi-lineage progenitors (HMLPs) from endothelial cells (ECs) by effecting forced expression of certain transcription factors in the ECs and culturing the ECs in serum free media in the presence of endothelial feeder cells. The HMLPs generated in accordance with this invention can produce erythroid, lymphoid, myeloid, and megakaryocyte cells. These generated HMLPs can be used in therapeutic treatment of disorders including hematopoietic conditions. | 12-17-2015 |
| 20150361400 | COMPOSITIONS AND METHODS FOR MAINTAINING AND IMPROVING PANCREATIC ISLET CELL FUNCTION AND STABILITY - Compositions and methods for production of beta islet cells exhibiting superior endocrine like functions are disclosed. | 12-17-2015 |
| 20150366914 | Methods for Mobilizing Hematopoietic Stem Cells - Disclosed are methods of mobilizing hematopoietic cells in a subject by administering to the subject a combination of Flt3 ligand (FLT3L) and a cell adhesion inhibitor. Also disclosed are methods of mobilizing hematopoietic cells in a cell culture population by contacting the cell culture population with Flt3 ligand. Mobilized hematopoietic cells can subsequently be harvested and used for hematopoietic cell transplantation. Further disclosed are compositions comprising a FLT3L, compositions comprising FLT3L and a cell adhesion inhibitor, and composition comprising FLT3L and Plerixafor. | 12-24-2015 |
| 20150366915 | PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS AND USES THEREOF - This disclosure provides the first description of hESC-derived cells transplanted into human patients. Results are reported for one patient with each of Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD). Controlled hESC differentiation resulted in near-100% pure RPE populations. Immediately after surgery, hyperpigmentation was visible at the transplant site in both patients, with subsequent evidence the cells had attached and integrated into the native RPE layer. No signs of inflammation or hyperproliferation were observed. The hESC-derived RPE cells have shown no signs of rejection or tumorigenicity at the time of this report. Visual measurements suggest improvement in both patients. | 12-24-2015 |
| 20150366918 | METHOD OF CONSTRUCTING MASSES OF MYOCARDIAL CELLS AND USE OF THE MYOCARDIAL CELL MASS - The object of the present invention is to improve the post-transplantation engraftment rate of cardiomyocytes that have been purified to such an extent that they are free from non-cardiomyocytes and any components derived from other species. | 12-24-2015 |
| 20150367020 | Methods of treating amniotic membranes using supercritical fluids and compositions and apparatuses prepared therefrom - A method of sterilizing compositions prepared from amniotic membrane tissues may include harvesting placental tissue, separation of amniotic membrane tissue, and treatment of the amniotic membrane tissue with a supercritical fluid such as carbon dioxide. Treatment with supercritical fluid may subject the amniotic membrane tissue to conditions sufficient to sterilize the tissue yet maintain at least some biological function of the sterilized composition. The tissue preparations and compositions having a sterility assurance level of at least 10 | 12-24-2015 |
| 20150367027 | PHOTOCROSSLINKED HYALURONIC ACID DERIVATIVES, AND THE PREPARATION PROCESS AND USE THEREOF - Disclosed are photocrosslinked hyaluronic acid (HA) derivatives consisting of HA, a bifunctional polyethylene glycol (PEG) spacer which is triethylene glycol, and a photoreactive compound selected from a coumarin derivative and propiophenone. | 12-24-2015 |
| 20150367034 | CREATION OF THREE-DIMENSIONAL SYNTHETIC TISSUE FROM PLURIPOTENT STEM CELL-DERIVED CELLS, AND OSTEOCHONDRAL REGENERATION TREATMENT USING SAID SYNTHETIC TISSUE - Provided are an improved three-dimensional synthetic tissue, a composite tissue thereof, and a production method of the same. The present invention provides: an implantable synthetic tissue substantially made of a mesenchymal stem cell induced from a pluripotent stem cell or an equivalent cell thereof, and an extracellular matrix derived from the cell; a composite tissue for treating or preventing a disease, disorder, or condition associated with an osteochondral defect, comprising a synthetic tissue and an artificial bone, wherein the artificial bone is smaller in size than a depth of a defect of a bone section in the osteochondral defect; and a production method of the same. | 12-24-2015 |
| 20150368234 | AGONISTS THAT ENHANCED BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS - A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal. | 12-24-2015 |
| 20150368613 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF STEM CELLS - The present disclosure relates to methods for expansion of stem cell populations using a polypeptide that enhances stem cell growth and proliferation. The present disclosure further relates to novel homeobox protein mutants (e.g., HOXA9 and HOXB4 mutant proteins) and the use thereof to expand certain stem cell populations. The present disclosure also provides methods for treating a subject in need of transplantation of stem cells. | 12-24-2015 |
| 20150368618 | MODULATION OF CARDIAC STEM-PROGENITOR CELL DIFFERENTIATION, ASSAYS AND USES THEREOF - The present invention relates to endogenous cardiac stem-progenitor cells (eCSCs). Provided herein are c-kitpos CD166pos eCSCs that are negative for the hematopoietic marker, CD45 and the mast cell marker, Tryptase. These single cell derived eCSCs can differentiate into a variety of specific cell types corresponding to the derivatives of the three germ layers. Also provided herein is a stage-specific TGF-P-Family/Wnt-Inhibitor cocktail for modulating in vitro myogenic specification and maturation of c-kitpos eCSCs. Also provided herein are methods of modulating eCSCs clonal expansion and differentiation. Also provided herein are screening assays for small organic molecules that modulate early cardiomyogenic progenitor cells. The invention further relates to the use of these modulated cells in prophylactic and therapeutic methods, including in pharmaceutical compositions of such cells, growth factors and/or small organic compounds. Finally, the invention relates to the use of such differentiated cells in transplantation and medical treatments. | 12-24-2015 |
| 20150368667 | COMPOSITIONS AND METHODS FOR TREATING TYPE 1 AND TYPE 2 DIABETES AND RELATED DISORDERS - The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder. | 12-24-2015 |
| 20150374581 | USE OF AUTOLOGOUS SERUM FOR TRANSPORT OF ISOLATED STROMAL VASCULAR FRACTION OR ADIPOSE DERIVED STEM CELLS FOR REINJECTION - This invention is directed to devices and methods for use of an autologous serum for transport of isolated stromal vascular fraction or adipose derived stem cells for reinjection. | 12-31-2015 |
| 20150374694 | TGF-BETA ENHANCING COMPOSITIONS FOR CARTILAGE REPAIR AND METHODS RELATED THERETO - This disclosure relates to compounds and compositions for cartilage repair and methods related thereto. In certain embodiments, the disclosure relates to methods of inducing cartilage growth and regeneration comprising administering an effective amount of a composition comprising a compound disclosed herein to the subject or implanting a cartilage matrix comprising a compound disclosed herein in the subject. In certain embodiments, the compound is used locally such as injection at any desired site of cartilage formation. | 12-31-2015 |
| 20150374741 | METHODS FOR MAINTAINING POPULATION OF THERAPEUTIC CELLS IN TREATMENT SITE OF SUBJECT IN NEED OF CELL THERAPY - Disclosed herein are methods for maintaining a population of therapeutic cells administered to a treatment site in a subject in need of cell therapy for a period of time. The methods include administering a therapeutically-effective amount of therapeutic cells and an effective amount of a biodegradable material to the treatment site. The biodegradable material includes a hyaluronan compound and has an in vivo degradation profile similar to that of a hyaluronic acid having a molecular weight of 20 kDa to 2,000 kDa. | 12-31-2015 |
| 20150374755 | Treated Cells and Therapeutic Uses - This invention relates to the use of mesenchymal stem cells in therapy. In particular it relates to a method of preparing the cells with enhanced immunosuppressive property and for use in the treatment of diseases of the immune system. | 12-31-2015 |
| 20150374756 | ABCB5(+) STEM CELLS FOR TREATING OCULAR DISEASE - Various aspects and embodiments of the present invention are directed to methods of treating a subject having an ocular condition, methods of isolating ocular stem cells, methods of selecting and/or producing ocular grafts for transplantation, and methods of promoting ocular cell regeneration as well as to grafts and preparations containing isolated ocular stem cells characterized by the expression of ABCB5 on their cell surface. | 12-31-2015 |
| 20150374757 | COMPOSITIONS AND METHODS FOR TREATING AND REPAIRING TENDONS - The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment or prevention of the tendon injuries. | 12-31-2015 |
| 20150374799 | PROTEIN TO PROMOTE BLOOD VESSEL GROWTH AND USES THEREOF - A method for stimulating angiogenesis in a tissue of a mammal comprising contacting tissue with a protein substantially similar to pyruvate kinase M2. | 12-31-2015 |
| 20150376560 | TISSUE ENGINEERED CONSTRUCTS - A method of forming an implantable tissue engineered construct, a bioreactor for forming a tissue engineered construct, and a tissue engineered construct itself are disclosed The method includes seeding a scaffold with cells to form a tissue construct; locating the tissue construct in a space defined by a tissue construct support element; locating the tissue construct support element within a bioreactor; and operating a load applicator of the bioreactor to apply a cyclical compressive mechanical load to the tissue construct, to stimulate the deposition of tissue matrix in the tissue construct, in which the tissue construct, the tissue construct support element and the load applicator are arranged so that the load applicator can at least initially contact both the tissue construct and the tissue construct support element, so that at least part of a total load generated by the load applicator is borne by the tissue construct support element. | 12-31-2015 |
| 20150376571 | Lgr5+ SOMATIC STEM CELLS - Described is an isolated somatic stem cell that is 2 to less than 6 micrometer in size and Lgr5+. Methods of preparing and using the cell are also described. | 12-31-2015 |
| 20150376573 | AUTOLOGOUS AND ALLOGENIC ADIPOSE-DERIVED STROMAL STEM CELL COMPOSITION FOR TREATING FISTULAS - The present invention relates to a method for producing clinically effective quantities of human adipose tissue-derived stromal cells for treating fistulas and a composition made with the same. The method of the present invention can efficiently produce clinically effective number of adipose tissue-derived stromal cells within a short period by improving conventional standard culturing methods. The adipose stem cells composition containing the adipose tissue-derived stromal cells obtained by the method of the present invention exhibit superior multipotency and immunomodulatory activity over those of a cell composition produced by conventional methods, and thus is more suitable for treating fistulas. The cell composition of the present invention has excellent clinical usages especially since immune response is suppressed in allogenic adipose-derived stem cells. | 12-31-2015 |
| 20150376574 | PANCREATIC INSULIN-PRODUCING BETA-CELL LINES DERIVED FROM HUMAN PLURIPOTENT STEM CELLS - Production of beta-cells from stem cells from pluripotent stem cells have always been significantly lacking in at least one of the following properties: 1) functional properties related to insulin-production and glucose signaling response, 2) mature phenotype such as biochemical markers or cell structures, 3) efficiency in production of differentiated cells. Described herein is multistep differentiation protocol which substantially overcomes all of the existing limitations. Pluripotent stem cells, including induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) can be differentiated using an embryoid body (EB) formation step, followed by B maturation via endothelial cells (EC) co-culturing and incubation with a sequential series of bone morphogenic protein (BMP)-related growth factor cocktails. The resulting cells displayed functional properties, including insulin-production and glucose signaling response, and mature phenotype of C-peptide expression. | 12-31-2015 |
| 20150376586 | RNA Modification to Engineer Cas9 Activity - The disclosure provides for compositions, methods and kits, for reducing off-target effects of genome engineering. | 12-31-2015 |
| 20150376647 | DESIGNER PH SENSOR AS UNIVERSAL TRANSGENE CONTROLLER - The invention relates to vectors and mammalian cells in a system useful for switching on or switching off gene expression in response to pH and gaseous carbon dioxide, taking advantage of signal transduction of the human proton-activated cell-surface receptor TDAG8, OGR1 and/or GPR4 and related receptors to chimeric promoters containing cAMP-response elements. The systems according to the invention can be used to precisely monitor culture pH within the physiologic range, or also to adjust expression by gaseous C02 which shifts the C02-bicarbonate balance towards hydrogen ions. Production of biopharmaceuticals of engineered cells cultivated in a bioreactor setup can be induced by gaseous C02. Also, implanting engineered cells provide novel treatment strategies for acidosis-related disorders and type 1 diabetes. | 12-31-2015 |
| 20160000699 | HAIR GROWTH PROMOTING CAPACITY OF CONDITIONED MEDIA OF STIMULATED STEM CELLS AND USE THEREOF - Provided is an a composition for preventing hair-loss and promoting hair growth containing as an active ingredient conditioned media of stem cells stimulated by particular hair catagen inducers including TGF-β, a method of manufacturing the same, and a use thereof. In particular, the present invention relates to a use of the function of very effective hair growth by secreting Wnt3a, Bcl-2, CyclinD-1 and the like, which are known as signal transduction proteins. | 01-07-2016 |
| 20160000811 | TREATMENT OF GRAFT VERSUS HOST DISEASE IN TRANSPLANT PATIENTS - The present invention relates to a method of treating patients who undergo hematopoietic stem cell transplantation (HSCT) with peripheral blood mobilized stem cells for hematological malignancies and for whom the risk for severe acute graft versus host disease (GVHD) is considerable. | 01-07-2016 |
| 20160000830 | USE OF ALLOGENEIC INTERSTITIAL VESSEL-LAYER CELL AND ALLOGENEIC MESENCHYMAL PROGENITOR CELL FOR PREVENTING OR TREATING OSTEOARTHRITIS - Provided are uses of allogeneic interstitial vessel-layer cells and allogeneic mesenchymal progenitor cells in the preparation of a pharmaceutical composition for preventing or treating osteoarthritis (OA). Also provided is a pharmaceutical composition containing the allogeneic interstitial vessel-layer cells and the allogeneic mesenchymal progenitor cells. | 01-07-2016 |
| 20160000835 | HUMAN UTERINE CERVICAL STEM CELL POPULATION AND USES THEREOF - The present invention relates to a method for isolating stem cells comprising preparing a cell suspension from uterine cervix tissue, to the stem cells isolated by said method, and to the conditioned medium obtained from the culture of said stem cells. The invention also encompasses the use of said stem cells or conditioned medium for treating or preventing cancer, precancerous lesions, inflammatory diseases, autoimmune diseases, chronic pathologies or infectious diseases, diseases associated to tissue loss, or for use in diagnostic, prognostic or treatment of fertility disorders, as well as for cosmetic treatment. | 01-07-2016 |
| 20160000836 | PREPARING TOOTH-LIKE STRUCTURE USING STEM CELL - The usage of a stem cell in preparation of a tooth-like structure is provided. And a culture medium, a method for preparing an epithelial-like cell, a kit for preparing an ameloblast, a method for preparing an ameloblast are also provided. Specifically, the culture medium comprises a basal medium, which is DMEM/F 12 medium; N2 supplement; retinoic acid; and BMP-4. | 01-07-2016 |
| 20160002595 | METHODS FOR GENERATING HEPATOCYTES AND CHOLANGIOCYTES FROM PLURIPOTENT STEM CELLS - Methods for producing hepatocyte and/or cholangiocyte lineage cells from pluripotent stem cells, the method comprising (a) specifying the extended nodal agonist treated induced endodermal cell population to obtain a cell population comprising hepatocyte and/or cholangiocyte progenitors by contacting the extended nodal agonist treated induced endodermal cell population with specification media comprising a FGF agonist and a BMP4 agonist and/or active conjugates and/or fragments thereof; (b) inducing maturation, and optionally further lineage specification and/or expansion of the hepatocyte and/or cholangiocyte progenitors of the cell population to obtain a population comprising hepatocyte lineage cells such as hepatoblasts, hepatocytes and/or cholangiocytes, the inducing maturation step comprising generating aggregates of the cell population. Optionally, the method also comprises activating the cAMP pathway within the aggregates and forming co-aggregates. | 01-07-2016 |
| 20160002597 | METHOD OF PRODUCING MICROPARTICLES - The invention is based on the finding that microparticles can be produced by conditionally-immortalised cells. The conditionally-immortalised cells may be stem cells. The Examples show the successful harvest of microparticles from conditionally immortalised neural stem cells and CD34+ cells. Conditional immortalisation provides a constant supply of clonal cells that produce microparticles such as exosomes. The conditionally immortalised cells are useful as “producer cells” for microparticles such as exosomes, which are typically harvested or isolated from the conditionally-immortalised cells. | 01-07-2016 |
| 20160002627 | COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT - Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. | 01-07-2016 |
| 20160008342 | METHODS OF IMPROVING CELL-BASED THERAPY | 01-14-2016 |
| 20160008400 | METHODS OF PRODUCING ENRICHED POPULATIONS OF TUMOR REACTIVE T CELLS FROM PERIPHERAL BLOOD | 01-14-2016 |
| 20160008401 | PROTECTION OF THE VASCULAR ENDOTHELIUM FROM IMMUNOLOGICALLY MEDIATED CYTOTOXIC REACTIONS WITH HUMAN CD34-NEGATIVE PROGENITOR CELLS | 01-14-2016 |
| 20160008402 | ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE | 01-14-2016 |
| 20160008403 | Transplantation of Neural Cells | 01-14-2016 |
| 20160008405 | METHOD OF TREATMENT FOR PULPITIS AND/OR ENHANCEMENT FOR DENTINOGENESIS | 01-14-2016 |
| 20160008407 | TISSUE PROCESSING APPARATUS WITH FLUID SUCTION FEATURES AND METHODS RELATING TO COLLECTING AND PROCESSING HUMAN BIOLOGICAL MATERIAL | 01-14-2016 |
| 20160008409 | SUPERCRITICAL CARBON DIOXIDE TISSUE PROCESSING METHODS | 01-14-2016 |
| 20160008428 | COMPOSITIONS AND METHODS FOR ENHANCING CARDIAC FUNCTION | 01-14-2016 |
| 20160008433 | PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE | 01-14-2016 |
| 20160008435 | COMPOSITION FOR PREVENTING OR TREATING B-CELL LYMPHOMA COMPRISING IL-21 EXPRESSING MESENCHYMAL STEM CELLS | 01-14-2016 |
| 20160008475 | COACERVATE MICRO AND/OR NANO DROPLETS AND HYDROGELS | 01-14-2016 |
| 20160008511 | Flowable Matrix Compositions and Methods | 01-14-2016 |
| 20160009781 | ANTIGEN-SPECIFIC HELPER T-CELL RECEPTOR GENES | 01-14-2016 |
| 20160015756 | CELL THERAPY: A METHOD AND A COMPOSITION FOR TREATING DIABETES - A method of increasing beta-islet cells from pancreases of rabbits and a composition for transplantation of beta-islet cells isolated and cultured from rabbit pancreases to promote natural insulin production among diabetic patients. | 01-21-2016 |
| 20160017285 | NEURAL PROGENITOR CELL DIFFERENTIATION - Differentiation and stability of neural stem cells can be enhanced by in vitro or in vivo culturing with one or more extracellular matrix (ECM) compositions, such as collagen I, IV, laminin and/or a heparan sulfate proteoglycan. In one aspect of the invention, adult mammalian enteric neuronal progenitor cells can be induced to differentiate on various substrates derived from components or combinations of neural ECM compositions. Collagen I and IV supported neuronal differentiation and extensive glial differentiation individually and in combination. Addition of laminin or heparan sulfate to collagen substrates unexpectedly improved neuronal differentiation, increasing neuron number, branching of neuronal processes, and initiation of neuronal network formation. In another aspect, neuronal subtype differentiation was affected by varying ECM compositions in hydrogels overlaid on intestinal smooth muscle sheets. The matrix compositions of the present invention can be used to tissue engineer transplantable innervated GI smooth muscle constructs to remedy aganglionic disorders. | 01-21-2016 |
| 20160017289 | TGIF2-INDUCED REPROGRAMMING OF HEPATIC CELLS TO PANCREATIC PROGENITOR CELLS AND MEDICAL USES THEREOF - Disclosed are genetically modified human pancreatic progenitor cells, comprising an exogenous nucleic acid molecule encoding TGIF2, for use as a medicament in the treatment of a subject with diabetes, in addition to methods for the production of said cells. Also disclosed is an expression vector encoding TGIF2 for use as a medicament in the treatment of a subject with diabetes. | 01-21-2016 |
| 20160022738 | METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY - A method of cell expansion is provided. The method comprising culturing adherent cells from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion. | 01-28-2016 |
| 20160022739 | CLOSED SYSTEM SEPARATION OF ADHERENT BONE MARROW STEM CELLS FOR REGENERATIVE MEDICINE APPLICATIONS - A method for isolating and processing bone marrow derived stem cells, including the steps of: (a) collecting a biological sample containing adherent bone marrow stem cells in a receptacle with interior walls coated with a cell-adherent substrate; (b) incubating the bone marrow cells on the adherent substrate so that a layer of adherent bone marrow stem cells adheres to the substrate; (c) washing any non-adherent cells from the substrate; and (d) collecting the bone marrow stem cell layer. Isolation kits and use of bone marrow cells harvested for cell therapies are also described. | 01-28-2016 |
| 20160022743 | HUMAN VERY SMALL EMBRYONIC-LIKE (VSEL) STEM CELLS FOR TREATMENT OF OCULAR DISEASE - The present invention relates to use of very small embryonic-like (VSEL) stem cells in therapies for ocular disease involving retinal degeneration or dysfunction. The invention also included pharmaceutical compositions made with VSELs which may be used to restore lost vision or reduce or halt vision loss due to diseases or disorders of the retina, or other diseases or retinal injuries that would benefit from stem cell replacement therapy. | 01-28-2016 |
| 20160022744 | Method Of Using Mitotically Inactivated Stem Cells For Damaged Tissue Repair - The present invention is directed to the use of mitotically and/or lethally inactivated stem cells for the repair of damaged organs and/or tissues. Stem cells are mitotically and/or lethally inactivated and transplanted into damaged tissue. Any form of ex vivo inactivation of stem cells may be used such that the stem cells cannot undergo mitosis or cell division before in vivo application. Mitotically and/or lethally inactivated stem may be used to ameliorate numerous disease, injury, traumatic, ischemic, aging, and/or degenerative conditions in different types of organs and/or tissues. | 01-28-2016 |
| 20160024170 | METHODS OF PROMOTING CARDIAC REPAIR USING GROWTH FACTORS FUSED TO HEPARIN BINDING SEQUENCES - The present invention is directed to proteins in which a heparin binding peptide is fused to a growth factor that promotes cell growth and survival. The compound thus formed is bound to the surface of cells which are then administered to damaged tissue. The growth factor is thereby maintained at the site of administration where it promotes repair. | 01-28-2016 |
| 20160024468 | SOMATIC STEM CELLS - A somatic stem cell that is CD10+, CXCR4+, and CD31+ and another somatic stem cell that is CD105+, CD44+, and nestin+. Also disclosed are both a method of preparing these stem cells and a method of using them to treat degenerative diseases, e.g., a muscle-degenerative disease. The invention further includes making and using liver cells derived from the somatic cell that is CD105+, CD44+, and nestin+. | 01-28-2016 |
| 20160030365 | PHARMACEUTICAL OR COSMETIC COMPOSITION SUITABLE TO PRESERVE EPITHELIAL STEM CELLS - The invention concerns the use of compounds of formula (I) R-N | 02-04-2016 |
| 20160030390 | METHODS OF TREATING MUSCULAR DYSTROPHY - Disclosed herein are α7β1 integrin modulatory agents and methods of using such to treat conditions associated with decreased α7β1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an α7β1 integrin modulatory agent to the subject with muscular dystrophy, wherein the α7β1 integrin modulatory agent increases α7β1 integrin expression or activity as compared to α7β1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing α7β1 integrin expression by use of the disclosed α7β1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed. | 02-04-2016 |
| 20160030445 | METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS - In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof; and agents that inhibit the expression of p27 | 02-04-2016 |
| 20160030478 | MATERIALS AND METHODS TO ENHANCE HEMATOPOIETIC STEM CELLS ENGRAFTMENT PROCEDURES - This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE | 02-04-2016 |
| 20160030480 | Cellular Therapy for Ocular Degeneration - Compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders comprising mesenchymal stem cells, particularly those characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45. | 02-04-2016 |
| 20160030481 | IL-18 INHIBITION FOR PROMOTION OF EARLY HEMATOPOIETIC PROGENITOR EXPANSION - Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of IL-18 to a recipient subject and also administering hematopoietic stem/progenitor cells to the subject. Another method involves administering an inhibitor of IL-18 to a donor prior to harvest of hematopoietic stem/progenitor cells. Pharmaceutical compositions relating to the methods are also described. | 02-04-2016 |
| 20160030482 | COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS - The invention encompasses compositions and method of treating a vascular disease such as peripheral artery disease, The methods involve—administering to a patient in need thereof, an effective amount of a composition comprising a population of cells such as mesenchymal stem cells (MSCs) and a non-muscle myosin 0 antagonist such as blebbistatin. Non-muscle myosin II antagonists are disclosed to surprisingly and dramatically accelerate MSC-triggered regeneration of damaged tissues arid unexpectedly and drastically reduce severe complications of stem cell treatment. | 02-04-2016 |
| 20160030485 | ADULT CARDIAC STEM CELL POPULATION - The present invention relates to the identification, isolation, expansion and characterization of a specific type of multipotent adult cardiac stem cell. These adult stem cells are characterised in that they naturally express a specific pattern of markers, which can be used to assist with their isolation and expansion. In particular, the cells express SOX17 and GATA4, but do not express Oct4, Nanog, c-kit and telomerase reverse transcriptase. These cells are able to differentiate into one or more of the following cell types: adipocytes, osteocytes, endothelial cells and/or smooth muscle cells. They also display an unprecedented capacity for immunoregulation as well as providing, activating and/or inducing repair of damaged cardiac tissue. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium. | 02-04-2016 |
| 20160030486 | PREPARATION OF COMPOSITIONS TO TREAT AND TREATMENT OF OSTEOARTHRITIS USING ADIPOSE-DERIVED STROMAL VASCULAR FRACTION CELLS - A method for preparing a treatment composition for treatment of osteoarthritis including un-cultured stromal vascular fraction cells from adipose tissue includes direct aspiration of material of a centrifugally-formed pellet phase including stromal vascular fraction cells from enzymatically-digested adipose tissue from an internal containment volume of a portable apparatus through an aspiration tube inserted into the pellet phase and into a fluid receptacle located outside of the internal containment volume. The treatment composition may be administered into or in the vicinity of a patient's joint to be treated for osteoarthritis. | 02-04-2016 |
| 20160030488 | USE OF PLACENTAL STEM CELLS IN TREATMENT OF ACUTE KIDNEY INJURY - Provided herein are methods of using human placental stem cells in the treatment of subjects having acute kidney injury (AKI). | 02-04-2016 |
| 20160030489 | METHODS AND APPARATUSES FOR AMNIOTIC FLUID COLLECTION AND ISOLATION OF CELLS - Disclosed herein are methods and apparatuses for the safe, high-yield collection of sterile amniotic fluid. The apparatus are configured to allow sufficient flexibility for the device to gain access to all areas of the amniotic cavity, to allow sufficient stiffness for the amniotic fluid collection device to puncture the amniotic and chorionic membranes, yet allow sufficient suppleness to pose no significant risk of maternal or fetal harm. Further disclosed are cells isolated from the full-term amniotic fluid, and methods for using, reprogramming, and differentiating these cells. | 02-04-2016 |
| 20160030490 | PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS - Methods are provided for the production of photoreceptor cells and photoreceptor progenitor cells from pluripotent stem cells. Additionally provided are compositions of photoreceptor cells and photoreceptor cells, as well as methods for the therapeutic use thereof. Exemplary methods may produce substantially pure cultures of photoreceptor cells and/or photoreceptor cells. | 02-04-2016 |
| 20160030635 | IMPROVED METHOD OF MAKING EXTRACELLULAR MATRIX COMPOSITIONS - Provided herein are methods of producing extracellular matrix (ECM) that are superior to previously-described methods. Extracellular matrix (ECM) comprises protein that forms many structures in the body including tendons, ligaments, and sheets that support skin and internal organs. There remains a need in the art for ECM compositions that have improved cell attachment characteristics and methods of making such ECM compositions. | 02-04-2016 |
| 20160030638 | USE OF PERFUSION DECELLULARIZED LIVER FOR ISLET CELL RECELLULARIZATION - The invention provides a method for preparing a perfusion based islet cell containing extracellular matrix of liver, an islet cell recellularized extracellular matrix, and methods of using the recellularized matrix. | 02-04-2016 |
| 20160032241 | PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD - Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC−/− progenitor cells, and is useful to grow and repair human tissues including bone. | 02-04-2016 |
| 20160038542 | TREATMENT OF INSULIN RESISTANCE AND DIABETES - Disclosed are methods, compositions, and cells useful for increasing insulin sensitivity, as well as lack of insulin production in a host in need thereof. One aspect of the invention discloses methods of increasing skeletal muscle perfusion through administration of cells capable of directly and/or indirectly stimulatory of angiogenesis and/or vascular responsiveness. Another aspect provides means of increasing sensitivity to insulin through administration of a cell composition capable of integrating into host insulin responsive tissue and upregulating responsiveness either through mobilization of host cells capable of responding to insulin, mobilization of host cells capable of endowing insulin responsiveness on other host cells, exogenously administered cells taking the role of insulin responsiveness, or exogenously administered cells endowing insulin responsiveness on other host cells. Another aspect comprises modifying said host to allow for concurrent insulin sensitization and upregulated production of insulin. | 02-11-2016 |
| 20160038544 | METHODS AND COMPOSITIONS FOR GENERATING CHONDROCYTE LINEAGE CELLS AND/OR CARTILAGE LIKE TISSUE - A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising: a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR-primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising: i. a FGF agonist; ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939; to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta; b. generating a chondrocyte precursor population comprising: i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media; ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and c. either i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue. | 02-11-2016 |
| 20160038545 | A METHOD OF ISOLATING CELLS FOR THERAPY AND PROPHYLAXIS - Disclosed are methods for isolating endothelial progenitor cells (EPC). More particularly, the present invention discloses methods for isolating endothelial progenitor cells that exhibit self-renewal and differentiation capacity. The isolated cellular population of the present invention is useful in a wide range of clinical and research setting including inter alia, the in vitro or in vivo generation of endothelial cells and the therapeutic or prophylactic treatment of a range of conditions via the administration of these cells. Also facilitated is the isolation of endothelial progenitor cells for research purposes such as in vitro based screening systems for testing the therapeutic impact and/or toxicity of potential treatment or culture regimes to which these cells may be exposed to. The present invention also discloses methods for isolating mesenchymal stem cells, in particular mesenchymal stem cells of fetal and/or maternal origin. These cells are also useful in a range of in vitro and in vivo therapeutic, prophylactic and research applications. | 02-11-2016 |
| 20160040131 | Method for Treating Diabetes and Other Glucose Regulation Disorders Using Stem Cells - Various embodiments of the invention provide methods of treating diabetes and other glucose regulation disorders. In one embodiment, the method comprises removing L-cells from a donor, obtaining stem cells from a patient, and culturing the L-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived L-cells (SCDLC). An amount of the SCDLC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. In another embodiment, the method comprises removing K-cells from a donor, obtaining stem cells from a patient, and culturing the K-cells in the presence of the stem cells under conditions such that the stem cells differentiate into stem cell-derived K-cells (SCDKC). An amount of the SCDKC is introduced into the patient sufficient to cause a lowering of the patient's blood glucose level after ingestion of food. | 02-11-2016 |
| 20160045548 | METHOD FOR TREATING CANCERS WITH DENDRITIC KILLER CELLS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is IL-15. Meanwhile a pharmaceutical composition comprises the above dendritic killer cell population for treating cancers is also disclosed in the present invention. | 02-18-2016 |
| 20160045552 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY BOWEL DISEASE WITHOUT COLECTOMY - Methods and compositions for treating diseased or damaged tissue, such as Inflammatory Bowel Disease, e.g., Ulcerative Colitis, include tissue regeneration using stem cells or tissue grafts which stimulate stem cell migration to the damaged tissue. The tissue grafts can be extracellular matrix (ECM) material, such as tissue-specific extracellular matrix (TS-ECM). The methods can also include mucosal resection of the damaged or diseased tissue prior to placement of the graft. | 02-18-2016 |
| 20160045554 | METHOD FOR GENERATING MATURE BETA-LIKE CELLS - The present invention relates to methods for generating mature insulin-producing β-like cells comprising the steps: (a) isolating, purifying and/or enriching β-cell progenitor cells from a population of cells; (b) differentiation of the β-cell progenitor cells into immature insulin-producing β-like cells; and (c) maturation of the immature insulin-producing β-like cells into mature insulin-producing β-like cells, comprising exposing the immature insulin-producing β-like cells to calcitriol or an analogue thereof. More particularly, the present invention relates to methods for generating mature insulin-producing β-like cells for use in treating diabetes. | 02-18-2016 |
| 20160045555 | Compositions and Methods for Improving the Functional Efficacy of Stem Cell-Derived Cardiomyocytes - An isolated stem cell that has been modified to provide, enhance orcontain the functional characteristics of the sarcoplasmic reticulum (SR). The isolated stem cells are modified in one or more of the following manners: by expressing a calcium channel protein; by expressing a calcium pump protein such as the sarcro/endoplasmic reticulum Ca | 02-18-2016 |
| 20160046078 | METHODS AND APPARATUS FOR COMPUTER-AIDED TISSUE ENGINEERING FOR MODELING, DESIGN AND FREEFORM FABRICATION OF TISSUE SCAFFOLDS, CONSTRUCTS, AND DEVICES - One aspect of the invention provides a method for multi-nozzle biopolymer deposition of heterogeneous materials to create or modify a composite biopolymer multi-part three-dimensional assembly having at least one biomimetic and at least one non-biomimetic feature. The method includes: (a) utilizing a CAD environment to design and/or modify a composite multi-part assembly, thereby producing a CAD design; (b) converting the CAD design into a three-dimensional heterogeneous material and multi-part assembly model in a format suitable for three-dimensional, multi-nozzle printing, wherein the design comprises at least one biomimetic feature and at least one non-biomimetic feature; and (c) printing the composite assembly by simultaneously depositing the heterogeneous materials using multiple, different, specialized nozzles, wherein the simultaneous depositing includes direct deposition of cells. | 02-18-2016 |
| 20160046608 | C-Linked Heterocycloaklyl Substituted Pyrimidines and their uses - The present invention provides for pyrimidine compounds of Formula I-I and embodiments thereof | 02-18-2016 |
| 20160046703 | MONOSPECIFIC POLYPEPTIDE REAGENTS - The present invention relates to a novel antigen-binding protein construct or “modubody”, which contains at least three functional single domain modules of an antibody. The modubodies contain a domain from the heavy chain variable region of an antibody (VH), a domain from the light chain variable region of an antibody (VL) and bind monospecifically to an antigen. The modubodies further contain a domain from the constant region of antibodies. The modubodies can be used for diagnostic or therapeutic purposes. | 02-18-2016 |
| 20160046903 | METHOD FOR PREPARING CHONDROCYTES - The present invention provides a method for preparing chondrocytes which enable construction of a cartilage tissue, the method being capable of solving the problems with conventional methods. | 02-18-2016 |
| 20160051588 | METHOD OF USING STEM CELLS AND NANOWHISKERS - The present invention relates to methods of improving stem cell delivery to a subject in need thereof and kits designed to assist in such. The methods comprise interchangeably allowing or promoting cell growth in conditions that permit three-dimensional growth, such as with a bioreactor and/or through the introduction of nanofibers to cells in suspension, utilizing allogeneic cells that are mixed with platelet rich plasma that is autologous to the subject, and site specific delivery of between 5 and 15 million stem cells at the site or of about 3-10 million stem cells per kilogram of the subject receiving the treatment. | 02-25-2016 |
| 20160051590 | COMPOSITIONS AND METHODS FOR TREATMENT OF VESSEL DISEASE - The present disclosure relates to compositions and methods for the treatment of blood vessel disease. More specifically, the compositions and methods of the present disclosure make use of a population of stromal vascular fraction cells. In some embodiments, the population of stromal vascular fraction cells comprises at least one macrophage. | 02-25-2016 |
| 20160051642 | TREATMENT OF PEYRONIE'S DISEASE - The invention relates to systems and therapeutic methods to reduce plaque causing Peyronie's disease. One approach uses high pressure injection of collagenase-containing composition into a penile plaque. Plaque disruption is enhanced by the mechanical force of the high pressure, followed by the enzymatic action of collagenase. Another approach uses collagenase as a pretreatment, followed by addition of adipose-derived stem cells ADSCs. The initial collagenase injection breaks down collagen (often more type III than type I in Peyronie's) to provide short term benefit. The longer-term benefit is provided by introduction of ADSCs to the plaque, which can produce cytokines and other signals for revascularization, and restoration of normal penile tissue. The resulting combination advantageously reduces the bulk of the plaque early on with ongoing reduction through the revascularization of the tissue. In addition, the treatment provides an advantageous shift of elastin and collagen ratios. | 02-25-2016 |
| 20160051722 | Mesenchymal Stem Cell-Hydrogel-Biodegradable or Mesenchymal Stem Cell-Hydrogel-Undegradable Support Composition for Skin Regeneration or Wound Healing - The present invention relates to a composition comprising mesenchymal stem cell-hydrogel-biodegradable support or mesenchymal stem cell-hydrogel-undegradable support, a sheet comprising the composition and a method for the preparation thereof. By using the sheet comprising the adipose-derived mesenchymal stem cell-hydrogel biodegradable or undegradable support, stem cells of high activity may be applied directly to the wound without isolation process using protease. The sheet has extracellular matrices such as collagen, laminin, fibronectin and elastin secreted by stem cells in the culture stage and included completely in the hydrogel, and therefore it has superior skin regeneration and wound healing effects compared with conventional pharmaceutical preparations and shortens therapeutic period. | 02-25-2016 |
| 20160051729 | Reparative Cell Isolation and Delviery - Methods are described for generating autologous tissue grafts, including generating grafts at the point of care, which include isolated cell populations that are enriched with stem cells and are mixed with biological fillers including hyaluronic acid and derivatives thereof. The hyaluronic acid localizes the cells to a desired injection site and stimulates collagen production thus enhancing the viability and the longevity of the graft. | 02-25-2016 |
| 20160051731 | HYBRID GEL COMPRISING PARTICULATE DECELLULARIZED TISSUE - A hybrid gel comprising a particulate decellularized tissue (obtained by pulverizing animal-derived biological tissues that are decellularized (decellularized biological tissues)), fibrinogen and thrombin; a cell culture material comprising the hybrid gel; a method for preparing the hybrid gel; and a kit comprising a particulate decellularized tissue and a biological tissue adhesive are provided. The hybrid gel of the present invention exerts the effect to promote differentiation and gain of function of stem cells and the therapeutic effect to a variety of diseases. | 02-25-2016 |
| 20160053226 | Method and Medium for Amplifying Neural Precursor Cells - The present invention relates to a method for amplifying a population of neural precursors comprising the step of culturing neural precursors in the presence of a PKA inhibitor. | 02-25-2016 |
| 20160053229 | USE OF JAGGED 1/FRIZZLED 4 AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS - The present invention provides Jagged 1 and Frizzled 4 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ Jagged 1+ ventricular progenitor cells and/or Islet 1+/Frizzled 4+ ventricular progenitor cells and/or Islet 1+/Jagged 1+/Frizzled 4+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated Jagged 1+ and/or Frizzled 4+ventricular progenitor cells are also provided. Methods of in vivo use of Jagged 1+ and/or Frizzled 4+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the Jagged 1+ and/or Frizzled 4+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided. | 02-25-2016 |
| 20160058695 | Topical Composition and Method for Skin Rejuvenation - A skin rejuvenation process combining skin resurfacing with post-procedure application of a composition including the patient's own mesenchymal hematopoietic stern cells and growth factors is described. The stem cells and growth factors are isolated from lipoaspirate or bone marrow. In certain embodiments, the skin may be resurfaced by chemical, light or mechanical means to remove the main diffusion barrier, the stratum corneum. In additional embodiments, the stem cells and growth factors are minimally processed and applied to the skin in the form of a topical serum, cream, emollient or lotion. | 03-03-2016 |
| 20160058794 | LYMPH NODE AS A SITE FOR TRANSPLANTATION, ORGANOGENESIS AND FUNCTION FOR MULTIPLE TISSUES AND ORGANS - The present invention relates to methods and compositions for transplanting non-lymphoid tissues into lymphoid organs. It may be used to cultivate organ tissues including for the purpose of supplementing or reconstituting organ function. Tissues that may be propagated in this manner include but are not limited to lung, kidney, thyroid, intestine, and brain. | 03-03-2016 |
| 20160058796 | RETINA EXTRACELLULAR MATRIX BASED BIOMATERIAL - The present technology relates to compositions and methods useful for preventing and treating degenerative eye diseases or disorders. The compositions and methods include ocular biomaterials. In some embodiments, the ocular biomaterial compositions include retinal biomaterial, interphotoreceptor matrix biomaterial or a combination thereof. In some embodiments, the ocular biomaterial compositions are formed into films, gels, scaffolds and matrices for cell delivery. | 03-03-2016 |
| 20160058797 | PHARMACEUTICAL COMPOSITION AND METHOD FOR REGENERATING MYOFIBERS IN THE TREATMENT OF MUSCLE INJURIES - A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages or injuries caused by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order. | 03-03-2016 |
| 20160058798 | METHOD OF TREATING PANCREATIC AND LIVER CONDITIONS BY ENDOSCOPIC-MEDIATED (OR LAPAROSCOPIC-MEDIATED) TRANSPLANTATION OF STEM CELLS INTO/ONTO BILE DUCT WALLS OF PARTICULAR REGIONS OF THE BILIARY TREE - A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted. The cells are specifically introduced to the hepato-pancreatic common duct of the subject for treatment of pancreatic conditions or to the bile duct wall near to the liver for treatment of liver conditions and allowed to migrate to the pancreas or to the liver and expand and then rebuild part or the entirety of the diseased or dysfunctional organ. | 03-03-2016 |
| 20160058799 | ADHERENT CELLS FROM PLACENTA AND USE OF SAME IN DISEASE TREATMENT - Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta. | 03-03-2016 |
| 20160058912 | SCAFFOLDS FOR PROMOTING CALCIFIED CARTILAGE AND/OR BONE FORMATION - Biomimetic hydrogel and selected ceramic interface scaffolds useful in regenerating calcified cartilage and promoting stable and integrative cartilage repair are provided. An aspect of this application relates to scaffolds for promoting calcified cartilage and/or bone formation. The scaffolds of this application comprise a biomimetic hydrogel and a ceramic structure or mineral source selected to modulate biosynthesis and mineralization of chondrocytes. | 03-03-2016 |
| 20160067213 | Combination Treatment of Cardiovascular Disease - Disclosed are methods, compositions of matter and cells for treatment of cardiovascular disease through concurrent inhibition of oxidative stress while administration of a cell therapy. The invention also concerts the modulation of oxidative stress for preferential induction of differentiation while concurrently inhibiting inflammatory processes that decrease efficacy of cellular therapy. | 03-10-2016 |
| 20160067282 | Glycosaminoglycan Compositions in Combination with Stem Cells - A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided. | 03-10-2016 |
| 20160067284 | METHOD FOR PRODUCING SHEET-SHAPED CELL CULTURE - A sheet-shaped cell culture and method for producing a sheet-shaped cell culture are disclosed having a high activity such as high cytokine productivity and a production method thereof. The method for producing a sheet-shaped cell culture can include freezing cells, thawing the frozen cells and forming a sheet-shaped cell culture. A sheet-shaped cell culture which is produced by the production method and which has a high activity and a method for treating a disease associated with an abnormality of a tissue with the sheet-shaped cell culture. | 03-10-2016 |
| 20160067377 | Stem Cell Seeded Natural Substrates and Methods Relating Thereto - This disclosure provides compositions for treating tissue injuries comprising a tissue-derived substrate and mesenchymal stem cells adhered thereto, as well as methods of making and using such compositions. The tissue-derived substrates include bone, cartilage, and collagen matrix. | 03-10-2016 |
| 20160067378 | DECELLULARIZATION AND RECELLULARIZATION OF WHOLE ORGANS - The present invention provides systems and methods for the decellularization and recellularization of tissue segments. In certain instances the invention comprises coating or sealing decellularized tissue segments with a cross-linked alginate hydrogel. The present invention also provides a decellularization kit, which may be used to generate decellularized tissue segments for high throughput studies. Also included are compositions and methods of tissue sealants comprising methacrylated alginate. | 03-10-2016 |
| 20160068813 | DIFFERENTIATION OF ADIPOSE STROMAL CELLS INTO OSTEOBLASTS AND USES THEREOF - The invention provides methods and compositions for differentiating stromal cells from adipose tissue into cells having osteoblastic properties, and methods for improving a subject's bone structure. The methods comprise culturing stromal cells from adipose tissue in β-glycerophosphate and ascorbic acid and/or ascorbate-2-phosphate for a time sufficient to allow differentiation of said cells into osteoblasts. Such methods and compositions are useful in the production of osteoblasts for autologous transplantation into bone at a surgical site or injury. The compositions comprise adipose stromal cells, a medium capable of supporting the growth of fibroblasts and amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2-phosphate sufficient to induce the differentiation of said stromal cells into osteoblasts. | 03-10-2016 |
| 20160074437 | IMMUNOLOGICAL TREATMENT OF LIVER FAILURE - Disclosed are means of treatment of liver failure and augmentation of liver regeneration by utilization of immune modulation through administration of immunocytes and mesenchymal stem cells. In one embodiment liver failure is treated by cord blood mononuclear cells administered allogeneic to the host that have been pretreated with hepatogenic cytokines. | 03-17-2016 |
| 20160074439 | TREATMENT OF PAIN USING PLACENTAL STEM CELLS - Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™). | 03-17-2016 |
| 20160074461 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT - The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α | 03-17-2016 |
| 20160075754 | CHIMERIC POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME - A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: | 03-17-2016 |
| 20160075994 | DIFFERNTIATION METHOD FOR PRODUCTION OF GLIAL CELL POPULATION - The present invention provides methods for generating oligodendrocyte progenitor cells from pluripotent cells, as well as methods for sustaining these oligodendrocyte progenitor cells in relatively pure cultures for long periods of time. The present invention also provides methods for further differentiating these oligodendrocyte progenitor cells into various glial cells. | 03-17-2016 |
| 20160075995 | SWEAT GLAND-DERIVED STEM CELLS AND METHODS OF USE - Provided herein is a method to isolate a sweat gland stem cell and novel compositions containing the cell. Also provided are compositions and methods to clonally expand the population and differentiate the cells into various phenotypes. Therapeutic methods for the compositions are further provided. | 03-17-2016 |
| 20160075999 | METHOD FOR ENHANCING THERAPEUTIC EFFECT OF STEM CELLS ON AUTOIMMUNE DISEASES, CARDIOVASCULAR DISEASES, AND/OR HEMATOLOGICAL DISEASES - A method for enhancing the therapeutic effect of a stem cell on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises treating the stem cell with ligustilide, wherein the treatment is conducted in a culture medium of the stem cell. A method of stem cell treatment is also provided, comprising administering to a subject suffering from autoimmune diseases, cardiovascular diseases, and/or hematological diseases an effective amount of a stem cell or a combination of ligustilide and a stem cell, wherein the stem cell has been treated with ligustilide. | 03-17-2016 |
| 20160076001 | CHEMICALLY TREATED INDUCED PLURIPOTENT STEM CELLS FOR SAFE THERAPEUTIC APPLICATIONS - This disclosure provides a chemically modified induced pluripotent stem (iPS) cells characterized by DNA hypomethylation and methods for generating the cells. The cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue in a patient in need thereof and to treat cardiac disease. | 03-17-2016 |
| 20160082049 | METHODS, SYSTEMS, AND COMPOSITIONS RELATING TO TREATMENT OF NEUROLOGICAL CONDITIONS, DISEASES, AND INJURIES AND COMPLICATIONS FROM DIABETES - Some embodiments comprise methods, systems, and/or compositions comprising the production and/or use of one or agents selected from a group comprising microRNA-126, a promoter of microRNA-126 expression, a microRNA-126 mimic, cells such as human umbilical cord blood cells (“HUCBCs”), endothelial cells (“EC”), endothelial progenitor cells (“EPC”), and microRNA-126-enriched Exosomes/Microvesicles (“EMVs”) to promote, increase, or improve recovery from conditions, diseases, or injuries and/or function or outcome in a patient in need thereof. | 03-24-2016 |
| 20160082157 | METHODS, SUBSTRATES, AND SYSTEMS USEFUL FOR CELL SEEDING OF MEDICAL GRAFTS - Described are methods, cell growth substrates, and devices that are useful in preparing cell-containing graft materials for administration to patients. Tubular passages can be defined in cell growth substrates to promote distribution of cells into the substrates. Also described are methods and devices for preparing cell-seeded graft compositions, methods and devices for preconditioning cell growth substrates prior to application of cells, and cell seeded grafts having novel substrates, and uses thereof. | 03-24-2016 |
| 20160083793 | RADIATION BIODOSIMETRY SYSTEMS - Disclosed herein are compositions and methods for accurately estimating the absorbed dose of radiation indicated by a subject based on the expression pattern of a panel of radiation-modulated (RM) genes at various time points following exposure of the subject to ionizing radiation. | 03-24-2016 |
| 20160084782 | METHODS AND SYSTEMS OF DETECTING EXOCYTOSIS OF A TARGET MOLECULE FROM A POPULATION OF CELLS - Embodiments of various aspects described herein relate to methods and systems for detecting exocytosis or endocytosis of a target molecule from or into a population of cells, in part based on impedance analysis of the population of cells after they are exposed to an alternating current applied at two or more frequencies or to a repetitive voltage waveform. In some embodiments, the methods and systems described herein can be used for assessing viability and/or potency of the population of cells, and/or identifying a secretagogue for the target molecule released from the population of cells. | 03-24-2016 |
| 20160089344 | NANOPARTICLE TARGETED DRUG DELIVERY TO THE LUNGS USING EXTRA-TESTICULAR SERTOLI CELLS - A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the injected nanoparticle load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection. | 03-31-2016 |
| 20160089401 | USES OF TREHALOSE IN CELL SUSPENSIONS - Disclosed are cellular compositions and methods relating to the use of aqueous trehalose media to suspend cells. A trehalose-containing medium can be used to inhibit cellular clumping, for example upon dilution of more concentrated cellular preparations into the trehalose-containing medium. In certain embodiments cells, after cryopreservation and thawing, are combined with a trehalose-containing medium to prepare a clumping-inhibited cell suspension. | 03-31-2016 |
| 20160095882 | TOLEROGENIC DENDRITIC CELLS FOR TREATING MYOCARDIAL INFARCTION AND MANUFACTURING METHOD THEREOF - Provided are the tolerogenic dendritic cells for treating a myocardial infarction and a method for preparing the same, and more particularly, the tolerogenic dendritic cells for treating a myocardial infarction, which can treat cardiac insufficiency that occurs by excessive remodeling of left ventricle in the heart muscle recovery process after an acute myocardial infarction, and a method for preparing the tolergenic dendritic cells. According to the present invention, the inflammatory reaction and the excessive remodeling of left ventricle in the heart muscle recovery process after a myocardial infarction can be inhibited, and thus, the incidence rate of cardiac insufficiency can be significantly reduced, thereby being effectively used for treating a myocardial infarction. | 04-07-2016 |
| 20160095885 | Induction Medium & Methods for Stem Cell Culture & Therapy - Novel MSC stem-cell culture and therapy methods and culture medium compositions for the purpose of inducing, activating, or priming discrete uniform cell phenotypes to selectively promote or suppress inflammation and immunity, yielding primed, activated, or induced cells used in cell-based therapy. | 04-07-2016 |
| 20160095886 | COMPOSITION FOR TREATMENT OF JOINT DISEASE AND METHOD THEREOF - The present invention provides a pharmaceutical composition comprising mesenchymal stem cells, a hyaluronan and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for the treatment of the joint disease. The mesenchymal stem cells in the composition are at least one selected from the group consisting of infra-patellar fat pad stromal cells, bone marrow stem cells, Wharton's jelly stem cells and adipose derived stem cells. The concentration of the hyaluronan is in a range from 25% (v/v) to 75% (v/v). The present invention further provides a method for treating a joint disease, comprising a step of administrating a composition containing mesenchymal stem cells, a hyaluronan and a pharmaceutically acceptable carrier to an injured joint tissue of a subject. | 04-07-2016 |
| 20160095887 | MULTIPOTENT NEURAL CELLS - The inventions disclosed herein are based on the identification of novel cell populations derived from human embryonic stem cells and other pluripotent cells. The inventive cell populations may be used for cell therapies for the treatment of various neurological diseases and as substrates in pharmacological assays. | 04-07-2016 |
| 20160095907 | PLANT CELL CULTURE EXPRESSING HUMAN LYSOSOMAL PROTEINS AND USES THEREOF - A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases. | 04-07-2016 |
| 20160095956 | IMPLANT AND METHOD OF PRODUCING AN IMPLANT - The invention provides a method for producing an implant from interstitial, connective or supporting tissue, the method comprising at least one step of perfusing the tissue with at least one decellularisation medium under negative pressure applied for substantially the whole time period of the perfusion. | 04-07-2016 |
| 20160095957 | METHOD FOR PREPARING BIOLOGICAL TISSUES FOR USE IN BIOLOGICAL PROSTHESES - A method of treating a biological tissue for biological prostheses includes steps of fixation of the biological tissue via a fixing solution including glutaraldehyde and detoxification of the fixed biological tissue via treatment with a detoxifying solution. The detoxification step includes one or both of eliminating phospholipids via treatment with an elimination solution and a treatment with a detoxifying solution. The elimination solution includes 1,2-octanediol and ethanol. The detoxifying solution includes taurine or homocysteic acid. | 04-07-2016 |
| 20160101134 | KITS AND METHODS FOR PROCESSING STEM CELLS FROM BONE MARROW OR UMBILICAL CORD BLOOD - Provided herein are kits for processing stem cells from bone marrow or umbilical cord blood, comprising: a) a precipitation reagent comprising an aqueous solution of 0.1-30% hydroxyethyl starch or 0.1-30% methyl cellulose, and 0.1-20% of cerebroprotein hydrolysate; and b) a separation reagent comprising an aqueous solution comprising Ficoll and diatrizoate and having a density of 1.0-1.2 g/ml, and methods of use. Further provided herein is a collection of stem cells obtained by the kits and methods disclosed herein comprising stem cells from bone marrow or umbilical cord blood, and uses thereof. | 04-14-2016 |
| 20160101217 | RAPID PREPARATION OF STEM CELL MATRICES FOR USE IN TISSUE AND ORGAN TREATMENT AND REPAIR - A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition. | 04-14-2016 |
| 20160102289 | GENERATION OF KERATINOCYTES FROM PLURIPOTENT STEM CELLS AND MAINTENANCE OF KERATINOCYTE CULTURES - Provided herein are methods for the generation of functional keratinocyte stem cells that are differentiated directly from human ESCs/iPSCs in a chemically defined serum-free cell culture system, as well as cells derived therefrom and methods of use thereof. Also provided are methods for culturing primary keratinocytes. | 04-14-2016 |
| 20160102292 | ISOLATION AND CULTIVATION OF STEM/PROGENITOR CELLS FROM THE AMNIOTIC MEMBRANE OF UMBILICAL CORD AND USES OF CELLS DIFFERENTIATED THEREFROM - The present invention relates to the generation of a chondrocyte using mesenchymal stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such chondrocytes. | 04-14-2016 |
| 20160102294 | ENDOCARDIUM-DERIVED ADULT STEM CELLS AND METHOD FOR PRODUCING SAME - The present invention relates to endocardium-derived adult stem cells obtained by culturing peripheral blood mononuclear cells (PBMCs) separated from peripheral blood, and a cell therapeutic agent for treating cardiovascular diseases containing the same as an active ingredient. The adult stem cells, according to the present invention, have an origin that is the endocardium and strong blood vessel formation, and is thus remarkably useful for treating cardiovascular diseases such as ischemia, myocardial infarction, and the like. | 04-14-2016 |
| 20160106780 | Methods and Compositions for Optimized Expansion and Implantation of Mesenchymal Stem Cells - Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. Autologous mesenchymal stem cells (MSCs) to a patient in need of MSCs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the patient's platelets. | 04-21-2016 |
| 20160106781 | HIGH TELOMERASE ACTIVITY BONE MARROW MESENCHYMAL STEM CELLS, METHODS OF PRODUCING THE SAME AND PHARMACEUTICALS AND TREATMENT METHODS BASED THEREON - Disclosed are isolated human bone marrow mesenchymal stem cells having high telomerase activity (tBMMSCs). Also disclosed are isolated human CD34 | 04-21-2016 |
| 20160106783 | METHOD FOR THE ANTI-SENESCENCE OF AND/OR REJUVENATING STEM CELLS - A method for the anti-senescence of and/or rejuvenating a stem cell is provided. The method comprising treating the stem cell with trans-cinnamaldehyde (TC). A kit is also provided. The kit comprising (1) a first part, comprising a stem cell; (2) a second part, comprising TC; and (3) a culture medium of the stem cell, placed in at least one of the first part, the second part, and a third part. In addition, a method for stem cell therapy is provided. The method comprising administering to a subject in need an effective amount of a stem cell, wherein the stem cell has been treated with TC before being administered. | 04-21-2016 |
| 20160106784 | ANGIOGENESIS USING PLACENTAL STEM CELLS - Provided herein are methods of treating individuals having diseases or disorders of the circulatory system, using placental cells, e.g., the placental stem cells and placental multipotent cells (PDACs) described herein, and populations of such placental cells. The invention also provides methods of angiogenesis using such cells or populations of cells comprising such cells. | 04-21-2016 |
| 20160108363 | USE OF LIFR OR FGFR3 AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS - The present invention provides LIFR and FGFR3 as cell surface markers for isolating human cardiomyogenic ventricular progenitor cells, in particular progenitor cells that preferentially differentiate into cardiac ventricular muscle cells. Thus, the invention provides human ventricular progenitor (HVP) cells. The invention provides in vitro methods of the separation of Islet 1+ LIFR+ ventricular progenitor cells and/or Islet 1+/FGFR3+ ventricular progenitor cells and/or Islet 1+/LIFR+/FGFR3+ ventricular progenitor cells, and the large scale expansion and propagation thereof. Large clonal populations of isolated LIFR+ and/or FGFR3+ ventricular progenitor cells are also provided. Methods of in vivo use of LIFR+ and/or FGFR3+ ventricular progenitor cells for cardiac repair or to improve cardiac function are also provided. Methods of using the LIFR+ and/or FGFR3+ ventricular progenitor cells for cardiac toxicity screening of test compounds are also provided. | 04-21-2016 |
| 20160108364 | PLURIPOTENT HUMAN ADIPOSE ADULT STEM CELLS: ISOLATION, CHARACTERIZATION AND CLINICAL IMPLICATIONS - Methods for the efficient isolation and use of pluripotent adipose-derived stem cells (PASCs) are provided. In certain embodiments the methods involve providing an adipose tissue sample from which the stromal vascular fraction is co-cultured with the adipocyte fraction. PASCs can be isolated with a high degree of purification without requiring an additional cell enrichment process (e.g. cell sorting). PASCs and their conditioned media can be used for tissue regeneration within hours of harvesting the adipose tissue, and without requiring cell expansion. PASCs can grow as floating individual cells, as clusters of cells, or attached to surface(s) of the culture vessel. PASCs do not produce teratomas in vivo, nor do they induce immunorejection upon transplantation, and they achieve a high efficiency in grafting. The cells and compositions can be used for cell therapy and to screen new drugs. | 04-21-2016 |
| 20160108370 | REPROGRAMMING OF AGED ADULT STEM CELLS - A method comprising (a) obtaining young adult stem cells (YASC) from a first subject; (b) lysing the YASC to generate a lysate comprising an intracellular matrix (ICM) and other cellular components; (c) filtering the lysate through a filter having a membrane size of equal to or less than 0.4 micron to obtain a filtrate; and (d) applying the filtrate to a culture of aged adult stem cells (AASC) for a time period ranging from about 24 hours to about 30 days to generate a reprogrammed AASC (R-AASC) wherein the AASC were obtained from a second subject and wherein the R-AASC when infused into a breast cancer stem model results in a reduced number of breast cancer cells in bone marrow in comparison to a breast cancer stem model having AASC that have not been reprogrammed. | 04-21-2016 |
| 20160113863 | Lipofilling with ex-vivo expanded adipose tissue-derived stem cells for cosmetic breast filling or for facial filling and/or rejuvenation - The present invention relates to a composition comprising ex-vivo expanded adipose tissue derived stem cell (ASC) or ex-vivo expanded adipose tissue-derived stem cells (ASC) mixed with harvested fat tissue at a ratio of 5.0×10 | 04-28-2016 |
| 20160113925 | METHODS OF TREATING CANCER WITH A COMBINATION OF GLUCOSE MODULATORS AND BCL-2 INHIBITORS - This disclosure relates to treating or preventing cancers, such as hematological malignancies, by administering a compound that binds BCL2 and one or more compounds that inhibit glucose or glutamine metabolism. In certain embodiments, the compounds that inhibit glucose metabolism are ritonavir optionally in combination with 6-diazo-5-oxo-L-norleucine or any derivative, prodrugs, or salts of these compounds. Contemplated BCL2 binding compounds are ABT-199 (venetoclax), ABT-263 (navitoclax), or ABT-737. | 04-28-2016 |
| 20160113967 | SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS FROM ADIPOSE TISSUE - The invention provides methods for manipulating regenerative cells from adipose tissue. Specifically, it provides methods for enrichment of desired cells and enhancement of their therapeutic effects. | 04-28-2016 |
| 20160113968 | HYPOXIA-CULTURED MESENCHYMAL STEM CELLS FOR TREATING ATHEROSCLEROTIC LESIONS - A method and a pharmaceutical composition for treating an atherosclerotic lesion are provided, including administering a subject in need thereof a therapeutically effective amount of a composition comprising hypoxia-cultured MSCs obtained by culturing auto- or allo-MSCs under low oxygen conditions. | 04-28-2016 |
| 20160113969 | Ameliorating Nervous Systems Disorders - The present disclosure provides methods for the treatment of a mammal having a neurological condition, disease, or injury. The methods involve increasing the number of functional GABAergic interneurons at or near the site of the neurological disease, injury, or condition | 04-28-2016 |
| 20160115446 | Technologies, Methods, and Products of Small Molecule Directed Tissue and Organ Regeneration from Human Pluripotent Stem Cells - Pluripotent human embryonic stem cells (hESCs) hold great potential for restoring tissue and organ function, which has been hindered by inefficiency and instability of generating desired cell types through multi-lineage differentiation. This instant invention is based on the discovery that pluripotent hESCs maintained under defined culture conditions can be uniformly converted into a specific lineage by small molecule induction. Retinoic acid induces specification of neuroectoderm direct from the pluripotent state of hESCs and triggers progression to neuronal progenitors and neurons efficiently. Similarly, nicotinamide induces specification of cardiomesoderm direct from the pluripotent state of hESCs and triggers progression to cardiac precursors and cardiomyocytes efficiently. This technology provides a large supply of clinically-suitable human neuronal or cardiac therapeutic products for CNS or myocardium repair. This invention enables well-controlled efficient induction of pluripotent hESCs exclusively to a specific clinically-relevant lineage for tissue and organ engineering and regeneration, cell-based therapy, and drug discovery. | 04-28-2016 |
| 20160115450 | HEMANGIO-COLONY FORMING CELLS - Methods of generating and expanding human hemangio-colony forming cells in vitro and methods of expanding and using such cells are disclosed. The methods permit the production of large numbers of hemangio-colony forming cells as well as derivative cells, such as hematopoietic and endothelial cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. | 04-28-2016 |
| 20160120170 | TREHALOSE AND DEXTRAN-CONTAINING SOLUTION FOR TRANSPLANTING MAMMALIAN CELLS - The problem of the present invention is to provide a method for preserving mammalian cells over a long period of time using a solution for cell transplantation, capable of effectively suppressing cell death when the mammalian cells have been preserved, and the solution for cell transplantation. The present invention is characterized in that mammalian cells are preserved in a physiological aqueous solution for cell transplantation, comprising 2.0 to 6.0% (w/v) of trehalose, a derivative thereof, or a salt of trehalose or the derivative (a trehalose) and 4.0 to 7.0% (w/v) of dextran, a derivative thereof, or a salt of dextran or the derivative (a dextran). The effects of a trehalose and a dextran contained in the physiological aqueous solution for cell transplantation can suppress a decrease in the cell survival rate when mammalian cells are preserved for a long period of time (at least 14 days). | 05-05-2016 |
| 20160120909 | Compositions And Methods For The Treatment Of Tinnitus - In one embodiment, the present invention relates to a method for treating tinnitus in a subject including administering to the subject a composition including a stromal vascular fraction from adipose tissue. In another embodiment, the present invention relates to a method for treating tinnitus in a subject including administering to the subject a composition including a bone marrow cellular fraction. In another embodiment, the present invention relates to a method of treating tinnitus in a subject including administering to the subject a composition including adult stem cells. | 05-05-2016 |
| 20160120910 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHODS FOR THE PREPARATION AND USES THEREOF - The present invention provides a method for treating rheumatoid arthritis comprising the use of mesenchymal stem cells. | 05-05-2016 |
| 20160120932 | TRANSPLANT SITE-FORMING AGENT, TRANSPLANT SITE-FORMING DEVICE, ANGIOGENIC AGENT AND ANGIOGENIC DEVICE - A method of forming a transplant site, the method comprising a process of contacting SEK-1005 (Ser,3-hydroxy-N-[2-hydroxy-1-oxo-2-tetrahydro-2-hydroxy-6-methyl-5-(2-methylpropyl)-2H-pyran-2-yl-propyl]-Leu-Pip(hexahydro-3-pyridazinecarbonyl)-N-hydroxy-Ala-N-methyl-Phe-Pip-rho-lactone) with a body tissue. | 05-05-2016 |
| 20160120942 | STABLE NEURAL STEM CELLS COMPRISING AN EXOGENOUS POLYNUCLEOTIDE CODING FOR A GROWTH FACTOR AND METHODS OF USE THEREOF - The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS. | 05-05-2016 |
| 20160122707 | PROTEIN MODIFICATION OF LIVING CELLS USING SORTASE - Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to nongenetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g. a method of modulating an immune response of a subject to an entity of interest, a method of neutralizing a substance in the body of a subject, a method of treating a subject in need of treatment for deficiency of a protein, and a method of treating a subject in need of treatment for a disease, are provided. | 05-05-2016 |
| 20160122710 | METHOD AND PHARMACEUTICAL COMPOSITION FOR CONTINUOUSLY MAINTAINING GROWTH OF A MOTOR NEURON PROGENITOR CELL - This present invention provides a method for continuously maintaining growth of a motor neuron progenitor cell and a pharmaceutical composition. Wherein, the method for continuously maintaining growth of a motor neuron progenitor cell is to culture the motor neuron progenitor cell in an environment which is constructed by the olfactory ensheathing cells to make the motor neuron progenitor cell sustain the ability to self-replicate and to be induced for differentiating into mature neuron, and therefore to elaborate the effect to protect the motor neuron. The motor neuron progenitor cell produced from the method disclosed in this present invention can be an effective ingredient of the pharmaceutical composition for treating related diseases of damaged motor neuron. | 05-05-2016 |
| 20160122711 | CHEMICAL DIFFERENTIATION OF PLURIPOTENTSTEM CELLS INTO RETINAL EPITHELIAL CELLS - The present invention is based in part on a chemically defined method of generating retinal epithelial cells and retinal pigmented epithelial cells from human pluripotent stem cells (hpSCs). The present invention also provides methods and kits for treating degenerative eye disorders. | 05-05-2016 |
| 20160128961 | DIETARY OMEGA-3 FATTY ACID DERIVED GLYCEROPHOSPHOLIPIDS TO TREAT NEUROPATHIC PAIN - Disclosed are methods and dietary compositions for the treatment and prevention of neuropathic pain and for pain prognosis. Some embodiments may include the administration of a diet rich in omega-3 fatty acids. Methods for the treatment and prevention of neuropathic pain by administering a diet rich in omega-3 fatty acids, N-acylated ethanolamines, or N-acylated ethanolamine precursors are also provided. Compositions for the treatment and prevention of neuropathic pain are also provided. | 05-12-2016 |
| 20160129043 | COMPOSITION OF MESENCHYMAL STEM CELLS - This invention relates in general to a mesenchymal stem cell (MSC) therapy. This invention further relates to the isolation and applications of gingiva derived mesenchymal stem cells. More particularly, this invention relates to the isolation and applications of the neural crest derived gingiva mesenchymal stem cells and/or mesoderm derived gingiva mesenchymal stem cells. This invention also relates to a composition comprising a neural crest derived gingiva mesenchymal stem cell and/or a mesoderm derived gingiva mesenchymal stem cell. This composition may be used for wound healing and/or in the treatment of inflammatory and/or autoimmune diseases. | 05-12-2016 |
| 20160129045 | COMPOSITION FOR WOUND-HEALING COMPRISING ADULT STEM CELLS AND ELASTIN-LIKE POLYPEPTIDES - Provided is a composition for wound-healing containing adult stem cells and elastin-like polypeptides, and more specifically, to a composition for wound-healing capable of effectively treating skin wounds by simultaneously administering elastin-like polypeptides along with adult stem cells thereby increasing the viability of the adult stem cells transplanted on the wounds and promoting angiogenesis. | 05-12-2016 |
| 20160129046 | METHOD AND COMPOSITION OF INDUCING HAIR FOLLICLE NEOGENESIS - The present invention provides a method of inducing hair follicle neogenesis in the skin of a subject in need by transplanting the mixture of the skin extract or the composition with epidermal cells or fibroblasts into the subject. The skin extract of the present invention is obtained by mincing and mixing a skin tissue with phosphate buffer solution, thawing the skin tissue after freeze. And the composition of the present invention includes at least lumican, galectin-1 and apolipoprotein A-I. | 05-12-2016 |
| 20160129048 | Placental Stem Cell Populations - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 05-12-2016 |
| 20160130555 | METHODS FOR MATURING CARDIOMYOCYTES AND USES THEREOF - Described herein are methods and compositions useful for inducing maturation of a cardiomyocyte to a mature (e.g., adult) phenotype, such that the function and morphology of the mature cardiomyocyte matches or more closely mimics that of the adult heart. The methods and compositions use Let-7 miRNAs and modified forms thereof. Such methods and compositions permit the study and treatment of adult-onset cardiac diseases, disorders or injuries with mature cardiomyocytes that mimic the heart function of an adult. Methods of using cardiomyocytes matured in this manner for drug identification and drug cardiotoxicity testing are also provided. | 05-12-2016 |
| 20160130556 | ENHANCED DIFFERENTIATION OF MESENCHYMAL STEM CELLS - Isolated populations of mesenchymal stem cells (MSCs) are provided, including mammalian mesenchymal stem cells (MSCs) characterized by the lack of CD54 (CD54 | 05-12-2016 |
| 20160130559 | CELL POPULATIONS, METHODS OF TRANSDIFFERENTIATION AND METHODS OF USE THEREOF - The present invention provides methods for the sequential and temporally-regulated administration of pancreatic transcription factors to induce non-pancreatic cells to transdifferentiate and mature along the pancreatic β-cell lineage. The present invention also provides methods for identifying, isolating and enriching transdifferentiation predisposed cells and methods for treating a degenerative pancreatic disorder such as diabetes. | 05-12-2016 |
| 20160130648 | DEEP SEQUENCING OF PERIPHERAL BLOOD PLASMA DNA AS A RELIABLE TEST FOR CONFIRMING THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME - Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum. | 05-12-2016 |
| 20160130664 | DETERMINING TUMOR LOAD AND BIALLELIC MUTATION IN PATIENTS WITH CALR MUTATION USING PERIPHERAL BLOOD PLASMA - Compositions and fragment length analysis methods are provided for detecting CALR mutations and determining tumor load in patients with myeloproliferative neoplasms. | 05-12-2016 |
| 20160135466 | NOVEL PEST CONTROL METHODS - The technology provided herein relates to methods of multi-species insect pest control by incorporating an inhibitor against the structural sheath protein (SHP) into the body of an agricultural target pest, and to pest control agents to be used in the method and to transgenic crop, greenhouse and ornamental plants. | 05-19-2016 |
| 20160136203 | SOMATIC STEM CELLS FOR TREATING BONE DEFECTS - A method of treating a bone defect in a subject, comprising administering to a subject in need thereof at a bone defect site an effective amount of isolated somatic stem cells, wherein the somatic stem cells are about 2 to 8.0 μm in size and are Lgr5+ or CD349+. | 05-19-2016 |
| 20160136206 | COMPOSITIONS AND METHODS FOR TREATING SKIN - The present invention relates to compositions and methods utilizing hair follicle derived Non-Bulbar Dermal Sheath cells for use in the treatment of skin | 05-19-2016 |
| 20160136331 | New Use of Dextran Sulfate - A graft composition intended for transplantation into a human patient comprises an injection solution comprising an isolated therapeutic cell transplant, wherein the therapeutic cell transplant is therapeutic to a human patient, and dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight of less than 20,000 Da. | 05-19-2016 |
| 20160137975 | GENERATION OF MALE GERM CELLS - Methods are provided for the generation of male germ cells from somatic cells. Included are methods of non-integrative reprogramming for germ cell differentiation with a reduced risk of neoplasia during in vivo differentiation by the inclusion of VASA with the reprogramming factors. Also included are methods of generating male germ cells from reprogrammed pluripotent cells by direct injection of the reprogrammed cells into the seminiferous tubules. In some embodiments the somatic cells are derived from a male with oligospermia or azoospermia, which may be the result of a genetic abnormality in Azoospermia Factor (AZF) region. | 05-19-2016 |
| 20160137978 | METHODS AND COMPOSITIONS FOR PRODUCING GERM CELLS FROM BONE MARROW DERIVED GERMLINE STEM CELLS - The present invention relates to the use of bone marrow derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof. | 05-19-2016 |
| 20160137982 | P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION - Here is provided a novel differentiation protocol, which was experimentally shown to give rise to osteoprogenitor cells in vitro. A novel medium composition containing a p38 MAPK inhibitor was found to promote differentiation of human adipose stem cells (hASCs) to osteoprogenitor cells. The early osteogenic precursor cells may further differentiated to osteoblasts. With the present method, it can be produced cells, expected to contribute to treatment and research of conditions, diseases, pathologies, transplant techniques as well as toxicology and drug development related to the skeletal system. | 05-19-2016 |
| 20160137985 | METHOD FOR PRODUCING RENAL PROGENITOR CELLS, AND DRUG COMPRISING THE SAME - The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGFβ signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells. | 05-19-2016 |
| 20160139012 | METHODS AND DEVICES FOR HIGH THROUGHPUT PURIFICATION - Described herein are devices and methods for high throughput purification of particles. In some cases, methods and devices described herein can be used to remove erythrocytes and purify leukocytes and raise the quality of umbilical cord blood and other transplant grafts, thereby significantly improving patient outcomes. | 05-19-2016 |
| 20160143949 | METHODS FOR GENERATION OF PODOCYTES FROM PLURIPOTENT STEM CELLS AND CELLS PRODUCED BY THE SAME - Embodiments of various aspects described herein relate to methods, kits, and cell culture media for generation of podocytes from pluripotent stem (PS) cells, as well as cells produced by the same, and methods of use. | 05-26-2016 |
| 20160143950 | STEM CELLS AND STEM CELL FACTORS FOR INHIBITING THE PROGRESSION OF ALZHEIMER'S DISEASE - Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture. The invention also contemplates the use of such stem cells in the treatment of neurodegenerative disorders including Alzheimer's disease and stroke. | 05-26-2016 |
| 20160143954 | Isolation and Therapeutic Application of Adult Retinal Stem Cells Collected From Extra-Retinal Tissues - The present invention is directed to an adult retinal cell line isolated from extra-retinal ocular tissue, and methods of isolating adult retinal cells from extra-retinal ocular tissue. The present invention is further directed to adult retinal stem cells isolated from vestigial tissue dissected from the eye of a donor mammal suffering from persistent fetal vasculature. The present invention is further directed to a culture medium for growing or maintaining retinal stem cells, and methods of maintaining adult retinal cells in culture. The present invention is further directed to methods of treating a treating an eye with retinal dystrophy using retinal stem cells, and an eye with glaucomatous injury with retinal stem cells. The present invention is further directed to kits for harvesting extra-retinal ocular tissue comprising a sterile container and a harvesting solution, wherein the kit allows the survival of the tissue until later dissociation of cells from the tissue. | 05-26-2016 |
| 20160143955 | METHOD FOR ISOLATING STROMAL VASCULAR FRACTION - Disclosed is a method for recovering stromal vascular fraction from a sample. The method comprises providing a mechanical force capable of breaking the sample into a single cell suspension whilst maintaining intact stromal vascular fraction cells cellular structures, wherein the mechanical force is mincing and/or homogenization. Also disclosed are methods of using the stromal vascular fraction. | 05-26-2016 |
| 20160143956 | PARTHENOGENIC ACTIVATION OF HUMAN OOCYTES FOR THE PRODUCTION OF HUMAN EMBRYONIC STEM CELLS - Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O | 05-26-2016 |
| 20160145579 | REGULATING STEM CELLS - Provided are methods for producing progenitor/precursor cells from a population of initiating cells (ICP) that have a density of less than 1.072 g/ml and at least 25% of which are CD31Bright by in vitro stimulating the ICP with different factors. | 05-26-2016 |
| 20160145581 | COMPOSITIONS AND METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS - The invention provides a composition and a method for inducing pluripotency in non-pluripotent eukaryotic cells. The composition comprises chemical inducers of pluripotency (CIPs) including glycogen synthase kinase (GSK) inhibitors, TGFp receptor inhibitors, cyclic AMP agonists, S-adenosylhomocysteine hydrolase (SAH) inhibitors, and optionally an agent that promotes histone acetylation. The method comprises contacting a cell with the CIPs for a sufficient period of time to reprogram the cell into a pluripotent stem cell. | 05-26-2016 |
| 20160146788 | METHOD FOR SCREENING DRUGS FOR TREATING/PREVENTING MYELODYSPLASTIC SYNDROME, ETC. - The present invention provides a method of screening for a therapeutic or prophylactic drug for acute myeloid leukemia or myelodysplastic syndrome, comprising the following steps:
| 05-26-2016 |
| 20160146821 | Detection of Acute Myeloid Leukaemia (AML) Leukaemic Stem Cells (LSC) - The present invention relates to diagnostic screens, gene expression profiles, methods and kits for detection of acute myeloid leukaemia leukaemic stem cells. Diagnostic and prognostic methods based on said diagnostic screens and/or gene expression profiles also form part of the invention. | 05-26-2016 |
| 20160151274 | Use of gingival fibroblasts in the treatment of alopecia | 06-02-2016 |
| 20160151419 | PERIPHERAL BLOOD STEM CELLS WITH IMPROVED ANGIOGENIC PROPERTIES AND USE THEREOF | 06-02-2016 |
| 20160151420 | COMPOSITION FOR PREVENTING AND TREATING LIVER FIBROSIS OR LIVER CIRRHOSIS, CONTAINING, AS ACTIVE INGREDIENT, MESENCHYMAL STEM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS | 06-02-2016 |
| 20160151421 | METHODS AND COMPOSITIONS FOR LONG TERM HEMATOPOIETIC REPOPULATION | 06-02-2016 |
| 20160151422 | ISOLATION AND PURIFICATION OF HEMATOPOIETIC STEM CELLS FROM POST-LIPOSUCTION LIPOASPIRATES | 06-02-2016 |
| 20160151425 | METHODS AND COMPOSITIONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONS | 06-02-2016 |
| 20160151451 | METHOD FOR GENERATING CARDIOMYOCYTES | 06-02-2016 |
| 20160153006 | OPTIMIZED CRISPR-CAS DOUBLE NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | 06-02-2016 |
| 20160158258 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS - In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells. | 06-09-2016 |
| 20160158288 | METHODS AND COMPOSITIONS FOR EXPANDING LONG-TERM HEMATOPOIETIC STEM CELL POPULATIONS - The invention generally features compositions and methods for expanding long term hematopoietic stem cells (HSCs) in a population of cells. In particular, the invention relates to a method of expanding long term HSCs by culturing an initial population of HSCs with macrophages that promote self-renewal of long term HSCs. The expanded cell population provides a source of cells for therapeutic treatments utilizing HSC transplantation. | 06-09-2016 |
| 20160158289 | MATERIALS AND METHODS FOR USING ADIPOSE STEM CELLS TO TREAT LUNG INJURY AND DISEASE - The present disclosure provides methods for treating patients with acute or chronic lung disease or injury to the lungs including injury caused by exposure to cigarette smoke other irritants or another cause of pulmonary distress. Typical conditions that can be treated include conditions that cause inflammation in the lung or the death of lung endothelial cells. Treatment of other conditions such as compromised bone marrow function and cachexia can also be treated by the inventive methods disclosed herein. These methods including contacting Adipose Stem Cells (ASC) or media conditioned by contact with ASC (ASC-CM) or various factors secreted by the same including the media or components of the media with lung tissue and cells. In some instances the ASC used is harvested from the patient's own adipose tissue while in other instances the source is an exogenous donor. | 06-09-2016 |
| 20160158292 | METHOD AND APPARATUS FOR RECOVERY OF UMBILICAL CORD TISSUE DERIVED REGENERATIVE CELLS AND USES THEREOF - Methods for the extraction and processing of umbilical stem cells for therapeutic and diagnostic purposes are disclosed. The methods provide high regenerative cell numbers and high cell viability. Further, the methods do not require culturing the cells in serum or growth factors. | 06-09-2016 |
| 20160158293 | Treatment of Ocular Conditions Using Progenitor Cells - Methods and compositions for treating ophthalmic disease, promoting development of functional neuronal synapses and improving neuronal outgrowth using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed. Trophic factors and other agents secreted by the cells that promote synapse formation and neuronal growth are also disclosed. | 06-09-2016 |
| 20160158314 | GLYCOSYLATED PROTEIN OF AN EXTRA-CELLULAR MATRIX FOR USE IN A METHOD OF TREATING AN ISCHEMIC HEART OF A HUMAN OR ANIMAL SUBJECT IN NEED THEREOF - The present invention relates to a glycosylated protein of an extracellular matrix, preferably of a mammalian extra-cellular matrix for use in a method of treating an ischemic heart of a human or animal subject in need thereof, a pharmaceutical composition comprising said glycosylated protein and a method for the in vitro production of differentiated cardiomyocytes. | 06-09-2016 |
| 20160159850 | BONE-SELECTIVE OSTEOGENIC OXYSTEROL-BONE TARGETING AGENTS - Compounds and compositions for the treatment of bone disorders are presented. | 06-09-2016 |
| 20160159909 | GENETIC MODIFIED PLURI- OR MULTIPOTENT STEM CELLS AND USES THEREOF - The invention concerns pluri- or multipotent stem cells (SCs), e.g. human pluri- or multipotent stem cells (hSCs) engineered to express a multispecific antibody and which further express, on their surface, a human immune cell co-stimulatory ligand or an active fragment thereof. | 06-09-2016 |
| 20160160177 | METHOD AND MEDIUM FOR NEURAL DIFFERENTIATION OF PLURIPOTENT CELLS - The invention relates to a culture medium comprising an inhibitor of the BMP signaling pathway; and an inhibitor of the TGF/activin/nodal signaling pathway and to a method for obtaining a population of neural precursors using said culture medium. | 06-09-2016 |
| 20160160179 | METHOD FOR OBTAINING A POPULATION OF ISOLATED BRITE ADIPOCYTES - The present invention relates to a method for obtaining a population of white/brite preadipocytes from precursor cells comprising the step of selecting cells for the expression of mesenchymal stem cell antigen 1 (MSCA1). The invention also relates to a method for obtaining brite adipocytes. | 06-09-2016 |
| 20160161486 | IDENTIFICATION, SELECTION AND USE OF HIGH CURATIVE POTENTIAL T CELL EPITOPES - A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprogramming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients. | 06-09-2016 |
| 20160161504 | METHOD FOR PREDICTING TREATMENT RESPONSE AND TEST FOR SAFE USE OF MESENCHYMAL STEM CELLS ON INFLAMMATORY DISEASES - The present invention refers to the use of tissue type plasminogen activator (tPA) and/or plasminogen activator inhibitor (PAI-1) for prognosticating or predicting a thrombotic event associated to the treatment with MSCs of a human subject suffering from an inflammatory disease. | 06-09-2016 |
| 20160166615 | Material for Treatment of Cerebral Infarction | 06-16-2016 |
| 20160166616 | COMPOSITIONS OF ACORBIC ACID AND BONE MORPHOGENETIC PROTEIN 4 (BMP-4) FOR CELL GROWTH AND USES RELATED THEREO | 06-16-2016 |
| 20160166617 | MACROMOLECULAR CLUSTERS OF CARDIAC STEM CELLS AND METHODS FOR MAKING AND USING THEM | 06-16-2016 |
| 20160166618 | TREATMENT OF PAIN USING AMNION DERIVED ADHERENT CELLS | 06-16-2016 |
| 20160166619 | Treatment of Retinal Degeneration Using Progenitor Cells | 06-16-2016 |
| 20160166734 | CARTILAGE-DAMAGE TREATMENT AGENT AND METHOD FOR PRODUCING SAME | 06-16-2016 |
| 20160166735 | INJECTABLE COMPOSITION FOR IN-SITU REPAIR AND REGENERATION OF AN INJURED LIGAMENT OR TENDON AND METHODS OF USE | 06-16-2016 |
| 20160168523 | Engineered Lumenized Vascular Networks and Support Matrix | 06-16-2016 |
| 20160168538 | Flk1+ and VE-Cadherin+ Endothelial Cells Derived from iPS or ES Cells, and Methods of Preparing and Using the Same | 06-16-2016 |
| 20160175353 | THERAPEUTIC OZONE AGENT AND TREATMENT | 06-23-2016 |
| 20160175360 | TREATMENT OF DISEASES OF ENDOTHELIAL DYSFUNCTION AND INFLAMMATION | 06-23-2016 |
| 20160175361 | PHOTORECEPTORS AND PHOTORECEPTOR PROGENITORS PRODUCED FROM PLURIPOTENT STEM CELLS | 06-23-2016 |
| 20160175367 | THERAPEUTIC PARASITE PREPARATION AND METHODS OF MAKING AND USING | 06-23-2016 |
| 20160175485 | COMBINATION THERAPY TO PROMOTE WOUND HEALING | 06-23-2016 |
| 20160177269 | METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND METHODS OF USE THEREOF | 06-23-2016 |
| 20160184058 | MATRIX FOR DENTAL TISSUE REGENERATION - The present invention relates to a biomimetic matrix for providing structural support and scaffolding that allows for regeneration of dentin, pulp, and periodontal tissues. A method of making the biomimetic matrix provides the ability to select both a size of a pore or tubule formed in the biomimetic matrix and a density of pores or tubules disposed throughout the biomimetic matrix. The present invention discloses an approach of successful tubular dentin regeneration both in vitro and in vivo using the biomimetic matrix. | 06-30-2016 |
| 20160184364 | MANAGEMENT OF OSTEOARTHRITIS USING POOLED ALLOGENEIC MESENCHYMAL STEM CELLS - The present disclosure relates to a composition and method for management of Osteoarthritis, including improvement in pain and cartilage regeneration of knee joint affected by osteoarthritis. The present disclosure also relates to a kit for treating Osteoarthritis and the method of assembling the same. The present disclosure relates to a pooled allogeneic mesenchymal stromal cell composition from multiple donors with diverse HLA genotypes suitable for transplantation into a diverse population without the risk of rejection. The pooled cell composition of the present disclosure shows increased potency and higher chondrogenic differentiation potential. | 06-30-2016 |
| 20160184365 | PLACENTA-DERIVED MULTIPOTENT STEM CELLS - This disclosure provides isolated cells and compositions comprising one or more isolated cell(s) as described herein. In one aspect, the isolated cell is a pre-term placenta-derived stem cell (also referred to placenta-derived multi potent stem cells (pmSCs). As used herein, the term “pre-term placenta-derived multipotent stem cell or placenta-derived stem cells” intends a cell isolated from placental tissue prior to delivery of the fetus by surgery or birth. In another aspect, the isolated cell is a chorionic villus (CV)-derived multipotent placental stem cells (C-mpSCs). Also provided are compositions comprising these cells, wherein the composition comprises an effective amount of the isolated cells as described herein. | 06-30-2016 |
| 20160184366 | COMPOSITIONS COMPRISING STEM CELLS EXPRESSING MESENCHYMAL AND NEURONAL MARKERS AND USES THEREOF TO TREAT NEUROLOGICAL DISEASE - The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition comprising systemically administering to a subject a pharmaceutical composition comprising hIDPSCs wherein the hIDPSCs express CD44 and CD13. For example, for treating neurological diseases or conditions including supporting the neuro-protective mechanism in subjects diagnosed with early HD or repairing lost DA neurons in subjects diagnosed with PD. | 06-30-2016 |
| 20160184367 | METHODS TO IMPROVE CELL THERAPY - Methods of treatment are provided herein, including administration of a population cells modified to enforce expression of an E-selectin and/or an L-selectin ligand, the modified cell population having a cell viability of at least 70% after a treatment to enforce such expression. | 06-30-2016 |
| 20160186131 | THREE DIMENSIONAL PURIFIED COLLAGEN MATRICES - Cell culture scaffolds presenting a more biologically relevant microenvironment are disclosed. More particularly, these cell culture scaffolds comprise three-dimensional matrices/biomaterials that are created from solubilized collagen compositions using controlled conditions to have the desired microstructure and mechanical properties. The engineered purified collagen based matrix compositions of the present invention can be used alone or in combination with cells as a tissue graft construct to enhance the repair of damaged or diseased tissues. | 06-30-2016 |
| 20160186133 | PATIENT-SPECIFIC STEM CELL LINES DERIVED FROM HUMAN PARTHENOGENETIC BLASTOCYSTS - Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application. | 06-30-2016 |
| 20160186139 | CELL AND GENE BASED METHODS TO IMPROVE CARDIAC FUNCTION - Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant. | 06-30-2016 |
| 20160186141 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES - Compositions and methods are described herein for chemically inducing cells to change their differentiation state and become cardiac progenitor cells or cardiomyocytes. | 06-30-2016 |
| 20160186142 | MAMMALIAN MUSCLE-DERIVED STEM CELLS - The present invention provides a new method of obtaining muscle-derived mesenchymal stem cells from microbiopsies of mammalian origin. The invention provides for a minimally invasive methodology yielding high amounts of MSCs that can differentiate into different cell lineages. | 06-30-2016 |
| 20160186144 | EPITHELIAL CELL DIFFERENTIATION OF HUMAN MESENCHYMAL STROMAL CELLS - The present invention relates to the discovery that different stem cell types (e.g., bone marrow-derived mesenchymal stem cells (BM-MSC) and adipose-derived mesenchymal stem cells (AT-MSC)) undergo large changes in lung epithelial marker expression depending on the substrate on which they are cultured. The present invention includes methods and compositions for differentiating of mesenchymal stem cells, such as bone marrow and adipose tissue mesenchymal stem cells, into lung cells, populations of lung cells, and methods of alleviating or treating a lung defect in a subject in need thereof. | 06-30-2016 |
| 20160186145 | Process for Enhancing Stem Cell Bioactivity Using Tauroursodeoxycholic Acid - The present invention relates to a process for enhancing stem cell bioactivity using tauroursodeoxycholic acid (TUDCA) or a pharmaceutical acceptable salt thereof. | 06-30-2016 |
| 20160186211 | RAAV-BASED COMPOSITIONS AND METHODS FOR TREATING ALPHA-1 ANTI-TRYPSIN DEFICIENCIES - The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency). | 06-30-2016 |
| 20160186250 | MULTIPLEX QUANTITATIVE PCR - Disclosed are methods and compositions for determining the average length or abundance of a first target nucleic by calculating the abundance of a first target nucleic acid (T) relative to the average abundance (S) of a second and a third target nucleic acid, in a single well using a separate detection label for each target nucleic acid. In various aspects, the first target nucleic acid is a telomere. In exemplary aspects, the disclosed methods and compositions can be used to determine the average telomere length in a biological sample. The average telomere length determined using the disclosed methods and compositions can be correlated to a variety of clinically important conditions and indices. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 06-30-2016 |
| 20160193250 | CHORION-DERIVED MSCS CELLS AND CONDITIONED MEDIA AS INDUCER FOR ANGIOGENESIS APPLICATION FOR THE TREATMENT OF CARDIAC DEGENERATION. | 07-07-2016 |
| 20160193254 | METHODS AND MATERIALS FOR TREATING ARTHRITIS | 07-07-2016 |
| 20160193255 | REPAIR AND REGENERATION OF OCULAR TISSUE USING POSTPARTUM-DERIVED CELLS | 07-07-2016 |
| 20160193264 | COMPOSITION COMPRISING NETTLE | 07-07-2016 |
| 20160193274 | PROCESS FOR THE LARGE SCALE PRODUCTION OF FRUIT CELLS AND TREATMENT OF DISEASES WITH SUCH CELLS | 07-07-2016 |
| 20160193384 | TRANSPARENT HYDROGEL AND METHOD OF MAKING THE SAME FROM FUNCTIONALIZED NATURAL POLYMERS | 07-07-2016 |
| 20160194605 | DESIGN AND USE OF SPECIFIC REGULATORY T-CELLS TO INDUCE IMMUNE TOLERANCE | 07-07-2016 |
| 20160194610 | Angiohematopoietic Progenitor Cells | 07-07-2016 |
| 20160199413 | MSCS IN THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES | 07-14-2016 |
| 20160199414 | USE OF MESENCHYMAL STEM CELLS FOR THE TREATMENT OF ORAL INFLAMMATION | 07-14-2016 |
| 20160199415 | METHODS OF TREATING OR PREVENTING RHEUMATIC DISEASE | 07-14-2016 |
| 20160199416 | Induced Hepatocytes and Uses Thereof | 07-14-2016 |
| 20160199418 | COMPOSITIONS AND METHODS FOR PROVIDING HEMATOPOIETIC FUNCTION | 07-14-2016 |
| 20160199419 | BIOMOLECULAR GROUP RELATED TO CELL ANTI-AGING | 07-14-2016 |
| 20160199538 | COLLAGEN SCAFFOLD MODIFIED BY COVALENT GRAFTING OF ADHESION MOLECULES, ASSOCIATED METHODS AND USE THEREOF FOR CARDIOVASCULAR AND THORACIC CELL THERAPY AND CONTRACTILE TISSUE ENGINEERING | 07-14-2016 |
| 20160201035 | Methods for Accelerated and Enhanced Cardiac Differentiation of IPS Cells by Electrical Stimulation | 07-14-2016 |
| 20160250202 | Mast Cell Stabilizers to Prevent or Treat Laminitis | 09-01-2016 |
| 20160250257 | ISOLATION, CULTIVATION AND USES OF STEM/PROGENITOR CELLS | 09-01-2016 |
| 20160250259 | METHODS AND DEVICES FOR OBTAINING AND PROVIDING COMBINATION CELL THERAPY | 09-01-2016 |
| 20160250260 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | 09-01-2016 |
| 20160250261 | CARDIAC NEURAL CREST CELLS AND METHODS OF USE THEREOF | 09-01-2016 |
| 20160250262 | CRYOPRESERVATION, HIBERNATION AND ROOM TEMPERATURE STORAGE OF ENCAPULATED PANCREATIC ENDODERM CELL AGGREGATES | 09-01-2016 |
| 20160250384 | Muscle cell patches and uses therefor | 09-01-2016 |
| 20160251616 | METHOD FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELLS | 09-01-2016 |
| 20160251619 | METHOD OF OBTAINING TERMINALLY DIFFERENTIATED NEURONAL LINEAGES AND USES THEREOF | 09-01-2016 |
| 20160251622 | POST-NATAL HEMATOPOEITIC ENDOTHELIAL CELLS AND THEIR ISOLATION AND USE | 09-01-2016 |
| 20160251623 | NOVEL CHONDROCYTE INDUCTION METHOD | 09-01-2016 |
| 20160251624 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | 09-01-2016 |
| 20160251628 | Apparatus And Method For Filtration Of A Suspension | 09-01-2016 |
| 20160252508 | Cell selection method and cells obtained therefrom | 09-01-2016 |
| 20160375062 | KIDNEY-DERIVED CELLS AND METHODS OF USE IN TISSUE REPAIR AND REGENERATION - Isolated or purified mammalian kidney-derived cell populations from mammalian kidney tissue are provided. Methods are provided for the isolation and purification of the mammalian kidney-derived cell population. Methods for treating kidney disease are provided by administration of the isolated or purified mammalian kidney-derived cell population to a mammalian subject. | 12-29-2016 |
| 20160375098 | MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES - An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed. | 12-29-2016 |
| 20160375099 | Glycosaminoglycans - Heparan sulphate HS/BMP2 is disclosed, together with the use of HS/BMP2 in the repair and regeneration of bone tissue. | 12-29-2016 |
| 20160375177 | SELF-ASSEMBLING PEPTIDES, PEPTIDOMIMETICS AND PEPTIDIC CONJUGATES AS BUILDING BLOCKS FOR BIOFABRICATION AND PRINTING - The present invention relates to the use of peptides, peptoids and/or peptidomimetics capable of self-assembling and forming a (nanofibrous) hydrogel in biofabrication. The present invention further relates to methods for preparing hydrogels and to methods for preparing continuous fibres and to methods for obtaining multi-cellular constructs with defined, precise geometrics. The present invention further relates to various uses of such hydrogels for obtaining mini-hydrogel arrays and 3D organoid structures or 3D macromolecular biological constructs. | 12-29-2016 |
| 20160376337 | PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE - The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis. | 12-29-2016 |
| 20160376554 | METHOD FOR MANUFACTURING CILIARY MARGINAL ZONE-LIKE STRUCTURE - The present invention provides a method for producing a cell aggregate containing a ciliary marginal zone-like structure, including a step of culturing a cell aggregate containing a retinal tissue in which Chx10 positive cells are present in a proportion of 20% or more and 100% or less of the tissue in a serum-free medium or serum-containing medium each containing a substance acting on the Wnt signal pathway and a substance inhibiting the FGF signal pathway for only a period before the appearance of a RPE65 gene expressing cell, followed by culturing the “cell aggregate in which a RPE65 gene-expressing cell does not appear” thus obtained in a serum-free medium or serum-containing medium each free of a substance acting on the Wnt signal pathway and so on. According to the production method of the present invention, a ciliary marginal zone-like structure can be produced with high efficiency. | 12-29-2016 |
| 20160376557 | METHOD FOR INDUCING HUMAN CHOLANGIOCYTE DIFFERENTIATION - The invention relates to a method for inducing human cholangiocyte differentiation of progenitor cells called hepatoblasts. More specifically, the invention relates to a method for differentiating hepatoblasts to cholangiocytes by culturing said hepatoblasts with a particular medium having interleukin-6 (IL-6) activity. The differentiation method can specifically induce cholangiocyte differentiation from hepatoblasts, and the human cholangiocytes differentiated according to the invention may be useful for drug discovery for treatment of cholangiopathies and bioengineered livers. | 12-29-2016 |
| 20170231901 | ADIPOSE DERIVED MESENCHYMAL STEM CELL COMPOSITIONS | 08-17-2017 |
| 20170232041 | TARGETED DELIVERY SYSTEM, SYSTEM COMPONENTS, AND METHODS | 08-17-2017 |
| 20170232145 | Composite Bone Implants | 08-17-2017 |
| 20170233698 | CULTURED MAMMALIAN LIMBAL STEM CELLS, METHODS FOR GENERATING THE SAME, AND USES THEREOF | 08-17-2017 |
| 20170233699 | TISSUE-SPECIFIC DIFFERENTIATION MATRICES AND USES THEREOF | 08-17-2017 |
| 20180021380 | COMPOSITION INCLUDING MESENCHYMAL STEM CELL DERIVED FROM ADIPOSE TISSUES AND HYALURONIC ACID DERIVATIVE, METHOD OF PREPARING THE SAME, AND METHOD OF PREVENTING OR TREATING LOW BACK PAIN USING THE SAME | 01-25-2018 |
| 20180021381 | ADIPOSE TISSUE-DERIVED STEM CELLS FOR VETERINARY USE | 01-25-2018 |
| 20180021382 | MODIFICATION OF REACTIVITY OF BONE CONSTRUCTS | 01-25-2018 |
| 20190142870 | ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT | 05-16-2019 |
| 20190142871 | ADIPOSE CELLS FOR CHONDROCYTE APPLICATIONS | 05-16-2019 |
| 20190142998 | SCAFFOLDS FABRICATED FROM ELECTROSPUN DECELLULARIZED EXTRACELLULAR MATRIX | 05-16-2019 |
| 20190142999 | MUSCLE CELL PATCHES AND USES THEREFOR | 05-16-2019 |
| 20190143000 | METHODS OF TRANSPLANTING CHONDROCYTES | 05-16-2019 |
| 20190144828 | HAEMATOPOIETIC STEM/PROGENITOR CELLS | 05-16-2019 |
| 20190144829 | Uses of Epithelial-to-Mesenchymal Inhibitors in Generating Pacemaker Cells | 05-16-2019 |
| 20190144862 | USING MICRORNAS TO CONTROL ACTIVATION STATUS OF HEPATIC STELLATE CELLS AND TO PREVENT FIBROSIS IN PROGRESSIVE LIVER DISEASES | 05-16-2019 |
| 20190144942 | METHODS FOR IDENTIFYING AND MODULATING IMMUNE PHENOTYPES | 05-16-2019 |
| 20220133799 | COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT - Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. In certain instances, compositions may include additional agents. | 05-05-2022 |
| 20220133805 | PHARMACEUTICAL COMPOSITION FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis. More specifically, the present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis, wherein the pharmaceutical composition comprises mesenchymal stem cells and is intravenously administered. | 05-05-2022 |
| 20220133806 | AMNIOTIC FLUID-DERIVED EXTRACELLULAR VESICLES AND USES THEREOF FOR WOUND HEALING - The described invention provides compositions and methods for wound healing in a subject. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles from amniotic fluid and a pharmaceutically acceptable carrier. | 05-05-2022 |
| 20220135948 | METHODS OF USING PDX1-POSITIVE PANCREATIC ENDODERM CELLS AND ENDOCRINE PRECURSOR CELLS - Disclosed herein are cell cultures and enriched cell populations of endocrine precursor cells, immature pancreatic hormone-expressing cells and mature pancreatic hormone-expressing cells. Also disclosed herein are methods of producing such cell cultures and cell populations. | 05-05-2022 |
